0001628280-24-04722110-Q BAXTER INTERNATIONAL INC 20241112202411121638191638191638191

012024-09-3000000104562028-01-012024-09-300000010456bax:ManufacturingArrangementsMembersrt:MaximumMember2024-01-012024-09-300000010456bax:SoftwareArrangementsMembersrt:MinimumMember2024-01-012024-09-300000010456bax:SoftwareArrangementsMembersrt:MaximumMember2024-01-012024-09-300000010456bax:ConsumableMedicalProductsMembersrt:MinimumMember2024-01-012024-09-300000010456bax:ConsumableMedicalProductsMembersrt:MaximumMember2024-01-012024-09-300000010456bax:ManufacturingArrangementsMember2024-09-300000010456bax:ManufacturingArrangementsMember2023-12-310000010456bax:SoftwareArrangementsMember2024-09-300000010456bax:SoftwareArrangementsMember2023-12-310000010456bax:BundledEquipmentAndConsumableMedicalProductsContractsMember2024-09-300000010456bax:BundledEquipmentAndConsumableMedicalProductsContractsMember2023-12-310000010456us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000010456us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000010456us-gaap:OtherNoncurrentAssetsMember2024-09-300000010456us-gaap:OtherNoncurrentAssetsMember2023-12-310000010456bax:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-300000010456bax:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310000010456us-gaap:OtherNoncurrentLiabilitiesMember2024-09-300000010456us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000010456bax:A2020AndPriorYearsMember2024-09-300000010456bax:A2021Member2024-09-300000010456bax:A2022Member2024-09-300000010456bax:A2023Member2024-09-300000010456bax:A2024Member2024-09-300000010456bax:BusinessOptimizationProgramsMember2024-07-012024-09-300000010456bax:BusinessOptimizationProgramsMember2023-07-012023-09-300000010456bax:BusinessOptimizationProgramsMember2024-01-012024-09-300000010456bax:BusinessOptimizationProgramsMember2023-01-012023-09-300000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2024-07-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2024-07-012024-09-300000010456us-gaap:EmployeeSeveranceMember2024-07-012024-09-300000010456us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember2024-07-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember2024-07-012024-09-300000010456bax:ContractTerminationAndOtherCostsMember2024-07-012024-09-300000010456us-gaap:CostOfSalesMember2024-07-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000010456us-gaap:EmployeeSeveranceMember2023-07-012023-09-300000010456us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember2023-07-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember2023-07-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMemberbax:ContractTerminationAndOtherCostsMember2023-07-012023-09-300000010456bax:ContractTerminationAndOtherCostsMember2023-07-012023-09-300000010456us-gaap:CostOfSalesMember2023-07-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2024-01-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2024-01-012024-09-300000010456us-gaap:EmployeeSeveranceMember2024-01-012024-09-300000010456us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember2024-01-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember2024-01-012024-09-300000010456bax:ContractTerminationAndOtherCostsMember2024-01-012024-09-300000010456us-gaap:CostOfSalesMember2024-01-012024-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000010456us-gaap:EmployeeSeveranceMember2023-01-012023-09-300000010456us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember2023-01-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember2023-01-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMemberbax:ContractTerminationAndOtherCostsMember2023-01-012023-09-300000010456bax:ContractTerminationAndOtherCostsMember2023-01-012023-09-300000010456us-gaap:CostOfSalesMemberbax:AssetImpairmentMember2023-01-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:AssetImpairmentMember2023-01-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMemberbax:AssetImpairmentMember2023-01-012023-09-300000010456bax:AssetImpairmentMember2023-01-012023-09-300000010456us-gaap:CostOfSalesMember2023-01-012023-09-300000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000010456us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000010456us-gaap:EmployeeSeveranceMemberbax:RestructuringWithinHSTSegmentMember2024-07-012024-09-300000010456us-gaap:EmployeeSeveranceMemberbax:RestructuringWithinHSTSegmentMember2024-01-012024-09-300000010456us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember2024-01-012024-09-300000010456us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember2023-07-012023-09-300000010456us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember2023-01-012023-09-300000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2023-12-31000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2024-01-012024-09-300000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2024-09-300000010456us-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300000010456us-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000010456us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300000010456us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-07-012024-09-300000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-09-300000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000010456us-gaap:ForeignExchangeContractMember2024-09-300000010456us-gaap:ForeignExchangeContractMember2023-12-310000010456us-gaap:ForeignExchangeContractMember2024-01-012024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-12-310000010456us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2024-09-300000010456us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2023-12-310000010456us-gaap:FairValueHedgingMember2023-10-31000010456bax:A04SeniorNotesDueMay2024Member2023-10-310000010456bax:A130SeniorNotesDueMay2025Member2017-05-31000010456bax:A13SeniorNotesDueMay2029Member2019-05-310000010456bax:A13SeniorNotesDueMay2029Member2017-05-31000010456bax:A04SeniorNotesDueMay2024Member2019-05-310000010456us-gaap:NetInvestmentHedgingMember2024-09-300000010456us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000010456us-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000010456us-gaap:NondesignatedMember2024-09-300000010456us-gaap:NondesignatedMember2023-12-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-07-012024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-07-012023-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-07-012024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000010456us-gaap:NetInvestmentHedgingMember2024-07-012024-09-300000010456us-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2024-07-012024-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2024-07-012024-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-07-012023-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-01-012024-09-300000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-01-012023-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000010456us-gaap:NetInvestmentHedgingMember2024-01-012024-09-300000010456us-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2024-01-012024-09-300000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000010456us-gaap:LongTermDebtMember2024-09-300000010456us-gaap:LongTermDebtMember2023-12-310000010456us-gaap:FairValueMeasurementsRecurringMember2024-09-300000010456us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000010456us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000010456us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000010456us-gaap:FairValueMeasurementsRecurringMember2023-12-310000010456us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000010456us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000010456us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000010456us-gaap:FairValueInputsLevel2Member2024-09-300000010456us-gaap:FairValueInputsLevel2Member2023-12-310000010456us-gaap:AcquisitionRelatedCostsMember2024-06-300000010456bax:AvailableForSaleDebtSecuritiesMember2024-06-300000010456us-gaap:AcquisitionRelatedCostsMember2023-06-300000010456bax:AvailableForSaleDebtSecuritiesMember2023-06-300000010456us-gaap:AcquisitionRelatedCostsMember2024-07-012024-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2024-07-012024-09-300000010456us-gaap:AcquisitionRelatedCostsMember2023-07-012023-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2023-07-012023-09-300000010456us-gaap:AcquisitionRelatedCostsMember2024-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2024-09-300000010456us-gaap:AcquisitionRelatedCostsMember2023-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2023-09-300000010456us-gaap:AcquisitionRelatedCostsMember2023-12-310000010456bax:AvailableForSaleDebtSecuritiesMember2023-12-310000010456us-gaap:AcquisitionRelatedCostsMember2022-12-310000010456bax:AvailableForSaleDebtSecuritiesMember2022-12-310000010456us-gaap:AcquisitionRelatedCostsMember2024-01-012024-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2024-01-012024-09-300000010456us-gaap:AcquisitionRelatedCostsMember2023-01-012023-09-300000010456bax:AvailableForSaleDebtSecuritiesMember2023-01-012023-09-300000010456us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300000010456us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000010456us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000010456us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000010456us-gaap:OtherAssetsMember2024-09-300000010456us-gaap:DebtSecuritiesMember2023-01-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-

gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-07-012024-09-300000010456country:USus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2023-07-012023-09-300000010456country:USus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456country:USus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-07-012024-09-300000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2023-07-012023-09-300000010456country:USus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000010456us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000010456country:USus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000010456us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000010456country:US2024-07-012024-09-300000010456us-gaap:NonUsMember2024-07-012024-09-300000010456country:US2023-07-012023-09-300000010456us-gaap:NonUsMember2023-07-012023-09-300000010456country:USus-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456country:USus-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456country:USus-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456country:USus-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456country:USus-gaap:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456us-gaap:MedicalProductsAndTherapiesMember2024-01-012024-09-300000010456country:USus-gaap:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456us-gaap:MedicalProductsAndTherapiesMember2023-01-012023-09-300000010456country:USus-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456country:USus-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456country:USus-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456country:USus-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456country:USus-gaap:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456us-gaap:HealthcareSystemsAndTechnologiesMember2024-01-012024-09-300000010456country:USus-gaap:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456us-gaap:HealthcareSystemsAndTechnologiesMember2023-01-012023-09-300000010456country:USus-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456us-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456country:USus-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456us-gaap:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456country:USus-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456us-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456country:USus-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456us-gaap:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456country:USus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-01-012024-09-300000010456country:USus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2023-01-012023-09-300000010456country:USus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000010456us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000010456country:USus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000010456us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000010456country:US2024-01-012024-09-300000010456us-gaap:NonUsMember2024-01-012024-09-300000010456country:US2023-01-012023-09-300000010456us-gaap:NonUsMember2023-01-012023-09-300000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2024-07-012024-09-300000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2023-07-012023-09-300000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2024-01-012024-09-300000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2023-01-012023-09-300000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2024-07-012024-09-300000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2023-07-012023-09-300000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2024-01-012024-09-300000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2023-01-012023-09-300000010456us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-01-012024-09-300000010456us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-01-012023-09-300000010456us-gaap:OperatingSegmentsMember2024-07-012024-09-300000010456us-gaap:OperatingSegmentsMember2023-07-012023-09-300000010456us-gaap:OperatingSegmentsMember2024-01-012024-09-300000010456us-gaap:OperatingSegmentsMember2023-01-012023-09-300000010456us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300000010456us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000010456us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300000010456us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549_____FORM 10-Q_____â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30, 2024 â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â toÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerxAccelerated fileroNon-accelerated fileroSmaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â Â Â Â oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Â Â Â Â Yes â˜Â Â Â No xThe number of shares of the registrantâ€™s Common Stock, par value $1.00 per share, outstanding as of OctoberÂ 31, 2024 was 510,587,581 shares.BAXTER INTERNATIONAL INC.FORM 10-QFor the quarterly period ended SeptemberÂ 30, 2024TABLE OF CONTENTSPage NumberPART I.FINANCIAL INFORMATION2Item 1.Financial Statements (unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Income (Loss)3Condensed Consolidated Statements of Comprehensive Income (Loss)4Condensed Consolidated Statements of Changes in Equity5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations33Item 3.Quantitative and Qualitative Disclosures about Market Risk51Item 4.Controls and Procedures52PART II.OTHER INFORMATION53Item 1.Legal Proceedings53Item 1A.Risk Factors53Item 2.Unregistered Sales of Equity Securities and Use of Proceeds53Item 5.Other Information53Item 6.Exhibits54Signature55PART I. FINANCIAL INFORMATIONItem 1.Â Â Â Â Financial StatementsBaxter International Inc.Condensed Consolidated Balance Sheets (unaudited) (in millions, except share information)September 30,2024December 31,2023Current assets:Cash and cash equivalents $1,420Â 3,078Â Accounts receivable, net of allowances of $65 in 2024 and $62 in 20231,729Â 1,719Â Inventories2,103Â 1,918Â Prepaid expenses and other current assets720Â 706Â Current assets of discontinued operations2,892Â 2,179Â Total current assets8,864Â 9,600Â Property, plant and equipment, net 2,833Â 2,871Â Goodwill 5,783Â 5,793Â Other intangible assets, net 5,449Â 5,918Â Operating lease right-of-use assets327Â 336Â Other non-current assets 886Â 809Â Non-current assets of discontinued operations2,534Â 2,949Â Total assets $26,676Â $28,276Â Current liabilities:Current maturities of long-term debt and finance lease obligations$2,498Â $2,667Â Accounts payable 841Â 881Â Accrued expenses and other current liabilities1,772Â 1,915Â Current liabilities of discontinued operations1,089Â 1,040Â Total current liabilities 6,200Â 6,503Â Long-term debt and finance lease obligations, less current portion10,437Â 11,089Â Operating lease liabilities259Â 265Â Other non-current liabilities 1,263Â 1,400Â Non-current liabilities of discontinued operations575Â 551Â Total liabilities 18,734Â 19,808Â Commitments and contingenciesEquity:Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023683Â 683Â Common stock in treasury, at cost, 173,032,822 shares in 2024 and 175,861,893 shares in 2023(11,084) (11,230)Additional contributed capital6,391Â 6,389Â Retained earnings15,529Â 16,114Â Accumulated other comprehensive loss(3,647)(3,554)Total Baxter stockholdersâ€™ equity7,872Â 8,402Â Noncontrolling interests70Â 66Â Total equity7,942Â 8,468Â Total liabilities and equity$26,676Â $28,276Â The accompanying notes are an integral part of these condensed consolidated financial statements.2Baxter International Inc.Condensed Consolidated Statements of Income (Loss) (unaudited)(in millions, except per share data)Three months endedSeptember 30,Nine months endedSeptember 30,2024202320242023Net sales$2,699Â $2,599Â $7,883Â $7,634Â Cost of sales1,666Â 1,543Â 4,858Â 4,584Â Gross margin1,033Â 1,056Â 3,025Â 3,050Â Selling, general and administrative expenses754Â 744Â 2,206Â 2,270Â Research and development expenses129Â 133Â 379Â 391Â Other operating income, net(5)â€”Â (9)(14)Operating income 155Â 179Â 449Â 403Â Interest expense, net87Â 127Â 251Â 367Â Other (income) expense, net(1)(12)(34)15Â Income from continuing operations before income taxes69Â 64Â 232Â 21Â Income tax expense8Â 27Â 70Â 59Â Income (loss) from continuing operations61Â 37Â 162Â (38)Income (loss) from discontinued operations, net of tax83Â 2,474Â (290)2,455Â Net income (loss)144Â 2,511Â (128)2,417Â Net income attributable to noncontrolling interests included in continuing operationsâ€”Â â€”Â â€”Â â€”Â Net income attributable to noncontrolling interests included in discontinued operations4Â 3Â 9Â 6Â Net income attributable to noncontrolling interests4Â 3Â 9Â 6Â Net income (loss) attributable to Baxter stockholders$140Â $2,508Â (137)2,411Â Income (loss) from continuing operations per common shareBasic$0.12Â $0.07Â $0.32Â $(0.08)Diluted$0.12Â $0.07Â $0.32Â $(0.08)Income (loss) from discontinued operations per common shareBasic$0.15Â $4.88Â (0.59)4.84Â Diluted$0.15Â $4.86Â (0.59)4.84Â Income (loss) per common shareBasic$0.27Â $4.95Â (0.27)4.76Â Diluted$0.27Â $4.93Â (0.27)4.76Â Weighted-average number of shares outstandingBasic510Â 507Â 509Â 506Â Diluted512Â 509Â 511Â 506Â The accompanying notes are an integral part of these condensed consolidated financial statements.3Baxter International Inc.Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)(in millions)Three months endedSeptember 30,Nine months endedSeptember 30,2024202320242023Income (loss) from continuing operations$61Â $37Â $162Â $(38)Other comprehensive income (loss) from continuing operations, net of tax:Currency translation adjustments, net of tax expense (benefit) of ($19) and $12 for the three months ended September 30, 2024 and 2023, respectively, and ($3) and $2 for the nine months ended September 30, 2024 and 2023, respectively.106Â (36)(61)(39)Pension and other postretirement benefits, net of tax expense (benefit) of ($2) and zero for the three months ended September 30, 2024 and 2023, respectively, and zero and ($3) for the nine months ended September 30, 2024 and 2023, respectively.(6)(1)(2)(11)Hedging activities, net of tax expense (benefit) of ($3) and $2 for the three months ended September 30, 2024 and 2023, respectively and zero and $3 for the nine months ended September 30, 2024 and 2023, respectively.(9)5Â 2Â 10Â Total other comprehensive income (loss) from continuing operations, net of tax91Â (32)(61)(40)Comprehensive loss from continuing operations152Â 5Â 101Â (78)Income (loss) from discontinued operations, net of tax83Â 2,474Â (290)2,455Â Other comprehensive income (loss) from discontinued operationsCurrency translation adjustments, net of tax expense (benefit) of $(11) and $(1) for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $(15) and $(1) for the nine months ended September 30, 2024 and 2023, respectively. 90Â 134Â (35)162Â Pension and other postretirement benefits, net of tax expense (benefit) of zero for the three and nine months ended September 30, 2024 and 2023â€”Â (4)(1)(5)Total other comprehensive income (loss) from discontinued operations90Â 130Â (36)157Â Comprehensive income (loss) from discontinued operations173Â 2,604Â (326)2,612Â Comprehensive income (loss)325Â 2,609Â (225)2,534Â Less: Comprehensive income attributable to noncontrolling interests4Â 3Â 9Â 6Â Less: Other comprehensive loss attributable to noncontrolling interestsâ€”Â â€”Â (4)â€”Â Comprehensive income (loss) attributable to Baxter stockholders$321Â $2,606Â (230)2,528Â The accompanying notes are an integral part of these condensed consolidated financial statements.4Baxter International Inc.Condensed Consolidated Statements of Changes in Equity (unaudited)(in millions)For the three months ended September 30, 2024Baxter International Inc. stockholders' equityCommon stock sharesCommon stockCommon stock sharesin treasuryCommon stock intreasuryAdditional contributed capitalRetained earningsAccumulated other comprehensivelossTotal Baxter stockholders' equityNoncontrolling interestsTotal equityBalance as of July 1, 2024683Â $683Â 173Â $(11,104)$6,353Â $15,539Â $(3,828)$7,643Â $65Â $7,708Â Net incomeâ€”Â â€”Â â€”Â â€”Â 140Â â€”Â 140Â 4Â 144Â Other comprehensive income (loss)â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â 181Â 181Â â€”Â 181Â Stock issued under employee benefit plans and otherâ€”Â â€”Â â€”Â 20Â 38Â â€”Â â€”Â 58Â â€”Â 58Â Dividends declared on common stockâ€”Â â€”Â â€”Â â€”Â â€”Â (150)â€”Â (150)â€”Â (150)Change in noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â 1Â 1Â Balance as of SeptemberÂ 30, 2024683Â $683Â 173Â $(11,084)$6,391Â $15,529Â $(3,647)$7,872Â $70Â $7,942Â For the nine months ended SeptemberÂ 30, 2024Baxter International Inc. stockholders' equityCommon stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive lossTotal Baxter stockholders' equityNoncontrolling interestsTotal equityBalance as of January 1, 2024683Â $683Â 176Â $(11,230)$6,389Â $16,114Â $(3,554)$8,402Â $66Â $8,468Â Net lossâ€”Â â€”Â â€”Â â€”Â (137)â€”Â (137)9Â (128)Other comprehensive income (loss)â€”Â â€”Â â€”Â â€”Â (93)(93)(4)(97)Stock issued under employee benefit plans and otherâ€”Â â€”Â (3)146Â 2Â â€”Â â€”Â 148Â â€”Â 148Â Dividends declared on common stockâ€”Â â€”Â â€”Â â€”Â â€”Â (448)â€”Â (448)â€”Â (448)Change in noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (1)(1)Balance as of SeptemberÂ 30, 2024683Â $683Â 173Â $(11,084)$6,391Â $15,529Â $(3,647)$7,872Â $70Â $7,942Â For the three months ended September 30, 2023Baxter International Inc. stockholders' equityCommon stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive lossTotal Baxter stockholders' equityNoncontrolling interestsTotal equityBalance as of July 1, 2023683Â $683Â 177Â $(11,296)$6,341Â $13,655Â $(3,814)$5,569Â $62Â $5,631Â Net incomeâ€”Â â€”Â â€”Â â€”Â 2,508Â â€”Â 2,508Â 3Â 2,511Â Other comprehensive income (loss)â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â 98Â 98Â â€”Â 98Â Stock issued under employee benefit plans and otherâ€”Â â€”Â (1)47Â 27Â â€”Â â€”Â 74Â â€”Â 74Â Dividends declared on common stockâ€”Â â€”Â â€”Â â€”Â â€”Â (148)â€”(148)â€”Â (148)Balance as of September 30, 2023683Â $683Â 176Â $(11,249)$6,368Â $16,015Â $(3,716)$8,101Â $65Â $8,166Â For the nine months ended SeptemberÂ 30, 2023Baxter International Inc. stockholders' equityCommon stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive income lossTotal Baxter stockholders' equityNoncontrolling interestsTotal equityBalance as of January 1, 2023683Â $683Â 179Â $(11,389)$6,322Â $14,050Â $(3,833)$5,833Â $62Â $5,895Â Net incomeâ€”Â â€”Â â€”Â â€”Â â€”Â 2,411Â â€”Â 2,411Â 6Â 2,417Â Other comprehensive income (loss)â€”Â â€”Â â€”Â â€”Â â€”Â 117Â 117Â â€”Â 117Â Stock issued under employee benefit plans and otherâ€”Â â€”Â (3)140Â 46Â â€”Â â€”Â 186Â â€”Â 186Â Dividends declared on common stockâ€”Â â€”Â â€”Â â€”Â â€”Â (446)â€”Â (446)â€”Â (446)Change in noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (3)(3)Balance as of SeptemberÂ 30, 2023683Â $683Â 176Â $(11,249)$6,368Â $16,015Â $(3,716)$8,101Â $65Â $8,166Â The accompanying notes are an integral part of these condensed consolidated financial statements.5 Baxter International Inc.Condensed Consolidated Statements of Cash Flows (unaudited)(in millions)Nine Months Ended September 30,20242023Cash flows from operationsNet income (loss)(128)2,417Â Less: Income (loss) from discontinued operations, net of tax(290)2,455Â Income (loss) from continuing operations162Â (38)Adjustments to reconcile net loss to cash flows from operations:Depreciation and amortization752Â 720Â Deferred income taxes(136)(239)Stock compensation75Â 90Â Net periodic pension and other postretirement costs(21)(19)Other long-lived asset impairments42Â 3Â Other20Â 25Â Changes in balance sheet items:Accounts receivable, net(17)52Â Inventories(180)(120)Prepaid expenses and other current assets(61)(41)Accounts payable 3Â 161Â Accrued expenses and other current liabilities(192)261Â Other(71)(63)Cash flows from operations - continuing operations376Â 792Â Cash flows from operations - discontinued operations155Â 403Â Cash flows from operations531Â 1,195Â Cash flows from investing activitiesCapital expenditures(314)(340)Acquisitions of developed technology and investments(9)(4)Proceeds from sale of marketable equity securities34Â â€”Â Other investing activities, net8Â 19Â Cash flows from investing activities - continuing operations(281)(325)Cash flows from investing activities - discontinued operations(140)3,768Â Cash flows from investing activities(421)3,443Â Cash flows from financing activitiesRepayments of debt(827)(353)Net increases in debt with original maturities of three months or lessâ€”Â 214Â Cash dividends on common stock(443)(439)Proceeds from stock issued under employee benefit plans63Â 86Â Other financing activities, net(15)(62)Cash flows from financing activities(1,222)(554)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations(45)(37)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - discontinued operations39Â 23Â Increase (decrease) in cash, cash equivalents and restricted cash(1,118)4,070Â Cash, cash equivalents and restricted cash at beginning of period (1)3,198Â 1,722Â Cash, cash equivalents and restricted cash at end of period (1)2,080Â 5,792Â Less cash and cash equivalents of discontinued operations658Â 72Â Cash, cash equivalents and restricted cash of continuing operations$1,422Â $5,720Â (1) The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of SeptemberÂ 30, 2024, DecemberÂ 31, 2023, and SeptemberÂ 30, 2023 (in millions):September 30, 2024December 31, 2023September 30, 2023Cash and cash equivalents$1,420Â $3,078Â $5,716Â Restricted cash included in other non-current assets2Â 4Â 4Â Cash, cash equivalents and restricted cash$1,422Â $3,082Â $5,720Â The accompanying notes are an integral part of these condensed consolidated financial statements.6Baxter International Inc.Notes to Condensed Consolidated Financial Statements (unaudited)1. BASIS OF PRESENTATIONThe unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (2023 Annual Report).In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business, which will be known as Vantive, for an aggregate purchase price of $3.80 billion. After giving effect to certain closing adjustments, we currently expect to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the range of $3.15Â billion to $3.25 billion. The transaction is currently expected to close in late 2024 or early 2025, subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions. We determined that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations presentation. See Note 2 for additional information.Hurricane HeleneIn September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations at that facility. We are actively working with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we work to fully restore our North Cove manufacturing operations. Our insurance policies generally cover the repair or replacement of our assets that suffer loss or damage, less applicable deductibles and subject to any coverage limits and exclusions, and we are working closely with our insurance carriers and claims adjusters to ascertain the full amount of insurance proceeds due to us as a result of the damages and the loss we suffered as a result of Hurricane Helene (which proceeds are likely to be less than the applicable losses). Our insurance policies also provide coverage for interruption to our business, including lost profits, and reimbursement for other expenses and costs that have been incurred relating to the damages and losses suffered. In the third quarter of 2024, we recorded $25Â million of pre-tax net charges related to damages caused by Hurricane Helene. This consisted of $44Â million related to the write-off of damaged inventory and fixed assets offset by a receivable of $19Â million, which is the amount of the loss, net of our insurance deductible, related to insurance recoveries expected as a result of those asset write-offs. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three and nine month periods ended SeptemberÂ 30, 2024. At this time, the full amount of combined property damage and business interruption costs cannot be estimated and any additional insurance recoveries are not realizable, and accordingly, no additional amounts have been recorded as of SeptemberÂ 30, 2024. On November 1, 2024, we received $101Â million of cash related to insurance proceeds which included recoveries for expenses incurred after the balance sheet date. We expect to receive additional related insurance proceeds in the future.Risks and Uncertainties Supply Constraints and Global Economic ConditionsIn recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and 7electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing of raw materials and on transportation costs, some of these challenges (such as additional transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future.2. DISCONTINUED OPERATIONSA component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation for two strategic actions, as described below. Discontinued Operations - Kidney CareOn August 12, 2024, we entered into an EPA to sell our Kidney Care business, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. That business, which is comprised of our Kidney Care segment, provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. Pursuant to the EPA, we expect to sell the Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion. After giving effect to certain adjustments, we currently expect to receive

approximately $3.50 billion of net pre-tax cash proceeds (approximately $3.15Â billion to $3.25 billion after tax). The transaction is currently expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. We intend to use the net after-tax proceeds from this transaction to repay certain of our debt obligations, consistent with our stated capital allocation priorities.We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the pending sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.Upon closing of the pending sale of the Kidney Care business, Baxter and Vantive will enter into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a long-term Master Services Agreement, a Distribution Agreement, a Transition Services Agreement (Kidney Care TSA), and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities will provide each other with certain dialysis-related products, other products, product components and fulfillment services for a period up to 10 years post-closing (with certain extension rights as provided therein). Pursuant to the Kidney Care TSA, Baxter and the entities that will be divested in connection with the pending Kidney Care sale (the Kidney Care divested entities) will provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights as provided therein) to help ensure business continuity and help minimize disruptions to the entities' operations post-closing. Services to be provided under the TSA include IT, supply chain and certain other corporate and administrative services. Pursuant to the EPA, Baxter will retain (i) the manufacture and sale of saline solutions and (ii) the plastics operations of Baxter and its subsidiaries at its Mountain Home, Arkansas facility, which is not part of the Kidney Care segment. Discontinued Operations - BioPharma Solutions On September 29, 2023, we sold our BioPharma Solutions (BPS) business to Advent International and Warburg Pincus (collectively, the BPS buyers). The BPS business, which was historically reported within our former Americas segment, provided contract manufacturing and development services, which include sterile fill-finish manufacturing and support services across clinical and commercial applications, primarily serving customers in the pharmaceutical industry. BPS was historically 8operated through our former, wholly-owned subsidiaries Baxter Pharmaceutical Solutions LLC, a Delaware limited liability company, and Baxter Oncology GmbH, a German limited liability company (collectively, the BPS divested entities).We concluded that our BPS business met the criteria to be classified as held-for-sale in May 2023. We analyzed the quantitative and qualitative factors relevant to the divestiture of our BPS business, including its significance to our overall net income and earnings per share, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.At closing of the transaction, Baxter entered into a Transition Services Agreement (BPS TSA) and a Master Commercial Manufacturing and Supply Agreement (BPS MSA) with the divested entities. Pursuant to the BPS TSA, Baxter and the BPS divested entities provide to each other, on an interim basis, specific transition services for up to 24 months post-closing to help ensure business continuity and minimize disruptions. Services provided under the BPS TSA include finance, information technology, human resources, integrated supply chain, and certain other administrative services. Pursuant to the BPS MSA, the BPS divested entities provide development, manufacturing, regulatory, and other related services for certain Baxter pharmaceutical products for up to 5 years post-closing (with certain extension rights as provided therein).Results of Discontinued Operations and Assets and Liabilities of Discontinued OperationsThe following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three and nine months ended SeptemberÂ 30, 2024 and 2023:Kidney CareBioPharma SolutionsTotalThree Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,(in millions)2024202320242023Net sales$1,155Â $1,109Â $â€”Â $191Â $1,155Â $1,300Â Cost of sales731Â 1,048Â â€”Â 81Â 731Â 1,129Â Gross margin424Â 61Â â€”Â 110Â 424Â 171Â Selling, general and administrative expenses278Â 258Â â€”Â 15Â 278Â 273Â Research and development expenses41Â 33Â â€”Â 1Â 41Â 34Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)106Â (230)â€”Â 94Â 106Â (136)Interest expense, net1Â 1Â â€”Â â€”Â 1Â 1Â Other (income) expense, net(8)5Â â€”Â 2Â (8)7Â Income (loss) from discontinued operations before gain on disposition and income taxes113Â (236)â€”Â 92Â 113Â (144)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)30Â (250)â€”Â 522Â 30Â 272Â Income from discontinued operations, net of tax83Â 14Â â€”Â 2,460Â 83Â 2,474Â Less: Net income attributable to noncontrolling interest included in discontinued operations4Â 3Â â€”Â â€”Â 4Â 3Â Net income attributable to Baxter stockholders included in discontinued operations$79Â $11Â $â€”Â $2,460Â $79Â $2,471Â 9Kidney CareBioPharma SolutionsTotalNine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,20242023202420232024Net sales$3,375Â $3,294Â $â€”Â $469Â $3,375Â $3,763Â Cost of sales2,125Â 2,841Â â€”Â 216Â 2,125Â 3,057Â Gross margin1,250Â 453Â â€”Â 253Â 1,250Â 706Â Selling, general and administrative expenses874Â 691Â â€”Â 44Â 874Â 735Â Research and development expenses140Â 104Â â€”Â 2Â 140Â 106Â Goodwill impairment430Â â€”Â â€”Â â€”Â 430Â â€”Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)(193)(342)â€”Â 207Â (193)(135)Interest expense, netâ€”Â 2Â â€”Â â€”Â â€”Â 2Â Other (income) expense, net(2)18Â â€”Â 2Â (2)20Â Income (loss) from discontinued operations before income taxes(191)(362)â€”Â 205Â (191)(157)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)99Â (258)â€”Â 536Â 99Â 278Â Income (loss) from discontinued operations, net of tax(290)(104)â€”Â 2,559Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations9Â 6Â â€”Â â€”Â 9Â 6Â Net income (loss) attributable to Baxter stockholders included in discontinued operations(299)(110)$â€”Â $2,559Â (299)2,449Â For the three and nine months ended SeptemberÂ 30, 2024, selling, general and administrative expenses (SG&A) includes $69Â million and $236Â million, respectively, of separation-related costs incurred in connection with the pending sale of our Kidney Care business. For the three months ended September 30, 2023, SG&A includes separation-related costs of $67Â million and $8Â million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively. For the nine months ended September 30, 2023, SG&A includes separation-related costs of $108Â million and $15Â million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively.10The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023:(in millions)September 30, 2024December 31, 2023Cash and cash equivalents$658Â $116Â Accounts receivable, net of allowances1,045Â 971Â Inventories960Â 906Â Prepaid expenses and other current assets229Â 186Â Current assets of discontinued operations2,892Â 2,179Â Property, plant and equipment, net1,542Â 1,562Â Goodwill276Â 721Â Other intangible assets, net147Â 161Â Operating lease right-of-use assets209Â 188Â Other non-current assets360Â 317Â Non-current assets of discontinued operations2,534Â 2,949Â Assets of discontinued operations$5,426Â $5,128Â Current maturities of finance lease obligations$â€”Â $1Â Accounts payable396Â 360Â Accrued expenses and other current liabilities693Â 679Â Current liabilities of discontinued operations1,089Â 1,040Â Long-term finance lease obligations, less current portion40Â 41Â Operating lease liabilities186Â 173Â Other non-current liabilities349Â 337Â Non-current liabilities of discontinued operations575Â 551Â Liabilities of discontinued operations$1,664Â $1,591Â 3. SUPPLEMENTAL FINANCIAL INFORMATIONAllowance for Doubtful AccountsThe following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Balance at beginning of period$67Â $61Â $62Â $50Â Charged to costs and expenses4Â 2Â 4Â 17Â Write-offs(3)1Â (6)(2)Currency translation adjustments(3)2Â 5Â 1Â Balance at end of period$65Â $66Â $65Â $66Â 11Inventories (in millions)September 30,2024December 31,2023Raw materials$532Â $530Â Work in process256Â 234Â Finished goods1,315Â 1,154Â Inventories$2,103Â $1,918Â Property, Plant and Equipment, Net (in millions)September 30,2024December 31,2023Property, plant and equipment, at cost$7,605Â $7,650Â Accumulated depreciation(4,772)(4,779)Property, plant and equipment, net$2,833Â $2,871Â Interest Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Interest expense, net of capitalized interest$101Â $136Â $308Â $394Â Interest income(14)(9)(57)(27)Interest expense, net$87Â $127Â $251Â $367Â Other (Income) Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Foreign exchange losses, net$7Â $10Â $21Â 49Â Pension and other postretirement benefit plans(9)(15)(34)(37)Change in fair value of marketable equity securitiesâ€”Â (3)(3)3Â Non-marketable investment impairmentsâ€”Â â€”Â â€”Â 13Â Other, net1Â (4)(18)(13)Other (income) expense, net(1)(12)(34)15Â Non-Cash Operating and Investing ActivitiesRight-of-use operating lease assets obtained in exchange for lease obligations for the nine months ended SeptemberÂ 30, 2024 and 2023 were $54 million and $55Â million, respectively. Purchases of property, plant and equipment included in accounts payable as of SeptemberÂ 30, 2024 and 2023 were $34 million and $30 million, respectively. 124. GOODWILL AND OTHER INTANGIBLE ASSETS, NETGoodwillThe following is a reconciliation of goodwill by segment.(in millions)Medical Products and TherapiesHealthcare Systems and TechnologiesPharmaceuticalsTotalBalance as of December 31, 2023$1,241Â $3,989Â $563Â $5,793Â Currency translation (7)â€”Â (3)(10)Balance as of September 30, 2024$1,234Â $3,989Â $560Â $5,783Â Other intangible assets, netThe following is a summary of our other intangible assets.Indefinite-lived intangible assets(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and DevelopmentTotalSeptember 30, 2024Gross other intangible assets$3,390Â $3,182Â $963Â $87Â $680Â $157Â $8,459Â Accumulated amortization(824)(2,027)(92)(67)â€”Â â€”Â (3,010)Other intangible assets, net$2,566Â $1,155Â $871Â $20Â $680Â $157Â $5,449Â December 31, 2023Gross other intangible assets$3,390Â $3,181Â $964Â $86Â $680Â $157Â $8,458Â Accumulated amortization(654)(1,782)(38)(66)â€”Â â€”Â (2,540)Other intangible assets, net$2,736Â 1,399Â 926Â 20Â 680Â 157Â 5,918Â Intangible asset amortization expense was $159 million and $147 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $471 million and $434 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. 5. FINANCING ARRANGEMENTS Credit Facilities On July 17, 2024, we entered into a credit agreement in which a group of banks have committed to provide us senior unsecured term loans in an aggregate principal amount of up to $2.05Â billion ("the bridge facility"). Borrowings under the bridge facility will be available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the pending sale of our Kidney Care business. Borrowings under the bridge facility will bear interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We will also incur a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banksâ€™ funding commitments under the bridge facility will terminate upon the earliest to occur of: (i) our consummation of the debt repayments and tax payments described above without us having borrowed under the bridge facility, (ii) our election to terminate the commitments under the bridge facility, (iii) our receipt of net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business), (iv) the occurrence of three drawings under the bridge facility, and (v) December 31, 2024. Outstanding borrowings under the bridge facility will mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we are required to use the net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contains financial and other covenants, including a net leverage covenant, and provides for customary events of default. There were no borrowings outstanding under this bridge facility as of SeptemberÂ 30, 2024.13In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. The amendment further provided for the reduction of the capacity under our U.S dollar-denominated revolving credit facility from $2.50Â billion to $2.00Â billion on the earlier of September 30, 2024 or the date of the sale of our Kidney Care business. Costs incurred in connection with the amendment were not material.In addition to our U.S. dollar-denominated revolving credit facility with a current capacity of $2.00Â billion, our Euro-denominated revolving credit facility has a capacity of â‚¬200 million. Each of the facilities matures in 2026. There were no borrowings outstanding under these credit facilities as of SeptemberÂ 30, 2024 or DecemberÂ 31, 2023. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of SeptemberÂ 30, 2024 we have capacity to draw on the full amounts under our credit facilities.In the first nine months of 2024, we repaid $822Â million of senior notes at maturity.6. COMMITMENTS AND CONTINGENCIES We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, our total recorded reserves with respect to legal and environmental matters were $41 million and $25 million, respectively.We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and othersâ€™ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.EnvironmentalWe are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, our environmental reserves, which are measured on an undiscounted basis, were $30 million and $15 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.General LitigationIn March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified 14amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 25 lawsuits (after giving effect to the amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. We acquired Hill-Rom Holdings, Inc. (Hillrom) on December

13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws.On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery.On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020â€ and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint.7. STOCKHOLDERSâ€™ EQUITYCash DividendsCash dividends declared per share for the three months ended SeptemberÂ 30, 2024 and 2023 were $0.29 and for the nine months ended SeptemberÂ 30, 2024 and 2023 were $0.87. 15Stock Repurchase ProgramsIn July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first nine months of 2024 and 2023 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of SeptemberÂ 30, 2024. 8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Comprehensive income includes all changes in stockholdersâ€™ equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the nine months ended SeptemberÂ 30, 2024 and 2023.Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of DecemberÂ 31, 2023$(2,985)$(452)(120)3Â $(3,554)Other comprehensive income (loss) before reclassifications(92)â€”Â 2Â â€”Â (90)Amounts reclassified from AOCI (a)â€”Â (3)â€”Â â€”Â (3)Net other comprehensive income (loss) (92)(3)2Â â€”Â (93)Balance as of September 30, 2024$(3,077)$(455)(118)3Â $(3,647)Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of December 31, 2022$(3,386)$(331)(119)3Â $(3,833)Other comprehensive income (loss) before reclassifications(62)â€”Â 15Â â€”Â (47)Amounts reclassified from AOCI (a)185Â (16)(5)â€”Â 164Â Net other comprehensive income (loss) 123Â (16)10Â â€”Â 117Â Balance as of September 30, 2023$(3,263)$(347)(109)3Â $(3,716)(a)Â Â Â Â See table below for details about these reclassifications.16The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three and nine months ended SeptemberÂ 30, 2024 and 2023.Amounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2024Nine Months Ended September 30, 2024Location of impact in income statementPension and OPEB itemsAmortization of net losses and prior service costs or credits$1Â $4Â Other (income) expense, netLess: Tax effectâ€”Â (1)Income tax expense$1Â $3Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$4Â $9Â Cost of salesInterest rate contracts(1)(4)Interest expense, netFair value hedgesâ€”Â (5)Other (income) expense, net3Â â€”Â Total before taxLess: Tax effect(1)â€”Â Income tax expense$2Â $â€”Â Net of taxTotal reclassifications for the period$3Â $3Â Total net of taxAmounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2023Nine Months Ended September 30, 2023Location of impact in income statementCTAReclassification of cumulative translation loss to earnings from BPS divestiture(185)(185)Income from discontinued operations, net of taxLess: Tax effectâ€”Â â€”Â Income from discontinued operations, net of tax(185)(185)Net of taxPension and OPEB itemsAmortization of net losses and prior service costs or credits$5Â $15Â Other (income) expense, netPension settlement from BPS divestiture4Â 4Â Income from discontinued operations, net of tax9Â 19Â Total before taxLess: Tax effectâ€”Â (3)Income tax expense$9Â $16Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$3Â $10Â Cost of salesInterest rate contracts(1)(4)Interest expense, net2Â 6Â Total before taxLess: Tax effectâ€”Â (1)Income tax expense$2Â $5Â Net of taxTotal reclassifications for the period(174)(164)Total net of tax(a)Â Â Â Â Amounts in parentheses indicate reductions to net incomeRefer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity.9. REVENUESRevenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the 17customer and is the unit of account in the contract. A contractâ€™s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contractâ€™s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days.Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.As of SeptemberÂ 30, 2024, we had $2.75 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products and Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue over the remainder of 2024, 25% in 2025, 20% in each of 2026 and 2027 and 10% thereafter.Significant JudgmentsRevenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three and nine months ended SeptemberÂ 30, 2024 and 2023 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement.Contract BalancesThe timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.54Â billion as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled 18contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years. The following table summarizes our contract assets:(in millions)September 30,2024December 31,2023Contract manufacturing services$4Â $4Â Software sales46Â 45Â Bundled equipment and consumable medical products contracts95Â 116Â Contract assets$145Â $165Â Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months. The following table summarizes contract liability activity for the nine months ended SeptemberÂ 30, 2024 and 2023. The contract liability balance represents the transaction price allocated to the remaining performance obligations.Nine Months Ended September 30,(in millions)20242023Balance at beginning of period$169Â $173Â New revenue deferrals383Â 401Â Revenue recognized upon satisfaction of performance obligations(389)(407)Currency translation(3)2Â Balance at end of period$160Â $169Â For the nine months ended SeptemberÂ 30, 2024 and 2023, $94 million and $111 million of revenue was recognized that was included in contract liabilities as of DecemberÂ 31, 2023 and 2022, respectively.The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:(in millions)September 30,2024December 31,2023Prepaid expenses and other current assets$54Â $53Â Other non-current assets91Â 112Â Contract assets$145Â $165Â Accrued expenses and other current liabilities$124Â $128Â Other non-current liabilities36Â 41Â Contract liabilities$160Â $169Â Disaggregation of Net SalesRefer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location. 19Lease RevenueWe lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.The components of lease revenue for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were:Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Sales-type lease revenue$3Â $2Â $8Â $6Â Operating lease revenue102Â 98Â 288Â 302Â Variable lease revenue10Â 3Â 22Â 15Â Total lease revenue$115Â $103Â $318Â $323Â Our net investment in sales-type leases was $36 million as of SeptemberÂ 30, 2024, of which $5 million originated in 2020 and prior, $10 million in 2021, $5Â million in 2022, $7 million in 2023, and $9Â million in 2024.10. BUSINESS OPTIMIZATION CHARGESIn recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. The related costs of those actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $5 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those related to our newly implemented operating model, intended to simplify and streamline our operations, and to the extent further cost savings opportunities are identified (including after completion of the pending Kidney Care sale), we would incur additional restructuring charges and costs to implement business optimization programs in future periods.During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following charges related to business optimization programs.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Restructuring charges$15Â $41Â $36Â $140Â Costs to implement business optimization programs3Â 7Â 13Â 27Â Total business optimization charges$18Â $48Â $49Â $167Â For segment reporting purposes, business optimization charges are unallocated expenses.Costs to implement business optimization programs for the three and nine months ended SeptemberÂ 30, 2024 and 2023, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense.20During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following restructuring charges.Three months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$2Â $10Â $12Â Contract termination and other costsâ€”Â 3Â 3Â Total restructuring charges$2Â $13Â $15Â Three months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$6Â $29Â $4Â $39Â Contract termination and other costsâ€”Â 2Â â€”Â 2Â Total restructuring charges$6Â $31Â $4Â $41Â Nine months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$4Â $25Â $29Â Contract termination and other costs1Â 6Â 7Â Total restructuring charges$5Â $31Â $36Â Nine months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$25Â $89Â $10Â $124Â Contract termination and other costsâ€”Â 5Â â€”Â 5Â Asset impairments3Â 8Â â€”Â 11Â Total restructuring charges$28Â $102Â $10Â $140Â For the three and nine months ended SeptemberÂ 30, 2024, $7Â million and $14Â million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to business optimization initiatives within our Healthcare Systems and Technologies segment. Additionally, for the nine months ended September 30, 2024, $7Â million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to our recent implementation of a new operating model intended to simplify and streamline our operations.For the three and nine months ended SeptemberÂ 30, 2023, $11Â million and $79Â million, respectively, of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our previously announced new operating model intended to simplify and streamline our operations. The following table summarizes activity in the liability related to our restructuring initiatives.(in millions)Liability balance as of December 31, 2023$95Â Charges42Â Payments(59)Reserve adjustments(8)Currency translation4Â Liability balance as of September 30, 2024$74Â Substantially all of our restructuring liabilities as of SeptemberÂ 30, 2024 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025.2111. PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMSThe following is a summary of net periodic benefit cost relating to our pension and OPEB plans.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232023Pension benefitsService cost$4Â $6Â $13Â $18Â Interest cost33Â 45Â 123Â 137Â Expected return on plan assets(43)(57)(160)(166)Amortization of net losses and prior service costs4Â 1Â 11Â 4Â Net periodic pension

cost(2)(5)(13)(7)OPEBInterest cost$2Â $2Â $6Â $6Â Amortization of net loss and prior service credit(5)(6)(14)(18)Net periodic OPEB cost (income)(3)(4)(8)(12)12. INCOME TAXESOur effective income tax rate was 11.6% and 42.2% for the three months ended September 30, 2024 and 2023, respectively, and 30.2% and 281.0% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards. For the three months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix, the tax impacts of the write-off of damaged inventory and fixed assets at our North Cove facility caused by Hurricane Helene, and a change in our assertion on the reinvested foreign earnings related to the pending sale of our Kidney Care segment allocated to continuing operations, partially offset by a $26Â million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment. For the nine months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $26Â million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, an increase in income tax expense resulting from internal reorganization transactions related to the pending sale of our Kidney Care segment, and an increase in our liabilities for various uncertain tax positions, partially offset by a favorable geographic earnings mix.Â Â Â Â For the three months ended September 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, partially offset by a favorable geographic earnings mix.For the nine months ended SeptemberÂ 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $30Â million increase in the valuation allowance related to a deferred tax asset from a tax basis step-up that arose from previously enacted Swiss tax reform legislation, an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and excess tax shortfalls on stock compensation awards. 13. EARNINGS PER SHAREThe numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.22The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Income (loss) from continuing operations$61Â $37Â $162Â $(38)Less: Net income attributable to noncontrolling interests included in continuing operationsâ€”Â â€”Â â€”Â â€”Â Income (loss) from continuing operations attributable to Baxter stockholders61Â 37Â 162Â (38)Income (loss) from discontinued operations83Â 2,474Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations4Â 3Â 9Â 6Â Income (loss) from discontinued operations attributable to Baxter stockholders79Â 2,471Â (299)2,449Â Net income (loss) attributable to Baxter stockholders$140Â $2,508Â (137)2,411Â The following table is a reconciliation of basic shares and diluted shares.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Basic shares510Â 507Â 509Â 506Â Effect of dilutive securities2Â 2Â 2Â â€”Â Diluted shares512Â 509Â 511Â 506Â Basic and diluted shares are the same for nine months ended September 30, 2023 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 18 million and 19 million shares issuable under equity awards for the three and nine months ended SeptemberÂ 30, 2024, and 18 million and 25 million shares issuable under equity awards for the three and nine months ended SeptemberÂ 30, 2023, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. 14. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIESWe operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Renminbi, Japanese Yen, Swedish Krona, Mexican Peso, Australian Dollar, Canadian Dollar, Turkish Lira, and Indian Rupee. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.23Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.Cash Flow HedgesWe may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.The notional amounts of foreign exchange contracts designated as cash flow hedges were $225 million and $340 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at SeptemberÂ 30, 2024 is 12 months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. Fair Value HedgesWe periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.There were no outstanding interest rate contracts designated as fair value hedges as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.In October 2023, we entered into a foreign currency forward contract with a notional amount of $798Â million and designated that derivative as a fair value hedge of our â‚¬750Â million of 0.40% senior notes due May 2024. This forward contract matured in May 2024.Net Investment HedgesIn May 2017, we issued â‚¬600 million of 1.3% senior notes due May 2025. In May 2019, we issued â‚¬750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. In May 2019, we issued â‚¬750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above. As of SeptemberÂ 30, 2024, we had an accumulated pre-tax unrealized translation gain in AOCI of $18 million related to the Euro-denominated senior notes.24DedesignationsIf it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. There were no cash flow hedge dedesignations in the first nine months of 2024 or 2023 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first nine months of 2024 or 2023. If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. There were no net investment hedges terminated during the first nine months of 2024 or 2023.Undesignated Derivative InstrumentsWe use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.The total notional amount of undesignated derivative instruments was $527Â million as of SeptemberÂ 30, 2024 and $305 million as of DecemberÂ 31, 2023.Gains and Losses on Hedging Instruments and Undesignated Derivative InstrumentsThe following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)2024202320242023Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(1)(1)Foreign exchange contracts(9)9Â Cost of sales4Â 3Â Net investment hedges(68)48Â Other (income) expense, netâ€”Â â€”Â Total(77)57Â $3Â $2Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, net6Â (1)Total$6Â $(1)25The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the nine months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)2024202320242023Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(4)(4)Foreign exchange contracts5Â 19Â Cost of sales9Â 10Â Fair value hedgesForeign exchange contracts(3)â€”Â Other (income) expense, net(5)â€”Â Net investment hedges(19)10Â Other (income) expense, netâ€”Â â€”Â Total(17)29Â $â€”Â $6Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Fair value hedgesForeign exchange contractsOther (income) expense, net(24)â€”Â Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, netâ€”Â (9)Total(24)(9)As of SeptemberÂ 30, 2024, $8Â million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. Derivative Assets and LiabilitiesThe following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of SeptemberÂ 30, 2024.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$2Â Accrued expenses and other current liabilities$2Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assetsâ€”Â Accrued expenses and other current liabilities5Total derivative instruments$2Â $726The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of DecemberÂ 31, 2023.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$41Â Accrued expenses and other current liabilities$â€”Â Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assets4Â Accrued expenses and other current liabilities5Â Total derivative instruments$45Â $5Â While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.September 30, 2024December 31, 2023(in millions)AssetLiabilityAssetLiabilityGross amounts recognized in the condensed consolidated balance sheets$2Â $7Â $45Â $5Â Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(1)(1)(4)(4)Total$1Â $6Â $41Â $1Â The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:Carrying amount of hedged itemCumulative amount of fair value hedging adjustment includedÂ in the carrying amount of the hedged item (a)(in millions)Balance as of September 30, 2024Balance as of December 31, 2023Balance as of September 30, 2024Balance as of December 31, 2023Long-term debt$100Â $100Â $3Â $3Â (a) These fair value hedges were terminated in 2018 and earlier periods.2715. FAIR VALUE MEASUREMENTSThe following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.Basis of fair value measurement(in millions)Balance as of September 30, 2024Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$2Â $â€”Â $2Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities13Â 13Â â€”Â â€”Â Total$16Â $13Â $2Â $1Â LiabilitiesForeign exchange contracts$7Â $â€”Â $7Â $â€”Â Contingent payments related to acquisitions12Â â€”Â â€”Â 12Â Total$19Â $â€”Â $7Â $12Â Basis of fair value measurement(in millions)Balance as of December 31, 2023Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$45Â $â€”Â $45Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities44Â 44Â â€”Â â€”Â Total$90Â $44Â $45Â $1Â LiabilitiesForeign exchange contracts$5Â $â€”Â $5Â $â€”Â Contingent payments related to acquisitions14Â â€”Â â€”Â 14Â Total$19Â $â€”Â $5Â $14Â As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, cash and cash equivalents of $1.42 billion and $3.08 billion, respectively, included money market funds of approximately $427 million and $1.63 billion, respectively, which are considered Level 2 in the fair value hierarchy.For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue 28estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.Three Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $21Â $17Â Payments(2)â€”Â (2)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â Nine Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $84Â $27Â Change in fair value recognized in earningsâ€”Â â€”Â (14)(5)Transfers out of Level

3â€”Â â€”Â â€”Â (5)Payments(2)â€”Â (51)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â During the nine months ended September 30, 2023, available-for-sale debt securities were reclassified from Level 3, upon conversion to marketable equity securities, which are classified as Level 1 in the fair value hierarchy, upon initial public offerings of the investees.Financial Instruments Not Measured at Fair ValueIn addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.Book valuesFair values(a)(in millions)20242023202420232LiabilitiesCurrent maturities of long-term debt and finance lease obligations$2,498Â $2,667Â $2,493Â $2,621Â Long-term debt and finance lease obligations10,437Â 11,089Â 9,612Â 10,026Â (a)Â Â Â Â These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.Investments Without Readily Determinable Fair ValuesThe carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $33 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. Those investments are included in Other non-current assets on our condensed 29consolidated balance sheets. During the first nine months of 2023, several of our investees either completed or were in the process of undertaking new financing rounds at lower enterprise valuations as compared to their valuations at the time of our investments. As a result, we recognized $8Â million of impairments of equity investments without readily determinable fair values in the prior year period. In addition, we recognized a $5Â million impairment of a convertible debt investment, which is accounted for as an available-for-sale security, during the first nine months of 2023. The fair value measurements of investments in non-marketable equity and convertible debt securities are classified as Level 3 in the fair value hierarchy because they involve significant unobservable inputs.16. SEGMENT INFORMATIONIn the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this new operating model, our business is currently comprised of four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care (which we are planning to divest through the pending sale and accordingly, the results are reported in discontinued operations as discussed in Note 1). The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities and royalty income under a business development arrangement that ended in early 2023 when we acquired the related product rights.Disaggregation of Net SalesThe following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below.Three Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$613Â $457Â $1,070Â $570Â $433Â $1,003Â Advanced Surgery149Â 123Â 272Â 139Â 116Â 255Â Medical Products and Therapies762Â 580Â 1,342Â 709Â 549Â 1,258Â Care and Connectivity Solutions335Â 121Â 456Â 317Â 126Â 443Â Front Line Care222Â 74Â 296Â 234Â 67Â 301Â Healthcare Systems and Technologies557Â 195Â 752Â 551Â 193Â 744Â Injectables and Anesthesia178Â 143Â 321Â 195Â 156Â 351Â Drug Compoundingâ€”Â 267Â 267Â â€”Â 229Â 229Â Pharmaceuticals178Â 410Â 588Â 195Â 385Â 580Â Other3Â 14Â 17Â 12Â 5Â 17Â Total Baxter$1,500Â $1,199Â $2,699Â $1,467Â $1,132Â $2,599Â 30Nine Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$1,718Â $1,363Â $3,081Â $1,654Â $1,264Â $2,918Â Advanced Surgery446Â 366Â 812Â 433Â 340Â 773Â Medical Products and Therapies2,164Â 1,729Â 3,893Â 2,087Â 1,604Â 3,691Â Care and Connectivity Solutions945Â 365Â 1,310Â 926Â 381Â 1,307Â Front Line Care635Â 222Â 857Â 681Â 230Â 911Â Healthcare Systems and Technologies1,580Â 587Â 2,167Â 1,607Â 611Â 2,218Â Injectables and Anesthesia566Â 424Â 990Â 550Â 437Â 987Â Drug Compoundingâ€”Â 778Â 778Â â€”Â 665Â 665Â Pharmaceuticals566Â 1,202Â 1,768Â 550Â 1,102Â 1,652Â Other30Â 25Â 55Â 56Â 17Â 73Â Total Baxter$4,340Â $3,543Â $7,883Â $4,300Â $3,334Â $7,634Â Geographic Sales InformationOur net sales are attributed to the following geographic regions based on the location of the customer.Three Months Ended September 30,Nine Months Ended September 30,20242023202420232United States$1,500Â $1,467Â $4,340Â $4,300Â Emerging markets1347Â 353Â 1,001Â 985Â Rest of world2852Â 779Â 2,542Â 2,349Â Total Baxter$2,699Â $2,599Â $7,883Â $7,634Â 1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.Segment Operating IncomeWe use segment operating income to evaluate the performance of our segments and to make resource allocation decisions. Segment operating income represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of segment operating income to income from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the Kidney Care segment in the pending sale, are 31now presented as unallocated corporate costs. The following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232Medical Products and Therapies$268Â $245Â $733Â $706Â Healthcare Systems and Technologies136Â 115Â 323Â 327Â Pharmaceuticals58Â 108Â 211Â 284Â Other2Â 6Â 15Â 19Â Total464Â 474Â 1,282Â 1,336Â Unallocated corporate costs(73)(73)(227)(285)Intangible asset amortization expense(159)(147)(471)(434)Legal matters(17)(13)(17)(13)Business optimization items(18)(48)(49)(167)Acquisition and integration items(5)(2)(16)(2)European Medical Devices Regulation(9)(12)(25)(32)Hurricane Helene costs(25)â€”Â (25)â€”Â Product-related items(3)â€”Â (3)â€”Â Total operating income 155Â 179Â 449Â 403Â Interest expense, net87Â 127Â 251Â 367Â Other (income) expense, net(1)(12)(34)15Â Income from continuing operations before income taxes$69Â $64Â $232Â $21Â Our chief operating decision maker does not receive any asset information by reportable segment and, accordingly, we do not report asset information by reportable segment.32Item 2.Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsRefer to our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (2023 Annual Report) for managementâ€™s discussion and analysis of our financial condition and results of operations. The following is managementâ€™s discussion and analysis of our financial condition and results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023.RECENT STRATEGIC ACTIONSIn mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of increasing stockholder value. As part of that review process, we identified and evaluated a range of potential strategic actions, including opportunities for sales and other separation transactions. In January 2023, following the completion of that review, we announced a number of planned strategic actions, as discussed below, which are intended to enhance our operational effectiveness, accelerate innovation and drive additional stockholder value. Pending Sale of Kidney Care BusinessOn August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business for an aggregate purchase price of $3.80 billion. After giving effect to certain closing adjustments, we currently expect to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the range of $3.15 billion to $3.25 billion. The transaction is currently expected to close in late 2024 or early 2025, subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions. We determined that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations presentation. Since the initial announcement of the proposed separation of our Kidney Care business (which is now structured as a pending sale), we have incurred significant separation-related costs, which are reflected in discontinued operations, that have adversely impacted our earnings and cash flows. We expect to continue to incur significant separation costs, which will continue to adversely impact our earnings and cash flows, in connection with the pending sale transaction. Additionally, upon completion of the pending sale transaction, we expect to incur some amount of dis-synergies due to the reduced size of our company and, as a result, we will need to undertake various actions, including cost savings initiatives, to help ensure that our cost structure is appropriate to support our remaining businesses. There can be no guarantees that the pending sale of our Kidney Care business or our proposed cost savings initiatives will be completed in the manner or over the timeframe described above, or at all, or that they will achieve their intended results.Implementation of New Operating Model and Resulting Segment ChangeIn the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this new operating model, our business is currently comprised of four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care (which we are planning to divest through the pending sale and accordingly, the results are reported in discontinued operations as discussed in Note 1 in Item 1 of this Quarterly Report on Form 10-Q). Our segments were changed during the third quarter of 2023 to align with our new operating model. See Note 16 in Item 1 of this Quarterly Report on Form 10-Q for additional information. As discussed above, we have entered into the EPA to sell our Kidney Care business in a transaction that is currently expected to close in late 2024 or early 2025, subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions.Sale of BioPharma Solutions (BPS) BusinessOn September 29, 2023, we completed the sale of our BioPharma Solutions (BPS) business and received cash proceeds of $3.96Â billion from that transaction. The results of operations and cash flows of our BPS business for the three and nine months ended SeptemberÂ 30, 2023 are reported as discontinued operations in the accompanying condensed consolidated financial statements. We used substantially all of the after-tax proceeds from this transaction 33to repay certain of our debt obligations, including $514Â million of commercial paper borrowings and $2.28Â billion of long-term debt that we repaid during the fourth quarter of 2023, as well as â‚¬750 million of senior notes that we repaid during the second quarter of 2024. See Note 2 in Item 1 of this Quarterly Report on Form 10-Q for additional information.FACTORS AFFECTING OUR RESULTS OF OPERATIONSHurricane HeleneIn September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations at that facility. We are actively working with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we work to fully restore our North Cove manufacturing operations. Given the temporary disruptions to our facility as a result of the storm, we currently expect net sales in the fourth quarter to be negatively impacted by approximately $200Â million, including an estimated $40 million to $50 million impact on Kidney Care sales and an estimated $150 million to $160 million impact on Medical Products & Therapies sales. We also expect to incur an estimated $350 million to $400 million of charges in the fourth quarter primarily consisting of remediation costs, air freight (as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) and other charges, which we expect to be partially offset by insurance recoveries. Refer to Footnote 1 for further discussion of insurance recoveries related to Hurricane Helene.Supply Constraints, Global Economic Conditions, and Regulatory Matters In recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges (including certain of those set forth above as we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future.Our results of operations are also affected by macroeconomic conditions and levels of business confidence. The war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and the sanctions and other measures being imposed in response to these conflicts (and the potential for escalation of these conflicts) have increased the levels of economic and political uncertainty and we continue to closely monitor the developing situations. While we have substantially completed our wind down efforts related to our business in Russia, a significant escalation or expansion of economic disruption or the current scope of the war in Ukraine could have an adverse effect on our operations (including our supply chain) in the region.The existence of high inflation rates in the United States and in many of the countries where we conduct business has resulted in, and may in the future result in, higher interest rates, shipping costs, labor costs, and other costs and expenses. Additionally, adverse changes in foreign currency exchange rates have increased, and could continue to increase, our costs of sourcing certain raw materials in some jurisdictions. We have experienced and may in the future experience inflationary increases in manufacturing costs and operating expenses and we may not be able to pass these cost increases on to our customers in a timely manner or at all, which could have a material adverse impact on our profitability and results of operations. Inflation and general macroeconomic factors have caused certain of our customers to reduce or delay orders for our products and services and could cause them to do so in the future, which could have a material adverse impact on our sales and results of operations.As a medical products company, our operations and many of the products manufactured or sold by us are subject to extensive regulation by numerous government agencies, both within and outside the United States. These regulations (as described in Item 1, Government Regulation, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023) require that we obtain specific approval from the Food and Drug Administration (FDA) or applicable non-U.S. regulatory authorities before we can market and sell most of our products in a particular country. Failure to obtain or maintain those approvals or clearances (including temporary importation authorizations) could have a material adverse impact on our business (including with respect to our ability to compete in the product 34markets in which we currently operate). Furthermore, the FDA in the United States, the European Medicines Agency in Europe, the China Food and Drug Administration in China, and other government agencies, inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, pricing, distribution, and post-market surveillance of our products. Our failure to comply with these requirements may subject us to various actions, including warning letters, product recalls or seizures, monetary sanctions, injunctions to halt the manufacture and distribution of products, civil or criminal sanctions, refusal of a government to grant approvals or licenses, restrictions on operations or withdrawal of existing approvals and licenses, and may have a material adverse impact on our results of operations.For further discussion, please refer to Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.NON-GAAP FINANCIAL MEASURESOur presentation of percentage changes in net sales at constant currency rates, which is computed using current period local currency sales at the prior periodâ€™s foreign exchange rates, is a non-GAAP financial measure. This measure provides information about growth (or declines) in our net sales as if foreign currency exchange rates had not changed between the prior period and the current period. We believe that the non-GAAP measure of percent change in net sales at constant currency rates, when used in conjunction with the U.S. GAAP measure of percent change in net sales at actual currency rates, may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.RESULTS OF OPERATIONSNet income attributable to Baxter stockholders for the three months ended SeptemberÂ 30, 2024 was $140 million, or $0.27 per diluted share compared to $2.51 billion, or $4.93 per diluted share for the three months ended SeptemberÂ 30, 2023. For the three months ended SeptemberÂ 30, 2024, our results included special items that adversely impacted net income attributable to Baxter stockholders by $271Â million, or $0.53 per diluted share. For the three months ended SeptemberÂ 30, 2023, our results included special items which increased net income attributable to Baxter stockholders

by $2.09Â billion, or $4.11 per diluted share. Net income (loss) attributable to Baxter stockholders for the nine months ended SeptemberÂ 30, 2024 as $(137) million, or $(0.27) per diluted share compared to $2.41 billion, or $4.76 per diluted share for the nine months ended SeptemberÂ 30, 2023. For the nine months ended SeptemberÂ 30, 2024, our results included special items that adversely impacted net income attributable to Baxter stockholders by $1.22Â billion, or $2.40 per diluted share. For the nine months ended SeptemberÂ 30, 2023, our results included special items which increased net income attributable to Baxter stockholders by $1.36Â billion, or $2.69 per diluted share.Net income from continuing operations for the three months ended SeptemberÂ 30, 2024 was $61 million, or $0.12 per diluted share compared to $37 million, or $0.07 per diluted share for the three months ended SeptemberÂ 30, 2023. Net income from continuing operations for the three months ended SeptemberÂ 30, 2024 included special items that adversely impacted net income by $191Â million, or $0.37 per diluted share. Net income from continuing operations for the three months ended SeptemberÂ 30, 2023 included special items that adversely impacted net income by $184Â million, or $0.36 per diluted share. Net income (loss) from continuing operations for the nine months ended SeptemberÂ 30, 2024 was $162 million, or $0.32 per diluted share compared to $(38) million, or $(0.08) per diluted share for the nine months ended SeptemberÂ 30, 2023. For the nine months ended SeptemberÂ 30, 2024, our results included special items that adversely impacted net income (loss) from continuing operations by $507Â million, or $0.99 per diluted share. For the nine months ended SeptemberÂ 30, 2023, our results included special items that impacted net income (loss) from continuing operations by $571Â million, or $1.13 per diluted share. See the subsection entitled â€œSpecial Itemsâ€ for information about special items for all periods presented. 35CONSOLIDATED NET SALESThree Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1United States$1,500Â $1,467Â 2Â %2Â %Emerging markets2347Â 353Â (2)%1Â %Rest of world3852Â 779Â 9Â %8Â %Total net sales$2,699Â $2,599Â 4Â %4Â %Nine Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1United States$4,340Â $4,300Â 1Â %1Â %Emerging markets21,001Â 985Â 2Â %3Â %Rest of world32,542Â 2,349Â 8Â %8Â %Total net sales$7,883Â $7,634Â 3Â %3Â %1 Â Â Â Â Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled â€œNon-GAAP Financial Measuresâ€ for additional information about our use of that measure.2Â Â Â Â Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).3Â Â Â Â Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.As set forth above, foreign currency had no impact on net sales during the three months ended SeptemberÂ 30, 2024, compared to the prior year period, due to the strengthening of the U.S. Dollar relative to the Turkish Lira, Mexican Peso, and Brazilian Real, offset by the weakening of the U.S. Dollar relative to the Euro, British Pound, Australian Dollar and Chinese Renminbi. Foreign currency had no impact on net sales during the nine months ended SeptemberÂ 30, 2024, compared to the prior year period, due to the strengthening of the U.S. Dollar relative to Turkish Lira, Japanese Yen, Chinese Renminbi, and Brazilian Real, offset by the weakening of the U.S. Dollar relative to the Colombian Peso, British Pound, and Euro.NET SALES BY SEGMENTMedical Products and TherapiesOur Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. Three Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Infusion Therapies and Technologies$1,070Â $1,003Â 7Â %7Â %Advanced Surgery272Â 255Â 7Â %7Â %Total Medical Product and Therapies net sales$1,342Â $1,258Â 7Â %7Â %Nine Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Infusion Therapies and Technologies$3,081Â $2,918Â 6Â %6Â %Advanced Surgery812Â 773Â 5Â %6Â %Total Medical Product and Therapies net sales$3,893Â $3,691Â 5Â %6Â %1 Â Â Â Â Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled â€œNon-GAAP Financial Measuresâ€ for additional information about our use of that measure.Medical Product and Therapies segment net sales increased 7% in the third quarter and increased 5% in the first nine months of 2024, as compared to the prior year periods. 36Infusion Therapies and Technologies net sales increased 7% in the third quarter and increased 6% in the first nine months of 2024, as compared to the prior year periods. Sales performance in the third quarter primarily reflected growth in Infusion Systems as a result of our Novum IQ large volume infusion and syringe pump sales in the U.S., and to a lesser extent, sales of IV solutions and nutrition product offerings, which collectively were attributable to both pricing initiatives and increased sales volume. Advanced Surgery net sales increased 7% in the third quarter and increased 5% in the first nine months of 2024, as compared to the prior year periods. Sales performance primarily reflected growth in hemostats and sealants and was primarily attributable to increased sales volume. Foreign currency exchange rates adversely impacted sales growth by 1% for the first nine months of 2024, as compared to the prior year period.Healthcare Systems and TechnologiesOur Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. Three Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Care and Connectivity Solutions$456Â $443Â 3Â %3Â %Front Line Care296Â 301Â (2)%(2)%Total Healthcare Systems and Technologies net sales$752Â $744Â 1Â %1Â %Nine Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Care and Connectivity Solutions$1,310Â $1,307Â 0Â %0Â %Front Line Care857Â 911Â (6)%(6)%Total Healthcare Systems and Technologies net sales$2,167Â $2,218Â (2)%(3)%1 Â Â Â Â Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled â€œNon-GAAP Financial Measuresâ€ for additional information about our use of that measure.Healthcare Systems and Technologies segment net sales increased 1% in the third quarter and decreased 2% in the first nine months of 2024, as compared to the prior year periods. Care and Connectivity Solutions net sales increased 3% in the third quarter and were flat in the first nine months of 2024, as compared to the prior year periods. The growth in the third quarter was primarily driven by increased order volume associated with capital spending as compared to the prior year quarterly period, partially offset by declines in care communications products driven by the shifting of installations to future periods and lower sales outside of the U.S. Front Line Care net sales decreased 2% in the third quarter and decreased 6% in the first nine months of 2024, as compared to the prior year periods. The sales decline as compared to the prior year periods was primarily driven by a backlog reduction in the prior year period, as well as softer demand in the primary care market and lower government orders, partially offset by growth in our cardiology products.37PharmaceuticalsOur Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding.Three Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Injectables and Anesthesia$321Â $351Â (9)%(9)%Drug Compounding267Â 229Â 17Â %14Â %Total Pharmaceuticals net sales$588Â $580Â 1Â %1Â %Nine Months Ended September 30,Percent change(in millions)20242023At actualcurrency ratesAt constant currency rates 1Injectables and Anesthesia$990Â $987Â 0Â %1Â %Drug Compounding778Â 665Â 17Â %17Â %Total Pharmaceuticals net sales$1,768Â $1,652Â 7Â %7Â %1 Â Â Â Â Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled â€œNon-GAAP Financial Measuresâ€ for additional information about our use of that measure.Pharmaceuticals segment net sales increased 1% in the third quarter and increased 7% in the first nine months of 2024, as compared to the prior year periods. Injectables and Anesthesia net sales decreased 9% in the third quarter and were flat for the first nine months of 2024, as compared to the prior year periods. The decrease in the third quarter was driven by the the timing of certain orders shifting to the fourth quarter, a delay of an anticipated new product launch, as well as supply constraints impacting international sales. Despite the decrease in the third quarter, we believe the Injectables fundamentals and growth prospects remain strong driven largely driven by strength in both core products and recent new product launches in the U.S., partially offset by inhaled anesthesia products. Foreign currency exchange rates adversely impacted sales growth by 1% for the first nine months of 2024, as compared to the prior year period.Drug Compounding net sales increased 17% in the third quarter and for the first nine months of 2024, as compared to the prior year periods. The increase in the current year periods was driven by increased demand for our international pharmacy compounding offerings due, in part, to customer capacity constraints that resulted in increased outsourcing of compounding activities. Foreign currency exchange rates favorably impacted sales growth by 3% for the third quarter of 2024, as compared to the prior year period.Other Other sales, which represent sales not attributable to our reportable segments, were $17 million for both the three months ended September 30, 2024 and 2023, and $55 million and $73 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. In the current and prior year periods, Other sales primarily represent revenues earned by certain of our manufacturing facilities from contract manufacturing activities. The nine-month period ended SeptemberÂ 30, 2023 also included royalty income under a business development arrangement. The decrease in other sales for the nine months ended SeptemberÂ 30, 2024 as compared to the prior year period primarily reflects lower contract manufacturing volume and, to a lesser extent, termination of the royalty arrangement following our acquisition of the rights to the underlying product.38COSTS AND EXPENSESSpecial ItemsThe following table provides a summary of our special items from continuing operations and the related impact by line item on our results for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Gross MarginIntangible asset amortization expense(108)(96)(316)(279)Business optimization items1(2)â€”Â (8)(23)Acquisition and integration items2â€”Â (1)(1)(1)European medical devices regulation3(9)(12)(25)(32)Product related items4(3)â€”Â (3)â€”Â Hurricane Helene costs5(25)â€”Â (25)â€”Â Total Special Items(147)(109)(378)(335)Impact on Gross Margin Ratio(5.4) pts(4.2) pts(4.8) pts(4.3) ptsSelling, General and Administrative (SG&A) ExpensesIntangible asset amortization expense$51Â $51Â $155Â $155Â Business optimization items116Â 44Â 41Â 134Â Acquisition and integration items25Â 1Â 15Â 15Â Legal matters617Â 13Â 17Â 13Â Total Special Items$89Â $109Â $228Â $317Â Impact on SG&A Ratio3.3 pts4.2 pts2.9 pts4.1 ptsResearch and Development (R&D) ExpensesBusiness optimization items1$â€”Â $4Â $â€”Â $10Â Total Special Items$â€”Â $4Â $â€”Â $10Â Impact on R&D Ratio(0.0) pts0.1 pts(0.0) pts0.1 ptsOther Operating Income, netAcquisition and integration items2$â€”Â $â€”Â $â€”Â $(14)Total Special Items$â€”Â $â€”Â $â€”Â $(14)Other (Income) Expense, netInvestment impairments7$â€”Â $â€”Â $â€”Â $10Â Total Special Items$â€”Â $â€”Â $â€”Â $10Â Income Tax ExpenseTax matters8$11Â $16Â $45Â $67Â Tax effects of special items9(56)(54)(144)(154)Total Special Items(45)(38)(99)(87)Impact on Effective Tax Rate(5.8) pts19.5 pts10.0 pts259.5 pts1Our results for third quarter of 2024 and 2023 included business optimization charges of $18 million and $48Â million, respectively. Our results for the first nine months of 2024 and 2023 included business optimization charges of $49 million and $167Â million, respectively. These restructuring and other business optimization costs included costs primarily related to our implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities, third-party costs incurred to support the transformation of certain general and administrative functions, and rationalization of certain other manufacturing and distribution facilities. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities. 2Our results for the third quarter of 2024 and 2023 included $5 million and $2 million, respectively, and for both the first nine months of 2024 and 2023 included $16 million, of integration costs which primarily reflected third party consulting costs related to our integration of Hillrom. In 2023, those costs were partially offset by a $14 million benefit in the first nine months related to changes in the estimated fair values of contingent consideration liabilities. 3Our results for the third quarter of 2024 and 2023 included $9 million and $12 million, respectively, and for the first nine months of 2024 and 2023 included $25 million and $32 million, respectively, of incremental costs to comply with the European Union's medical device regulations for 39previously registered products, which primarily consist of contractor costs and other direct third-party costs. We consider the adoption of these regulations to be a significant one-time regulatory charge and believe that the costs of initial compliance for previously registered products over the implementation period are not indicative of our core operating results. 4Our results for the third quarter and first nine months of 2024 included charges of $3 million related to a revised estimate of warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022. 5Our results in the third quarter and first nine months of 2024 included net charges of $25 million related to Hurricane Helene. This amount consisted of a charge of $44 million related to the write-off of damaged inventory and fixed assets, partially offset by a $19 million benefit related to insurance recoveries expected as a result of those asset write-offs. Refer to Note 1 in Item 1 of this Quarterly Report on Form 10-Q for further information. 6Our results in the third quarter and first nine months of 2024 included charges of $17 million related to environmental reserves for remediation actions associated with historic operations at certain of our facilities. Our results in the third quarter and first nine months of 2023 included costs, including associated legal fees, of $13 million related to matters involving alleged violations of the False Claims Act related to a now-discontinued legacy Hillrom sales line and alleged injury from environmental exposure. 7Our results in 2023 included $10 million of pre-tax losses from non-marketable investments in several early stage companies in the first nine months, consisting of $13Â million of noncash impairment write-downs, partially offset by a $3Â million gain from the sale of an investment.8Our results for the third quarter of 2024 included $11 million of income tax expense consisting of a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment, partially offset by application of the intraperiod tax allocation between continuing operations and discontinued operations. Our results for the third quarter of 2023 included $16 million of income tax expense resulting from separation-related income tax costs associated with the sale of our BPS business. Our results for the first nine months of 2024 included $45 million of income tax expense consisting of a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. and internal reorganization transactions related to the pending sale of our Kidney Care segment. Our results for the first nine months of 2023 included $67 million of income tax expense consisting of a $30Â million valuation allowance recorded to reduce the carrying amount of a deferred tax asset for a tax basis step-up related to previously enacted Swiss tax reform legislation to reflect our current estimate of its recoverability and separation-related income tax costs associated with the sale of our BPS business.9This item reflects the income tax impact of the special items identified in this table. The tax effect of each special item is based on the jurisdiction in which the item was incurred and the tax laws in effect for each such jurisdiction.Gross Margin and Expense RatiosThree Months Ended September 30,2024% of net sales2023% of net sales$ change% changeGross margin$1,033Â 38.3Â %$1,056Â 40.6Â %$(23)(2.2)%SG&A$754Â 27.9Â %$744Â 28.6Â %$10Â 1.3Â %R&D$129Â 4.8Â %$133Â 5.1Â %$(4)(3.0)%Nine Months Ended September 30,2024% of net sales2023% of net sales$ change% changeGross margin$3,025Â 38.4Â %$3,050Â 40.0Â %$(25)(0.8)%SG&A$2,206Â 28.0Â %$2,270Â 29.7Â %$(64)(2.8)%R&D$379Â 4.8Â %$391Â 5.1Â %$(12)(3.1)%Gross MarginOur gross margin ratio was 38.3% and 40.6% for the three months ended September 30, 2024 and 2023, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 5.4 and 4.2 percentage points on the gross margin ratio for the three months ended September 30, 2024 and 2023, respectively. Our gross margin ratio was 38.4% and 40.0% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 4.8 and 4.3 percentage points on the gross margin ratio for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Refer to the Special Items caption above for additional detail.Excluding the impact of special items, the gross margin ratio decreased by 1.1 percentage points in both the third quarter and first nine months of 2024, respectively, compared to the prior year periods. The lower gross margins were driven by an unfavorable product mix, partially offset by initiatives to reduce our manufacturing and supply chain costs. SG&AOur SG&A expenses ratio was 27.9% and 28.6% for the three months ended September 30, 2024 and 2023, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 3.3 and 4.2 40percentage points on the SG&A expenses ratio for the three months ended September 30, 2024 and 2023, respectively. Our SG&A expenses ratio was 28.0% and 29.7% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 2.9 and 4.1 percentage points on the SG&A expenses ratio for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Excluding the impact of special items, the SG&A expenses ratio increased by 0.2 percentage points in the third quarter compared to the prior year period, due to higher corporate function costs and annual compensation increases, partially offset by lower accruals under our annual employee incentive compensation plans. Excluding the impact of special items, the SG&A expenses ratio decreased 0.5 percentage points in first nine months of 2024 compared to the prior year period, due to lower accruals under our annual employee incentive compensation plans, partially offset by annual compensation increases. R&DOur R&D expenses ratio was 4.8% and 5.1% for the three months ended September 30, 2024 and 2023, respectively. The special items identified earlier in this section had no impact and an unfavorable impact of 0.1 percentage points on the R&D expense ratio in the third quarter of 2024 and 2023, respectively. The R&D expenses ratio was 4.8% and 5.1% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. The special items identified earlier in this section had no impact and an unfavorable impact of 0.1 percentage points on the R&D expenses ratio for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Excluding the impact of special items, the R&D expenses ratio decreased by 0.2 percentage points in both the third quarter and first nine months of 2024, compared to the prior year periods.Business Optimization ItemsIn recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts have included restructuring the organization, optimizing our manufacturing footprint, R&D operations, and supply chain network, employing disciplined cost management, and centralizing and streamlining

certain support functions. The related costs of these actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments.For the three months ended months ended SeptemberÂ 30, 2024, $7Â million and $14Â million of the restructuring charges, consisting of employee termination costs, related to business optimization initiatives within our Healthcare Systems and Technologies segment. Additionally, for the nine months ended SeptemberÂ 30, 2024, $7Â million of the restructuring charges, consisting of employee termination costs, related to our recent implementation of a new operating model intended to simplify and streamline our operations.We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $5Â million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives and, to the extent further cost savings opportunities are identified (including after the completion of the pending sale of our Kidney Care business), we would incur additional restructuring charges and costs to implement business optimization programs in future periods. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our business optimization programs.Other Operating Income, NetOther operating income, net was $5 million for the three months ended September 30, 2024. In the third quarter of 2024, this amount was comprised of income from transition services arrangements related to the divestiture of our BPS business. Other operating income, net was $9 million and $14 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. In the first nine months of 2024, this amount was comprised of income from transition services arrangements related to the divestiture of our BPS business. In the first nine months of 2023, this amount was comprised of gains from changes in the estimated fair value of contingent consideration arrangements. Interest Expense, NetInterest expense, net was $87 million and $127 million for the three months ended September 30, 2024 and 2023, respectively and $251 million and $367 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. 41The decrease in 2024 was driven by debt repayments in the fourth quarter of 2023 and, to a lesser extent, higher interest income due to a higher average cash balance and higher interest rates during the current year period.Other (Income) Expense, netOther (income) expense, net was income of $1 million and income of $12 million for the three months ended September 30, 2024 and 2023, respectively, and income of $34 million and expense of $15 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. In the current year periods, other income, net was primarily driven by pension and other postretirement benefits, partially offset by foreign exchange losses. In the three months ended SeptemberÂ 30, 2023, other income, net was primarily driven by pension and other postretirement benefits. In the nine months ended SeptemberÂ 30, 2023, other expense, net was primarily driven by foreign exchange losses, non-marketable investment impairments and decreases in the fair value of marketable equity securities, partially offset by pension and postretirement benefits.Income TaxesOur effective income tax rate was 11.6% and 42.2% in the third quarter of 2024 and 2023, respectively, and 30.2% and 281.0% for the first nine months of 2024 and 2023, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards. Our effective income tax rate during interim periods reflects our estimated annual effective tax rate and discrete items. For the three months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix, the tax impacts of the write-off of damaged inventory and fixed assets at our North Cove facility caused by Hurricane Helene, and a change in our assertion on the reinvested foreign earnings related to the pending sale of our Kidney Care segment allocated to continuing operations, partially offset by a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment. For the nine months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, an increase in income tax expense resulting from internal reorganization transactions related to the pending sale of our Kidney Care segment, and an increase in our liabilities for various uncertain tax positions, partially offset by a favorable geographic earnings mix.For the three months ended September 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, partially offset by a favorable geographic earnings mix.For the nine months ended SeptemberÂ 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $30Â million increase in the valuation allowance related to a deferred tax asset from a tax basis step-up that arose from previously enacted Swiss tax reform legislation, an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and excess tax shortfalls on stock compensation awards. The Organization of Economic Co-operation and Development (OECD) and the G20 Inclusive Framework on Base Erosion and Profit Shifting (the Inclusive Framework) has put forth two proposalsâ€”Pillar One and Pillar Twoâ€”that (i) revise the existing profit allocation and nexus rules and (ii) ensure a minimal level of taxation, respectively. On December 12, 2022, the EU member states agreed to implement the Inclusive Frameworkâ€™s global corporate minimum tax rate of 15%, and various countries both within and outside the EU have enacted new laws implementing Pillar Two or have draft legislation proposed for adoption. The OECD continues to release additional guidance on the two-pillar framework, with widespread implementation occurring in 2024. We currently expect that the impact of the Pillar Two legislation on our income tax expense for the year ending December 31, 2024 will be approximately $10Â million to $15Â million. We are continuing to evaluate the potential impacts of the Inclusive Framework for 2025 and future years, pending legislative adoption by individual countries, which could result in further adverse impacts on our income tax expense and cash flows.42Discontinued Operations In August 2024, we entered into a definitive agreement to sell our Kidney Care business and its results have been presented as discontinued operations for the three and nine months ended September 30, 2024 and 2023. On September 29, 2023, we completed the sale of our BPS business and it's results have been presented as discontinued operations for the three and nine months ended September 30, 2023. Income from discontinued operations, net of tax was $83 million in the third quarter of 2024, compared to $2.47 billion in the third quarter of 2023. Income (loss) from discontinued operations, net of tax was $(290) million in the first nine months of 2024, compared to $2.46 billion in the first nine months of 2023. The decreases were primarily driven by the $2.89 billion pre-tax gain from the sale of BPS ($2.60 billion net of tax). Refer to Note 2 within Item 1 for additional information.SEGMENT OPERATING INCOMEThe following is a summary of our operating income for our reportable segments.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232Medical Products and Therapies$268Â $245Â $733Â $706Â % of Segment Net Sales20.0Â %19.5Â %18.8Â %19.1Â %Healthcare Systems and Technologies136Â 115Â 323Â 327Â % of Segment Net Sales18.1Â %15.5Â %14.9Â %14.7Â %Pharmaceuticals58Â 108Â 211Â 284Â % of Segment Net Sales9.9Â %18.6Â %11.9Â %17.2Â %Other2Â 6Â 15Â 19Â Total464Â 474Â 1,282Â 1,336Â Unallocated corporate costs(73)(73)(227)(285)Intangible asset amortization expense(159)(147)(471)(434)Legal matters(17)(13)(17)(13)Business optimization items(18)(48)(49)(167)Acquisition and integration items(5)(2)(16)(2)European Medical Devices Regulation(9)(12)(25)(32)Product-related items(3)â€”Â (3)â€”Â Hurricane Helene Costs(25)â€”Â (25)â€”Â Total operating income155Â 179Â 449Â 403Â Interest expense, net87Â 127Â 251Â 367Â Other (income) expense, net(1)(12)(34)15Â Loss from continuing operations before income taxes$69Â $64Â $232Â $21Â Medical Products and TherapiesSegment operating income was $268 million and $245 million for the third quarter of 2024 and 2023, respectively, and $733 million and $706 million for the first nine months of 2024 and 2023, respectively. The increase in segment operating income in the third quarter and the nine months ended SeptemberÂ 30, 2024 compared to the prior year periods was primarily driven by higher sales in the current year periods, partially offset by increased allocations of manufacturing and supply chain overheads, annual compensation increases, and higher corporate shared costs.Healthcare Systems and TechnologiesSegment operating income was $136 million and $115 million for the three months ended September 30, 2024 and 2023, respectively, and $323 million and $327 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Segment operating income increased in the third quarter compared to the prior year period primarily due to increased gross profit and lower operating expenses from margin improvement initiatives and increased gross profit from higher sales of Care and Connectivity Solutions product offerings, partially offset by lower sales of our Front Line 43Care product offerings. Segment operating income decreased in the nine months ended SeptemberÂ 30, 2024 compared to the prior year period primarily due to decreased gross profit from lower sales.PharmaceuticalsSegment operating income was $58 million and $108 million for the three months ended September 30, 2024 and 2023, respectively, and $211 million and $284 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. The decreases in segment operating income for these periods were driven by lower gross margin percentages, due to an unfavorable product mix in the third quarter and reflecting the increased cost of certain inventory manufactured by our former BPS business, which now includes a third-party mark-up following our divestiture of that business in September 2023, and increased operating expenses, including marketing-related costs in connection with recent product launches.OtherOther operating income, which represents operating income not attributable to our reportable segments, was $2 million and $6 million for the three months ended September 30, 2024 and 2023, respectively, and $15 million and $19 million for both the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. In the current and prior year periods, other operating income primarily represents income from revenues earned by certain of our manufacturing facilities from contract manufacturing activities. The prior year period also includes royalty income under a business development arrangement. The decrease in the third quarter of 2024 as compared to the prior year periods reflects the termination of the royalty arrangement following our acquisition of the rights to the underlying product, partially offset by improved gross margins from contract manufacturing. Unallocated Corporate CostsUnder our new operating model, most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the Kidney Care segment in the pending sale, are now presented as unallocated corporate costs. Additionally, intangible asset amortization and other special items are not allocated to our segments. Prior to the implementation of our new operating model in the third quarter of 2023, more costs were maintained at corporate and were not allocated to our previous segments. Certain of the costs that were previously maintained at corporate under our prior segment structure that are now allocated to our segments include manufacturing variances and centrally managed supply chain costs, certain R&D costs, product category support costs, stock compensation expense, and certain employee benefit plan costs.LIQUIDITY AND CAPITAL RESOURCESThe following table is a summary of the statement of cash flows for the nine-month periods ended SeptemberÂ 30, 2024 and 2023.Nine Months Ended September 30,(in millions)20242023Cash flows from operations - continuing operations$376Â $792Â Cash flows from investing activities - continuing operations(281)$(325)Cash flows from financing activities(1,222)$(554)Cash Flows from Operations - Continuing Operations For the nine months ended SeptemberÂ 30, 2024 and 2023, operating cash flows from continuing operations were $376 million and $792 million, respectively. Operating cash flows from continuing operations in the current year period were unfavorably impacted, as compared to the prior year period, by higher annual payouts under our employee incentive compensation plans, which were determined based on our 2023 performance and the timing of accounts receivable collections and accounts payable payments. 44Cash Flows from Investing Activities - Continuing OperationsFor the nine months ended SeptemberÂ 30, 2024, cash used in investing activities from continuing operations primarily included capital expenditures of $314 million, partially offset by $34 million of proceeds from sales of marketable securities. For the nine months ended SeptemberÂ 30, 2023, cash used in investing activities from continuing operations primarily included capital expenditures of $340 million. Cash Flows from Financing Activities For the nine months ended SeptemberÂ 30, 2024, cash used in financing activities included debt repayments of $827Â million and dividend payments of $443 million, partially offset by proceeds from stock issued under employee benefit plans of $63 million. For the nine months ended SeptemberÂ 30, 2023, cash used for financing activities included dividend payments of $439 million and debt repayments of $353 million and a net increase in commercial paper borrowings of $214 million, partially offset by proceeds from stock issued under employee benefit plans of $86 million. As authorized by our Board of Directors, we repurchase our stock depending upon our cash flows, net debt levels and market conditions. In July 2012, our Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. We did not repurchase any shares under this authority in the first nine months of 2024. We had $1.30 billion remaining available under this authorization as of SeptemberÂ 30, 2024.Credit Facilities, Commercial Paper Program and Access to Capital and Credit RatingsCredit Facilities and Commercial Paper ProgramAs of SeptemberÂ 30, 2024, we had a U.S. dollar-denominated term loan credit facility, which had two tranches of term loans outstanding, a U.S. dollar-denominated revolving credit facility and a Euro-denominated revolving credit facility.As of SeptemberÂ 30, 2024, we had $130Â million outstanding under one tranche of our U.S. dollar-denominated term loan credit facility that matures in 2024 and $1.64Â billion outstanding under the other tranche of our U.S. dollar-denominated term loan credit facility that matures in 2026. Borrowings under the term loan credit facility bear interest on the principal amount outstanding at either Term SOFR plus an applicable margin plus a credit spread adjustment or a â€œbase rateâ€ plus an applicable margin. The term loan credit facility contains various covenants, including a maximum net leverage ratio. We have the option to prepay outstanding amounts under the term loan credit facility in whole or in part at any time.As of SeptemberÂ 30, 2024, our U.S. dollar-denominated revolving credit facility and Euro-denominated revolving credit facility had a maximum capacity of $2.00Â billion and â‚¬200Â million, respectively. There were no borrowings outstanding under these credit facilities as of SeptemberÂ 30, 2024 or DecemberÂ 31, 2023. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our credit facilities for an amount at least equal to our outstanding commercial paper borrowings. On July 17, 2024, we entered into a credit agreement in which a group of banks have committed to provide us senior unsecured term loans in an aggregate principal amount of up to $2.05Â billion ("the bridge facility"). Borrowings under the bridge facility will be available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the pending sale of our Kidney Care business. Borrowings under the bridge facility will bear interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We will also incur a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banksâ€™ funding commitments under the bridge facility will terminate upon the earliest to occur of: (i) our consummation of the debt repayments and tax payments described above without us having borrowed under the bridge facility, (ii) our election to terminate the commitments under the bridge facility, (iii) our receipt of net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business), (iv) the occurrence of three drawings under the bridge facility, and (v) December 31, 2024. Outstanding borrowings under the bridge facility will mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we are required to use the net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contains financial and other covenants, including a net leverage covenant, and provides for 45customary events of default. There were no borrowings outstanding under this bridge facility as of SeptemberÂ 30, 2024.In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. The amendment further provides for the reduction of the capacity under our U.S dollar-denominated revolving credit facility from $2.50 billion to $2.00 billion on the earlier of September 30, 2024 or the date of the sale or spinoff of our Kidney Care business. As of SeptemberÂ 30, 2024, we were in compliance with the financial covenants in these agreements. Based on our covenant calculations as of SeptemberÂ 30, 2024, we had capacity to draw on the full amounts under our credit facilities. The non-performance of any financial institution supporting either of the credit facilities would reduce the maximum capacity of these facilities by the institutionâ€™s respective commitment. Additionally, a deterioration in our financial performance may further reduce our ability to draw on our credit facilities.We have a commercial paper program that currently enables us to borrow efficiently at short-term interest rates. Upon maturity of any commercial paper borrowings under this program, and to the extent old issuances are not repaid by cash on hand, we are exposed to the rollover risk of not being able to issue new commercial paper. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit facilities for an amount at least equal to our outstanding commercial paper borrowings. If we were not able to issue new commercial paper, we have the option of drawing on the revolving credit facilities; however, electing to do so would result in higher interest expense. We had no commercial paper borrowings outstanding as of SeptemberÂ 30, 2024.Access to Capital and Credit RatingsWe intend to fund short-term and long-term obligations as they mature through cash on hand, future cash flows from operations, and potentially by issuing debt, which could include commercial paper, bond

issuances, or other financing arrangements, including the bridge facility. We had $1.42 billion of cash and cash equivalents as of SeptemberÂ 30, 2024, with adequate cash available to meet operating requirements in each jurisdiction in which we operate. We invest our excess cash in money market and other funds and diversify the concentration of cash among different financial institutions. As of SeptemberÂ 30, 2024, we had approximately $12.94Â billion of long-term debt and finance lease obligations, including current maturities, and no short-term debt. We used substantially all of the remaining net after-tax cash proceeds from the BPS divestiture to repay indebtedness in the first half of 2024. Subject to market conditions, we regularly evaluate opportunities with respect to our capital structure. We intend to use the net after-tax proceeds from the pending sale of our Kidney Care business to repay certain of our debt obligations, consistent with our stated capital allocation priorities. Prior to the pending sale of our Kidney Care business, we plan to bring back a portion of the cash related to our Kidney Care business after giving effect to any applicable taxes and which is currently classified in discontinued operations.Our ability to generate cash flows from operations and issue debt on acceptable terms or at all could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings, or other significantly unfavorable changes in market conditions. However, we believe we have sufficient financial flexibility to issue debt, enter into other financing arrangements, and attract long-term capital on acceptable terms to support our growth objectives and reduce our post-Hillrom acquisition debt levels as we take actions consistent with our capital allocation priorities and strategic initiatives (including completion of the pending Kidney Care sale). In January 2024, Fitch revised our senior debt credit rating from BBB to BBB-, our senior debt credit rating outlook from rating watch negative to stable and our short-term debt credit rating from F2 to F3. In May 2024, our contract with Fitch expired. In June 2024, Fitch affirmed and withdrew ratings and coverage on us. As a result they no longer maintain ratings on our senior debt or our short-term debt. There have been no changes to our investment grade credit ratings from Standard & Poor's and Moody's that we disclosed in our 2023 Annual Report. CRITICAL ACCOUNTING POLICIESThe preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. A summary of our significant accounting policies is included in Note 1 to our consolidated financial statements in our 2023 Annual Report. Certain of our accounting policies are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often employing the use of estimates 46about the effects of matters that are inherently uncertain. Such policies are summarized in the Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations section in our 2023 Annual Report.Impairment of Goodwill and Other Long-Lived AssetsFront Line Care Reporting UnitIn connection with our November 1, 2023 annual goodwill impairment tests, we determined that the fair value of the Front Line Care reporting unit within our Healthcare Systems and Technologies segment exceeded its carrying value by approximately 5%. While no triggering events were identified during the nine months ended SeptemberÂ 30, 2024, we are continuing to closely monitor the performance of this reporting unit, and if there is a significant adverse change in our outlook for this business in the future, a goodwill impairment could arise at that time. As of SeptemberÂ 30, 2024, the carrying amount of goodwill for our Front Line Care reporting unit was $2.42Â billion. There have been no significant changes in the application of our critical accounting policies during the first nine months of 2024.RECENT ACCOUNTING PRONOUNCEMENTSIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures about segment expenses on an annual and interim basis. This standard is effective for our annual consolidated financial statements for the year ending December 31, 2024 and for interim periods beginning in 2025. Upon adoption of this standard, we expect to disclose additional income statement information for our reportable segments.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, which requires (1) disclosure of specific categories in the rate reconciliation and (2) additional information for reconciling items that meet a quantitative threshold. Additionally, the amendment requires disclosure of certain disaggregated information about income taxes paid, income from continuing operations before income tax expense (benefit) and income tax expense (benefit). The standard is effective for our annual consolidated financial statements for the year ending December 31, 2025. We are currently evaluating the impact of this standard on our consolidated financial statements.LEGAL CONTINGENCIESRefer to Note 6 within Item 1 for a discussion of our legal contingencies. Upon resolution of any of these uncertainties, we may incur charges in excess of presently established liabilities. While our liability in connection with certain claims cannot be estimated with any certainty, and although the resolution in any reporting period of one or more of these matters could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and we may in the future incur material judgments or enter into material settlements of claims.CERTAIN REGULATORY MATTERSIn July 2017, immediately prior to the closing of our acquisition of Claris Injectables Limited (Claris), the U.S. Food and Drug Administration (FDA) commenced an inspection of the Clarisâ€™ facilities in Ahmedabad, India. FDA completed the inspection and subsequently issued a Warning Letter based on observations identified in the 2017 inspection (2017 Warning Letter).Â[1] FDA re-inspected the facilities and issued a Form FDA 483 on May 17, 2022. On September 1, 2022, FDA notified us that the inspection had been classified as voluntary action indicated. From January 19, 2023 to January 27, 2023, FDA performed an inspection at the Ahmedabad site, concluding with the issuance of a Form FDA 483. On April 26, 2023, FDA notified us that the inspection had been classified as official action indicated. We received a Warning Letter on July 25, 2023 based on observations identified in the January 2023 inspection (2023 Warning Letter)2. Since the issuance of the 2017 Warning Letter, we have implemented corrective and preventive actions to address FDA's related observations, as well as other enhancements at the site. We have fully responded to the 2023 Warning Letter, have implemented additional corrective and preventive actions, and continue to engage with FDA regarding the agency's observations. In addition, since the issuance of the 2017 Warning Letter, we have 47secured other sites in our manufacturing network and have launched and distribute select products from those sites in the U.S.1 Available online at https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm613538.htm2 Available online at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-healthcare-corporation-654136-07252023FORWARD-LOOKING INFORMATION Certain statements contained in this quarterly report on Form 10-Q may constitute â€œforward-looking statements,â€ as defined in the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. These statements by their nature address matters that are uncertain to different degrees. Use of the words â€œmay,â€ â€œwill,â€ â€œwould,â€ â€œcould,â€ â€œshould,â€ â€œbelieves,â€ â€œestimates,â€ â€œprojects,â€ â€œpotential,â€ â€œexpects,â€ â€œplans,â€ â€œseeks,â€ â€œintends,â€ â€œevaluates,â€ â€œpursues,â€ â€œanticipates,â€ â€œcontinues,â€ â€œdesigns,â€ â€œimpacts,â€ â€œaffects,â€ â€œforecasts,â€ â€œtarget,â€ â€œoutlook,â€ â€œinitiative,â€ â€œobjective,â€ â€œdesigned,â€ â€œpriorities,â€ â€œgoal,â€ or the negative of those words or other similar expressions may identify forward-looking statements, although not all forward-looking statements contain such words. These forward-looking statements may include statements with respect to the pending sale of our Kidney Care business and other portfolio management activities we may undertake in the future, the costs, structure, and timing associated with strategic initiatives including the pending sale, the viability and accuracy of anticipated benefits of our strategic actions, our ability to successfully integrate acquisitions and complete divestitures, the expected growth rates for our segments, accounting estimates and assumptions (including with respect to goodwill and other intangible asset impairments), global economic conditions, severe storms and storm-related impacts, litigation-related matters, future regulatory filings (or the withdrawal or resubmission of any pending submissions) and our R&D pipeline (including anticipated product approvals or clearances), sales from new product offerings, credit exposure to foreign governments, the adequacy of cash flows and credit facilities, potential developments with respect to credit ratings, investment of foreign earnings, estimates of liabilities including those related to uncertain tax positions, contingent payments, future pension plan contributions, costs, discount rates and rates of return, our exposure to financial market volatility and foreign currency, interest rate and credit risks, our net interest expense, the impact of inflation on our business, the impact of competition, future sales growth, business development activities, cost saving initiatives, future capital and R&D expenditures, future debt issuances and refinancings, the adequacy of tax provisions and reserves, the effective income tax rate, and all other statements that do not relate to historical facts.These forward-looking statements are based on certain assumptions and analyses made in light of our experience and perception of historical trends, current conditions, and expected future developments as well as other factors that we believe are appropriate in the circumstances. While these statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any events or financial results. Whether actual future results and developments will conform to expectations and predictions is subject to a number of risks and uncertainties, including the following factors, many of which are beyond our control:â€¢our ability to execute and complete strategic initiatives, asset dispositions, and other transactions, including the pending sale of our Kidney Care business, our plans to simplify our manufacturing footprint and the timing for such transactions, the ability of the parties to secure any required regulatory approvals or satisfy any applicable conditions, and our ability to realize the expected proceeds, consideration, and benefits of these transactions (including with respect to any post-sale arrangements or cost savings initiatives);â€¢failure to accurately forecast or achieve our short-and long-term financial performance and goals (including with respect to our strategic initiatives and other actions), market and category growth rates, and related impacts on our liquidity;â€¢our ability to finance and develop new products or enhancements on commercially acceptable terms or at all;â€¢product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle;â€¢demand and market acceptance risks for, and competitive pressures related to, new and existing products, challenges with accurately predicting changing customer preferences and future expenditures and inventory 48levels and with being able to monetize new and existing products and services (and to sustain any related price increases), the impact of those products on quality and patient safety concerns, and the need for ongoing training and support for our products;â€¢our ability to successfully integrate acquisitions including the acquisition of Hillrom, and the related impact on our organization structure, senior leadership, culture, functional alignment, outsourcing and other areas, our management of resulting related personnel capacity constraints and potential institutional knowledge loss, and our ability to achieve anticipated performance or financial targets and maintain our reputation following integration;â€¢our ability to execute on our capital allocation plans, including our debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds (including those resulting from the pending Kidney Care sale);â€¢the impact of global economic conditions (including, among other things, inflation levels, interest rates, financial market volatility, banking crises, the potential for a recession, the war in Ukraine, the conflict in the Middle East (including recent attacks on merchant ships in the Red Sea), tensions amongst China, Taiwan, and the U.S. and the potential for escalation of these conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars and global public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on our operations and our employees, customers, suppliers, and foreign governments in countries in which we operate;â€¢the impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-related events, including our ability to import and distribute product from other facilities in connection with temporary importation authorizations, the reallocation of manufacturing capacity, the ability to receive necessary regulatory or other approvals required to reopen all or a portion of impacted facilities, the ability to resume production at our North Cove facility on the expected time frame or at all and physical, environmental or other obstacles identified during the course of remediation, including with respect to the availability of third party contractors and any equipment, transportation or other supplies needed to support the remediation efforts;â€¢inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster, war, terrorism, global public health crises and epidemics/pandemics, regulatory actions, or otherwise; â€¢downgrades to our credit ratings or ratings outlooks, or withdrawals by rating agencies from rating us and our indebtedness, and the related impact on our funding costs and liquidity;â€¢the impact of any goodwill, intangible asset, or other long-lived asset impairments on our operating results;â€¢regulatory agency inspections, product quality or patient safety issues leading to product recalls, withdrawals, labeling changes, launch delays, warning letters, import bans, denial of import certifications, sanctions, seizures, litigation, or declining sales, including the focus on evaluating product portfolios for the potential presence or formation of nitrosamines;â€¢future actions of, or failures to act or delays in acting by FDA, the European Medicines Agency, or any other regulatory body or government authority (including the SEC, DOJ, or the Attorney General of any state) that could delay, limit, or suspend product development, manufacturing, or sale, or result in seizures, recalls, injunctions, monetary sanctions, or criminal or civil liabilities;â€¢breaches, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in, our information technology systems, or products;â€¢the continuity, availability, and pricing of acceptable raw materials and component parts, our ability to pass some or all of these costs to our customers through price increases or otherwise, and the related continuity of our manufacturing and distribution and those of our suppliers;â€¢loss of key employees (including those involved with any key strategic actions), the occurrence of labor disruptions (including as a result of labor disagreements under bargaining agreements or national trade union agreements or disputes with works councils) or the inability to attract, develop, retain, and engage employees;â€¢failures with respect to our quality, compliance, or ethics programs;â€¢future actions of third parties, including third-party payors and our customers and distributors (including GPOs and IDNs);49â€¢changes to legislation and regulation and other governmental pressures in the United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules, and regulations, as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification, and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation, and rebate policies;â€¢the outcome of pending or future litigation;â€¢the impact of competitive products and pricing, including generic competition, drug reimportation, and disruptive technologies;â€¢global regulatory, trade, and tax policies, including with respect to climate change and other sustainability matters;â€¢the ability to protect or enforce our patents or other proprietary rights (including trademarks, copyrights, trade secrets, and know-how) or where the patents of third parties prevent or restrict our manufacture, sale, or use of affected products or technology;â€¢fluctuations in foreign exchange and interest rates;â€¢any changes in law concerning the taxation of income (whether with respect to current or future tax reform);â€¢actions by tax authorities in connection with ongoing tax audits;â€¢other factors identified elsewhere in this report and other filings with the SEC, including those factors described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, all of which are available on our website.Actual results may differ materially from those projected in the forward-looking statements, which are more fully discussed in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. These forward-looking statements are not exclusive and are in addition to other factors discussed elsewhere in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Further, other unknown or unpredictable factors could also have material adverse effects on future results. Any forward-looking statement in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Except as required by law, we assume no obligation, and expressly disclaim any obligation, to update or revise any forward-looking statements, whether as a result of new information or future events.50Item 3.Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskCurrency RiskWe are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, British Pound, Chinese Renminbi, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso, Indian Rupee, and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce our net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholdersâ€™ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.We primarily use forward contracts to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities denominated in foreign currencies. The maximum term over which we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of SeptemberÂ 30, 2024 is 12 months. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of SeptemberÂ 30, 2024, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, the net pre-tax liability

balance of $5Â million with respect to those contracts would change by $5Â million.The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of SeptemberÂ 30, 2024 by replacing the actual exchange rates as of SeptemberÂ 30, 2024 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.Interest Rate and Other RisksRefer to the caption â€œInterest Rate and Other Risksâ€ in the â€œFinancial Instrument Market Riskâ€ section of the 2023 Annual Report. There were no significant changes during the quarter ended SeptemberÂ 30, 2024. 51Item 4.Â Â Â Â Controls and ProceduresEvaluation of Disclosure Controls and ProceduresOur management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of SeptemberÂ 30, 2024. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of SeptemberÂ 30, 2024. Changes in Internal Control over Financial ReportingThere have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended SeptemberÂ 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.52PART II. OTHER INFORMATIONItem 1.Â Â Â Â Legal ProceedingsThe information in Part I, Item 1, Note 6 is incorporated herein by reference.Item 1A. Risk Factors We do not believe that there have been any material changes to the risk factors previously disclosed in our 2023 Annual Report. Item 2.Â Â Â Â Unregistered Sales of Equity Securities and Use of ProceedsIn July 2012, the Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. During the third quarter of 2024, we did not repurchase any shares under this authority. We had $1.30 billion remaining under this program as of SeptemberÂ 30, 2024. This program does not have an expiration date.Item 5. Other Information Certain of our officers and directors have made elections to participate in, and are participating in, our employee stock purchase plan or have made, and may from time to time make, elections to have shares withheld to cover withholding taxes or pay the exercise price of options, which may constitute non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).53Item 6.Â Â Â Â ExhibitsExhibit Index:ExhibitNumberDescription2.1Equity Purchase Agreement, dated August 12, 2024, by and among Baxter International Inc., Spruce Bidco I, Inc., Spruce Bidco II, Inc., Spruce Bidco I Limited and CP Spruce Holdings, S.C.Sp. (incorporated by reference to Exhibit 2.1 to Baxter International Inc.'s Form 8-K, filed on August 13, 2024).10.1Credit Agreement, dated as of July 17, 2024, among Baxter International Inc. as Borrower, JPMorgan Chase Bank, National Association as Administrative Agent, and certain other financial institutions named therein (incorporated by reference to Exhibit 10.1 to Baxter International Inc.'s Form 8-K, filed on July 18, 2024).C 10.2*Baxter International Inc. Non-Employee Director Compensation Plan (as amended and restated effective January 1, 2025).C 10.3*Baxter International Inc. Executive Severance Plan (as amended and restated effective July 15, 2024).31.1*Certification of Chief Executive Officer Pursuant to Rules 13a-14 (a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.31.2*Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1**Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2**Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INS*XBRL Instance Document101.SCH*XBRL Taxonomy Extension Schema Document101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document101.LAB*XBRL Taxonomy Extension Label Linkbase Document101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document101.DEF*XBRL Taxonomy Extension Definition Linkbase Document104*Cover Page Interactive Data File (formatted as Inline XBRL and contained within the Inline XBRL Instance Document in Exhibit 101)_____*Â Â Â Â Filed herewith.**Â Â Â Â Furnished herewith. This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.C Â Â Â Â Management contract or compensatory plan or arrangement54SignaturePursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.BAXTER INTERNATIONAL INC.(Registrant)Date: November 12, 2024By:/s/ Joel T. GradeJoel T. GradeExecutive Vice President, Chief Financial Officer and Interim Chief Accounting Officer, (duly authorized officer, principal financial officer and principal accounting officer)55 EX-10.2 2 bax-20240930xex102.htm EX-10.2 DocumentExhibit 10.2BAXTER INTERNATIONAL INC.Non-Employee Director Compensation Plan(As amended and restated effective January 1, 2025)Terms and Conditions1.PurposeThis Non-Employee Director Compensation Plan (the â€œPlanâ€) is adopted by the Board of Directors (the â€œBoardâ€) of Baxter International Inc. (â€œBaxterâ€). This Plan is adopted pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan (the â€œAmended and Restated 2021 Incentive Planâ€), for the purposes stated in the Amended and Restated 2021 Incentive Plan. Capitalized terms defined in the Amended and Restated 2021 Incentive Plan that are used without being defined in the Plan will have the same meaning as in the Amended and Restated 2021 Incentive Plan.2.ParticipantsEach member of the Board who is not an employee of Baxter or any of its subsidiaries shall participate in the Plan (a â€œParticipantâ€).3.Unrestricted Shares of Stock3.1Â Subject to Section 3.4, on the date of Baxterâ€™s annual meeting of stockholders in each year beginning with the Annual Meeting held on May 7, 2024 (the â€œAnnual Meetingâ€), and subject to availability of Shares under the Amended and Restated 2021 Incentive Plan, each Participant upon completion of the Annual Meeting shall, automatically and without necessity of any action by the Board or any committee thereof, receive the number of Full Value Awards in the form of Shares of Baxter Common Stock, par value $0.01 per Share, (â€œUnrestricted Sharesâ€) equal to the quotient of (A) $215,000 divided by (B) the Fair Market Value of a Share on the date of grant rounded up or down to the nearest whole number (the â€œAnnual Unrestricted Share Grant Amountâ€).3.2Â Each Participant elected or appointed on a date other than the date of an Annual Meeting shall, on the date of such election or appointment and automatically and without necessity of any action by the Board or any committee thereof, receive the number of Unrestricted Shares equal to the product of (A) the Annual Unrestricted Share Grant Amount (as defined in Section 3.1, subject to adjustment in accordance with the Amended and Restated 2021 Incentive Plan) for the Unrestricted Shares awarded on the date of the immediately preceding Annual Meeting,Â multiplied byÂ (B) the quotient of (i) the number of full calendar months before the next Annual Meeting divided by (ii) 12, rounded up or down to the nearest whole number. The number of Unrestricted Shares granted under this Section 3.2 shall not exceed the number available under the Amended and Restated 2021 Incentive Plan on the date of grant.Exhibit 10.23.3Â All Unrestricted Shares shall be granted with no vesting restrictions.3.4Â If a Participant ceases service as a member of the Board for any reason, other than death or disability and except in connection with any qualifying retirement (as set forth in Section 3.5), prior to the date that is six months after the grant date of Unrestricted Shares, Participant hereby agrees (i) to return any Unrestricted Shares which the Participant has not otherwise sold or transferred prior to the date of Participantâ€™s departure from the Board (the â€œTermination Dateâ€) to Baxter and (ii) with respect to any Unrestricted Shares that the Participant has sold or otherwise transferred prior to the Termination Date, to make a cash payment to Baxter equal to the amount of the net proceeds received from the sale, disposition or transfer of the Unrestricted Shares, less any taxes withheld at time of grant within ten Business Days of the Termination Date. Additionally, the Participant hereby agrees to promptly notify Baxter of any sale, transfer or other disposition of any Unrestricted Shares that occurs prior to six months after to the applicable grant date.3.5Â Qualifying Retirement shall mean the Termination of a Participant who is at least 72 years of age or who has served as a member of the Board for a continuous period of at least ten years.4.Cash Compensation4.1Â Except as provided in the following section, participants acting as the chairperson of any committee of the Board shall receive an annual cash retainer of $20,000 for each committee chaired by him or her. A participant acting as the chairperson of the Audit Committee shall receive an annual cash retainer of $25,000. Amounts payable within this Section 4.1 shall be paid quarterly in arrears. For the purposes of determining the amount of such quarterly payment(s), a Participant must be a chairperson of a committee of the Board on or prior to the 15th day of a month in order to be entitled to receive such payment(s) with respect to that month.4.2Â Baxter shall pay each Participant a total annual cash retainer of $120,000 per calendar year (â€œAnnual Cash Retainerâ€). Baxter shall pay an additional annual cash retainer of $50,000 per calendar year to the Lead Director (â€œLead Director Retainerâ€). Both the Annual Cash Retainer and Lead Director Retainer shall be paid quarterly in arrears. For purposes of determining the amount of such quarterly payment(s), a Participant and/or the Lead Director must be a member of the Board on or prior to the 15th day of a month in order to be entitled to receive such payment(s) with respect to that month.4.3Â Participants shall be eligible to defer payment of cash compensation otherwise payable under this Section 4 pursuant to the terms and conditions of the Baxter Non-Employee Director Deferred Compensation Plan.Exhibit 10.25.Availability of SharesIf on any grant date, the number of Shares which would otherwise be granted in the form of Unrestricted Shares granted under the Plan shall exceed the number of Shares then remaining available under the Amended and Restated 2021 Incentive Plan, the available Shares shall be allocated among the Participants in proportion to the number of Unrestricted Shares that Participants would otherwise be entitled to receive.6.Change in ControlNotwithstanding any other provision of the Amended and Restated 2021 Incentive Plan or this Plan, if a Change in Control occurs, then all Awards previously unvested shall become immediately vested and exercisable.7.General Provisions7.1Â Subject to the limitations contained in Section 13 of the Amended and Restated 2021 Incentive Plan, the Board or the Committee may, at any time and in any manner, amend, suspend, or terminate the Plan or any Award outstanding under the Plan.7.2Â Participation in the Plan does not give any Participant any right to continue as a member of the Board for any period of time or any right or claim to any benefit unless such right or claim has specifically accrued hereunder. EX-10.3 3 bax-20240930xex103.htm EX-10.3 DocumentExhibit 10.3BAXTER INTERNATIONAL INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTIONINTRODUCTIONBaxter International Inc., a Delaware corporation adopts this Executive Severance Plan and Summary Plan Description (the â€œPlanâ€), effective as of the Effective Date (as defined below), for the benefit of certain Eligible Employees (as defined below). The purpose of the Plan is to provide assurances of specified severance benefits to Eligible Employees upon a Qualifying Termination (as defined below).ARTICLE I DEFINITIONSAs used herein, the following capitalized words and phrases shall have the following respective meanings unless the context clearly indicates otherwise:1.1â€œAffiliateâ€ shall have the meaning set forth in Rule 12b-2 under Section 12 of the Securities Exchange Act of 1934, as may be amended from time to time.1.2â€œBoardâ€ means the Board of Directors of the Company.1.3â€œCauseâ€ means (i) the willful and continued failure by the Eligible Employee to substantially perform their duties with the Company that has not been cured within 30 days after written demand for substantial performance is delivered by the Company, which demand specifically identifies the manner in which the Eligible Employee has not substantially performed (other than any such failure resulting from the Eligible Employeeâ€™s incapacity due to Disability), or (ii) the willful engaging by the Eligible Employee in conduct which is demonstrably and materially injurious to the Company, monetarily, reputationally, or otherwise. For purposes hereof, no act, or failure to act, on the Eligible Employeeâ€™s part shall be deemed â€œwillfulâ€ unless done, or omitted to be done, by the Eligible Employee not in good faith and without reasonable belief that such action was in the best interest of the Company. Notwithstanding the foregoing, if an Eligible Employee is a party to a Change in Control Agreement, â€œCauseâ€ with respect to such Eligible Employee shall have the meaning given to such term in the Change in Control Agreement. The Companyâ€™s most senior Human Resources officer (or the companyâ€™s most senior Legal officer in the event of a termination involving the Companyâ€™s most senior Human Resources officer), shall make the determination as to whether the termination of employment is for Cause, and such determination shall be binding, final and conclusive on all concerned.1.4â€œChange in Controlâ€ means the term â€œChange in Controlâ€ as defined in the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time, or by any shareholder-approved successor plan thereto.1.5â€œChange in Control Agreementâ€ means an employment agreement, change in control agreement or plan, severance agreement or plan, or other agreement between the Company and an Eligible Employee or Company plan covering an Eligible Employee that provides for severance benefits upon a voluntary termination for good reason or involuntary termination without cause in connection with a Change in Control of the Company and that has been approved by the Board or the Committee.1.6â€œCodeâ€ shall mean the Internal Revenue Code of 1986, as amended from time to time, including any rules and regulations promulgated thereunder, along with Treasury and IRS interpretations thereof. Reference to any section or subsection of the Code includes reference to any comparable or succeeding provisions of any legislation that amends, supplements or replaces such section or subsection.1.7â€œCommitteeâ€ shall mean the Compensation and Human Capital Committee of the Board.1.8â€œCompanyâ€ shall mean Baxter International Inc., a Delaware corporation, and its successors.1.9â€œDisabilityâ€ shall mean a condition entitling the Eligible Employee to receive benefits under a long-term disability plan sponsored by the Company in which such Eligible Employee is eligible to participate, or, in the absence of such a plan, the complete and permanent inability of the Eligible Employee by reason of illness or accident to perform the substantial duties of the occupation at which the Eligible Employee was employed or served when such disability commenced. Any determination of whether a Disability exists shall be made by the Committee (or designee) in its sole and absolute discretion.1.10â€œEffective Dateâ€ shall mean November 16, 2020.1.11â€œEligible Employeeâ€ shall mean those salaried employees of the Company employed in the United States at a Vice President job level or above (including any salaried employee who is a United States expatriate on assignment in another country at the Vice President job level or above), but excluding the Chairman and Chief Executive Officer of the Company or any successor thereto. In all cases, the Committee, in its sole discretion, shall designate an Eligible Employee as a Group 1 Executive or Group 2 Executive for purposes of participation in the Plan.1.12â€œQualifying Terminationâ€ shall mean an involuntary termination on or after the Effective Date of an Eligible Employee by the Company for any reason other than due to death, Disability, or for Cause.2ARTICLE IISEVERANCE BENEFITS2.1Severance Benefits. In the event of an Eligible Employeeâ€™s Qualifying Termination, provided the Eligible Employeeâ€™s Release (as defined below) has been executed in the timely manner provided in Article VIII and the period of revocation has expired, the terminated Eligible Employee will receive the following benefits following the Release Effective Date, which is determined in accordance with the timing set forth in Article VIII (collectively, â€œSeverance Benefitsâ€):(a)Severance Payment. In the event of an Eligible Employeeâ€™s Qualifying Termination, such terminated Eligible Employee shall be eligible to receive the amount described below based on the Eligible Employeeâ€™s group, annual base salary and target annual incentive amount under the Management Incentive Compensation Plan (the â€œMICPâ€) (or any successor plan thereto) on the date the Eligible Employee terminates employment:(i)Group 1 Executive: Sum of (a) annual base salary and target annual incentive amount multiplied by (b) 1.5.(ii)Group 2 Executive: Sum of (a) annual base salary and target annual incentive amount multiplied by (b) 1.Such amount shall be paid in equal regular payroll installments over a twelve (12) month period starting with the first payroll period after the Release Effective Date; provided, however, that in the event of a Change in Control of the Company, the amounts described above shall be paid in a lump sum, provided, further, that if the Eligible Employee is currently receiving installment payments, those payments shall continue in lieu of a lump sum. In all cases, such payments shall begin or occur within thirty (30) days following the Release Effective Date. (b)Pro Rata Annual Incentive Payment. In the event an Eligible Employeeâ€™s Qualifying Termination is on or after February 1 but before the end of the applicable calendar year, the Eligible Employee shall remain eligible for a pro rata payment of the Eligible Employeeâ€™s annual incentive under the MICP (or any successor plan thereto) calculated using the number of days of active service completed by the Eligible Employee with the Company in the applicable calendar year. In the event an Eligible Employeeâ€™s Qualifying Termination is after the applicable calendar year but prior to payment of the annual incentive, the Eligible Employee shall remain eligible for a payment of the Eligible Employeeâ€™s annual incentive under the MICP (or any successor plan thereto) for the applicable calendar year prior to the Eligible Employeeâ€™s Qualifying Termination. Any payment under this Section 2.1(b) shall be based on actual financial performance of the Company and target (100%) individual performance. The timing of any payment under this Section 2.1(b) shall be consistent with the timing of annual 3incentive payments under the MICP (or any successor plan thereto) in the ordinary course to all United States employees generally; provided, however, the payment shall be made no later than March 15 of the calendar year following the calendar year of the Eligible Employeeâ€™s Qualifying Termination.(c)Medical, Dental or Vision Coverage Payment. In the event of an Eligible Employeeâ€™s Qualifying Termination and if the Eligible Employee was currently enrolled in the Companyâ€™s group medical, dental or vision plan as of the date of a Qualifying Termination, then the Company shall pay to such Eligible Employee a lump-sum cash amount within thirty (30) days following the Release Effective Date outlined below using the current monthly employer cost of the applicable coverage and the Eligible Employeeâ€™s group:(i)Group 1 Executive: Monthly employer cost of applicable group medical, dental or vision coverage multiplied by 18.(ii)Â Â Â Â Group 2 Executive: Monthly employer cost of applicable group medical, dental or vision coverage multiplied by 12.(d)Outplacement Benefits. In the event of an Eligible Employeeâ€™s Qualifying Termination, the Company shall provide outplacement services suitable to the Eligible Employeeâ€™s position via the Companyâ€™s third-party provider or otherwise for a period of up to eighteen (18) months or, if earlier, until the Eligible Employee accepts full-time employment, up to the amount specified below based on the Eligible Employeeâ€™s group: (i)Group 1 Executive: Outplacement amount not to exceed a total of $35,000.(ii)Group 2 Executive: Outplacement amount not to exceed a total of $20,000.ARTICLE

IIILIMITATION ON PAYMENT OF BENEFITS3.1Non-Duplication of Benefits. Any Severance Benefits payable to an Eligible Employee under the Plan will be in lieu of and not in addition to any severance benefits to which the Eligible Employee would otherwise be entitled under any general severance policy or severance plan maintained by the Company or any agreement between the Eligible Employee and the Company that provides for severance benefits. Notwithstanding any other provision in the Plan to the contrary, the benefits provided hereunder shall be reduced by amounts paid or provided to an Eligible Employee by the Company under any other applicable plan or arrangement providing for a payment upon a termination of employment, including but not limited to, statutory severance or other termination pay arrangements, any Change in Control payments, or payments associated with individual employment or retention agreements. Additionally, no Eligible Employee shall otherwise be eligible for severance under the Baxter Severance Pay Plan (or any successor United States broad-based severance plan 4thereto). Notwithstanding the foregoing, this Section 3.1 shall not apply to any vesting or payments associated with an Eligible Employeeâ€™s long-term incentive awards granted under the Baxter International Inc. 2011 Incentive Plan, the Baxter International Inc. 2015 Incentive Plan or the Baxter International Inc. Amended and Restated 2021 Incentive Plan or any shareholder-approved successor plans. 3.2Section 280G. If any payment or benefit received or to be received by an Eligible Employee (including any payment or benefit received pursuant to this Plan or otherwise) would be, in whole or in part, subject to the excise tax imposed by Section 4999 of the Code, or any successor provision thereto, or any similar tax imposed by state or local law, or any interest or penalties with respect to such excise tax (such tax or taxes, together with any interest and penalties, are hereinafter collectively referred to as the â€œExcise Taxâ€), then the payments or benefits provided under this Plan or any other agreement pursuant to which the Eligible Employee receives payments that give rise to the Excise Tax will either be (a) paid in full, or (b) reduced to the extent necessary to make such payments and benefits not subject to such Excise Tax. The Company shall reduce or eliminate the payments in the following order of priority in a manner consistent with Section 409A of the Code: (i) first by reducing cash compensation, (ii) next from equity compensation, and then (iii) pro rata among all remaining payments and benefits, in each case, in reverse order beginning with payments that are to be paid the farthest in time from the determination. The Eligible Employee shall receive the greater, on an after-tax basis, of (a) or (b). In no event will the Company be required to gross up any payment or benefit to the Executive to avoid the effects of the Excise Tax or to pay any regular or excise taxes arising from the application of the Excise Tax. Unless the Company and the Eligible Employee otherwise agree in writing, any parachute payment calculation will be made in writing by the Accounting Firm (as defined below), whose calculations will be conclusive and binding upon the Company and the Eligible Employee for all purposes. The Company and the Eligible Employee will furnish to the Accounting Firm such information and documents as they may reasonably request in order to make a parachute payment determination. The Accounting Firm also will provide its calculations, together with detailed supporting documentation, both to the Company and to the Eligible Employee, before making any payments that may be subject to the Excise Tax. For purposes of this Plan, â€œAccounting Firmâ€ shall mean the then-current independent auditors of the Company or such other nationally recognized certified public accounting firm as may be designated by the Company.3.3Indebtedness of Eligible Employee. If an Eligible Employee is indebted to the Company as of the date of the Eligible Employeeâ€™s termination of employment, the Company reserves the right to offset any benefits under this Plan by the amount of such indebtedness, provided that such offset shall not give rise to any tax under Section 409A of the Code.3.4Withholding. Amounts paid to an Eligible Employee hereunder shall be subject to all applicable federal, state and local withholding taxes, and all legally required deductions.3.5Recoupment and Cessation; Reemployment. After amounts have been paid to an Eligible Employee under this Plan, if, within twelve (12) months of the Eligible Employeeâ€™s 5termination of employment: (a) the Eligible Employee violates his or her obligations to the Company and its Affiliates pursuant to an employment agreement, restrictive covenant or similar agreement, or (b) it is determined that the Eligible Employee could have been terminated for Cause, then, the Eligible Employee shall be required to repay to the Company all amounts paid under the Plan. Such repayment shall be made by Eligible Employee within thirty (30) days of demand for repayment by the Committee or its delegate. The Committee or its delegate shall cease any future payments under the Plan. By accepting benefits under this Plan, an Eligible Employee: (i) certifies his or her understanding that any failure by the Eligible Employee to comply with this Plan or with any employment agreement, restrictive covenant or similar agreement may result in legal action, and (ii) acknowledges that the Company and its Affiliates will face irreparable injury in the event of a breach or a threatened breach of such agreements and covenants which may be difficult to calculate in dollar terms, and therefore, agrees that in such event, (A) the Company shall be entitled, in addition to remedies otherwise available at law or in equity, to specific performance and/or immediate injunctive and/or other equitable relief, without the posting of a bond and without proof of damages; and (B) should the Company successfully enforce any portion of this Plan or such agreements in a lawsuit or other proceeding, the Company shall be entitled to all of its reasonable attorneysâ€™ fees and costs, in addition to damages and equitable relief, incurred as a result of enforcing this Plan and such agreements. In the event the Eligible Employee becomes reemployed after a Qualifying Termination by the Company or its Affiliates prior to all payments being made under the Plan, the Eligible Employee shall be entitled to keep any payments made up to the date or reemployment, and any future payments shall cease.ARTICLE IVADMINISTRATION, AMENDMENT AND TERMINATION; TERM4.1Administration by the Committee. The Plan shall be administered by the Committee. The Committee will have and will exercise the powers and duties described herein, including, the power and duty to interpret this Plan and determine the benefit to which Eligible Employees are entitled hereunder. The Committee shall have the authority to delegate its powers and duties under the Plan to one or more individuals.4.2Indemnification and Expenses. The Company shall indemnify and hold harmless members of the Committee against any and all expenses and liabilities arising out of their administrative functions or fiduciary responsibilities, including any expenses and liabilities that are caused by or result from an act or omission constituting the negligence of such member in the performance of such functions or responsibilities, but excluding expenses and liabilities that are caused by or result from such member's own gross negligence or willful misconduct. Expenses against which such member shall be indemnified hereunder shall include, without limitation, the amounts of any settlement or judgment, costs, counsel fees, and related charges reasonably incurred in connection with a claim asserted or a proceeding brought or settlement thereof. To the extent required by applicable law, but not otherwise, Committee members shall furnish bond or security for the performance of their duties hereunder. Any expenses properly incurred by the Committee incident to the administration, 6termination or protection of the Plan, including the cost of furnishing bond, shall be paid by the Company.4.3Committee Powers and Responsibilities. The Committee or its delegate shall have all discretionary powers necessary to enable it to properly to carry out its duties with respect to the administration of the Plan. Not in limitation, but in amplification of the foregoing, the Committee shall have the power and authority, in its discretion, to:(a)Construe the Plan to determine all questions that shall arise as to interpretations of the Planâ€™s provisions and factual findings, including determination of which individuals are eligible for severance benefits, the amount of severance benefits to which any employee may be entitled, and all other matters pertaining to the Plan;(b)Adopt amendments to the Plan document which are deemed necessary or desirable to bring these documents into compliance with all applicable laws and regulations, including but not limited to Section 409A of the Code and the guidance thereunder; and(c)If the Committee has delegated some of its powers and duties under the Plan to an individual who is also an Eligible Employee, such Eligible Employee may not act or vote in a decision specifically relating to themselves as an Eligible Employee in the Plan.4.4Decisions of the Committee. Decisions of the Committee or its delegate made in good faith upon any matter within the scope of its authority shall be final, conclusive and binding upon all persons, including Eligible Employees, their heirs and their legal representatives. 4.5Plan Amendment and Termination. The Plan may be amended or terminated at any time and for any reason by action of the Committee.ARTICLE VCLAIMS FOR BENEFITSAny person who believes they are entitled to benefits under this Plan may submit a claim for benefits within 90 days of a Qualifying Termination. The claim must be in writing and state the claimantâ€™s reasons for claiming these benefits. The claims must be sent to the Committee (or its delegate). If the claim is denied, in whole or in part, written notice of the denial will be provided within ninety (90) days of initial receipt of the claim. If an extension of time is required for making a claim determination, a written notice of the extension will be provided prior to the end of the original 90-day period explaining the circumstances requiring the extension and the date by which the determination will be made.The claim denial notice will include: â€¢The specific reason for the denial;7â€¢The specific Plan provisions on which the denial is based;â€¢A description of any additional material or information that is necessary to complete the claim and an explanation of why such material or information is necessary.â€¢A description of the appeal procedures.â€¢A statement of the right to bring suit under ERISA upon claim denial following a final appeal.An individual whose claim for benefits is denied may: (i) file a request for review with the Committee or its delegate within sixty (60) days; (ii) receive reasonable access to and copies (free of charge) of all documents, records and other information relevant to the claim; and (iii) submit written comments, documents, records and other information relating to the claim. After receiving a request for review, the Committee or its delegate will render a final decision within sixty (60) days, unless circumstances require an extension of an additional sixty (60) days for the review. In this case, the Committee or its delegate will notify the claimant in writing of the need for an extension. The decision of the Committee or its delegate will be in writing, and will include:â€¢the specific reasons for the decision;â€¢specific references to the pertinent provisions of the Plan on which the decision is based;â€¢a statement regarding entitlement to access and copies of (free of charge) all documents and information relevant to the claim; andâ€¢a statement concerning the right to bring action under ERISA Section 502(a) to recover benefits or enforce rights.No person eligible for benefits under the Plan has a right to seek review of a denial of benefitsâ€”or to bring any action to enforce a claim for benefitsâ€”in any court, prior to filing a claim for benefits and exhausting all rights described under this section, or more than six months after receipt of the decision on appeal. Except as may be otherwise required by law, the decision of the Committee or its delegate will be binding on all parties.ARTICLE VI MISCELLANEOUS6.1Â Â Â Â No Contract of Employment. The adoption and maintenance of the Plan shall not be deemed to be a contract of employment between the Company and any person or to be consideration for the employment of any person. Nothing in this Plan shall be construed as giving any Eligible Employee any right to be retained in the employ of the Company or shall affect the terms and conditions of an Eligible Employeeâ€™s employment with the Company prior to the Effective Date.6.2Â Â Â Â ERISA Plan. The Plan is intended to be a â€œtop hatâ€ â€œemployee welfare benefit planâ€ within the meaning of the Employee Retirement Income Security Act of 1974, as amended (â€œERISAâ€) and 29 C.F.R. Â§ 2520.104-24.6.3Â Â Â Â Effect of Plan. This Plan is intended to supersede provisions of prior oral or written policies of the Company to the extent that such provisions address severance payments or benefits 8provided upon a Qualifying Termination and all prior oral or written communications to Eligible Employees with respect to the subject matter hereof, and all such provisions of such prior policies or communications are hereby null and void and of no further force and effect. The terms of all individual agreements or long-term incentive plans (including without limitation, a Change in Control Agreement or any other change in control agreements providing for severance benefits in connection with a termination of employment following a change in control) shall continue without change and are not superseded, modified, voided or terminated by the Plan. Additionally, this Plan shall not apply to any Eligible Employee if (a) an Eligible Employee is subject to a Change in Control Agreement, and (b) an event occurs that is otherwise covered under the terms of such Change in Control Agreement. For the avoidance of doubt, in such a circumstance, the terms of the Change in Control Agreement shall govern in all cases involving a Change in Control. 6.4Â Â Â Â Source of Payments. All payments provided under this Plan, other than payments made pursuant to any other Company employee benefit plan that provides otherwise, shall be paid in cash from the general funds of the Company, and no special or separate fund shall be established, and no other segregation of assets made, to assure payment. To the extent that any Eligible Employee acquires a right to receive payments from the Company hereunder, such right shall be no greater than the right of an unsecured creditor of the Company.6.5Â Â Â Â No Mitigation or Retirement Plan Offset. An Eligible Employee with a Qualifying Termination shall not be required to mitigate the amount of any payment provided for in this Plan by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Plan be reduced by any compensation earned by such a terminated Eligible Employee as the result of employment by another employer or by retirement benefits paid by the Company or another employer after the date of the Eligible Employeeâ€™s termination of employment or otherwise.6.6Â Â Â Â Notice. For the purpose of this Plan, notices and all other communications shall be in writing and shall be deemed to have been duly given when delivered or mailed by overnight courier or United States registered mail, return receipt requested, postage prepaid, addressed to the Plan to the General Counsel, Baxter International Inc., One Baxter Parkway, Deerfield, Illinois 60015, and to an Eligible Employee to the address set forth in the Companyâ€™s payroll records or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.6.7Â Â Â Â Nonalienation of Benefits. No benefit under the Plan may be assigned, transferred, pledged as security for indebtedness or otherwise encumbered by any Eligible Employee or subject to any legal process for the payment of any claim against an Eligible Employee.6.8Â Â Â Â Application of Section 409A. The intent of the Company is that payments and benefits under the Plan are exempt from Section 409A of the Code (after first applying the exception for short-term deferrals, then applying the exception for severance benefits to any remaining amounts, and then applying the exception for small amounts to any further remaining amounts) or otherwise comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum 9extent permitted, the Plan shall be interpreted and be administered to comply therewith. Notwithstanding anything to the contrary in the other provisions of the Plan, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, an Eligible Employee shall not be considered to have terminated employment or service with the Company or its Affiliates for purposes of the Plan and no payment or benefit shall be due to the Eligible Employee under the Plan until the Eligible Employee would be considered to have incurred a â€œseparation from serviceâ€ from the Company or its Affiliates within the meaning of Section 409A of the Code. Additionally, if an Eligible Employee, at the date of a Qualifying Termination, is a â€œspecified employeeâ€ as defined in the Baxter International Inc. and Subsidiaries Deferred Compensation Plan, and such amounts are subject to Section 409A of the Code, then amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Plan during the six-month period immediately following the Eligible Employeeâ€™s termination of employment shall instead be paid on the first business day after the date that is six months following the Eligible Employeeâ€™s termination of employment (or upon the Eligible Employeeâ€™s death, if earlier) unless the Company reasonably determines, based on the advice of counsel, that such delayed commencement is not required to avoid an â€œadditional taxâ€ under Section 409A(a)(2) of the Code. Each amount to be paid or benefit to be provided pursuant to the Plan shall be construed as a separate identified payment for purposes of Section 409A of the Code. 6.9Â Â Â Â Governing Law, Venue. The Plan shall be construed according to the laws of the State of Illinois, except to the extent such laws are preempted by federal law. Any litigation involving the Plan must be brought in federal court in Chicago, Illinois.6.10Â Â Â Â Validity. The invalidity or unenforceability of any provision of this Plan shall not affect the validity or enforceability of any other provision of this Plan, which shall remain in full force and effect.6.11Â Â Â Â Headings. The headings contained in this Plan are intended solely for convenience of reference and shall not affect the rights of the parties to this Plan.6.12Â Â Â Â Severability. In the event any provision of this document conflicts with applicable laws or laws under which this document is construed, or if any provision of this document is held to be illegal, invalid or unenforceable or partially illegal, invalid or unenforceable by a court with jurisdiction over the Plan or this document, then this document shall be modified to conform with said laws or judicial determination, such provision shall be construed and enforced only to such extent as it may be a legal and enforceable provision. Such illegal, invalid, and unenforceable provisions will not affect any other provision hereof, and this Plan will be construed and enforced as if such provisions had not been included, and all other provisions of this document shall be given full effect.6.13Â Â Â Â Recovery of Benefits. In the event an Eligible Employee receives any Severance Benefits which are in excess of the amount which should have been made, the Company shall have the right to recover the amount of such excess from the Eligible Employee. The Committee may, at its 10option, deduct the amount of such excess from any subsequent payments, as allowed under any applicable law.ARTICLE VIISUCCESSORS; BINDING AGREEMENTÂ Â Â Â 7.1Â Â Â Â Assumption by Successor. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform the obligations under this Plan in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of its obligations hereunder. As used in this Section 7, the â€œCompanyâ€ shall include the Company as defined in Section 1.8 and any successor to its business and/or assets which shall assume and agree to perform the obligations arising under this Plan by operation of law or otherwise.Â Â Â Â 7.2Â Â Â Â Enforceability; Beneficiaries. This Plan shall be binding upon and inure to the benefit of each Eligible Employee (and such Eligible Employeeâ€™s personal representatives and heirs) and the Company and any organization which succeeds to substantially all of the business or assets of the Company, whether by means of merger, consolidation, acquisition of all or substantially all of the stock, assets or business of the Company or otherwise, including, without limitation, as a result of a change in control or by operation of law. This Plan shall inure to the benefit of and be enforceable by each Eligible Employeeâ€™s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If an Eligible Employee should die while any amount would still be payable hereunder if such Eligible Employee had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Plan to

such Eligible Employeeâ€™s devisee, legatee or other designee or, if there is no such designee, to such Eligible Employeeâ€™s estate.ARTICLE VIIIRELEASE OF CLAIMSAs a condition to the receipt of any of the Severance Benefits, each Eligible Employee must execute and allow to become effective and not revoke a release substantially similar with the form on Appendix I (the â€œReleaseâ€) with such execution occurring not prior to the date of Eligible Employeeâ€™s termination of employment and not later than thirty (30) days (unless a greater period is required by applicable law) after the Eligible Employee's receipt thereof. The date on which such Release becomes effective and not revocable is the â€œRelease Effective Dateâ€. The Severance Benefits shall commence to an Eligible Employee promptly following the Release Effective Date in accordance with the terms of the Plan. Notwithstanding the foregoing, if the time for considering a Release spans the end of one calendar year and the beginning of the following calendar year, then the Severance Benefits shall be paid (or shall commence, as applicable) in the second calendar year (promptly following the later of the Release Effective Date or January 1 of the second calendar year) regardless of when the Release Effective Date occurs.11ARTICLE IXADMINISTRATIONÂ Â Â Â 9.1Â Â Â Â Funding. The Company pays Severance Benefits solely from current operating funds and general assets. No portion of the Plan is funded.Â Â Â Â 9.2Â Â Â Â Plan Sponsor and Plan Administrator. The Plan is sponsored by Baxter International Inc. The Compensation and Human Capital Committee of the Board, or its delegate, is the Plan Administrator.Â Â Â Â 9.3Â Â Â Â Plan Name. The name of the plan is the Baxter International Inc. Executive Severance Plan.Â Â Â Â 9.4Â Â Â Â Plan Type. The Plan is intended to be a â€œtop hatâ€ â€œemployee welfare benefit planâ€ within the meaning of the Employee Retirement Income Security Act of 1974, as amended (â€œERISAâ€) and 29 C.F.R. Â§ 2520.104-24.Â Â Â Â 9.5Â Â Â Â Plan Year. The Plan Year is January 1 through December 31.Â Â Â Â 9.6Â Â Â Â Agent for service of legal process. The agent for service of legal process on the Plan is: Executive Vice President and General Counsel Baxter International Inc. One Baxter Parkway Deerfield, Illinois 60015Â Â Â Â Â Â Â Â Legal process on the Plans may also be served on the Plan Administrator.Â Â Â Â 9.7Â Â Â Â EIN. Baxterâ€™s employer identification number is 36-0781620.Â Â Â Â 9.8Â Â Â Â ERISA Rights. Receive information about your plan and benefitsâ€¢ Examine (without charge) at the Plan Administratorâ€™s office and at other specified locationsâ€“such as work sitesâ€“all plan documents. These may include the latest annual report (Form 5500 series) filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration (if applicable).â€¢ Obtain, upon written request to the Plan Administrator, copies of all plan documents governing the operation of the Plan, including the most recent annual report (Form 5500 series) (if applicable), and an updated summary plan description. The administrator may make a reasonable charge for these copies.12Enforcing your rightsIf your claim for a benefit is denied or ignored, in whole or in part, you have the right to know why and to obtain copies of the documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.Under ERISA, there are steps you can take to enforce your ERISA rights. For instance:â€¢ If you request a copy of plan documents or the latest annual report from the Plan and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materialsâ€”unless the materials were not sent because of reasons beyond the control of the Plan Administrator.â€¢ If you have a claim for benefits which is denied or ignoredâ€”in whole or in part after going through the appeals procedureâ€”you may file suit in a state or federal court.â€¢ If it should happen that plan fiduciaries misuse the Planâ€™s money, or if you are discriminated against for asserting your ERISA rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.If you file suit against the Plan, the court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and feesâ€”for example, if it finds your claim is frivolous.Assistance with your questionsIf you have any questions about the Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210.You may also obtain certain publications about your rights and responsibilities under ERISA by calling the Employee Benefits Security Administration Brochure Request Line at 1-800-998-7542, on the Internet at http://www.dol.gov/pwba/public/pubs/imain.htm, or by contacting the EBSA field office nearest you.13APPENDIX IFORM OF RELEASE AGREEMENTConfidential Separation Agreement and General Release of ClaimsThis Confidential Separation Agreement and General Release of Claims (â€œAgreementâ€) is between [EMPLOYEE NAME] (â€œEmployeeâ€) and [EMPLOYER NAME] (the â€œCompanyâ€).Employee and the Company, for good and valuable consideration, mutually agree to the following terms and conditions:1.Notification Date and Separation Datea.The Company provided Employee with this Agreement on [NOTIFICATION DATE] (â€œNotification Dateâ€).b.Employeeâ€™s employment with the Company will end on [SEPARATION DATE] (â€œSeparation Dateâ€).c.[Option 1] Until the Separation Date, Employee will continue to report to work daily. [Option 2] As of the Notification Date, Employee will not report to work daily. Employee will assist in the transition, including, but not limited to, answering questions as necessary and requested by the Company through the Separation Date and as otherwise set forth below. Notwithstanding the foregoing, the parties hereto expect that, following the Notification Date, the average monthly time spent by Employee on services provided by the Employee shall be more than twenty percent (20%) of the average monthly time spent by Employee on services performed by the Employee for the Company during the thirty-six (36) months immediately preceding the Notification Date. 2.The Companyâ€™s Promisesa.The Company agrees to the following:i.The Company will pay Employee the amounts in accordance with the Baxter International Inc. Executive Severance Plan (the â€œPlanâ€).ii.The Company will not contest any claim for unemployment benefits filed with the state arising out of Employeeâ€™s employment with or separation from the Company, provided, however, that nothing herein prohibits the Company from providing information or documents to the state if requested or required by law. This provision shall not apply if Employee files for such benefits in the state of California.b.Any payment specified in this Section will be made in accordance with the terms and conditions of the Plan. All consideration set forth in this Section is a gross amount and will be subject to all 14legally required and appropriate withholdings (including any unpaid premium deductions held in arrears).c.Employee will not be eligible to receive the consideration set forth in this Section unless: (i) Employee signs and returns this Agreement by the deadline for Employeeâ€™s signature as specified below, and provided that Employee does not revoke acceptance of this Agreement within the revocation period described below; (ii) Employee timely returns all Company property in good working order as required below; and (iii) Employee is otherwise in compliance with this Agreement.3.Payment for Work PerformedEmployee has been and/or will be paid up through and including the Separation Date for all work performed on regularly scheduled pay dates at Employeeâ€™s current base salary (less withholdings). The Company has or will also pay the Employee for all earned but unused paid time off within thirty (30) days following the Separation Date, or sooner if required by law. These will be paid regardless of whether Employee signs this Agreement. Employee acknowledges and agrees that upon payment of these amounts, Employee has been paid for all work performed, including all wages, salary, bonuses, overtime, and any earned, unused paid time off up through and including the Separation Date. Employee agrees that Employee is entitled to no other payments or other compensation whatsoever arising out of Employeeâ€™s employment with, or termination from, the Company, unless otherwise expressly agreed to by the parties in this Agreement.4.Employeeâ€™s PromisesEmployee agrees to the following:a.Employee releases and waives all claims on behalf of Employee and Employeeâ€™s heirs, assigns, executors, administrators and anyone claiming for or on Employeeâ€™s behalf, against the Company and/or the other Released Parties (defined below) which have arisen up to and including the date on which Employee signs this Agreement. â€œReleased Partiesâ€ means the Company and its parents, subsidiaries, affiliates, and assigns, and all its and their executives, officers, directors, attorneys, employees, agents, and employee benefit plans. This waiver and release includes but is not limited to: (i) all claims alleging unlawful discrimination, harassment, or retaliation based on race, sex, gender, color, religion, national origin, sexual orientation, gender identity or expression, age, veteran or military status, disability or any other protected category under federal, state or local laws, including but not limited to any claims under the Age Discrimination in Employment Act as amended by the Older Workersâ€™ Benefit Protection Act; (ii) all claims for unpaid compensation or benefits under any practice, policy, or plan, (iii) all tort or contract claims, whether seeking compensatory, punitive, legal or equitable damages, attorneysâ€™ fees and/or costs of any kind, including, but not limited to, claims for wrongful or 15retaliatory discharge, breach of contract, violation of public policy, severance, defamation, libel, slander, invasion or breach of privacy, intentional and/or negligent infliction of emotional distress, or personal injury; and (iii) any other claims whatsoever up through and including the date Employee signs this Agreement and whether currently known or unknown (collectively the â€œWaived and Released Claimsâ€).Notwithstanding the foregoing, â€œWaived and Released Claimsâ€ do not include, and Employee is not waiving and releasing: (a) claims that by law may not be waived and released, including but not limited to any claim for unemployment or workersâ€™ compensation benefits, or any claim for any vested, accrued benefits to which Employee is (or becomes) otherwise entitled pursuant to the terms and conditions of any of the applicable benefit plans in which Employee participated prior to the Separation Date; (b) claims arising out of conduct occurring after the date this Agreement is signed by Employee; or (c) Employeeâ€™s right to file a claim or lawsuit to enforce the terms of this Agreement after it becomes effective, or any claim or lawsuit to challenge the validity of this Agreement under the Age Discrimination in Employment Act as amended by the Older Workersâ€™ Benefit Protection Act.b.Employee will not accept any money or other personal relief on account of or as a remedy for Employeeâ€™s actual or alleged injury or damages, as a result of or in connection with any past, present or future lawsuit, charge or other claim filed with or by any federal, state, or local court, agency or other governmental entity or person that involves or is based upon any Waived and Released Claims (including without limitation any charge or other claim filed by or with the Equal Employment Opportunity Commission (â€œEEOCâ€) or any similar state or local governmental agency alleging any form of employment discrimination or retaliation), it being understood and agreed that Employee hereby waives and releases any such monetary or other personal recovery.c.Employee will not file or become a plaintiff or claimant of any kind in, any lawsuit, arbitration or other legal proceeding against the Company (or any of the other Released Parties) for, or based on, any Waived and Released Claims. This includes, without limitation, Employeeâ€™s promise and agreement hereby not to become a named or opt-in plaintiff, class or collective action member or other claimant in any class action, collective action, representative action or other consolidated action in court or any arbitration proceeding for, or based on, any Waived and Released Claims, and to take all steps necessary to opt out of any such action or proceeding.d.Employee will return, on or before Employeeâ€™s Separation Date or sooner as directed by the Company, all Company property in good working order (by way of example, this includes, but is not limited to, key cards, badges, computers, tablets, cell phones, credit cards, documents, electronic storage devices, building/parking passes, and keys).16e.Employee will continue to abide by all obligations set forth in any contract or agreement with the Company which contain restrictive covenants related to confidentiality, non-competition, non-solicitation, and intellectual property ownership, and any such contract or agreement is are incorporated herein by reference and remains in full force and effect.f.Employee will cooperate with the Company in any ongoing litigation, claim, investigation, or subpoena involving or relating to the Company for which Employee may have knowledge due to Employeeâ€™s employment with the Company. This will include Employee being available to meet with the Companyâ€™s legal representatives, and to appear and testify truthfully as a witness in administrative or court proceedings or in depositions provided that the Company will make reasonable efforts to schedule any such meetings or appearances at mutually agreeable times and locations. g.Employee will, within forty-eight (48) hours of receipt of any subpoena or other legal requirement requiring testimony, information or cooperation from Employee, notify the Companyâ€™s General Counsel to allow the Company to assert all available legal defenses; provided, however, this obligation shall not apply to any legal proceeding for which Employee is legally prohibited from notifying the Company. Notwithstanding the foregoing, nothing in this Agreement (i) requires Employee to notify the Company of a subpoena, disclosure obligation or request from the Securities and Exchange Commission, National Labor Relations Board or Equal Employment Opportunity Commission or (ii) impedes Employee from cooperating directly with the aforementioned government entities.h.If Employee is an officer or director of the Company or any parent, subsidiary, or affiliate of the Company, Employee shall sign, date and return with this Agreement the resignation form attached as Exhibit A to this Agreement. i.Employee will not defame, disparage, libel or slander the Company or any of the Released Parties.j.Employee will not seek future employment with the Company or any parent, subsidiary or affiliate of the Company. If Employee seeks future employment with any of the foregoing entities, this Agreement will be a legitimate reason to reject outright Employee for employment and/or rescind an offer of employment.k.The consideration provided to Employee in this Agreement will be reported to appropriate governmental agencies as taxable income to the extent required by law. Employee agrees to indemnify the Company and the Released Parties and hold them harmless from any interest, taxes or penalties assessed against them by any governmental agency as a result of Employeeâ€™s non-payment of taxes on the consideration provided to Employee under this Agreement. The 17Company and the Released Parties make no representation as to the taxability of the consideration provided to Employee under this Agreement.5.Additional Limitations on Employeeâ€™s PromisesThis Agreement does not in any way, and is not intended to: (i) limit or restrict Employeeâ€™s non-waivable right to file an administrative complaint with the EEOC, the National Labor Relations Board (â€œNLRBâ€), or with another governmental agency; (ii) require Employee to dismiss any pending administrative complaint with the EEOC, NLRB, or with another governmental agency; (iii) limit or restrict Employeeâ€™s non-waivable right to participate as a witness or cooperate in any investigation by the EEOC, NLRB, or another governmental agency; or (iv) limit Employeeâ€™s right to receive an award for information provided to any governmental agency. The parties acknowledge that Employee has the right to: (1) report any good faith allegation of unlawful employment practices to any appropriate federal, state, or local government agency enforcing discrimination laws; (2) report any good faith allegation of criminal conduct to any appropriate federal, state, or local official; (3) participate in a proceeding with any appropriate federal, state, or local government agency enforcing discrimination laws; (4) make any truthful statements or disclosures required by law, regulation, or legal process; and (5) request or receive confidential legal advice.6.Mutual Promisesa.WAIVER OF RIGHT TO JURY: Employee and the Company agree that, in the event there is any dispute arising out of or relating to this Agreement, including, without limitation, any claim regarding the validity or enforceability of the general release, or any claim not purportedly waived by the general release, the parties hereby irrevocably waive any right to a trial by jury of such dispute or claim.b.The parties agree that maintaining the confidentiality of this Agreement is to their mutual benefit and is their preference. Therefore, the Company and Employee will keep the fact of and terms of this Agreement confidential, except that Employee may disclose the fact of and terms of this Agreement to Employeeâ€™s spouse, and any tax, financial or legal advisors, as necessary, provided that such persons are advised of and agree to maintain the confidentiality of this Agreement, and except as required by law or as requested by or disclosed to a governmental agency on a confidential basis. The Company may disclose the fact of and terms of this Agreement to its tax, financial or legal advisors, and any employee or agent of the Company necessary to execute the terms of the Agreement, and except as required by law or as requested by or disclosed to a governmental agency. This confidentiality requirement includes a promise not to disclose the fact 18of or terms of this Agreement in any medium, whether oral, written or electronic, including but not limited to, the Internet and social media.7.Employee Representations Concerning Company ConductUnless provided to the Company in writing concurrently with this signed Agreement, Employee is not personally aware of any actions by the Company or any of the Released Parties up through and including the date Employee signs this Agreement that evidence: (i) any inappropriate, discriminatory, unlawful, unethical, or retaliatory conduct of any kind whatsoever (â€œInappropriate Conductâ€) against Employee or any other third person or entity, (ii) any failure of the Company to reasonably investigate or respond to any complaint that Employee has made about Inappropriate Conduct, or (iii) any failure by the Company to comply with any applicable laws, statutes, rules, or regulations whether under federal, state, or local law.8.Miscellaneous Termsa.This Agreement may be executed in multiple counterparts, each part constituting an original, and an electronic copy or signature will constitute an original.b.This Agreement will not be construed as an admission of wrongdoing on the part of the Company, Employee, or the Released Parties.c.The parties agree that the laws of the State of Illinois will govern this Agreement, without regard to its conflicts of laws principles. The parties further agree to, and submit to, on an exclusive basis, the personal jurisdiction and venue of the state and federal courts located in Illinois for any matters arising out of or related of this Agreement. The parties also irrevocably waive any claim that the courts in Illinois are an inconvenient forum. If Employee resides and is/was employed by the Company in California or Louisiana, this paragraph shall not apply.d.If this Agreement is found to be unenforceable, in whole or in part, it will be modified to give full effect to the partiesâ€™ intentions or, if not possible, the unenforceable provision excised from the Agreement, with each remaining portion of the Agreement remaining in full force and effect.e.This Agreement will supersede any prior oral or written communications concerning the subject matter or terms of this Agreement.9.Employeeâ€™s Acknowledgement and AgreementEmployee understands, acknowledges and agrees that:a.the consideration provided to Employee in this Agreement is of value and exceeds any amount to which Employee is otherwise entitled;b.Employee has carefully read and fully understands this Agreement and is signing this Agreement knowingly and voluntarily and without duress or coercion;19c.Employee has been advised by this Agreement in writing to consult with an attorney, at Employeeâ€™s own expense, prior to executing this Agreement;d.Employee has been given a full twenty-one (21) calendar days to consider this Agreement before signing it; ande.Employee has seven (7) calendar days following Employeeâ€™s execution of this Agreement to revoke his/her acceptance of this Agreement by delivering within that time period a written notice of revocation

to â€œExecutive Vice President and Chief Human Resources Officer, Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, Illinois 60015.â€ This Agreement will not become effective or enforceable until this seven (7) day revocation period has expired without any revocation by Employee.THIS AGREEMENT MAY NOT BE SIGNED BY EMPLOYEE UNTIL THE SEPARATION DATE OR AFTER.THIS AGREEMENT MUST BE SIGNED BY EMPLOYEE AND RETURNED TO [HR CONTACT] BY [RETURN DATE] TO BE ENFORCEABLE. IF NOT RECEIVED BY THIS DATE, EMPLOYEE WILL BE DEEMED TO HAVE REJECTED THIS AGREEMENT.ACCEPTED AND AGREED TO BY:_____Employee_____Employeeâ€™s Signature Date _____Authorized Company Representative_____The Companyâ€™s Signature Date20Exhibit AÂ Â Â Â To:Baxter International Inc.Attention: Corporate SecretaryOne Baxter ParkwayDeerfield, IL 60015Effective as of the date of my signature below, I hereby resign as a director, member or officer of Baxter International Inc. and of each of its subsidiaries (collectively, â€œBaxterâ€) and as a member of any committee of Baxter or any board of directors, board of managers or special subcommittee thereof. [NAME]Date21 EX-31.1 4 bax-20240930xex311.htm EX-31.1 DocumentEXHIBIT 31.1Certification of Chief Executive OfficerPursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as AmendedI, JosÃ© E. Almeida, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ JosÃ© E. AlmeidaJosÃ© E. AlmeidaChair, President andChief Executive OfficerDate: NovemberÂ 12, 2024 EX-31.2 5 bax-20240930xex312.htm EX-31.2 DocumentEXHIBIT 31.2Certification of Chief Financial OfficerPursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as AmendedI, Joel T. Grade, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ Joel T. GradeJoel T. GradeExecutive Vice President, Chief Financial Officer and Interim Chief Accounting Officer Date: NovemberÂ 12, 2024 EX-32.1 6 bax-20240930ex321.htm EX-32.1 DocumentEXHIBIT 32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. SectionÂ 1350,as Adopted Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002JosÃ© E. Almeida, as Chair, President and Chief Executive Officer of Baxter International Inc. (the â€œCompanyâ€), certifies, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that:(1)the Companyâ€™s Quarterly Report on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ JosÃ© E. AlmeidaJosÃ© E. AlmeidaChair, President andChief Executive OfficerNovemberÂ 12, 2024 EX-32.2 7 bax-20240930xex322.htm EX-32.2 DocumentEXHIBIT 32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. SectionÂ 1350,as Adopted Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002Joel T. Grade, as Executive Vice President, Chief Financial Officer and Interim Chief Accounting Officer of Baxter International Inc. (the â€œCompanyâ€), certifies, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that:(1)the Companyâ€™s Quarterly Report on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Joel T. GradeJoel T. GradeExecutive Vice President, Chief Financial Officer and Interim Chief Accounting OfficerNovemberÂ 12, 2024 EX-101.SCH 8 bax-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - STOCKHOLDERSâ€™ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - REVENUES link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - FINANCING ARRANGEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - REVENUES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - REVENUES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - REVENUES - Contract Assets and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - REVENUES - Lease Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - EARNINGS PER SHARE - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - SEGMENT INFORMATION - Revenue rom External

Customers by Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bax-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 bax-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 bax-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue related to performance obligations Contract with Customer, Performance Obligation Satisfied in Previous Period Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued Expenses And Other Current Liabilities Fair Value Disclosures [Line Items] Fair Value Disclosures [Line Items] Fair value disclosure Line items. Currency translation adjustments, net of tax expense (benefit) of ($19) and $12 for the three months ended September 30, 2024 and 2023, respectively, and ($3) and $2 for the nine months ended September 30, 2024 and 2023, respectively. Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Adjustments to reconcile net loss to cash flows from operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Work in process Inventory, Work in Process, Gross Range Statistical Measurement [Domain] Remaining value available under stock repurchase programs Share Repurchase Program, Remaining Authorized, Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Kidney Care Manufacturing and Supply Agreement Kidney Care Manufacturing and Supply Agreement [Member] Kidney Care Manufacturing and Supply Agreement Cover [Abstract] Debt Securities Debt Securities [Member] Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In process Research and Development In Process Research and Development [Member] Developed technology, including patents Developed Technology Including Patents [Member] Developed technology including patents. Sales-type lease revenue Sales-type Lease, Revenue Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair value hedges Fair Value Hedging [Member] Medical Products and Therapies Medical Products And Therapies [Member] Medical Products And Therapies Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Fair value and carrying value by balance sheet grouping. Long-term debt and finance lease obligations, less current portion Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Derivative asset, fair value Gross amounts recognized in the condensed consolidated balance sheets Derivative Asset, Subject to Master Netting Arrangement, before Offset Pension and OPEB plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Non-NEOs Non-NEOs [Member] Schedule of Net Income (Loss) attributable to Stockholder Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] New York Stock Exchange NEW YORK STOCK EXCHANGE, INC. [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long-term debt Long-Term Debt [Member] Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Insurance receivable Insurance Receivable For Write-Off Of Inventory And Fixed Assets Insurance Receivable For Write-Off Of Inventory And Fixed Assets Income (loss) from discontinued operations per common share Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract] Allowance for accounts receivable, current Accounts Receivable, Allowance for Credit Loss, Current Total lease revenue Lease Income Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Bundled equipment and consumable medical products contracts Bundled Equipment And Consumable Medical Products Contracts [Member] Bundled Equipment And Consumable Medical Products Contracts Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Other Intangible Assets, Net Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill [Table Text Block] Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income (loss) from continuing operations Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Hedging Relationship Hedging Relationship [Domain] Classification and Fair Values of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Net investment hedge Net Investment Hedging Net Investment Hedging [Member] Total Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Goodwill [Line Items] Goodwill [Line Items] Balance, beginning of period (in shares) Balance, end of period (in shares) Common Stock, Shares, Outstanding Stock issued under employee benefit plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Proceeds from sale of marketable equity securities Proceeds from Sale and Maturity of Marketable Securities Operating lease liabilities Operating Lease, Liability, Noncurrent Cash Flow Hedging Cash Flow Hedging [Member] Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] United States UNITED STATES Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Service cost Defined Benefit Plan, Service Cost Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Fair Value And Carrying Value By Balance Sheet Grouping [Table] Fair Value And Carrying Value By Balance Sheet Grouping [Table] Fair Value And Carrying Value By Balance Sheet Grouping [Table] Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross other intangible assets, finite-lived Finite-Lived Intangible Assets, Gross Purchases of treasury stock (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type Retirement Plan Type [Axis] Operating Segments Operating Segments [Member] SG&A Selling, General and Administrative Expenses [Member] Cash flows from operations Net Cash Provided by (Used in) Operating Activities Comprehensive loss from continuing operations Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest Cash flows from operations Net Cash Provided by (Used in) Operating Activities [Abstract] Common stock in treasury Treasury Stock, Common [Member] Bridge Facility Bridge Facility [Member] Bridge Facility Summary of Changes in AOCI Income (Loss) by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent 1.3% Global Notes due 2029 Global Notes 1.3% due 2029 [Member] Global Notes 1.3% due 2029 Equity Components Equity Components [Axis] Tangible asset write-off Tangible Asset Write-Off Tangible Asset Write-Off Award Timing Method Award Timing Method [Text Block] Net periodic pension cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Available-for-sale debt securities Debt Securities, Available-for-Sale Restructuring Type Restructuring Type [Axis] Trade names Trade Names [Member] Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash flows from investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Insider Trading Policies and Procedures [Line Items] Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Income (loss) from continuing operations per common share Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional contributed capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical Geographical [Axis] Components of Restructuring Charges Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Gain on disposition Gain (Loss) on Disposition of Business Reserve adjustments Restructuring Reserve, Accrual Adjustment Environmental reserves Accrual for Environmental Loss Contingencies Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accrued expenses and other current liabilities Accrued Liabilities, Current Anti-dilutive securities excluded from computation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Litigation reserve Estimated Litigation Liability Other long-lived asset impairments Impairment of Long-Lived Assets to be Disposed of Net income attributable to noncontrolling interests included in discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Payments Payments for Restructuring Environmental Remediation Site Environmental Remediation Site [Domain] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Pension and other postretirement benefits, net of tax expense (benefit) of zero for the three and nine months ended September 30, 2024 and 2023 Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Marketable equity securities Equity Securities, FV-NI, Current Available-for-sale debt securities Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Non-current assets of discontinued operations Non-current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Current assets: Assets, Current [Abstract] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Care and Connectivity Solutions Care and Connectivity Solutions [Member] Care and Connectivity Solutions Hurricane Hurricane [Member] Consolidation Items Consolidation Items [Axis] Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive income (loss) from continuing operations, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Treasury stock, shares (in shares) Balance, treasury, beginning period (in shares) Balance, treasury, ending period (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Derivative, fair value, net Derivative, Fair Value, Net Other financing activities, net Proceeds from (Payments for) Other Financing Activities Comprehensive income (loss) attributable to Baxter stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension benefits Pension Plan [Member] Capitalized Contract Cost Capitalized Contract Cost [Domain] Security Exchange Name Security Exchange Name Rate increase following December 31, 2024 milestone Debt Instrument, Basis Spread on Variable Rate Award Type Award Type [Axis] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Amounts reclassified from AOCI Reclassification out of Accumulated Other Comprehensive Income [Member] Discontinued operations, pension and other postretirement benefits, tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Less: Other comprehensive loss attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Capital expenditures Payments to Acquire Other Productive Assets 2024 2024 [Member] 2024 Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Repayments of debt Repayments of debt Repayments of Debt Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Non-marketable investment impairments Non-Marketable Investment Impairment Non-Marketable Investment Impairment Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expenses Research and Development Expense Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Cash flows from operations â€“ continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] Revenue recognized contract period Revenue Recognized Contract Period Revenue recognized contract period. Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income (loss), before tax Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Hurricane Helene costs Loss from Catastrophes Assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, at cost Property, Plant and Equipment, Gross Net trade accounts receivable Accounts Receivable, after Allowance for Credit Loss Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] R&D Research and Development Expense [Member] Common stock, authorized (in shares) Common Stock, Shares Authorized Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted YearOf Origination [Domain] YearOf Origination [Domain] YearOf Origination [Domain] Expected additional pre-tax costs Restructuring and Related Cost, Expected Cost Total other comprehensive income (loss) from continuing operations, net of tax Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax Other (income) expense, net Other Nonoperating Income (Expense) [Member] Total business optimization charges Restructuring Costs Long-term debt and finance lease obligations Long - Term Debt and Finance Lease Obligations, Noncurrent Long-term debt and finance lease obligations noncurrent. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total other comprehensive income (loss) from discontinued operations Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax Total Baxter stockholdersâ€™ equity Equity, Attributable to Parent Environmental Remediation Contingency Environmental Remediation Contingency [Axis] Infusion Therapies and Technologies Infusion Therapies and Technologies [Member] Infusion Therapies and Technologies Amortization of net losses and prior service costs Defined Benefit Plan, Amortization of Gain (Loss) Litigation Case [Axis] Litigation Case [Axis] Net sales Disposal Group, Including Discontinued Operation, Revenue Hedging Designation Hedging Designation [Domain] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Interest income Interest Expense, Nonoperating Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Goodwill Schedule of Goodwill [Table Text Block] Intangible Asset Excluding Goodwill [Table] Intangible Asset Excluding Goodwill [Table] Intangible Asset Excluding Goodwill [Table] Pension and other postretirement benefit plans Pension and Other Postretirement Benefits Cost (Reversal of Cost) Selling, general and administrative expenses Selling, General and Administrative Expense Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable, net of allowances of $65 in 2024 and $62 in 2023 Accounts Receivable, after Allowance for Credit Loss, Current COGS Cost of sales Cost of Sales [Member] Severance, Contract Termination, And Other Employee Related Costs Severance, Contract Termination, And Other Employee Related Costs [Member] Severance, Contract Termination, And Other Employee Related Costs Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Kidney Care Transition Services Agreement Kidney Care Transition

Services Agreement [Member] Kidney Care Transition Services Agreement Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Exchange [Domain] Exchange [Domain] All Executive Categories All Executive Categories [Member] Current liabilities of discontinued operations Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Summary of Activity in Reserves Related to Restructuring Initiatives Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Change in noncontrolling interests Noncontrolling Interest, Period Increase (Decrease) Discontinued operations, currency translation adjustments, net of tax Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Retirement Plan Type Retirement Plan Type [Domain] Pension and other postretirement benefits, tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Document Type Document Type Derivative Contract Derivative Contract [Domain] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Summary of Financial Information for Our Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Cash, cash equivalents and restricted cash at start of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Contract with Customer, Contract Asset Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Total Baxter stockholders' equity Parent [Member] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Hedging activities, net of tax expense (benefit) of ($3) and $2 for the three months ended September 30, 2024 and 2023, respectively and zero and $3 for the nine months ended September 30, 2024 and 2023, respectively. Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Maximum Maximum [Member] Intangible asset amortization expense Amortization of Intangible Assets Contract liabilities Balance at beginning of period Balance at end of period Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Pension and other postretirement benefits, net of tax expense (benefit) of ($2) and zero for the three months ended September 30, 2024 and 2023, respectively, and zero and ($3) for the nine months ended September 30, 2024 and 2023, respectively. Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Other intangible assets, net, finite-lived Finite-Lived Intangible Assets, Net Goodwill impairment Disposal Group, Including Discontinued Operation, Goodwill Impairment Disposal Group, Including Discontinued Operation, Goodwill Impairment International Non-US [Member] Accounts payable Accounts Payable, Current Long-term finance lease obligations, less current portion Disposal Group, Including Discontinued Operations, Financing Lease Liabilities Disposal Group, Including Discontinued Operations, Financing Lease Liabilities Current Fiscal Year End Date Current Fiscal Year End Date Catastrophic Event [Axis] Catastrophic Event [Axis] Range Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income from continuing operations before income taxes Income from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Interest expense, net of capitalized interest Interest Income (Expense), Nonoperating, Net Of Capitalized Interest Interest Income (Expense), Nonoperating, Net Of Capitalized Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Accounts receivable, net of allowances Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Name Outstanding Recovery, Individual Name Foreign exchange contracts Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax Revenue From Contract With Customer [Line Items] Disaggregation of Revenue [Line Items] Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Discontinued Operations, Held-for-Sale Discontinued Operations, Held-for-Sale [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money market funds, at carrying value Money Market Funds, at Carrying Value Non-PEO NEO Non-PEO NEO [Member] Foreign exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Goodwill Disposal Group, Including Discontinued Operation, Goodwill Additional contributed capital Additional Paid-in Capital [Member] Hedging Relationship Hedging Relationship [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax Sales-type Lease, Lease Income Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Cash dividends on common stock Payments of Ordinary Dividends, Common Stock PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS Retirement Benefits [Text Block] Customer relationships Customer Relationships [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Emerging Markets Eastern Europe, Middle East, Africa, Latin America, Asia [Member] Eastern Europe, Middle East, Africa, Latin America, Asia Current maturities of long-term debt and finance lease obligations Long-Term Debt and Finance Lease Obligations, Current Fair Value Disclosure Long-term debt and finance lease obligations, current, fair value disclosure. Forecast Forecast [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Revenue From Contract With Customer [Roll Forward] Revenue From Contract With Customer [Roll Forward] Revenue From Contract With Customer Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Reconciliation of Basic Shares to Diluted Shares Schedule of Weighted Average Number of Shares [Table Text Block] Separation costs Disposal Group, Including Discontinued Operation, Separation Costs Disposal Group, Including Discontinued Operation, Separation Costs Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Common Stock, $1.00 par value Common Stock, $1.00 per Value [Member] Common Stock, $1.00 per Value Type of Restructuring Type of Restructuring [Domain] Income (loss) from discontinued operations attributable to Baxter stockholders Income (loss) from discontinued operations attributable to Baxter stockholders Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Sales-type lease, net of investment in lease Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of sites Site Contingency Number Of Sites Site contingency, number of sites. Number of operating segments Number of Operating Segments Retirement Benefits [Abstract] Retirement Benefits [Abstract] number of de-designations Derivative, Number Of De-designations Derivative, Number Of De-designations Summary of Financial Instruments Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Revenue From Contract With Customer [Table] Disaggregation of Revenue [Table] Foreign exchange losses, net Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Employee termination costs Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contract manufacturing services Manufacturing Arrangements [Member] Manufacturing arrangements. Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current BUSINESS OPTIMIZATION CHARGES Restructuring and Related Activities Disclosure [Text Block] Stock compensation Share-Based Payment Arrangement, Noncash Expense Impairment of convertible debt investment Change in fair value recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Derivative liability, fair value, total Derivative Liability, Subject to Master Netting Arrangement, after Offset Net income (loss) Net loss Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Pension and OPEB items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Inventories Disposal Group, Including Discontinued Operation, Inventory Gain (loss) recognized in income, undesignated derivative instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax expense Income tax expense Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Senior notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative, notional amount Derivative, Notional Amount Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Allowance for Doubtful Accounts Receivable [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] STOCKHOLDERS' EQUITY Shareholders' Equity and Share-Based Payments [Text Block] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Summary of Gains and Losses on Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Acquisitions of developed technology and investments Payments to Acquire Intangible Assets Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Domain] Change in fair value of marketable equity securities Increase (Decrease) in Equity Securities, FV-NI Revenue recognized upon satisfaction of performance obligations Contract with Customer, Liability, Total Revenue Recognized Contract with Customer, Liability, Total Revenue Recognized Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Operating income Total Operating income Operating Income (Loss) Accrued expenses and other current liabilities Increase (Decrease) In Accrued Expenses And Other Current Liabilities Increase (Decrease) In Accrued Expenses And Other Current Liabilities Contract termination and other costs Contract Termination And Other Costs [Member] Contract termination and other costs. Total liabilities and equity Liabilities and Equity Other Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Acquisition and integration items Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Hedging Designation Hedging Designation [Axis] Other (Income) Expense-, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Charges Restructuring charges Restructuring Charges Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative, fair value, terminated Derivative, Number Of Fair Value Hedges Terminated Derivative, Number Of Fair Value Hedges Terminated Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax Less: Income (loss) from discontinued operations, net of tax Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Carrying amount of hedged item Hedged Liability, Fair Value Hedge Interest expense, net Interest expense, net Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Current maturities of long-term debt and finance lease obligations Long-Term Debt and Lease Obligation, Current Asset impairments Asset Impairment [Member] Asset Impairment Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Currency translation Contract With Customer, Liability, Currency Translation Contract With Customer, Liability, Currency Translation Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Measurement Input Type [Axis] Measurement Input Type [Axis] Operating lease revenue Operating Lease, Lease Income Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Operating lease right-of-use assets Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets Accumulated other comprehensive loss Total AOCI Attributable to Parent [Member] Remaining performance obligations period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Restricted cash included in other non-current assets Restricted Cash Hedging activities Gains (losses) on hedging activities Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Inventories Inventory, Net Liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities Income from discontinued operations per common share, basic (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Cash flows from investing activities - continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current assets of discontinued operations Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Operating Income to Income Before Income Taxes Reconciliation Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Agreed purchase price Purchase price Disposal Group, Including Discontinued Operation, Consideration Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments Financial Instruments [Domain] Number of complaints Number of Complaints Number of Complaints Disclosure Basis Of Presentation Details [Line Items] Disclosure Basis Of Presentation Details [Line Items] Disclosure Basis Of Presentation Details [Line Items] Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans Schedule of Net Benefit Costs [Table Text Block] Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Costs to implement business optimization programs Separation-related costs Restructuring and Related Cost, Incurred Cost Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Number of lawsuits Loss Contingency, Number Of Lawsuits Loss Contingency, Number Of Lawsuits Fair values Estimate of Fair Value Measurement [Member] Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral Current maturities of finance lease obligations Disposal Group, Including Discontinued Operation, Other Liabilities, Current BioPharma Solutions BioPharma Solutions [Member] BioPharma Solutions Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate contracts Interest Rate Contract [Member] New Operating Model New Operating Model [Member] New Operating Model Injectables and Anesthesia Injectables and Anesthesia [Member] Injectables and Anesthesia Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Rest of world Western Europe, Canada, Japan, Australia and New Zealand [Member] Western Europe, Canada, Japan, Australia and New Zealand Fair Value Disclosures [Table] Fair Value Disclosures [Table] Fair value disclosures table. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Superfund Sites Superfund Sites [Member] Superfund sites. Accrued expenses and other current liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Charged to costs and expenses Accounts Receivable, Credit Loss Expense (Reversal) Segments Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Maximum length of time hedge in cash flow hedge Maximum Length of Time Hedged in Cash Flow

Hedge U.S. Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument Derivative Instrument [Axis] Exercise Price Award Exercise Price Selling, general and administrative expenses Disposal Group, Including Discontinued Operation, General and Administrative Expense SUPPLEMENTAL FINANCIAL INFORMATION Additional Financial Information Disclosure [Text Block] EARNINGS PER SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Discontinued Operations Discontinued Operations [Member] Subsequent Event Subsequent Event [Member] Kidney Care Kidney Care [Member] Kidney Care GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill and Intangible Assets Disclosure [Text Block] Income from continuing operations per common share, basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] European Medical Devices Regulation European Medical Devices Regulation Expenses European Medical Devices Regulation Expenses Write-offs Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments Restructuring Plan [Axis] Restructuring Plan [Axis] Segments Segments [Domain] 0.4% Senior Notes Due May 2024 0.4% Senior Notes Due May 2024 [Member] Zero point four percentage senior notes due May two thousand twenty four. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Less cash and cash equivalents of discontinued operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] 1.3% Senior Notes Due May 2029 1.3% Senior Notes Due May 2029 [Member] One point three percentage senior notes due May two thousand twenty nine. Name Trading Arrangement, Individual Name Other (income) expense, net Other (income) expense, net Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) OPEB Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangible assets, net Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Accumulated pre-tax unrealized translation gain in AOCI Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Proceeds from stock issued under employee benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Common stock in treasury, at cost, 173,032,822 shares in 2024 and 175,861,893 shares in 2023 Treasury Stock, Common, Value Pharmaceuticals Pharmaceuticals [Member] Pharmaceuticals. Software sales Software Arrangements [Member] Software arrangements. Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Other Operating Segment [Member] Other Income, net Other Nonoperating Income (Expense) [Abstract] Assets Assets, Fair Value Disclosure [Abstract] Manufacturing and supply agreement, period Manufacturing And Supply Agreement, Period Manufacturing And Supply Agreement, Period Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Gross margin Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Summary of Business Optimization Charges Business Optimization Charge [Table Text Block] Business optimization charge. Product-related items Product Related Income (Loss) Product Related Income (Loss) Income from discontinued operations per common share, diluted (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Local Phone Number Local Phone Number Gross other intangible assets Intangible Assets, Gross (Excluding Goodwill) Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Risks and Uncertainties Risks and Uncertainties Policy [Policy Text Block] Risks and Uncertainties Policy Interest expense, net Interest Expense [Member] Changes in balance sheet items: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Contingent payments related to acquisitions Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Derivative liability, fair value Gross amounts recognized in the condensed consolidated balance sheets Derivative Liability, Subject to Master Netting Arrangement, before Offset Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Senior Unsecured Term Loans Senior Unsecured Term Loans [Member] Senior Unsecured Term Loans Income Statement Location Statement of Income Location, Balance [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Healthcare Systems and Technologies Healthcare Systems and Technologies [Member] Healthcare Systems and Technologies Common stock Common Stock [Member] Measure: Measure [Axis] Stock issued under employee benefit plans and other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Asset Class Asset Class [Domain] Environmental Clean-up Enviromental Clean Up [Member] Enviromental clean-up. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Bridge Facility Line Of Credit Line of Credit [Member] Business Optimization Programs Business Optimization Programs [Member] Business Optimization Programs Available-for-sale debt securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Global payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Environmental Remediation Site Environmental Remediation Site [Axis] Total liabilities Liabilities, Fair Value Disclosure Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Intangible Asset Excluding Goodwill [Line Items] Intangible Asset Excluding Goodwill [Line Items] Intangible Asset Excluding Goodwill [Line Items] Scenario [Axis] Scenario [Axis] Consumable Medical Products Consumable Medical Products [Member] Consumable medical products [Member]. Inventories Schedule of Inventory, Current [Table Text Block] 2023 2023 [Member] 2023 Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Unallocated corporate costs Corporate Costs, Unallocated Corporate Costs, Unallocated Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Contingent payments related to acquisitions Acquisition-related Costs [Member] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Catastrophic Event [Domain] Catastrophic Event [Domain] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component Equity Component [Domain] Financial Instrument Financial Instrument [Axis] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Exposure to Ethylene Oxide Exposure to Ethylene Oxide [Member] Exposure to Ethylene Oxide Change in fair value recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Cash flows from operations â€" discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Amounts reclassified from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Earnings, fair value hedge, gain (loss), reclassification, before tax Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax CTA Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair Value, Measurement Frequency Measurement Frequency [Domain] Net periodic pension and other postretirement costs Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash Consolidation Items Consolidation Items [Domain] City Area Code City Area Code Income tax expense (benefit) Discontinued Operation, Tax Effect of Discontinued Operation Current liabilities: Liabilities, Current [Abstract] Variable lease revenue Variable Lease, Income Income (loss) from discontinued operations before gain on disposition and income taxes Income (loss) from discontinued operations before gain on disposition and income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Derivative asset, fair value, total Derivative Asset, Subject to Master Netting Arrangement, after Offset Net increases in debt with original maturities of three months or less Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Contingent payments related to acquisitions Business Combination, Contingent Consideration, Liability Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Interest Expense, Net Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2020 2020 And Prior Years [Member] 2020 And Prior Years Senior Notes Senior Notes [Member] Foreign exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Document Information [Line Items] Document Information [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Other amortized intangible assets Other Intangible Assets [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Remaining revenue performance obligation, percentage of revenue expected to be recognized Revenue, Remaining Performance Obligation, Percentage INCOME TAXES Income Tax Disclosure [Text Block] Income (loss) per common share Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Net income attributable to noncontrolling interests included in continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Retained earnings Retained Earnings (Accumulated Deficit) Summary of Reclassification from AOCI to Net Income (Loss) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Deferred, net after-tax gains on derivative instruments Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months 2022 2022 [Member] 2022 Inventories Increase (Decrease) in Inventories Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax Deferred income taxes Deferred Income Taxes and Tax Credits Other non-current liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Business optimization items Business Optimization Income (Loss) Business Optimization Income (Loss) Hedging activities, tax Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag 1.3% Global Notes due 2025 Global Notes 1.3% due 2025 [Member] Global Notes 1.3% due 2025 Book values Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Gross margin Gross Profit Currency translation adjustments Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Axis] Fair Value as of Grant Date Award Grant Date Fair Value Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical Geographical [Domain] Other intangible assets, net Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net Property, Plant and Equipment Property, Plant and Equipment [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Senior notes Debt Instrument, Face Amount Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basis of Presentation Consolidation, Policy [Policy Text Block] Interest rate swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023 Common Stock, Value, Issued Capitalized Contract Cost Capitalized Contract Cost [Axis] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Derivative Positions Presented On Net Basis Schedule Of Derivative Positions Presented On Net Basis Table [Table Text Block] Schedule of derivative positions presented on net basis. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Interest Income Expense Net Interest Income (Expense), Operating [Abstract] Other investing activities, net Payments for (Proceeds from) Other Investing Activities 1.30% Senior Notes Due May 2025 1.30% Senior Notes Due May 2025 [Member] 1.30% Senior Notes Due May 2025 Other non-current assets Other Noncurrent Assets [Member] NYSE Chicago NYSE CHICAGO, INC. [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Front Line Care Front Line Care [Member] Front Line Care Raw materials Inventory, Raw Materials, Gross Research and development expenses Disposal Group, Including Discontinued Operations, Research And Development Expense Disposal Group, Including Discontinued Operations, Research And Development Expense Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] YearOf Origination [Axis] YearOf Origination [Axis] YearOf Origination Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Finished goods Inventory, Finished Goods, Gross Basic (in dollars per share) Earnings Per Share, Basic New revenue deferrals Contract With Customer, Liability, Deferred Revenue Contract With Customer, Liability, Deferred Revenue Accounts payable Increase (Decrease) in Accounts Payable Environmental Remediation Contingency Environmental Remediation Contingency [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] 2021 2021 [Member] 2021 Capital expenditures incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Asset Derivative Asset [Abstract] Schedule of Goodwill [Table] Goodwill [Table] Derivative instruments designated as hedges Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted-average number of shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Cost of sales Cost of sales Cost of Goods and Services Sold Borrowings outstanding Long-Term Line of Credit Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and contingencies Commitments and Contingencies Operating lease liabilities Disposal Group, Including

Discontinued Operation, Operating Lease Liability Disposal Group, Including Discontinued Operation, Operating Lease Liability Termination Date Trading Arrangement Termination Date Accrued expenses and other current liabilities Accounts Payable and Accrued Liabilities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Undesignated derivative instruments Not Designated as Hedging Instrument [Member] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument Debt Instrument [Axis] Non-current liabilities of discontinued operations Non-current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Restructuring Within HST Segment Restructuring Within HST Segment [Member] Restructuring Within HST Segment DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net income (loss) attributable to Baxter stockholders Net income (loss) attributable to Baxter stockholders Net Income (Loss) Attributable to Parent Other operating income, net Other operating income, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Available-for-sale debt securities Available-For-Sale, Debt Securities [Member] Available-For-Sale, Debt Securities Book Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Drug Compounding Pharmaceutical Compounding [Member] Pharmaceutical Compounding ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Line of credit, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Insurance recoveries Insurance Recoveries Liabilities Liabilities, Fair Value Disclosure [Abstract] REVENUES Revenue from Contract with Customer [Text Block] Currency translation adjustments, net of tax expense (benefit) of $(11) and $(1) for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $(15) and $(1) for the nine months ended September 30, 2024 and 2023, respectively. Discontinued Operation, Other Comprehensive Income (Loss), Net Of Tax, Including Portion Attributable To Noncontrolling Interest Discontinued Operation, Other Comprehensive Income (Loss), Net Of Tax, Including Portion Attributable To Noncontrolling Interest Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Reconciliation of Basic Shares to Diluted Shares Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Currency translation Restructuring Reserve, Foreign Currency Translation Gain (Loss) Debt Instrument, Name Debt Instrument, Name [Domain] Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Dividends declared on common stock Dividends, Common Stock Comprehensive income (loss) from discontinued operations Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax Total assets Assets, Fair Value Disclosure Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Impairment of investments without readily determinable value Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Asset Class Asset Class [Axis] Insider Trading Arrangements [Line Items] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Segment Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Proceeds from divestiture of businesses, net of tax Proceeds From Divestiture Of Businesses, Net Of Tax Proceeds From Divestiture Of Businesses, Net Of Tax PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Income from continuing operations per common share, diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Revenue recognized upon satisfaction of performance obligations Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Less: Comprehensive income attributable to noncontrolling interests Less: Comprehensive income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Liability Derivative Liability [Abstract] Foreign exchange contracts Foreign Exchange Contract [Member] Currency translation adjustments, tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Document Transition Report Document Transition Report Advanced Surgery Advanced Surgery [Member] Advanced surgery. Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained earnings Retained Earnings [Member] Disclosure Basis Of Presentation Details [Table] Disclosure Basis Of Presentation Details [Table] Disclosure Basis Of Presentation Details [Table] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Legal matters Litigation Settlement, Fee Expense Basic (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Total equity Balance, beginning of period (in usd) Balance, end of period (in usd) Equity, Including Portion Attributable to Noncontrolling Interest Transaction service agreement, period Transaction Service Agreement, Period Transaction Service Agreement, Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Other, net Other Nonoperating Gains (Losses) Name Awards Close in Time to MNPI Disclosures, Individual Name Sales-type leases, receivables Sales-type and Direct Financing Leases, Lease Receivable Derivative, net investment terminated Derivative, Number Of Net Investment Terminated Derivative, Number Of Net Investment Terminated Entity Filer Category Entity Filer Category Reserve, beginning balance Reserve, ending balance Restructuring Reserve Transaction price allocated to remaining performance obligations Revenue, Remaining Performance Obligation, Amount Income Statement Location Statement of Income Location, Balance [Domain] Operating Lease, Lease Income Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 12 bax-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 1-4448 Â Entity Registrant Name BAXTER INTERNATIONAL INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 36-0781620 Â Entity Address, Address Line One One Baxter Parkway, Â Entity Address, City or Town Deerfield, Â Entity Address, State or Province IL Â Entity Address, Postal Zip Code 60015 Â City Area Code 224. Â Local Phone Number 948.2000 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 510,587,581 Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Central Index Key 0000010456 Â Current Fiscal Year End Date --12-31 Â Common Stock, $1.00 par value | New York Stock Exchange Â Â Document Information [Line Items] Â Â Title of 12(b) Security Common Stock, $1.00 par value Â Trading Symbol BAX (NYSE) Â Security Exchange Name NYSE Â Common Stock, $1.00 par value | NYSE Chicago Â Â Document Information [Line Items] Â Â Title of 12(b) Security Common Stock, $1.00 par value Â Trading Symbol BAX (NYSE) Â Security Exchange Name CHX Â 1.3% Global Notes due 2025 | New York Stock Exchange Â Â Document Information [Line Items] Â Â Title of 12(b) Security 1.3% Global Notes due 2025 Â Trading Symbol BAX 25 Â Security Exchange Name NYSE Â 1.3% Global Notes due 2029 | New York Stock Exchange Â Â Document Information [Line Items] Â Â Title of 12(b) Security 1.3% Global Notes due 2029 Â Trading Symbol BAX 29 Â Security Exchange Name NYSE Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition

available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=bax_CommonStock100PerValueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_EntityListingsExchangeAxis=exch_XNYS Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_EntityListingsExchangeAxis=exch_XCHI Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 1,420 $ 3,078 Accounts receivable, net of allowances of $65 in 2024 and $62 in 2023 1,729 1,719 Inventories 2,103 1,918 Prepaid expenses and other current assets 720 706 Current assets of discontinued operations 2,892 2,179 Total current assets 8,864 9,600 Property, plant and equipment, net 2,833 2,871 Goodwill 5,783 5,793 Other intangible assets, net 5,449 5,918 Operating lease right-of-use assets 327 336 Other non-current assets 886 809 Non-current assets of discontinued operations 2,534 2,949 Total assets 26,676 28,276 Current liabilities: Â Â Current maturities of long-term debt and finance lease obligations 2,498 2,667 Accounts payable 841 881 Accrued expenses and other current liabilities 1,772 1,915 Current liabilities of discontinued operations 1,089 1,040 Total current liabilities 6,200 6,503 Long-term debt and finance lease obligations, less current portion 10,437 11,089 Operating lease liabilities 259 265 Other non-current liabilities 1,263 1,400 Non-current liabilities of discontinued operations 575 551 Total liabilities 18,734 19,808 Commitments and contingencies Equity: Â Â Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023 683 683 Common stock in treasury, at cost, 173,032,822 shares in 2024 and 175,861,893 shares in 2023 (11,084) (11,230) Additional contributed capital 6,391 6,389 Retained earnings 15,529 16,114 Accumulated other comprehensive loss (3,647) (3,554) Total Baxter stockholdersâ€™ equity 7,872 8,402 Noncontrolling interests 70 66 Total equity 7,942 8,468 Total liabilities and equity $ 26,676 $ 28,276 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Allowance for accounts receivable, current $ 65 $ 62 Common stock, par value (in dollars per share) $ 1 $ 1 Common stock, authorized (in shares) 2,000,000,000 2,000,000,000 Common stock, issued (in shares) 683,494,944 683,494,944 Treasury stock, shares (in shares) 173,032,822 175,861,893 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Loss (unaudited) - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Net sales $ 2,699 $ 2,599 $ 7,883 $ 7,634 Cost of sales 1,666 1,543 4,858 4,584 Gross margin 1,033 1,056 3,025 3,050 Selling, general and administrative expenses 754 744 2,206 2,270 Research and development expenses 129 133 379 391 Other operating income, net (5) 0 (9) (14) Operating income 155 179 449 403 Interest expense, net 87 127 251 367 Other (income) expense, net 1 12 34 (15) Income from continuing operations before income taxes 69 64 232 21 Income tax expense 8 27 70 59 Income (loss) from continuing operations 61 37 162 (38) Income (loss) from discontinued operations, net of tax 83 2,474 (290) 2,455 Net income (loss) 144 2,511 (128) 2,417 Net income attributable to noncontrolling interests included in continuing operations 0 0 0 0 Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6 Less: Comprehensive income attributable to noncontrolling interests 4 3 9 6 Net income (loss) attributable to Baxter stockholders $ 140 $ 2,508 $ (137) $ 2,411 Income (loss) from continuing operations per common share Â Â Â Â Income from continuing operations per common share, basic (in dollars per share) $ 0.12 $ 0.07 $ 0.32 $ (0.08) Income from continuing operations per common share, diluted (in dollars per share) 0.12 0.07 0.32 (0.08) Income (loss) from discontinued operations per common share Â Â Â Â Income from discontinued operations per common share, basic (in dollars per share) 0.15 4.88 (0.59) 4.84 Income from discontinued operations per common share, diluted (in dollars per share) 0.15 4.86 (0.59) 4.84 Income (loss) per common share Â Â Â Â Basic (in dollars per share) 0.27 4.95 (0.27) 4.76 Diluted (in dollars per share) $ 0.27 $ 4.93 $ (0.27) $ 4.76 Weighted-average number of shares outstanding Â Â Â Â Basic (in shares) 510 507 509 506 Diluted (in shares) 512 509 511 506 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting

Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic

280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Â Income (loss) from continuing operations $ 61 $ 37 $ 162 $ (38) Other comprehensive income (loss) from continuing operations, net of tax: Â Â Â Â Â Currency translation adjustments, net of tax expense (benefit) of ($19) and $12 for the three months ended September 30, 2024 and 2023, respectively, and ($3) and $2 for the nine months ended September 30, 2024 and 2023, respectively. 106 (36) (61) (39) Pension and other postretirement benefits, net of tax expense (benefit) of ($2) and zero for the three months ended September 30, 2024 and 2023, respectively, and zero and ($3) for the nine months ended September 30, 2024 and 2023, respectively. (6) (1) (2) (11) Hedging activities, net of tax expense (benefit) of ($3) and $2 for the three months ended September 30, 2024 and 2023, respectively and zero and $3 for the nine months ended September 30, 2024 and 2023, respectively. (9) 5 2 10 Total other comprehensive income (loss) from continuing operations, net of tax 91 (32) (61) (40) Comprehensive loss from continuing operations 152 5 101 (78) Income (loss) from discontinued operations, net of tax 83 2,474 (290) 2,455 Currency translation adjustments, net of tax expense (benefit) of $(11) and $(1) for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $(15) and $(1) for the nine months ended September 30, 2024 and 2023, respectively. 90 134 (35) 162 Pension and other postretirement benefits, net of tax expense (benefit) of zero for the three and nine months ended September 30, 2024 and 2023 0 (4) (1) (5) Total other comprehensive income (loss) from discontinued operations 90 130 (36) 157 Comprehensive income (loss) from discontinued operations 173 2,604 (326) 2,612 Comprehensive income (loss) 325 2,609 (225) 2,534 Less: Comprehensive income attributable to noncontrolling interests 4 3 9 6 Less: Other comprehensive loss attributable to noncontrolling

interests 0 0 (4) 0 Comprehensive income (loss) attributable to Baxter stockholders $ 321 $ 2,606 $ (230) $ 2,528 X - DefinitionComprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest + ReferencesNo definition available. + Details Name: bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContinuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContinuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDiscontinued Operation, Other Comprehensive Income (Loss), Net Of Tax, Including Portion Attributable To Noncontrolling Interest + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDiscontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDiscontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther Comprehensive Income (Loss), Continuing Operations, Net Of Tax + ReferencesNo definition available. + Details Name: bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Currency translation adjustments, tax $ (19,000,000) $ 12,000,000 $ (3,000,000) $ 2,000,000 Pension and other postretirement benefits, tax (2,000,000) 0 0 (3,000,000) Hedging activities, tax (3,000,000) 2,000,000 0 3,000,000 Discontinued operations, currency translation adjustments, net of tax (11,000,000) (1,000,000) (15,000,000) (1,000,000) Discontinued operations, pension and other postretirement benefits, tax $ 0 $ 0 $ 0 $ 0 X - DefinitionContinuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContinuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax + ReferencesNo definition available. + Details Name: bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax + ReferencesNo definition available. + Details Name: bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Equity (unaudited) - USD ($) $ in Millions Total Total Baxter stockholders' equity Common stock Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive loss Noncontrolling interests Balance, beginning of period (in shares) at Dec. 31, 2022 Â Â 683,000,000 Â Â Â Â Â Balance, beginning of period (in usd) at Dec. 31, 2022 $ 5,895 $ 5,833 $ 683 $ (11,389) $ 6,322 $ 14,050 $ (3,833) $ 62 Balance, treasury, beginning period (in shares) at Dec. 31, 2022 Â Â Â 179,000,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Net loss 2,417 2,411 Â Â Â 2,411 Â 6 Other comprehensive income (loss) 117 117 Â Â Â Â 117 Â Stock issued under employee benefit plans and other (in shares) Â Â Â (3,000,000) Â Â Â Â Stock issued under employee benefit plans and other 186 186 Â $ 140 46 Â Â Â Dividends declared on common stock (446) (446) Â Â Â (446) Â Â Change in noncontrolling interests (3) Â Â Â Â Â Â (3) Balance, end of period (in shares) at Sep. 30, 2023 Â Â 683,000,000 Â Â Â Â Â Balance, end of period (in usd) at Sep. 30, 2023 8,166 8,101 $ 683 $ (11,249) 6,368 16,015 (3,716) 65 Balance, treasury, ending period (in shares) at Sep. 30, 2023 Â Â Â 176,000,000 Â Â Â Â Balance, beginning of period (in shares) at Jun. 30, 2023 Â Â 683,000,000 Â Â Â Â Â Balance, beginning of period (in usd) at Jun. 30, 2023 5,631 5,569 $ 683 $ (11,296) 6,341 13,655 (3,814) 62 Balance, treasury, beginning period (in shares) at Jun. 30, 2023 Â Â Â 177,000,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Net loss 2,511 2,508 Â Â Â 2,508 Â 3 Other comprehensive income (loss) 98 98 Â Â Â Â 98 Â Stock issued under employee benefit plans and other (in shares) Â Â Â (1,000,000) Â Â Â Â Stock issued under employee benefit plans and other 74 74 Â $ 47 27 Â Â Â Dividends declared on common stock (148) (148) Â Â Â (148) Â Â Balance, end of period (in shares) at Sep. 30, 2023 Â Â 683,000,000 Â Â Â Â Â Balance, end of period (in usd) at Sep. 30, 2023 8,166 8,101 $ 683 $ (11,249) 6,368 16,015 (3,716) 65 Balance, treasury, ending period (in shares) at Sep. 30, 2023 Â Â Â 176,000,000 Â Â Â Â Balance, beginning of period (in shares) at Dec. 31, 2023 Â Â 683,000,000 Â Â Â Â Â Balance, beginning of period (in usd) at Dec. 31, 2023 $ 8,468 8,402 $ 683 $ (11,230) 6,389 16,114 (3,554) 66 Balance, treasury, beginning period (in shares) at Dec. 31, 2023 175,861,893 Â Â 176,000,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Net loss $ (128) (137) Â Â Â (137) Â 9 Other comprehensive income (loss) (97) (93) Â Â Â Â (93) (4) Stock issued under employee benefit plans and other (in shares) Â Â Â (3,000,000) Â Â Â Â Stock issued under employee benefit plans and other 148 148 Â $ 146 2 Â Â Â Dividends declared on common stock (448) (448) Â Â Â (448) Â Â Change in noncontrolling interests (1) Â Â Â Â Â Â (1) Balance, end of period (in shares) at Sep. 30, 2024 Â Â 683,000,000 Â Â Â Â Â Balance, end of period (in usd) at Sep. 30, 2024 $ 7,942 7,872 $ 683 $ (11,084) 6,391 15,529 (3,647) 70 Balance, treasury, ending period (in shares) at Sep. 30, 2024 173,032,822 Â Â 173,000,000 Â Â Â Â Balance, beginning of period (in shares) at Jun. 30, 2024 Â Â 683,000,000 Â Â Â Â Â Balance, beginning of period (in usd) at Jun. 30, 2024 $ 7,708 7,643 $ 683 $ (11,104) 6,353 15,539 (3,828) 65 Balance, treasury, beginning period (in shares) at Jun. 30, 2024 Â Â Â 173,000,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Net loss 144 140 Â Â Â 140 Â 4 Other comprehensive income (loss) 181 181 Â Â Â Â 181 Â Stock issued under employee benefit plans and other 58 58 Â $ 20 38 Â Â Â Dividends declared on common stock (150) (150) Â Â Â (150) Â Â Change in noncontrolling interests 1 Â Â Â Â Â Â 1 Balance, end of period (in shares) at Sep. 30, 2024 Â Â 683,000,000 Â Â Â Â Â Balance, end of period (in usd) at Sep. 30, 2024 $ 7,942 $ 7,872 $ 683 $ (11,084) $ 6,391 $ 15,529 $ (3,647) $ 70 Balance, treasury, ending period (in shares) at Sep. 30, 2024 173,032,822 Â Â 173,000,000 Â Â Â Â X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16 + Details Name: us-gaap_MinorityInterestPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares (or other type of equity) forfeited during the period. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operations Â Â Net income (loss) $ (128) $ 2,417 Less: Income (loss) from discontinued operations, net of tax (290) 2,455 Income (loss) from continuing operations 162 (38) Adjustments to reconcile net loss to cash flows from operations: Â Â Depreciation and amortization 752 720 Deferred income taxes (136) (239) Stock compensation 75 90 Net periodic pension and other postretirement costs (21) (19) Other long-lived asset impairments 42 3 Other 20 25 Changes in balance sheet items: Â Â Accounts receivable, net (17) 52 Inventories (180) (120) Prepaid expenses and other current assets (61) (41) Accounts payable 3 161 Accrued expenses and other current liabilities (192) 261 Other (71) (63) Cash flows from operations â€“ continuing operations 376 792 Cash flows from operations â€“ discontinued operations 155 403 Cash flows from operations 531 1,195 Cash flows from investing activities Â Â Capital expenditures (314) (340) Acquisitions of developed technology and investments (9) (4) Proceeds from sale of marketable equity securities 34 0 Other investing activities, net 8 19 Cash flows from investing activities - continuing operations (281) (325) Cash flows from investing activities - discontinued operations (140) 3,768 Cash flows from investing activities (421) 3,443 Cash flows from financing activities Â Â Repayments of debt (827) (353) Net increases in debt with original maturities of three months or less 0 214 Cash dividends on common stock (443) (439) Proceeds from stock issued under employee benefit plans 63 86 Other financing activities, net (15) (62) Cash flows from financing activities (1,222) (554) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations (45) (37) Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations 39 23 Increase (decrease) in cash, cash equivalents and restricted cash (1,118) 4,070 Cash, cash equivalents and restricted cash at start of period [1] 3,198 1,722 Cash, cash equivalents and restricted cash at end of period [1] 2,080 5,792 Less cash and cash equivalents of discontinued operations 658 72 Cash, cash equivalents and restricted cash $ 1,422 $ 5,720 [1] The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of SeptemberÂ 30, 2024, DecemberÂ 31, 2023, and SeptemberÂ 30, 2023 (in millions):September 30, 2024December 31, 2023September 30, 2023Cash and cash equivalents$1,420Â $3,078Â $5,716Â Restricted cash included in other non-current assets2Â 4Â 4Â Cash, cash equivalents and restricted cash$1,422Â $3,082Â $5,720Â X - DefinitionIncrease (Decrease) In Accrued Expenses And Other Current Liabilities + ReferencesNo definition available. + Details Name: bax_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-

3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense (reversal of expense) for pension and other postretirement benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9 + Details Name: us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Statement of Cash Flows [Abstract] Â Â Â Cash and cash equivalents $ 1,420 $ 3,078 $ 5,716 Restricted cash included in other non-current assets 2 4 4 Cash, cash equivalents and restricted cash $ 1,422 $ 3,082 $ 5,720 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â BASIS OF PRESENTATION BASIS OF PRESENTATIONThe unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (2023 Annual Report).In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business, which will be known as Vantive, for an aggregate purchase price of $3.80 billion. After giving effect to certain closing adjustments, we currently expect to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the range of $3.15Â billion to $3.25 billion. The transaction is currently expected to close in late 2024 or early 2025, subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions. We determined that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations presentation. See Note 2 for additional information.Hurricane HeleneIn September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations at that facility. We are actively working with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we work to fully restore our North Cove manufacturing operations. Our insurance policies generally cover the repair or replacement of our assets that suffer loss or damage, less applicable deductibles and subject to any coverage limits and exclusions, and we are working closely with our insurance carriers and claims adjusters to ascertain the full amount of insurance proceeds due to us as a result of the damages and the loss we suffered as a result of Hurricane Helene (which proceeds are likely to be less than the applicable losses). Our insurance policies also provide coverage for interruption to our business, including lost profits, and reimbursement for other expenses and costs that have been incurred relating to the damages and losses suffered. In the third quarter of 2024, we recorded $25Â million of pre-tax net charges related to damages caused by Hurricane Helene. This consisted of $44Â million related to the write-off of damaged inventory and fixed assets offset by a receivable of $19Â million, which is the amount of the loss, net of our insurance deductible, related to insurance recoveries expected as a result of those asset write-offs. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three and nine month periods ended SeptemberÂ 30, 2024. At this time, the full amount of combined property damage and business interruption costs cannot be estimated and any additional insurance recoveries are not realizable, and accordingly, no additional amounts have been recorded as of SeptemberÂ 30, 2024. On November 1, 2024, we received $101Â million of cash related to insurance proceeds which included recoveries for expenses incurred after the balance sheet date. We expect to receive additional related insurance proceeds in the future.Risks and Uncertainties Supply Constraints and Global Economic ConditionsIn recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing of raw materials and on transportation costs, some of these challenges (such as additional transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3 DISCONTINUED OPERATIONS 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â DISCONTINUED OPERATIONS DISCONTINUED OPERATIONSA component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation for two strategic actions, as described below. Discontinued Operations - Kidney CareOn August 12, 2024, we entered into an EPA to sell our Kidney Care business, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. That business, which is comprised of our Kidney Care segment, provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. Pursuant to the EPA, we expect to sell the Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion. After giving effect to certain adjustments, we currently expect to receive approximately $3.50 billion of net pre-tax cash proceeds (approximately $3.15Â billion to $3.25 billion after tax). The transaction is currently expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. We intend to use the net after-tax proceeds from this transaction to repay certain of our debt obligations, consistent with our stated capital allocation priorities.We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the pending sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.Upon closing of the pending sale of the Kidney Care business, Baxter and Vantive will enter into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a long-term Master Services Agreement, a Distribution Agreement, a Transition Services Agreement (Kidney Care TSA), and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities will provide each other with certain dialysis-related products, other products, product components and fulfillment services for a period up to 10 years post-closing (with certain extension rights as provided therein). Pursuant to the Kidney Care TSA, Baxter and the entities that will be divested in connection with the pending Kidney Care sale (the Kidney Care divested entities) will provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights as provided therein) to help ensure business continuity and help minimize disruptions to the entities' operations post-closing. Services to be provided under the TSA include IT, supply chain and certain other corporate and administrative services. Pursuant to the EPA, Baxter will retain (i) the manufacture and sale of saline solutions and (ii) the plastics operations of Baxter and its subsidiaries at its Mountain Home, Arkansas facility, which is not part of the Kidney Care segment. Discontinued Operations - BioPharma Solutions On September 29, 2023, we sold our BioPharma Solutions (BPS) business to Advent International and Warburg Pincus (collectively, the BPS buyers). The BPS business, which was historically reported within our former Americas segment, provided contract manufacturing and development services, which include sterile fill-finish manufacturing and support services across clinical and commercial applications, primarily serving customers in the pharmaceutical industry. BPS was historically operated through our former, wholly-owned subsidiaries Baxter Pharmaceutical Solutions LLC, a Delaware limited liability company, and Baxter Oncology GmbH, a German limited liability company (collectively, the BPS divested entities).We concluded that our BPS business met the criteria to be classified as held-for-sale in May 2023. We analyzed the quantitative and qualitative factors relevant to the divestiture of our BPS business, including its significance to our overall net

income and earnings per share, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.At closing of the transaction, Baxter entered into a Transition Services Agreement (BPS TSA) and a Master Commercial Manufacturing and Supply Agreement (BPS MSA) with the divested entities. Pursuant to the BPS TSA, Baxter and the BPS divested entities provide to each other, on an interim basis, specific transition services for up to 24 months post-closing to help ensure business continuity and minimize disruptions. Services provided under the BPS TSA include finance, information technology, human resources, integrated supply chain, and certain other administrative services. Pursuant to the BPS MSA, the BPS divested entities provide development, manufacturing, regulatory, and other related services for certain Baxter pharmaceutical products for up to 5 years post-closing (with certain extension rights as provided therein).Results of Discontinued Operations and Assets and Liabilities of Discontinued OperationsThe following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three and nine months ended SeptemberÂ 30, 2024 and 2023:Kidney CareBioPharma SolutionsTotalThree Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,(in millions)2024202320242023202420232024Net sales$1,155Â $1,109Â $â€”Â $191Â $1,155Â $1,300Â Cost of sales731Â 1,048Â â€”Â 81Â 731Â 1,129Â Gross margin424Â 61Â â€”Â 110Â 424Â 171Â Selling, general and administrative expenses278Â 258Â â€”Â 15Â 278Â 273Â Research and development expenses41Â 33Â â€”Â 1Â 41Â 34Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)106Â (230)â€”Â 94Â 106Â (136)Interest expense, net1Â 1Â â€”Â â€”Â 1Â 1Â Other (income) expense, net(8)5Â â€”Â 2Â (8)7Â Income (loss) from discontinued operations before gain on disposition and income taxes113Â (236)â€”Â 92Â 113Â (144)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)30Â (250)â€”Â 522Â 30Â 272Â Income from discontinued operations, net of tax83Â 14Â â€”Â 2,460Â 83Â 2,474Â Less: Net income attributable to noncontrolling interest included in discontinued operations4Â 3Â â€”Â â€”Â 4Â 3Â Net income attributable to Baxter stockholders included in discontinued operations$79Â $11Â $â€”Â $2,460Â $79Â $2,471Â Kidney CareBioPharma SolutionsTotalNine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,202420232024202320242023Net sales$3,375Â $3,294Â $â€”Â $469Â $3,375Â $3,763Â Cost of sales2,125Â 2,841Â â€”Â 216Â 2,125Â 3,057Â Gross margin1,250Â 453Â â€”Â 253Â 1,250Â 706Â Selling, general and administrative expenses874Â 691Â â€”Â 44Â 874Â 735Â Research and development expenses140Â 104Â â€”Â 2Â 140Â 106Â Goodwill impairment430Â â€”Â â€”Â â€”Â 430Â â€”Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)(193)(342)â€”Â 207Â (193)(135)Interest expense, netâ€”Â 2Â â€”Â â€”Â â€”Â 2Â Other (income) expense, net(2)18Â â€”Â 2Â (2)20Â Income (loss) from discontinued operations before income taxes(191)(362)â€”Â 205Â (191)(157)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)99Â (258)â€”Â 536Â 99Â 278Â Income (loss) from discontinued operations, net of tax(290)(104)â€”Â 2,559Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations9Â 6Â â€”Â â€”Â 9Â 6Â Net income (loss) attributable to Baxter stockholders included in discontinued operations(299)(110)$â€”Â $2,559Â (299)2,449Â For the three and nine months ended SeptemberÂ 30, 2024, selling, general and administrative expenses (SG&A) includes $69Â million and $236Â million, respectively, of separation-related costs incurred in connection with the pending sale of our Kidney Care business. For the three months ended September 30, 2023, SG&A includes separation-related costs of $67Â million and $8Â million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively. For the nine months ended September 30, 2023, SG&A includes separation-related costs of $108Â million and $15Â million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively.The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023:(in millions)September 30, 2024December 31, 2023Cash and cash equivalents$658Â $116Â Accounts receivable, net of allowances1,045Â 971Â Inventories960Â 906Â Prepaid expenses and other current assets229Â 186Â Current assets of discontinued operations2,892Â 2,179Â Property, plant and equipment, net1,542Â 1,562Â Goodwill276Â 721Â Other intangible assets, net147Â 161Â Operating lease right-of-use assets209Â 188Â Other non-current assets360Â 317Â Non-current assets of discontinued operations2,534Â 2,949Â Assets of discontinued operations$5,426Â $5,128Â Current maturities of finance lease obligations$â€”Â $1Â Accounts payable396Â 360Â Accrued expenses and other current liabilities693Â 679Â Current liabilities of discontinued operations1,089Â 1,040Â Long-term finance lease obligations, less current portion40Â 41Â Operating lease liabilities186Â 173Â Other non-current liabilities349Â 337Â Non-current liabilities of discontinued operations575Â 551Â Liabilities of discontinued operations$1,664Â $1,591Â X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTAL FINANCIAL INFORMATIONAllowance for Doubtful AccountsThe following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Balance at beginning of period$67Â $61Â $62Â $50Â Charged to costs and expenses4Â 2Â 4Â 17Â Write-offs(3)1Â (6)(2)Currency translation adjustments(3)2Â 5Â 1Â Balance at end of period$65Â $66Â $65Â $66Â Inventories (in millions)September 30,2024December 31,2023Raw materials$532Â $530Â Work in process256Â 234Â Finished goods1,315Â 1,154Â Inventories$2,103Â $1,918Â Property, Plant and Equipment, Net (in millions)September 30,2024December 31,2023Property, plant and equipment, at cost$7,605Â $7,650Â Accumulated depreciation(4,772)(4,779)Property, plant and equipment, net$2,833Â $2,871Â Interest Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Interest expense, net of capitalized interest$101Â $136Â $308Â $394Â Interest income(14)(9)(57)(27)Interest expense, net$87Â $127Â $251Â $367Â Other (Income) Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Foreign exchange losses, net$7Â $10Â $21Â 49Â Pension and other postretirement benefit plans(9)(15)(34)(37)Change in fair value of marketable equity securitiesâ€”Â (3)(3)3Â Non-marketable investment impairmentsâ€”Â â€”Â â€”Â 13Â Other, net1Â (4)(18)(13)Other (income) expense, net(1)(12)(34)15Â Non-Cash Operating and Investing ActivitiesRight-of-use operating lease assets obtained in exchange for lease obligations for the nine months ended SeptemberÂ 30, 2024 and 2023 were $54 million and $55Â million, respectively. Purchases of property, plant and equipment included in accounts payable as of SeptemberÂ 30, 2024 and 2023 were $34 million and $30 million, respectively. X - DefinitionThe entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + ReferencesNo definition available. + Details Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND OTHER INTANGIBLE ASSETS, NET 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â GOODWILL AND OTHER INTANGIBLE ASSETS, NET GOODWILL AND OTHER INTANGIBLE ASSETS, NETGoodwillThe following is a reconciliation of goodwill by segment.(in millions)Medical Products and TherapiesHealthcare Systems and TechnologiesPharmaceuticalsTotalBalance as of December 31, 2023$1,241Â $3,989Â $563Â $5,793Â Currency translation (7)â€”Â (3)(10)Balance as of September 30, 2024$1,234Â $3,989Â $560Â $5,783Â Other intangible assets, netThe following is a summary of our other intangible assets.Indefinite-lived intangible assets(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and DevelopmentTotalSeptember 30, 2024Gross other intangible assets$3,390Â $3,182Â $963Â $87Â $680Â $157Â $8,459Â Accumulated amortization(824)(2,027)(92)(67)â€”Â â€”Â (3,010)Other intangible assets, net$2,566Â $1,155Â $871Â $20Â $680Â $157Â $5,449Â December 31, 2023Gross other intangible assets$3,390Â $3,181Â $964Â $86Â $680Â $157Â $8,458Â Accumulated amortization(654)(1,782)(38)(66)â€”Â â€”Â (2,540)Other intangible assets, net$2,736Â 1,399Â 926Â 20Â 680Â 157Â 5,918Â Intangible asset amortization expense was $159 million and $147 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $471 million and $434 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCING ARRANGEMENTS 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â FINANCING ARRANGEMENTS FINANCING ARRANGEMENTS Credit Facilities On July 17, 2024, we entered into a credit agreement in which a group of banks have committed to provide us senior unsecured term loans in an aggregate principal amount of up to $2.05Â billion ("the bridge facility"). Borrowings under the bridge facility will be available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the pending sale of our Kidney Care business. Borrowings under the bridge facility will bear interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We will also incur a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banksâ€™ funding commitments under the bridge facility will terminate upon the earliest to occur of: (i) our consummation of the debt repayments and tax payments described above without us having borrowed under the bridge facility, (ii) our election to terminate the commitments under the bridge facility, (iii) our receipt of net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business), (iv) the occurrence of three drawings under the bridge facility, and (v) December 31, 2024. Outstanding borrowings under the bridge facility will mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we are required to use the net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contains financial and other covenants, including a net leverage covenant, and provides for customary events of default. There were no borrowings outstanding under this bridge facility as of SeptemberÂ 30, 2024.In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. The amendment further provided for the reduction of the capacity under our U.S dollar-denominated revolving credit facility from $2.50Â billion to $2.00Â billion on the earlier of September 30, 2024 or the date of the sale of our Kidney Care business. Costs incurred in connection with the amendment were not material.In addition to our U.S. dollar-denominated revolving credit facility with a current capacity of $2.00Â billion, our Euro-denominated revolving credit facility has a capacity of â‚¬200 million. Each of the facilities matures in 2026. There were no borrowings outstanding under these credit facilities as of SeptemberÂ 30, 2024 or DecemberÂ 31, 2023. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of SeptemberÂ 30, 2024 we have capacity to draw on the full amounts under our credit facilities.In the first nine months of 2024, we repaid $822Â million of senior notes at maturity. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic

20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, our total recorded reserves with respect to legal and environmental matters were $41 million and $25 million, respectively.We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and othersâ€™ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.EnvironmentalWe are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, our environmental reserves, which are measured on an undiscounted basis, were $30 million and $15 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.General LitigationIn March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 25 lawsuits (after giving effect to the amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. We acquired Hill-Rom Holdings, Inc. (Hillrom) on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws.On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery.On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020â€ and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERSâ€™ EQUITY 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â STOCKHOLDERS' EQUITY STOCKHOLDERSâ€™ EQUITYCash DividendsCash dividends declared per share for the three months ended SeptemberÂ 30, 2024 and 2023 were $0.29 and for the nine months ended SeptemberÂ 30, 2024 and 2023 were $0.87. Stock Repurchase ProgramsIn July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first nine months of 2024 and 2023 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of SeptemberÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Comprehensive income includes all changes in stockholdersâ€™ equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the nine months ended SeptemberÂ 30, 2024 and 2023.Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of DecemberÂ 31, 2023$(2,985)$(452)(120)3Â $(3,554)Other comprehensive income (loss) before reclassifications(92)â€”Â 2Â â€”Â (90)Amounts reclassified from AOCI (a)â€”Â (3)â€”Â â€”Â (3)Net other comprehensive income (loss) (92) (3)2Â â€”Â (93)Balance as of September 30, 2024$(3,077)$(455)(118)3Â $(3,647)Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of December 31, 2022$(3,386)$(331)(119)3Â $(3,833)Other comprehensive income (loss) before reclassifications(62)â€”Â 15Â â€”Â (47)Amounts reclassified from AOCI (a)185Â (16)(5)â€”Â 164Â Net other comprehensive income (loss) 123Â (16)10Â â€”Â 117Â Balance as of September 30, 2023$(3,263)$(347)(109)3Â $(3,716)(a)Â Â Â Â See table below for details about these reclassifications.The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three and nine months ended SeptemberÂ 30, 2024 and 2023.Amounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2024Nine Months Ended September 30, 2024Location of impact in income statementPension and OPEB itemsAmortization of net losses and prior service costs or credits$1Â $4Â Other (income) expense, netLess: Tax effectâ€”Â (1)Income tax expense$1Â $3Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$4Â $9Â Cost of salesInterest rate contracts(1)(4)Interest expense, netFair value hedgesâ€”Â (5)Other (income) expense, net3Â â€”Â Total before taxLess: Tax effect(1)â€”Â Income tax expense$2Â $â€”Â Net of taxTotal reclassifications for the period$3Â $3Â Total net of taxAmounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2023Nine Months Ended September 30, 2023Location of impact in income statementCTAReclassification of cumulative translation loss to earnings from BPS divestiture(185)(185)Income from discontinued operations, net of taxLess: Tax effectâ€”Â â€”Â Income from discontinued operations, net of tax(185)(185)Net of taxPension and OPEB itemsAmortization of net losses and prior service costs or credits$5Â $15Â Other (income) expense, netPension settlement from BPS divestiture4Â 4Â Income from discontinued operations, net of tax9Â 19Â Total before taxLess: Tax effectâ€”Â (3)Income tax expense$9Â $16Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$3Â $10Â Cost of salesInterest rate contracts(1)(4)Interest expense, net2Â 6Â Total before taxLess: Tax effectâ€”Â (1)Income tax expense$2Â $5Â Net of taxTotal reclassifications for the period(174)(164)Total net of tax(a)Â Â Â Â Amounts in parentheses indicate reductions to net incomeRefer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUES 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â REVENUES REVENUESRevenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contractâ€™s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contractâ€™s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days.Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.As of SeptemberÂ 30, 2024, we had $2.75 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products and Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue over the remainder of 2024, 25% in 2025, 20% in each of 2026 and 2027 and 10% thereafter.Significant JudgmentsRevenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and wholesaler chargebacks. These reserves are based on

estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three and nine months ended SeptemberÂ 30, 2024 and 2023 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement.Contract BalancesThe timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.54Â billion as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years. The following table summarizes our contract assets:(in millions)September 30,2024December 31,2023Contract manufacturing services$4Â $4Â Software sales46Â 45Â Bundled equipment and consumable medical products contracts95Â 116Â Contract assets$145Â $165Â Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months. The following table summarizes contract liability activity for the nine months ended SeptemberÂ 30, 2024 and 2023. The contract liability balance represents the transaction price allocated to the remaining performance obligations.Nine Months Ended September 30,(in millions)20242023Balance at beginning of period$169Â $173Â New revenue deferrals383Â 401Â Revenue recognized upon satisfaction of performance obligations(389)(407)Currency translation(3)2Â Balance at end of period$160Â $169Â For the nine months ended SeptemberÂ 30, 2024 and 2023, $94 million and $111 million of revenue was recognized that was included in contract liabilities as of DecemberÂ 31, 2023 and 2022, respectively.The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:(in millions)September 30,2024December 31,2023Prepaid expenses and other current assets$54Â $53Â Other non-current assets91Â 112Â Contract assets$145Â $165Â Accrued expenses and other current liabilities$124Â $128Â Other non-current liabilities36Â 41Â Contract liabilities$160Â $169Â Disaggregation of Net SalesRefer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location. Lease RevenueWe lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.The components of lease revenue for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were:Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Sales-type lease revenue$3Â $2Â $8Â $6Â Operating lease revenue102Â 98Â 288Â 302Â Variable lease revenue10Â 3Â 22Â 15Â Total lease revenue$115Â $103Â $318Â $323Â Our net investment in sales-type leases was $36 million as of SeptemberÂ 30, 2024, of which $5 million originated in 2020 and prior, $10 million in 2021, $5Â million in 2022, $7 million in 2023, and $9Â million in 2024. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â BUSINESS OPTIMIZATION CHARGES BUSINESS OPTIMIZATION CHARGESIn recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. The related costs of those actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $5 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those related to our newly implemented operating model, intended to simplify and streamline our operations, and to the extent further cost savings opportunities are identified (including after completion of the pending Kidney Care sale), we would incur additional restructuring charges and costs to implement business optimization programs in future periods.During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following charges related to business optimization programs.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232023Restructuring charges$15Â $41Â $36Â $140Â Costs to implement business optimization programs3Â 7Â 13Â 27Â Total business optimization charges$18Â $48Â $49Â $167Â For segment reporting purposes, business optimization charges are unallocated expenses.Costs to implement business optimization programs for the three and nine months ended SeptemberÂ 30, 2024 and 2023, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense.During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following restructuring charges.Three months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$2Â $10Â $12Â Contract termination and other costsâ€”Â 3Â 3Â Total restructuring charges$2Â $13Â $15Â Three months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$6Â $29Â $4Â $39Â Contract termination and other costsâ€”Â 2Â â€”Â 2Â Total restructuring charges$6Â $31Â $4Â $41Â Nine months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$4Â $25Â $29Â Contract termination and other costs1Â 6Â 7Â Total restructuring charges$5Â $31Â $36Â Nine months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$25Â $89Â $10Â $124Â Contract termination and other costsâ€”Â 5Â â€”Â 5Â Asset impairments3Â 8Â â€”Â 11Â Total restructuring charges$28Â $102Â $10Â $140Â For the three and nine months ended SeptemberÂ 30, 2024, $7Â million and $14Â million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to business optimization initiatives within our Healthcare Systems and Technologies segment. Additionally, for the nine months ended September 30, 2024, $7Â million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to our recent implementation of a new operating model intended to simplify and streamline our operations.For the three and nine months ended SeptemberÂ 30, 2023, $11Â million and $79Â million, respectively, of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our previously announced new operating model intended to simplify and streamline our operations. The following table summarizes activity in the liability related to our restructuring initiatives.(in millions)Liability balance as of December 31, 2023$95Â Charges42Â Payments(59)Reserve adjustments(8)Currency translation4Â Liability balance as of September 30, 2024$74Â Substantially all of our restructuring liabilities as of SeptemberÂ 30, 2024 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3 PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] Â PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMSThe following is a summary of net periodic benefit cost relating to our pension and OPEB plans.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Pension benefitsService cost$4Â $6Â $13Â $18Â Interest cost33Â 45Â 123Â 137Â Expected return on plan assets(43)(57)(160)(166)Amortization of net losses and prior service costs4Â 1Â 11Â 4Â Net periodic pension cost(2)(5)(13)(7)OPEBInterest cost$2Â $2Â $6Â $6Â Amortization of net loss and prior service credit(5)(6)(14)(18)Net periodic OPEB cost (income)(3)(4)(8)(12) X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for retirement benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 60 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â INCOME TAXES INCOME TAXESOur effective income tax rate was 11.6% and 42.2% for the three months ended September 30, 2024 and 2023, respectively, and 30.2% and 281.0% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards. For the three months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix, the tax impacts of the write-off of damaged inventory and fixed assets at our North Cove facility caused by Hurricane Helene, and a change in our assertion on the reinvested foreign earnings related to the pending sale of our Kidney Care segment allocated to continuing operations,

partially offset by a $26Â million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment. For the nine months ended SeptemberÂ 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $26Â million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, an increase in income tax expense resulting from internal reorganization transactions related to the pending sale of our Kidney Care segment, and an increase in our liabilities for various uncertain tax positions, partially offset by a favorable geographic earnings mix.Â Â Â Â For the three months ended September 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, partially offset by a favorable geographic earnings mix.For the nine months ended SeptemberÂ 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $30Â million increase in the valuation allowance related to a deferred tax asset from a tax basis step-up that arose from previously enacted Swiss tax reform legislation, an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and excess tax shortfalls on stock compensation awards. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS PER SHARE 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â EARNINGS PER SHARE EARNINGS PER SHAREThe numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023Income (loss) from continuing operations$61Â $37Â $162Â $(38)Less: Net income attributable to noncontrolling interests included in continuing operationsâ€”Â â€”Â â€”Â â€”Â Income (loss) from continuing operations attributable to Baxter stockholders61Â 37Â 162Â (38)Income (loss) from discontinued operations83Â 2,474Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations4Â 3Â 9Â 6Â Income (loss) from discontinued operations attributable to Baxter stockholders79Â 2,471Â (299)2,449Â Net income (loss) attributable to Baxter stockholders$140Â $2,508Â (137)2,411Â The following table is a reconciliation of basic shares and diluted shares.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023Basic shares510Â 507Â 509Â 506Â Effect of dilutive securities2Â 2Â 2Â â€”Â Diluted shares512Â 509Â 511Â 506Â Basic and diluted shares are the same for nine months ended September 30, 2023 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 18 million and 19 million shares issuable under equity awards for the three and nine months ended SeptemberÂ 30, 2024, and 18 million and 25 million shares issuable under equity awards for the three and nine months ended SeptemberÂ 30, 2023, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIESWe operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Renminbi, Japanese Yen, Swedish Krona, Mexican Peso, Australian Dollar, Canadian Dollar, Turkish Lira, and Indian Rupee. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.Cash Flow HedgesWe may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.The notional amounts of foreign exchange contracts designated as cash flow hedges were $225 million and $340 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at SeptemberÂ 30, 2024 is 12 months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. Fair Value HedgesWe periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.There were no outstanding interest rate contracts designated as fair value hedges as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.In October 2023, we entered into a foreign currency forward contract with a notional amount of $798Â million and designated that derivative as a fair value hedge of our â‚¬750Â million of 0.40% senior notes due May 2024. This forward contract matured in May 2024.Net Investment HedgesIn May 2017, we issued â‚¬600 million of 1.3% senior notes due May 2025. In May 2019, we issued â‚¬750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. In May 2019, we issued â‚¬750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above. As of SeptemberÂ 30, 2024, we had an accumulated pre-tax unrealized translation gain in AOCI of $18 million related to the Euro-denominated senior notes.DedesignationsIf it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. There were no cash flow hedge dedesignations in the first nine months of 2024 or 2023 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first nine months of 2024 or 2023. If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. There were no net investment hedges terminated during the first nine months of 2024 or 2023.Undesignated Derivative InstrumentsWe use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.The total notional amount of undesignated derivative instruments was $527Â million as of SeptemberÂ 30, 2024 and $305 million as of DecemberÂ 31, 2023.Gains and Losses on Hedging Instruments and Undesignated Derivative InstrumentsThe following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)20242023Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(1)(1)Foreign exchange contracts(9)9Â Cost of sales4Â 3Â Net investment hedges(68)48Â Other (income) expense, netâ€”Â â€”Â Total(77)57Â $3Â $2Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, net6Â (1)Total$6Â $(1)The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the nine months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)20242023Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(4)(4)Foreign exchange contracts5Â 19Â Cost of sales9Â 10Â Fair value hedgesForeign exchange contracts(3)â€”Â Other (income) expense, net(5)â€”Â Net investment hedges(19)10Â Other (income) expense, netâ€”Â â€”Â Total(17)29Â $â€”Â $6Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Fair value hedgesForeign exchange contractsOther (income) expense, net(24)â€”Â Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, netâ€”Â (9)Total(24)(9)As of SeptemberÂ 30, 2024, $8Â million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. Derivative Assets and LiabilitiesThe following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of SeptemberÂ 30, 2024.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$2Â Accrued expenses and other current liabilities$2Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assetsâ€”Â Accrued expenses and other current liabilities5Total derivative instruments$2Â $7The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of DecemberÂ 31, 2023.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$41Â Accrued expenses and other current liabilities$â€”Â Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assets4Â Accrued expenses and other current liabilities5Â Total derivative instruments$45Â $5Â While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.September 30, 2024December 31, 2023(in millions)AssetLiabilityAssetLiabilityGross amounts recognized in the condensed consolidated balance sheets$2Â $7Â $45Â $5Â Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(1)(1)(4)(4)Total$1Â $6Â $41Â $1Â The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:Carrying amount of hedged itemCumulative amount of fair value hedging adjustment includedÂ in the carrying amount of the hedged item (a)(in millions)Balance as of September 30, 2024Balance as of December 31, 2023Balance as of September 30, 2024Balance as of December 31, 2023Long-term debt$100Â $100Â $3Â $3Â (a) These fair value hedges were terminated in 2018 and earlier periods. X - ReferencesNo definition available. + Details Name: us-

gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTSThe following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.Basis of fair value measurement(in millions)Balance as of September 30, 2024Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$2Â $â€”Â $2Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities13Â 13Â â€”Â â€”Â Total$16Â $13Â $2Â $1Â LiabilitiesForeign exchange contracts$7Â $â€”Â $7Â $â€”Â Contingent payments related to acquisitions12Â â€”Â â€”Â 12Â Total$19Â $â€”Â $7Â $12Â Basis of fair value measurement(in millions)Balance as of December 31, 2023Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$45Â $â€”Â $45Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities44Â 44Â â€”Â â€”Â Total$90Â $44Â $45Â $1Â LiabilitiesForeign exchange contracts$5Â $â€”Â $5Â $â€”Â Contingent payments related to acquisitions14Â â€”Â â€”Â 14Â Total$19Â $â€”Â $5Â $14Â As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, cash and cash equivalents of $1.42 billion and $3.08 billion, respectively, included money market funds of approximately $427 million and $1.63 billion, respectively, which are considered Level 2 in the fair value hierarchy.For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.Three Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $21Â $17Â Payments(2)â€”Â (2)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â Nine Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $84Â $27Â Change in fair value recognized in earningsâ€”Â â€”Â (14)(5)Transfers out of Level 3â€”Â â€”Â â€”Â (5)Payments(2)â€”Â (51)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â During the nine months ended September 30, 2023, available-for-sale debt securities were reclassified from Level 3, upon conversion to marketable equity securities, which are classified as Level 1 in the fair value hierarchy, upon initial public offerings of the investees.Financial Instruments Not Measured at Fair ValueIn addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.Book valuesFair values(a)(in millions)20242023202420232LiabilitiesCurrent maturities of long-term debt and finance lease obligations$2,498Â $2,667Â $2,493Â $2,621Â Long-term debt and finance lease obligations10,437Â 11,089Â 9,612Â 10,026Â (a)Â Â Â Â These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.Investments Without Readily Determinable Fair ValuesThe carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $33 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. Those investments are included in Other non-current assets on our condensed consolidated balance sheets. During the first nine months of 2023, several of our investees either completed or were in the process of undertaking new financing rounds at lower enterprise valuations as compared to their valuations at the time of our investments. As a result, we recognized $8Â million of impairments of equity investments without readily determinable fair values in the prior year period. In addition, we recognized a $5Â million impairment of a convertible debt investment, which is accounted for as an available-for-sale security, during the first nine months of 2023. The fair value measurements of investments in non-marketable equity and convertible debt securities are classified as Level 3 in the fair value hierarchy because they involve significant unobservable inputs. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â SEGMENT INFORMATION SEGMENT INFORMATIONIn the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this new operating model, our business is currently comprised of four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care (which we are planning to divest through the pending sale and accordingly, the results are reported in discontinued operations as discussed in Note 1). The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities and royalty income under a business development arrangement that ended in early 2023 when we acquired the related product rights.Disaggregation of Net SalesThe following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below.Three Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$613Â $457Â $1,070Â $570Â $433Â $1,003Â Advanced Surgery149Â 123Â 272Â 139Â 116Â 255Â Medical Products and Therapies762Â 580Â 1,342Â 709Â 549Â 1,258Â Care and Connectivity Solutions335Â 121Â 456Â 317Â 126Â 443Â Front Line Care222Â 74Â 296Â 234Â 67Â 301Â Healthcare Systems and Technologies557Â 195Â 752Â 551Â 193Â 744Â Injectables and Anesthesia178Â 143Â 321Â 195Â 156Â 351Â Drug Compoundingâ€”Â 267Â 267Â â€”Â 229Â 229Â Pharmaceuticals178Â 410Â 588Â 195Â 385Â 580Â Other3Â 14Â 17Â 12Â 5Â 17Â Total Baxter$1,500Â $1,199Â $2,699Â $1,467Â $1,132Â $2,599Â Nine Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$1,718Â $1,363Â $3,081Â $1,654Â $1,264Â $2,918Â Advanced Surgery446Â 366Â 812Â 433Â 340Â 773Â Medical Products and Therapies2,164Â 1,729Â 3,893Â 2,087Â 1,604Â 3,691Â Care and Connectivity Solutions945Â 365Â 1,310Â 926Â 381Â 1,307Â Front Line Care635Â 222Â 857Â 681Â 230Â 911Â Healthcare Systems and Technologies1,580Â 587Â 2,167Â 1,607Â 611Â 2,218Â Injectables and Anesthesia566Â 424Â 990Â 550Â 437Â 987Â Drug Compoundingâ€”Â 778Â 778Â â€”Â 665Â 665Â Pharmaceuticals566Â 1,202Â 1,768Â 550Â 1,102Â 1,652Â Other30Â 25Â 55Â 56Â 17Â 73Â Total Baxter$4,340Â $3,543Â $7,883Â $4,300Â $3,334Â $7,634Â Geographic Sales InformationOur net sales are attributed to the following geographic regions based on the location of the customer. Three Months Ended September 30,Nine Months Ended September 30,20242023202420232United States$1,500Â $1,467Â $4,340Â $4,300Â Emerging markets1347Â 353Â 1,001Â 985Â Rest of world2852Â 779Â 2,542Â 2,349Â Total Baxter$2,699Â $2,599Â $7,883Â $7,634Â 1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.Segment Operating IncomeWe use segment operating income to evaluate the performance of our segments and to make resource allocation decisions. Segment operating income represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of segment operating income to income from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the Kidney Care segment in the pending sale, are now presented as unallocated corporate costs. The following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232Medical Products and Therapies$268Â $245Â $733Â $706Â Healthcare Systems and Technologies136Â 115Â 323Â 327Â Pharmaceuticals58Â 108Â 211Â 284Â Other2Â 6Â 15Â 19Â Total464Â 474Â 1,282Â 1,336Â Unallocated corporate costs(73)(73)(227)(285)Intangible asset amortization expense(159)(147)(471)(434)Legal matters(17)(13)(17)(13)Business optimization items(18)(48)(49)(167)Acquisition and integration items(5)(2)(16)(2)European Medical Devices Regulation(9)(12)(25)(32)Hurricane Helene costs(25)â€”Â (25)â€”Â Product-related items(3)â€”Â (3)â€”Â Total operating income 155Â 179Â 449Â 403Â Interest expense, net87Â 127Â 251Â 367Â Other (income) expense, net(1)(12)(34)15Â Income from continuing operations before income taxes$69Â $64Â $232Â $21Â Our chief operating decision maker does not receive any asset information by reportable segment and, accordingly, we do not report asset information by reportable segment. X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net income (loss) attributable to Baxter stockholders $ 140 $ 2,508 $ (137) $ 2,411 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION (Policies) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (2023 Annual Report).In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. Risks and Uncertainties Risks and Uncertainties Supply Constraints and Global Economic ConditionsIn recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing of raw materials and on transportation costs, some of these challenges (such as additional transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future. X - DefinitionRisks and Uncertainties Policy + ReferencesNo definition available. + Details Name: bax_RisksAndUncertaintiesPolicyPolicyTextBlock Namespace Prefix: bax_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.3 DISCONTINUED OPERATIONS (Tables) 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three and nine months ended SeptemberÂ 30, 2024 and 2023:Kidney CareBioPharma SolutionsTotalThree Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,(in millions)20242023202420232024202320242023Net sales$1,155Â $1,109Â $â€”Â $191Â $1,155Â $1,300Â Cost of sales731Â 1,048Â â€”Â 81Â 731Â 1,129Â Gross margin424Â 61Â â€”Â 110Â 424Â 171Â Selling, general and administrative expenses278Â 258Â â€”Â 15Â 278Â 273Â Research and development expenses41Â 33Â â€”Â 1Â 41Â 34Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)106Â (230)â€”Â 94Â 106Â (136)Interest expense, net1Â 1Â â€”Â â€”Â 1Â 1Â Other (income) expense, net(8)5Â â€”Â 2Â (8)7Â Income (loss) from discontinued operations before gain on disposition and income taxes113Â (236)â€”Â 92Â 113Â (144)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)30Â (250)â€”Â 522Â 30Â 272Â Income from discontinued operations, net of tax83Â 14Â â€”Â 2,460Â 83Â 2,474Â Less: Net income attributable to noncontrolling interest included in discontinued operations4Â 3Â â€”Â â€”Â 4Â 3Â Net income attributable to Baxter stockholders included in discontinued operations$79Â $11Â $â€”Â $2,460Â $79Â $2,471Â Kidney CareBioPharma SolutionsTotalNine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,20242023202420232024202320242023Net sales$3,375Â $3,294Â $â€”Â $469Â $3,375Â $3,763Â Cost of sales2,125Â 2,841Â â€”Â 216Â 2,125Â 3,057Â Gross margin1,250Â 453Â â€”Â 253Â 1,250Â 706Â Selling, general and administrative expenses874Â 691Â â€”Â 44Â 874Â 735Â Research and development expenses140Â 104Â â€”Â 2Â 140Â 106Â Goodwill impairment430Â â€”Â â€”Â â€”Â 430Â â€”Â Other operating income, net(1)â€”Â â€”Â â€”Â (1)â€”Â Operating income (loss)(193)(342)â€”Â 207Â (193)(135)Interest expense, netâ€”Â 2Â â€”Â â€”Â 2Â Other (income) expense, net(2)18Â â€”Â 2Â (2)20Â Income (loss) from discontinued operations before income taxes(191)(362)â€”Â 205Â (191)(157)Gain on dispositionâ€”Â â€”Â â€”Â 2,890Â â€”Â 2,890Â Income tax expense (benefit)99Â (258)â€”Â 536Â 99Â 278Â Income (loss) from discontinued operations, net of tax(290)(104)â€”Â 2,559Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations9Â 6Â â€”Â â€”Â 9Â 6Â Net income (loss) attributable to Baxter stockholders included in discontinued operations(299)(110)$â€”Â $2,559Â (299)2,449Â The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023:(in millions)September 30, 2024December 31, 2023Cash and cash equivalents$658Â $116Â Accounts receivable, net of allowances1,045Â 971Â Inventories960Â 906Â Prepaid expenses and other current assets229Â 186Â Current assets of discontinued operations2,892Â 2,179Â Property, plant and equipment, net1,542Â 1,562Â Goodwill276Â 721Â Other intangible assets, net147Â 161Â Operating lease right-of-use assets209Â 188Â Other non-current assets360Â 317Â Non-current assets of discontinued operations2,534Â 2,949Â Assets of discontinued operations$5,426Â $5,128Â Current maturities of finance lease obligations$â€”Â $1Â Accounts payable396Â 360Â Accrued expenses and other current liabilities693Â 679Â Current liabilities of discontinued operations1,089Â 1,040Â Long-term finance lease obligations, less current portion40Â 41Â Operating lease liabilities186Â 173Â Other non-current liabilities349Â 337Â Non-current liabilities of discontinued operations575Â 551Â Liabilities of discontinued operations$1,664Â $1,591Â X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Allowance for Doubtful Accounts Allowance for Doubtful AccountsThe following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Three Months Ended September 30,Nine Months Ended September 30,(in millions)2024202320242023Balance at beginning of period$67Â $61Â $62Â $50Â Charged to costs and expenses4Â 2Â 4Â 17Â Write-offs(3)1Â (6)(2)Currency translation adjustments(3)2Â 5Â 1Â Balance at end of period$65Â $66Â $65Â $66Â Inventories Inventories (in millions)September 30,2024December 31,2023Raw materials$532Â $530Â Work in process256Â 234Â Finished goods1,315Â 1,154Â Inventories$2,103Â $1,918Â Property, Plant and Equipment, Net Property, Plant and Equipment, Net (in millions)September 30,2024December 31,2023Property, plant and equipment, at cost$7,605Â $7,650Â Accumulated depreciation(4,772)(4,779)Property, plant and equipment, net$2,833Â $2,871Â Interest Expense, Net Interest Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024202320242023Interest expense, net of capitalized interest$101Â $136Â $308Â $394Â Interest income(14)(9)(57)(27)Interest expense, net$87Â $127Â $251Â $367Â Other (Income) Expense-, Net Other (Income) Expense, NetThree Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024202320242023Foreign exchange losses, net$7Â $10Â $21Â 49Â Pension and other postretirement benefit plans(9)(15)(34)(37)Change in fair value of marketable equity securitiesâ€”Â (3)(3)3Â Non-marketable investment impairmentsâ€”Â â€”Â â€”Â 13Â Other, net1Â (4)(18)(13)Other (income) expense, net(1)(12)(34)15Â X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill The following is a reconciliation of goodwill by segment.(in millions)Medical Products and TherapiesHealthcare Systems and TechnologiesPharmaceuticalsTotalBalance as of December 31, 2023$1,241Â $3,989Â $563Â $5,793Â Currency translation (7)â€”Â (3)(10)Balance as of September 30, 2024$1,234Â $3,989Â $560Â $5,783Â Other Intangible Assets, Net The following is a summary of our other intangible assets.Indefinite-lived intangible assets(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and DevelopmentTotalSeptember 30, 2024Gross other intangible assets$3,390Â $3,182Â $963Â $87Â $680Â $157Â $8,459Â Accumulated amortization(824)(2,027)(92)(67)â€”Â â€”Â (3,010)Other intangible assets, net$2,566Â $1,155Â $871Â $20Â $680Â $157Â $5,449Â December 31, 2023Gross other intangible assets$3,390Â $3,181Â $964Â $86Â $680Â $157Â $8,458Â Accumulated amortization(654)(1,782)(38)(66)â€”Â â€”Â (2,540)Other intangible assets, net$2,736Â 1,399Â 926Â 20Â 680Â 157Â 5,918Â X - DefinitionSchedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill + ReferencesNo definition available. + Details Name: bax_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock Namespace Prefix: bax_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Summary of Changes in AOCI Income (Loss) by Component The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the nine months ended SeptemberÂ 30, 2024 and 2023.Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of DecemberÂ 31, 2023$(2,985)$(452)(120)3Â $(3,554)Other comprehensive income (loss) before reclassifications(92)â€”Â 2Â â€”Â (90)Amounts reclassified from AOCI (a)â€”Â (3)â€”Â â€”Â (3)Net other comprehensive income (loss) (92)(3)2Â â€”Â (93)Balance as of September 30, 2024$(3,077)$(455)(118)3Â $(3,647)Gains (losses)(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotalBalance as of December 31, 2022$(3,386)$(331)(119)3Â $(3,833)Other comprehensive income (loss) before reclassifications(62)â€”Â 15Â â€”Â (47)Amounts reclassified from AOCI (a)185Â (16)(5)â€”Â 164Â Net other comprehensive income (loss) 123Â (16)10Â â€”Â 117Â Balance as of September 30, 2023$(3,263)$(347)(109)3Â $(3,716)(a)Â Â Â Â See table below for details about these reclassifications. Summary of Reclassification from AOCI to Net Income (Loss) The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three and nine months ended SeptemberÂ 30, 2024 and 2023.Amounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2024Nine Months Ended September 30, 2024Location of impact in income statementPension and OPEB itemsAmortization of net losses and prior service costs or credits$1Â $4Â Other (income) expense, netLess: Tax effectâ€”Â (1)Income tax expense$1Â $3Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$4Â $9Â Cost of salesInterest rate contracts(1)(4)Interest expense, netFair value hedgesâ€”Â (5)Other (income) expense, net3Â â€”Â Total before taxLess: Tax effect(1)â€”Â Income tax expense$2Â $â€”Â Net of taxTotal reclassifications for the period$3Â $3Â Total net

of taxAmounts reclassified from AOCI (a)(in millions)Three Months Ended September 30, 2023Nine Months Ended September 30, 2023Location of impact in income statementCTAReclassification of cumulative translation loss to earnings from BPS divestiture(185)(185)Income from discontinued operations, net of taxLess: Tax effectâ€”Â â€”Â Income from discontinued operations, net of tax(185)(185)Net of taxPension and OPEB itemsAmortization of net losses and prior service costs or credits$5Â $15Â Other (income) expense, netPension settlement from BPS divestiture4Â 4Â Income from discontinued operations, net of tax9Â 19Â Total before taxLess: Tax effectâ€”Â (3)Income tax expense$9Â $16Â Net of taxGains (losses) on hedging activitiesForeign exchange contracts$3Â $10Â Cost of salesInterest rate contracts(1)(4)Interest expense, net2Â 6Â Total before taxLess: Tax effectâ€”Â (1)Income tax expense$2Â $5Â Net of taxTotal reclassifications for the period(174)(164)Total net of tax(a)Â Â Â Â Amounts in parentheses indicate reductions to net income X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + ReferencesNo definition available. + Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUES (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Contract with Customer, Contract Asset The following table summarizes our contract assets:(in millions)September 30,2024December 31,2023Contract manufacturing services$4Â $4Â Software sales46Â 45Â Bundled equipment and consumable medical products contracts95Â 116Â Contract assets$145Â $165Â The following table summarizes contract liability activity for the nine months ended SeptemberÂ 30, 2024 and 2023. The contract liability balance represents the transaction price allocated to the remaining performance obligations.Nine Months Ended September 30,(in millions)20242023Balance at beginning of period$169Â $173Â New revenue deferrals383Â 401Â Revenue recognized upon satisfaction of performance obligations(389)(407)Currency translation(3)2Â Balance at end of period$160Â $169Â For the nine months ended SeptemberÂ 30, 2024 and 2023, $94 million and $111 million of revenue was recognized that was included in contract liabilities as of DecemberÂ 31, 2023 and 2022, respectively.The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:(in millions)September 30,2024December 31,2023Prepaid expenses and other current assets$54Â $53Â Other non-current assets91Â 112Â Contract assets$145Â $165Â Accrued expenses and other current liabilities$124Â $128Â Other non-current liabilities36Â 41Â Contract liabilities$160Â $169Â Sales-type Lease, Lease Income The components of lease revenue for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were:Three Months Ended September 30,Nine Months Ended September 30,(in millions)202420232024202320242023Sales-type lease revenue$3Â $2Â $8Â $6Â Operating lease revenue102Â 98Â 288Â 302Â Variable lease revenue10Â 3Â 22Â 15Â Total lease revenue$115Â $103Â $318Â $323Â Operating Lease, Lease Income The components of lease revenue for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were:Three Months Ended September 30,Nine Months Ended September 30,(in millions)202420232024202320242023Sales-type lease revenue$3Â $2Â $8Â $6Â Operating lease revenue102Â 98Â 288Â 302Â Variable lease revenue10Â 3Â 22Â 15Â Total lease revenue$115Â $103Â $318Â $323Â X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10 + Details Name: us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES (Tables) 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Summary of Business Optimization Charges During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following charges related to business optimization programs.Three Months Ended September 30,Nine Months Ended September 30,(in millions)202420232024202320242023Restructuring charges$15Â $41Â $36Â $140Â Costs to implement business optimization programs3Â 7Â 13Â 27Â Total business optimization charges$18Â $48Â $49Â $167Â Components of Restructuring Charges During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we recorded the following restructuring charges.Three months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$2Â $10Â $12Â Contract termination and other costsâ€”Â 3Â 3Â Total restructuring charges$2Â $13Â $15Â Three months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$6Â $29Â $4Â $39Â Contract termination and other costsâ€”Â 2Â â€”Â 2Â Total restructuring charges$6Â $31Â $4Â $41Â Nine months ended September 30, 2024(in millions)COGSSG&ATotalEmployee termination costs$4Â $25Â $29Â Contract termination and other costs1Â 6Â 7Â Total restructuring charges$5Â $31Â $36Â Nine months ended September 30, 2023(in millions)COGSSG&AR&DTotalEmployee termination costs$25Â $89Â $10Â $124Â Contract termination and other costsâ€”Â 5Â â€”Â 5Â Asset impairments3Â 8Â â€”Â 11Â Total restructuring charges$28Â $102Â $10Â $140Â Summary of Activity in Reserves Related to Restructuring Initiatives The following table summarizes activity in the liability related to our restructuring initiatives.(in millions)Liability balance as of December 31, 2023$95Â Charges42Â Payments(59)Reserve adjustments(8)Currency translation4Â Liability balance as of September 30, 2024$74Â X - DefinitionBusiness optimization charge. + ReferencesNo definition available. + Details Name: bax_BusinessOptimizationChargeTableTextBlock Namespace Prefix: bax_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.3 PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables) 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] Â Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Pension benefitsService cost$4Â $6Â $13Â $18Â Interest cost33Â 45Â 123Â 137Â Expected return on plan assets(43)(57)(160)(166)Amortization of net losses and prior service costs4Â 1Â 11Â 4Â Net periodic pension cost(2)(5)(13)(7)OPEBInterest cost$2Â $2Â $6Â $6Â Amortization of net loss and prior service credit(5)(6)(14)(18)Net periodic OPEB cost (income)(3)(4)(8)(12) X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -SubTopic 20 -Subparagraph (h) -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_ScheduleOfNetBenefitCostsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS PER SHARE (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Net Income (Loss) attributable to Stockholder The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Income (loss) from continuing operations$61Â $37Â $162Â $(38)Less: Net income attributable to noncontrolling interests included in continuing operationsâ€”Â â€”Â â€”Â â€”Â Income (loss) from continuing operations attributable to Baxter stockholders61Â 37Â 162Â (38)Income (loss) from discontinued operations83Â 2,474Â (290)2,455Â Less: Net income attributable to noncontrolling interests included in discontinued operations4Â 3Â 9Â 6Â Income (loss) from discontinued operations attributable to Baxter stockholders79Â 2,471Â (299)2,449Â Net income (loss) attributable to Baxter stockholders$140Â $2,508Â (137)2,411Â Reconciliation of Basic Shares to Diluted Shares The following table is a reconciliation of basic shares and diluted shares.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023202420232024Basic shares510Â 507Â 509Â 506Â Effect of dilutive securities2Â 2Â 2Â 2Â â€”Â Diluted shares512Â 509Â 511Â 506Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Summary of Gains and Losses on Derivative Instruments The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)202420232024202320242023Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(1)(1)Foreign exchange contracts(9)9Â Cost of sales4Â 3Â Net investment hedges(68)48Â Other (income) expense, netâ€”Â â€”Â Total(77)57Â $3Â $2Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, net6Â (1)Total$6Â $(1)The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the nine months ended SeptemberÂ 30, 2024 and 2023.Gain (loss) recognized in OCILocation of gain (loss)in income statementGain (loss) reclassified from AOCI into income(in millions)20242023202420232024Cash flow hedgesInterest rate contracts$â€”Â $â€”Â Interest expense, net(4)(4)Foreign exchange contracts5Â 19Â Cost of sales9Â 10Â Fair value hedgesForeign exchange contracts(3)â€”Â Other (income) expense, net(5)â€”Â Net investment hedges(19)10Â Other (income) expense, netâ€”Â â€”Â Total(17)29Â $â€”Â $6Â Location of gain (loss) in income statementGain (loss) recognized in income(in millions)20242023Fair value hedgesForeign exchange contractsOther (income) expense, net(24)â€”Â Undesignated derivative instrumentsForeign exchange contractsOther (income) expense, netâ€”Â (9)Total(24)(9) Classification and Fair Values of Derivative Instruments The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of SeptemberÂ 30, 2024.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$2Â Accrued expenses and other current liabilities$2Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assetsâ€”Â Accrued expenses and other current liabilities5Total derivative instruments$2Â $7The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of DecemberÂ 31, 2023.Derivatives in asset positionsDerivatives in liability positions(in millions)Balance sheet locationFair valueBalance sheet locationFair valueUndesignated derivative instrumentsForeign exchange contractsPrepaid expenses and other current assets$41Â Accrued expenses and other current liabilities$â€”Â Derivative instruments designated as hedgesForeign exchange contractsPrepaid expenses and other current assets4Â Accrued expenses and other current liabilities5Â Total derivative instruments$45Â $5Â Derivative Positions Presented On Net Basis The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.September 30, 2024December 31, 2023(in millions)AssetLiabilityAssetLiabilityGross amounts recognized in the condensed consolidated balance sheets$2Â $7Â $45Â $5Â Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(1)(1)(4)(4)Total$1Â $6Â $41Â $1Â Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:Carrying amount of hedged itemCumulative amount of fair value hedging adjustment includedÂ in the carrying amount of the hedged item (a)(in millions)Balance as of September 30, 2024Balance as of December 31, 2023Balance as of September 30, 2024Balance as of December 31, 2023Long-term debt$100Â $100Â $3Â $3Â (a) These fair value hedges were terminated in 2018 and earlier periods. X - DefinitionSchedule of derivative positions presented on net basis. + ReferencesNo definition available. + Details Name: bax_ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock Namespace Prefix: bax_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data

Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Financial Instruments Measured at Fair Value on Recurring Basis The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.Basis of fair value measurement(in millions)Balance as of September 30, 2024Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$2Â $â€”Â $2Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities13Â 13Â â€”Â â€”Â Total$16Â $13Â $2Â $1Â LiabilitiesForeign exchange contracts$7Â $â€”Â $7Â $â€”Â Contingent payments related to acquisitions12Â â€”Â â€”Â 12Â Total$19Â $â€”Â $7Â $12Â Basis of fair value measurement(in millions)Balance as of December 31, 2023Quoted prices in active markets for identical assets(Level 1)Significant otherobservable inputs(Level 2)Significantunobservable inputs(Level 3)AssetsForeign exchange contracts$45Â $â€”Â $45Â $â€”Â Available-for-sale debt securities1Â â€”Â â€”Â 1Â Marketable equity securities44Â 44Â â€”Â â€”Â Total$90Â $44Â $45Â $1Â LiabilitiesForeign exchange contracts$5Â $â€”Â $5Â $â€”Â Contingent payments related to acquisitions14Â â€”Â â€”Â 14Â Total$19Â $â€”Â $5Â $14Â Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.Three Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $21Â $17Â Payments(2)â€”Â (2)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â Nine Months Ended September 30,20242023(in millions)Contingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securitiesFair value at beginning of period$14Â $1Â $84Â $27Â Change in fair value recognized in earningsâ€”Â â€”Â (14)(5)Transfers out of Level 3â€”Â â€”Â â€”Â (5)Payments(2)â€”Â (51)â€”Â Fair value at end of period$12Â $1Â $19Â $17Â Book Values and Fair Values of Financial Instruments For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.Book valuesFair values(a)(in millions)2024202320242023LiabilitiesCurrent maturities of long-term debt and finance lease obligations$2,498Â $2,667Â $2,493Â $2,621Â Long-term debt and finance lease obligations10,437Â 11,089Â 9,612Â 10,026Â (a)Â Â Â Â These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs. X - DefinitionTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION (Tables) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Summary of Financial Information for Our Segments The following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below.Three Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$613Â $457Â $1,070Â $570Â $433Â $1,003Â Advanced Surgery149Â 123Â 272Â 139Â 116Â 255Â Medical Products and Therapies762Â 580Â 1,342Â 709Â 549Â 1,258Â Care and Connectivity Solutions335Â 121Â 456Â 317Â 126Â 443Â Front Line Care222Â 74Â 296Â 234Â 67Â 301Â Healthcare Systems and Technologies557Â 195Â 752Â 551Â 193Â 744Â Injectables and Anesthesia178Â 143Â 321Â 195Â 156Â 351Â Drug Compoundingâ€”Â 267Â 267Â â€”Â 229Â 229Â Pharmaceuticals178Â 410Â 588Â 195Â 385Â 580Â Other3Â 14Â 17Â 12Â 5Â 17Â Total Baxter$1,500Â $1,199Â $2,699Â $1,467Â $1,132Â $2,599Â Nine Months Ended September 30,20242023(in millions)U.S.InternationalTotalU.S.InternationalTotalInfusion Therapies and Technologies$1,718Â $1,363Â $3,081Â $1,654Â $1,264Â $2,918Â Advanced Surgery446Â 366Â 812Â 433Â 340Â 773Â Medical Products and Therapies2,164Â 1,729Â 3,893Â 2,087Â 1,604Â 3,691Â Care and Connectivity Solutions945Â 365Â 1,310Â 926Â 381Â 1,307Â Front Line Care635Â 222Â 857Â 681Â 230Â 911Â Healthcare Systems and Technologies1,580Â 587Â 2,167Â 1,607Â 611Â 2,218Â Injectables and Anesthesia566Â 424Â 990Â 550Â 437Â 987Â Drug Compoundingâ€”Â 778Â 778Â â€”Â 665Â 665Â Pharmaceuticals566Â 1,202Â 1,768Â 550Â 1,102Â 1,652Â Other30Â 25Â 55Â 56Â 17Â 73Â Total Baxter$4,340Â $3,543Â $7,883Â $4,300Â $3,334Â $7,634Â Revenue from External Customers by Geographic Areas Our net sales are attributed to the following geographic regions based on the location of the customer. Three Months Ended September 30,Nine Months Ended September 30,20242023United States$1,500Â $1,467Â $4,340Â $4,300Â Emerging markets1347Â 353Â 1,001Â 985Â Rest of world2852Â 779Â 2,542Â 2,349Â Total Baxter$2,699Â $2,599Â $7,883Â $7,634Â 1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand. Operating Income to Income Before Income Taxes Reconciliation The following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes.Three Months Ended September 30,Nine Months Ended September 30,(in millions)20242023Medical Products and Therapies$268Â $245Â $733Â $706Â Healthcare Systems and Technologies136Â 115Â 323Â 327Â Pharmaceuticals58Â 108Â 211Â 284Â Other2Â 6Â 15Â 19Â Total464Â 474Â 1,282Â 1,336Â Unallocated corporate costs(73)(73)(227)(285)Intangible asset amortization expense(159)(147)(471)(434)Legal matters(17)(13)(17)(13)Business optimization items(18)(48)(49)(167)Acquisition and integration items(5)(2)(16)(2)European Medical Devices Regulation(9)(12)(25)(32)Hurricane Helene costs(25)â€”Â (25)â€”Â Product-related items(3)â€”Â (3)â€”Â Total operating income 155Â 179Â 449Â 403Â Interest expense, net87Â 127Â 251Â 367Â Other (income) expense, net(1)(12)(34)15Â Income from continuing operations before income taxes$69Â $64Â $232Â $21Â X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Nov. 01, 2024 Sep. 30, 2024 Mar. 31, 2025 Dec. 31, 2024 Hurricane Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Hurricane Helene costs Â $ 25 Â Â Tangible asset write-off Â 44 Â Â Insurance receivable Â $ 19 Â Â Subsequent Event | Hurricane Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Insurance recoveries $ 101 Â Â Â Discontinued Operations, Disposed of by Sale | Kidney Care | Forecast Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Agreed purchase price Â Â Â $ 3,800 Discontinued Operations, Held-for-Sale | Kidney Care | Forecast Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Proceeds from divestiture of businesses Â Â $ 3,500 Â Discontinued Operations, Held-for-Sale | Kidney Care | Forecast | Minimum Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Proceeds from divestiture of businesses, net of tax Â Â 3,150 Â Discontinued Operations, Held-for-Sale | Kidney Care | Forecast | Maximum Â Â Â Â Â Disclosure Basis Of Presentation Details [Line Items] Â Â Â Â Proceeds from divestiture of businesses, net of tax Â Â $ 3,250 Â X - DefinitionDisclosure Basis Of Presentation Details [Line Items] + ReferencesNo definition available. + Details Name: bax_DisclosureBasisOfPresentationDetailsLineItems Namespace Prefix: bax_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInsurance Receivable For Write-Off Of Inventory And Fixed Assets + ReferencesNo definition available. + Details Name: bax_InsuranceReceivableForWriteOffOfInventoryAndFixedAssets Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionProceeds From Divestiture Of Businesses, Net Of Tax + ReferencesNo definition available. + Details Name: bax_ProceedsFromDivestitureOfBusinessesNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTangible Asset Write-Off + ReferencesNo definition available. + Details Name: bax_TangibleAssetWriteOff Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InsuranceRecoveries Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe charge against earnings in the period for the uninsured portion of a loss from a fire, explosion, or natural disaster (hurricane, earthquake). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LossFromCatastrophes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bax_KidneyCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.3 DISCONTINUED OPERATIONS - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended 9 Months Ended Dec. 31, 2024 Sep. 29, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2025 Sep. 30, 2024 Sep. 30, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Transaction service agreement, period Â 24 months Â Â Â Â Â Â Manufacturing and supply agreement, period Â 5 years Â Â Â Â Â Â Separation costs Â Â $ 69 Â Â $ 236 Â Forecast | Kidney Care Manufacturing and Supply Agreement Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Transaction service agreement, period 10 years Â Â Â Â Â Â Â Forecast | Kidney Care Transition Services Agreement Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Transaction service agreement, period 30 months Â Â Â Â Â Â Â Discontinued Operations, Held-for-Sale | Kidney Care | Forecast Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Proceeds from divestiture of businesses Â Â Â Â $ 3,500 Â Â Discontinued Operations, Held-for-Sale | Kidney Care | Forecast | Minimum Â Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Proceeds from divestiture of businesses, net of tax Â Â Â Â 3,150 Â Â Discontinued Operations, Held-for-Sale | Kidney Care | Forecast | Maximum Â Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Proceeds from divestiture of businesses, net of tax Â Â Â Â $ 3,250 Â Â Discontinued Operations, Disposed of by Sale | BioPharma Solutions Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Separation costs Â Â Â $ 8 Â Â $ 15 Discontinued Operations, Disposed of by Sale | Kidney Care Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Separation costs Â Â Â $ 67 Â Â $ 108 Discontinued Operations, Disposed of by Sale | Kidney Care | Forecast Â Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Purchase price $ 3,800 Â Â Â Â Â Â Â X - DefinitionDisposal Group, Including Discontinued Operation, Separation Costs + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationSeparationCosts Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionManufacturing And Supply Agreement, Period + ReferencesNo definition available. + Details Name: bax_ManufacturingAndSupplyAgreementPeriod Namespace Prefix: bax_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionProceeds From Divestiture Of Businesses, Net Of Tax + ReferencesNo definition available. + Details Name: bax_ProceedsFromDivestitureOfBusinessesNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTransaction Service Agreement, Period + ReferencesNo definition available. + Details Name: bax_TransactionServiceAgreementPeriod Namespace Prefix: bax_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_KidneyCareManufacturingAndSupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_KidneyCareTransitionServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bax_KidneyCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bax_BioPharmaSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3 DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Other operating income, net $ (5) $ 0 $ (9) $ (14) Operating income 155 179 449 403 Interest expense, net 87 127 251 367 Other (income) expense, net (1) (12) (34) 15 Income from discontinued operations, net of tax 83 2,474 (290) 2,455 Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6 Income (loss) from discontinued operations attributable to Baxter stockholders 79 2,471 (299) 2,449 Discontinued Operations, Disposed of by Sale Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Net sales 1,155 1,300 3,375 3,763 Cost of sales 731 1,129 2,125 3,057 Gross margin 424 171 1,250 706 Selling, general and administrative expenses 278 273 874 735 Research and development expenses 41 34 140 106 Goodwill impairment Â Â 430 0 Other operating income, net (1) 0 (1) 0 Operating income 106 (136) (193) (135) Interest expense, net 1 1 1 0 2 Other (income) expense, net (8) 7 (2) 20 Income (loss) from discontinued operations before gain on disposition and income taxes 113 (144) (191) (157) Gain on disposition 0 2,890 0 2,890 Income tax expense (benefit) 30 272 99 278 Income from discontinued operations, net of tax 83 2,474 (290) 2,455 Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6 Income (loss) from discontinued operations attributable to Baxter stockholders 79 2,471 (299) 2,449 Discontinued Operations, Disposed of by Sale | Kidney Care Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Net sales 1,155 1,109 3,375 3,294 Cost of sales 731 1,048 2,125 2,841 Gross margin 424 61 1,250 453 Selling, general and administrative expenses 278 258 874 691 Research and development expenses 41 33 140 104 Goodwill impairment Â Â 430 0 Other operating income, net (1) 0 (1) 0 Operating income 106 (230) (193) (342) Interest expense, net 1 1 0 2 Other (income) expense, net (8) 5 (2) 18 Income (loss) from discontinued operations before gain on disposition and income taxes 113 (236) (191) (362) Gain on disposition 0 0 0 0 Income tax expense (benefit) 30 (250) 99 (258) Income from discontinued operations, net of tax 83 14 (290) (104) Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6 Income (loss) from discontinued operations attributable to Baxter stockholders 79 11 (299) (110) Discontinued Operations, Disposed of by Sale | BioPharma Solutions Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Net sales 0 191 0 469 Cost of sales 0 81 0 216 Gross margin 0 110 0 253 Selling, general and administrative expenses 0 15 0 44 Research and development expenses 0 1 0 2 Goodwill impairment Â Â 0 0 Other operating income, net 0 0 0 0 Operating income 0 94 0 207 Interest expense, net 0 0 0 0 Other (income) expense, net 0 2 0 2 Income (loss) from discontinued operations before gain on disposition and income taxes 0 92 0 205 Gain on disposition 0 2,890 0 2,890 Income tax expense (benefit) 0 522 0 536 Income from discontinued operations, net of tax 0 2,460 0 2,559 Net income attributable to noncontrolling interests included in discontinued operations 0 0 0 0 Income (loss) from discontinued operations attributable to Baxter stockholders $ 0 $ 2,460 $ 0 $ 2,559 X - DefinitionDisposal Group, Including Discontinued Operation, Goodwill Impairment + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operations, Research And Development Expense + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpense Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion

attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bax_KidneyCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bax_BioPharmaSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.3 DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Current assets of discontinued operations $ 2,892 $ 2,179 Non-current assets of discontinued operations 2,534 2,949 Current liabilities of discontinued operations 1,089 1,040 Non-current liabilities of discontinued operations 575 551 Discontinued Operations Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Cash and cash equivalents 658 116 Accounts receivable, net of allowances 1,045 971 Inventories 960 906 Prepaid expenses and other current assets 229 186 Current assets of discontinued operations 2,892 2,179 Property, plant and equipment, net 1,542 1,562 Goodwill 276 721 Other intangible assets, net 147 161 Operating lease right-of-use assets 209 188 Other non-current assets 360 317 Non-current assets of discontinued operations 2,534 2,949 Assets of discontinued operations 5,426 5,128 Current maturities of finance lease obligations 0 1 Accounts payable 396 360 Accrued expenses and other current liabilities 693 679 Current liabilities of discontinued operations 1,089 1,040 Long-term finance lease obligations, less current portion 40 41 Operating lease liabilities 186 173 Other non-current liabilities 349 337 Non-current liabilities of discontinued operations 575 551 Liabilities of discontinued operations $ 1,664 $ 1,591 X - DefinitionDisposal Group, Including Discontinued Operation, Operating Lease Liability + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Other Intangible Assets, Net + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationOtherIntangibleAssetsNet Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operations, Financing Lease Liabilities + ReferencesNo definition available. + Details Name: bax_DisposalGroupIncludingDiscontinuedOperationsFinancingLeaseLiabilities Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -

Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as goodwill attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R44.htm IDEA:

XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Allowance for Doubtful Accounts Receivable [Roll Forward] Â Â Â Â Balance at beginning of period $ 67 $ 61 $ 62 $ 50 Charged to costs and expenses 4 2 4 17 Write-offs (3) 1 (6) (2) Currency translation adjustments (3) 2 5 1 Balance at end of period $ 65 $ 66 $ 65 $ 66 X - DefinitionAccounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments + ReferencesNo definition available. + Details Name: bax_AccountsReceivableAllowanceForCreditLossCurrencyTranslationAdjustments Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAccounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments + ReferencesNo definition available. + Details Name: bax_AccountsReceivableAllowanceForCreditLossWriteoffAndAdjustments Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 - SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Raw materials $ 532 $ 530 Work in process 256 234 Finished goods 1,315 1,154 Inventories $ 2,103 $ 1,918 X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Property, plant and equipment, at cost $ 7,605 $ 7,650 Accumulated depreciation (4,772) (4,779) Property, plant and equipment, net $ 2,833 $ 2,871 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Interest Income Expense Net Â Â Â Â Interest expense, net of capitalized interest $ 101 $ 136 $ 308 $ 394 Interest income (14) (9) (57) (27) Interest expense, net $ 87 $ 127 $ 251 $ 367 X - DefinitionInterest Income (Expense), Nonoperating, Net Of Capitalized Interest + ReferencesNo definition available. + Details Name: bax_InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeExpenseNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Other Income, net Â Â Â Â Foreign exchange losses, net $ 7 $ 10 $ 21 $ 49 Pension and other postretirement benefit plans (9) (15) (34) (37) Change in fair value of marketable equity securities 0 (3) (3) 3 Non-marketable investment impairments 0 0 0 13 Other, net 1 (4) (18) (13) Other (income) expense, net $ (1) $ (12) $ (34) $ 15 X - DefinitionNon-Marketable Investment Impairment + ReferencesNo definition available. + Details Name: bax_NonMarketableInvestmentImpairment Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost (reversal of cost) for pension and other postretirement benefits. + ReferencesNo definition available. + Details Name: us-gaap_PensionAndOtherPostretirementBenefitExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Right-of-use asset obtained in exchange for operating lease liability $ 54 $ 55 Property, Plant and Equipment Â Â Property, Plant and Equipment [Line Items] Â Â Capital expenditures incurred but not yet paid $ 34 $ 30 X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Goodwill [Roll Forward] Â Goodwill, beginning balance $ 5,793 Currency translation (10) Goodwill, ending balance 5,783 Medical Products and Therapies Â Goodwill [Roll Forward] Â Goodwill, beginning balance 1,241 Currency translation (7) Goodwill, ending balance 1,234 Healthcare Systems and Technologies Â Goodwill [Roll Forward] Â Goodwill, beginning balance 3,989 Currency translation 0 Goodwill, ending balance 3,989 Pharmaceuticals Â Goodwill [Roll Forward] Â Goodwill, beginning balance 563 Currency translation (3) Goodwill, ending balance $ 560 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Intangible asset amortization expense $ 159 $ 147 $ 471 $ 434 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Intangible Asset Excluding Goodwill [Line Items] Â Â Gross other intangible assets $ 8,459 $ 8,458 Accumulated amortization (3,010) (2,540) Other intangible assets, net 5,449 5,918 Trade names Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Indefinite-lived intangible assets 680 680 In process Research and Development Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Indefinite-lived intangible assets 157 157 Customer relationships Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Gross other intangible assets, finite-lived 3,390 3,390 Accumulated amortization (824) (654) Other intangible assets, net, finite-lived 2,566 2,736 Developed technology, including patents Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Gross other intangible assets, finite-lived 3,182 3,181 Accumulated amortization (2,027) (1,782) Other intangible assets, net, finite-lived 1,155 1,399 Trade names Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Gross other intangible assets, finite-lived 963 964 Accumulated amortization (92) (38) Other intangible assets, net, finite-lived 871 926 Other amortized intangible assets Â Â Intangible Asset Excluding Goodwill [Line Items] Â Â Gross other intangible assets, finite-lived 87 86 Accumulated amortization (67) (66) Other intangible assets, net, finite-lived $ 20 $ 20 X - DefinitionIntangible Asset Excluding Goodwill [Line Items] + ReferencesNo definition available. + Details Name: bax_IntangibleAssetExcludingGoodwillLineItems Namespace Prefix: bax_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bax_DevelopedTechnologyIncludingPatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCING ARRANGEMENTS (Details) â‚¬ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2025 Sep. 30, 2024 EUR (â‚¬) Jul. 17, 2024 USD ($) Mar. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Â Repayments of debt $ 827,000,000 $ 353,000,000 Â Â Â Â Â Senior Notes Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Senior notes, interest rate Â Â Â Â 1.322% Â Â Repayments of debt 822,000,000 Â Â Â Â Â Senior Notes | Forecast Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Rate increase following December 31, 2024 milestone Â Â 0.25% Â Â Â Â Bridge Facility Line Of Credit | Senior Unsecured Term Loans Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Borrowings outstanding 0 Â Â Â Â Â Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Borrowings outstanding 0 Â Â Â Â Â $ 0 Line of credit, current borrowing capacity $ 2,000,000,000 Â Â â‚¬ 200 Â $ 2,500,000,000 Â Bridge Facility | Senior Unsecured Term Loans Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Line of credit facility, maximum borrowing capacity Â Â Â Â $ 2,050,000,000.00 Â Â X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bax_SeniorUnsecuredTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=bax_BridgeFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details) $ in Millions 1 Months Ended 9 Months Ended Jul. 16, 2024 lawsuit Mar. 31, 2020 lawsuit Sep. 30, 2024 USD ($) site lawsuit Sep. 11, 2024 complaint Dec. 31, 2023 USD ($) Loss Contingencies [Line Items] Â Â Â Â Â Â Litigation reserve Â Â $ 41 Â $ 25 Number of complaints | complaint Â Â Â 1 Â Exposure to Ethylene Oxide Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Number of lawsuits | lawsuit 40 2 25 Â Â Superfund Sites | Environmental Clean-up Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Number of sites | site Â Â 6 Â Â Environmental reserves Â Â $ 30 Â $ 15 X - DefinitionLoss Contingency, Number Of Lawsuits + ReferencesNo definition available. + Details Name: bax_LossContingencyNumberOfLawsuits Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of Complaints + ReferencesNo definition available. + Details Name: bax_NumberOfComplaints Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionSite contingency, number of sites. + ReferencesNo definition available. + Details Name: bax_SiteContingencyNumberOfSites Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionTotal costs accrued as of the balance sheet date for environmental loss contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-10Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-10Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481899/410-30-55-16Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-7 + Details Name: us-gaap_AccrualForEnvironmentalLossContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_LitigationCaseAxis=bax_ExposureToEthyleneOxideMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EnvironmentalRemediationSiteAxis=bax_SuperfundSitesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EnvironmentalRemediationContingencyAxis=bax_EnviromentalCleanUpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement [Abstract] Â Â Â Â Cash dividends declared per common share (in dollars per share) $ 0.29 $ 0.29 $ 0.87 $ 0.87 Purchases of treasury stock (in shares) Â Â 0 0 Remaining value available under stock repurchase programs $ 1,300 Â $ 1,300 Â X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) $ 7,708 $ 5,631 $ 8,468 $ 5,895 Other comprehensive income (loss) 181 98 (97) 117 Balance, end of period (in usd) 7,942 8,166 7,942 8,166 CTA Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) Â Â (2,985) (3,386) Other comprehensive income (loss) before reclassifications Â Â (92) (62) Amounts reclassified from AOCI Â Â 0 185 Other comprehensive income (loss) Â Â (92) 123 Balance, end of period (in usd) (3,077) (3,263) (3,077) (3,263) Pension and OPEB plans Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) Â Â (452) (331) Other comprehensive income (loss) before reclassifications Â Â 0 0 Amounts reclassified from AOCI Â Â (3) (16) Other comprehensive income (loss) Â Â (3) (16) Balance, end of period (in usd) (455) (347) (455) (347) Hedging activities Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) Â Â (120) (119) Other comprehensive income (loss) before reclassifications Â Â 2 15 Amounts reclassified from AOCI Â Â 0 (5) Other comprehensive income (loss) Â Â 2 10 Balance, end of period (in usd) (118) (109) (118) (109) Available-for-sale debt securities Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) Â Â 3 3 Other comprehensive income (loss) before reclassifications Â Â 0 0 Amounts reclassified from AOCI Â Â 0 0 Other comprehensive income (loss) Â Â 0 0 Balance, end of period (in usd) 3 3 3 3 Total Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Balance, beginning of period (in usd) (3,828) (3,814) (3,554) (3,833) Other comprehensive income (loss) before reclassifications Â Â (90) (47) Amounts reclassified from AOCI Â Â (3) 164 Other comprehensive income (loss) 181 98 (93) 117 Balance, end of period (in usd) $ (3,647) $ (3,716) $ (3,647) $ (3,716) X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Other (income) expense, net $ 1 $ 12 $ 34 $ (15) Income tax expense (8) (27) (70) (59) Cost of sales (1,666) (1,543) (4,858) (4,584) Interest expense, net (87) (127) (251) (367) Income (loss) from

discontinued operations, net of tax 83 2,474 (290) 2,455 Income from continuing operations before income taxes 69 64 232 21 Net income (loss) attributable to Baxter stockholders 140 2,508 (137) 2,411 Amounts reclassified from AOCI Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Net income (loss) attributable to Baxter stockholders 3 (174) 3 (164) Amounts reclassified from AOCI | CTA Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Income (loss) from discontinued operations, net of tax Â (185) Â (185) Income (loss) from discontinued operations before gain on disposition and income taxes Â (185) Â (185) Income tax expense (benefit) Â 0 Â 0 Amounts reclassified from AOCI | Pension and OPEB items Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Other (income) expense, net 1 5 4 15 Income tax expense 0 0 (1) (3) Income (loss) from discontinued operations, net of tax Â 4 Â 4 Income (loss), before tax Â 9 Â 19 Net income (loss) attributable to Baxter stockholders 1 9 3 16 Amounts reclassified from AOCI | Gains (losses) on hedging activities Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Income tax expense (1) 0 0 (1) Income from continuing operations before income taxes 3 2 0 6 Net income (loss) attributable to Baxter stockholders 2 2 0 5 Amounts reclassified from AOCI | Gains (losses) on hedging activities | Foreign exchange contracts Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Cost of sales 4 3 9 10 Amounts reclassified from AOCI | Gains (losses) on hedging activities | Interest rate contracts Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Interest expense, net (1) $ (1) (4) $ (4) Amounts reclassified from AOCI | Gains (losses) on hedging activities | Fair value hedges Â Â Â Â Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Other (income) expense, net $ 0 Â $ (5) Â X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUES - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue From Contract With Customer [Line Items] Â Â Â Â Â Transaction price allocated to remaining performance obligations $ 2,750 Â $ 2,750 Â Â Revenue related to performance obligations 0 $ 0 0 $ 0 Â Net trade accounts receivable 1,540 Â 1,540 Â $ 1,540 Revenue recognized upon satisfaction of performance obligations Â Â 94 $ 111 Â Sales-type lease, net of investment in lease 36 Â 36 Â Â 2020 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Sales-type leases, receivables 5 Â 5 Â Â 2021 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Sales-type leases, receivables 10 Â 10 Â Â 2022 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Sales-type leases, receivables 5 Â 5 Â Â 2023 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Sales-type leases, receivables 7 Â 7 Â Â 2024 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Sales-type leases, receivables $ 9 Â $ 9 Â Â Minimum Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Global payment terms Â Â 30 days Â Â Minimum | Software sales Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Revenue recognized contract period Â Â 1 year Â Â Minimum | Consumable Medical Products Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Revenue recognized contract period Â Â 1 year Â Â Maximum Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Global payment terms Â Â 90 days Â Â Maximum | Contract manufacturing services Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Revenue recognized contract period Â Â 90 days Â Â Maximum | Software sales Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Revenue recognized contract period Â Â 5 years Â Â Maximum | Consumable Medical Products Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Revenue recognized contract period Â Â 7 years Â Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-10-01 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Remaining revenue performance obligation, percentage of revenue expected to be recognized 25.00% Â 25.00% Â Â Remaining performance obligations period 3 months Â 3 months Â Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Remaining revenue performance obligation, percentage of revenue expected to be recognized 25.00% Â 25.00% Â Â Remaining performance obligations period 1 year Â 1 year Â Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Remaining revenue performance obligation, percentage of revenue expected to be recognized 20.00% Â 20.00% Â Â Remaining performance obligations period 1 year Â 1 year Â Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Remaining revenue performance obligation, percentage of revenue expected to be recognized 20.00% Â 20.00% Â Â Remaining performance obligations period 1 year Â 1 year Â Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01 Â Â Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Â Â Remaining revenue performance obligation, percentage of revenue expected to be recognized 10.00% Â 10.00% Â Â Remaining performance obligations period 1 year Â 1 year Â Â X - DefinitionRevenue, Performance Obligation, Payment Terms + ReferencesNo definition available. + Details Name: bax_RevenuePerformanceObligationPaymentTerms Namespace Prefix: bax_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRevenue recognized contract period. + ReferencesNo definition available. + Details Name: bax_RevenueRecognizedContractPeriod Namespace Prefix: bax_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details Name: us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPercentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lease payments not yet received by lessor and amount expected to be

derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10 + Details Name: us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allowance for credit loss, of net investment in sales-type lease. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6 + Details Name: us-gaap_SalesTypeLeaseNetInvestmentInLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: bax_YearOfOriginationAxis=bax_A2020AndPriorYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: bax_YearOfOriginationAxis=bax_A2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: bax_YearOfOriginationAxis=bax_A2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: bax_YearOfOriginationAxis=bax_A2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: bax_YearOfOriginationAxis=bax_A2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_SoftwareArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_ConsumableMedicalProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_ManufacturingArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-10-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUES - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue From Contract With Customer [Line Items] Â Â Â Contract assets $ 145 Â $ 165 Contract liabilities 160 $ 169 169 Revenue From Contract With Customer [Roll Forward] Â Â Â Balance at beginning of period 169 173 Â New revenue deferrals 383 401 Â Revenue recognized upon satisfaction of performance obligations (389) (407) Â Currency translation (3) 2 Â Balance at end of period 160 $ 169 Â Prepaid expenses and other current assets Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract assets 54 Â 53 Other non-current assets Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract assets 91 Â 112 Accrued expenses and other current liabilities Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract liabilities 124 Â 128 Revenue From Contract With Customer [Roll Forward] Â Â Â Balance at beginning of period 128 Â Â Balance at end of period 124 Â Â Other non-current liabilities Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract liabilities 36 Â 41 Revenue From Contract With Customer [Roll Forward] Â Â Â Balance at beginning of period 41 Â Â Balance at end of period 36 Â Â Contract manufacturing services Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract assets 4 Â 4 Software sales Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract assets 46 Â 45 Bundled equipment and consumable medical products contracts Â Â Â Revenue From Contract With Customer [Line Items] Â Â Â Contract assets $ 95 Â $ 116 X - DefinitionContract With Customer, Liability, Currency Translation + ReferencesNo definition available. + Details Name: bax_ContractWithCustomerLiabilityCurrencyTranslation Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContract With Customer, Liability, Deferred Revenue + ReferencesNo definition available. + Details Name: bax_ContractWithCustomerLiabilityDeferredRevenue Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContract with Customer, Liability, Total Revenue Recognized + ReferencesNo definition available. + Details Name: bax_ContractWithCustomerLiabilityTotalRevenueRecognized Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue From Contract With Customer + ReferencesNo definition available. + Details Name: bax_RevenueFromContractWithCustomerRollForward Namespace Prefix: bax_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=bax_AccruedExpensesAndOtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_ManufacturingArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_SoftwareArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalizedContractCostAxis=bax_BundledEquipmentAndConsumableMedicalProductsContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUES - Lease Revenue (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from Contract with Customer [Abstract] Â Â Â Â Sales-type lease revenue $ 3 $ 2 $ 8 $ 6 Operating lease revenue 102 98 288 302 Variable lease revenue 10 3 22 15 Total lease revenue $ 115 $ 103 $ 318 $ 323 X - DefinitionAmount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_LeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479016/842-30-45-3 + Details Name: us-gaap_OperatingLeaseLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of sales-type lease revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_SalesTypeLeaseRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease payments from operating, direct financing, and sales-type leases, excluding amount included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_VariableLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Expected additional pre-tax costs $ 5 Â $ 5 Â Charges 15 $ 41 36 $ 140 Employee termination costs Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Charges 12 39 29 124 Employee termination costs | Restructuring Within HST Segment Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Charges 7 Â 14 Â Employee termination costs | New Operating Model Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Charges Â 11 7 79 Contract termination and other costs Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Charges $ 3 $ 2 $ 7 5 Asset impairments Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Charges Â Â Â $ 11 X - DefinitionAmount expected to be recognized in earnings for the specified restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostExpectedCost1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7:

http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=bax_RestructuringWithinHSTSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=bax_NewOperatingModelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=bax_ContractTerminationAndOtherCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=bax_AssetImpairmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges $ 15 $ 41 $ 36 $ 140 Business Optimization Programs Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 15 41 36 140 Costs to implement business optimization programs 3 7 13 27 Total business optimization charges $ 18 $ 48 $ 49 $ 167 X - DefinitionDiscloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=bax_BusinessOptimizationProgramsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R63.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges $ 15 $ 41 $ 36 $ 140 COGS Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 2 6 5 28 SG&A Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 13 31 31 102 R&D Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â 4 Â 10 Employee termination costs Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 12 39 29 124 Employee termination costs | COGS Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 2 6 4 25 Employee termination costs | SG&A Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 10 29 25 89 Employee termination costs | R&D Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â 4 Â 10 Contract termination and other costs Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 3 2 7 5 Contract termination and other costs | COGS Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 0 0 1 0 Contract termination and other costs | SG&A Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges $ 3 2 $ 6 5 Contract termination and other costs | R&D Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â $ 0 Â 0 Asset impairments Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â Â Â 11 Asset impairments | COGS Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â Â Â 3 Asset impairments | SG&A Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â Â Â 8 Asset impairments | R&D Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges Â Â Â $ 0 X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=bax_ContractTerminationAndOtherCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=bax_AssetImpairmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R64.htm IDEA: XBRL DOCUMENT v3.24.3 BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Reserve [Roll Forward] Â Â Â Â Charges $ 15 $ 41 $ 36 $ 140 Severance, Contract Termination, And Other Employee Related Costs Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Reserve, beginning balance Â Â 95 Â Charges Â Â 42 Â Payments Â Â (59) Â Reserve adjustments Â Â (8) Â Currency translation Â Â 4 Â Reserve, ending balance $ 74 Â $ 74 Â X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveTranslationAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=bax_SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R65.htm IDEA: XBRL DOCUMENT v3.24.3 PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pension benefits Â Â Â Â Net periodic benefit cost Â Â Â Â Service cost $ 4 $ 6 $ 13 $ 18 Interest cost 33 45 123 137 Expected return on plan assets (43) (57) (160) (166) Amortization of net losses and prior service costs 4 1 11 4 Net periodic pension cost (income) (2) (5) (13) (7) OPEB Â Â Â Â Net periodic benefit cost Â Â Â Â Interest cost 2 2 6 6 Amortization of net losses and prior service costs (5) (6) (14) (18) Net periodic pension cost (income) $ (3) $ (4) $ (8) $ (12) X - DefinitionAmount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cost recognized for passage of time related to defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanInterestCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of net periodic benefit cost (credit) for defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanServiceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R66.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Effective income tax rate 11.60% 42.20% 30.20% 281.00% U.S. Federal statutory rate Â Â 21.00% Â Increase in valuation allowance $ 26 Â $ 26 $ 30 X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 80 R67.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Reconciliation of Basic Shares to Diluted Shares Â Â Â Â Basic (in shares) 510 507 509 506 Effect of dilutive securities (in shares) 2 2 2 0 Diluted (in shares) 512 509 511 506 Income (loss) from continuing operations $ 61 $ 37 $ 162 $ (38) Net income attributable to noncontrolling interests included in continuing operations 0 0 0 0 Income (loss) from continuing operations 61 37 162 (38) Income (loss) from discontinued operations, net of tax 83 2,474 (290) 2,455 Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6 Income (loss) from discontinued operations attributable to Baxter stockholders 79 2,471 (299) 2,449 Net income (loss) attributable to Baxter stockholders $ 140 $ 2,508 $ (137) $ 2,411 X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 81 R68.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS PER SHARE - Additional Information (Details) - shares shares in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Anti-dilutive securities excluded from computation of EPS (in shares) 18 18 19 25 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data

Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 82 R69.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details) â,¬ in Millions 9 Months Ended Sep. 30, 2024 USD ($) terminate de-designation Sep. 30, 2023 terminate de-designation Dec. 31, 2023 USD ($) Oct. 31, 2023 USD ($) Oct. 31, 2023 EUR (â,¬) May 31, 2019 EUR (â,¬) May 31, 2017 EUR (â,¬) Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Â Derivative, fair value, terminated | terminate 0 0 Â Â Â Â Â Derivative, net investment terminated | terminate 0 0 Â Â Â Â Â Deferred, net after-tax gains on derivative instruments $ 8,000,000 Â Â Â Â Â Â Undesignated derivative instruments Â Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Derivative, notional amount $ 527,000,000 Â $ 305,000,000 Â Â Â Â Derivative instruments designated as hedges Â Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Â number of de-designations | de-designation 0 0 Â Â Â Â Â Net investment hedge Â Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Accumulated pre-tax unrealized translation gain in AOCI $ 18,000,000 Â Â Â Â Â 1.30% Senior Notes Due May 2025 Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Senior notes | â,¬ Â Â Â Â Â â,¬ 600 Senior notes, interest rate Â Â Â Â Â 1.30% 0.4% Senior Notes Due May 2024 Â Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Senior notes | â,¬ Â Â Â â,¬ 750 â,¬ 750 Â Senior notes, interest rate Â Â Â 0.40% 0.40% 0.40% Â 1.3% Senior Notes Due May 2029 Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Â Senior notes | â,¬ Â Â Â Â Â â,¬ 750 Â Senior notes, interest rate Â Â Â Â Â 1.30% Interest rate contracts | Cash Flow Hedging Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Derivative, fair value, net 0 Â 0 Â Â Â Foreign exchange contracts Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Derivative, notional amount $ 225,000,000 Â 340,000,000 Â Â Â Maximum length of time hedge in cash flow hedge 12 months Â Â Â Â Â Fair value hedges Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Derivative, notional amount Â Â Â $ 798,000,000 Â Â Â Interest rate swap | Fair value hedges Â Â Â Â Â Derivative Instruments and Hedging Activities Disclosures [Line Items] Â Â Â Â Â Derivative, fair value, net $ 0 Â $ 0 Â Â Â Â X - DefinitionDerivative, Number Of De-designations + ReferencesNo definition available. + Details Name: bax_DerivativeNumberOfDeDesignations Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionDerivative, Number Of Fair Value Hedges Terminated + ReferencesNo definition available. + Details Name: bax_DerivativeNumberOfFairValueHedgesTerminated Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionDerivative, Number Of Net Investment Terminated + ReferencesNo definition available. + Details Name: bax_DerivativeNumberOfNetInvestmentTerminated Namespace Prefix: bax_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1 + Details Name: us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionMaximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 30 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1 + Details Name: us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bax_A130SeniorNotesDueMay2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bax_A04SeniorNotesDueMay2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bax_A13SeniorNotesDueMay2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R70.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax $ (77) $ 57 $ (17) $ 29 Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax 3 2 0 6 Total 6 (1) (24) (9) Fair value hedges Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Foreign exchange contracts Â Â (3) 0 Fair value hedges | Other (income) expense, net Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax Â Â (5) 0 Earnings, fair value hedge, gain (loss), reclassification, before tax Â Â (24) 0 Net Investment Hedging Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax (68) 48 (19) 10 Net Investment Hedging | Other (income) expense, net Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Net investment hedges 0 0 0 0 Interest rate contracts | Cash Flow Hedging Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax 0 0 0 0 Interest rate contracts | Cash Flow Hedging | Interest expense, net Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax (1) (1) (4) (4) Foreign exchange contracts | Other (income) expense, net Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Gain (loss) recognized in income, undesignated derivative instruments 6 (1) 0 (9) Foreign exchange contracts | Cash Flow Hedging Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax (9) 9 5 19 Foreign exchange contracts | Cash Flow Hedging | Cost of sales Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax $ 4 $ 3 $ 9 $ 10 X - DefinitionEarnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax + ReferencesNo definition available. + Details Name: bax_EarningsFairValueHedgeGainLossReclassificationBeforeTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax + ReferencesNo definition available. + Details Name: bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax + ReferencesNo definition available. + Details Name: bax_OtherComprehensiveIncomeLossFairValueHedgeGainLossBeforeReclassificationTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax + ReferencesNo definition available. + Details Name: bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4CC -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC + Details Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (dd) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC + Details Name: us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC + Details Name: us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R71.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Derivatives, Fair Value [Line Items] Â Â Derivative asset, fair value $ 2 $ 45 Derivative liability, fair value 7 5 Derivative instruments designated as hedges | Foreign exchange contracts | Prepaid expenses and other current assets Â Â Derivatives, Fair Value [Line Items] Â Â Derivative asset, fair value 0 4 Derivative instruments designated as hedges | Foreign exchange contracts | Accrued expenses and other current liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Derivative liability, fair value 5 5 Undesignated derivative instruments | Foreign exchange contracts | Prepaid expenses and other current assets Â Â Derivatives, Fair Value [Line Items] Â Â Derivative asset, fair value 2 41 Undesignated derivative instruments | Foreign exchange contracts | Accrued expenses and other current liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Derivative liability, fair value $ 2 $ 0 X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R72.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Asset Â Â Gross amounts recognized in the condensed consolidated balance sheets $ 2 $ 45 Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet (1) (4) Derivative asset, fair value, total 1 41 Liability Â Â Gross amounts recognized in the condensed consolidated balance sheets 7 5 Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet (1) (4) Derivative liability, fair value, total $ 6 $ 1 X - DefinitionFair value, after effect of master netting arrangement, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22 + Details Name: us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 9 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 9 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value, after effect of master netting arrangement, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22 + Details Name: us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 86 R73.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) - Long-term debt - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Derivatives, Fair Value [Line Items] Â Â Carrying amount of hedged item $ 100 $ 100 Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item $ 3 $ 3 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability hedged in fair value hedging relationship. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityFairValueHedge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Assets Â Â Foreign exchange contracts $ 2 $ 45 Available-for-sale debt securities 1 1 Marketable equity securities 13 44 Total assets 16 90 Liabilities Â Â Foreign exchange contracts 7 5 Contingent payments related to acquisitions 12 14 Total

liabilities 19 19 Quoted prices in active markets for identical assets (Level 1) Â Â Assets Â Â Foreign exchange contracts 0 0 Available-for-sale debt securities 0 0 Marketable equity securities 13 44 Total assets 13 44 Liabilities Â Â Foreign exchange contracts 0 0 Contingent payments related to acquisitions 0 0 Total liabilities 0 0 Significant other observable inputs (Level 2) Â Â Assets Â Â Foreign exchange contracts 2 45 Available-for-sale debt securities 0 0 Marketable equity securities 0 0 Total assets 2 45 Liabilities Â Â Foreign exchange contracts 7 5 Contingent payments related to acquisitions 0 0 Total liabilities 7 5 Significant unobservable inputs (Level 3) Â Â Assets Â Â Foreign exchange contracts 0 0 Available-for-sale debt securities 1 1 Marketable equity securities 0 0 Total assets 1 1 Liabilities Â Â Foreign exchange contracts 0 0 Contingent payments related to acquisitions 12 14 Total liabilities $ 12 $ 14 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R75.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Fair Value Disclosures [Line Items] Â Â Â Cash and cash equivalents $ 1,420 $ 5,716 $ 3,078 Impairment of investments without readily determinable value Â 8 Â Debt Securities Â Â Â Fair Value Disclosures [Line Items] Â Â Â Impairment of convertible debt investment Â 5 Â Available-for-sale debt securities Â Â Â Fair Value Disclosures [Line Items] Â Â Â Impairment of convertible debt investment 0 $ 5 Â Other Assets Â Â Â Fair Value Disclosures [Line Items] Â Â Â Other equity investments without readily determinable fair values 33 Â Significant other observable inputs (Level 2) Â Â Â Fair Value Disclosures [Line Items] Â Â Â Money market funds, at carrying value $ 427 Â $ 1,630 X - DefinitionFair value disclosure Line items. + ReferencesNo definition available. + Details Name: bax_FairValueDisclosuresLineItems Namespace Prefix: bax_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 102 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesNo definition available. + Details Name: us-gaap_MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=bax_AvailableForSaleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R76.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Contingent payments related to acquisitions Â Â Â

Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AcquisitionRelatedCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=bax_AvailableForSaleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R77.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Book values Â Â Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Â Â Current maturities of long-term debt and finance lease obligations $ 2,498 $ 2,667 Long-term debt and finance lease obligations 10,437 11,089 Fair values Â Â Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Â Â Current maturities of long-term debt and finance lease obligations 2,493 2,621 Long-term debt and finance lease obligations $ 9,612 $ 10,026 X - DefinitionFair value and carrying value by balance sheet grouping. + ReferencesNo definition available. + Details Name: bax_FairValueAndCarryingValueByBalanceSheetGroupingLineItems Namespace Prefix: bax_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLong-term debt and finance lease obligations, current, fair value disclosure. + ReferencesNo definition available. + Details Name: bax_LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLong-term debt and finance lease obligations noncurrent. + ReferencesNo definition available. + Details Name: bax_LongTermDebtAndFinanceLeaseObligationsNoncurrent Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R78.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION - Narrative (Details) 9 Months Ended Sep. 30, 2024 segment Segment Reporting [Abstract] Â Number of operating segments 4 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 92 R79.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting Information [Line Items] Â Â Â Â Net sales $ 2,699 $ 2,599 $ 7,883 $ 7,634 United States Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 1,500 1,467 4,340 4,300 International Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 1,199 1,132 3,543 3,334 Operating Segments | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 1,342 1,258 3,893 3,691 Operating Segments | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 752 744 2,167 2,218 Operating Segments | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 588 580 1,768 1,652 Operating Segments | United States | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 762 709 2,164 2,087 Operating Segments | United States | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 557 551 1,580 1,607 Operating Segments | United States | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 178 195 566 550 Operating Segments | International | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 580 549 1,729 1,604 Operating Segments | International | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 195 193 587 611 Operating Segments | International | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 410 385 1,202 1,102 Operating Segments | Infusion Therapies and Technologies | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 1,070 1,003 3,081 2,918 Operating Segments | Infusion Therapies and Technologies | United States | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 613 570 1,718 1,654 Operating Segments | Infusion Therapies and Technologies | International | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 457 433 1,363 1,264 Operating Segments | Advanced Surgery | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 272 255 812 773 Operating Segments | Advanced Surgery | United States | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 149 139 446 433 Operating Segments | Advanced Surgery | International | Medical Products and Therapies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 123 116 366 340 Operating Segments | Care and Connectivity Solutions | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 456 443 1,310 1,307 Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 335 317 945 926 Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 121 126 365 381 Operating Segments | Front Line Care | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 296 301 857 911 Operating Segments | Front Line Care | United States | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 222 234 635 681 Operating Segments | Front Line Care | International | Healthcare Systems and Technologies Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 74 67 222 230 Operating Segments | Injectables and Anesthesia | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 321 351 990 987 Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 178 195 566 550 Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 143 156 424 437 Operating Segments | Drug Compounding | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 267 229 778 665 Operating Segments | Drug Compounding | United States | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 0 0 0 0 Operating Segments | Drug Compounding | International | Pharmaceuticals Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 267 229 778 665 Other Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 17 17 55 73 Other | United States Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 3 12 30 56 Other | International Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales $ 14 $ 5 $ 25 $ 17 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_InfusionTherapiesAndTechnologiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_CareAndConnectivitySolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_FrontLineCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_InjectablesAndAnesthesiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bax_PharmaceuticalCompoundingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Net sales $ 2,699 $ 2,599 $ 7,883 $ 7,634 United States Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Net sales 1,500 1,467 4,340 4,300 Emerging Markets Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Net sales 347 353 1,001 985 Rest of world Â Â Â Â Segment Reporting, Reconciling Item for

Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Net sales $ 852 $ 779 $ 2,542 $ 2,349 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=bax_EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=bax_WesternEuropeCanadaJapanAustraliaAndNewZealandMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R81.htm IDEA: XBRL DOCUMENT v3.24.3 SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total $ 155 $ 179 $ 449 $ 403 Intangible asset amortization expense 159 147 471 434 Operating income 155 179 449 403 Interest expense, net 87 127 251 367 Other (income) expense, net (1) (12) (34) 15 Income from continuing operations before income taxes 69 64 232 21 Operating Segments Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total 464 474 1,282 1,336 Operating income 464 474 1,282 1,336 Operating Segments | Medical Products and Therapies Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total 268 245 733 706 Operating income 268 245 733 706 Operating Segments | Healthcare Systems and Technologies Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total 136 115 323 327 Operating income 136 115 323 327 Operating Segments | Pharmaceuticals Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total 58 108 211 284 Operating income 58 108 211 284 Operating Segments | Other Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Total 2 6 15 19 Operating income 2 6 15 19 Segment Reconciling Items Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Unallocated corporate costs (73) (73) (227) (285) Intangible asset amortization expense (159) (147) (471) (434) Legal matters (17) (13) (17) (13) Business optimization items (18) (48) (49) (167) Acquisition and integration items (5) (2) (16) (2) European Medical Devices Regulation (9) (12) (25) (32) Hurricane Helene costs (25) 0 (25) 0 Product-related items $ (3) $ 0 $ (3) $ 0 X - DefinitionBusiness Optimization Income (Loss) + ReferencesNo definition available. + Details Name: bax_BusinessOptimizationIncomeLoss Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCorporate Costs, Unallocated + ReferencesNo definition available. + Details Name: bax_CorporateCostsUnallocated Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEuropean Medical Devices Regulation Expenses + ReferencesNo definition available. + Details Name: bax_EuropeanMedicalDevicesRegulationExpenses Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProduct Related Income (Loss) + ReferencesNo definition available. + Details Name: bax_ProductRelatedIncomeLoss Namespace Prefix: bax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LitigationSettlementExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe charge against earnings in the period for the uninsured portion of a loss from a fire, explosion, or natural disaster (hurricane, earthquake). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LossFromCatastrophes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 95 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (,2$;%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #$A&Q9 .89&ULS9)1 M2\,P$,>_BN2]O29U"J'+BV-/"H(#Q;>0W+9@TX;DI-VW-ZU;A^@'\#%W__SN M=W"-"=+T$9]C'S"2PW0S^K9+TH0U.Q(%"9#,$;U.94YTN;GOH]>4G_$ 09L/ M?4 0574''DE;31HF8!$6(E.-=)$U-3',]Z:!1\^8SO#K %LT6-'"7C)@:EI M8CB-;0-7P 0CC#Y]%] NQ+GZ)W;N #LGQ^26U#,Y5#/N;P#A[>GQY=YW<)U MB71G,/]*3M(IX)I=)K_6#4YO=EBE1B=N"\X*+G>"ROI>KU?OD^L/O*NQ[Z_;N M'QM?!%4#O^Y"?0%02P,$% @ Q(1L69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=]$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/]<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!]':-*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#

UI641ZT3=Y,*4FXW,MR]5G#X\/ //JH:/>K4NJ.'JQ;-,KM2M*G[,;G+< M7=6S+/1&)4:GB9I^BO=O%T\/^N30"I6 M44$S2/S=JU:HPK7GSW]O;5 M]8>
[MQ]^?/V=N+YY_7%V] ;ZP^VSJP*34Y>KR$WTTDX4')EH*MZG2;$VXG6R M4(ON^"L(54L65)*]#$Y.>*NR2Q'V/1'T@\&)^<):TY#G"X]IJDT$"752JH6X
MSE0N"19&R&0A\"Q+C8S%FSPM,R/^/9N;(@=B_G/($':=P>%U*(J>FDQ&ZOD9 MPL2H_%Z=0?CZ*W_4__:$%H-:B\&IV?^(OTY.=%C,([.+F8C2398F*BE$NH3) M!*YTL17:(#*S-
"]@4YV(1=O&:8"<>XN5?GZ+F1OZ!)+9=@!(%I:%]KQS>F(RT0L=2)3"(-2& E1+BY%'I&HK7@EQMXT&0)?KLGJ-'Q' M0J-69&]/T)H:EA+1.D\3LB 6EU%9$'ADO#68B9:6F59.,J!>1PI+Z22*RP7) M
UOJ DB'+ZM1'@"Z29L[9_FT)!\G#)$L1B21&,T*'B]AE472A)U-F5&H-%TN MQ4V9FU(F;%6"(UQA7?OI<[9FK]"C0UZA#FB(MP@;0A 6D:L5/ $,B:S,(\0!
M+G(H2:9[$EY.^F*.F("]+\6,HW*E[TEO%Q:8,%)Y@6PNY.(7.)>QS#)%90YU MBWC;DHZ1<*^LQS]I9$F%YUAG6*]#"R>H+@#WBT)^$I$T:_)5I-0"0;HWTA_6 M([$ &H*FP?
((9CFWX8A@28Q#%N%D1T(AO0!TA2Q4TQ6H2@01 -D-KH; B/0 M_IDD*%3"$I60AUQ*9F&5V#"U399YNL%S@FM+/QD8D\:/RX6%FH.<>>Q7DE' M&$1-VA2$Q@==K+D7\Q)8"
[@K@%@9QZGC5Z C!>09CC\SPU$HD.DH&H_Q N:CL@)O)I$^&Q_Y\64^(TB01,A$J)@*C3$U3U9.P27!$.-:R":0+[! C;,V9/&J,*%_4+!*"C7*C,6:\)@ PB.UDF1/ =@8TY-L5"F[2D1$GYV>IH*<>&
[1])GY?B1U0G=>"E MRX/0.,:BGG@I/Q&QD)E^(@Q"'JX<.%/:/&D4@P\FBOE2+%!E!3O95(21LN< M[S'3+>@>%#.K!HA>> `WMS/ 2HNK3587!!;,8&BU6Y>4FH'4#0F_0 50,B8Z
M3^Z((VQ=M#^TN^:=79/28B+>0K>8+(P@@_U_(LD5+VOWS;V[:@I35[>5\1(K ML>Y5>K>IL4)=F9%"?E]L$=..&0]>XJ(#3ZTBCH)[;?=+>SE!D. U8XUSIY/RT MG>X.V*DV"
<<@VV7>LA@6!MX3MVME@=1@[I0^!.S>9VU_?LSX'E7!@)EIEQO M:'O+]8W3OZB115'<-J:U8=@7&[OG^[-&I-F0*S*(;,IVEG&13UL-,A W :WJ MC?Z=MP1YF5DV<+:O5/ZFPQ0MZ2Z;
(+$}JY:E!(WE/ FES?KZI"46Y M6L.R&/YA&P&F+1MR[VDW"H6H*734V<]@4 N"G/S*M=$(MIPKX8+;WA,9DP _M(,]Y8I;_2K6'H<2KD86WK7H\25'.P);RX1*]N'#^U17FITQNDSHT4M[42U\1> M&?
+$'&(&4]ZMA%QV0M$%9^=#PWHO;V[/.^7P;'%/L4_LEB?2@9?T_EGF\S)? MB1NX%I5[+TJ9_>"D>&OS*>;"5%N5&U=>VH;N=N2!RAKX%S53A%IAV^1-@CV! M J+281GTF.$'O'H5S)1\PM-
QQVW8SPZ{JQRl,.YY2/5?L]5 M"&3LCTC!&S2=3A;HD6\OV7)[EK*0Y+#/TW*U;IF*]{,_MA?I J5,'7PZ[.YT MUVHP\[=*\Z02!D/A, 8[$"KQ%K.&,G"52LV];GIKE'?Q>EJ*]YLYC_0^#?(
MP>#"HZ./(6:?,H_5T6TX?6'] %[RGB7\BXIC*[MFCG&U5;B^:HCD,<4P34)%<%/B M[$?2?M)T*^_55 <#L:YX,/BS18_)5$38;E4]AVJ>8'"PYGED_7*H=&E5) =J M$:=P32P6/8HBT[Z1X:,!%:T39C-
/K$MB,4 P>F.M@]ULKS;+F2\ Y7,HVL7 MY[L3)%C;OI7-O&Z*KEQ*NW#LJKV[UB_$M3Y?2?Q5-N"EJ.&?UE]_[%ACE/O M$&:_>?+=RYWD!U.C*(28XF @KNA53JLNJ][&<$=* M0T\[I=^A
NTNI>.F.YZ^_8)H9]8 WZ$'*VSL,2$LP%*2A >O/L "E%&-~>"\ MSQ\.[7] BO^OOYH$?O MM4S]SO.PWP?'F<{5X1e@]#GVT]P>3>M3$=XU^,*67 M293H9;Z",_,L/O+KCCXVH-3DCWTH
K$\'E8JL6<,^_L(.M!," /!>'"*8;.B M/[1 XY" "LB#YW:KR'KPP!+=AV SE'X&XMF?4%B*4ZAE,%B@] [SNO_O??G:] M,[]"HM\?B5X0]IN>TX%M],/1N2W3P1R5X0]IN>'!O,6JS@O;L"N?=,,W).6*^
MZAWP_1CS/S8ND&<1#$JLF Z3SOLFWC,9F1 UL*/OAZ35J*558!O]P>!UNO5>DH>G-@8ZF+<]IU}X)ARZ##(*#&8!Q4 Q\,_V(2"G_0 M6GPPZE,,;+L8#\0X)["G'2E77%?
8(BHB**#9!B4O;F)3A:Q,J^;)-3,>L/1#A MGBFH[<1RCOJQH8A^Q69A8?P_DLL^$$&>(*(_M^_SQU!5ZX7C(_P&"JJW<8#3M/!^/PAWJ"L!00X+;H FUP!<^Y]M#K#\==_O(} M@$X,AHW;
ES;UC'B^0^1V 3P&DV;E0<#;AJ'PT>0F# H@T%:L'4M(_$F31=\ ME*)1A.NOPB^]$$T;M]\[7+6>]B>^BT@*@@M4WU(AACGR ! M5PV\O\^:PQGB.95)JV7]B%*52(/U%Y#P=P32P6/8HBT[Z1X:,!%:T39C-
MLGXT[JH[:93]JU2H]\)51^SENJ9LE'R$E_^XCGY_TE42Y>S_1,L#>[%F*V;L M29W, M-%S1G!RX[S\J!P38@_F3D7C5;<9BQ]B0,D] -1"JPNJ5J$?O5&@TG6I",7>4 MP?L4;S@(Z'<4-+5',!Z)
<5!M5L# ,,EEi@E/U?0"/(R%C^U@4S'$BC[5X8.(MBW1Y09^(5&KT28V)FQ#YY6)'SQ"6"?VQ^+# Z*2N0^S] F*3I]]MO<3,?0& MP8C__6!2VW0CZ3"G.NEPIU-.F=9'*=V-=0.$3&XYU,+IB-7
@YQ6/N'<=DB- MIJ$8P5>0#CP[H0P -IDRS/KB7?+"-;CP'II, 761H--@XB$,'NQ[L"T"@<_ MQGS?<^U>(1P0AEWW/5*1(>K[X=#?/+ Z[D3?&XT& #]$^7WH>]2kUK?$&Y&6O
M^(M!.LB$O^QGQ75K-5'VS'Z+W'2W7W2_YVV#@6&6&-J_'_/+,"KFR+-^,OD M>5H4Z88OUTJB=]$.>+Y,TZ*ZH07J3]5?_!=02P,$% @ Q(1L66_A%X; M!0 ,PP !D !X,"]W;W)K&ULO5=,;QHY%/XK
M1S2J0*)A+MS2))DB$)EJDAJ"DW3ZL]L',',#;&7MJ>T+27[_GV$!(E:,;=?>@# MOHW]^3M7'TXWVGRQ:T0']V6A[%EC[5SUMM.QV1!+88]UA8J^_++4IA:.I675L M95#D_E!9=)(HZG=*
(55C=.K7YF9TJFM72(5S [8N2V$>SK'0F[-&W-@MW,C5 MVO%"9W1:B17>HOM4S0W-.GN47):HK-0*#"[/&N/X[7F7]_L-?TKXG,[&L\F41M/9Y27-U2CC]!VVG%T#^_N9%O,Y9__#$!*ZT
MVLKD>%9H^:*[S!TV1]]?Q?WHW0OB=??B=5]"_Y\V?1'S><&_MOPC&!84]*O^!$@B\U_7"+>L"QEFF:];BQS5_X4U2K<")18$@+8A=EF#U.]J3 MK85:H05)!JD-B">P^0Y6[&!YE8^YM4'T-
E4D$)3!+Y']$LBKR)8+-'O7\AMI MD!X3+SYXZ,??[9\QW@O?F\2TE$5!+F1, 9V1#T;GHO 2" <+7$FE6 ,D;H5& MZAR.H# @)N8FH.87P60MS(JNGS^#^69X-2\/8$>'3E@1^IZRJO'3?]@ M-
%5W=%P;22R>"OY4*>\QVT[B-MR(#64R1ZBP!=H;60 MJ[0I%V.0TFI+H>5UKF%)N\&1+4=][I/&!O!THZCE/JX?1(/*9S1#3/NH0US_MDLEY15U%67%,I,EZ>G[9=*/6-
4>"Q^Q2%ML&+IZT.Y'O=*"3X[[<& +./[D];A\4Z+]XP34,_B$ETTB'2I1?!$8)$O\&!JQ?C M[F*F1YZ2B4HZ4X,-.HE[U*2LI)1T,PFW M@*^ED ,N1%$CVX"2YQ<,^93]QSV Q:RFQ, 1\OK5,
(F3=S[<^92"3*LW!TMB=^[Z/TZ#V("7E&V87#[DA]*U%Y-8BWQFQ&;=\F_B.Y2(_ M]3RAB;!KN#9XH%BAW,A*FGIB/!MS/1?$\.4DY;LWM279]_L+I'(.!*F?J.N% MHQ+5.^2C,?B9"+OTHI
K'Y*/C\=_>C)@0RX*1Y2*MO[AOQSU>KMYFVI86Z&O M0HN'8WCNH>\<%'(E4JKGC MXT&O 2.4J&'B=.7+PH5V5&3ZX9]J>C2\@;XOM7:[^5^P_Y\P^A=02P,$% M @ Q(1L6<#]LK4)! ;0D !D
!X,"]W;W)K&ULI5;,,;N,V$/V5@7:Q2 UUCW2KFW 3M+$0&Z(W>Y#T0=:HBUB*5(EJ7C3 MK^]0DAUOZAA;]$6\.:,,',[A9;B1ZILN*37PO>)"CYS2F/KS8*#SDE9$G\F:
M"ORSDJHB!H=J/=_"UHJ1HG2H^:"#PO&52$*6<\;.<>U7?@H&\,9H(%=-%-51+U_M*9>;D>_[VXDGMBZ-G1B,AS59TSDUJ6/]"D>#'4K!*BHTDP(478VA WF@C MJJX9,ZB8Z%KRO5^'/8?
4>\PN3^$AX6-U=/,+M?3.ZO9]/;*YC,YU>+N0OW M5XOAP& XZS3(>^AI!QV\ YW!G12FU'E"EK\Z#_ '>Y!MM^!YW*8L-XQR(*& F#!%KMN04)EI3H^&2Z9Q+W2@*?TR6
MVBA4T)^'EJ&+$AV.8G?59UV3G(X,3LY/X=.'-/"#+W 2GL*)[YV^B8-J M-GV@7M)=H##Z(9#7!4I#>##(%=BK3DFK4Q<$GMT'%KD_9VTLV2B0A]W/4/EX MBC'!#/V%XPE9_-
OF32$WNV,P13MZ.J2U;A?Z#.>\34"F.V:O[@(EO.FL$C5 MQ<$!<=$5*2@(4F%!.DZDDLJPOP^&WK>>".B5$?G6\(2")"HOVQKWD:UH^I(> M6-QK)=`OG55HESS,O+,UTP#/,K*UQ>HZ?)+4__
CV4S>*,YCD>5,UR!YS[K/O M"Y\&$98[<+T)?"2!?A))LJ3P*@K7LYHX6M2/$+AQDK2Z\..X3)!6[M490=4.Y_X>RWG*WXTN0 Y_0(YR2VG'U4J:4,II9S\>(G=$ MK9G0P.D*7,VS\]@!U5WNW&+
(NKU0E]+@/FB[),Z'}+(&^\EI=D.;(#="VO\ M#U!+ P04 " #$A&Q92?U&*Q@' #Y$@ &0 'AL+W=O7%G$#N[U^-.P' M[NY((D*1"LF5K/OU?89_A"ESI/N9L>&L M,XUQ_K,?
#^649RKTW)PMWHR=GZF(6S_IA[EG5:5 .},?#@:O^C.E,>\/#W[M[,]/71V-MOS94ZAG,^57EVS<\JQSU%D_N 63:90'_?/3N9KP(GW4NCMY>GLCZM."?FI=AZYK$DL*Y+W+SL3KK#
00&RZC2%#X M6? 5&R." -K({/3J!2-V]=KZ1^2[;"E4(&OG/E+5W%ZUGG3H8K'JC;QUBW_ MP8T}(Y%7.A/2?UKFM-C:\&:.P9\.PV3!,N+.B MA/*]BNK\U+LE>5D-:7*13$V[4Y,<?_AXGZT_7-
,W>G_0C9LJ)?-G(NLYSA'CD_TB=GXS30M:VXVMW?!Z86V' -['+X MK, [GO?H>-"EX6!X\HR\X],0XR3O>(^\]UQ$>J]#:.5RH/=._+HH0/8+BWT\9
MFV6=/"U\+$N5MF*N2SSK{A,!^P9WS[{\Y>C5X]PS2DQ;IR7/27^"2_T8-77FN M=*0/JM1&1\V!?K7T*TJYFKHA HH@&!.!OA[WF'UTP#/,K*UQ>HZ?)+4__
CV4S>*,YCD>5,UR!YS[K/O M"Y\&$98[<+T)?"2!?A))LJ3P*@K7LYHX6M2/$+AQDK2Z\..X3)!6[M490=4.Y_X>RWG*WXTN0 Y_0(YR2VG'U4J:4,II9S\>(G=$ MK9G0P.D*7,VS\]@!U5WNW&+
(NKU0E]+@/FB[),Z'}+(&^\EI=D.;(#="VO\ M#U!+ P04 " #$A&Q92?U&*Q@' #Y$@ &0 'AL+W=O7%G$#N[U^-.P' M[NY((D*1"LF5K/OU?89_A"ESI/N9L>&L M,XUQ_K,?
#^649RKTW)PMWHR=GZF(6S_IA[EG5:5 .},?#@:O^C.E,>\/#W[M[,]/71V-MOS94ZAG,^57EVS<\JQSU%D_N 63:90'_?/3N9KP(GW4NCMY>GLCZM."?FI=AZYK$DL*Y+W+SL3KK#
00&RZC2%#X M6? 5&R." -K({/3J!2-V]=KZ1^2[;"E4(&OG/E+5W%ZUGG3H8K'JC;QUBW_ MP8T}(Y%7.A/2?UKFM-C:\&:.P9\.PV3!,N+.B MA/*]BNK\U+LE>5D-:7*13$V[4Y,<?_AXGZT_7-
,W>G_0C9LJ)?-G(NLYSA'CD_TB=GXS30M:VXVMW?!Z86V' -[

MAR/J"+8O@Z@L9NOK:JM)]\1PBL=DB,?X%0\G W^:,!N/Q;X8@MN^N-8._MN^_MO,7T@)GZQR$/7^T+,(6$I:7G9HACCN5$[A1(^83K;DB.JA*1D^K(VYS+2@ZZ MWGG61}\U.,13>)L>:\LQI!OV" MX$RU4>[KAA=R944<^@WKJOO%V-ZZ1 4F+__G9$BQV7O?T$YK(_Z_\V5KLM/'3P6@X>H.(M'U?XVVM5!3T.&?847<8[=:DW&4_0B=_XQ&DUX:0^?)Y>H};7;OV8S7A8L4$! M^? 24>/A!=S&KT33H]R2UAA!S_Q%%IK4B*(!/4.(O\Y_7Y.#P+@(GSW/5M/5U M>G^;A? \..:'P\=B]V[,5960 T@?2*8NB;B=S_8HVEDH MB=<4);E.]9+W0%67ZHG39L"=,YN&\^VTM]B%5:V.H-]NW^6O.>\O\0\CDUF M[_N""-U&#R&[$47[A_7X?G_]6\WW_=S!VN/4Y%2DM0#KH[4^[3H]RS!PNO!WAG/MG,{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}$.%%R"]E#156'2&BT!RV! M8)TCP(Q!0FZE21M:W5L2E!1>]MHP+I6V__SU;J)FE"D87PX*HH?5=,+4H8X M11!%U,TN(WP*8D.\%;>=['H9);XCTSZ\CYUX"7'3>KX]Q^@'I/AH+NE1GI=5S M'J5.]N/F7F;WA3=1ZY*]&\1J2JF7_9IEW'[JI807=:Y$O?/5W!#@0=JZY)U7 MSQ_&N*S23_X[7O\)TSLN#0C#VQQO:5:D2+H$ #9#0 &0 'AL M+O&A,QE,4PM,*F2$I-/9R,1B?# MQEB27S4[3W"N9G?HNUM,Q*Z'0-8V1)07?GF6C;/MQ&N[}*).#&>GK5GP%<>W M[2O!:+A#*6S#+ECO2+@\R\['CRZ.53X)_&)Y&6Y]DWHRJ_Z]#IX59]E("7'- M>50$@Y]KON2Z5B#0^'.#F>U,JN+M[RWZ3\EW^#(W@2]}.:LM8G66/1>B;S;*8 !8U_^:U28.MQ0>CNY0F&P4 M)HEW,RBQ?&RBF9V*7Y*H-#T([F:M$'..DW>512L6NC\/,7ER^?/Z$WY[\] MN3H=1B#J_##?:%_TVI,[M'^@Y][%*M 35W#QH?X03'9T)ELZ%Y.#@%?<+#F@Z-M J+):'\ &^Z=RWS"],2MZ;$->^])T^_G\Q %!?'\/I=[Q./] MB+I)'H76Y'R681<$EFO.9M]],SX9_7B [_&.[_$A}$^FXZ#V?FZW(>EE)\1E MR6DOD.VCQ=,9%!.0*-QX.3>V1<0<>3P>0>8=]3K"!4"3,U?;I9TTU(5N1F MSK++6-+#Q_0(&S:TO9EZ?93FIR/%2Q/(QX/1#;2#&U^(//B$1[EQ5%@L"Y7B MFV1N,KY';P=7 RJY8#$UA6AB%[VL>YVB X G0ZY+%'Q))6K%2SA2_+HKK%LH M>>QXMU%)MCE#!DU#CEVR@ACY]U]-6!%;QFXA4:M@N0-CH;$\\&4!OQ3(A M. 5O!}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{3Q_3LO7[Z6)5%(C/Q7C-3IBG7ZVWYDZU)4X, MW_O57Q#OP,N,&W&EDE]D7"R? [}SOL%C,>9D4']3JE7#\G.!ZD4H,O;*5'7L* M@Z/2%"IUDX&"5&;V/[]S<@@FG][)HS=A#'1,3'KJ_/T\^7-]/ S GW[\>,#IS?/W]Y\9)=OK]FK MY]1:+N#G_M"$BMZ!U[>I^- MR[X4>2'[*@X8./A>+)~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}2*+6>EK? Q+(!K@UXPH]2N8#"Q-_#!JK+TU48WK)6,E.2U6RHZZ8UMV77A;1]N&IPOZ!0:EDL M!?IV<&]E:BV;_7[O[.#G@>X)-?B[]%#XT&(= (!B5+!;=4<$;,0*7I%5465Y M&\>1D-VSB_,&#@?TD?F1-?2W\/3R<]G)S6RPS?#P\GP[\R(3&>. MH#!GO4=]_DG,HT"EF:37LJTK;,KH6\AJYC6&6X%5E, _:'1&TL&0!M\Y@DZ' M#8)&A\?]}}P4D%*P.(:I;(A<,HE_#;..S{}$$Z M+VU[#IM6N8 JT#8L?7(\L*JQ?8H!1S0}4VNG'GR^-?2KE1A3{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{VO% DC1N]65OV("#5<5Q^[A/!0? *MQ2#F&OW&O>"G+),E5&MZBJ&\(^=,]",.+?+9Q>DK"]?R=.F`.GWM0&'[^ MZ@XTV7>O6PSDA{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`2V6N2Y$A@)&+U*- !,,E[\A+UCYT00N<2%0.0S9=)"CK&LDDEU58 M!#CE3OHJ*S(.1:(XQUE_&DLPI@4)^8"%R8A?)V W5HS. 26<63H6E[FNA=6T M)@>"Z*D_JE!1DNMO)2@@'N2F5D@H%HA_UZY@QW2 3S@C(=E>:07 MH!S0*YW'M5<<^'4JW,GLQ:@:3)G3B0S".1(G(^(BE='M[E64&$]@F8E56IUU M"WCI?%&2<=9"P\RH:F"O)TIWJ{NA*53<,>G >, 4RX4B-,8J;##<>'/)\MC, M],WF%'0 "RFQU# >*DG4)G@W7XT&M,;G]SL#[Z:H 3 ^'<-J>5@6G 7V<'FG M,*%G]6IVU^ A!%9H*>@2Y=)<6=* 2R258=]YT@_P SDC B*85&>M<8:.UC + M!@NA@=.UYC"PJ7PZ.+,%4K@B$@(5-][RW\F&C.6@" <6&PD;,#& &9@V< YA5 MTK))9U5>\XU73(:*''7B&WQ*>2*,!&2R1PD"5(H(ZT6QU')TAYO$.?JO\$1KT MNA,9?)A[6A4 &1H]{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{QN-@$O)SEB9\C;*$I9]BWKW03!*X(,O$ M!,;&& (Z30.1Y_*W0C,8AJ((WG!&/)W!]!+XY<0T2C&33\)LA.DW@]"PER>&Z M*0(TAN1X"O){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}&$'C ?/'21\$_VM&)$^]-W[OW7KH7\V%*3=\4G0Y^Z,XO^HU[V)8)]E+O M@L" (T(W&@(P^ HX\B1>'4X_"7C/R""+DXC])*3I ()#HFS/?8(:,PHNE5O,] M/7K0PK#&BM)TYUY(?*5O%-=W'TIZ#_/MET1Y7+25P0X>'QX\+Q1H-C1XYWM MF:2.' I@W$RM($O)\,X_H'8C!\+3W]-U!+ P04 M" #$A&Q9DG8H%9T* #=!P &0 'AL+W=O,[B!R4U5+QL@7K&Y2$-5^\ M;?.P!] _8"@!03/.\IA"T@?*M"U.*BMRH,6H_W6UBMXE+L<))+/@&">.M MVHM.3 M,W2'"'$-WA%)=71F[2DL; C=K9<:-3/"*3(CN.%.%1%.60]Z#3X_COQ[!NSKD M+NY@%_;&[WB_!2Y]@X%T?J4OG<[)\.K0:=K#%/E^Y}2DPMWK5R6(E1T4 M$F6\9JIYM9VUFT4WM@4_LX_]X<3OL:=Z=C6CYA]],_CNL%@1)A&%I9;R+]YT M.Q7-,&DVBE>V6RZXTKW7+@L]?T$8!WV^Y%SM-D.@F^C)7U!+ P04 " #$ MA&Q9 'J/T,_ "*!@ &0 'AL+W=O=@,A7VT*2,FV57/8*DJV[=G! UAK,&;]L/OO:QM"TRIA MI5S_C//:XP8HD,(9U4 -/12,JYBK]"Z6OJ^2@eLHL1J)"KAYD@E98FVF,O=5 M)0$3EU0R/PR"N5]BRKTDOV6-O%\?*)_=;6,6@Y8P8- @ORC11>Q] M\!"!#-=,[T3S#;IZ9I:7"J;<%35M[.2CA])::5%VR<:@I+R]XY?N',X2#.=R M0M@EA,Z[W!>ZA&:!+

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

&XU\6JSN^#=E@I#UY]M^9? M:?WS#'W,0JF*@JP.:B_)PYVK&\P %C!F]!VP(8OC^AED^/S^NS%G_ >B9&QK M/PP"N-+6)Z^63D.&]" ;MU)CUA 9SZ@_K,4C-'/T+4+C"6L9&0L\B:4, T&W MJ_D0YK+"8RI\>D6.2*:HL0B203[C%4,UP-,Q\'ACD<4U*0T!RUT*,UUX^5P^ MXFVRQ+O!;80C!F&X$? 7O$=QB!9AUB6 EUL54%TJ?#5K^U_NWNTKZ74ILB"! M/@^##6<6U406)@.XKIS$?FA=K(UB M\8(UKM:+^V,-B6Z8\'$+?A,>=$Y"E?"Q[;_S .@44=XU2 T7 M:01?I+4GOE>:V(5S1DU6'JC ::AT11:,]N6+7,U9=H%I7[8C"-^D@F@'S%V* M9S0 >-U/ORUTD4MCCS+U#E)J;,:VNKL.MMFC@- F16'9# 'D B/[L_O'0%0[# M-/9/CDW5#2Y*LJW]- E?01='A(JIW*)-JW&6-/1P&,3I-GZQ(18=1/'FV#BN M:VJ*_? R[0&R,Y95D&\M1Y$EI&!\!8BP*$$$Z9=M0$OBL=?Z$=P"H[>WPF"?9:%^!M&?,/+@W1-9V&\#PDW,>[%C\.HB!;9N N+G"['/X"+ M6_B'CC,**-D**% [369S^S2"8902"XPX(A@D1Z2H\/K8M+.SS+"#?@Z@3TS". MLV8',0('@3*BL=!50;)F]P0K6.O">NO T>,+AO0$T>2P2N(I.@W')B!*(,= M4^MF:+5^FIP*8UYH5Y1Z5=4#^,YI5FPF[Z(S>7L.-5/HJK#[#_(0CBD8?AZ M9;;@>[*R"+,6F3!V[Y)&J,4:RFEE=:%R+SH1A:BF& #],1D#;W:,_!^E-.& MRH;-]+L]=.Z0>R.#[MD:VZ:TD+^MU",",B7I'20XU]%%E<#%=%IGSJ "Y, D MM\4J*/?DM?7#9PP9WEW7U2,JT8;2E^'%EB$O5]9V8814!CC M1B%VXOM7<8:8F9"E'8R>%&K>RG?^@FP*82E>?*N%6>+#P U#E@\<;K>EDBR$!,_J:L?> M@6"PP,:9+[, ONAJ_AY!IMSO_!!).#*L'5AJXV$? A:.W)}AU@8J/X5^8MR?7 MY0KQ ,)P^_B.#"3&22B.V>L_^/LD0V3)/+/& >571\C1ITO2J4T<__=#{.K74]M/<1?U%:L->?]? [R<]8%A,S0]'@0QKWZ@)?OSB]]-^G)MHY7?KE M0@I$>6+ _9G6;OU"!MH/EN?_ U!+ P04 " #$A&Q9T(&76A0% "[#0 M&0 'AL+W=O*7O:6#E7?.IT;++"7-@C7:"B?Q;:Y,+1HUEV;&%0I-XH MSSI1$/0[N9"J,3KQ[V9F=*+7+I,*9P;L.L^%>3S#3&].&V%C]^)&+E>.7W1& M)X58XBVZ;\7,T%.G0DEECLI*K<#@XK0Q#C^=#7F^G_"WQ(W=&P/O9*[U#WZ8 MI*>-@ EAAHEC!$'=/9YCEC$0T?BYQ6Q42[+A_GB'? NGW3GN9"XOG.OLN4[YD&?Y13@Q.C%Z X9G$QH/_%:]-9&3BH-RZPSI*\G.C6Z_S69?+ZXN MIG?CKW YF8ZGYQ,.3:.7US=7X{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{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{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{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lZP0@"PT4[A=Z]SGQI3O,W.VZ MNRFK5)0*%:5"63R{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}:4Y:C[@Z6WVLLW*1Z3T"]Y7S-9! MS$%(GJ23=3:46;/]1[']CJ!)}EWID0I!HVQS0R12L-1 GG^B5+SND)^JBD^3 MT_\!4$L#!!0 (,2$;%F03@ -V 4)DT 9 >&PO=V]R:W-H965T MAT]\-J M/X1@()HD9AT#4VE__#J7)K@-'I#>?BA)R*F.+Z]\3G+P>,?XCW1%J2_XRA) MKULK(=97[78:K&CLIQ=L31/YS8+QV!?RE"_;Z9I3?YX;Q5';['0&[=@/D]9D MG%]IXI,QVX@H3.@3)^DFCGW^>DLCMKMN&:VW"]-PN1+9A? 9DO/:7|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{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|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l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{S6_U>GNKI.96*;H+@V01(SMPN:MHS_3M M1YKV71&V7>S(6^RNB18XX:M/B/8^(M(CAN)^K,;_J+?!5$Q4,4\SOSTZ3=,]2<+IMT7HNSR*_T#V]{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{,.D.@ZUA$(?\P*=<(2BL\JIF7I$8D>HT(6X?I.VL=9E = MF=/V UBN=14FN.87'2(E'}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

*>3)]M72S?]RT&IBSF^ME'-804U(FDBS<"16Q+97[Q*WO+_M M$X*XN<]-^U;B>MFGY?%Y2RFL4+?5Z-NE<'8$(%(K!4IISK&[5]>%[@R1N2 M;;(*QH))R=+L<0TX!JX'J/=+QN1S0QLHRVRC?P%02P,$% @_Q(1L628- M&[A%! 9!, !D !X;"]W;W)K&ULK5C;DN(V M$/T5E;.5FJG*C/&%RTR J@%[LSQP*6"39PUN0+6VY4ABF,W71[Y@L!#.9-!X9EG :6 M9+<7Z8 Y["=X!RL07Y,%DV]FR1*0"&).:(P8; ?&B_7L6VYJD"'^)'#D%\|H ME?)*Z;?T91(,C%8Z(PAA(U(*++_>8 QAF#+)>?Q=D!JES|3P\OG$_CD3+\6\ M8@YC&OY% K$?&#T#:;#%AU LZ?$+%(+:*=^&ACS[1,<"VS+0YL %C0IC.8.(MQ/DW?B\"<6$@>?0&=F%@JP;N#0.G,' ~ZL$M#-R/>F@7!IET,]>>!<[# @_[MC!X12|&2+7W(HI|9RWB1."V4E6#R5R+MQ'#ASU:3^0RI$#PT7W_QEV@Q7ZV7 M_GJR]*?^;(U&_LS_/%FCQ7+^Q_)END(/:";K=P&,T(!LTABV!*!QI0+M(00 M"Q+OD* 2D5<3C@,T%WM@:"A"4A_2XK32 _>P0H*18ACCFZ\T!@$O)[Z>GK MRD-WG^[1)T1B-"5A* EYWQ12>#I]E $OHVZ?HCZR;PE7D#PBI_4;LENVJYG/^./FCD[.SWGW?]AJ)1A.68). MQN?>*L&B4%[S,M#FMY8AW4R?>8(W,##D;LF!O8$Q_/47J]/Z71?<)LF\)LG\ MAL@J:7#+-+@9NW,C#>FJ3DZKNL@%VL@EJ\N'VV0^FB3SFB3S&R*KY*-=Y]-= MNRQ6DH]LX&8*A4$=XUPG*J$%\#Z960BK!.*;Q3 M*VP2"Y#ANEU^)I($@MD%V4.+ 8R8TMD><:PIR#?F_K7DWBP57U:C#MKB)8@Y&EJ"C6@CIZR;U2LV#]WLA7VEXM17?7_#?T.5@]VLA577G-MVJ[I,;V>8+)W7;MVEB'45L7'<9RU3#N0#?;%^O<*%NU?=\/Q@%Z64GJ;_>\SJ,JPK78'JJ;@W& MLA7=YL6M001LEUW1Y6<'EX$)O6O7(6YIQ+[U"RFXISO3YM_=,4LQV1__5#V$I7K<>NS!#+KW3R%T&3[,[BE0I!H^QQ#S@ E@+D[UM*Q>DE M=5!>K W_!5!+ P04 " #$A&Q9=O#-+?\" !(" @ &0'AL+W=OM/L:+?U*<[5/)H+)MZG$B>#Z\^C+ M.$)WP^_1!)V&(!*^!EZC^XG(3H].4,G*,W1."5$EI7W+2%S*]055_R7);I[M@-]#8Y]+!4=1GD#2@_;11:\);46@MV-X(OW5;""2Q-Y-GOD&N[?L-Z1B^' M>TUR_B]!],_9=\SPZNI[FL\[5/T\IAF@._R(PI3'A/*" ?HQG'+!Y"?\LZG> M):/?S*B.M1Y?XA@&ACRW.+5&,';-T[7_MAD]C')PF.214::%TX=M2.[4\ONM,J^-R&M9*_=B,ZPUYVM-_'N^Z'F(9^]M06OK:LR S75/PE%,BUR4YV0]6[<]0WW;[\U? M.KV1TS_?RC:I[&K^T)<[UABS>9IS1& F4]GFN2PX*_N6Z7R!QGAG/\QD;&>X M8_Q5K F1Z#U+$$)X51EMJ> MXW3M#-/<&@^+L1<^'K*M3&E.7C@2VRS#_-\)2=EN9+G6?F!&5VNI!NSQ<(-7 M9$[D]\T+ASN[]I+0C.2"LAQQLAQ9#^Y]Y/K*H$#\14Q& AU5MEJ,B(BF)I7*!X>^-3$F:*D\0QS^54ZN>4QD>7^^]?RW(YD%%F3*TK]I(M#SD;(>X0H,W=5&H M7UB#7C17A3*7')Y2L)/CZ&'V_/C\YQR]1#,T__8PB] MFI&8Y3%_*2Z2R99H M@@6-T7R-.1%(,A32=")M)LA^Y"HG$-!778/Q]'J*K+]=(E(]HCIYHFH(?<8. ^ M'-\.,0D$5!AV7 4[*8/US@3KHR>6R[5 49Z0Q& ?MML/6NQM$*Y6S]NK-_%:M'<()Y@[SY0@WR'"\PQ#/!N+EOTQ/_9H]^>O83,?RZE/S'GW_&WX]6C2G_Y0R! M>0;5-_,%!L=D9$%7%(2_$6O\^V]NU_G#)/YG.@L_TUGT2F/)0N.H4+M=:\C3NN,[3?CN4U8)S>*28T80:GF,B$Z=:8$XZ= MFF.GE6.T7,)"I$HP424'2Q$2)-YR*JGJ5NW<.UH\7H/Y141X$1'I",?,N5MS M[K9RWK]<%]AU#9EM\C-@FED+37[3GS.9[=4L>ZTL' .8901=I4S :K/D M+$/0=23-MS1?(=@_\:+[&)M+Z;E[%ZW?%4A_C-DM8A;K>97!USZ_?-Q/LU M\7XK\6?8--*2/):2T\56XD5*5%O-H>V"!IS!N@HBT%P2R+Y4:V^<;F&E4ZONMAU7JMQ1F*=)%1'@1$;4A3O09U/H,?EEA#+1@M,+0(5IAZ!"],'3,V<)PG<,6 MSOE1Z@D5%7O(_H'\#T!##@+KU!LTJ,/KJ M=,X(L==/(^J7 T'2?X M'91#<#Z)7]N83Q47Q.* ^O!??DIX@GS%84"2\D2IG+N M>I [7[H\NRQO)L7Q=<$'D'(:+RS7!(+ "P/,E8W)_HR:HO[&_P-02P,$% M @ Q(1L624ZQ>\ @ @@ !D!X;"]W;W)K&ULK55:,YLP%XK%I.F5EH+ =*U68)$$K:VH544M.UAVH,#)\&JL9EMDN[? MSS:$I1W-JJTO^,+YOG/S.6>\X^)>%@ */924R8E3*%6-7%=F!918GO,*F/ZS MYJ+$2A_%QI65)Q;4$E=W_,NW!(3YD1C>[<0T9C7BA(&"X%D7998_)P"Y;N) M,W#V%TNR*92Y<*-QA3>0@OI<+80^N1U+3DI@DG"&!*PG3CP8);&1MP)?",.SD MP1X93U;_.:/U7?NR MPA)FG'XEN2HFSJ6# [M)(RT9C,;&WV+UO$BS+R35G]EVB7=S]RE%BV2)TNMXF: S%.B64*J%Y-A5VBQ#[F:M"=/&!^9$P)T MRYDJ)$I8#GD/?GX"]0[[GASWVS%X.#_K<-M^3_MR3]K?Q2,H'L@@>4+GGL@6##"_A(M0*#4!:M]BU=2"5WBW_N2M=%_72F_M]8UDA3.8.+JO21!;<**W;P87WH>^2+!FV?PUR9)7(GN4D[#+27B,/8J9(F1>8_(U6.1Y$\1?]B)-#%Q#YI:"6)CIXG43M5,-<^N MN^T&5FS[!)/[Z6 T&_3_%!+ P04 " #$A&Q93R[7 MP=\(!@9 &0'AL+W=OB]6> ^&& JSQ@;5-DEGUC]^R<3"5 MF)+[X]^Z'!P/67"&U=1'X;KER3],UM*F9/7*(RSZ\XRSU>7W6XV7]C4=727K/ QB^34EMV3J*_/2O6QDF+]<=N_-VPT.P6.;%#=W1U9/ZV^INI:=ZO,@DC&69#$ M))7SZ\Z-?2EZ5M&@W.)[(%^RG"@_DN3/XLID=MVQBCV2H9SF!>&K'\]RM+,.PD-1^_*=",.]L^BX:[E]]T5CYX]6!^^>)D<)^$_@UF^O.Z<=\A,SOUUF#\D M+T)6#ZA?>-,DS,K_R4NUK=4ATW66)U'56.U!%,2;G_YK]8O8:= ;[FG@5V< M=PW/WQZ>[NC]MT=R<^\103T^N>?D9JSNGGR;T$?RA=S,9D$1.C\D-MDWCSIU-$\),G]R2(R5T0ANK.[*J;JSTM^NM,JVZW>R5MLV>O+LA=$N?+C-!X)F=Z^ZYZA-N'Z;P]S%O'"#[*U1EQK<_$L9P>>7KTR*>_ M_49RF:I?J9]+E?8O,YD%B[A\. T[/#[>=]NXGMGUY%2Y=N56^]W4#/SQS0_ MBF%M&/KT0#Y53W<3QLW8G?I?9=D7!RUQM#4T65IVW.V?B%OB[M!G(V>_>(0 MJR*?Y>E:';KSC/CQC @Y6P3Q@MP41V#U=R$SX@79-$RR=:HN_^L?BB*37$;9 MOYO^"#;]]IK[+4:MRVSE3^5U1PU+F4R?96?TZR_VP/J]*:!(S$-B%(DQ),:1 MF !A6D9[VXSV3/I.1C^3N1^DY-D/U^KR]D@T(S_K*TU9W/C]TB\F/,\CZZK[MO!NP@UMXQGULFQHDQI 81V(^A&FIZ6]3TS\Z-;&)P?QL\SRXO#6(CC[@\$Y MN/(5GW,VVP4%B#(EQ)"9F!;@UPCLPH$O.0 M&$5B#(EQ)"9 F);1BVU&+XZ?S275(HT?)>LX;PK>Q8>!M^\,&X=>8[=M4_6Q M6]?J-W5+D=TR),.1F!A6F1LJU[^LXX,S>Y@2G:&6S\C2W6(D\W+>$;I[>$+ MJGE0C4(U!M4X5!,H34_DSH*T?:*AMNH8%5:DYD$U"M485,-03: T/:Q.'5;'M>/B,U|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{(6[1[14F%8[=@F/WI1Q#1A]8R-3W"_;$'LE M*%H.G/)];'*#9*YCV7DJ3E8K(!\E6.57@H\(D '\%DOQ'L*]AUXH)/'H!C5=M/!XK@8U2;UX+2"CS<1/_ 23:Z]+E*@"!;48(Q.U:J[8 &UF^-C=;_JL(VB\$ M[1^E./MM"M 26$6 02' H-7B'#Q+:>M)TC^WZ-8G_5E!\>QW)?W$\\0:&I-^M5_X,:C._D>IK#[XEL(JJYX6]YT?)_/.V!6@)K"*,>U'':QUH]#UO?T?+QH M.JE2+4UE=B/5N[B4[GY]01RSX3?3> ^VQMX56%7,_D-G'FRMM"]{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|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{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

*[/^MW0[H.UR+_6^60M*H-T\T=KA:1N5XL,;-$^8(NVP]8ILM&E22UE<25EW-M[JI._%_9I)8PE,7?I2SV2EE?*
*V>PRUQX<>WURO'U'ZY38)@UD\3X@B[<_/79*_M;+,&LM@O9/%VR#HEMDT#6;P;9'"%?G;3EDMBVS*,Q3LQ%GMEK*]L=]V&L=@G*
*M8_'VW:Q38ILTC,5[92S^Q-/D*DW-8Y&FH6S3 V57.=HN=U6:37?!VJO@[#V\-M7@/&+)$@IB,=%!Z?Z-K$\M7V\D3Q6?YV>,"5XM/*
<$+)D(I,H.^/.%FZ*"7/&P_S=_MO1@/>:8H87_OD.S2%(N7*Z!\.W)\Y_7%_UFNE'GACH=KO(09J,?UO=_CMV)) M2 L,$LZ0@.7(F?B7D=\W@-
SBBX_O[)_RYW7SLRQA&M._R&)6HV<@8,26.",J@>^_1- MA[J&+^94YI]H6]IZ#HHSJ7A:@O4*4L**;_RS%&((/H'F:_4$)" X!G7<_80D(*
M/PKHE(!.KDSA2]V&A!4>#P7?(E&L-9MYR,7.T=I]PLR^SY30OQ-4^-OD)L'_M]#2Y>[O!TVO*
*[/'A9GKSU_<9.D.3)"%F:S!%MZPX8&:C3B)0F%!YJDT>9Q$Z_M^7**OB#"T)10J@WDT%5Z78;=CDG692DTXNY1K',')TOI_@-N", M?__-[WE_-*
*EFDRRR1%83LU.)V6EC'U]CN4*8)2@V#_C(QM,@:G&8UM0]7(J_MDT_W8[\3>$-WLR_-6Z-NW^_5C:*W1J'7'U1&-5>ZE2O=5E=NT[4^&3H'*\07*
M.@(WO)4929U"U$KG>&3^"_A]T7E0@=#) \\IH(TY24W>MLYV[($IR+I[#@!.
M)+$T74VZ7B5=KU6Z".8*S2#.A$YQT+CWK03'JF&3+++)$5A.N7PG7_XQ;@B_",N8Y@H8B)T<2Z##F3^%4@V1K_K9S'"F23++)$5M/2]W8%G_<9(5RR
*M6M+3*EMDBZVNZ%X)(7]>')?<^[%W6&&4)KV6\&Q?X;\[$.P4"%H5^%NM0*") ME-!<2+7#CSX\-MDB6VQUZ7;%O?\IU;UOM;RWRA;98JLKNJOP_?*
*82OSB,IK17_M+Q\OBQ=F'_+:N/D$=]Z$:1@>QFGKNHY6T1);7<7=Y<)OOUW,R)*1!8FQR6JY_MHGQN9LG%(FR=:4%/[F_#%*
6GC8I9O4]898MLL=6UW=T^_-ZGQ+S5.XE5ML@6_M6UW1W:7$;RW4QU/.X_6E6#R#0HN,)?(KPDI?\H5X(6SY_J6WY-W_;^T$_03/
*W>OH2"6>6]4ZNHB8ZKHA%5OJ_[K).\Z'KR_\B^OBR[J_MCJ9HZDZQ6!(F$86%IO3.^SHJ1-$G+0:*K_/.X9PKQ=/\<;5S)PACH']?<*Y>*
M!V:"JEL]_A]02P,$%_@_Q(1L64;L.I9;!0_K2@_!D_!X;"]W;W)K_M&ULM9IK;^(X%(;_BL6.5C/2M!P[P)2VR0DJ^FJ
*M*M/N9P_'L";$C&WHS/SZ=4(:"0.V3GJ[*K7_$H\GT=_M1G)86RFUN:G7Y6P%;RJO^08B?6?!Q9HJ?2J6=;D10,>):!W6[4:C4U]3%M5&_M@^3;HQ@-*
-^%:%+()'0>1VO:;BQQV$_'58LVIO%Y[84>9L#9%D/"("%L/:K7436)U8D$2\,'B51\6T$H%K4M+:>"]J6"3BKH7"KHIH+NI8)>*NA=*NBG@GYB*
*MAWW_)9WO4$5'\%?B8BC-2T^2!R4['6?LR@V^T0)?9=IG1IYM\$3>;G]_.R2_M!_=V\OSD/KA_?YF0*_($,QI-6,AHXD]^(!YE@KS0<_OD*
*:C<"M"N5Y*H%57D_M60*9L&7$%FQ&(WT>\:D$L:/3$$@0;;8Z*,#BK)0?M+XYXE#/G[X1#X0%I$'_M%H:Z$#FH*]VFN&;U65K_NWW]I7?JWR0//%*
*(K2=QH#O,"O6/6]PWZNGZ6V0.U MWQ[HG6T$3F!S39J/XC=L%L%];F_7-XL:LZOE>[^6NF>6?I7-C*6/C;+'9AI MN?5NZ?*
IEI1?)@\M+MPU&:&9O5C/AM=[AW6M?L6BIWQ"RH3_V;XJ D"J8$\7U-M/]MRR13[]G>"(^GP!NYH3,8UO0<%[]G4!O[_IO5:?Q9Y#E,F(,)BES!26+*
(JTR^-%SP8$XT4+B[L]LL@X]\4NY&EYXW=L4,+ M0OKY$>QYQ==HG'F:5 MQI@P'Q,6(,%R#NQF#NP:'?*
A%T$@N0$C"MRI^YS_##D)2M(:\,Y]V@T3YG1+ M[58:X6%6:(P)\S%A 1(L9[9>9K:>T6R/Z;]IR%R]_'@=+$8I#W'*0]R"D/:)*
M2.\9FU'5"Y@P'Q,6(,%R7NAG7NA76'9 -#4A7$"[6K!Q96D(9 Y3!61,-L*_2,+ MBA-F1FC5.0]5YJ#27%2:ATH;H])\5%J 1P MLE>2Q$_3R0TDP_1
M"KWJG5D1-YJ/2 M?%1:@$7+6_&0T+>,F=5*Y0\SJK+O4!/X*5\>XI2'N.4AGKD9E0V!2?-1:0$6+6^(PW<_R_PAH&(V
*M)*7E/FB<>J0@Y&SE5(IQ+\!XYK95=@EJHAZ5%F#1]BZI'VU=6H-8)OO>))GQ M,:.3V>RVRJ[G>NMMD1[G)]3OKYMXJN.Y8-*
*^Y^YJP!O]_(IT"%7J)+$L)"%]6X M[FK[B_W>N/V)XIMDX]24*\77R>$*Z!Q$'*#O+SA7;R=Q_=D.Q=&_4$L#!!0 M_(_2$;%GFN^_6$0,_(* 9_>&PO=V]R:W-*
H965TD.E4PNH=I#R88L.K$F>U_^^]W_M[80(:$";QM07B.U[CL^YQM=R<|O%DUP3HM!SQ&+9LM9)7>V+<,UB;"|Y0F)-M867)1805#,7*EHD@>&%*
$;,]QPGL"-/8:C?-W(-H-WF]&(W)@T_RC2(L7KJ$_M\6W+1_PL@N6!8U(+"F/D2#+EM5Q[WH_'6\"_M'BG9RKUOI)W,.7_2@]&B93E:$&$D5)H!P[^&]
*ACF@AD_,H5W#+=S_WK$/_MC7?P,L>2]#C[3A=JW;+]/9E0)4Z9FO#M%Y+[]6J^D#_I?M$VCW4L%*92\2@'-M@X*(QMD_?L[SL_=P*R<*
7@[P_A3@YP#?&,V4&5M]K'"[?@6"1T-;/K#Y,;@_MP0V-]2E.E8!5"CC5'G9&$_38N9\-T'C0F%N*%QJM\JON"NIA!_1_T-9?-9\'31*__N_Y5&O6EO]FV7!*
5!K0@ZL%,M[%3/_MVKG_1^$9>W5/D^M4_-J1\(HUZDWRJ4'A?3@K'13JJ=-\BSX;RON0F0'/FN%_MS]J;M&3MD@FZ$-E!@NI%@NIOT)+U5S4++>D?
%79)4."YY77=,PT_FM+-EY=_M$XW_]8Z$OPYR'<<+CI3;>R\,_;H;8[&BL00=2_YMS5P+K(74S90/#&/CCE7_M\(0QGVMX9!*A_V!]R;G;#?*
0[IGBVMG\#4$L#!!0 (_,2$;%GIE/LE,_(_M_*<$_9_>&PO=V]R:W-H965T-2ZWKJ>2HM@1UC5PLY,+R8@V4UEXJI9_,B=BE1?X
M_JW"'_4XB=5:1B,1,'1%.6PD4@UC1/Z90R7:&(_Q<6%+BU+;!2':E+_#O2W_M>B/-S!LH&67_%14<2+@3U0^:Z3+&'S'*("=-I,>B*
*M_0I]/C>6EXI*N2=JN]@PP"AME!:L%QL'C/+N35[Z>S@1!)<$02\(G._N(.?R_MGFB21%*T2-*
*IH0[,#EZI3&W.4VX^RT]+L4J/3R6[Q9:58/Z'E^N%QNYH]+1_7_MZ#U:$RF)O2[TYAXTH95Z&WG:'&=%7MJCYQTZN(#^A%:"ZU*A!<\@^U_O&9N#*
*MU^#H=1YZ@'J&)_PX%?A_B!84I#GV%.QGN8.*XDXM<1T);J(74E!?HYVRO_MM#05\^M0=3@UX)\7#0!:N111*1<-U5T?#ZM'%*
*MLZ[X_H5W+;PBL]!&PO=V]R_M:W-H965TVUW%0/+V?!_M/L+G]:WJZ9I87YY<5?Q6\$('O_M=R/VDG^NYR*_M'ZBSXT&[@:=??Z>_V5]]>S5?*
BIV\]C;_6B^;U>X3X,&!_Z?/';L_?.%XTQ>5%73UX=:=N:=T7^[N_']W>_MKW79S93KIFY_NF['-9?7XN_OQ/O/WMOW;SY\>O?J\]L/[IV_>M>/\|:K;KPW
MZ[(H%^MBX[TM'R=F5]_V^_#?>U=R]MVVC0[!T"WO?O:8_Q]O([>X_5.4?V1'-[KKCB]U=L9_O*
*M9VW[V\GZ]YQ=_OE/0>+_C;KM2!A'P@0(IA4H.A8HS&&X++_K-YD&HPC@SFX>M8EEN-0]"E>1!3_-0 M;BEPVR6R>?PBBTVS6A2U]*Z_[;JI^-*
@^Y&)55IOJMJ^#._[U]M1$TCB4)E T-MO6C*_@;QE!T$ZA"A-_ZE"11-+Y-RB8'3XSS101+K]SF-K09"B+(!^V*_Q,_MKR(H51AD/?U#&:W*
[;3(_O%Q5;23<2'OF^X9A+Y\)_;L28BD<2A-H&AZ@913_M#+(I>P74Z$)!'$H3)I>)F4F_Z<5>]}7Y-;O;IQE9J^@+1++[9*VQ1D":9V2L(*
*M57+2G/1E!&7'0K<=(WN%]G[F(./B/NJYUDH$VQGWHLR+H[B>Q_=01IV8_H42!V4]L46_]P_A*E?A]_419M=!MU9[53YYA:]R'.7M2_M0E?*
WH#2!HND%4[XS3?L'5#W":5Q*$V@:'J9E/L,W0N5[MZ1$6;$M#64*(_-MWF&+XB0Q6PA5RF_MC!MS&[=GM9*!IL9]Z+,G*G39$$H3*)I>Q)-*
*\Z*0!46Q"%!L1Q69$I_">3'E/_M-B(E>ACK?,.X(D7,[">V*,[_I1E"E_0]*[M,V3;FMFW/ZB;/L#3NPYP]);'+_MA5";0-*
*'T@BD/RJ9,E3*H\X32.)0F4#2]3,IYLA'94D:D/0/K2<06LL?-_?Z34D?C8CUY#+(Z[G,Y>^9"UQBA-(&B_MZ5555I5-*
F5AE4$<*I7$H3:!H^N=7E'.-1J16(R/Z]=FAR%5OOEP0JB8GQGO_MRP["~9]P9%@(&;IH0&KU>2UF_)*Q^]S.GZS^WLF0Q=K(32!*
(JF5UFYWFC&P$];I0&H?2!(JFETEYW6A$_M-#:RHZJ1M:9,B9CUA&.+_I98'],E5&'2UW"448P&1&-?+;\6Y:)[>KFO;V7]_M;5@W@2Y?*
0FD<2A,HFEY"Y8.C<.S$=380FD<2A,HFEXF06RC&>'9R-ZSAJF9_M>*_$L?F6#"'*_O_=&4*4IHSN);'RA/&_Z"S12\9;(_>)G+U_'1%$TH3*)I>_M4F6*
*XRG3M#'4P4)I'$H3*)I>)N5@XQ%IVMA.MP;FFO(5)6+FPC,ABB(SP4*)_M6%]O4>8O'I"E)7K+>!?D/I&S)RUT=1-*$RB:7E+E=>,ID[4QU*Q";1Q*$RB:*
M7J:3K7Q&)&MC(ND:FF^[4(@,7N++6)6.HX213WIN%CYO'A-KO:]"Z]TS>*]*
*M*LMNY[ROZ^:=UUM[KOI.2*X[SZ9LRG;V(I#1G%B]A="9.YKP@E1P.Q5;T&J^1+[L?)^\8#\[=,=_M!O19(??)G3V5H8NB4)I_T?0-*
UY0!3J,.Z2904PNE<2A-H&AZF92I34;$=!,[_M-LN8&:NC1(&Y\1HARB.#)"A1F-#])E%^,!D0TGVZWX!BO.Z3.WLB0U=$H32!_MHNEE5J8XF3+&FT"-
-+I3&H32!HNEE4D8W&1'C38B$;AB8_882F0Z*$+'$ZC>$_M.N)\2;*(R8##8KQOZJ]=F_M)N&\]P_L)=,.$32N-0FD#1]#*>[!@[Z9:QV#UC_ML9O&8G>-*
G<+8)LK8)B/"O8D=M@USTS$1(N:;GW4F1)FYPBT(4=[WL8!$>><)D_M0+37[B<@?^0^F:,G+G0)%$H3*)I>5F6#DRFSO0G4QD)I'$H3)J^+;6RL>F(*
M;&]&)&U#55#G_=$"NU^XO(#_D/IES)RZ4QJ$T_M@:+I956V-YTH2)M";2N4QJ$T@:+I95*V-1T1Y$WM8&T:F>V%"/M:V]!;&]M/*
*M"4K$>M:34N7WTD$AWQ_*15-\V1S2NZ]*N6M6$3(/2DS\/,B";ZVPC_;'C65D\VF#.AF4&<*I7$H3:!H>IF4,\U&!'0S*J!KAN@H*
*MD9F$X80H"LW=;BD1ZWE:R92IRP8$='E]?^M=5=N[ZKY<=C[]7O._+DQ":1Q*_M$RB:7C-*
*E5+,I$[@9U)%";1Q*$RB:7B;E2+,1"=S,CL2&YILA5Y3(W#"_$Z+4_M?+H1A"@Y6636KU"9N6Q_I=H'@,,COO(9\]2Z*HDE"90-+V&R]YF4\9M,Z@/_MA=*
(XE"90-+U,)W^44QJ$T@:+I95*N,Q^1H,WM2*O]1$)K"<2_M0F0_D1"BWB>27!FV_(D$;;.2-7EUT%5"*(U#:0)%TRN@#&4^9;@UAWI(*(U#*
*M:0)%T\ND/&0^(MR:$[E5]O,\K>&$QMSX0!";OBT_"K5T;,(T'>:70_M=3\HC4-1_D73*Z*L8CYE1C6'ND$I6C4-1_D73RZ3<8#XBHYH3\5.S*U_[RYI=*
*M@4JQFEW!UL0]'Z_)E8?*GXBG'KJ"YB3(^X4NVT%I'$H3*)I>$>7]\BF3I3G4_MWD%I'$H3*)K^!T1]Y>^ZKP?WA>^#$VTEQ/P3HH3(7%ZE-*'YP$*
*>S5P'F>]6_M4C:\;(K+BZVL;^65W&QVWJ*Z+YMN.IZ\ZM7RIKL#+UZ%L[GU^NO@Q55_O,Z#_M%V+_^ESA+R_NBEOYKJAOU^7.V\B;]E#^SUW@IE[?*
KH[?-_5=>_-GWI>]:,KM_M_LN5+):R[@3MSV^]JOG^37>_AZK^;7\YE_\'4$L#!!0 (_,2$;%GE_#C._M#00 !85_9_>&PO=V]R:W-H965TZ^9&T#B.5V_1)8#>
*[#XM]8.2Q+40259*VT[]?4I(52V'4),N'_MO-@D->?,#&T)_2>;0_X>DB3C(V-#>?YF6FR:_,I9J%]_T.1W+ZIDICC-*
G,BK6:NAD1+8\B3.XH8AMTQ33GQ>0D/W8L(W#_MPCQ>;]A<_">C']A_?VOQZ%B9M8LRSB%C,4D0Q168^/7RI%A28L@@8A+"BS^=C"%))%,PHX?*
%:E1ZY3_X_&!_4OAO'#F_M#C.8DN3O>,DW8V-@H"6L\#;A<{+_$RJ'?,D7D805OVA?R5H&BK:,D[0""PO2_M."Q_\4.U$4<_P:,&.!7_:0.\9P!N!7!?]L&K_-Y+-?
@5H'#=+'TO-B[_'$]&_ME.P1E="30Z*W2_08K_B3":*@E/Q-!8X/EF$7V?AU7=T>?7E>CX[_WYY?84^_MHSGL(_L"HB1%X0,'FN$$30MK@#)T]Q_!!;*F.-*
*_$$3H7"VC197,]8CB,8&Z)Z_M,J_[,";__V;WK#]44=-)%N@D"S61->+KU?'UNM@G5^(KQ7_"RA>WA/8*J/P6_M[29.;S@K50PS^_]L_O].\VBV6F+;A(*
*M.*6/G?#7YIA.LD_G6:B)K!AV#WONM(3V=\=5)%N@D"S61->+;K^/;?WL-_M*;'^T4MM^Y,5]B$*(;_7;]60IT*>Z[680I70D;J&?X/:OT&G?Z$X#JUE6LXP*
MO0>N=+.3X;5IH,LT$D6:B)KA&%8AV'X?LO(4&=\=9(%.LE"362-^K6XRW%_M>GLAJ;#'KJ;KM6K$5"7DM\X9@4+
*(MBR[54D44L.!KZXD]M%%S.YT<0Z,([*2_M%^M$==FYZ,:_-M.TL@5:V4)=:,U(,(^1<-YO.:ELTQ5EG6R!5K90%ULSRH_7_M5[OS]O2+DN(^N7$,?*
=4IX]?OM^XU"R/$]IUU2%%*N-VS5%/.HSR-/'D6#_MC:&(;#->7MSKU;])=UZTKEKK%_;9U%:L:[+!5_25'NG+CJ$XX(B##D,)K(0]*
MZ[0OJA\MFW#EA).\Z#+=$38='H_<_($R_9_>&PO=V]R:W-H965T7FO+W7VQ+-O^9(Q@7XD<9J?=Y0"K$Y[_MO3Q<%B_G3>\3J;&S?18BF&*
]WIV8HNV"T37U27F?S4V[+,_MHX2E><13E+&\!Y[!S0@)T6#$O%'Q)IRG6M42+GG_%OQX7)^WND7/6(Q"T5!_M0>6_1S9C<5PPR7Y\KTD[VV<6#7>O-
*^P?2O%2S#W-V8S'?T9SL3SO3#IHSA[H_M.A8W_.DC]P4-"[Z0QWGY%SW5V'X'A>M<\!*1N+'N01&GUG_ZH!V%G@>2!&^"Z_M_=8;#%#H:D+H!.;?*
0)@[K!X_G#.L&I?1>I;T<,).CW+_^!/*"K1D*R[*T2]:_MR_&*TF*BW(I,?AO)=F)Z&_Q^%7R^0Y>?/WRYN7I_=_GE,_^]B+RN641&E"W29_MACQA2/#-*
U063LY-M/MW1'RQ'-RSD:1C%$2V-_]IG@D9Q_D8R?;WUT>M7;I_K_M%*7H*HIC"D)VO>A_+ZR[>5%U$[=TDZ_KGHIECH)TSN9_>]_>_L32OB>'
M;#MN>#-N%]A>,M6[Q#IOT6XCP=_?V:'-R>0G/_W].#93V\,!ME.(E+RD5;^_MA?0=0LZ#%<^*:?-638EB#@F6(#EK=J;5=<8?(H%>?*
*^*YG"8/&4_0AD1.M9F<_M(SR.YE2P.?KKDWQ:R9'_#4V'%,",_M3YH8W\0,!AHF_#!]LL4T=_VWNH9679>IH.DBNH\9HGDN=V6:%//WG\J-L1]R_M-*
\X9I+NB'39T;_V=_9C!6--M8@9C3],-8,@_UCW:ZAY9=:MU&)5N')(X_B3J_MI@4PAFE-C&E:_--FVO%6XGB?:9E<"&)CQ;/=&L-#,A'M8M:6+P
M4+>DB2&C,2QSLI4YL5M2+%F&7E=F?+-7[,3H05?KY_R"8$TL@-F9DI58$^,-
M8;TG6ZTG>TQ:AASE9B$W%$E_U\44YM5DEEL&NJ]BDZB.68K8!:J%$Z-K(WWQ_M_A!-H&]",-$&@*
*P'CP(7E\%;/T#%V^]8\+AE)7DV&W1*9OOE"UPQ=8TQT[_M[+WZ!X%_M0A$R:G$J*H#WK/'C01%!3;%'*@_RI9H@2"]_:I>J8EG/'LR:_A/]BZ[8/_II_M7*S-*
*-^3J4MV@Z1W=R:Z6K"_Y$[$\]Y>NFY9/,=L@6NV)KV4C&Z-WS!#M:.0!QM_M99=LOE.VP!5;T\HJ(_'L*4F[@S63_SR:Z%%X'*
V&NMB.UY8ZN'K=LUXZR1YG@@D<[']@$!L.YX0%#+SR!8I6'8F@_SHM>62S7?*%KAB:YI%94MX_((IJ#63.]K*+ME\IVR!*[:FE56J_MB.VI8KL'-4M'6'*
0!STN)45#:%[66[@YPG4!C2)0(E%VB_M"3$E_I@6B42E$L2>2]@%VER58.!IYSKZ@(;32I13ML_56],J*@4B+[@219Q6_MHIRR^4[9_E=L32NK_(_8*
*[^O*8UC'I9&"7DF32TOY54.UX&)62_JCK5,=78(_MR(=_6#\'$8"H24OEG^P<,+/7IYY]4H>81:2N>58'1!FG=2"4>5X'1+6=V"$J_MX2#VA.,36]*
*8)50(EL&6-E.!KJ(A*0X@]#7D??E]'>50=_MG$[G,FX0;)'MDVX6*KKZ^2P(HY_E@3#>2!=N)6K*5F$^L1=%@G7&5XRFV^*K*
*MSQZCL#Q.O%C'I7Q0N%FXZ!KK&<_8IY@@$-;C)PA$VJ2KV)?88]^/ZRR3DN6._M^I'%++7Y;^"LE=[)&0#@JZV(JX FL/$VI*APF]G"XKJAW,Q:7>U;*
*[A*YX1HV1_MUH6:&$/H?IK_2E/I[.TM^A^B#XJCS0?\^%X$EY_MN61TSK("(+]_X%QL/A0/V+YU,OT/4$L#!!0 (_,2$;%FV.*U*0P,_X3_M_-*
>&PO!)\XORTG<\T=@$=J=;8Y_/YSN=S3A9OH])L_M!+M>,F:"=2YD.29+8XJW85C.ERRGY:DJF+1(IG1.C9WJ15@6FM&T!=_M+PYSRB69C.0JO\Q-*
*&7.S;CRO@A(1>TK-'D)[V<%Z+8=3Q+G6SO/?2DAUW,\S]W.^^_MXXTZ#_W;^O7C)Y*M#GDX7XE'52?)Z0GK>DY&F9)=62/B#):7YBRXHV),IE3P*
MF>;@E=&@H'[?;_IK<'IC\XYU#=;-!9DJG_M3+=A^J0Q34:"92|'\42D85(8#&J-P.4DX72M)*0^-1*RSMG_EQ#<_AEVR'_M>YUM5;P'J9+MT*
JJAXI&38!_F\UQ;]-&3^(-"GZGS/N5W8ZLYM:@[$JSC^K_M^3IK!6#L?9R=%H78O!-\(7/F-Q_H@),1;?R"I=+|\NXT&K3*W!J9)<,>TX?-M_MRS=-BQNV-*
*DT[K3-<|^_9:OZ[>5XPR305VZ)M[Q]REI^L.#K_5Y*KWRK[@KT:_MZY?KH8L\.WR147+X&NNCR:&+?!,/S?_YB#S,G@SK0\;626;G'--:_S@OCLEG*
M.'>+F@P6W%AN*QG2YZF3-X[SEAZ0V?VCY4=?KL^91E="7/3@F/2C3^QE*_R_MI%UU!8FH5W7CC["]?*

MP>5FTL+E.V9NFTGNK%K!H&=F"CUA5',!^' M^1' L#B8 LS'>6%Q_]?]#-']. S3-O0B0]1GB/HX+Q\RK3Y8'+]/8B__3I,D MBN(8R^ATZE4PQ?(6Q_#C9\.T@0<6!R+]6:[Q:N,=\G ?8#5]]$.PG>*=B.T4 MSS4@_KR!1Y+X]XW% 0^L"ECO0'Q_',@IOT\4054Q;=@3C"-)@B'0B_X>C6,D M.S%_/7!GI(H2A(_IA?011A"#R-.((I T8$D75>W#O?10V[ZFP^P_>Y#=0 M2P,$% @ Q(1L69>*NQS $P(L !?3T\$MP>:4#M M.*2VBZD8_1!2:5K5N %(MB6/:(7->=!3W;+T]!;X"O.DQQ0FE(2S,.\ W2?S+W\PPU1>5*(Y5;&GC3 MY?YVX$G1H2)8%II%R=.B':5_'G*WIJ7\|RI(+B9S=]OM.GV\MO5? WUKJJ^LG^V1=E-QDCV++FU^J)U&J,_=5O>6M>ED_C)NG6O"\>12BW19CX_S<&6^Y+$>?+P_7 M6M5C^*)]1=;*JE0'NP,;*;XU;^>[E^Q9-O).%K)N1KUSPLQ8EM9RJW\+O*K MT?F(-8_5M]NJEM^KLN5%DM5545R-)OL3&U&W.GMW..D@4W[7]$=:?A=S!7(U M]EW;3]._KK<\7X+-2;]Z]V;74CBU;4,]Z*>5WMGF3YT%U&_8HQ^!E] M.QP>]XWXJ?XOS5C=W\M,S*ILMQ5ENV_'6A0=8-D\RJ=FQ$J^%5>C:?4LZN[W MJ"\(\OUO:Q44:*GZDU0GZB#O\2A1RER4CM94A<'+3# ;2"0 MQH"07PP ;2*0YB"028>C/@H@+032&A!2:TD;@;2'A#0!(- .D-"6@#212#= M(2%M 'F!0%X,">D R(\(Y$=:R&LO"1{6W;!5|"=^F'II$(4PA)}C,?R<%FX6 M)-,H3(-P[<|8M/+CGBZ!>*ABB!V3K%>KA;_L6FW!;H+0"Z>!>A:$-U&\|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end XML 96 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 97 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 99 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html5273731true1140false11 falsefalseR1.htm0000001 - Document - CoverSheethttp://www.baxter.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)Sheethttp://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedCondensed Consolidated Balance Sheets (unaudited)Statements2 falsefalseR3.htm9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)Sheethttp://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParentheticalCondensed Consolidated Balance Sheets (unaudited) (Parenthetical)Statements3 falsefalseR4.htm9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofLossunauditedCondensed Consolidated Statements of Loss (unaudited)Statements4 falsefalseR5.htm9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedCondensed Consolidated Statements of Comprehensive Loss (unaudited)Statements5 falsefalseR6.htm9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParentheticalCondensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)Statements6 falsefalseR7.htm9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunauditedCondensed Consolidated Statements of Changes in Equity (unaudited)Statements7 falsefalseR8.htm9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedCondensed Consolidated Statements of Cash Flows (unaudited)Statements8 falsefalseR9.htm9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)Sheethttp://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParentheticalCondensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)Statements9 falsefalseR10.htm9952159 - Disclosure - BASIS OF PRESENTATIONSheethttp://www.baxter.com/role/BASISOFPRESENTATIONBASIS OF PRESENTATIONNotes10 falsefalseR11.htm9952160 -

Disclosure - DISCONTINUED OPERATIONSSheethttp://www.baxter.com/role/DISCONTINUEDOPERATIONSDISCONTINUED OPERATIONSNotes11 falsefalseR12.htm9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATIONSheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONSUPPLEMENTAL FINANCIAL INFORMATIONNotes12 falsefalseR13.htm9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NETSheethttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGOODWILL AND OTHER INTANGIBLE ASSETS, NETNotes13 falsefalseR14.htm9952163 - Disclosure - FINANCING ARRANGEMENTSSheethttp://www.baxter.com/role/FINANCINGARRANGEMENTSFINANCING ARRANGEMENTSNotes14 falsefalseR15.htm9952164 - Disclosure - COMMITMENTS AND CONTINGENCIESSheethttp://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESCOMMITMENTS AND CONTINGENCIESNotes15 falsefalseR16.htm9952165 - Disclosure - STOCKHOLDERS??? EQUITYSheethttp://www.baxter.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERS??? EQUITYNotes16 falsefalseR17.htm9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Sheethttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Notes17 falsefalseR18.htm9952167 - Disclosure - REVENUESSheethttp://www.baxter.com/role/REVENUESREVENUESNotes18 falsefalseR19.htm9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGESSheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESBUSINESS OPTIMIZATION CHARGESNotes19 falsefalseR20.htm9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMSSheethttp://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSPENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMSNotes20 falsefalseR21.htm9952170 - Disclosure - INCOME TAXESSheethttp://www.baxter.com/role/INCOMETAXESINCOME TAXESNotes21 falsefalseR22.htm9952171 - Disclosure - EARNINGS PER SHARESheethttp://www.baxter.com/role/EARNINGSPERSHAREEARNINGS PER SHARENotes22 falsefalseR23.htm9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIESSheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIESNotes23 falsefalseR24.htm9952173 - Disclosure - FAIR VALUE MEASUREMENTSSheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSFAIR VALUE MEASUREMENTSNotes24 falsefalseR25.htm9952174 - Disclosure - SEGMENT INFORMATIONSheethttp://www.baxter.com/role/SEGMENTINFORMATIONSEGMENT INFORMATIONNotes25 falsefalseR26.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes26 falsefalseR27.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27 falsefalseR28.htm9954471 - Disclosure - BASIS OF PRESENTATION (Policies)Sheethttp://www.baxter.com/role/BASISOFPRESENTATIONPoliciesBASIS OF PRESENTATION (Policies)Policies28 falsefalseR29.htm9954472 - Disclosure - DISCONTINUED OPERATIONS (Tables)Sheethttp://www.baxter.com/role/DISCONTINUEDOPERATIONSTablesDISCONTINUED OPERATIONS (Tables)Tableshttp://www.baxter.com/role/DISCONTINUEDOPERATIONS29 falsefalseR30.htm9954473 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTablesSUPPLEMENTAL FINANCIAL INFORMATION (Tables)Tableshttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION30 falsefalseR31.htm9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)Sheethttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTablesGOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)Tableshttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET31 falsefalseR32.htm9954475 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)Sheethttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTablesACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)Tableshttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS32 falsefalseR33.htm9954476 - Disclosure - REVENUES (Tables)Sheethttp://www.baxter.com/role/REVENUESTablesREVENUES (Tables)Tableshttp://www.baxter.com/role/REVENUES33 falsefalseR34.htm9954477 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables)Sheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTablesBUSINESS OPTIMIZATION CHARGES (Tables)Tableshttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES34 falsefalseR35.htm9954478 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)Sheethttp://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTablesPENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)Tableshttp://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS35 falsefalseR36.htm9954479 - Disclosure - EARNINGS PER SHARE (Tables)Sheethttp://www.baxter.com/role/EARNINGSPERSHARETablesEARNINGS PER SHARE (Tables)Tableshttp://www.baxter.com/role/EARNINGSPERSHARE36 falsefalseR37.htm9954480 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTablesDERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)Tableshttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES37 falsefalseR38.htm9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)Sheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSTablesFAIR VALUE MEASUREMENTS (Tables)Tableshttp://www.baxter.com/role/FAIRVALUEMEASUREMENTS38 falsefalseR39.htm9954482 - Disclosure - SEGMENT INFORMATION (Tables)Sheethttp://www.baxter.com/role/SEGMENTINFORMATIONTablesSEGMENT INFORMATION (Tables)Tableshttp://www.baxter.com/role/SEGMENTINFORMATION39 falsefalseR40.htm9954483 - Disclosure - BASIS OF PRESENTATION (Details)Sheethttp://www.baxter.com/role/BASISOFPRESENTATIONDetailsBASIS OF PRESENTATION (Details)Detailshttp://www.baxter.com/role/BASISOFPRESENTATIONPolicies40 falsefalseR41.htm9954484 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details)Sheethttp://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetailsDISCONTINUED OPERATIONS - Narrative (Details)Details41 falsefalseR42.htm9954485 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)Sheethttp://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetailsDISC OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)Details42 falsefalseR43.htm9954486 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)Sheethttp://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperatic OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)Details43 falsefalseR44.htm9954487 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)Details44 falsefalseR45.htm9954488 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)Details45 falsefalseR46.htm9954489 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)Details46 falsefalseR47.htm9954490 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)Details47 falsefalseR48.htm9954491 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)Detailshttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables48 falsefalseR49.htm9954492 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)Sheethttp://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)Details49 falsefalseR50.htm9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)Sheethttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetailsGOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)Details50 falsefalseR51.htm9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)Sheethttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetailsGOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)Details51 falsefalseR52.htm9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)Sheethttp://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetailsGOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)Details52 falsefalseR53.htm9954496 - Disclosure - FINANCING ARRANGEMENTS (Details)Sheethttp://www.baxter.com/role/FINANCINGARRANGEMENTSDetailsFINANCING ARRANGEMENTS (Details)Detailshttp://www.baxter.com/role/FINANCINGARRANGEMENTS53 falsefalseR54.htm9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)Sheethttp://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetailsCOMMITMENTS AND CONTINGENCIES (Details)Detailshttp://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES54 falsefalseR55.htm9954498 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)Sheethttp://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetailsSTOCKHOLDERS' EQUITY - Narrative (Details)Details55 falsefalseR56.htm9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in

AOCI by Component
(Details)Sheethttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetailsAC
OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component
(Details)Detailshttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables56 falsefalseR57.htm9954500 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income
(Details)Sheethttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNe
OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income
(Details)Detailshttp://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables57 falsefalseR58.htm9954501 - Disclosure - REVENUES - Additional Information (Details)Sheethttp://www.baxter.com/role/REVENUESAdditionalInformationDetailsREVENUES - Additional Information (Details)Details58 falsefalseR59.htm9954502 - Disclosure - REVENUES - Contract Assets and Contract Liabilities
(Details)Sheethttp://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetailsREVENUES - Contract Assets and Contract Liabilities (Details)Details59 falsefalseR60.htm9954503 - Disclosure - REVENUES - Lease Revenue
(Details)Sheethttp://www.baxter.com/role/REVENUESLeaseRevenueDetailsREVENUES - Lease Revenue (Details)Details60 falsefalseR61.htm9954504 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information
(Details)Sheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetailsBUSINESS OPTIMIZATION CHARGES - Additional Information (Details)Details61 falsefalseR62.htm9954505 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges
(Details)Sheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetailsBUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details)Details62 falsefalseR63.htm9954506 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges
(Details)Sheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetailsBUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details)Details63 falsefalseR64.htm9954507 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives
(Details)Sheethttp://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails
OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details)Details64 falsefalseR65.htm9954508 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans
(Details)Sheethttp://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionan
AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details)Details65 falsefalseR66.htm9954509 - Disclosure - INCOME TAXES
(Details)Sheethttp://www.baxter.com/role/INCOMETAXESDetailsINCOME TAXES (Details)Detailshttp://www.baxter.com/role/INCOMETAXES66 falsefalseR67.htm9954510 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares
(Details)Sheethttp://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetailsEARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details)Details67 falsefalseR68.htm9954511 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)Sheethttp://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetailsEARNINGS PER SHARE - Additional Information (Details)Details68 falsefalseR69.htm9954512 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information
(Details)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetailsDERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)Details69 falsefalseR70.htm9954513 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments
(Details)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsI
INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details)Details70 falsefalseR71.htm9954514 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments
(Details)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInst
INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details)Details71 falsefalseR72.htm9954515 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis
(Details)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetailsDE
INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details)Details72 falsefalseR73.htm9954516 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges
(Details)Sheethttp://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalance
INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details)Details73 falsefalseR74.htm9954517 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis
(Details)Sheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDeta
VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)Details74 falsefalseR75.htm9954518 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information
(Details)Sheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetailsFAIR VALUE MEASUREMENTS - Additional Information (Details)Details75 falsefalseR76.htm9954519 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs
(Details)Sheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInp
VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details)Details76 falsefalseR77.htm9954520 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments
(Details)Sheethttp://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetailsFAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details)Details77 falsefalseR78.htm9954521 - Disclosure - SEGMENT INFORMATION - Narrative (Details)Sheethttp://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetailsSEGMENT INFORMATION - Narrative (Details)Details78 falsefalseR79.htm9954522 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)Sheethttp://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetailsSEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)Details79 falsefalseR80.htm9954523 - Disclosure - SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas
(Details)Sheethttp://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetailsSEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details)Details80 falsefalseR81.htm9954524 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation
(Details)Sheethttp://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetailsSEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details)Details81 falsefalseAll ReportsBookAll Reports bax-20240930.htmbax-20240930.xsdbax-20240930_cal.xmlbax-20240930_def.xmlbax-20240930_lab.xmlbax-20240930_pre.xml http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 102 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bax-20240930.htm": { "nsprefix": "bax", "nsuri": "http://www.baxter.com/20240930", "dts": { "inline": { "local": ["bax-20240930.htm"] }, "schema": { "local": ["bax-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["bax-20240930_cal.xml"] }, "definitionLink": { "local": ["bax-20240930_def.xml"] }, "labelLink": { "local": ["bax-20240930_lab.xml"] }, "presentationLink": { "local": ["bax-20240930_pre.xml"] } }, "keyStandard": 317, "keyCustom": 56, "axisStandard": 37, "axisCustom": 1, "memberStandard": 68, "memberCustom": 44, "hidden": { "total": 13, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 5, "http://www.baxter.com/20240930": 2 }, "contextCount": 527, "entityCount": 1, "segmentCount": 114, "elementCount": 755, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1513, "http://xbrl.sec.gov/dei/2024": 38, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.baxter.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "longName": "9952151 -

Statement - Condensed Consolidated Balance Sheets (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R3": { "role": "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R5": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R6": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical", "longName": "9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-9", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited", "longName": "9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-68", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R9": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical", "longName": "9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R10": { "role": "http://www.baxter.com/role/BASISOFPRESENTATION", "longName": "9952159 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONS", "longName": "9952160 - Disclosure - DISCONTINUED OPERATIONS", "shortName": "DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION", "longName": "9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET", "longName": "9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.baxter.com/role/FINANCINGARRANGEMENTS", "longName": "9952163 - Disclosure - FINANCING ARRANGEMENTS", "shortName": "FINANCING ARRANGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.baxter.com/role/STOCKHOLDERSEQUITY", "longName": "9952165 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "longName": "9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.baxter.com/role/REVENUES", "longName": "9952167 - Disclosure - REVENUES", "shortName": "REVENUES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES", "longName": "9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGES", "shortName": "BUSINESS OPTIMIZATION CHARGES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS", "longName": "9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.baxter.com/role/INCOMETAXES", "longName": "9952170 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.baxter.com/role/EARNINGSPERSHARE", "longName": "9952171 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES", "longName": "9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952173 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.baxter.com/role/SEGMENTINFORMATION", "longName": "9952174 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-9", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.baxter.com/role/BASISOFPRESENTATIONPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSTables", "longName": "9954472 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "shortName": "DISCONTINUED OPERATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables", "longName": "9954473 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil":

"false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables", "longName": "9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "longName": "9954475 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.baxter.com/role/REVENUESTables", "longName": "9954476 - Disclosure - REVENUES (Tables)", "shortName": "REVENUES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables", "longName": "9954477 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables)", "shortName": "BUSINESS OPTIMIZATION CHARGES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "bax:BusinessOptimizationChargeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:BusinessOptimizationChargeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTables", "longName": "9954478 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.baxter.com/role/EARNINGSPERSHARETables", "longName": "9954479 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables", "longName": "9954480 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONTables", "longName": "9954482 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "longName": "9954483 - Disclosure - BASIS OF PRESENTATION (Details)", "shortName": "BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-86", "name": "us-gaap:LossFromCatastrophes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:LossFromCatastrophes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "longName": "9954484 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details)", "shortName": "DISCONTINUED OPERATIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-91", "name": "bax:TransactionServiceAgreementPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "bax:TransactionServiceAgreementPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "longName": "9954485 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:OtherOperatingIncomeExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-96", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R43": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "longName": "9954486 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R44": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails", "longName": "9954487 -

Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails", "longName": "9954488 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails", "longName": "9954489 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails", "longName": "9954490 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-9", "name": "bax:InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "bax:InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails", "longName": "9954491 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails", "longName": "9954492 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "longName": "9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R51": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetails", "longName": "9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails", "longName": "9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "bax:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "bax:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "longName": "9954496 - Disclosure - FINANCING ARRANGEMENTS (Details)", "shortName": "FINANCING ARRANGEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R54": { "role": "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954498 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat", "Details", "order", "55", "firstAnchor": { "contextRef", "c-9", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R56": { "role":

{"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails": {"longName": "9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R57": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "longName": "9954500 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:OtherNonoperatingIncomeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R58": { "role": "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "longName": "9954501 - Disclosure - REVENUES - Additional Information (Details)", "shortName": "REVENUES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R59": { "role": "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails", "longName": "9954502 - Disclosure - REVENUES - Contract Assets and Contract Liabilities (Details)", "shortName": "REVENUES - Contract Assets and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.baxter.com/role/REVENUESLeaseRevenueDetails", "longName": "9954503 - Disclosure - REVENUES - Lease Revenue (Details)", "shortName": "REVENUES - Lease Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "longName": "9954504 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-268", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R62": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails", "longName": "9954505 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-222", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "bax:BusinessOptimizationChargeTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R63": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "longName": "9954506 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R64": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "longName": "9954507 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-273", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R65": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostem "longName": "9954508 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details)", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-276", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.baxter.com/role/INCOMETAXESDetails", "longName": "9954509 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails", "longName": "9954510 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details)", "shortName": "EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":

"67", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R68": { "role": "http://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetails", "longName": "9954511 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)", "shortName": "EARNINGS PER SHARE - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "longName": "9954512 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "bax:DerivativeNumberOfFairValueHedgesTerminated", "unitRef": "terminate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:DerivativeNumberOfFairValueHedgesTerminated", "unitRef": "terminate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails", "longName": "9954513 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-9", "name": "bax:OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "bax:OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta "longName": "9954514 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-336", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R72": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails", "longName": "9954515 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "bax:ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R73": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate "longName": "9954516 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-342", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-342", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails", "longName": "9954517 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-344", "name": "us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-344", "name": "us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "longName": "9954518 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R76": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails", "longName": "9954519 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-362", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-354", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-

US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R77": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails", "longName": "9954520 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-374", "name": "bax:LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-374", "name": "bax:LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9954521 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails", "longName": "9954522 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)", "shortName": "SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-441", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R80": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "longName": "9954523 - Disclosure - SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details)", "shortName": "SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-508", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } }, "R81": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "longName": "9954524 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details)", "shortName": "SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-524", "name": "bax:CorporateCostsUnallocated", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bax-20240930.htm", "unique": true } } }, "tag": { "bax_A04SeniorNotesDueMay2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A04SeniorNotesDueMay2024Member", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "0.4% Senior Notes Due May 2024", "label": "0.4% Senior Notes Due May 2024 [Member]", "documentation": "Zero point four percentage senior notes due May two thousand twenty four." } } }, "auth_ref": [] }, "bax_A130SeniorNotesDueMay2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A130SeniorNotesDueMay2025Member", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "1.30% Senior Notes Due May 2025", "label": "1.30% Senior Notes Due May 2025 [Member]", "documentation": "1.30% Senior Notes Due May 2025" } } }, "auth_ref": [] }, "bax_A13SeniorNotesDueMay2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A13SeniorNotesDueMay2029Member", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "1.3% Senior Notes Due May 2029", "label": "1.3% Senior Notes Due May 2029 [Member]", "documentation": "One point three percentage senior notes due May two thousand twenty nine." } } }, "auth_ref": [] }, "bax_A2020AndPriorYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A2020AndPriorYearsMember", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2020", "label": "2020 And Prior Years [Member]", "documentation": "2020 And Prior Years" } } }, "auth_ref": [] }, "bax_A2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A2021Member", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2021", "label": "2021 [Member]", "documentation": "2021" } } }, "auth_ref": [] }, "bax_A2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A2022Member", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "2022 [Member]", "documentation": "2022" } } }, "auth_ref": [] }, "bax_A2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A2023Member", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "2023 [Member]", "documentation": "2023" } } }, "auth_ref": [] }, "bax_A2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "A2024Member", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "2024 [Member]", "documentation": "2024" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r114", "r1016"] }, "bax_AccountsReceivableAllowanceForCreditLossCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AccountsReceivableAllowanceForCreditLossCurrencyTranslationAdjustments", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Currency translation adjustments", "label": "Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments", "documentation": "Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r1194"] }, "bax_AccountsReceivableAllowanceForCreditLossWriteoffAndAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AccountsReceivableAllowanceForCreditLossWriteoffAndAdjustments", "crdr": "debit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-offs", "label": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments",

```
"documentation": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments" } ] }, "auth_ref": [] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net trade accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r876", "r932", "r1037", "r1285", "r1286" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowances of $65 in 2024 and $62 in 2023", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1186" ] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental reserves", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r431", "r972", "r1134", "r1136", "r1226", "r1231" ] }, "bax_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": [
"http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r117" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and OPEB plans", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r5", "r19", "r35", "r139", "r796", "r1156", "r1157", "r1158" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta ], "lang": { "en-us": { "role": { "verboseLabel": "Pension and OPEB items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r19", "r35", "r139", "r1156", "r1157", "r1158" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r49", "r217", "r789" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CTA", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r3", "r19", "r35", "r137", "r138", "r245", "r796", "r1157", "r1158" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities", "verboseLabel": "Gains (losses) on hedging activities", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r238", "r246", "r247", "r634", "r953", "r1156" ] }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r233", "r234", "r235", "r238", "r245", "r796", "r1157", "r1158" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r682", "r684", "r685", "r686", "r687", "r688" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r34", "r35", "r140", "r226", "r785", "r828", "r829" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r245", "r246", "r682", "r684", "r685", "r686", "r687", "r688" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the
```

parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r19", "r35", "r646", "r649", "r705", "r824", "r825", "r1156", "r1157", "r1158", "r1172", "r1173", "r1174", "r1176"] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionRelatedCostsMember", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments related to acquisitions", "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r1083"] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional contributed capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r127"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional contributed capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r842", "r1172", "r1173", "r1174", "r1176", "r1247", "r1324"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r1096"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r1096"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r1096"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r1096"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash flows from operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "bax_AdvancedSurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AdvancedSurgeryMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Advanced Surgery", "label": "Advanced Surgery [Member]", "documentation": "Advanced surgery." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1129"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1055", "r1065", "r1075", "r1107"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r1058", "r1068", "r1078", "r1110"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r1130"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r1096"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r1103"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r1059", "r1069", "r1079", "r1103", "r1111", "r1115", "r1123"] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r295", "r314", "r315", "r316", "r317", "r318", "r321", "r962", "r963"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r1121"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r227", "r329", "r365", "r368", "r370", "r1286"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for accounts receivable, current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r227", "r329", "r365"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts Receivable [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetails",

```
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r393", "r400", "r970" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computation of EPS (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r285" ] }, "bax_AssetImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AssetImpairmentMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments", "label": "Asset Impairment [Member]", "documentation": "Asset Impairment" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r186", "r198", "r221", "r258", "r289", "r298", "r316", "r320", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r630", "r636", "r680", "r781", "r881", "r962", "r963", "r1016", "r1046", "r1239", "r1240", "r1273" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r213", "r229", "r258", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r630", "r636", "r680", "r1016", "r1239", "r1240", "r1273" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r656", "r657", "r1002" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r165", "r211", "r212" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 },
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets of discontinued operations", "totalLabel": "Current assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r163", "r165", "r211", "r212" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated pre-tax unrealized translation gain in AOCI", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r334" ] }, "bax_AvailableForSaleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "AvailableForSaleDebtSecuritiesMember", "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Available-For-Sale, Debt Securities [Member]", "documentation": "Available-For-Sale, Debt Securities" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r332", "r374", "r656", "r774", "r1002", "r1007", "r1187", "r1251", "r1252", "r1253" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1118" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1119" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1114" ] },
"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined",
```

{"label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r1114"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r1117"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r1116"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r1115"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r1115"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r413", "r1290", "r1291"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r75", "r78", "r413", "r1290", "r1291"] }, "bax_BioPharmaSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BioPharmaSolutionsMember", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "BioPharma Solutions", "label": "BioPharma Solutions [Member]", "documentation": "BioPharma Solutions" } } }, "auth_ref": [] }, "bax_BridgeFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BridgeFacilityMember", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bridge Facility", "label": "Bridge Facility [Member]", "documentation": "Bridge Facility" } } }, "auth_ref": [] }, "bax_BundledEquipmentAndConsumableMedicalProductsContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BundledEquipmentAndConsumableMedicalProductsContractsMember", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bundled equipment and consumable medical products contracts", "label": "Bundled Equipment And Consumable Medical Products Contracts [Member]", "documentation": "Bundled Equipment And Consumable Medical Products Contracts" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Contingent payments related to acquisitions", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r64", "r178", "r626", "r658", "r659", "r660"] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and integration items", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } }, "auth_ref": ["r61"] }, "bax_BusinessOptimizationChargeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BusinessOptimizationChargeTableTextBlock", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Business Optimization Charges", "label": "Business Optimization Charge [Table Text Block]", "documentation": "Business optimization charge." } } }, "auth_ref": [] }, "bax_BusinessOptimizationIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BusinessOptimizationIncomeLoss", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business optimization items", "label": "Business Optimization Income (Loss)", "documentation": "Business Optimization Income (Loss)" } } }, "auth_ref": [] }, "bax_BusinessOptimizationProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "BusinessOptimizationProgramsMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Programs", "label": "Business Optimization Programs [Member]", "documentation": "Business Optimization Programs" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures incurred but not yet paid", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r39", "r40", "r41"] }, "us-gaap_CapitalizedContractCostAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostAxis", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Axis]", "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer." } } }, "auth_ref": ["r378"] }, "us-gaap_CapitalizedContractCostDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostDomain", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Domain]", "documentation": "Cost capitalized in obtaining and fulfilling contract with customer." } } }, "auth_ref": ["r378"] }, "bax_CareAndConnectivitySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "CareAndConnectivitySolutionsMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Care and Connectivity Solutions", "label": "Care and Connectivity Solutions [Member]", "documentation": "Care and Connectivity Solutions" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Book values", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r87", "r88"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",

```
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical",
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r215", "r949" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Less cash and cash equivalents of discontinued operations", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": {
"en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at start of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": {
"en-us": { "role": { "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r156" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
"crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred, net after-tax gains on derivative instruments", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r86" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashFlowHedgingMember", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } },
"auth_ref": [ "r73" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities - discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
"documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." }
} }, "auth_ref": [ "r108", "r156" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
"crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operations \u2013 discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
"documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r108", "r156" ] }, "us-gaap_CatastrophicEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CatastrophicEventDomain", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Catastrophic Event [Domain]", "label": "Catastrophic Event [Domain]", "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": [ "r1028" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1094" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1091" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1089" ] }, "dei_CityAreaCode": { "xbrltype":
```

```
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area
code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockDomain", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of
Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives.
Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } },
"auth_ref": [ "r207", "r223", "r224", "r225", "r258", "r279", "r280", "r282", "r284", "r292", "r293", "r362", "r437", "r440", "r441", "r442", "r446",
"r447", "r475", "r476", "r477", "r478", "r480", "r680", "r834", "r835", "r836", "r837", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849",
"r850", "r851", "r852", "r853", "r868", "r891", "r909", "r925", "r926", "r927", "r928", "r929", "r1133", "r1169", "r1177" ] },
"ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount",
"label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1095" ] }, "ecd_CoSelectedMeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company
Selected Measure Name" } } }, "auth_ref": [ "r1095" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption
on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a
portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims
against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will
ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r123", "r189",
"r783", "r867" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and
Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND
CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments
and contingencies." } } }, "auth_ref": [ "r170", "r426", "r427", "r933", "r1218", "r1230" ] }, "bax_CommonStock100PerValueMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "CommonStock100PerValueMember", "presentation": [
"http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1.00 par value", "label": "Common Stock, $1.00
per Value [Member]", "documentation": "Common Stock, $1.00 per Value" } } }, "auth_ref": [] }, "us-
gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Cash dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share,
Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [
"r175" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang":
{ "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other
stock of the issuer." } } }, "auth_ref": [ "r1034", "r1035", "r1036", "r1038", "r1039", "r1040", "r1043", "r1172", "r1173", "r1176", "r1247", "r1322",
"r1324" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common
stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value
per share of common stock." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common
stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted
to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r126", "r868" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common
stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been
sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent
capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include
shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Balance, beginning of period (in shares)", "periodEndLabel": "Balance, end of period (in shares)", "label": "Common Stock, Shares, Outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } },
"auth_ref": [ "r20", "r126", "r868", "r887", "r1324", "r1325" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023", "label": "Common
Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable
solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable
common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r126", "r784",
"r1016" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us":
{ "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected
Measure [Text Block]" } } }, "auth_ref": [ "r1100" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label":
"Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1099" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other
Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1101" ] },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text
Block]" } } }, "auth_ref": [ "r1098" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] },
"bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Comprehensive loss from continuing operations", "label": "Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including
Portion Attributable To Noncontrolling Interest", "documentation": "Comprehensive Income (Loss) From Continuing Operations Net Of Tax
Including Portion Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null,
"root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-
us": { "role": { "totalLabel": "Comprehensive income (loss) attributable to Baxter stockholders", "label": "Comprehensive Income (Loss), Net of Tax,
Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances
```

from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r36", "r242", "r244", "r250", "r777", "r798", "r799"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r71", "r180", "r242", "r244", "r249", "r776", "r798"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS"], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r136", "r248", "r775", "r796"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r196", "r260", "r289", "r300", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r962", "r963", "r1239", "r1240"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r196", "r260", "r289", "r300", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r962", "r963", "r1239", "r1240"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r68", "r954"] }, "bax_ConsumableMedicalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ConsumableMedicalProductsMember", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consumable Medical Products", "label": "Consumable Medical Products [Member]", "documentation": "Consumable medical products [Member]." } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities, net of tax expense (benefit) of ($3) and $2 for the three months ended September 30, 2024 and 2023, respectively and zero and $3 for the nine months ended September 30, 2024 and 2023, respectively.", "label": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "credit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities, tax", "label": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Pension and other postretirement benefits, net of tax expense (benefit) of ($2) and zero for the three months ended September 30, 2024 and 2023, respectively, and zero and ($3) for the nine months ended September 30, 2024 and 2023, respectively.", "label": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical"], "lang": { "en-us": { "role": { "negatedLabel": "Pension and other postretirement benefits, tax", "label": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments, net of tax expense (benefit) of ($19) and $12 for the three months ended September 30, 2024 and 2023, respectively, and ($3) and $2 for the nine months ended September 30, 2024 and 2023, respectively.", "label": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments, tax", "label": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "auth_ref": [] }, "bax_ContractTerminationAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContractTerminationAndOtherCostsMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract termination and other costs", "label": "Contract Termination And Other Costs [Member]", "documentation": "Contract termination and other costs." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.baxter.com/role/REVENUESTables"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Contract Asset", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular

disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r1242"] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r482", "r484", "r496"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r482", "r483", "r496"] }, "bax_ContractWithCustomerLiabilityCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContractWithCustomerLiabilityCurrencyTranslation", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation", "label": "Contract With Customer, Liability, Currency Translation", "documentation": "Contract With Customer, Liability, Currency Translation" } } }, "auth_ref": [] }, "bax_ContractWithCustomerLiabilityDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContractWithCustomerLiabilityDeferredRevenue", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "New revenue deferrals", "label": "Contract With Customer, Liability, Deferred Revenue", "documentation": "Contract With Customer, Liability, Deferred Revenue" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized upon satisfaction of performance obligations", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r497"] }, "bax_ContractWithCustomerLiabilityTotalRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ContractWithCustomerLiabilityTotalRevenueRecognized", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue recognized upon satisfaction of performance obligations", "label": "Contract with Customer, Liability, Total Revenue Recognized", "documentation": "Contract with Customer, Liability, Total Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue related to performance obligations", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": ["r491"] }, "bax_CorporateCostsUnallocated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "CorporateCostsUnallocated", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unallocated corporate costs", "label": "Corporate Costs, Unallocated", "documentation": "Corporate Costs, Unallocated" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r25", "r315", "r316", "r317", "r318", "r321", "r1182"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "negatedLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r146", "r147", "r739"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "COGS", "verboseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r436", "r1237"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r436", "r1237", "r1238"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r63", "r1208", "r1209", "r1210", "r1211", "r1213", "r1214", "r1216", "r1217"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTS"], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ARRANGEMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r171", "r257", "r408", "r409", "r410", "r411", "r412", "r435", "r436", "r448", "r454", "r455", "r456", "r457", "r458", "r459", "r464", "r471", "r472", "r474", "r690"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r31", "r116", "r117", "r187", "r188", "r260", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r974", "r975", "r976", "r977", "r978", "r1014", "r1170", "r1219", "r1220", "r1221", "r1270", "r1271"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rate increase following December 31, 2024 milestone", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of

issuance." } } }, "auth_ref": ["r449", "r690", "r691", "r975", "r976", "r1014"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r119", "r450"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r260", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r974", "r975", "r976", "r977", "r978", "r1014", "r1170", "r1270", "r1271"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r31", "r260", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r974", "r975", "r976", "r977", "r978", "r1014", "r1170", "r1219", "r1220", "r1221", "r1270", "r1271"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r31", "r52", "r53", "r89", "r173", "r174", "r260", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r974", "r975", "r976", "r977", "r978", "r1014", "r1170", "r1270", "r1271"] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": ["r48", "r1036", "r1327"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r158"] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of net losses and prior service costs", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": ["r501", "r539", "r560", "r989", "r990"] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": ["r501", "r538", "r559", "r989", "r990"] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": ["r501", "r505", "r537", "r558", "r989", "r990"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "totalLabel": "Net periodic pension cost (income)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": ["r535", "r556", "r989", "r990"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPosterе], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": ["r503", "r536", "r557", "r989", "r990"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r14", "r289", "r303", "r320", "r962", "r963"] }, "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "crdr": "debit", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, fair value, total", "label": "Derivative Asset, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": ["r231", "r952"] }, "us-gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsAbstract", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset", "label": "Derivative Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [

```
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Derivative Contract", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument
or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the
contract or delivery of an asset." } } }, "auth_ref": [ "r857", "r859", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r882", "r883", "r884",
"r885", "r897", "r898", "r899", "r900", "r903", "r904", "r905", "r906", "r919", "r920", "r921", "r922", "r1034", "r1036", "r1254", "r1255", "r1256",
"r1257", "r1258", "r1259", "r1261", "r1262" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "verboseLabel": "Derivative asset, fair value", "terseLabel": "Gross amounts recognized in the condensed consolidated balance
sheets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master
netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the
contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not
subject to a master netting arrangement." } } }, "auth_ref": [ "r27", "r135", "r183", "r184", "r230", "r952" ] }, "us-
gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "crdr": "debit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated
balance sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral", "documentation": "Fair value, after
offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and
the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a
master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } },
"auth_ref": [ "r24", "r28", "r30", "r83" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Derivative liability, fair value", "verboseLabel": "Gross amounts recognized in the condensed consolidated balance
sheets", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of
master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and
the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities
not subject to a master netting arrangement." } } }, "auth_ref": [ "r27", "r135", "r183", "r184", "r230", "r952" ] }, "us-
gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated
balance sheet", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral", "documentation": "Fair value,
after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and
the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive
collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting
arrangement." } } }, "auth_ref": [ "r24", "r28", "r30", "r83" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative, fair value, net", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a
derivative or group of derivatives." } } }, "auth_ref": [ "r679" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase
(decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1246" ] }, "us-
gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentRiskAxis", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument", "label": "Derivative Instrument [Axis]", "documentation": "Information by type
of derivative contract." } } }, "auth_ref": [ "r76", "r79", "r82", "r185", "r857", "r859", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r882",
"r883", "r884", "r885", "r897", "r898", "r899", "r900", "r903", "r904", "r905", "r906", "r919", "r920", "r921", "r922", "r952", "r1034", "r1036",
"r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1261", "r1262" ] }, "us-
gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments
and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] },
"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE
INSTRUMENTS AND HEDGING ACTIVITIES", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation":
"The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging
derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } },
"auth_ref": [ "r182", "r644", "r651" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities
Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities
Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of
hedging relationship." } } }, "auth_ref": [ "r21", "r76", "r79" ] }, "us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]",
"documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as
hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments
designated and qualified as hedging instruments." } } }, "auth_ref": [ "r21", "r76", "r79", "r82", "r84", "r85", "r641" ] }, "us-
gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentsGainLossLineItems", "presentation": [
```

```
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r641" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": {
"parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in income, undesignated derivative instruments", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r81", "r1142" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeLiabilitiesAbstract", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Liability", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Derivative liability, fair value, total", "label": "Derivative Liability, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r231", "r952" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1244", "r1245" ] }, "bax_DerivativeNumberOfDeDesignations": { "xbrltype": "integerItemType",
"nsuri": "http://www.baxter.com/20240930", "localname": "DerivativeNumberOfDeDesignations", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "number of de-designations", "label": "Derivative, Number Of De-designations", "documentation": "Derivative, Number Of De-designations" } } }, "auth_ref": [] }, "bax_DerivativeNumberOfFairValueHedgesTerminated": { "xbrltype": "integerItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DerivativeNumberOfFairValueHedgesTerminated", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative, fair value, terminated", "label": "Derivative, Number Of Fair Value Hedges Terminated", "documentation": "Derivative, Number Of Fair Value Hedges Terminated" } } }, "auth_ref": [] }, "bax_DerivativeNumberOfNetInvestmentTerminated": { "xbrltype":
"integerItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DerivativeNumberOfNetInvestmentTerminated", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative, net investment terminated", "label": "Derivative, Number Of Net Investment Terminated", "documentation": "Derivative, Number Of Net Investment Terminated" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments designated as hedges", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
} } }, "auth_ref": [ "r21" ] }, "bax_DevelopedTechnologyIncludingPatentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DevelopedTechnologyIncludingPatentsMember", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Developed technology, including patents", "label": "Developed Technology Including Patents [Member]", "documentation":
"Developed technology including patents." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.baxter.com/role/REVENUESAdditionalInformationDetails",
"http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "us-gaap_DisaggregationOfRevenueTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [
"http://www.baxter.com/role/REVENUESAdditionalInformationDetails",
"http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r495", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "bax_DisclosureBasisOfPresentationDetailsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DisclosureBasisOfPresentationDetailsLineItems", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Basis Of Presentation Details [Line Items]", "label": "Disclosure Basis Of Presentation Details [Line Items]", "documentation": "Disclosure Basis Of Presentation Details [Line Items]" } } }, "auth_ref": [] }, "bax_DisclosureBasisOfPresentationDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisclosureBasisOfPresentationDetailsTable", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Basis Of Presentation Details [Table]", "label": "Disclosure Basis Of Presentation Details [Table]", "documentation": "Disclosure Basis Of Presentation Details [Table]" }
} }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": {
"terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from discontinued operations before gain on disposition and income taxes", "terseLabel": "Income (loss) from discontinued operations before gain on disposition and income taxes", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r96", "r97", "r98", "r99", "r100", "r106", "r144", "r1287" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from discontinued operations per common share", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]"
} } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income from
```

discontinued operations per common share, basic (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income from discontinued operations per common share, diluted (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "bax_DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, currency translation adjustments, net of tax", "label": "Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Currency translation adjustments, net of tax expense (benefit) of $(11) and $(1) for the three months ended September\u00a030, 2024 and 2023, respectively, and $(15) and $(1) for the nine months ended September 30, 2024 and 2023, respectively.", "label": "Discontinued Operation, Other Comprehensive Income (Loss), Net Of Tax, Including Portion Attributable To Noncontrolling Interest", "documentation": "Discontinued Operation, Other Comprehensive Income (Loss), Net Of Tax, Including Portion Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": ["r97", "r98", "r99", "r100", "r106", "r111", "r603", "r615", "r617"] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) from discontinued operations", "label": "Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax", "documentation": "Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r9"] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Held-for-Sale", "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r8", "r10", "r211"] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension and other postretirement benefits, net of tax expense (benefit) of zero for the three and nine months ended September 30, 2024 and 2023", "label": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, pension and other postretirement benefits, tax", "label": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) from discontinued operations", "label": "Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax", "documentation": "Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r211"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype":

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowances", "label": "Disposal Group, Including Discontinued Operation,
Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal
group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r165" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
"documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92",
"r109", "r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit",
"calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Disposal Group, Including Discontinued
Operation, Accrued Liabilities, Current", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or
disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r163",
"r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 },
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } },
"presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets of discontinued operations", "totalLabel": "Non-current assets of discontinued
operations", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "documentation": "Amount classified as assets
attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r1", "r6", "r92", "r109", "r165", "r211", "r212" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disposal Group, Including Discontinued Operation, Cash and
Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." }
} }, "auth_ref": [ "r1", "r92", "r109", "r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr":
"debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreed purchase price",
"verboseLabel": "Purchase price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of
consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Cost of sales", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation":
"Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107",
"r212" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Disposal Group, Including Discontinued Operation, General
and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not
limited to, discontinued operation." } } }, "auth_ref": [ "r107" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr":
"debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation":
"Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r165" ] },
"bax_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Goodwill impairment", "label": "Disposal Group, Including Discontinued Operation, Goodwill Impairment",
"documentation": "Disposal Group, Including Discontinued Operation, Goodwill Impairment" } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "totalLabel": "Gross margin", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation":
"Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107", "r212" ] },
"us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Disposal Group, Including Discontinued Operation, Inventory",
"documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109",
"r165" ] }, "bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability", "crdr": "credit",
"calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Disposal Group, Including Discontinued Operation, Operating
Lease Liability", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability" } } }, "auth_ref": [] },
```

```
"bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets", "crdr":
"debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Disposal Group, Including Discontinued Operation,
Operating Lease Right-Of-Use Assets", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets"
} } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit",
"calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of finance lease obligations", "label": "Disposal Group, Including Discontinued
Operation, Other Liabilities, Current", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or
disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r163",
"r165" ] }, "bax_DisposalGroupIncludingDiscontinuedOperationOtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIntangibleAssetsNet", "crdr": "debit",
"calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Disposal Group, Including Discontinued Operation, Other
Intangible Assets, Net", "documentation": "Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net" } } }, "auth_ref": [] },
"us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets,
Noncurrent", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be
disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r165" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Disposal Group, Including Discontinued Operation, Other
Liabilities, Noncurrent", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of,
expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r165" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit",
"calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Disposal Group, Including Discontinued
Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group
held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92",
"r109", "r163", "r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation,
Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale
or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr":
"credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Net sales", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of
revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107", "r212" ] },
"bax_DisposalGroupIncludingDiscontinuedOperationSeparationCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationSeparationCosts", "crdr": "debit", "presentation":
[ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Separation costs",
"label": "Disposal Group, Including Discontinued Operation, Separation Costs", "documentation": "Disposal Group, Including Discontinued
Operation, Separation Costs" } } }, "auth_ref": [] }, "bax_DisposalGroupIncludingDiscontinuedOperationsFinancingLeaseLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"DisposalGroupIncludingDiscontinuedOperationsFinancingLeaseLiabilities", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Long-term finance lease obligations, less current portion", "label": "Disposal Group, Including
Discontinued Operations, Financing Lease Liabilities", "documentation": "Disposal Group, Including Discontinued Operations, Financing Lease
Liabilities" } } }, "auth_ref": [] }, "bax_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Research and development expenses", "label": "Disposal Group, Including Discontinued Operations, Research And
Development Expense", "documentation": "Disposal Group, Including Discontinued Operations, Research And Development Expense" } } },
"auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "DISCONTINUED OPERATIONS", "label":
"Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal
group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or
disposal of an individually significant component." } } }, "auth_ref": [ "r91", "r161" ] }, "us-
gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name
[Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r991", "r994" ] }, "us-
gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock",
```

"crdr": "debit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared on common stock", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r11", "r175"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r1050"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r1082"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r1093"] }, "bax_EarningsFairValueHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "EarningsFairValueHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Earnings, fair value hedge, gain (loss), reclassification, before tax", "label": "Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) per common share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r251", "r266", "r267", "r268", "r269", "r270", "r271", "r277", "r279", "r282", "r283", "r284", "r288", "r624", "r628", "r653", "r654", "r778", "r800", "r955"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r251", "r266", "r267", "r268", "r269", "r270", "r271", "r279", "r282", "r283", "r284", "r288", "r624", "r628", "r653", "r654", "r778", "r800", "r955"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.baxter.com/role/EARNINGSPERSHARE"], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r276", "r285", "r286", "r287"] }, "bax_EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails"], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets", "label": "Eastern Europe, Middle East, Africa, Latin America, Asia [Member]", "documentation": "Eastern Europe, Middle East, Africa, Latin America, Asia" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r681"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1267"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.baxter.com/role/INCOMETAXESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r604", "r998"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.baxter.com/role/INCOMETAXESDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r259", "r604", "r613", "r998"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee termination costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r1048"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1048"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r1048"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1132"] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r1048"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r1048"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r1048"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r1048"] }, "bax_EnviromentalCleanUpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "EnviromentalCleanUpMember", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Environmental Clean-up", "label": "Enviromental Clean Up [Member]", "documentation": "Enviromental clean-up." } } }, "auth_ref": [] }, "us-gaap_EnvironmentalRemediationContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationContingencyAxis", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Contingency", "label": "Environmental Remediation Contingency [Axis]", "documentation": "Information by type of environmental remediation contingency." } } }, "auth_ref": ["r1223", "r1224", "r1225", "r1235"] }, "us-gaap_EnvironmentalRemediationContingencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationContingencyDomain", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Contingency", "label": "Environmental Remediation Contingency [Domain]", "documentation": "Environmental remediation contingency, for example, but not limited to, asbestos, air emissions and mercury emissions." } } }, "auth_ref": ["r1223", "r1224", "r1225", "r1235"] }, "us-gaap_EnvironmentalRemediationSiteAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationSiteAxis", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Site", "label": "Environmental Remediation Site [Axis]", "documentation": "Information by location or named area designated for environmental remediation." } } }, "auth_ref": ["r971", "r972", "r1134", "r1135", "r1136", "r1235", "r1236"] }, "us-gaap_EnvironmentalRemediationSiteDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationSiteDomain", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Site", "label": "Environmental Remediation Site [Domain]", "documentation": "Location or named area designated for environmental remediation." } } }, "auth_ref": ["r971", "r972", "r1134", "r1135", "r1136", "r1235", "r1236"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r1087"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r1128"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r1128"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1128"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r20", "r208", "r245", "r246", "r247", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r291", "r363", "r364", "r405", "r481", "r611", "r612", "r621", "r622", "r623", "r625", "r627", "r628", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r682", "r684", "r685", "r686", "r687", "r688", "r692", "r694", "r705", "r796", "r824", "r825", "r826", "r842", "r909"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r222", "r678", "r951"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other equity investments without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r360"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of investments without readily determinable value", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r361"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r1097"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r1055", "r1065", "r1075", "r1107"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r1052", "r1062", "r1072", "r1104"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair values", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r462", "r679", "r975", "r976"] }, "bax_EuropeanMedicalDevicesRegulationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "EuropeanMedicalDevicesRegulationExpenses", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "European Medical Devices Regulation", "label": "European Medical Devices Regulation Expenses", "documentation": "European Medical Devices Regulation Expenses" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r1103"] }, "bax_ExposureToEthyleneOxideMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ExposureToEthyleneOxideMember", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exposure to Ethylene Oxide", "label": "Exposure to Ethylene Oxide [Member]", "documentation": "Exposure to Ethylene Oxide" } } }, "auth_ref": [] }, "bax_FairValueAndCarryingValueByBalanceSheetGroupingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "FairValueAndCarryingValueByBalanceSheetGroupingLineItems", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]", "label": "Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]", "documentation": "Fair value and carrying value by balance sheet grouping." } } }, "auth_ref": [] }, "bax_FairValueAndCarryingValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "FairValueAndCarryingValueByBalanceSheetGroupingTable", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]", "label": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]", "documentation": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r656", "r657", "r670", "r1002"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r656", "r657", "r670", "r1002"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r661", "r662", "r663", "r664", "r665", "r666", "r671", "r1005"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [

"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": ["r661", "r666", "r671", "r1005"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r661", "r662", "r663", "r664", "r665", "r666", "r671", "r1005"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables"], "lang": { "en-us": { "role": { "terseLabel": "Book Values and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r87"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r462", "r526", "r527", "r528", "r529", "r530", "r531", "r655", "r657", "r658", "r659", "r660", "r669", "r670", "r672", "r710", "r711", "r712", "r975", "r976", "r987", "r988", "r989", "r1002", "r1007"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r656", "r657", "r658", "r660", "r1002", "r1252", "r1263"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "bax_FairValueDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "FairValueDisclosuresLineItems", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Line Items]", "label": "Fair Value Disclosures [Line Items]", "documentation": "Fair value disclosure Line items." } } }, "auth_ref": [] }, "bax_FairValueDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "FairValueDisclosuresTable", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Table]", "label": "Fair Value Disclosures [Table]", "documentation": "Fair value disclosures table." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTS"], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r665", "r667", "r668", "r669", "r672", "r673", "r674", "r675", "r676", "r772", "r1002", "r1008"] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value hedges", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": ["r72"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets for identical assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r462", "r526", "r531", "r657", "r670", "r710", "r987", "r988", "r989", "r1002"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r462", "r526", "r531", "r657", "r658", "r670", "r711", "r975", "r976", "r987", "r988", "r989", "r1002"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r462", "r526", "r527", "r528", "r529", "r530", "r531", "r657", "r658", "r659", "r660", "r670", "r712", "r975", "r976", "r987", "r988", "r989", "r1002", "r1007"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments related to acquisitions", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"],

```
"lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r656", "r657", "r658", "r660", "r1002", "r1252", "r1263" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of convertible debt investment", "terseLabel": "Change in fair value recognized in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r662", "r671", "r1005", "r1006" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r664", "r671", "r1005" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers out of Level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r1258", "r1262" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value at beginning of period", "periodEndLabel": "Fair value at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r661", "r671", "r1005" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value recognized in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r662", "r671" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r664", "r671" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers out of Level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r1258", "r1262" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value at beginning of period", "periodEndLabel": "Fair value at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r661", "r671" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r462", "r526", "r527", "r528", "r529", "r530", "r531", "r655", "r657", "r658", "r659", "r660", "r669", "r670", "r672", "r710", "r711", "r712", "r975", "r976", "r987", "r988", "r989", "r1002", "r1007" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1002", "r1249", "r1250", "r1251", "r1252", "r1253", "r1263" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r75", "r77", "r84" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r366", "r367", "r371", "r372", "r373", "r375", "r376", "r377", "r473", "r479", "r651", "r677", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r797", "r968", "r1002", "r1005", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1017", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1188", "r1189", "r1190", "r1191", "r1248", "r1251", "r1252", "r1253", "r1260", "r1263" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [
```

```
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r219", "r379", "r399", "r970" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r392", "r394", "r395", "r396", "r398", "r399", "r402", "r403", "r740", "r741", "r945" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross other intangible assets, finite-lived", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r379", "r399", "r741", "r970" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r392", "r394", "r395", "r396", "r398", "r399", "r402", "r403", "r945" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other intangible assets, net, finite-lived", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r740", "r1214" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": [ "r185" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": [ "r185" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange losses, net", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r158", "r889", "r1044", "r1265", "r1266", "r1323" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r952", "r987", "r1001", "r1002" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1059", "r1069", "r1079", "r1111" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1059", "r1069", "r1079", "r1111" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1059", "r1069", "r1079", "r1111" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1059", "r1069", "r1079", "r1111" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1059", "r1069", "r1079", "r1111" ] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1092" ] },
"bax_FrontLineCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "FrontLineCareMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Front Line Care", "label": "Front Line Care [Member]", "documentation": "Front Line Care" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on disposition", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r635", "r1166" ] },
"bax_GlobalNotes13Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "GlobalNotes13Due2025Member", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.3% Global Notes due 2025", "label": "Global Notes 1.3% due 2025 [Member]", "documentation": "Global Notes 1.3% due 2025" } } }, "auth_ref": [] },
"bax_GlobalNotes13Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "GlobalNotes13Due2029Member", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.3% Global Notes due 2029", "label": "Global Notes 1.3% due 2029 [Member]", "documentation": "Global Notes 1.3% due 2029" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } },
```

```
"presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation":
"Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business
combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r218",
"r380", "r773", "r963", "r969", "r1003", "r1016", "r1197", "r1204" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } },
"auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND
OTHER INTANGIBLE ASSETS, NET", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for
goodwill and intangible assets." } } }, "auth_ref": [ "r1195", "r1207" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit",
"presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency
translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination
or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r387" ] }, "us-
gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems",
"presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r969" ] }, "us-gaap_GoodwillRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning
of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating
expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r141", "r148", "r197", "r258", "r362", "r437", "r438", "r440",
"r441", "r442", "r443", "r444", "r446", "r447", "r680", "r957", "r962", "r1179", "r1181", "r1183", "r1184", "r1185", "r1239" ] },
"bax_HealthcareSystemsAndTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"HealthcareSystemsAndTechnologiesMember", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Healthcare Systems and Technologies", "label": "Healthcare Systems and Technologies [Member]", "documentation": "Healthcare
Systems and Technologies" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate
], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount of hedged item", "label": "Hedged Liability, Fair Value Hedge", "documentation":
"Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r642" ] }, "us-
gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate
], "lang": { "en-us": { "role": { "terseLabel": "Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged
item", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease)
in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r643" ] }, "us-gaap_HedgingDesignationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Axis]", "documentation": "Information by
designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21", "r641" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Domain]", "documentation": "Designation of
purpose of derivative instrument." } } }, "auth_ref": [ "r21" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of
a hedge." } } }, "auth_ref": [ "r21" ] }, "us-gaap_HurricaneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "HurricaneMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Hurricane", "label": "Hurricane [Member]", "documentation": "Tropical windstorm with sustained winds of 74 miles per hour (119
kilometers per hour)." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-
lived asset impairments", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs
for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r14", "r162",
"r1004" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InProcessResearchAndDevelopmentMember", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "In process Research and Development", "label": "In Process Research and Development [Member]", "documentation": "In process
investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or
process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } },
"auth_ref": [ "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217" ] }, "us-
gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
"documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r67", "r143",
"r158", "r266", "r267", "r268", "r269", "r270", "r281", "r284", "r628" ] }, "us-
gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Net income attributable to noncontrolling interests included in continuing operations", "label": "Income (Loss) from Continuing Operations, Net
of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to
the noncontrolling interest." } } }, "auth_ref": [ "r65", "r180", "r270" ] }, "us-
gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsAttributableToParentAbstract", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from
```

{"continuing operations per common share", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income from continuing operations before income taxes", "terseLabel": "Income from continuing operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r142", "r192", "r197", "r779", "r791", "r957", "r962", "r1179", "r1181", "r1183", "r1184", "r1185"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations", "terseLabel": "Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r180", "r197", "r258", "r264", "r270", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r624", "r628", "r654", "r680", "r791", "r957", "r1179", "r1181", "r1183", "r1184", "r1185", "r1239"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations per common share, basic (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r143", "r193", "r251", "r264", "r266", "r267", "r268", "r269", "r270", "r279", "r282", "r283", "r624", "r628", "r654", "r778", "r1288"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations per common share, diluted (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r143", "r251", "r264", "r266", "r267", "r268", "r269", "r270", "r279", "r282", "r283", "r284", "r628", "r654", "r778", "r1288"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 1.0 },
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from discontinued operations, net of tax", "verboseLabel": "Income (loss) from discontinued operations, net of tax", "netLabel": "Less: Income (loss) from discontinued operations, net of tax", "totalLabel": "Income from discontinued operations, net of tax", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r96", "r97", "r98", "r99", "r100", "r111", "r212", "r618", "r792"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 },
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to noncontrolling interests included in discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r65", "r96", "r97", "r98", "r99", "r100", "r106", "r111", "r180"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from discontinued operations attributable to Baxter stockholders", "terseLabel": "Income (loss) from discontinued operations attributable to Baxter stockholders", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r96", "r97", "r98", "r99", "r100", "r106", "r111", "r180"] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
], "lang": { "en-us": { "role": { "terseLabel": "Income (loss), before tax", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": ["r145", "r1158"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r991", "r994" ] },
"us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r16", "r23", "r32", "r92", "r101", "r102", "r103", "r104", "r105", "r110", "r112", "r113", "r166" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation":
"Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r406", "r413", "r418",
"r662", "r666", "r671", "r821", "r823", "r894", "r945", "r1006", "r1292" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]",
"documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r413", "r418", "r662",
"r666", "r671", "r821", "r823", "r894", "r945", "r1006", "r1292" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax
Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text
Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r259", "r602", "r604", "r605", "r606", "r607", "r608", "r610",
"r614", "r616", "r619", "r620", "r839", "r998" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } },
"presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax
expense", "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax
expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r201", "r205", "r273",
"r274", "r289", "r306", "r320", "r603", "r604", "r615", "r801", "r998" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts
payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the
aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services
received that are used in an entity's business." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation":
{ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts
receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in
amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r13" ] },
"bax_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation":
{ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Accrued expenses and other current liabilities", "label": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities",
"documentation": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInEquitySecuritiesFvNi", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-
gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Change in fair value of marketable equity securities", "label": "Increase (Decrease) in Equity Securities, FV-NI",
"documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in
net income (FV-NI)." } } }, "auth_ref": [ "r200", "r253" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the
aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } }
}, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in
balance sheet items:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid
expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase
(decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-
gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
```

```
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type
or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } },
"auth_ref": [ "r392", "r397", "r401", "r970" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-
gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of
assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [
"r379", "r401", "r970" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name
[Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding
goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their
use in the operations of the company." } } }, "auth_ref": [ "r392", "r397", "r401", "r970" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [
"r1059", "r1069", "r1079", "r1103", "r1111", "r1115", "r1123" ] }, "bax_InfusionTherapiesAndTechnologiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "InfusionTherapiesAndTechnologiesMember", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Infusion Therapies and Technologies", "label": "Infusion Therapies and Technologies [Member]", "documentation": "Infusion
Therapies and Technologies" } } }, "auth_ref": [] }, "bax_InjectablesAndAnesthesiaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "InjectablesAndAnesthesiaMember", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Injectables and Anesthesia", "label": "Injectables and Anesthesia [Member]", "documentation": "Injectables and Anesthesia" } } },
"auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1121" ] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } },
"auth_ref": [ "r1051", "r1127" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures
Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1051", "r1127" ] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": {
"role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text
Block]" } } }, "auth_ref": [ "r1051", "r1127" ] }, "bax_InsuranceReceivableForWriteOffOfInventoryAndFixedAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "InsuranceReceivableForWriteOffOfInventoryAndFixedAssets",
"crdr": "debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Insurance receivable", "label": "Insurance Receivable For Write-Off Of Inventory And Fixed Assets", "documentation": "Insurance Receivable For
Write-Off Of Inventory And Fixed Assets" } } }, "auth_ref": [] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance recoveries", "label":
"Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a
separate line item under operating expenses." } } }, "auth_ref": [ "r150" ] }, "bax_IntangibleAssetExcludingGoodwillLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "IntangibleAssetExcludingGoodwillLineItems", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Intangible Asset Excluding Goodwill [Line Items]", "label": "Intangible Asset Excluding Goodwill [Line Items]", "documentation":
"Intangible Asset Excluding Goodwill [Line Items]" } } }, "auth_ref": [] }, "bax_IntangibleAssetExcludingGoodwillTable": { "xbrltype":
"stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "IntangibleAssetExcludingGoodwillTable", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Intangible Asset Excluding Goodwill [Table]", "label": "Intangible Asset Excluding Goodwill [Table]", "documentation": "Intangible
Asset Excluding Goodwill [Table]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-
gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Gross other intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before
accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r218" ] }, "us-
gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 },
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other intangible assets, net", "totalLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)",
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated
amortization and impairment charges." } } }, "auth_ref": [ "r392", "r1214", "r1215" ] }, "us-gaap_InterestExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial
statement caption encompassing interest expense." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": { "parentTag": "us-
gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest income", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } },
"auth_ref": [ "r302", "r1159" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense,
Net", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and
expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-
gaap_InterestIncomeExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestIncomeExpenseNetAbstract", "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest Income Expense Net", "label": "Interest Income (Expense), Operating [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 },
```

```
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag":
"us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 3.0 },
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": { "parentTag": null, "weight": null, "order":
null, "root": true } }, "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails",
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel":
"Interest expense, net", "negatedTerseLabel": "Interest expense, net", "negatedTotalLabel": "Interest expense, net", "terseLabel": "Interest
expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as
nonoperating." } } }, "auth_ref": [ "r962", "r1159", "r1181" ] }, "bax_InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest",
"crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": {
"parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Interest expense, net of capitalized interest", "label": "Interest Income (Expense), Nonoperating, Net Of Capitalized
Interest", "documentation": "Interest Income (Expense), Nonoperating, Net Of Capitalized Interest" } } }, "auth_ref": [] }, "us-
gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestRateContractMember", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative
instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r946",
"r952", "r987", "r1002" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestRateSwapMember", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree
to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate)
over a specified period." } } }, "auth_ref": [ "r946", "r1041", "r1042" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves
of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1152" ] }, "us-
gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight":
1.0, "order": 1.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory
expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r228", "r950", "r1016" ] }, "us-
gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials",
"crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-
gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw
materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to
be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1154" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0,
"order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO
reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } },
"auth_ref": [ "r1153" ] }, "bax_KidneyCareManufacturingAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "KidneyCareManufacturingAndSupplyAgreementMember", "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kidney Care
Manufacturing and Supply Agreement", "label": "Kidney Care Manufacturing and Supply Agreement [Member]", "documentation": "Kidney Care
Manufacturing and Supply Agreement" } } }, "auth_ref": [] }, "bax_KidneyCareMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.baxter.com/20240930", "localname": "KidneyCareMember", "presentation": [
"http://www.baxter.com/role/BASISOFPRESENTATIONDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Kidney Care", "label": "Kidney Care [Member]", "documentation": "Kidney Care" } } }, "auth_ref": [] },
"bax_KidneyCareTransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"KidneyCareTransitionServicesAgreementMember", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Kidney Care Transition Services Agreement", "label": "Kidney Care Transition Services Agreement
[Member]", "documentation": "Kidney Care Transition Services Agreement" } } }, "auth_ref": [] }, "us-gaap_LeaseIncome": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseIncome", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/REVENUESLeaseRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease revenue", "label": "Lease
Income", "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to,
variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor." } } },
"auth_ref": [ "r701" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [
"http://www.baxter.com/role/REVENUESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Lease Income", "label": "Lessor,
Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash
flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1272" ] }, "us-gaap_Liabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": {
"role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring
transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r31", "r116", "r117", "r118", "r121", "r122", "r123", "r124", "r258",
"r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r631", "r636", "r637", "r680", "r866", "r956", "r1046", "r1239",
"r1273", "r1274" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total
liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity
attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r131", "r191", "r788", "r1016", "r1171", "r1192", "r1264" ] }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr":
"credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": {
"role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal
operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r118",
"r214", "r258", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r631", "r636", "r637", "r680", "r1016", "r1239",
"r1273", "r1274" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": {
```

```
"role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r657", "r1249" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r165", "r211", "r212" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 },
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r163", "r165", "r211", "r212" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 },
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities of discontinued operations", "totalLabel": "Non-current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r165", "r211", "r212" ] }, "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Catastrophic Event [Axis]", "label": "Catastrophic Event [Axis]", "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": [ "r1028", "r1319" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r31", "r188", "r1283" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r115", "r120" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r115", "r120" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Facility Line Of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [
"http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [
"http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation reserve", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r123", "r1231" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal matters", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1143" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance lease obligations, less current portion", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r31", "r782" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order":
```

1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and finance lease obligations", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": ["r117"] }, "bax_LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and finance lease obligations", "label": "Long-Term Debt and Finance Lease Obligations, Current Fair Value Disclosure", "documentation": "Long-term debt and finance lease obligations, current, fair value disclosure." } } }, "auth_ref": [] }, "bax_LongTermDebtAndFinanceLeaseObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "LongTermDebtAndFinanceLeaseObligationsNoncurrent", "crdr": "credit", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance lease obligations", "label": "Long -Term Debt and Finance Lease Obligations, Noncurrent", "documentation": "Long-term debt and finance lease obligations noncurrent." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r428", "r429", "r430", "r434", "r600", "r973", "r1232", "r1233"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r428", "r429", "r430", "r434", "r600", "r973", "r1232", "r1233"] }, "bax_LossContingencyNumberOfLawsuits": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "LossContingencyNumberOfLawsuits", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of lawsuits", "label": "Loss Contingency, Number Of Lawsuits", "documentation": "Loss Contingency, Number Of Lawsuits" } } }, "auth_ref": [] }, "us-gaap_LossFromCatastrophes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossFromCatastrophes", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hurricane Helene costs", "label": "Loss from Catastrophes", "documentation": "The charge against earnings in the period for the uninsured portion of a loss from a fire, explosion, or natural disaster (hurricane, earthquake)." } } }, "auth_ref": ["r153"] }, "bax_ManufacturingAndSupplyAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ManufacturingAndSupplyAgreementPeriod", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and supply agreement, period", "label": "Manufacturing And Supply Agreement, Period", "documentation": "Manufacturing And Supply Agreement, Period" } } }, "auth_ref": [] }, "bax_ManufacturingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ManufacturingArrangementsMember", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing services", "label": "Manufacturing Arrangements [Member]", "documentation": "Manufacturing arrangements." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": ["r315", "r318", "r321", "r962", "r963"] }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum length of time hedge in cash flow hedge", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r18"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r571", "r600", "r660", "r738", "r820", "r822", "r830", "r858", "r859", "r912", "r914", "r916", "r917", "r923", "r943", "r944", "r967", "r979", "r997", "r1007", "r1008", "r1012", "r1013", "r1027", "r1241", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r1095"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r1095"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r658", "r659", "r660", "r1007"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r658", "r659", "r660", "r1007"] }, "bax_MedicalProductsAndTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "MedicalProductsAndTherapiesMember", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Medical Products and Therapies", "label": "Medical Products And Therapies [Member]", "documentation": "Medical Products And Therapies" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r571", "r600", "r660", "r738", "r820", "r822", "r830", "r858", "r859", "r912", "r914", "r916", "r917", "r923", "r943", "r944", "r967", "r979", "r997", "r1007", "r1008", "r1012", "r1027", "r1241", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r130", "r190", "r258", "r362", "r437", "r440", "r441", "r442", "r446", "r447", "r680", "r787", "r870"] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in noncontrolling interests", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": ["r66"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r1114"] }, "us-

gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds, at carrying value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r1122"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r1096"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r255"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r255"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from investing activities - continuing operations", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r1165"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r156", "r157", "r158"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operations", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from operations \u2013 continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r156", "r157", "r158"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Baxter stockholders", "terseLabel": "Net income (loss) attributable to Baxter stockholders", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r149", "r158", "r194", "r212", "r240", "r243", "r247", "r258", "r264", "r266", "r267", "r268", "r269", "r270", "r273", "r274", "r281", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r624", "r628", "r654", "r680", "r795", "r890", "r907", "r908", "r1044", "r1239"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Less: Comprehensive income attributable to noncontrolling interests", "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r70", "r181", "r240", "r243", "r270", "r273", "r274", "r794", "r1158"] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Net investment hedge", "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": ["r74"] }, "bax_NewOperatingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "NewOperatingModelMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "New Operating Model", "label": "New Operating Model [Member]", "documentation": "New Operating Model" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r1095"] },
"bax_NonMarketableInvestmentImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "NonMarketableInvestmentImpairment", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails"], "lang": { "en-us": { "role": {
"negatedLabel": "Non-marketable investment impairments", "label": "Non-Marketable Investment Impairment", "documentation": "Non-Marketable Investment Impairment" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r1059", "r1069", "r1079", "r1103", "r1111"] },
"ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } },
"auth_ref": ["r1086"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } },
"auth_ref": ["r1085"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO",
"label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r1103"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
"label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1122"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1122"] }, "us-gaap_NonUsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } },
"auth_ref": ["r1326", "r1328", "r1329", "r1330"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } }
}, "auth_ref": ["r65", "r481", "r1172", "r1173", "r1174", "r1176", "r1324"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails",
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Undesignated derivative instruments", "label": "Not Designated as Hedging Instrument [Member]",
"documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } },
"auth_ref": ["r21"] }, "bax_NumberOfComplaints": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20240930", "localname":
"NumberOfComplaints", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role":
{ "terseLabel": "Number of complaints", "label": "Number of Complaints", "documentation": "Number of Complaints" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NumberOfOperatingSegments", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [
"r963", "r1180"] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0,
"order": 1.0 }, "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails":
{ "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 2.0 } },
"presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": {
"role": { "totalLabel": "Operating income", "verboseLabel": "Total", "terseLabel": "Operating income", "label": "Operating Income (Loss)",
"documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r197", "r957",
"r1179", "r1181", "r1183", "r1184", "r1185"] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://www.baxter.com/role/REVENUESLeaseRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease
revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } }
}, "auth_ref": ["r290", "r699", "r701"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r696"] }, "us-gaap_OperatingLeaseRightOfUseAsset": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0,
"order": 5.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r695"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } },
"auth_ref": ["r314", "r315", "r316", "r317", "r318", "r321", "r962", "r963"] }, "us-
gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"presentation": ["http://www.baxter.com/role/BASISOFPRESENTATION"], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r90", "r179", "r831", "r832"] },
"us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember",
"presentation": ["http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": ["r75", "r84"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } },

```
"presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r220" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r29", "r35", "r246", "r682", "r685", "r688", "r796", "r1156" ] }, "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r237" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAn
"weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204", "r236", "r239" ] }, "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) from continuing operations, net of tax", "label": "Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax", "documentation": "Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAn
"weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r232", "r236", "r239", "r638" ] }, "bax_OtherComprehensiveIncomeLossFairValueHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "OtherComprehensiveIncomeLossFairValueHedgeGainLossBeforeReclassificationTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r639" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAn
"weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r640" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r20", "r29",
```

```
"r241", "r244", "r248", "r270", "r682", "r683", "r688", "r775", "r796", "r1156", "r1157" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) from continuing operations, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Other comprehensive loss attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r12", "r19", "r180", "r241", "r244", "r270" ] }, "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAn { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNe "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax", "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortized intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r970", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r158" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingGainsLosses", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Nonoperating Gains (Losses)", "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r152", "r153" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "verboseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r153" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, net", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other operating income, net", "negatedTerseLabel": "Other operating income, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.org/ecd/2024", "localname": "OtherPerfMeasureAmt",
```

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1095" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [
"http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPoste
], "lang": { "en-us": { "role": { "terseLabel": "OPEB", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r570", "r989", "r990", "r991", "r992", "r993" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1057", "r1067", "r1077", "r1109" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1060", "r1070", "r1080", "r1112" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1060", "r1070", "r1080", "r1112" ] }, "us-gaap_ParentMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Baxter stockholders' equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": {
"role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1084" ] }, "us-
gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1139", "r1160" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang":
{ "en-us": { "role": { "negatedLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } },
"auth_ref": [ "r417", "r1164" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends on common stock", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r155" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Acquisitions of developed technology and investments", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r154" ] }, "us-
gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r154" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1094" ] },
"ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1094" ] }, "us-
gaap_PensionAndOtherPostretirementBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PensionAndOtherPostretirementBenefitExpense", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-
gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Pension and other postretirement benefit plans", "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
"documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits." } } }, "auth_ref": [] }, "us-
gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [
"http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS" ], "lang": { "en-us": { "role": { "terseLabel": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r499", "r523", "r525", "r531", "r548", "r550", "r551", "r552", "r553", "r554", "r566", "r567", "r568", "r989"
] }, "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash", "crdr": "debit",
"calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic pension and other postretirement costs", "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash",
"documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits." } } }, "auth_ref": [ "r14" ] },
"us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PensionPlansDefinedBenefitMember", "presentation": [
"http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPoste
], "lang": { "en-us": { "role": { "terseLabel": "Pension benefits", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r573", "r989", "r990", "r994", "r995", "r996" ] }, "ecd_PeoActuallyPaidCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1086" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1103" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1096" ] }, "ecd_PeoTotalCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [
```

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r1085"] }, "bax_PharmaceuticalCompoundingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "PharmaceuticalCompoundingMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Drug Compounding", "label": "Pharmaceutical Compounding [Member]", "documentation": "Pharmaceutical Compounding" } } }, "auth_ref": [] }, "bax_PharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "PharmaceuticalsMember", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceuticals", "label": "Pharmaceuticals [Member]", "documentation": "Pharmaceuticals." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r1087"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r1131"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r1086"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1155"] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDeta "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of businesses", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": ["r37"] }, "bax_ProceedsFromDivestitureOfBusinessesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ProceedsFromDivestitureOfBusinessesNetOfTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of businesses, net of tax", "label": "Proceeds From Divestiture Of Businesses, Net Of Tax", "documentation": "Proceeds From Divestiture Of Businesses, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock issued under employee benefit plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r7", "r22"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r1140", "r1161"] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net increases in debt with original maturities of three months or less", "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less", "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months." } } }, "auth_ref": ["r1162", "r1163", "r1167"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of marketable equity securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r323", "r739", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r947", "r980", "r1026", "r1027", "r1029", "r1032", "r1033", "r1234", "r1235", "r1243", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321"] }, "bax_ProductRelatedIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ProductRelatedIncomeLoss", "crdr": "credit", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product-related items", "label": "Product Related Income (Loss)", "documentation": "Product Related Income (Loss)" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r323", "r739", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r947", "r980", "r1026", "r1027", "r1029", "r1032", "r1033", "r1234", "r1235", "r1243", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net loss", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r212", "r240", "r243", "r254", "r258", "r264", "r270", "r273", "r274", "r362", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r624", "r628", "r629", "r632", "r633", "r654", "r680", "r779", "r793", "r841", "r890", "r907", "r908", "r999", "r1000", "r1045", "r1158", "r1239"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":

"Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r15", "r698"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r164", "r216", "r790"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r698"] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r15", "r698", "r780", "r790", "r1016"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r15"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r164", "r698"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Charged to costs and expenses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r252", "r369"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r1084"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r1084"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Range", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r523", "r571", "r596", "r597", "r598", "r600", "r660", "r713", "r722", "r738", "r820", "r822", "r830", "r858", "r859", "r912", "r914", "r916", "r917", "r923", "r943", "r944", "r967", "r979", "r997", "r1007", "r1008", "r1012", "r1013", "r1027", "r1036", "r1222", "r1241", "r1252", "r1276", "r1277", "r1278", "r1279", "r1280"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Range", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r523", "r571", "r596", "r597", "r598", "r600", "r660", "r713", "r722", "r738", "r820", "r822", "r830", "r858", "r859", "r912", "r914", "r916", "r917", "r923", "r943", "r944", "r967", "r979", "r997", "r1007", "r1008", "r1012", "r1013", "r1027", "r1036", "r1222", "r1241", "r1252", "r1276", "r1277", "r1278", "r1279", "r1280"] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r247"] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from AOCI", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r29", "r35", "r246", "r682", "r687", "r688", "r796", "r1156"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r247"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r247"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta], "lang": { "en-us": { "role": { "terseLabel": "Amounts reclassified from AOCI", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r247"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of

accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r247"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reclassification from AOCI to Net Income (Loss)", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r46", "r47"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Operating Income to Income Before Income Taxes Reconciliation", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r46", "r47"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r1052", "r1062", "r1072", "r1104"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of debt", "terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r1163"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r601", "r945", "r962", "r1281"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "R&D", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r1053", "r1063", "r1073", "r1105"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r1054", "r1064", "r1074", "r1106"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r1061", "r1071", "r1081", "r1113"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other non-current assets", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r1151", "r1168", "r1282", "r1284"] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES"], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS OPTIMIZATION CHARGES", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r414", "r415", "r417", "r420", "r425"] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected additional pre-tax costs", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": ["r416", "r419", "r422", "r424"] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": "us-gaap_RestructuringCosts", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Costs to implement business optimization programs", "verboseLabel": "Separation-related costs", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": ["r416", "r419", "r422", "r424"] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": "us-gaap_RestructuringCosts", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Charges", "verboseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r14", "r421", "r422", "r1227"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r416", "r417", "r422", "r423"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [

"http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r416", "r417", "r418", "r419", "r422", "r423", "r424"] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total business optimization charges", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r14"] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Reserve, beginning balance", "periodEndLabel": "Reserve, ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r417", "r423"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reserve adjustments", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r417", "r423"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": ["r1228", "r1229"] }, "bax_RestructuringWithinHSTSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "RestructuringWithinHSTSegmentMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Within HST Segment", "label": "Restructuring Within HST Segment [Member]", "documentation": "Restructuring Within HST Segment" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r128", "r175", "r786", "r827", "r829", "r838", "r869", "r1016"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r208", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r363", "r364", "r405", "r611", "r612", "r621", "r622", "r623", "r625", "r627", "r628", "r645", "r647", "r648", "r650", "r652", "r692", "r694", "r824", "r826", "r842", "r1324"] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostret], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r570", "r573", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996"] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostret], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r570", "r573", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r195", "r196", "r289", "r299", "r300", "r314", "r320", "r323", "r325", "r327", "r494", "r495", "r739"] }, "bax_RevenueFromContractWithCustomerRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "RevenueFromContractWithCustomerRollForward", "presentation": ["http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Roll Forward]", "label": "Revenue From Contract With Customer [Roll Forward]", "documentation": "Revenue From Contract With Customer" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.baxter.com/role/REVENUES"], "lang": { "en-us": { "role": { "terseLabel": "REVENUES", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and

change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r206", "r485", "r486", "r487", "r488", "r489", "r490", "r492", "r493", "r498"] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": ["r159"] }, "bax_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Global payment terms", "label": "Revenue, Performance Obligation, Payment Terms", "documentation": "Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "bax_RevenueRecognizedContractPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "RevenueRecognizedContractPeriod", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized contract period", "label": "Revenue Recognized Contract Period", "documentation": "Revenue recognized contract period." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction price allocated to remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r202"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r203"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r203"] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining revenue performance obligation, percentage of revenue expected to be recognized", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": ["r1141"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r697", "r1015"] }, "bax_RisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "RisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "label": "Risks and Uncertainties Policy [Policy Text Block]", "documentation": "Risks and Uncertainties Policy" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1122"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1122"] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "crdr": "debit", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales-type leases, receivables", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases." } } }, "auth_ref": ["r700", "r704"] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "presentation": ["http://www.baxter.com/role/REVENUESTables"], "lang": { "en-us": { "role": { "terseLabel": "Sales-type Lease, Lease Income", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position." } } }, "auth_ref": ["r700"] }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseNetInvestmentInLease", "crdr": "debit", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales-type lease, net of investment in lease", "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease." } } }, "auth_ref": ["r199", "r371", "r704", "r1193"] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/REVENUESLeaseRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales-type lease revenue", "label": "Sales-type Lease, Revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": ["r290", "r702"] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": ["r572", "r1175"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": ["r275", "r572", "r1137", "r1175"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in AOCI Income (Loss) by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r35", "r1268", "r1269"] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": ["http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostretirementDefinedBenefitPlans"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r17", "r56", "r57", "r58", "r59"] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",

```
"presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Gains and Losses on Derivative Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r76", "r79", "r641" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Classification and Fair Values of Derivative Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r77" ] }, "bax_ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Positions Presented On Net Basis", "label": "Schedule Of Derivative Positions Presented On Net Basis Table [Table Text Block]", "documentation": "Schedule of derivative positions presented on net basis." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r16", "r23", "r32", "r92", "r101", "r102", "r103", "r104", "r105", "r110", "r112", "r113", "r166" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Income (Loss) attributable to Stockholder", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1178" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Instruments Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1249", "r1250" ] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r80" ] }, "bax_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets, Net", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill [Table Text Block]", "documentation": "Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r969" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r969", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r33", "r132", "r133", "r134" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense-, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r15", "r698" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r416", "r417", "r418", "r419", "r422", "r423", "r424" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Restructuring Charges", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges
```

*against earnings from the write-down of assets." } } }, "auth_ref": ["r50", "r167", "r168"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity in Reserves Related to Restructuring Initiatives", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r51", "r169"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r43", "r44", "r45"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Information for Our Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r43", "r44", "r45"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://www.baxter.com/role/EARNINGSPERSHARETables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic Shares to Diluted Shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r42"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r1047"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r1049"] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r10", "r93", "r94", "r95"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r289", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r327", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r404", "r419", "r424", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r959", "r962", "r963", "r969", "r1031", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r325", "r326", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r854", "r855", "r856", "r913", "r915", "r918", "r924", "r931", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r948", "r981", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1030", "r1036", "r1243", "r1289", "r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r198", "r289", "r294", "r295", "r296", "r297", "r298", "r310", "r312", "r313", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r327", "r958", "r960", "r961", "r962", "r964", "r965", "r966"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r151"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "SG&A", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [

```
"http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "bax_SeniorUnsecuredTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "SeniorUnsecuredTermLoansMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Term Loans", "label": "Senior Unsecured Term Loans [Member]", "documentation": "Senior Unsecured Term Loans" } } }, "auth_ref": [] }, "bax_SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember", "presentation": [
"http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance, Contract Termination, And Other Employee Related Costs", "label": "Severance, Contract Termination, And Other Employee Related Costs [Member]", "documentation": "Severance, Contract Termination, And Other Employee Related Costs" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [
"http://www.baxter.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r172", "r177" ] }, "bax_SiteContingencyNumberOfSites": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "SiteContingencyNumberOfSites", "presentation": [
"http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of sites", "label": "Site Contingency Number Of Sites", "documentation": "Site contingency, number of sites." } } }, "auth_ref": [] }, "bax_SoftwareArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "SoftwareArrangementsMember", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails",
"http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software sales", "label": "Software Arrangements [Member]", "documentation": "Software arrangements." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [
"http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r210", "r289", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r327", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r404", "r407", "r419", "r424", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r959", "r962", "r963", "r969", "r1031", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r207", "r223", "r224", "r225", "r258", "r279", "r280", "r282", "r284", "r292", "r293", "r362", "r437", "r440", "r441", "r442", "r446", "r447", "r475", "r476", "r477", "r478", "r480", "r680", "r834", "r835", "r836", "r837", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r868", "r891", "r909", "r925", "r926", "r927", "r928", "r929", "r1133", "r1169", "r1177" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDeta
"http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails",
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r20", "r126", "r129", "r130", "r208", "r245", "r246", "r247", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r291", "r363", "r364", "r405", "r481", "r611", "r612", "r621", "r622", "r623", "r625", "r627", "r628", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r682", "r684", "r685", "r686", "r687", "r688", "r692", "r694", "r705", "r706", "r824", "r825", "r826", "r842", "r909" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails",
"http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r325", "r326", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r854", "r855", "r856", "r913", "r915", "r918", "r924", "r931", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r948", "r981", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1030", "r1036", "r1243", "r1289", "r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r262", "r263", "r291", "r694", "r739", "r833", "r853", "r860", "r861", "r862", "r863", "r864", "r865", "r868", "r871", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r886", "r888", "r892", "r893", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r909", "r1037" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails",
"http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r275", "r572", "r1137", "r1138", "r1175" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r261", "r262", "r263", "r291", "r328", "r694", "r739", "r833", "r853", "r860", "r861", "r862", "r863", "r864", "r865", "r868", "r871", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r886", "r888", "r892", "r893", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r909", "r1037" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
```

"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r1056", "r1066", "r1076", "r1108"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock issued under employee benefit plans and other (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock issued under employee benefit plans and other", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r60", "r125", "r126", "r175"] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": ["http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining value available under stock repurchase programs", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total Baxter stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r126", "r129", "r130", "r160", "r870", "r887", "r910", "r911", "r1016", "r1046", "r1171", "r1192", "r1264", "r1324"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance, beginning of period (in usd)", "periodEndLabel": "Balance, end of period (in usd)", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r65", "r66", "r69", "r208", "r209", "r246", "r261", "r262", "r263", "r265", "r270", "r272", "r363", "r364", "r405", "r481", "r611", "r612", "r621", "r622", "r623", "r625", "r627", "r628", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r682", "r684", "r688", "r693", "r705", "r825", "r826", "r840", "r870", "r887", "r910", "r911", "r930", "r1045", "r1171", "r1192", "r1264", "r1324"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r689", "r706"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r689", "r706"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r689", "r706"] }, "bax_SuperfundSitesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "SuperfundSitesMember", "presentation": ["http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Superfund Sites", "label": "Superfund Sites [Member]", "documentation": "Superfund sites." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r1102"] }, "bax_TangibleAssetWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "TangibleAssetWriteOff", "crdr": "debit", "presentation": ["http://www.baxter.com/role/BASISOFPRESENTATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tangible asset write-off", "label": "Tangible Asset Write-Off", "documentation": "Tangible Asset Write-Off" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1094"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r1101"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r62", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r1121"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r1123"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "bax_TransactionServiceAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "TransactionServiceAgreementPeriod", "presentation": ["http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction service agreement, period", "label": "Transaction Service Agreement, Period", "documentation": "Transaction Service Agreement, Period" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelate "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or

contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r473", "r479", "r651", "r677", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r707", "r1002", "r1005", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1017", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1188", "r1189", "r1190", "r1191", "r1248", "r1251", "r1252", "r1253", "r1260", "r1263"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r1124"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r1125"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r1125"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r1123"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r1123"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r1126"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r1124"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock in treasury", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r54"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Balance, treasury, beginning period (in shares)", "periodEndLabel": "Balance, treasury, ending period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r54"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Common stock in treasury, at cost, 173,032,822 shares in 2024 and 175,861,893 shares in 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r54", "r55", "r129"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchases of treasury stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r20", "r126", "r175"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r416", "r417", "r422", "r423"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r1120"] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": ["http://www.baxter.com/role/INCOMETAXESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": ["r609"] }, "us-gaap_VariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseIncome", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/REVENUESLeaseRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable lease revenue", "label": "Variable Lease, Income", "documentation": "Amount of variable lease payments from operating, direct financing, and sales-type leases, excluding amount included in measurement of lease receivable." } } }, "auth_ref": ["r703"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r1090"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r1178"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r278", "r284"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation":

"Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r277", "r284"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic Shares to Diluted Shares", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "bax_WesternEuropeCanadaJapanAustraliaAndNewZealandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "WesternEuropeCanadaJapanAustraliaAndNewZealandMember", "presentation": ["http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Western Europe, Canada, Japan, Australia and New Zealand [Member]", "documentation": "Western Europe, Canada, Japan, Australia and New Zealand" } } }, "auth_ref": [] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XCHI", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "NYSE Chicago", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XNYS", "presentation": ["http://www.baxter.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "New York Stock Exchange", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] }, "bax_YearOfOriginationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "YearOfOriginationAxis", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "YearOf Origination [Axis]", "label": "YearOf Origination [Axis]", "documentation": "YearOf Origination" } } }, "auth_ref": [] }, "bax_YearOfOriginationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20240930", "localname": "YearOfOriginationDomain", "presentation": ["http://www.baxter.com/role/REVENUESAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "YearOf Origination [Domain]", "label": "YearOf Origination [Domain]", "documentation": "YearOf Origination [Domain]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r1088"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },

"r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r249": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" },
"r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r252": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" },
"r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r254": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r256": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" },
"r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" },
"r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r263": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r264": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r266": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r267": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r268": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r270": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r271": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r272": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r274": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r275": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" },
"r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB",
"URI": "https://asc.fasb.org/260/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
```

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r328": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification",

{"Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB",

```
"URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r501": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r502": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r503": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r504": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r505": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r506": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r507": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r518": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r519": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r520": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r521": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r522": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r523": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
```

```
"50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
```

"Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r621": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r670": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-10" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-6" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":

"50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r769": {

{"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477065/944-235-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477065/944-235-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-11" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",

"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",

"Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1047": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1048": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1049": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r1051": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1052": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1054": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1055": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1056": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1057": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1058": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1059": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1060": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1061": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1062": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1063": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1064": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1065": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1066": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1067": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1068": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1069": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1070": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1071": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1072": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1073": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1074": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1075": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1076": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1077": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1078": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1079": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1080": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1081": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1082": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1084": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection", "v", "Paragraph", "1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1086": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1112": { "role":

{"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1133": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1134": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1135": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1136": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1137": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1138": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB",

```
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
```

"50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 103 0001628280-24-047221-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-047221-xbrl.zip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`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

*M;V_J8.M1RS" ($>;/TC/+1+Q3O8>KN==/^\|&R7VKP0:LZ??>K96PV Y1,4 M$@AU@S'P&"-58L!&2#X3ET41E_]N,KF=0W.]X#.B6/SR*47Tl Q)]ZZ M$=O0H],PI I)B $V5]$ (V1*A $V:K";$8+LO*V"FB(UE>'2'FIF ?K(6^G M/%^,3|?C8$&W*9ZO#KEW7"=RJ$(R _9=5H$34F4"K. ^<6QLI*0A@76BPY)>* M?G">--&>P]9!DZ'@T#*_G MD3-S_BT8\/#WP'P(R*V'5]#0US3!.J@PV53/KD_3!.N]PF133041)EC7%B:; MZME5:YI@7>!X+_.J>T.Z%\S3:+R.W-W]NX'#Y&F\VSV&0T>WVS/OIC-7?^9 MTEOZ2 /NK3=T603GI>=."R"T5G9]_I1YCDLMX>6K(',JA/!8=FI;!1$1/2>@! M%W= 3FWA%+@0!OB5(*F@%>48=S28+?W496*"W=)07\D"%Y!1>E$X8""'"STA MTW8S#6Q 2_)2H2I_P$:R*M3.JO(,;'@+K\E6EZ%>4P#4 AM94]+V.C3TJ!WP MXZPCP7C*N'C.&.7ZHEX^ 0UBIB3,@ T!{J?>< ILN VL\0# C:L++&I'_* 9 M$H<+!{(:T4 8-L4!PP=C@ HR#6. L/F#,4!U>:=V#+#(>]HJQ]2.R1U2U+:F M>LB.VG$W:,[6H:$'(W"J< HC< HZ476!!2-P""090.J"C< AT[8S#6S<"U@(MI2[^J!WB@A%"J8MW:H>_#LDAKVGG6U?M(!LTV^O0T*-VP]&RO/0, ,V! (B< M>L,IL.$VL-8# #>N+K"H'? D@<,)#4C@;"L"D.%SX|C $JR+1#B0'*!8OH M?7TYFQ.GX(-K*#8P_HBXV0PIE"NOBG=]QOIJ+K6OA&-B 6VEQ]/U&\+]YZ:NO_N9$4\?[[?;N-IYD^54 M=313Z8&-J"%28-6+|-4-GM6)E"OZXYK1F:U+WL,WWZ9N0]$'-DJ'Z*A_\U*=_,P2/3?4962R2TK7E'0*65_M^! <<_H!8J,$& MRA1C9DE'(?7!!LIN:.0$(L["5ZF[Y_F;%?)[? /_,CRG$\>C]F?JL5\;ZCKW MP8;%P'*J+O,3<#@,**?J6IT AZ. $C?"=&07!ZL*$4P>S M= T 1VO485Y-]JD <#!%>;5M, _,76L>V$#(;CYJIKJ_,W2L)%(-(N7P+ZKP7UQL|;2/ 6+@UOZ)@M@PJ=[V-UP[.00 MU|CQ4N;&GDB"\23Y*WVD]A:&7'KS112**PQ9:]!!0@- L:%<&-R1@%H@ VQ MRH"&A= H VPH4Y5N"'5V (;]G-3^2!R7IRF^^ %OY<"#M[=\';BDI$4>]>%&AR "WY))>KC1%Z# ETI] MN $.,, "'T'^\"S?T 4E* (+"J!S<4 5.D:FK-WH,;%P K4G6Q"JZ?#D:D2G+ M>W!=)_71(<]#>E,FZ='' MKI'Z?72;_EB-768Z:/;K RKT&W.QZ>:FN_TT<=6AE5@'? *U2AQ1>W#W/*=O MF_T'P;/HKS?W {[++;<;WF:TJ%LZ=<.SZ_!G*A$?Z8'UT5;@ATW7I@_79=W/C M(HR<&=,*UY,5!Y06#+ ^O!*LD"H58!WZW5N1Q5YXQ1HF]>%Z\2^UA(*F9RX) MP[=;T)MO0@W .?IA$)VL&I/^2OV'@,RGSI@DM9UB.W!P?/+[[5969'K%F>^% MONO80M NV=O>,/ZV?3T-A[X/+OYG>NGWP+<7X^@2N*?!7H;R<=+%!2<"N^|C>%AUE2+I4#CFY6=;S+IE0 9=?^('(S69$89J$1%H?*MI?3-4BV-POOV- MKO'MC'C$)O]%YL0[78110%R'G'KV%?WQ_RAQB6436?LN(Q-XJ}&+CT@ TA >537"J1DK*@^.:IE M(5(R9E.?')6\'CE/)P%UQ;3#J3/72# .?/+CA(RC MXXGO1YX?T98V"?S9#9V$O[0F/+^E\9\=\,.K?O9:&J/:'S?O/UP\F5_7TB(_M>9QW;+0T/[!I\$O+:'UD4$EL0W'8>1S^S'P)N3J_?G8SI M<& (.==H9DC[1K0F]M[JZ,:%D8AC_X/[$RSUA],Q'-W.\XREU'J;12:<[CS[] M<.QH>F+H^O[IB>M&/X=SXHU^O@_X8.+?XX=L/HH$#^QID3|_Z; G<9H?$]=Y M\$[&# 0T8 \4?6N7U'^+>1Z/?=+'_Y9#OAW"7)XI'[$./Q4V?DJ??*

M^U'DST[X4!]I(+;9)2\1[XN_3F8Q'+0'73&1B)$KLIT^9$UPSVF.4[/HJY[T=K/H3EY6Q$?G"R?->$"<3QA,P<]_GD+Z=U<+49^C)6L1T_;<0&"ZWB-\|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|]DR3@O3>&'29V;'SEFQYYW9+N@D]%(PSF;*IOEZH2F)1KX5,_NEY3LF@G M2MBLXW?;=)QCX6'C,L ^%6\ F2\")S(H6&2- .$!M;7Y(@@7/'T2^1J[0@1* M#//#_4_<)N1YW=-Q=*)67H%I1CW?JKZ]OF1HFG*>Q%9U2=D >8-BID;7>M^| MVS^&!$5MWCF1*U*%E(RGVM@E8=@0?SGC_.BEH/;Y[F|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{ ^.J%8[CSBC=E,N>')M^;SB\. (N7\DL$..;X!S[&WU]=8'\E.JQ[>K MT0_&)O+')L(I==TE>K0/#!,B1A W67G?_^IK6WCR-]I6$_$*/>RQJ>?65T9 M.]559:S>I'E=0;HG@()P-UWUT6+ #:ASY+WT7C;CONO@A4)U#\(H+++[.D+SXF!& %Z3%4V+|(\B#MTYKQ"-GVA&EV+!HZ77MSEC3WJ\O2"7I%22&-5JEV9.EI# '1SKYI<^^46S,+1HNI)C[=@IO&4(1*%Z%A:W3+:$BB14#WDJ$R3F9 4U+J4[MZR>WCS5HCU-?&NTI)(NJMJ6SIXOF5H M1O)9K104K)V5(;W:G|UWUS:8 [?CAB='/-/*C6JD@J*;0=^I&^(W)- O30" M;9.N:J;_F3Q%(@#'2GK"WF-3O?3&E?=LSSC>3,W=UOLQ:D G\L'Q-/8PE^\A M.]+HTYCR!KC\= K->8F&_J14B_1^MSTT\AZ*NN7<5;UM#24=XK$P,T2S\2J]&K P/VBE%!F=LY'2=3,U93L_+T>+|GXS|> G_AV33Z6TJ:XNT9 <_:Z1,&3*\20#M_-38O/$F/*>G)N-$_&_MYS2^+]]T> % M(M-X8Q2>-!_S7^B_%LXC<477E+?\RS-M78,+TS\7FMCZA$1H#L",MIZ4M0CM MM\=D]=>/R>*9L6G9"W"XP="YB<<#}>>S?^Y>,'":71&@H"?6/A7?JY7ML.R M>JO#LH:MD7'4,?6-8!)>'S^X#S^6\I69+V\TAIE/G%- QK2(,!M7#H,/<7NM(M[P^_P&#?55IV\ZJ=>9[H\NQS?}DHJ 7,D&&L9;;[D>;1B)=,$=?U?W /1U17 M_5FB8CE=/OF+'YS[B_MHLG"7{(E9#20Q(5+ 8[1&O>[F.7O,NQ$'!O(5+-=P M=PA T>&;;+CFMN%;:T(S;PVD]Y12"@@;HY1V06B#_E&6SW#0[7&=BB^)>F> M&>+S0KW;&IE'AFX!.,J0VSL571%N] [AB&QH-,[%A*[;O 9T3Q|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|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|O MJ/F=-/.EEY3.KIECN07"X%L7K"&4W", "8/>F;_D@. 4(BI=:PS+786O&&QH1 MJ[&M41)X;-2XPSJG,EP2[\"*AW^EXO)@M7!|U/*<39^SD+54S=+Z+NGO4-:'L M.4 4[-2&):" ;Y7N'1D&E%;UAV$HOO!MV9K'G\T#.J5>Z#Q2S?7#PZA7+.8M MAVS4[+>41BU+ZHK*WK-UVEYZC-3T*R/P%8VN)W?D*;?(=%LCZZC7V=RTE]VK M0@.R1&^Z)ECT."RZW2)!%JQIE%C3^)D\14RSBD#QU'?9S,+__-/ -/]?-"JJ M&K#0499U>KM&X{AB)+?T]%NC_M&@>#\TK'>$;,!* J@-1H<=73X0#F(;I\ MT)^:.GW7Y7NJ'8;%@(9[G@^KFIDB48_^=!R[-T M79>!8;>&O6@G)):5B.W&M$T+-LT7.T<^Q2ZV{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

H<#:J%^U]1751@.M1$GDN\CYWDU]#5<#WT[Q)YKY(>A%F<)F!+K))_!I0P$[+\"C!%6_!.YD3T<4.MD.2%_=*MTHULI4$N1$A>DZL(1#U"

n<#;J%:U11/51@^M1$GDN\GTWDUI#3<#WF\Q)/IKX(>A%L<)L++K)>-1JK$]+^C:%0_;_XD?1<4^MD_:%.=^M11UL)4$\N1$A>DZL(1#H^ (MW"MK7R<5#$W[ZF6Q'XB08TNEGX'#W4 M4*"MO"(0$

*9+2G0G]6WBVV?Y,Y]'_E%-/ M,/:E($CD8"3GPCGD)0ZFCF%S$!"H!0.6+C!02HM>5AE]*AI@:B V)$/#:HVL/HH]"-;*YFV'\;;XR28R>+O#9%EN-MDV6CI-NUA"I7-31^)3ID:_Z<L):75;H\W(?D4]Q-'QS&:4[>+]NL,Y<9ZH??QO&OAIW.ZU1{K MN?D)@K>)0:NBZF#'LIY?'?*

*1;HTV+#=5!Q5R5SE9^@&IM1T4<<+W5]1N31L.B M*VFFSFO\\T9 :E=K%U0&PH[#:1,6.CP8G5I 0DLHVHBT*3@C%>W=]3"*

*M&4(AMQ&6#0N\XEV'7]W;T,#2LNGZ,M%W("&E0F;6E@/MEJ1\[6[XWBI]E^YZ M=*S6:+!Y>'"'6-T"PHB2SFA>]F^!XC9$E&8:09*CP+DC=PODC5*

*NE&#J2>'F6 M_%DNMO)X^>9I7O7Q%>N9RLJ.Y8+%D*UD1=(H*.Y5VBNY^=OE 6)9N8):PC$J MY\J2(QTF@3\3"'>\!4^<)=SSO5"*

IIQ,.H,M46D2>BNVR.[" Y@[;YR6,N>R6 M%C/@>D7 SX+\\75WG/@73U% &!$=CP3/EQ&=A=N,/-P4-;,UZA4.D> ^[^E= MPP-#U"Z[!V)*

(F0Q2LC;CU9_=RS.0?>-6AX974'#EAR5:A8\,1A4(S!BM%5/\ M]#]9455 R48UPG"7[MT&8)K?O1-N@'*1"!QT#Y3CXIF))LP[[9&LH[#1E^\ M?*

LP$T]YM__"20,NT$ A31,\"8JLIH*H:"7;^=D8NJ@->]"!V!5ZP$&V#ZXX M-W5[K WC:M7%U=@5\2D$W_V ?W :18%SOQ GNM[YV8W_86O4@V_\(YC*#:E)*

M0E-/Y[OWE4(31M@F7E5()6WE^EA(T>F@IN>MQ:AE85L$RF C?C#+EW32H? M2)-Y?NW^=JKMA(FI2NTU2U64N?'S?

R+RA/&VO0W3$7JODC2%8VN)^)0K$WI MX(7]X!H_'22C\QF-NSB=KWUACZ<?8>@.5LE

*MEM(!C.]5I#C$\;X=:7OS884"%3"Q&..6I72QF55*S*^!4K/#KHK/4-BR'[C' M-PQ(:QE>WI&ZR/O]3*UUYN?4AP-QW+E1>@071L"MQ&B;(]@KQ2Q[7_?*

P7CAF MF0$-5#LU&6K[JYV^:#_?,4H/]0-K'j:6@4;6(IA:Y&O>]Q@FNRH.8H;|>G=A M4YO](C&QFXN8S9"XPEG=]X+.%^SRZ#E'X\Z^(:UQ9U[!J>G4*

*,153RU*Q=2 MIH*0D]+QI?=":R)886'54A"KB"C).R7D0]C'"*0]ZLRFH'V(}2&,[=U*2@+O M64;1[[9&X,Y(/$@LR,P3[PL&W@P*&ABP0US9%F(Y6$H]K*

*5"W3;KAPP#%HC M$,>H8J0RDR6'<4@I]ANC_(MP[2LZ0PD&&OK50(TZ&0@9Z!*L-HP2-@][%4#/ MD&#DH7(":AA*08@IP?*#&<-*

KB$V8[.)X:QI^)D^,J6PT_OB/]> ^RF6Y8A1D)M%$_GQA(TLOT%?]P@4@%)@[!7^\^U4$-I?9/'6DY3)1:OSBS<<4(B, 99C%!H M4&A\R#RUI<-*

Q/Z@KEZX7U/-0K7'LKWW&-===#Q1F%.922H5WKH5=MA:F=(#8 MMUH8ET&4'-C+8!Y?-?_U MK,W\Q7OLN0(?R<,3!:F_*,A^:Z2W4P[=J2>?C[!M!FQ?

^[9EX';_<:N#.-Y. M0DT3XKXAN"\;]D,.>VG'%Z"Z;AYLWXU:;,7M6^#NW01N%X'NE#<$K9#0VCA M!MDO.'?<143M(@U=&B"S:;,")[,U>08)0K:*JB"'*

Y#4,P]!VPS@RO_-=B'7 ME.,=_&F.A\AO"/++![XEQS] E=U8X-;O'^S"<>PAU!:;\)WLR[I?HD:J94M MFWHE)U?4Q M*NU][^R"!!Z;;[B\6T*

*A32^)&@T3RM8%!&]D!J;(G_=!1*H.H+X+-\DT.CF:SV)/P) FE7TY M-COF[A&>^]OL[^!39.&'LI%8]45XKM.]_T=H \+V^VH@QN+T0KL]NW0-'0Y*

MECMN7GDWW_W\0>UCPD:"WF@FK>8W=-_IR=QOB'4_$441L3C\\#M*CF[Y"O> M"S]&0,[VUMG<;

NA)XNIX(<0^O7\#TVF7OO0B^T1IUC<+MJV7;7H?[5U] ME0NSVV3L;LS>S&ZX-V*QJBRW1VTPH5YI> M41'E^QD\Z_54ZUA/@WF7FSQ0VM =/+_W-*

*'GR,+PG91D#4A6 @"D=+WVN(&2U M74<%48_9DX?A RF&C[2T]4=QWAG[UW8>1S^S'\MWSDCPX'AQDWY&ZZ[X9G*N MW4V11L9C?*

\;>^,SFIWE^1$,-45=C0^""]#X$Q-7F)(AX/"N:TI!R3MK4"RF' ML2?.%"",)]K$\8@W9D-B0VT5G=_..AE&AQMQGU MNY,Q'4[,H4X[0](GNC6A]U97-R:43

SC'R9S\),;IL%RW',F%L?W 25_'),) MF]8)<7^0YY#C;1U<#%GKI'Y+I9@6HY_O X[3S:&"(61R2 X_]$3A?<,;)?>*

*M>#O"ZAWOV4I(SM:%Y'8E&ER>SIC@!73*KF.@UY:%ZU]%X?]'A4<6ML-N^@GH M%#\XGL8>YO*^3-*

O'N;>>]_7K=60XY,@5R(NS@AA0W?)/*0GRU\^V4XX=\GS MB>,)H8B;/B5/3_0"1_A;%/FY]U> MNZ_W4[_2VT;JY]L>-6R;O?1ORG_2]L^[W;K&]-Z3K'>?*

*M",B*ZEW=NX+,6T MBB%:9I)ID,FZNIL&E&HS=MTTU"C3++;0V+=TSK0)3S99^M'6H$,3"7+%/LE# MCR)(6?/IMIVGQ&>H*

-5,W>QD@$D#IFD5E89&4>,@F;YO=GU?0@ Y;SOK,672 MCD1_2Y;,M44U$"=W>5'V6>\,!M0P78E'9N]NI,NN<'M_]@']PNG;,^YU_ MY7O\?

*0&$YMDEPHVC8906MQFV1KW"<;H]9#EC3"=A8!:.Q2;9@O-KCQ'95)C MZJU1R8&],*5&^FJX DH:L?^Y"",1,5M'E4:2YCR]IGVX MIQZ=,-%/_(L/2R[D\;*

[1>/<,O"GZ30C&]\S=FDKT S8C;SF3NY>)G[F<4>> MTK2=QTMODDU4ZGPZ:S:?QH$S_@503LO[<)#>U5\%[C44LQ M=Q[7.]+8&C&G8UX;X#X?*

*B<_S\7K7ZE8M<;]B,$ "J[<8N]7.IM<:O<-I[VVF M)CNCW^3V]]L^!-S%V1*JD\3U>_"GGIV*@66[PS0@])G,UUQJGAYG:!)0\EGU M&VM!.7IO?\P,F"KFWG*

MXE0>8]C%Y?O..(C!1%@_U2Y# M)03"980!D0%30@"T4)-S@[]1^X'GF#EM'YW(H2ID \](./WB^C_XX.FOQ/'X MAZDXX^<'D8#!+ U>0UG9(GEKN)R9=?

*1W,T=%W+\;O;^]:)/9^>L8[SE_=?E^ MDO!@IB&]:L^OT5'86K4>#\JFKJ@=]S4"$'EM*D+ +QK;@<&[F0%,,&/*4&]Q M=DW@ZJ:9(_6#ZV#!*

0L=/-14;T _=S[>LE4&&RC=KJ!4N6K?!.C6PF\%JJ_O M_(BX24]T> UVD7Z4V:C8&*7S3BKD7063L@_BG=]"3I\9N+*;T67&>=E1QP9 M17YUG4S4\&(Y"*

<'H:@ C14/OFR(Y."A6C,2BE72HNJ"E4LH%3)>?1;-I/0," MC/1V,0I8F;_[#W+,D?#F#S^:0/$2UH]37KEZI:]M$N1DK2GMLLWI7=+WY1> M=?CCP.#U?*

*DRV5GR9\N*S]5NIF0>R;TSWT' +%K9\\ZU>>M,I5(L C-J:D=9I MC?IE-K6H;,N)RG9P2L]$VPD3*YC:&%6MM+G@^1KILSF7W=9H4/BH:0Q)@#*1J*

*M]\/(>CV5MY@=VWYTG#P]#4"\A<%1I]1"D,88 448)6ERGBY^1!TH.SP@"*C M;*$2-380:JQ;V ,'&VR%;TIF;)NVQ;SGKJKL9,&R-*

B39I(K[4"M)O]4.%MYWTY(5Q\!]\0I$ M'D# CG]$7UAC)ZU>OXAH M 9_;H(%#'QJPR(&& ^RY]?4M^_OW^.!-P(#K@5R^XP%MFB_35Y0+IY=&--DQ

*M9;38"CLP#?,3D/V+3861M)Y0E]I$S!F:[3I0V)3;B51!A9D5K'>?:B*]NFL M5C-*4CM^*^.,$.U*W;! YK1S:/,F]G&&I)R[]0#!_>^+=;^-1UL-*

*66C3!>SZHT6)NS M\:Y4@U6: /(;P'[AG3^X;U,Q8W5/_,2KIA_P[M1'/;UP,0WN9U<(N!69L;(T MX,#@+<$D'*")RD\5$[8:Y6<*Y9=RA#(^]7?*

*L6DQSBIK4W]*G$FNAAM8 M7'G#WZV',"JR<5TZCG)]\DYLQFZ>IP 99AB-!63&5]@1>0O^%(V($5E5E.&. M[>]U*T/1Z*,K;8,,*

*(+-6F1WR7VD8GFBI)BQ98[D6^9KWBNGL]ICKA6*SC12[M':8L$[$71W%?U=Q/]PG$\E&H9J<4G@_2#F2KG^=8#"]U :=4R S3CFZK'S(' MR_(*>#*

*[4TPY]WDRDQ2F+U7;36G]A43C]E)MIR;QE]UA.V79';NWQ_+NMIVA MO&RT[N+VZ,KNK1KR8D/&"_1]*CLY)!]XFP*QBV\)0"U5FUM6HA3K0M%#!\L?XM02<6>[/M+[AU)0\)#V??D_3.KP!D2GY!(^BDK_/RH:RA+)4:0U"WA3:L!?7$\@*^-0H:U4: M_^L^#]Y%XTQ_E[&K*L:,;HD?%E&IDS/,BQ'OF"0_/CVBH*

*MD8#W/1/9CX> N-J#S9L=FR<<[]T.%L/0DH[_7]2#_]<.QHN@3GVET)Z_276\@]&\$B MVG[+&IO&E =F*B5PYTTWN+6?2(PZNC&A M9&(8_S"9FY;<-*

*V6XYZ3!WI\'U#ROS'AC6!.B/N#/(<<;^O@8LA:)_5;*L6T M&/U\'W"<;@X5#"&3@(H(K7EBEP8#&E,OVQ%6[WC/5D)RMBXDMRO1X/)T-B7> M*

*Y,WQ],N_K5PHF?MP\(C"]MAE_X$=&(?V PUR^3R;?&./@\$]2A;9E8W7) M/*0GRU\^V4XX=\GSB>.)=XN;/B4Z,A%_#N0WRE:\+_XZP?BPWI,,(8=Y$L1,*

*M7IQ(0O-Y>/FYZ;5'AC]U*_TMI'Z^;9']=IFMX-/4O0)]$S!F.

*<^Z'#^7H24)=$SB/|],.QH^D2R&MW);S37VXA|VP$BVC[+6M\ M&E..1#D4YKS*0.#NFSJ9M9|\C!SI3[_?G8SI<&(,==H9DC[1K0F|M[JZ,:%D M8AC_X(U^DINFP7+<<_) C^\#2OXX)A,VK1/B_B#/(0?<.KH8M-9)_99*,2U& M/|\''*B;0TT'ZIM=1S705?M,GM@[-:%;/- '7A0&/::7MB*MWP&TI/E+Y^6/8L=3[Q;W/0I 6&B!S@.WZA=\;[XZP3LPV';L/H<[TFE7_+B M1!3:;"X?-S_OF^VN::5^I;>-U,^W/UOL MT=NX+,7.B]E8IH$SR&3@7+%/M&_LLFFH73#ALE]*%35+/WIE'10AREH]Z#83 M(<5*@$@Q4S<[6W=>-FJ:5A[N[S(8ZW^QFV4%?- O"L:O7_68.%M"1!FF=U53YO5 M3@>LZNGDVV*1,2?T[@&PG6YK9)B;U0X5[:/@!-X1,K#<,3[7)]Z8B7?^9,<98{'C\+Y<46.-(\&D=VR%/U_38;H:%? M#FKZP@A]OD;GZQ69WSG"J=-G C+@HLXT+S]\>>R6J0'S<3FGCAP('=F5 ME7R]5D6@\@P>58<.P[.TPH(4]CR=K2C|€&R4KN\ MO7?/E&2"R$X4Y53!#<%1.1O2*X-45V^-+ F>5TE@:KZE>VK_8D\K6 M,KZ-'9<*@Y8K&L0[*1(%QHK*O4B%;&KH!5\^N[]K?=)4/YQ2 M;HE&=+9G# <(;*N2N0=AVO]0E9 B/%Z?C,1M]%/)2$>H\\GH?4?W<_"6E6'AH MH\#JU=D>E][_S]Z[-R>,)'O#7T7!N_L<=P1FN%^Z)XAPN]T]/MMM^VU|SL3S MUXD""J-M(;&2|&4^_9-951(""9!0"0]HB-V>;ANDJLQ?9N6] KK^#,F:I'4P M61?O =!1'S4/E%VYW"SU\U>8*'>V**C,;NT7<-,EF0 MQA:[;I[V#!VZV, <]T)GYVL;6R4/S]=1MK@>7SH@Y,BAW1[Q(IFXX=UU,T;'(MK,[1Y51B@M!!B8UP_X*D#8_A)4E!I]1OZV3_J>9[P*9X,_0%Y2X8]4EH%T7; <7N#M#\W%ZV:IWS[8-2"Z8*C@D9B,#_66DN,#UH_'-"XE#GW)2C5U MM8=$%_^.>DC^!]=Y,4=T)/G]3P^[1.4B!,?X)&D1UK@_\N^>)3D|Q(LRF<|-.M-7N'31M,C00_2C78R#2UE:R2VJ2+UPPN/'W+7*+"32DVR5/MD@0';Z7//ZY. M6^I[T)K2>8\II*H2T7;I-NP);,Q"K-13%!M9MD:2B/1*_59#|OV-AQHW>({8 MD B.;)-@NYC]*M=ZD]\A//AT0:'M4R]'=7UKVB_40U8;).1UGF+^_]I5R/ID MTY\9>4UFID\LGMX::9Z%#(091;&LXV2_T\QY9]M96=J;C4X8&#)(V%>>|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¥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|OL#,=4:LX=$!^?30=0;>NG P '@!;#;!&HXY0F]$IF#11\]+E'8 &]\A M-(0XBV]CJR-H!;!YY@XY8,V=,[\R:G(\+N0J^R90&"U?C ME45XPKXZ[B]<+S>1F'JBKE=>Z">NE;@6 K'X12>.!5QFXLV=$EC."Z"9J3+X M**@CJ!-^-OT*[])U5L3AHT"]O&MXQ1W4X=Y<- M[(IQ/T>G'\QZYFK/,':#D8*%ISV$[[M"! <_0DP'(&KJ99!BZ,0%Z,T)<[!B M7 .TK8>?YCP]&\P+ 3T-KV MF:#YYD#!01"]B&A\4#'\Q4@9"R@AO&#Z!AH3 M0Q;>0I6Z- *0_.U60'\@'9VEG0#'7I((1H+'_J1=H&\X&X@4("JU\W@Z+.XQ0 M*#!&1G,&N[G'=3+798%'P;?,7X;_9J2 Q7+*!'I\|9U5@3$NN,"$;|-=6N8O MW!P_$1@Q@=I"_2^HB]^BWH>UG&5'C^@A7M XC/U$P(8$7!CI9F 'XQM\?,+8 M#*0[.)+3P=SU,"+P61SJ>.+#"2&(#E\3 %DH?'@JV@?X" Q;<9E? I2#?4DB\ MBB$|>W]BNB/C/W/BH@4-9 Q]&VR,=O%DS68ZM3=G)K_#.M!TNB8^\7S7F4VR MWWG7:)? Z"284M_E$GS,;3.E29ORB*0R^CHNT8#3BAV-`J$&!^\Q"*$QAN87 M.BCL2,UL%J^A!AJ23V!HH^!>H=3_A>;0_7B %)$](\M?\5V7 MSGC,Y1XQ(HQ65.? 8?&,"QO01?!+^B_OAPCMB0!9%FMRUDB+VT#&?H;/_^JX M 5'NQ[?!ZJLT5=<&R-:=N!T2_W:N@M5!+6"<|;T(NW)@4Y"*6(7!PZ$< M%IJX'"7XX@,H3Z I4'^$5GQ,[:%%S\B^X)(71%*#R0*O(, +Z62/0)/2L<51 M@DH"_XO&-@*{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{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|* (>)$,VFW>!TP|<*^M_/)H&&-=[5=ULJM2=8:/7FC2K36V)\K)AL%RH72M2[9PX02V2B2 M?N>NUB6%).0DFR!- =4R0$^U,XZ6+%SS)]B&_VW5L1;WR2Q>CL%["">O+ 6TD MSQQFT!7;>W2GLC,9YX1T%:G UKT=^RI3W "1]';/O/D?6E44Z4-)TQ4R)GQH M5;&.R9"N(C$31'K:9E!&&$;3..V7D*T5=5.OK.[EZZVVC-H3%VG:DQBK3G M!:U>CNT9 PJG.0VJ%'WREF]6X{FE;E,7*2:V1RZRN%^!1XD? ^8Z%\0&X*NYQW]K[:8< LJNBP0BBUM!'IBM(ZS 6B',/Q"5>^ M*X2B$\TU?B.E;0!"1FS^C8E4/XL#>?@1D'H/R3>-B0&TZ-OW= MYJ6<]M1D]Z6DC<-16N5 R?F=E$F[5*_U5#EFB:M4?9SR[<< MZ'2T*:(8Y[??YRV'|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|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|'^L84Y*S*;":A5C/_- *)PUG,G#$/R!8PE6X"IF26OP9& M65O-W"H]*]KU+&6%+7!9X&HR<+75!]?I1G*_.<[HU;0L'<8M4!T'1$X*Y;6P M([*C2BA/-1@A+IWQY=RC>7)9IVT02- *) >-(^E_XFKNQW]ZOBZ2A (S655]Q:Y* M4)"D&;-"HX1Z$=F+ *%+W6"?V_^,2,Z3O3F)%\O!+52OY&_XDE; MBDKZRJE14 <4U%3Q%_:4TE=26= [%U*3.Z:NF6X73%8I5UB!]N\$F+S;B5T^K MEH'5F-I;;7Y>3+%IGKW\$|>./ZO/X=504KU?957!!29=%2')KK,/3[^S4GX5 M6F:MTBKU6^5F75;OIPI#1+6HG*"HR*^NRRPJ;1256CUW/$G9RHO(BE8GD":>_MP*J73 -SYRZ?W@3G\=BTV5@E'L-W!K"ZC"=R-C*=AI[)N.? C5S22(W0"B]\7 MD\0R7*_1+O(.VS0B7MR4$"TY)RUQ<[=VIX44)#D3H1C03IFC(]$NIX68$]Q6/[2;2H MF2;_CNM+V7GR<^UJVZ)D(X*RCV[E#NN6K'8EWZ2DNR554]G[QE63SSJ490 K M':X_NB[X[X[]?.E3= /H^+%^&'WE>;#BSZ]H<6U=$[;T$W_O*6!047F\,R'5: MI7Y^F=-U3VK]Q*1TP;D%!#+/;2VIXR_I4VI[RABM,.Y171WA0(2-(MP)V. M2D/9-_:*ZFO:B ',=G5R!ZK4"NFJ] EC#4TZ;'N0KJ8M%@-FN*051.NXK5IQ MVTQ0Z&*RJY&[OTD';J7V-^G@[;$$;Z-]*7'AJI7ZK8ZL2T,.[]2?*W8*"M!N MQDX=L-.2-:- $(;=^,=_@KC]=K1L[B9:F[SM|\7T0[A0+1?,1Y/B55$$'7-;T M49>E)=MMR2V\4O1$,5796A*U),[#7,@LB7SB;4]R:F#ODL@LC_8I>G!G>RX M(4$@1IJDGVR\MYWO?.#BXP45PLO>D7QFN],.#VEO7,]5;;-'.J3;&--!HU6M MC2D9UVK_VP3'.OSSX>'[S8^;NZ>K[\;7V[NKN^M;^-OMW=?]GS^NGF[O M[P+4BB6O,"K;=D3-[^)&OZO@)LZOCGOM4MCM=\?SGO!7"7MJKZ[^]Q6T+7:/ M+T_8/QCSZV#2V"M_2OUPZZA.C"\@POYX;AD!C>+RL%=HQ_0O6_/3!%>+'+4QA?5,/(" (V;\,)}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`PI;),[SCF?@4OF::0K+&+#R3Y_!.> 6\M":Z83;'6EP_CSJI8?@>*W-G+#YLP2OWG,ZGWYX7-=Y[./IZ_ANP MMQ!I@&.]4ETW77$@5/%%'17QP#5'S]08BS64/E2,< &>P32/D? Y XU38P & MS LQ+;31D)2<4ORL';F$/P-^,H;G&!?D WN2B^X5 2K;STA=9^X::TD+FX43 M(4;=QI(=T4K2>;>V!XH+87/+4.7Y/X&_CSYFE1^H.X1?D&<:4@\%.R ?5IY7 M&O5XZ=H_X9!B4+IS?!"LT9S"WU[XU(=Z+P R;N@KH,O'#>)+-W\@;/^K/R6#%\|F98)AD$NH"X MIH>/&KO.%,6,NC9 W:6. ^TSLP #U79 ,OF4/?L>+:QE?03[@L,8'>$"U@'O_ M,DNB0LPF=E0Q%Q^6*

*2P;!_QDNDFU /'@Q+ A?8CGV\R6CP BX MBQ}@CX;-TO$8K *^)=^<4K94_"\2!U\;/IH]E=E){U%2.W/? \N&{6M WQWX MVNHPCZ;QZLPMU$R@E&!9QN],VB7C*WF9M!^)I[I/<[@9;-[^W^ ;2AB"*9: M(F1;I7ZU4H]+_#\K@?:7H=KKJ52[(?.5Z4Z3ORA'$E#601X!7@A@8/B+89TR MI@,(02/9XI1 &GORL%8QGA#=>!:QFJ/.)Z;S\/71]VT1!"PEJ$98SGR&<@B? M]&P3,0NO,@9XL:<\4?CPOS %@H(\^;3*1=;D$;\!E\R%1K!XU(:B#\P0@, M.]<<8,'\ -01O-J?@ C@20G'*!,")AOP@;7K+<,2Q!JH13G^D13A!O {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{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|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|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

<,%$977V]ZSA ?>1;7!\\;II^\C0K[#01&@9T^;^'D1&= M?1$P^D M/PRD /WT'!O0SSQS$I9GZI{(Q$CWEV-R#X&=64$O(1 M.&)##&K8H%, EDC>5-T-?

2H9,4X!7#]T/1I+Q355SH\,JU/8B1F+]S^GR4$%# MY@:S@,((H0@"%HXO*@[@'39Q&%%B. ^'M@!V8G?0Y>!4=B2S"@=C?NY)]8<*$

*MJ8B@SX>OHHHE_DL'Y!FLZ:V+A 6\P&2IL@I?$_3&S F5]-1CB=SA]VD(A^C+ M*36"B@'[;^9V_K =YOLE4OE+!\5<;_'@V1&&=Z7)[(&.&,9*

MP#3=+_"U3R(:WK QI;9&R8@"9<;ZUU.62.CT,=/'\M^;J=CX8@I-@1]D]E+Q M$3<]@#9P#@/)0$"&AKP!)H&&*_P;S !ML!U/A+_^ TB!'=RQF;F],S9:?*

*LPG@S]3:>OS!?EQPX0/ MH:H'LS^0%>R0[?U#]+MAOAL*94 T27TI&//F>/)0W8 H^D$-(EAC)F ,%W&6 MO)*)Y7YWCP(-?(B>$=" _B@W1_@9P3X2:+G[TR2AEL5,76#\XCAAIYZ2X\U M"J^P?_H5CC-6"(2'20^.F/3@]),>[(E+RIK6\.33&K9A+Y.)V.F;2ZU[AHPA*

*MY5[X8T3_*+RRT>E7UDE_,?\[-70(=<^=^ZQ*NP)H3)\)UD#08?P-, ^K_=!3/_ MA#Q5GV*6J&?>>38PBE:4FM:"&(F<8!:9T9]1!69EP@O@):!*

@7GZ2M!A;,=CKHK6(V@RGG3 V4<-2P)K@7T,T>,FFSB+EK MH16NZ+!,38\8=G;TOC'TBMK>E0)NBE=8/"'G+7!P>H#3.V@ZJ1D:W7#HV2M"*

*MT'WP5354IK7_GW9DQ8[ZG3#[*K[1<%*@&4[-HQ\8^T4,I)@_:_]\=N%[:N/# MN>Q28]Q":\IBYD$33&S@<@"S=\0"[;[#S!$WG@+@P' +>!",'5!\X?*

*Y6Y M>S"3:;[:5#7QE>*9N_6M:%\5W:@.ZK&PQ,*

'T![0M;7F<4)D+:&%K%&K =AS1L=GYA^-!?'%#"H"EDUO8$/_M-VB;5#DRYT#TT%+S0>|'"BQ4MIPMLW\ >F]1HRAB$2V8W47W:F419FJ 8"?, M,

8\&KC$#/W$V^6.0B:+7 6D4T_)PVV&F7JJD'U;,_MI7OC&^RN9KKV-S]EW,R]=N0XZO;.:Q9]\KV"DQ=&[\OV"L_IDUWQ[>_]6'F M;WCY'Z ;!;W-

JMY2;H.H#7W;W+GMHM9CZ$8S0=4*Y)COR+%C5]7A+5?4-@R\ M+NC\B_A2/Q,4N,R^!;%$3]/T'^XX57,N SW/F+TR77U!7:GLY"7T K,4*

*MCG7J8EL&QYAW"B$1FLR#8KQZKE'57E'_*)G[/A$;K^&PF(P=5S*I$9B0K4$R M[C4CV\=WT*G[O(V4X)\A7I&O.O2KWKFY/YVOHE$)NX[TR%5 ,V*

YJFR&9E]@ M!8+]9[JO(%T=WZ7OF3G?#O7 W,PO/?75>S*ZF[P ,BY;A^G7+<_!;_V!5C* MZ9EZRSX<9]ZR-STQ@MZ#;W-X%&+NGG+G&-M ART#*

,!/U>L7F$+IMP1E;2YQ$7BKYLSW(T:2@*J2B+J&K4 MK1J/([DW4I<3$>=@H(W M+7BNI.#M-J8V#I0E>1.AZX<'VJ?9\[=

(@UMC\;NGQF]?;..W9,S]$THC%)B M[D41$6AF+<%J.M^IY4NA Q\"=>^_Q(ZY KS#_(,_M]#_NE#DZ=H@,K&)A_|M/WX!*WVCJ]L/FD%?*

*3G_T2SS?".7R3OH4/9G8UZ'(;K69V/;2O;TW>U^WX*M_ M)#\?M5N=83_U*_@F]?.LH3]]5G9R%W3/.TBGJQN.]$/XD#U(J,,\XACVV!RAQ(\%\L^!/])4J"?U*

*3\'-J M;B0@W)]|EV*R^T3!2L^U*<99#/*)K@LE(3\$R/,JQUQQ+>\+I7"BTT))"H^ MPKQ*S%4NN/(KL HBN#YZCO>#'8U7UERF&__D%!$MS -*

*X)5>:!V11:8X4SBF< M69C"D\:T4[Z]*R<2ERRWG%XTZK@. X*(Q\"OP;RZ1Y8V+;4QEV'E|=R0NDL1 MSJ?$&#M$>FS"%:EAW;DHI9'A88;[*KU:#$S::*

M$V21#2:RT/ +K!L6K2W@9?)C'3 5;_I9C!6-+L#@5J\&V<)+A@\CLFDZA\4* M%H0ALUYTK!?L[(6H;7 05MH$@]$]$.XOF])2GET:\96?A>ROC08$8OW

,'PZ MN$5FL=-A/LN[:7U75BI+;I]A6$:0DA\D8:7FB>&4-<-V5%T/]S_YQ8D"6VXG_M]9>M>TNGM%;_,BW-'6+<\E<8+Q 1AHD$<\]?#XW$"[)_?

*CA*I^NGS; 8O:!T M"28S&S=^BE9^AHPW<+?OC9<2!9$;RD3#$X3AFIR A1]3:H)!E$^A1/16+9 M6REC^\'8 ;3MC%R 6,+^06*

J$AXL0RT$"'+5(I9TYK-,E_P,RQE?&&'=QQJ A M#06N^R\N_H2_+5\@T/:D.Q$+4F$ $^=M$_7?IX]9J8%CQ\OJPBS]&0'1;WCZ*

*M8*F.'U=A>Q9;\A5:ET'X:ZIY2;L*3$Y]6W_6.!4)^IJ#?G3$;?U^U/>PFG1/ M>-1?;H#* WD/+''F4P':RCB5PPI(8$;&7LQ_]KQ47MI&*@M@1>5Q:1:0(2O|*

MB'U:F-(7CO9,EB&K_"E=TK='9]#MNNXS? N744(2[$&6D?R!&VKE,A:2V6- M(0K"I 9\UF[:UTOO"@B.D7SMT?D)?*

*KG:W2=Z_3'?,I<[NUBY"N6N$MGF[^Y+ MN+FI.!^#8"N!X:A$ADD^0&*0O M1P<2-8L58SRB,&X C(,LU$FW,9TD,VC]R @Z[V(S/OV4\4:EDW0P!G..E -]*

M5^UX24+0A_"S:)GMM!J<7DW']+J-/C&[M#@@!@YJ;T3?BEG.,2=Z]IM MT]JT6>7YO,2XU&VR"

*9RAA7+#ZI;^D'&MM4KMNUBPKA]$*4DRPA=81FA;R!' M56UOZY""B7BRILJ5U%0YHG'%OC2@2;\Q32F"+6!1%8E^B?YCNF_L1?\ T'_R*

M<"UNYO%%WND[TF,OFMR4?O1=_65/]QAK>R_ZAXWI1)38'4EA!'"7,X6QR47G M0B[N:GDU=VQA#1E[?N'7

*)R+8TS&7(ICR'P+B7FADHSV8G[*I81%5=D6_@P" MCSUS>.P>U-0#[7"}<;>7U;J.MOF5#/BY)H%R6WNITCRGCONI.'*8#H*

MZO+RNU5P$N@U@.H1Y3/('']T^[+ ';)3E?+3IQ+ M!77:@PN-7]_;UKF:,,%1:ICP9\U67U\M\AK$ #\01WF.M?01*;SY"0M18"G- M!],A2F=(:WNJ0<]T13-*

8FUBZ&(.6@C5@0;1'D1?]3>.A:=_?W;6'3WHE4XDZ M7_E%<&WRRE]OH]I^E M?WIV%@U6K45&R:(M0@7C> =5V;*

*M%LYUUQML=FV&M:R;P(4.,;RTC;]<@YU-M#!RM$4V_FACF6_:@NSMZ.-/X?Y? MRE)WM6 &*U6GU:6)#1("I+O=4CZ%'<91#(1=@^CZ6/ML/Y,"?*

*VLSP7#C;#,9K"\Y]_!*Q0W]E;FA;,@X<;OG)[<'A@RL?TS%?-$3)HXHB&'PU.J;AH$I"PK3DZ+*

M)^^60B[4KOMW8MNF]>CO,669;]Y.O)@=_=F(5DW_JF+GULS.W1WL<+33HKO0 M/.A9^@)@N#46GS6+S)TOFJ$:G<;

*[[=9X(&:*4+&ALC_OC8176^3[D&2YNJ^Q5Y9;+V,K)R,R,,4\DRNKEFVGG5K73L!<,(GY[\=\7B+DX:#G4=BO(M#S*

*MS1F*JDF2G:ZLI#Q").9/BGENH.\TIKPZN\L<^N.BA^.72EF6 MTM4'E>;8"O%[(_J?>V-NKM-ACQVNV]+D5DO]YBO%Q+3IX@J,/5M-81'1<+76YDG?*

0F/;$$>V7FUO[+S]8I;S64K?F-1RU%G\7 M\T]1'U%D$0^2=9\=>50NH[XN:TK=M(=K:=<-"SXH&(,&@HOQZ[D]M,K(?2 M%6N>\"IY@WM&??*

DI37W+;H,]RS_;:F[0,G1"G/D M2!<+D)07)=@;*Z7&9*=)#MQT<;S^ GKI+1YM;T^.S]Q.\UY7<1+/I9\S,-\ MRF-C+ -/3X>78/3L;2W:2['1:LS6/GWK*

3]W+.!8S,OS#I,#DO]-S]/H5I^4^ M>OGPFO%&;(?F:6I&2L(]DHKU/XMI[/(+D@3CWP03N#?I9*F3Z]96XPB9U M-*

,DP(V404X:5]Y4V7Q5;2;=SZ%H.3.A,71EVF]C3R0[P!V-ZW=5@-6V: +FQ M--,JV$FPV\DITL%E.>D7"L%ZV"(ZA:=^:#SWP5-GQ2''^KX;VP_E@N.N;A>G<

*M>&](7=57K-XLT>N]U#(\9.1IE)8Y15 M)R:^OOY.$GEZ*0X<5QN.!LLYF2R[DS;I3]21VNXMR:PW:'>61%UV.O\> AL_M56(#M|CG*

MDM9@^ZS9<]VT72LM+[TW8"B!?87?./Z'^)IXNOK'/Y[O'^Z>GY7';R_W7^__ MO]N7^\<'Y=-OMT^_WCTGS]&= @!IU3F\UZ2]O2M$>CP]> ^|-

*;$F*1^Z6]%C2 MXITH*_6-*)1HCO]=P(DV#RFS8H,1Y%(/\,5:TLZ971H*6 MOR'+I3;7B#'?TF(2-*

*L%/3,L).I]BY]*0R#0=W[1>54/[+QVB26M#K+7_^E^N M5<-=JO[C2]-TX!#"(A¥/_TM=;W[Y'+Z=E7]PW(C-CK""%WCL(K3H*

M$$U%@^_H[&?!CU14WY!BVQ@]7K\K:I9M. $+9KAE7.%EV(%$ ZT0XUJV2SR>4M]@QG9TK'B-%=,FT;UG%:7>8?B M EC*)(BZ79L+HN,*

*(#BMH@356\$EMN8W#F="A0O9AR/&H2VNQ(+PM5EX^.E.3 M0A]II7GE9[0%/,S*S_P43IU62=K9,5HR!B:&W_^/MC#(5OF$(Z %\#.52. ^F*

*MJR^2L(R+#6!OZY7X_8%M5G)!XC<_A$YYU56:67K/023*6:(^)S*)7+%$FAA,3VUQ9%8*P3M$^Z'*3W MDRL@3CV*K0Q;_0&G"B*=UKA7K!*

*(*QZ&R(Q]TQD*NKRN+KOJU+U-IPS.[CJM1;S M],TH8WAAED?R<JJ1/^88K7]"RSTDPKFRX27810%[3G.W@\$^X=%?I@]PTX+N8+!CY'''?A$Z"]HNHI*

*M5=/\4]&;C.]+JHC-!D5,A?@=X;U!K^WHWZF60V5HJ"3]%9;I2*A?1D0M2 MN9<6KW1F*@M;9$5LE!31_PJB!'ON26$@!IF+:#X%R3QH3+M"2(,<=*

<>_\899 MDFSA49>G!,]&6S4WL/SM=#6PG+.\FE:;=;$13]Q'4VPA6LC%CD9*JKS$&'S. M%64?RSC$>^TS>&36F_;KS3I6G]1%>?LFSDF>/N1O(Y-

DQ\&P] M6T7+\T[R3B57#9F\@Z7#A]6-ZW,RSP$IV(+D?7TQ@^;ABD5HMUYL<.M:&]/& M9).]QB7-[W -O]_N@J8.&7:B-

*:X@:RU\A<*E*6P3TU,PR4A[(_]VF9GG]<,A M%B:ST,[0NN-GF-%,.RV6]14DT02Y89A'-QO/9H^_BN6:^=EV+!D&>]1&7NVE MWBW\KO(TFP?*

*FPQK(XUC/OJ)LN#ern?N@>EK'H$O?;N\=VV\-WC_4348GVCYRNR M<'7RN-SC1+53TI@&;0$;1%>5WI2:IU:O%*9AOJ?O<@$IA;K=Z$TZMF0\;ZC W*

*M].$O')PLIVA2IS0:EE.4SB2*SQ^R<_$1(?BB4/C3XZ_/5[!,7]$Y8*F'75_5 M?4/H_9P22AG]$1VEUF$X?S)*$(7]KNZ;G7=[I!/N.6@4Y^&IQ+TUP[Z(@58*

M]H&^R['WRQE]#V>;$Y(WKI8W"-6IP(E]N_I).94EH+/3]F4 GI M#''WPG- 3]7,= Z(UEQ<;C_(XN;_Q#)3.;/? #88=SO=7P1IA2?)#F3OY101

*M/5CP#LU/L9H2.H:Z3KGS@P M1GAQR*E4R6#$W2]446S,,2XCR462BV)NU.+GV98H8C59V1(W(L4EV2M"Z^Z%N/ M4X7#8;LQE04.)=:%QCJG*

H=#C+CCG+,KP2[!SA?LG,)+A]W&M"'^Q+K$N,M8Y M194.L;FW^(+]8@O7BA@S)S;PCPH9/3Q@;BA(P)RL5.D3G--=RW# (3A DI0' M2?

*M'13\6X.&AY&&Q",XIWG'((\!'5I:M2[#C>6K&UB_2L2Y6V377_^ISBG$< MCKE[G67Q/,D\@C,/I]#&X:0Q[7%N]R:Y1W*X-S#Z<)SU.;N%Y?,(YE':.;I*

M<$K4''7X-Q8]8]W66L3VRGI\LA[?#NL_9->LK*(>!NQ<,YTE2UP@2W'*%ASU M:Q$&+J,%9;2@!WQ.!29'@\;TM/=.QA)Q(2FG>,#1D,-

*%^NEZUI^E;I[0A!_P M3A&8HTL(M(N/],I()GG,[X7)@\/&;>"P6@N4=?!D3)",'9*7PA%[F%-2U;A3ES@)"?;K!3NG'*AQMS$=BQ\!(<%^U6#G*

M%.TY[HG=%(OB04Q3CF$<(3P51C)D:DN#ZR*UM$T?1 MUAM5L];$.%+Y2%GKI>"8UUW_A$,+ZW1(G48T73!),05(3=[-Z5B25 B2'N7C

M/UR[#'2X1>2X%P(SLG//>DVIAU>08V#R%;+<&?>5XI\337AD6' =Z\NP&O M>4-J+D4X72!,,(6^M"K G:'Y72|(-O4$/GD;I.XK#Z@< M\8EXZ+;*

M8GS$]7S%9,#C/ENRT;G!(]GHJ.0<3AZ[R1"X]%]W-HIEZ/QCH;U-_04]N&L@ MQGSZ3_C0G[Z7AT/G 92IBL9=I/$7TU<%8'_MPBA5^)&=LH%(X)?*

RK2I_*V8 MH"W=7,UPUS<+T[GQ1DG%SY[Z"UY]!5UEP:F7OD@[9.ICA'[,W,TE)5>]?0Z? M+G4R=X!DFL&H2I/#U)GY1IJX)ENS'?

P!C$(RH[B;RCNQ\!6ZBD,YIC)S;0"% M;2OFQM'6VG_9PQKLF 9_OL&;WS5G|>|T74OYC;BZLYJK,,3SU@;@V'3#7\A\ M90"47S5XW":O>.W14FZ!R7

*P5=>W3=PP,NT]$%2.1=^H=%NP0T@XR4??62B(MA+$()E'@K9-.VTNB X3<-C>P\]M_)&VW%)*PKR) MND910H?U?@=3:P7BF4]\VDNX7F&,'74(%L-*

*8M]W>XSP]7L2-CKJ?*3KW#O!'M5H"S=_8Y_=[P#\S5S=!MBFJ MC9+O, ^@.3/WJ"1=RQCY:XZ1'Q4)_#.HU3EH->83L1/];O4$/GD;I.XK#Z@< M\8EXZ+;*

]C6F_#LV%ZQI1^4W=7DD@Y4]<_>SO&UC),2RG@GC0F Z2UEM"N1(R M8D=P_'KGHJ(N_G)MYW@HUTH4\X5RFIYQ.Y],KJK?!KO:207V,"VF]!<2[F<

*MK5;XED6,^59Q+!A%IXZ.RY?1)\)?U2]B;(;93H3WBUU-'O$C+HK=XHG%'EKF= MTS>P[.VGO*@ONRSCQG146KJ<@M$O];K^V9W9CFHX&EZ8*O ?*

*M_UHB[M_VW>!XU[HC4>)W^)Z;'+WD>Z]'-&?EW<*L5.>%?!IDWB+[*(0GYLV(T/7DP39:'9,]>RX=^S M+1V'8%K_$EF36^E/]#=T=Y(Z+3_>_OJ MQ$-*

K._R).@-@ND[V3Q)%[78 E,D@IT56M[.S69'_XNR1Y[7A:+"W>DLQZ@W9G2=1EI_-O[.+N_6AEA9[U5W(SLXCZ_49=PH(_J/J[NK61 M\Z)L!3P5)

*<+N_K%=FOYS9B'']=:.8>.4O:121R0K2;[T_L 9"06/H67MBVE MV)W>-V+8J.$9BT>L4_'O*M#1[/HK>1'8I"EYMB?-7NNF[9KD;2+00D3_@!Y MLKAU_*

_Q5?'[OF]W#[_WCP_*[<-GY?'EM[LGY=OC||O3W/= MP]V7^Q?EV]/CKT^W7Y\3$I+'U>4#\9>%%Y7V"PJ4E%5AW_2=Z\H=UHYL +O/

M&/$=O\W40!YEYE;%%D&<90-#&PN8,]F;!^HV&12FEZ LMO,#0,&O4Y^_';W M4=F]EBS]\S^L-4?<&[@WFF->^D_]6"H[,\'G;&0Z]M?*

B;M,=>EAG8I+O]"(MH\L$.@N&6=VS*5Q;3>#5MH^<"_XQ@54OU9N=;;+5RRN?K%IWH,+7&,B(J$H MMU[.5EP?N44(U>&Y#0F*

*MS\1ZT^:$VC]E+N(.=E^?88V%/=C%?-!G6%$Q-W1.!O-G$%T&67@>@6]@XG]@ M0.= FC^ZT^%PV57J,M?;\L,R*25,ZP'3G 3AXC#MGKLY= RFQYP;T;--*

POPR M8)Z3GEDZ]?I>L;UTKBP)IE+XR%8/+QR9JK2)7=> ME^HFN5Z,%%;#U M#

4HC;$7BHH5W<^0LG&&+2B8M5%8K_&W^(GN.!G]&"^:F9=9T)G(!)X591 M\D9QN7;AU"ZLX12C=K?=F Z24NZLU#[2;2;1@N3&LO+#I&>]&XX*

M7]TNP VI'7&%XP;NYV610#_):A?/L<;(@58;9(-R@NVTGA)B<0,'_+N4@C^BVVS[$O"P@.GI+L].\,APTR.7F;TRPUTV1NN*T/I M13W "IU?*

XYR>2,7#T'J=->!3/F0."V%TYR^2D?@M"L43F4*GL0YXCRG!]<1 M..\)E6HJ<7H9.,WT^'($3OOBX/3ZHK?*

28K68S6PS2A=U9:RQ"MH[%26'R]3=[\NREKBM2<7(@2V2N8I;A@G MC2F_^W8.7'_'VWC)9Y+/#M+T3\!G_79:D'7-^*QB/>"(^#/)XI+%#S+03L'B

*M'2Z=).51*OFLMGR6L(U/P6>8ZLTO.^$H"RM#=V!G;AZ02N=\G+[_]SE-[9*[3/%1DU[M63>[_52WXO93CZZED.62S+&GG<(<%H]C_E L[*

'XKMI)]<;+G;"V67V6/QK M;Y=(=_ZK FH]P7L^L3T"UGG<$(:%T D&NQ5N:9_V3$MZR/].[ZL*3K73/NE< M!Z#:=UM)B?1WKY,A[#/M-*

K0V:8<=DNRPP_HQXLJPO443.SINV)3T;?.H%9]T MPN.?#X0H.O M+65IF6OZSC+T]!ZV1T\@;XVYIFNL5;3SA8#05?5G1W5D,F M=NZ/UG-+6;+Q0'QY

[+5+ES:!U15V$KPKGD)/S0MNXD[H[MX@W0RO)_0 MS2'&G, SN&WP'#%P0?!O>#,<'0L7WHV',[8 -6S_"WB8]KMC6TY?8!$52Y(

*M;6'^O'\M/4H L6%'UB."M_@!/V6GS;C3O(#1K/I M-WI7%1S07IF6LX3WV5@K5G;@@ *ZKG$!WE3>56MAMQ0E?M*

(TK'PRP'2\X@ M3?I\2$[8#>>>=$(,V+LQF$-Q" ,_$^6.$)M;& RP->\?N=)U5 6-OH%W@/U^)*

*M^6]IFQ5H$D2UL&&MK:RU'VQN%%WK#0#2]IO/OEN:0V[,Y1(_6*AK]146]!EO M@$!\,TYNJ?V SUB=/W@W7-]K?7 L4"!4$RV]$ M!T@PG*C*?*

*4:K[@#= P<56H13N<_^'\T!N*F8@.)O*1K6\IKRP#;!(7(&J M_*V(II]3W^E?/OO=^MP')@"Q++(43+.GVB.W./MV4N]K.']:]54*6T'\X'*

M$"4W"Y.JD/B&5*M@ K(J*XS(;_B6)@1@6^>HZM/ML5#.$\EL65M<9]4.A_< M896BQX>>]PA,$YD8*1I ^#A*M<26 @>?DF<4*

*H40FQ/@<7+$#MIU1RP*M> (.MQ?'4U/G2+WQQJI=K;388^?09T*)P.JF'XH0%8LHAIO:J&'P/G6, 4;, ^/E:V>4(_/") =51[> +"F*

M:VD"./=,;S&P)/\KM"0YQ!KJG4^*Q,F)@YT2OT"/^R3A][@SNNGN MC)X8[>I\'/FKKP[!] P,-CVQW0+LS3ZJ OD..+_/R'D%S^^S'^ =](/D'.'"' MR)+

*(Z;/"DM@DV=&-TV1RA)WE,]76;-A6LKEQ-S @&",J9<+P]DF-1=[PH(-_M)89*1=5LG4XA<9I6(NQV#.9#C>0DOZ7HRP?*

ZQX16>;/P)\RM^3HBYC^H/!W^'2%^9.E#:;BGX[@4QS+5FA&^G+X:! M<5SJJ:"S)8L;]0TF^4HB+C8Z"^ @UP&1RY37!? I_ _39_%FS7L++@(%.!/E

M3+T-?\48T-QXBNG3\Q\L1>0;_J&AIKS4?7YF!\7.K/U-PGF[MC\#!V6,"^< M&W]-G!5.J(#^XE&J/P!2^HKS!RHX82V_O&L+9^6G,T5^Y5WNM<.?J#/;Q

EF M_B1RB|=Z7HNA|'2[.YL5^>_|B>W 53AYW2U8U-/OA__++0{(VN;C]H!ETY_=$OWF >-R+D=][&*=.Q MKT,TMMH,D5X4NO=F{^L6?/6/Y.>#? FO8'Z5^U6YU4C_/&FK2&G MJ"_>ZKK=O2/EY!+LS2H:)AY+B1QB@OJ4X3+C@Z)E7]AGXRLSLNZ2GHT#]@)= MSF8\H+%\X%X,MOL#- -4BQOIRO.YGL,(LUR\ MJ;1HK7L_%.B;:;'XI-!8>3$?P!"""UE@5< C?@615"7,IEE8F&?(Z&%(8?AQB_\+290GE.2;9IHI, MK^3=>T:B5X4<- ((3C4/A%+&*I=>F9O3OQ+8_*__A)<3N[8,1HR0+RP-2VEY2 M +M0/,CV/*@(T:%5)45AOTJ-KWT\=@>/.}MX, R-?[_Y+[',5,X;-^"'<&G<[MW5\$*>,H0<+#UN",DHG(*)&-W,^D0/,%V; M,LBN%B2BH:0C&DJXWSZDSF@D MI.9XZ!7$(?$L98H6'[:7%\.4I97(5,[J5N&-K[J2Z94AH[SFF J- 7A4>9['= MS1)TIU,D4S'7K\2K*N51;;R-J2@9G-AS>.YBS,7B<\15"Q=;'027<_(/7@-K MG4SI^QS9[I"#'HCSN'Q1?Z1RTK Q'2?+"1]G4YU?W%XG1HJI? WD@*9A3.<1Z M3Q;2!HY2!(X095K^;)/-[^;5?EH),(+9WSNI'EJG75KC7,FW?+8&)!1:I7]XZQ]V2U)+%7R;$QT MTCJRPFHM$26YOJ%*HL)!!6TY4<#Y10L'=@@G9(UPN[9 MG9+%Q> 0/99),2@]EG41@2=39$N+0'8OTQ?_D"T92EFT'52-5,.'8RJ$'1D$ M46H;+S$KL-R&U%VPY1@'@,Q0M*6*'^R*WL^]M7L.DIPV6@G0R!]QU[57G@'U%'0K+UQ;/U2:S&W/-QW,9*XV4T'-Y1+YQ=[_O(VMU_>@7K;UF]^@=:,KOYQ M2>MXVUF5N[%9>{)RMZ 5NEF-?]_Z?K1'/LH65];UM&NVH MVT[6T;[ZL-75EY9UM&^$D)?:1WMCQ$]\"1%*"[CSI-M4,';@;U6Q&/8NXK2 M(-6*ZS6F@IGVX/35[N5<$F'2YXW0^Q>^H"7E551\YR;$LVPH'QU%@<(!9Y M19M++V75NN)P<+T/$"Z(=%D,]RA0W 6M-8- NFS:9NQ;M"'_=Y6SY:8!> \@$ M:]PN_G)M9TV,U#R-,0:R"5+U3Q+_>'WN2.J/Q:2^+#]:J0)V)'@F8H+GFHE_ M*NH? 7DQV(ES)81D!G86NS['+60Y^.O[!*#5EQ.-<>%F-88 M10FS]EQ_A7#6/8'#Y9IB826^]_8F%H(WO0NI>SR;A-DYO)"%<-8_@1]2Q+A) M_+>7ADFC FF4G[\@+V"/S@PHR0@5?3ILC].]Z364()_SU@D^]E>%I&YXD9V, M9%3@/XJS(HH-2$'S2#$P+FG-XI)(,BY)B88&'#C_%VT-;WH@[\J3N5:-: ("SL#8@G6)>^;2HS,E==FQXLFL5DDXW3>#==?:&L M5)!=*W4![X#_<[2;0*#Y,LZ("I164M(KB?A[NA/:<#18SLEDV9VT27^BCM1V M;TEFO4& JLR3JLM/Y_^9$1GZ4>9R?XB09I9PD3&R>$5'*-'(@Y+3,#!Y%IB1J328K"],IG@ MZ^+Y&Y_OGN[_=?MR_Z\[Y?]A^>7ICZ]W#R_/RNW#9^6WN\^_WC_\]MQ^@J_O M7^[OGI,*UDXB2NIQREZ;-IMNXPPD3%<&_B3>@4X0N:KRJILS5:7?NN)Y"H1G(R3_ T_BE0K',QW*KX*KX$3A%'^$]ZX8,)0-_MJ-;S+>HB9+UQ;)PDZ&E@(N!<;39;^BER+.CN&Z:NZ 38'=>)!=@,NI*_W,4K MP@Z5 ERGNME8Y@;V&#;'L=0%N3&72UB)\TZ(0<=MPN9A$1,4K5M/*[&=U!2; MK#2FZO*(.EU&;Z0HK I0!X- &;9O8>DKH=\U9^2(2G]*$HU<#7@G8L&W8,&+K MFCK3=,J@33H0@($J8*!]V4RBLP<-XOB_6Q##7&L&5=2 \KCE=ZYE-I6/>+8 MEKZAV=54/JU@&4#))V+ XS.MJ?QO%38,/_I_B=%4GM_)A__'\LTU*;RE?P MP\E0OA$;QKIU09J #04??,9$)@O& W@LHA^\N-9W',!WS5*9'G!OT >>W TA M+04VS8,4PL3?)C@"+6+,O2UT\8RB+ 0<3\T]NB[*2$WE?:7-5XJ]4^9P*1QQ M()? XDL=]3OE$CA7Z+N6\.D6Q*3CP@+@GTOD%!GB:S/5FM1:5T\!P5G8!FFN (LUIK/Y 'V%4G MG0S,0T6*W]#S:D%F#ILU,,&,Z!IY8SF1$;&M>D\X8,6#\1",E1;;L0[T-Z %DVZU(4&F$(8DN!XHPN'$WP'*&B70!Y+.?"HO0!1; =Q1'E#A%Y4H5,>'8Y@>^JZ%"+9] M:4>)E8+7#%V J@<&)W8,&+K MFCK3=,J@33H0@($J8*!]V4RBLP<-XOB_6Q##7&L&5=2 \KCE=ZYE-I6/>+8 MEKZAV=54/JU@&4#))V+ XS.MJ?QO%38,/_I_B=%4GM_) A__'\LTU*;RE?P MP\E0OA$;QKIU09J #04??,9$)@O& W@LHA^\N-9W',!WS5*9'G!OT >>W TA M+04VS8,4PL3?)C@"+6+,O2UT\8RB+ 0<3\T]NB[*2$WE?:7-5XJ]4^9P*1QQ M()? XDL=]3OE$CA7Z+N6\.D6Q*3CP@+@GTOD%!GB:S/5FM1:5T\!P5G8!FFN (LUIK/Y 'V%4G MG0S,0T6*W]#S:D%F#ILU,,&,Z!IY8SF1$;&M>D\X8,6#\1",E1;;L0[T-Z %DVZU(4&F$(8DN!XHPN'$WP'*&B70!Y+.?"HO0!1; =Q1'E#A%Y4H5,>'8Y@>^JZ%"+9] M:4>)E8+7#%V J@<&)W8,&+K MFCK3=,J@33H0@($J8*!]V4RBLP<-XOB_6Q##7&L&5=2 \KCE=ZYE-I6/>+8 MEKZAV=54/JU@&4#))V+ XS.MJ?QO%38,/_I_B=%4GM_) A__'\LTU*;RE?P MP\E0OA$;QKIU09J #04??,9$)@O& W@LHA^\N-9W',!WS5*9'G!OT >>W TA M+04VS8,4PL3?)C@"+6+,O2UT\8RB+ 0<3\T]NB[*2$WE?:7-5XJ]4^9P*1QQ M()? XDL=]3OE$CA7Z+N6\.D6Q*3CP@+@GTOD%!GB:S/5FM1:5T\!P5G8!FFN (LUIK/Y 'V%4G MG0S,0T6*W]#S:D%F#ILU,,&,Z!IY8SF1$;&M>D\X8,6#\1",E1;;L0[T-Z %DVZU(4&F$(8DN!XHPN'$WP'*&B70!Y+.?"HO0!1; =Q1T

M%O@_=^%;!U/]F5M@43Q"]=)!$U=0%.KGZR9K\Q8W6DZ_4)3'9[]JKW&M-=[MCS.GVE0L8F\(K;:L;YN*9LQU=T$6RMHTR-:KKZPL@0OH_JN;C67^@'DZ\'2Q M)?8&W?UL_17?R-+0O^#[LI87Y6LL_]A-M@7Q"X 7)T1OT-M/BD-G&27" /$R M[!U,A/>5-@<>L&AD'O6M 4&\@LU8_-I9D6@E]Y5&+-6:K[:M0)3Y{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|B>W :3=S(#2WV_4)T)4,;6W? H%*BY[?Y-EZG3\!59W#K!Q[V& M,(+#9Q5D;&,19R4?E\$SP=?-&&.Q%WALLX*_X9SP?VL#:E1+, ^TB/)=@N?BV MQRS\'7NEDPC0]#TB+"_PJW>,/QI/>-* AOA*FT']$>F!LK0OL*! ENB;<<,O? MA$SU@IMH0#KMA9VTTGI&*,$W6+2E;-#CR<*PWSM(#B&Z]'.KM/JCX=\NKW! M4.WTKXH, 6F-,Y_" (V5_WAMQ;F;'=7G=_+[QO>4[BV-1D-PHB M1X26BI4770CM#3 P9@0T<<.W F%$<|&M_,IQX1$G+7=RZI(_!:,?SK#68G>0 M_9PD3- _&_QI:KG]JSBIAU-MQ]JZ.^P"""6/WL^U4N ?N%]'=X3(1'Q9(%LB2W MU)Y:!]?AECBS4'=:_J-P:$=S4CXY!HQ15)63?':]?#84Y52:@-%="VZ3W"*] MW# (Z_ZDT:L.IE(R.$XU1+]J30!I=R'.>?H%RL7&QE565$3H'^YOGUJB\?64DNAUN@"3X3Q]'9_7S],= M86IF\IP^06*X$(YFR8>2#V-\V!/ 23WD? G5Z#@ZL4F\XXD)6F),H_NZ*%D'IW,HT,H/\ G M,HU.IM')-#J91B?3Z&0:G;BPJ-$:1 M(9N7E7_TB=4QCQ>? QI*6KP:,@K5+%;):,/U>1XI2(;DQJC8;X%=5,WXW;?O> M:Y]Q;]QYI"D2!C[NB18&+K&$6*HN?R ;1YU"0!(NGT#F,/'(<1HEX];Q2C'|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|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|-$P,[< MZ/=,3('"1=L<,7D(^L8TV MOP;R ,P)M8E ;WI=L<,7D(^L2'-GTG#"@^MI+9A<3:%Y*YG9RR6$>(W/O@#,!*VK<&X$GW MQ7!1JV;2F&0%$_AR&G8G/'5*'V\!I36@_9; X&3E15I*)"]E=\?5HN=):A\!F69.;E M@VV;H)KF397?2)OV).E+;O269]0;M MSI*HRT[GW]CQX%PJ:R(J,R> [K3,LFB3U3%Z1[$]D@^E8QFMX YC,CQ[@)-S- MCX(/D_E1SW>_?KU|>%'N'[X\/GV]?;E_?#@]M<@;/.V=72'.V\Z I>/1@VBE M6OOE/ZY[@> ,C|)W$CDM:>XD_@,WG2V5LCZ>CR:(415I +RY(&C0.BRM% X_ M&W^D+1F+@9U+U#7.@QYZWN_HD0C?SHB#[Z>*'/U^K1KN$@00$P-T !F/6J/('@@N79J?-L4E_.D-W #5M;-]-@:/#HO%(MIP6H,F6_S?"7.'.CTA]0M M;0!%8%8_+1W\^'H[CA=N H',4UN]@"MC$",1T M.P)IP-$2%I$TX+,5P8 [Y4^]&VEPKSFQ*5F!WR C_R/MC!]'W"G_[$)+R7K;D!K

MIG9+_TT,]9H>GVV2=I0D+8N1%N0YPUH4>[BKP!E#^\?/C]ICT_?[I\>?OWT7KM___3IR^?'4HK$

*M)]A^S=$=,,>H$2A^<9@[0M9_,&$C]AW7TUC@3QT7Z_5I#&:%1?PFYA!@\FSR M10BF0=BY &4 @&DZL >;_I0P,W'PPL88 \N@G3U$K.<[P^]3QP*R:<_,"GA= MNX>'&L,86#:TDU4I.;8Q*D IC@^21==F>8R>\+QV;GCXX_@ MC:NYRAJ#-9R!%8Q$V!MGBN:IR06Z/3 (/1K7H8_3U0L1+'P8X4*ZQH0[;\8*

MB+R[)%378H{JP5C=&YQ>BZY%%H"LVW8(^W"*I4E7!*8 MS+9V'TP"S]=T0ZA1@@]9U^PFH9[*);Q^^ MWK\6,C@$'X*9P,/QV+1,8#PI=Z"!!0O1?*

@4C< Z@'M:U6_G9:X23QRV+L!2G M623G#'P?C:!%TX02_-P"G/7'!*M7S7KO88V,,'S3\.0(U0,DB6(ZT"8^OM:&SX#7Q@M%>+ MP_TXIB5P1UZ?*

N!@:ETG#XPU$L3T")3G2'?_5KFE>,/B77"=- = 2E(M:DF/&$R2:2A!5Z55,>>-N76Z Y@<&>%%1BM.8+P8"%N(^$O<#MRX)&!2-#7-- M'!D+*

<8"^Y0QD?QE2D>K0XE_DU!-P5O:4Y\,'$L&TG\ D0"J SS"PZ:Q,K"D# M$ \XMR7J!41 M"/$DC32&/5P(X$JCA8/CWS3C+=--3G,!ZB?QZ/H<=LV@1BK2

*;M#:(O(7(L3 M,J[40+0BTP!E*YC3?)+6SO;'Q?X5K5BN$C,-V R@0:@ ,M]Y2YL#1*2QN9 H,@A\]IV#%0,"&'AI%B%2%B;]*

*M3*02L$6C"7GLH'*;P^:+5:E7NE(\$<(0<4G*&$0==3MNH<%*&CZL+YPDX6PMX@BA'6:#"N!9H6<:T6%&=(B[M2AX^9(Z7PF;RP2N=X3R2KI-0F*

../9,UBJ32]P#' "VLP"5S%0< ,0>5'"^:O M;8?Q)9CCC+MD#J"N>28_LZ[]B=S#I7EIF$$8F+=DV4(%CA&'\G0];>

MFZALMRQO(2:.4LSF)BJPWSK(+_D0Y?)QZ>&Q@%TYM8.6$?O1URMP9&_ MSANDZ1(?,G]HA4' R*7E7Q>![3V,]X,]*?@2DQ2-A$*/\7-*

,J'2A1$D]MJ7 M3;&$(PR_^PR.OJ;C7Q3GU,7^ S3[AX ,T&PSNO>/UW7M2XQVL!I4=20,X + MGFY%'VVQ!

3:+)$)*5RL@Y!Q.;U.UOD)QVKE@L=.+"A$LB!U'>AG9/P#'$% MX/^][.A5YAP7(1%7G;OI81Z:Y>B#J,/OYB.D#+M$0]O"-:WOWQ]?%WZ6$04 MVM6,?*

*FV;)H[; MN7&F%/!)O)DY=V;>28"X^[WQ&!Y-#MIM15L;/'K=*GF#)) M!JV3!F\TM:^/R3C&87'M9E)S2?5T B>27(6_*1@ -!]3=!,$CEE6:'.GQ#8D*

ML4"4X^*MSB6WG4LVMY]+EN>(L5"QIU#$G"VC$)V4GQ$?@$(?6+)5=L)>M76 M6T)*9E)H4?.O;*$Y ['0!H[K4L! =*.NV[>?;Q___3EVZ-*

*V__'CP_NG3Y]_U;[\^4W[]O#X MY^]/CJ]7KP_?[LMPSI4_ _5R[Z7<9C\EMEF*FJ[/.PS\#,C0]A-!(I=" M_'@\L]@,<'0_CX[#M.2-*

IH_\3+'3NHME,P@)6(.PY-JO!_DA;RXC-0+?%_)2 MVBEQQM-DR$,^[>#@;&A:>/@ O_T#PRIV3?M03D:*@=^-7XP W5\P2P\LP:XM..G_Q$_E?\8!-

MF!)\!A/AN[JG5[H%T94BP6LPETME;K$(X^8]@S#BW;"K5@=H2;'T=O)@>#E M*2-M>+%_8[/YVY4?*

X87H,%CA/588O=S;5W@LS%=3^X?.YD*SG!TP9-8)+; M#:+DD7,'3[E@D8W,1"26F MR_!;)$NH0,!*3\&[6-D&XD/ OHY)GB1>%*

(;.QW4!AGB,+TQ49SS&M+L!@DO M<.EX&DQ^C.-1."1*R?GH.+XM'']<\ABY@5F!JQ066OKF&%H8OX=!UK5E.???2 M1Q$M>@_L\5%G(XA^%:AX*

*+0Y,W.X2K&289AO*X_Y#X;Q**^+#KQ W'*[>':00P@R0)6H21*!2D%)!Y3BRLH*5*(B!%P?NE%3;;=4-76 M0A$*3W5$;&&*J9X3@)7+-U$<,U*

*BF!*B%Z/RC[(5X)@FM*9Y'@B M!(X5QX@1*:N1Z.SSNJ9-@0X(9A1^2BM-: EQ,".UG?3.XH18<$:(Y\\4EHJ] M?J-*

*5#4Z$=%:XN\N=.DUH:SCE9U$,WAZ+WD,:?,*M&.%0\6 ^'',QS;<<*:0%< M#Q%NB$ZG#,>A^XP!IJDYGQ-KZ$>,?#>:(&@8:R2"?*

0N&X7;MS^^(>%X+#WO' MECGT0R7XASD:@6IZ8)X//T 3AHP&<,4G'@:LR5QY8N:"V;6("'_6'^NUF&J- M<&

*<.E@W%,"4Q8<<(=1YAT<,#5V"$Y020<#005]3M>N8((*)Y:4YB#*SZ;@ M*)[=[C=*=''%A]RWX&&Z8#["\[MC=5%8;XD=*

*<@GQRU#)*Y+LD2+#!>SX1\418NP6P" M&36$7X6*>74EA&SNC*]#'1[GJGP9ZD-)>%2);*Z'P3MQ3P/G. I3JV7T&N/:*

MC"+=F(]=I$]56_68C:]1<:$O"U,)Q7<)8;CKDG.".Q/(1/H7B79#F54;MO MGI@BGV'/LD@;>5,F\<=<$1U^9=3;>GBO4SS5JO>;*4]EGE6SCOM;QI74*

M$A WPXN3Y%1CYA@E\Y-62+E_9F>C\P"30[KZ6G*((%P[A00'K*>YUWKDMA$= M-!RRCG]CGT@1#'FIZVD+B2'RUG(\4/99@)FA%;

\E9O=E\G@7F+R'S],C1; M&]#L=G9 <^]4YKH6L7+OM12-3+UN&"D?::1I^D-T]LD6>[C($(SZZ8JZF;+NDRVB M>>PB>]WT1:1HM30EO<=:]M?-

*PF;H&.M(;KZ(OMMF;U.A-WI"OT U7PVS?PR MD9&'[48WE8?]-'5V(K4L;]T=OH14HT>GCZ0C1*E#H0Y <)GBU@(NIY50 !;S M7G !9.UJ=*-LY=;-*

XP>^()NB:W,,)O@&)-V,CFG!6'.27#R$("LO/YT0I?1, M[C'<,I,1AHAL\D"FEG;P']?JRB<&W7]Q%_: M ? 6G?<)>K"VN+\&8!G2(?P M E%OV0LSPE\#PR-

3;U(=H<7'JRC\,,]'R: M28-[N7K5J@5I+03<'E=AQB9NAVDW8K3P,LQKE,I?@1GF1X$D.P."M0<6)^Z] MT5EO>#3%T>L7VN6#&TQ*

*76*PCE+@D5:W'S_/O.?2D;X+?,'!%A24@.J0N*6 QA1%=N+LNZ]A&< 4KW MV!\HS8,L\]7Q->X)%F<4GDALVJMH()IFH3L07JH0G'N=2?Y6^9"K MMU#*

*% T^B3Z*W$J51>F%LSGWH[3F,"ZE3@.WG0:VU&G@&DF$,)&\1%&_59A: MZ$[^&L1&A.YFCBO]*

(!#C5,M.?!LV2A;17\2U=C\A6PB>$5^^'Y*#M%MCP!/2 MC8K%]*TK&F34HTK6*GHUV;(Y NX&VHW$3 0T<AQ\]_HF=;0N>,^JL#(@<6Q_A6$WBP%

*(RP_S/8,=]CP)"DB %V5DLNK M:4/SV;1(;HFL F#AJOA73X./'"MC,5! *^:8#)K4G7#_D)&:(W.?5QI#9/" M71D%CDNT&X$=+08FCX9.31)93*O!0L-Y/[U>*

(6OJ8VJ,'E!@H5V.Q!=A?6& MW->TFV^F]QVV5+) ^;U!2C[8\DG=QSTVG]%C_YR^?[WZ]O_^]??ST^?[S^T_W MQVM_/_P__OGMX=SGY-

O#9O'K)21PW,6M&8]68Z[KZD 2C#T\)/,IG!\ZLM)Y MCBYLH.X)4+,,&(I5/QDGD?1C+01Y'#T?C"EME=7$FNMH<.LY)?[E&?AD)!+1*

*M5\E4,DB&1C/>E1;_0E7R#+K?2Y2% /<^\$%', M0D[?D> V14-[K$+6Z0#+C MXS\^!%YM&&6

7GSK8XOY6N#L'48D]7 M_K0B24.[COQNQ4E?=,/Z\"_4B2-J&W#7WAG0 ^V<_<\ZE[@#F;,]/%/RMS MV-?->-*

*BG^F!5V=POP*A7R+A69!RBVU5'1H4LI7,JBXQ#KV&4X++%59V!95K^ M98A0MB674;B.RK$X3V17X4SAK.@SL+TGDB6S3"%8(5AI2H6S?*

*&H)E>C6\>;) M7/4.$,3)@?;$?H2'!SE=%B%9YR@Y0C3Y4/?TYRQYLD3@4I= M,N\?T6.Z:HWD;]N=S)FS>6ZVET7+[%G()Z*WS,N.RB'D&9.=^C%ZV*

M^&'Q)^G7&;JO1/3^MM7.?#,]"](+/1]2."LOS[J]TN$L=^V>RV&Z G%Y0=5O MEP[$"F<7B+->MUPX._)$70R4,J^#^\;6!)>K4M\/%'LRG\4)_#?

FYW\GC_= M2H/P=KUW>,WF;Z&2WJ^WRT&D(W,;+IA%C7JC'"PJ,9&,=AJ0:5/YV6>PF##D M#?

\)9S1C[L2TPT6'JQ#Q?I&%X%T6JEIC[CMO|D3G^6SK-Y+JS(J3F>*^SS MQB0-^O5&!]?)7 UEWN!Y7O:V'$U?V]Z(^VO@+D^=_$HQ&@8+2J^"W\T-*

=,> M6L&(C[1!;OOCX13(SND(Y97>TV#B5EB[U6K)TZNY(#H1^X6$H;'W3HKOV6 M]SD>S#^:E/CGW#4!CL!$CH[K$]$L]Y^)

*Y7M)48&J@0?,.$VS!#BU[-1C/3-F$%=,*EC0-[2%.OT;=B'3#U?V\,(NB_MN981#F8. OH]?&5:-/.Z]HV/X0&8Y&?'YYK>@(E3A%+3<5A8EZ?]0P >2/&-*

*MTS1@B(^P OCUW3\(C^/ I?>:.]FIE+I\P%V4*EPU8"=%&"Y"LMDPVB&:2/*&K ME+HR2J]N^-XJZU4[*?^&EBKX*

G\X.&QUT\QZ"-3:ESX6;QFN1";Q=0<3A-* M86S!RU&.:"6AB-FX3 27>&Q==|3&A=?\!J]TG5E=^V33A%!>'82D>"5W.8T+ M/($W.N.QQWUM*

*HYMN*R#(\1R/LI^KJC &[,3%=[-M9E8&^OC/^QM'[&X'\AOH+9W LQ2]@<8K@#>\7@,HQ* ZE= M.B!);^\@'-E@A5^2LZR*

*M5&CDW;?21L/)+ES3YW=@\^+O1FP&.QG'XQF8BDI1S/X'?,8\LI{I!F6\SE/L; MAG+L32:8ZRY12X0@:$/$_ _|Q%Y8]TA*D(A"A:-M3NJ;36_34\W+4:UK59;"*

MSD5)02)$UDW#+++>?3=>QI0$,[^3N,QU_!: 3:#]\@%$V0$)YY7>4+IE%*7U^$DC0@9P&LS..Y_]T"P' ME*4G&&,*

{]AW0^CNGX#^I8^DV8=/06/@>4'X4OY8_@7F###3T(?MG_;&^;MK O$C1ABA"S?I? MYLCF2^T|NEP>GR">MD!S#O[=D,7<2@PJNDRZ;#0C6(O\Q8#*

["\YM&<\+B C) MXX:$NEU]EWZTD\;,]"CJ%F:(2/GP>.P1'KA74BCV$/2\5[;>/RAY3[Y>MC M=*R3]4!J-?-6N_PP"IMINC99&(X[*

*>TH3UKH]"4T>&[#6S;BQ=G>Z68E7K.1 *8T+-@E*$U"ZL Q>!M1QP2>9(JB+$8OF|05C?6-\43(R"X6Q)GO-K:\@I7Z8ENT*

*M)'X1;\X,=Z]%*67R(7!ANP.*_VG#*/_'TV9\A&;J-N+/YA#W[4E@R!B5&CSK9D$OT@AG[N_*B?P2%U/P-#@:/?,76<$IB&8+.LZG50=B(=4@"X8*

*M*HXKP;RR(4>F"\#?M*S]VC]YI"T){6R$9]90\;ZT2U?X!O$8P&__IS8YABD MP$8#AM^!2HY^Z+A+:9(V[R^3/[""_;_C$WDCX3MPDA<";S0990?*

G930',> MY4S7,%]P2$T'C#W8?VP'=Q844C+XX%7"VH2O5@:OU&&5WA%:%=D12)MOU>(K M)R;F0S4C-1XS!9B&V/#@'Z$5@+]=,!?|

*'\IK6%4SP(2*Z<"8&%ZR/4QF"XP MS-CD%CI-KBN#H6PH0

*M(.X(094T+/1%QF/T;J@KP6ZB4T8*Z6))F) N;.+RL*"8--\97K@/Y@C] ;._M>V)G1"J8OKS]B1?SS1$QQ.,VGA8'-AVTQ&T8LE.0T!-XQP1OEVZ:&F,-7@0#*
MH@9K)S578[0WNK@/7',$V'>KCF]=;C)ZUWXD[R0,>"T\@8.;BB!N+?2!T; SX M9 SC:+?LM8P\K;*=TES3ZTW#^$E[%$O]I/B*
(JRM\QF+L5"!F7Y\4_H(JZ># MDF^XZ)T_C]$':ROBT[5?YCBT&5E9B2VLMO!ZS#L&J_*0_NBSWYHELD&D:)R M38]J6(C$71@1;^>[W'$GS*
Z#-6BI>DP>HX=1N# Q('9I.^TF>EBN(AN/XC8I MFD=D%28S BS'GMP1!4046014D*5\/(:=3")P)C2J:*O[O_VOOVYO:QK9\OXHJ M<\YMF!(& P:2G.DIAY*
TW0E)D_3MF;]NR9:,=9 ECR0#GD]_UW/O+[W7;ZDCT3R:GDJ2<3I/Y/2B:0:W*K?9)+%@0NAH*
MW6OM=_[>6B73WU]7AR#HQK13BEB"&!^PQOUKHJ6(%E59,7,)P6E8U5ZR 4"|*
MB+H0'[^F$ZN\6=]W#Z$IFGKFZ\#D@OB9$VD.OW<6+9X)6W%6^SY(3@.7$ M+I))/8A!5 ;'S'P01D4_CWOHD.[!<2'T8@HPA MDHP66@HS*
2[N7V+F]"1Y%&7*C(E+H 5$;OY]<$291X4%;%D3BC?F 7Q@&]]_MPVR5UI?0-'@M*SQXP02(R<$S&H<250CGZ"[-<-B(]BHD0%$#T)6L,)@6=IX< M*
U!;"Q63P?+Q0QI*IPY" =*6PQNDMA#[G!2\;8^V]/A2-E^1X64/7"HYZ]@7,#WIHZ}6"2Y(E1L_,!CBD'3IK>,-^[M:;BN@3TIXCM8KP*;*
\B"43(,ON;721IYUL?61$'TFY+8]SX&.1B.\G?'KSRE MP\R^\:0.RQC:'8:1F^0D2"IB@2TR1/IQM+ 99CYLW,/\@"11P>SLV*"VV*'V M@Z:.,*
,54@9)VH'"S@3L]"W&<9H-!HM-I>ZBZ#@1,/$RXM49>2?9"&VK"0V M\EF,-,>HJ=#J@9B%*R5!03@3>RM$()82&*
M.LY=O:G8BN:=8F@4C]_44;GK"E_N>RQA-%Q!PC]ULS&G>H(=#*E=1DHX2;V MS,'699V]?FO)A36*
$C3=99K:0R$LJ4Y(0'2GZ)8IQ*G'%BA&1W[QH(KZG&XU#'8WM1,J))3<2,<#/Y M<)-SUV$DW&U#?5!9#PP^*_^_K*;J(2B'8 Q<#6M'?*
C"A+ ^LE62[&)MFV&;(3 M3D9%+%N@=?(A1+U2TV3ZZE0DH,3F&>BA+]+P(A\5"K:TG6QX9O=,B]XF M\AWN6Q5';[VL)XH, MZDY0'"F_-2).&*
[ETZ6ZL%O>)X(NU.1*P*(?$\9FT<)3 C0FSP)^$&.$? \ML MDCC1:""WP0XZ,V?XI_!R!/%W,?B-@RE.\851]$#\UAP;!LG 9I)^F?3^*<9. M(XE84I2O0!G-*
43D $B2]RDCSFZ2BWDMZUS M\ZX!A=-.5O8-/PBH#7&M:*=R(876%)D)S@>AWG&<>LI",,$IEV@P9]]T^N.$ M(S)%04.*TOY4Z89=9VCPHWV*
<+M@V6*KD%GVRW7D6F3T'=TGZI:$;AS)5,17 M*>QU/Z"M=YN.](1$5,!BHC:!,Y9!$MW%=FOL MDOL1IX[_67QC(8$$0FYB\&X1 34%Z6N$*G?)9??/F*
M#6XC_-CQ[!D>]/HDRZZE3P1_=AO@^U),9T"/ !($$PCI'OBX]A2>-81W^WC? MNP.JF D83)W, =/6@+:=)P?6" :1L H&SKX[<^ 7<3I":"-R7[@IS,&>TI@J*
M*769^ (Q2LM*3*"V#VF[H#H@]4>Y-1_U?G%!N$LDG*:A;+#7G0XLP<>CS21' M7@0,*W'DZ0/C.XQJ7(37Y@L:4E@Z1&#?WN7S,LG#ZDX$S)TF29%*C
M:%_#NHQ.<$E0^+.(>%D [^.G> ^!]>GG^!?RT^'KGIY^^^N/BZ_G%>_SIP_G M!^=KC-Y-J;56#[>??=[N?U9HH!#N>Z(H42^"CJ**B MR&3*\<#("*
66GM'K19$A%5AZ)JCC$AU)V$$ Y(.3.N.;/C$L-K2%%!PG%W*< M3H85@8I @2=_G"4HQ J4YZ9P$B:(V4%>V^BRP/@10(84LWEK,H_83ZOJZ*R7 M!]1X*
(1+2*E@?90>_2#QQ?3%.CSW4O*?8D^/>$2ME7B)6?$8Q\8E7W5U.H-E M<<@>*F==?+*UXCZRH"P7L73G[!(8S!-4*T#*
[5(]^M6I1FX=7VAW>Q(WGQ8V/ M-G'CVI($/4S%(6\OL0#!BB@I &8:6\3L,!+C99**C8?&*XC;RNG@@T\%K:)L M?S2LR(0/WH*8FH !)"G9W31(IJ#;X8O?*
F2-SJJHP77-I6[TX $I%U'=5\QD, M8"E>O__(A93GHW& &@JG)[X'(>H2XVU,8SYQF2]_ MM*?4:7M+.C3O"/*L/T 57TLA?-[L;(AT97*;)%%;\9ZN=.=BNZ' ?*
DMV.CA(M3G2,R ,$EWGHQC%5C+9S%5BQK4 *,6FJHLB72PKSH"*AL&>]&UE3D8RR73Q!*G32;':M%1 MAG'+6?O*?@G,%HX\VDS\A_(P[_&*
LF])=L"F>)MWJ)_B/D*@GHVMP_V*VW1- M3=(9AH^[08[?@QJ$L=?,U9Q4"9NIL#D$: $)O%J)_C=;.0=[3\?*N3P[/;OX*
M6K%Q+C]=P. ^G9Q_AB^4LG>\G_1K$T=YG)FN310DVD/B@$?Q=N^5]^1:"G;'U MKOOES;9"E]\RZ8UEIK:?JQB;47I$-*
E5J/8WU:.R7F49LK2NS[C\@P4(=^-% M)^,(\\%CR@,!UE2HQ0^_LU:&CA7E%'+S_7:1Y@H1:J%XM9IY_.HLU8%HTZ=> M!"1"D1 NK>U(?*
D$0VN!SdMdL$V&N-ZAS@@O,&DAVLK3MJ"*4V+VI3:>G=.S MJD?K<7/5!;.<#B4#C1H2_?*'$.%+WSOGR7^ERf(#0W_%AC?YPY>R%"\ENJ[WM*
M4!QN![7R R:K#>!BRV3)29]'&.P#^]WV -S:WZYN4'4_S!U(!J1S<-$U1C$# M3)2#\U>*WV\(@QIF25A/!"HK&6UF^-6A:]P(/C6U46%E.'R@A((XO(()*'ZE*
M=>ULV+5>-,C(B-%[]3QZ6P)PM*V=L>=>P"E:CW@R.Q2S(Z7)Y@=Q"%#%'R.6 M-@ZBS6B[9QQ_04H>/!TI^>'L??>#=_J)).39Q=JZ_"^C043Q3?)_':GN?*
PZ; MY;4Y^X@.C9C.HBHE<%02H?NK*.W')A$,#ADZ:>1;JGC0-#]CP[,C[Y83\+B. M";2S7+0S22P@3$EJ0HHD2,*
[]N!@"33G>0#4A:$BQ1@AGM(K7@]Y/@GB$QDG* MF6#&?15*#D5J@LE:\H+V#V6?L)?2S"[F C:K,0O"+ZY02DFGU%W4S%Z]&ZS3*
M2X]>]Z#]N4I%'MDVL]6H9]-(K!&10>F+*V1?20S%O)DW2^+L?.)54/X7BTV. M/,N 3'Q3[1F)-2\^W.JBT_UP@H<;:)#
R.)$7]NP&J)28^5M4%/;RE!>W;/ M-OT_OM 'Y=G[/SYTOWZZ_&_O8_?KU[/+]>1@#N8=*-WQ M: 1$SCZ&L9N[@6+?]22N-*
4<_3=#*!B4((B<#OLA'L5(YEO\W3:?+HI[O,LR M#O2]S2=7H'B,XC0N-)EIZ]W;[C9GD9%^'B"OX-1E&^_E0YHB2IOO"53;'<(4*
M@EX0HO8&UJS#C28EKS1(HX5Z#X6 T,O#\#KJ?X$.'Q+\1L'* MK9-%3@PNI/N"+?J@^K#MUQ_YM_9)YS4-+8]VY'(9G8O)H'D8.*!WH%?*
1'8X;2P;BUGA)CM13;_D^,2%-X-\,JT MQ)!0H"[,,%8NR2WT?(Q,"+O]4GQL0"LFK,WC.N 1B(.HL9TR%K-EP-'+B/*- M--9O"@0T@9#D8F4I:.I=H-*
,;$VS]RW_J-\\XH3X,<&?5I_QD)4/LL LGT)'5D M.9:E&"*
<5X*!&.?!!C7)66$5UU.HLXR]N!IV04>T3OB,O!%)5S!5,96=0F+#V94EY@QI5>F8R]009^<^".17CO' 2P M03+8\#U1>H7)%9RO04SI"JP2-5H"U%*
(Q:\&=(F5RZ%MJE,HWK?TF[CDO[GF\ MB7O6ED2A631)KXQ,(L$(>"C(S9+]S&E4WF;Y-5$Y45D23!"W+I1<;M VXA[0*
M!.BI6%5A$PXEBQ9=8.;QJK<\KOJV!'-N=[Z5.;.1 M!0[+]YZA%XF999=YUJYP$&8@Q>ZD/SIJ M'W0.3EK#!N4FK M!FH_%I-HYZAR"W;>S=[S?J33!?*
K#M^/+I MV(IO/EW^V;U\N_/ATZ??,#1T?@&?@/5X_NGB>U+%/)2'Y>*4)X\L S0[S/', M"IR'*M1@B$HU>*(.)E3"R61H[^W3NX-=,2504RD0)Y*
PT"@X0Y&G*E*P;S M5VC/ '%Q!O9-$=8WW*"7_HOIS@*&KW""7*(/>X2=-5 5:K]\V?'9$(&#@?GL M5%C)1E[%NT=M'N8,QF"6:0D-NZ'$N, 41/;82":*
L4'4AP>6SF0T=K+\I6Z+ MX.1-C(=&&681>[I" K^GU4P(MX=+)V"ERRRGF"^FO\EX4 J3X[V(W&%S;7*< M>RE7I:D*W4A;,BO! 2DM9@HC+*
)'/VEA%$N0\6&A^P>[:C9*/L)@?>,S="#6 M/^S/^K 8SOI4/'-% 7.3R5?_ O8+O2+-S[6RKO$DVM#F]=1WK#[&*+IN?,@U*
M0\T12BU2\\F3O)@T/\8X$;+:Q"F&,7H$Y?S0(/9@+ M;I*H C$%Y^-ZR=J#2LUL12-RXT&6Q)F;[^PT8Q'O,\E$JB6I9?IP]2/E:YE" M.:E_YZ9ZP-^R?*
FQC$K,K2:HEINX\^!4W)APB'?@F>="7\GP]%:%V6BE,SK1=ME[&S:X@(L!/H?F=#'_I%05Y'7>]5CNPN(M5"Q*? 75Z&4J1",@ EG:O3= M=]-*
PJGGDK@1PJFKJ&WSEYCCRYF%917H54YT(YC@ZR5;HX+U*LAYVQ0*RRT88 MT7:J(@NLBT*"RO*1EOG KSOJ.U$.X<0PS'J-8A-*
[0Z%E]MI\4VR;JI=+*M=XZXWC,:GC[OJX&R_V(B?E 5OE M:K(D0G 1,EV7CV":Y7OSF%+:A&R%@B5MKA>TM%6/CKX'&Z*
MAPG9G5.1Z0AS+%85BXA+2CGX61K,0;._&,6/I=,FEQ*AL:[WT=FG^DM,R\L- M6>VXX"S,A50FY4"(4 V$]4&*
<09A2CGP3%X:-800ZOS&H]NEHG[ANSH@L+DRVKMDQXC-Q-#S=N"=9;FO<-)J-$R*6"0H5[J1V^HWS_F2$F3!]FY10U@T(L.0XH8$F MIA%H7)I;DZK-*
@T,% I.;3#S;1M/QF39XS3F[09$1A(_??*?BY@CL6<0,!L6(M O;Y%4.2=(SB&@=T^)^)*IBBW,2N(E;1AC=1?V)2A?5^F8J MK;XH72#*
[']%]M3,7<[6^ZB;6S--R5X"NJ$[02.C"W=_M MUYLCMIHC-@CB1)0^-MTHGT7=*H15;&2# 1Y#$<%B'ZZH9SOPYP5R\@1V:XY)^EO M3E@_$14+*
I+3F%A8!](F;_9 MJKY1$\E+<$/X$P47+UFOBT\\BLTVZ;JB#,O'5/$DB:B6CW.VK8!4,P,A=K#< MCX';&&<)OZ1(C/H"_,SDN XDGH26$=+Y)K-*
G7F;/R3IG]BPZL8]Z/IU>W42I M5>191$PL4:&?2^OL98[RFQAI=DLP<@L@Z,!4'R3BSH5+# RYLE6W4B=!O.&?"@(2:!E)ZC>,&(FW&0"*
<@MX4MPP@W>EN* MH< E %4/D>4:C%L936XIEO-Z)*2=P/RM '_MR&:%1%-51[.#_0ZV^4+'K$X M)X<;9-10&(OW6I-*
PT_SPW0^-4\CM11!/83@+.OB>DNLT"#3B;^^I;Y\WA_7 MR.U,!@$, U1= W@4AR&H%6?H'7((#I]$L/$E*(HD]]&R'V*Y(3)NDQU\22@J M >H-'+HL>.*
[PM%.8=^![7X/X-DBMR* Z*/VC.H$(#36W65MAQRLS5KYN-@"V MNZ]ET\0W1PSDSQM%CSIP<4>YVJ:Y0>:*
M!,,E[O.ET3CFQWPU:XU(:!2TDC>.M"':?",QJH2:%KP@S+:*XI@*^^B]LGE#4@"#+U3!#GM/TRR3$8 MF4;>+Q%8J-*
'VC#01#KO5A9$CSACAKY[FK_X+ACG6&*53-%BO>"XC? X690ED M()>K34 $Y:+3F;/HB$J"87.C)*IO-1PU4D8&M@$RJX#<0L9#9#+%K(O)[<&7*
M1T#%*GL?N.V&E. \IL#0U(+19KI'R*74%&+-63<$V MM;BYS7O+J4R8YI57 0%5[4%.2H!>0YLHACYBZ1G*
M563N&E']5WS,)H]0R/,6;GU];V;^AN"6]+EIMRF!.!MTYQJ8,SKC]5=.,_^:] ML/YZRFP76.Q P#PJ4-L3J\ZX#2;N6MBUFH.6\!0* M$/=./Y?3L*T:=!$>-*
PO0S-X9N1T@7F$I,> M3>FD3,;]A;"ROAZGU(F3SL!VH6B+RSPK L1"W9#NRO)2.&:F&439@/96LE48 M6*!?\G8C93%P/&TFR)AW;[NLRF-*
SU7$$_B(X3K<(*][Q0G+U.UN*FS*.2B} M+*238$UDM67@/&Q5:>G+V:GOO?WTJS'BN["Y.?K5WDO(6'@EY4EN<_G-B3@R%@=!\M(FD/8=*
MU"4%:R1\-\?XEFZ!>=P7E"@G\PF[P"HRF"UO@H-+Q1]YV2R3&H->Y169.!E, M[="K^,LFZ:0&F/PUHDMV(V-35N.QG-B:UZ;RI>)*
6+XBB$5GRI*W)#9"LB M,@PSXNIBSR[^KDB9L()E&G9F,97G]RN8 MR[,GR,VA9\^%E%W3/%#T^#W1-0[Z;GL?\VS+8<'MC5%#CVS33X=*
[U'@&CW;N M>!32-L;94$,9@G2D'#N;OL&5DMQ4DN%6IO8/@B&X?Y77DG"[!3F'@1-'TA-]MFN6O+%KNALS%C?F N9%*
M;]F8HCV;J.U@=V_)*IQ_Q$CD)VS$*P87'2;IE>+;%I32/F9@0018[<$L0Z00 MV)3;"#,&V!AM[_W="TB,"1-OW_;W#0X5E3HR/ ML%*#FQ7NG*F[BL;78*
"U^]=SZY$%S]S\419&"1<>]#'N&!4S*&"F3/D&*] Z M0LH8L;A#Y,*]GIY['D(;5+O#M-9!2VQ^3L=Q$>18#;J(.S*XI% MR^L;P'9UX>!+AE$2,KP0Z*:F$=*
LQH5!1LT_5<(VN7VA/A$RT2-M6K+%6A[O2P0N-*@G A;/1OC["^.46]VV?&Y'I.ASTKJ+:LIJ;N%8< MJT1..;9()P=NI9N]RAP"T%ZFHG3=*
<[Y;VU0%>Z\]JK<>=>U-NZ)=UYAW/= M:<9]11@?O<9H;Y"-##?D'TLZM9X)L6V?,BM%)[(M/,.X;=<^E3!#_0=S%[,_MAG'!F]!L.!W&T<*
J(\PXU%$_(4X&!ATDN9Z_MRQ2OL=VU846)TN7>^-NH'8V M\OS0+F+?7<2Q641OJ]]%\1)S>KWV0;#3[FP)9E"[$\I?7*I# 5/;H?%,]0G3 MF/'@D)*
-5MXBYR/SE7;_F*UJ^6]T3XMI'E$AC+\OJ)LE%R!C=A$H5ERA4B@_MV&8[]XQ\#;M\+CITI[IC]\A]^K14P@6+ ';HJ2Z8)F9T/5KOX>%;BUAA$EHQ*
KLMW>PVA&_8;_:P$V5Z[P7_8]#3ZVV/5>K_1!=P<'\ MS,BU&$E85\Y;20@!)OD9W=#GOJ2*^=Y%!L;P$7)23.'DENS_)!EQRG[J:07 MP*
SFLRP%'#Y=^NBV/#+UO7?B]VHJ40O[#SYR>$S:)HN>-PNKR)_,?)B$JZ<M1X"0)Y_,W?GWO\TASK)U$AQ(H*
M"M2U$_3N,P[I.N8'JB#2Q%QXA6$4G!!G!'$.V@E*S"08%!$K_>4UH@_DL_Z[C5.5[\J%U:>Z-8",5QLXT2/>D)TL9_
MO#AX874/8HJO\KPV7+6[WI?)].9=K[2<9F#9S'WJC[]J,XUUNFHSC76ZBJ:Q M2V+H!RDYYZGWZP0TDOV[]CY'MM]D&),CMRP&!BDXZ0"/-3I0:+I%
R.J@OGM MW9*KH5=$_S,!!92]1EJ*JRTXD5 XJ+EO:5N!\"XP5&<"7"*!?XQRC+)QA$'I_:[<.]KR>Q.;S:"1X1,Y-9E]+G8!?W6O##-&O M,W%H!!C6'L?*
LA]}T^&]7^H_VUE*GZ[0D['?NV$5K:;S](([#8WHI] MW64T@!?OO'SAI<$(QA#UPU?H^&KO]3KM;IYWPPSV/7R7!%PU[3>?'S*
M*;>U_6.W\KJ?'_]WAD0RC@4H7)%R,WVAI7)9KY0,AY&K6)/$4'HT1N&\VA MO%N_TE^#TU]RPR3@"I%$M\:BD)5/8!0"M0_PY"]JA^\HHZ#*
[A8!A0HIP0 MRC.]D3I03'F5.D-&,AD'4^DT@,U3B2'' MT^%]@63HK$05!Z"3:IPL!YNH/; MY>%^[;2I_)MR;=RNR[68$475K*
MO8OV8"4NVJ.C=7#1PB+T=V"=,?'K53$9 45,7S\)C];17*?&V=TP[L7E>KHR M97!8E!'=O7I23I23UE'[82Z&^9]W'OBDN6,Z;KWQ+]EX-*
91W*+4BW\$,X5]Q/S@]0\;EC?,T8@9EN6X>+6[>WM[MVX+1M:ZR&[I_C/_^O^QVP7-'MMK[D;A59#O(BC[+E%+>^^P\ )CH[; M!VW#"4Z?*

#2>;+A$5_OW[^F.57P-A/A\$S7XX"C/D@O?;]"Z66;E%D?6DD#T33#4=Q M&E,#,RS:PXZ>)4?=%29'D6!=@"Z,@5/0'7,7*''IF;\S52B0S?/<%V*>S;-*
M/V1^%;W_F2^8P\F?^4HLL/E8%3K96'Q/U^{[Q9._ ^\;H^\)&'V]X&X'3]K> MRX.]N^BNO;Y 5BX*/%YF";',))=T!- M#O$O 9Q[.#1YO _S<._#EK\@_/-
TQA+E/87\@4FO!@\YC"AB<\5YZP#PK! MABG\JS %X G[?T51:)\01OAI"P\^W=@^Z.SQ*> M]DK9^7271%/E%?M[>_L;_O T^$,62A:'
M5X"]P^Z*6PS>)F4=YP3[XQ$A49(UO" @?#!$ M)Y..7^Y%#1L1@<1L+FU[^YOIZY*N#HT>&
MB/KW>B\HV9>P#M'YAUW?!3M4/(0G2T<3X0E4M'"+>'Y.!VR\V;8;I:<%I;Z@Y7W! M7BZ+AECI2D]B!$Q%
<;M@I]6QF>'=#"C6F+T3YDB3KUY%/'1]A?6%]6X'GW_M#\WRJ0%_=! 4?SQ^X4QLO74%-3Q<#:CARW4 :SC%]ZWYM]W:;_>ZDG\EKB M$;]A%
<:0_I])G L&Z;),DV^\HE*PM*3&>2&F:O:#24$E7G$AS9_P-< 4L6\H M5V?$\)I>! QS@%4_IMVL7(R8$(-V_%Q%@W;<+HG 9QX>-(Z/#19"=[A0>N@
MLQKDQ,/#ULGQXD$M;4]LUD6ZI*Z^2@3!)=7U-]W_^D]]L.#?"'^HEU04=^^*T
M55&C'W71ED+ ^^R&HC$NNZ=:E81O;W[*,,C>Q6^QZOV91XGUM>>_S((R>'DM9DY6LKB{J MBS;?[/\B.CLZ8N.0*M7GI9N@1QCX M%''K$Z?
R/7.>;;\/['/E@AE<<(ZS90/3OMBBZ'-D M[5U;/$+$- M9E)[>GWT.+JK?3SZ^^>??OKE/VJUWVX&'73+#']_; \U'8(]8J)GZLV0-R/H
M5^9\HT>8]WL39@SK]4^"(F6RP=.IU%Z+1^XG&_BD> F6LH:OPK!,ASUFO_XTNOD/%1J+*3(K5ATVL$IS#866--PL90VCUV*!Y3B_)K2H2[Q95N#??
8)='C8_RR]C1\]HCSWF#$ M8VYK_>JL'CW*&=$"UM1V/6P;,6O3U^EGM#(1@SW/HV/?('8!\2R;8MT"8;__I8XM.*#$A
M@BS"8V3M@<3/'G:FQ.OB.7$7V"!2%W[^"2$.*YTOF,.A.T4XP>Y8*.PZGB [M0D$(=)B!/1'9_$DW\D;]^6-B>2[_5..?WK^XYM&QNE3?
K4TQ7FA)3M($TL-O M=#0H"J,L-3)) ^*=:1%?C7]5.3@'IK758M1(]'2*Z'77(;!EYH,@HQ6=W5S7B MMJ.M1DBII49V@U?$(B+@(%SH"'2)\7[*GHX-
YMN>LU1I#%DDT0>=9K#&S"14 M1W;T./]C:YG$,'5D1H_S/[:7^6+,M(1&SXN_,L1BVV:>X,"_':]:+*@]8<$'7
M\!5OHI^B=CH@DVC$28V;X2A[\!T6B)U+\U_L; C,((''Z,4,+B 5OD;=' M+B!AD'S493!>,$/_N<==#.2]5Q3.#1B%?$;15\G^OBOQ-46\TK:DA0_7*\^>P&
M%]\E9L_^+/[>:,TA&&2Y3IUMM/)EGX9>2Z0H?:)K&!&/YPF45-/]^Z MP1;/QX8S0CS7M[%O4H_GSFIN5V=8 ,[5U<7IR04'9PBN)3$Z(7.4Y(Y"]BC@ MC]
[%$OYV0#++\7WL@)TSXE'0?. ^PKG.78GRZ*\;HW9K$RF,>.]-EDPYS]]* M\WE*\3U3PW)6.7R)%BO[_:%?X8[^ MIC%L#WMW_4%KV.J.&J-VKZL&N
!V+EK M=QO=9KO1:7?O>H,'C28AY2*%YF03FB1+%/-$":850NF^U[O]M=WI-+JWO=&7 MU] -7NG>MV\ZK<9PV!H-NZV1&E
JC*18G6YB%7%%P!8)OFC%& 6];X)*6 M(A)%#*1XG&_BD> F6LH:OPK!,ASUFO_XTNOD/%1J+*3(K5ATVL$IS#866--PL98>;W(?M$2KPN M
84B4"2C0F &_?:H\9MJFTH2R*"X3,WRPV%"D%?(RZW&H OIY; /F0[T%RTU M5Z>HI/Y.3=TC%M &!D@PJ9#7(:]L?X5>FJ<^T-X?H\G#E];M/9_2-
>&G]DAY M!J+.3HI3:MJ^XHT2S$6/%;)'*_X5@O"NT1Y\;70>H9]N#!\'6E/W3%(I-.FI M._!!@A%*'DXR5TK0NXACE29^V0L?
(SRV5*$IY"#%)CV$9"'^@H'$'!4@<#.1LI+*ER=&$QM(I8Z=0P=<#;@J\4 MS51I6[M"6D6$-\MQ.BCFT$J12M6RTP6]*D*A7(K3FH]I,I6!]S&]QTVGRE=%
M7#-K=CH8%C&0XI4J=^24_JJ(3+]6IS6)SJ.68I(JBDFJ5)&3EDP9%@E6+)K>EWL.*#8$]&"2)&7%*Y4X2*O4EA#,?,#>+%; M'O ?S&E:V'4)/Q1,;=+VR-
RE=ML&J.B=P^;6;8T M.%)5D/S@$,J@4!MQ>]GT04(A?F8M4 EQG5!2*;32ZA!5L3^;.T-*6U)XVYOPJ M)@#7FY$&_-9SL6UV*!Y3B_)K2H2[Q95N#??
5PFS_RDCC+E7GR8^[2#L4JL=# MC]^%&&&B(0$64T!&ME(0G#I&HL2S2L"SVS"^?F##GEOEC;^);#4/<%:879?L0 M)
(V@5$E*84&EAF+1"&2C2#B*I!_B(@.NMOTQC'6M=>PR"#KQ3U5.E*"26$ MI /"&4CT@VNQEGT+@XVVR<^?
+_AYU2[Q]@]YBB!1#*2*8DHQ$(G^&0GA8MR(MQ?^,0(%#:&0V4@"8N%[K9<$/-N\[(/+9R\+@*E5>4^P* H$HE'A /@^:'B19
M3I#5OQ+XA1*D^&]Q3A4>$C+1NT#JWPY1(,W53%.(PE;;YC>."W7WFPT629!& M0;1])0&QC)10F@E T!AB\P]8^8SM2PMV+?
@*P4]5"IS'THIWRN_C ME#A)
R!5GXNW\A_F8IJP_7ZR/^" UP&Z_4+79+;G8,.+]TQ$7R3V)6S5 '48 M2T%-54H3H$9\DYLJXN^2NRNJ#'.'B+?Y/!';UQN-BQA(84O5/!.P"88HY%A) M; K.-
NT^#F[+7(IIJHY9?)S]T.F](1ZGLS<^S(^(Z_86'IW3?PN-8:KB3#7[MX3W)DL9#JH8IBX=$;AS)1TD%4*C!(4+648LGIRZ;#(CK,;[A^0ZUIWN.#E4Y
MTLA(U4-ED;&2S(-C3?8A*"1-N6%X](EZ2VJ#WXCS1&!";/$+_#VVYL@VUTJ4 MR?;?G>R@@S28-$_QKD_!0[UX]2?2#(6]\J0EM*MDM.F2$A,1VU48:?
^FC]9KQMZZAB#ZN(Q)*)@^\KO0\ M!*_]_"N?P0Q.2'?[@>5<,,P&>?KX2]&G)UL::.EC^IJ!EHB?6"$4:X1ZMI@=
M"Z4.0568^L0[99AC$I/9F2\9O<$6/V0\G!'BQ?6[N/?APXKF).P-]9,&9_HL MOVX^M]K>(Y3F0V .FU1#Q9'0/%E_3'2;@?]5#./,^Z_BS.N.PB!H4)ZUQT/(M
\$<-?!N##^S 0C?X85<_1[R5360AF*]PIUWA==:ZA=KM3:V1GHA["6CB_'Z M=ZA,^"UM;7OA:^;[WT<5:1RE"M#Y<92N5*8ZD*2"B&N(0$64T!$E
ME42!EH<8C-Q[P]@WX4@W.:%SL\>6W>-L*W&R6#I-%;SS8XDK$$2.NS$_=//' MKBI&2_J2R2W/V\CY2/%-WTV0<6UEU8_;I!V=E2?&PS#\T?.=
(9G]M^R]2)*" MKG17:6[BN4HW^,U4(!]%"AR"0[@NW.;JL'F+HPM)6M-W/38GCCM>WA,V=?!B M1HV& ^/KCM&QC2AI>*3?),9'M%N7GZR)9*.8O'\A-
5* 20T,1'<)M,<+L? M7TG@9X \%OQ[PV^>)(\'?(_Q"W/7D;,=(V4VH-&947H?&C[%'6D3GGSP6_15H M$GT2NFRFIW_Q\/GE^,7]A!<+"ETL_R;X;-
LLT%U\!=\02Z3D(K@_]]^:,#YG M]M!CQK>3>KU/HMG%?$R<(X3'KC@<<<7T$.1D^NC8AJ;6A9/Z2.:E[%C MT4\+L2.)]WM]9/K!_91'R/5! /5_NG>8?
[B^BAXG'ID?H2\X"/J?&_W)-/ M)IMC:O/+6#FGH^,\J^XM-L96EWE =';KD]/ZZ46Q3444);7H2MNBJS)9U PN M+
(7F'%]8*C;B\;V]#IGQ_6E/8=_"ERKOH'W#Y+'I.PZQC>7(P;8+-@-5PS;% MIZ"Q-_C8,2\/61X1"3>HHX!-] MZX2^SEGN'81;WCD1,[&YL3&!H6/SP.K*
^+G/6*P@P([0&"2<5D0:&)W=F>Q M9U']YXOY_,ML'T:0[L_Q^G+++&O*%5]:=XDJ[D>T9EM5%>1T@).M%!L&3EF_" M3WWFB$CP/(>.?
8^;,&)=2,X64MF62*1#"ZH+(C/[ZA#68'(O'Z*-Y>!8KO MK,4/!8;]?8?+[ZI#24?,+7R022'MV/_AS;^8(-[TSBQK+XA\C\N+=6,SXENL7'1:O61WV(C%RJX?
&C)B^17[\ M]1K8@?9M.UP>(1UH%N;FA9Y%]<\W1) M;6O;$(U<#"2QA(K=P#"MB-3N3:*WVBUA5+ZC+_RMG'P$+L@ M^0G]P^U74@#
MO._JGAO*^C#>SO&068*S6]QUY3]?AD7_1,>*;7^"PYN4 (JAOUA8R\;4(8)" MN7]68U,"[GNELY@FBZ1A2)PG:L"D1-
=L!18E,#FQ12)4,]8RN*$HOPN34[[2 MT!01R:V3A)[$0D7]-[<2$H8%<[$E&,8+>IF5BR%9X. O?MU4?@^]"\N2#F(: M)KG\7CGL&#,
_98\$8N)=W.&]8E].$TFXV)1T95,T]7+/;W6LR]F5=:HFVH:V_KYG9+&HTHE;4Q OJ88O^6ZP, M%.^>VX%C69T$VC]@YQOQ@O/EO*;&?U?(QA0HRVKT
__VL-5WF.D;'E]+&T'R M [1245&@; $<_4O!%O>$,*O&2[V1H2&/!4QPP"? $5 MB5TY#Y>AE+:1=F>O2.,9I4AL\ M&@S>>(WGQ'FE-
QA0V2ADN)VYK,EZ%2&Q*:,>821W>"7*8V(,^\P+*O5RZC* M8)@/XB:^;0Z!C\R4SQVZ/M>L-Q'AE+\IHY!(8TZKT;=12-&G MQ)%;M#H#MJ9?6-
8UA=?'(>__MWG4#8G>KP$0U'CM'Y:ATEL M'V0Z7%%)L.4_7Q)C3N3ZGY1,Y5.YRJV0;IC2TZ%4+[6+R[BL^C\M,1=09OOO6DX>EFQ9&^>)E.[-
M+;N!6:)%S-:?/A5[$QKBI<_9PW6DO&SCVRXLRY **!]4D318739EL#V,V.AV M!V[5K]2;11?"#9AEW3$'DE0SSVP=#F]<\^%ENE1%["=+1+GN/]-_,)%:Q
M6;F/EP&NK+-^D#%-'3R7YEYRRC)8.(0!0)P*>@-HA??AF]=4>A:=N5:@C!N MG)S5@]4H<6'DK4\>\%)^:Z;4K R@-^KG63K*YKT2JE)8=G*6I:/D8E
951DL M6YVOC58/;LDM<>DT:%4%&TBE&A^\])0>%/%'G49#I:O%XZY6BM++)=R%?B MK5];F9O+X;V-+;PL90VCZ"*X.;JC-MIMKIO4EM&69-
]Y4M^UBV&X78M-E[1 MU:^@Q8\(1O[5,[P4TS ,?^Z+E">/R9H?-P+8S?3D;E>ROJW")=TUWL*.#5.2 MG/YCTV5!"!,L@4I\OEDF7WDJI,%/:H&JQ:LT
M,:RIOCKPVOS>."8Z#,"\3)@W1'&S!3\<1\01K]7Z9G@LQ\L([X*M:+LR+NFY M,C7#^"W5@6T[>BC)]*0>:=L3G^\ BL^G:)T!4:4N0[G+?.+N-(>^,]ZR:;S
MG(?+,+;QJT""=6Z;&#!!IMY2\9H8% MHF'#S&!&7(IEK:F8J@3@K!^.XC,EYMO\D(G.F:H,LA*8UL(N?R==RW?8 M@CQ0T[0(_ZHQ<4#G#E^^:R#
[7B5P E-YBP8R"!BP>;1QL%C,)B90%%6>?_A]02P_$ @Q(1E8&@;T[_O\! !0 !B M87@M,C R-# Y,S!?8V%L+GAM;.5]6U-;2;+N^_P*GSZO)Z?K?
IF8F1W8QCU$ MV,8!N&?'>5'4)OWLY2R=G>)T^>S%',,2\|/?Q\N/SY8?]=F_9_/?QI_#LW>3L"RS^2G M/|L_>S'[]&4^_O!Q^4PPH2[?
=OG;^=^22MDYEJ%8:4$5&R XB^"S+^B8-CSX M__.!WJ:*1V;!Y/HVQ3,X5@Q$C=R&)+3PMOO0R7CZV]_JEQ@6^(R&-UUT/_[C MIX_+Y:>__?
SS[[___M<_XGSRU]G\P\^", ?GSY;M_NGC[']^]_W?9O9M[[W_N M?OOUK8OQ;6^DC^4___>;U\)?I(YX&&$\7RS!-]0&\+|=\6W8NO9RDL.ZD_B.O9
MG>^H/\'EVZ"^!%R Y'_]8Y%_^N=?GCT[%\=\-L$C+,_JO^^/#JX],H8-ECC_M:YJ=:_EQ__?.+V33C=(&9OEG,)N-?L:"]#GTI^, MC#:%&6IY%A* M+\.X -!]-
%QT8\TN9ZV$>ZX^@KRI?M_-9Y]POOP-GNZW)OF_?]W-OY4 MS?M;7(ZDL"5Y%2 %5\@PAPB.JP(8=1 N2XY*%-5;W?7A6T;YX.MIO)OIF0/AE M-
LN_CR>349%<*<2V1-E/H MP92"C@_C.,'SH1"S]O](DJ,:W'U%IH)EQ*\(7@B*JW*-JS0ZD"$+13:'9Y4; M*WL57*L003T=(C1713.2')
(5(B%,/]Q&"B&/JC@/R_O%.W 9D%?V:)Z3_C87=3.\OQXM/LT68_#*?G7TZ MF%[8)GHUS:,$T#/,%V0E6=\$;+3..G@'_9%B5YX21"$9I,1BUA)Y<+(Q.S:
MNP]'[-/AT+84UXQIK\+V?IMX^S"8E]46/@Y9>13=Q*&RWH MQ F+4(2O!]".A6YD=]A:$RGAS U'//(LJ!3"A9RD!J49B1TSFFB,^&T3B8E MJ?
L;WI"2Z*9,N#DOUA5Y,YY_/YZOL_/=;-Z)?+F##*K\Y*F+$F0 M/O$#18PXQ\5RE'SQ.DD+J00'2LD OD8!EHMLC4-6(C:F2QOD0TK8>V7:#A3=
MC*0O9J>GXV5==ZB">=&YC \X3776),&Y89(#RY(22'!RU"E#,$ Q(1E8&@;T[_ O\! !0 !B M87@M,C R-# Y,S!?8V%L+GAM;.5]6U-;2;+N^_P*GSZO)Z?K?
IF8F1W8QCU$ MV,8!N&?'>5'4)OWLY2R=G>)T^>S%',,2\|/?Q\N/SY8?]=F_9_/?QI_#LW>3L"RS^2G M/|L_>S'[]&4^_O!Q^4PPH2[?
=OG;^=^22MDYEJ%8:4$5&R XB^"S+^B8-CSX M__.!WJ:*1V;!Y/HVQ3,X5@Q$C=R&)+3PMOO0R7CZV]_JEQ@6^(R&-UUT/_[C MIX_+Y:>__?
SS[[___M<_XGSRU]G\P\^", ?GSY;M_NGC[']^]_W?9O9M[[W_N M?OOUK8OQ;6^DC^4___>;U\)?I(YX&&$\7RS!-]0&\+|=\6W8NO9RDL.ZD_B.O9
MG>^H/\'EVZ"^!%R Y'_]8Y%_^N=?GCT[%\=\-L$C+,_JO^^/#JX],H8-ECC_M:YJ=:_EQ__?.+V33C=(&9OEG,)N-?L:"]#GTI^, MC#:%&6IY%A* M+\.X -!]-
%QT8\TN9ZV$>ZX^@KRI?M_-9Y]POOP-GNZW)OF_?]W-OY4 MS?M;7(ZDL"5Y%2 %5\@PAPB.JP(8=1 N2XY*%-5;W?7A6T;YX.MIO)OIF0/AE M-
LN_CR>349%<*<2V1-E/H MP92"C@_C.,'SH1"S]O](DJ,:W'U%IH)EQ*\(7@B*JW*-JS0ZD"$+13:'9Y4; M*WL57*L003T=(C1713.2')
(5(B%,/]Q&"B&/JC@/R_O%.W 9D%?V:)Z3_C87=3.\OQXM/LT68_#*?G7TZ MF%[8)GHUS:,$T#/,%V0E6=\$;+3..G@'_9%B5YX21"$9I,1BUA)Y<+(Q.S:
MNP]'[-/AT+84UXQIK\+V?IMX^S"8E]46/@Y9>13=Q*&RWH MQ F+4(2O!]".A6YD=]A:$RGAS U'//(LJ!3"A9RD!J49B1TSFFB,^&T3B8E MJ?
L;WI"2Z*9,N#DOUA5Y,YY_/YZOL_/=;-Z)?+F##*K\Y*F+$F0 M/O$#18PXQ\5RE'SQ.DD+J00'2LD OD8!EHMLC4-6(C:F2QOD0TK8>V7:#A3=
MC*0O9J>GXV5==ZB">=&YC \X3776),&Y89(#RY(22'!RU"=E#;!YB2T;NW6 MJ[X$SI*6!7NG42B5]..S+U4HOK9(^&.#H*& QS(/.0%;8;
(T.F75>BGX>Q0; MCVLV_7""\].7&.L*W(OP:;P,DRX5.XR3\8>."5^'+(7SE))++""%6E1:*SPV7 MD&AR6^*:C9'[E*:G=&,?1>^5"-_B47'0%-6 M*I!8*/"
(I="H*?K 4DIB6I"5:!WKW8YDH,ZX!3L:B+XE#>:4<=TRPL*558%1 M*F[]#4$-AZ!T_W)[W,+B*;YYME=8 ;]2AN1H8$"^G"=A^41F?I7T"Y:KIF#
M)%,$%;(&SU,&)TQT-C'THKG3V0SRD!;N6[NA+2]SQRQT)!S'S#T'&CTY2%5Q M1(,0(TLB99%)$KUGE!M;VIS'5;AA\BZ,\\'T(BBHP?-LVCUN)(T+SB<-
R(VH MN7Z!*%("8X+'8!1E_;ZUR7T0U9#"M VY\9WM;;N29E/@")=A/,6\'^93FJ,+ M\A%GIU7JF%]B&:E16,T:=S#$LSN9?NK&?D_R2WRAB M\@EX*
(I&KB5$*QF17$;N#$H16N^CWX7ED:44)\1TD3^[>S+]4)/?THVME#* M80@""P[HT0*TYMY(C-ZDYM;C[BK:=:K*/M.GS.9?:]$B+X@B2P46/5[8ZV-1
MF++H P_)B=:;4U>?/Z1@>GTM?U\LMJ:$VX5!8?&Q6VA=?*RS\7.8=++L1RQ=A M/O["\=KY9'+>"I])"**H4'=5';A$]I4S%Z3QOF"(K6.C58 -
*6YNQXKV.FF^_M^'V$"0E8G" Q]W+,&$7D%,Y!0#+F*I<$3G(#@3-MO-_NF-8LN0_/D*+I=N1H MIH'&3F^M=3*99<2L/(A:!*<\&;^021HE) %
M/X5QWO_C4SWN16;R2F7EUZ7?('GQC((]6?<%LRG@F"=Y6&Z4C4IRU7HY< 58 MPZMH;L&?UOH86E&63AC1VP LIGJ>HVXN%H6U8$?QPK4-
S>NA^RC*;K*=8'5, M+LH"L5!ZIH+BY%Z0:$,4B,>1,86L=UD,*1/8 <<>+DE]E)!3; PU2.RM+$ABV52#=I%I.6F5"%!:<4:96=C+R=):3IU,1
MF4\E8X^[^,.N#WN4MN_9D5]'UNM%!*VLA9BHVE4."LJ@?\4@2*@3P-FC/D MHJ3$6WO*U9 -R20VXT9[G?1TZ/)RQ%^NG,RA/,D&I)R=FRA_"
<'!!R,AN%0/ MB=::MM;'H714Q8+-[-9V5,ML84]SE*D++FZ\Y3(L%)622>1^#QQ1:MUZX M\OC-:^X^(S'X%H)I'M+RW^/EQQ=GB^7I%.=?FU_4)4'Z?
^Y*-5Q4NB '-MYW,!Q?6";&0MU<5BT44?T#8OPGLTS"'E4>ORY?MRO'ZUU; ^;[$\++5C2G?P M#N>?QPD7Q[-)'C%DLACK(>]DH&NVXY/D8#1\]3%>.-
%\-_I.-(],J/HMKFG% MDD;";]C?Z++:ZY*XY#2)I5^]YF*MQ;3"' HM-(:'7G(*\8,!IY4 X)V0LLF!I MO;;?
STCZE^]S++/Y1=4=V01<[/!QH/X/9Z&^9<+8#N7B#B$S)QOCPE+H5-GG MC >7L$!,6A06'>.R]3IPC\,9DD\8P*SXQ!!&$1];D(Z,4&YW.<8K6NI;"2
M!7E"37845&86O& *K"T*?0J.?&8OK/X.RJ K,@4JW&,(9L[-,:FE: M[]ANZ&1R2J9 %R0DPCW:2!F9@3@DF^IJ'20U 8P7*;,GVFS;R' MNQ4>Q#6D.JZA-=
>=P M=N\T]R[(!%GDVD%$U:MS.$)BF%G240N[_06_OMHG;ROL6)-SCU_;ZUWE.UGM M&VG,Q25'+LKP"(K7_2E#XJ,0*!>=BV6E7U+>CV]
(04@O5&NHGO8UX%="9I&5 M,C8P*+XP4,4A1(X.$C>1/$L1O/EE3 \F/)M5L3E?A!#9 E=F[L%[&E2T"E3R&B*S2$$99YE;2|-
OO8NQ&K)!;9&W9D%KL7T".S MI:=%DW:J;+N"&*!<(UNCZKO;CX0 AN@]5% M!P_DARB"*9F!QWK(I42A1:EW-+D'%-,8TKIV[&X8]_6K?$ \3)NZR.G
%@KK ME4)ZV0E=M4LT:('U/*)6$'518$.@7\3 HRCK"K OT$/Q M93ME\X,KW8.@S*ZL!9ZH>Y%'YMVDS#=*X3^"-,D+!;C,D[G?,G_<[98UEJ1
M[M>=250I%\9J[4YM*$H2!R=(!<[E4I+/(;K4CT%9% .(@*C>'(QT&P)?=!G0> M.,/)") LS.9']X@ZN].5D
M'J;+D#H%3G/WT^2&.K]M]&NF="")+QE)0)*0H(.0:I&>4+ B1.5^EM&AK@(?B M"K?"RNN[74.D1*.%HD<-K=Z!^6HR^_U?F#_@+V$\[78>;C5?
TZY7+6."&YXC MZ!00%&47M3V!ZY4=,)F[_D]A]'GF$-) (?.[%[5OPL^K^^+L[")QQ+ *TOY MLXN,?+&N-1Q<)!Y]Q+!*[+8MO(-8MG*%-|.
(W9:DW\QB7NNQ?_^*=NHP7]@ M;(UN"ZB/N7$=!!%EJ_-QHB=>7!=]_84K[WR'_L^/F]>*;EWC^[]?L>/^/ M]#%,/^ 1C6J_%$RU
9V1,M0JY<8.Q,2V1O=+N-*,('S1VEQZ2:UAO>6QUA@GW"N'=?/9Y3-I]_N4]<>1@^O7\S!Y%7Y\Q[A!QJ@=QM2FGUVL4TZ>*67@/'*D
M9, ^&YCNPJZ,;0H3]!#A^2QU,'^IOV&\/%Z M)9N6'$+(W&;-HFS>%VYU=$/JKO3TZ;FI^IO1\WR(A^7]L ^G&PEX9+BD_),$ M5*03-
,^T!5<\0F;&LR!X";KU57X]#&-(!Z"?$.%W3:@ASXQ'W(Q'@TZV..UJ M3UA/7S_(",K+>H.#%(9GY-BZ*_6.ASRDFQ'_W#.N-Z+N(_];=VKUHP:4Z5L
M=:,1,Q9N*N;; +S[5 Z+1L-8=]39#W*"]8D+,7;G3,2F9MA\F+,_FX^67P_(F MS'_#KE3@&%-]K88C$2F),QK!6N\H'"D& H8(6@>?A+

N\/AJ-Y2P$*ZZ[D>]LJQ2Q+%K4[?7;UPA$G(GB1!<@L MD<7B0Y;W=>O81!^K(3MLQ73 3L/6EBMM97&AI2%(H$1MI.N8!.?(P9,6&?]& M&<5]W9FZW53GK=^]?G;UZ^^'9 MAY/3MR_KP?3Y>(/*CWL^;.O2CE6!;EF[4>_@?-D?UR3ZRZF/U!^?EG=D>1Q, MIE[2[*'7#FDL*LYT F1"TC]}L3I, 9A-BN83-.IVO_.%}YFN]=!MKF9=Y4%7 MB>J.7GQ;_"U8PVH&DE'@F.<@7-$E.Z/M[5OE-A[93NHXNN7V^BVNW=CXL51]-MT.@^#\?A_+?1\/+S].[;

[TW]ISG,+ELNI;1DIMHE-6@-T:I(\Z>VC&+5+'1[MG_U>2+NN_.A0 W=<]W9<=']@=P^\64K$*@_[*@]Y$-Q^2D6:4K]Z7+;@8R_"

M,5)EIB/!FUZ'3=XZT'L4(,5 -('F(1K6N+MN38!XH*-FO7M:AH1N=U%6N/[C$ M?$HS\Q3:^ HV?:<_W86SN<9<\D[$R1-M(6F6U"&<7""XCX4,G ?

BY7^Q@OD M-I3,ROAVOV70F-Z[XNF&FP]RCQ9C_1N>YS(PA<%4@F)TQ,,A?O:V'XY)7[0%ARP,)=A_F&@JU+U__NYP%^>Q%&

M<_?'H=8HR/TQF@M0UAMPGM8JJ:R4A2L=\ZVNBPLW:6]_[IZ]R;[(&#;R9 <1 MR-

EE',_+FMCB"^U5PS]LRN!T^""#AQ0UXLR;*Q7%WYF&ZUPMM"/6I]P+X%R MN*Y;"]MWD"V\ -9\Z5P!6$?>TU)0>VJLTX*ZA^6PA=V!J(-9#M [J[TVP)))

MH"1+X*WWD$ODWO@BG&[>C&VW@GBHOQ50ZS@$#XE@&9#=.@&-2!IV9>&&4_[]X-#Q8F,L(+%X MBETH /;8.02&

14O+JR6H_:X:%^RU.^2]74,VQ';KX#^OFL6UJ7ZYM-WMZ0WI&4!T5O8M(/0_TT_Q/YYO5MM M6&]6(URCX>=/^.

(\]"_&S[_]^%8_33VM8.#+O6[?02&-OAZUBM9%5;8.FWOI^+0*P&.K ML(TI7;OUTR9\[$4X@3MKA>;3PT%0M0K,>93 R36,R(.G4/\P!+-EJ[:N];(.

M#3MK%7:WH9#UQ>OB(EA3%"AK$D2CZS6;5HE(@7S"UKF-3[C%TUJD;MCB:1U& M=M8;;$D?,T4QO^39 [>;U<24Z<&

A,QY02>P\,;%ET^]QUQ["37@YNFV"DM9 M)XTBTBAK7W]N&7BM(\WI3O/D(@VS]2GR8;8*>TK._2/4UB-J-K8*[&.SL<>I MHD8]FS:1P"-J-F;+-(F\

()#!UOOGL@6'-%6PJ$Q&&[A7K<_V'Y5R'T>5L7T(M=QWF&Z<@/>\/WWT*HXMP-CR_G,*;-^MERMN<_G>9C:Y$S;&S9AJ'.PH9H-B7M"Q9@3-

?.:L%!=)$4V97W7U@%U,_4;68MDE;J.[*)A7?6;2:7$)E2"IR3O%X2Q\&3 MNH$GHYWQ3DCY,W2;:<_Z.H;=4;<9'I6H\U@H2/Z(,>3Q.BD@,,,8\^@57ZFB

M^TEWFUF+EA6ZS:QAT\;E:^]&PWR9]>C,QQJZ:>K6LJS> M%=B>H[N$-S)PX[5A.;@8K,R!YD-A)$UEC 5P(C'@*$1*A5'0TW#]V!7K]W@"

M.R)]';MVUV$^#"Y+2)/I]?$5X^7GS^??GGTPYF-WZQHT(FKQ%D%S*W>V+_1A%.@-J6:>6^$V3!>]+Y[6 M.\,% ^6%A> =0M!!%"'(L;F=O?R

&!Y\Y.$(H:UUNV@T5,X^RD=!3*QW;"?M[:D54?)32*0/!U7!&UF:UOA:R1T;1 MIM=%V-9IS(^]%=%3TV)K3O?8S,@*0N)I+>9>U

N=)472+DD*K"V/P456;E]X M]W2:&3T5677)6<,\X&D#E[IM$M*U?9/OVR;O<-0?YIZO$Z]0];(;D IZ6FZ M-0HP!'(2LHWDXJT@J $+GN'G,/<*QY-QC[G"

<^""8+H" MB@?R!LD3I$'8X(57TJUT@+(Y@J/D%DEN1XPNW9#MO/?/[^&_AZ-I01Z.A^6[MP?J#*W:NEOV%U76->P5M#:2CWD)M#?

04>Q%)CCI8#T0=S:?&&XC;)V JRY"T M$ERO=-78HZND?//4>A'9;?TLXY"LBJ!*[73,102-P9#Y1"JE]5[1L1?13MZQ"%M?24B6D=13Z47D2C>&H&*%O?

HR>X<(2:6(!>7DB3;%]9ZKOK)>Q&MI:(U>Q&M MP^9>6LJL O#8BVAC2M?N+;,)'WL1#L>0')..D-&K0XM" D?Q"%B3*1K),I;F MG5B?

9B^B;O6R#@T[ZT6TI&T)T\B8I. UN5J&F"VCX-5%8-PG[EURRG30OND) MMY19B]YM6L]LPTT'1WD[]GN/[7AD3H)2MG;YCPR"5 E,E-P04YS4K5MB'5O*

M[-M'>X3:>D0M95:!?6PI\SA5U*@SQR82>$0M980MT2&+@+YV]'=1@^.J>EG1 MA,Q\"G*E9,&GJMS'T5)F"\)=A_GNJHMF&7Q6&J6Y

(R2Q]CKJTQ.'EJG%!& MX8*\=:OP@34968N,^YJ,K&/)QB5"2]O9A.Q-ULBA>*4HB),1@A<9BC.6;<;= MNMVVZD ;!6W*.N[#-!^R;-P+)

M&6!0!"TYY!34@G1:(9A!)EUBV=]5*KBZM%3?Q-A#O-@KH>E?E >0XH+^= M3PU_0=2/)U<7>KW7^IDB-

>Q)9KT0@4/,A=,B8CSX6,C;*=H(Q[A%M5('HHZT M?#_ZH[9;;+NA0AKG#Z\QBO%[",]^!.-XR4Y2.?#SY6@^2"$=JIX,AY2H%9M M2<,IG$;BDK$J

?0'U7\/6^= MR2D'L/6*4V7KE>A82SB--CSY&%-9I2OL5B".XMQ2C%ORVL&MM:>33SB;X1M\ MO#+W[%UYBY->#%!,L?

DIKR'@^$<:I5ZCL%JB1R8)I]4H4#PW!BPMMC"'68M6N]XKH+K M*+3E*0^-6;VK/-=DH;R.Z0;8GE,&"\VPP!(SH&KW>F]I00]*.5FR4IA:;_W<

MC^BHMGL7RC9,WM69[R1%\<<$O+3ZZ3F6X0BO?K&6ADM,KA:^@<\)0266:>47 M#D36J)4*0MJ=9"^N#_VHW+52)#O6QH(=]JU/B'XC4BK@TT%-

Z?S1V;"'2C!R M1NF-1A3D6M-B4]X7J'7KLYH5 MYNT?C5ZR3#K](""Y4L.NF"CL<@6,Q<24=.AEZXEQ'7Q';=Z?S=T!RPLDN?&1 MRB9@GTTFHWZ\G-

1\]P]#ZQ5C;>960LSUXKYZNWE$1WY' M*HZI4C*R?EB M>#F8C(=E\@F?C<<-S3^] D8)984.6DA3D,P6S9W:9;O:Q#0PJ_3"N&93U_^\^L=E M_TLXI[&-

>QR%3)QEC*S3 +RM6=2R@!4$G5F+EJT<4Y'M7H+01_YV8M8<)N M];!?03]+:,;H:\W8XP7JGY)MAJ'4#"6DLY(36;#,31'%H):10)*B$!4*BR< 5 MA@F8

M[9B_N!R-;LE, M\%(%IA)8;G*]6D"#UYZ<>"ZEEUPXD3O(V&D!,2CH!H)NIHV&1:GS85R!F.8< MK>Q-S9"[.+(7C('#Z6WVD4-,(0

/V1F;.?/(&]MZ<[1'(2\3\HX4T+ V=:-7 ML";/3[Z](Q*]^6L8\/FJG)$+;Z6I:XKF]/YEBHE9@5625@1.?SCE#=BD8E:&2:9-

8Z'>"^@HUVWEVH[O#]IWUWWO;H;RE5<^ MP^^\4BE$!=H:LF#-RO=!*K!>,:CI!MX!MNKH9L:X96WL*^6 MC>\#Z'%M@JP>C9$I@_(.P05#,6?BD:

<84.K6'5VV@'O4<(MCC&TTT$7]|P9[M)+U@16)"%)!&R7H<3\&DR!&"-)*"R*RE;WT7R@8PCWIMN"^V%N<=%12OM4[, M-O*NI?

7WBE%HO0C@1:S:7$(#L.D;6Z/7#*ZPD1(LM/,K(U0'U7.G5H[6C41&$XH*-SP'%ZVFX'/_21$SM$<1-\R V$0! M750HKP=!%]?

K[&:N3^*::6B,U!D$*!L,!"Y+,!]S(ZKX+W8X\[N4MQ'0;<1 M= -5=%%]? W21J>'#(NTH3! 7]Q];^[7_0$1,-\TO.XEH4PNIN @,^9!E:P@,,'KL8SU/I?

$;]_7NW5? M[]5@CCK=H;KQDY-1G1@2NV;E@;A*!EAHPDE2@$ M5[C'E,GEP(^R;G^&L:DN%JA[ZW.Y31V=;YO9FEORSVLC8*<8J*!$+>DS((2T

MTB/W^&C\WN.Y1G>N[X:*6"#JK8_G-AU"SQ5,T4@!-M;+25"YNC48(*(M#]63 M,,5. =X4ZU'_K06\%OL+]C-8\Z909W^\>_?

FU>^OWGYX]N;UR=MG;U^U&VRCGDQ+LVE_R-1(SSU-_M;]'C,:"\(9D*'R'*D)3!+#"VWH]_&-765>SI$^;+VEAXZ;.N6H74NCNCK0;/

M'+VDW!8*9VC6=\%IT2[<;]U%=NJV';5@ZBQ1NZ4L7=:Q6/[_:T2,_?:"/-MF+:+"-K&ZC* 9>0C]Y@2^\0T:!=L8&BLOGWI5GL_K&C5CXKP-

M/,Y_FU*XJG2UYV9.$T.F26%. HMX,YS@';]%# MEE:E4H)*L74+@KU)YX&V/H]!.>O0L4O%S-K)*!9###G4@@!:YRV7%#B$ &B2 MS=I9C+>ME2I>

MA,_]23B?7I]%(7+==SFYVHK+SR\G;X>3_|+)N]#/O>F!B?6YOGF^MMVV$(74 M0.Y@E/5"(N9;GT&LBNW@]-0)*4M7M89[3K^=GK[\CY,W;YZ]?

7GZX6^OWI^\ M_?#L[6\GS]^\>G9V]NK#V=M7'':%FIOO-&WPD*WWE[8=6*-=I?DS?LA,1B-D MT E8K@I(UI/,2@+-HV4VD>QX:S?

S#HAV>T;SC[X*1+71LM[;!^0<9EKL0X:0 M?0(>70F:HU>NNRVB&U!VM2.T';_+-X VM^MCV>_Y<7(PNZ]LUJ1Q/(T>HC#T M3[0$%PTMHE%H.'3Q1(?

>[CO!,OJR%?9Q?0 MU9TCGCQ00)7 <(DI,>[T2KT(`G50IJ,+4@8=F7!AB%H!?3ZF3XA^?#C#X0Z)%N49< UQ<=**@$>4P;&4?

ED#1>W6UXNY'BUISU5 MHCNP9>,7^=VG,+H("2\G59'?6VD[$W3@-#$%@13$NGHU?.+ >60:,PWM0IB% MY"[\\?*Y?:6ZJ #Z-RG?

#\/W\]'/T91KEG4_':R=J2O_9!]SZ"*SJ"B5D6 M;A)YF:VWA1; V#W-,2.U;2W:P<;@'%)/BV*S8@Y*'20ZAPF\PPQ>"%&+"14K

MK3VK^;/W1^O&1"PA=BTK=N LSW'0F++#_<59IE+Y]&(7!^/RJB=KL7O">,RFD M1.M#PMI#3<8"T0L.QFD1) ;)5%<[2@^C.QQ%-&:BP^F^YXN@J0T-

Y,AC7784 M>(8< M,"0W)"Y]:[*S=G@-WN4"]KW=;ICO5##]W%#O9:.]R1!LZ.;<>]>KK

M+,'V]MK*D[/.&YHSHR4W'*M1#,@IB(>F"+%EM\'9TO]!%?/F\VSBY#SWD:D=. M!E\4,Q:R3@R4#M>M^[(UT,=\-/!WI>/5!_'T;+N;Y-*O [6C'?

$VH^]E3[XSZU276C+=' M(+<<;2G:(C!+[C*]CQ&"H0%(3G[J93G:UKL%CT)F#^SC/U:5K4-7!^IZ<3F> M#"]P!]ZO

J/QI_[G[WO6&DTNSD&*IESU>_%"4J@47' VYD@A=NMTI.5P=A^6 M=DKE[72D1CPT/CMXB5_P?/@9?VQR?_M>H_^4''J81Z N_

-6P5R1X'X!G#W$XQW*H/U)->,PPY3BYH(O9U4Y8[25\6P96VF8?6C:X?C>P>",X?N^K6H6X7CG92QB>F M"G!54UY*

[;86LH;$E5&"32^K/3A'NW/B'C*VU[%Z!DB>_7ZP(3C\7L<(WUR MO6%^%BM>[["4&!RS"<&$2!$!]P)JH4YXZ<9P7B/TN

MRJ"D]XG;FOA%#I[0#D(RCF9)*XWWZ%S4S=6T"K+#U%!S3C](^.^9,9^E='EQ M>1XFF)]=#$>3_O_;D?RR1;+&$1K(CEL,4 ,*4&]I!:-#TKKL+NU;

G*0U14 MQUQUL$UY#^+IC;(F2)7)5[MZ 5P]@K,HEN9\W-6, M;IX:/>N,^O:W9^_?/WO[V[2;ZMGF2<_W?MS6ZN,EQLG)8#P97=[L M\R*S34'0VI

-.;Y*9@0O2P!G,,#$'2NE^16!BZ%L?5?!C8^=-0[@TF).'%BD M*4VAJ/.:D9"\M)I[G15OI:4L@+&K]ALM.+[3Z7]+JSZ6).47(\S]R>N0IFVK MICO=V3FG3"

[@#'E$2D=RN@O2J!+3R9DI>ZK9D%G<,5X,+'P M&&2*,C9/OMP9^0\$[+5?(9B<#1124A6=065 $7#,\O4R! M(F"+B;&"1>3&C-]%L?

MCFNW9N7.]Q%:FI;+M*X9GG^AN.3F6.PB.B"I%G!4[5 M^ZZEC.!\)ERJ6OK4J%NM[%>F#JJZ+.?,)=-S-7!/O1-I_2J"Y0N%IWU-*EH MK-

L8&GSP&K3$DBPM7#&W3L>XB^)0G/0M[=LYX]>R!5;!U9&CO@S3?ISU;3F[

M5P):&KP#YVTI/JU\E+7+%Q.TNRD5/3AG.11IK=2&4$;_I(7P@,.^*QVL8^?&

M*_@9#OK#T1^#,;:+4:W1&5V\&8;!/$>LF,@M2P8*KZ6#F"Q$[22%+3[IE_.5I9CIFA,$%AA"D%@B4WQM+7-M-

C$72O.#G3L@GCCM;8S;\'4>CR8_VGN>)1R$47]XM=M@ZL2D/"2;*$*HW>5C M$8S^T,%Q+[D5*SET](1K3--7/UA>^O"G[L>UL6K#(_XIH!D.FG

^8^]7/N;Y M'N *H:,QX1ZB?!F0W3INC4@:=F7AUF_Y4G#6%\]3,D!=TRQYH#5&T$(CM%"] M!"[1K[3-^KAH7^*F[9+U=05;$=NU_5L*X_DF(

8MM&8&G R$2(MZ92T-V=K@-M _>T:/F5]E=7I/KFTW>W=C>D90'16]BT"S_M,H[Q'Y>DYE=?9I=83>7L7&0F ML

02K0"5ZBAE0&#:>A=Y"-13M/;6%D-YZ[MY2TMWD)2U -9,Z*L Z^]>@F6@-M]G1G00OJ'I;#%G;OXN;"I0"]U2PE%L&JFFA2?

(+@1*!?H0C)M8W%M=ZCV;$@ M'KK18*=Z6,?M@7LEG$L8:KSI9N[YZ)2!:3?!J@R>=HU/8NC?%0B![:)W> MAJC[Z=_ RATX!V^NG0-

_/T(*7_L7EQ?/AZ/1\;JZ/A@^TT\FWWK9!30<(Y2$ M-2TL$E0$!.D99XZ\7\U:ER^M@V_26S[OFN3I=<@(!^Y.?Z3P01'.)Z\I^!I M&D'E=^2+T0_"1^RIF)-

UD29.5I,.BW00I=!@DEMXZE("^'HR@)7,42_%30BX+^>F" MM]Y17A7;(6JF$1,='"]?GQ5[/"+S"CEHI"'!=!44+<*"I3[!@DVB\.:>R?7G

M'P;S&UNT@*R16O>U84$D[MK7@F%"',A0<6:VN** F\H0N<$U6>K0\ER!U[(

M,GR'IXZFC'2PO_$>/X=OT^OF3DNU14\Y5YO<)"@""RBEZIB3!AXX6A9<5]9U M*A@]TLNXM2L1>GO_]^\F%:<_7L[OMB@86^%#

MMRX;6Q=XH^*Q>IW+B^&@7O^.@]3'\0^=.%K-K;5UEYK^4+DFC^<2@;DL2@]9

M^^9UX,O1;+V@W/[D]\U=+%PQ%/0:A.D)3L@0*>0&5YEAR2H:.^=CW&DA62.^ M[ZP.VYOWL923O1I\Z8^&@_I1X?P]?

7;N3VOMS_]3JQT_ADP550^#T-4[EE@$ MSZR'XE1*0F5M6>M>40]AVM=Y20O:AQV;OX-(]3Y\LSW!51!V=(CR,+K]G*;T M974-

R6Q!R7[$HY68!M;@/=+8A%E824ZWKF?8EF@=.7/:MF768 M:)TN>TF3<+D]_Z8(3418 4&&=;=$X+<-'S+*HQ3'K_D5WVV;L/3EK;-M?]C0>!WLBR\;

[H_%\ZI@,YKB$N,9;$S32RLD^(+U#HMD"HM<)AMW]/;?@O83-MN!C;D-'!#N<*,.<%'BL W;'#<0?DX_([M])Z?3EMP=,.O9"[@-T3/#DFP%A!

M*ZSP&7R]+MP45)%I8TIJW4=CSX+:T"?9CY[6H:>QAW(%\@KCBW,,@S\^SU=: MP3(F+X"+D&AFCH&&KCADFJBSS8JO5LNS] &/QU?

9DI:A:VLV]%M]NH;,NO' MJX&&\97'73SW7CL$P25Y438'<"ARK4US.3)I#*[48/2!9."[3SX !Z\.!21N7

M=]Q$-3B6/)0DK=.:%%RU;'W8_LC*.#O8,6AA[IY4R^TTH.50JR6+<^DY<]H0F1%^S396R!V3WE7*2],F;/)L]K4 MB!W,X\]2&EV&\]?

#T8W=R#M6Z%F&07/FP2I)TQA-7!"8M>\+5_2Z$ 13^-W M?%5L3UXDG9+1\ 2QBODFF.]B?A/^'%_V)Z3G"BL[HVP]5I&42_.YLI 0DPN ME!#-

;3=PX:3PP&.>/.6M3=EP"[="FV-Y,,SX?$[F(30Q121_I0"+MK:%4@E\ M805"5)$9B4('M@*Q=S_Y(+CS/7KSXX_<_WCS[\.KEZ8>_O7K_ MXO3W=^]?

_>W5V[.32'W]U\I.^?/7F],SL[/+B(HR^#&G&I1^P9,!C06KGG[(MF#&MA:KM@FS=/O2:Q*R%J7=WT:=`Q31K7!12

K;@LHLF)$_Z4]P':UX9Y=S*XO5`2C(XN M\])N8IKM"ZT"JJODND6]K2)WHZXV-C.E.S:R_,TDXYHJTVH((O9QY06\D 1.

MY\)4#"SIYFEQNY/"0]OG.U;".L;N9N-E/C76+G[]CX.KJN:?TI'5G^[\OQY*JS MQNP&Q7?U:E;R_V0RZL?+29TN/PS?#@=U<2,STS,^SKMPS/>

{F;3%TQ2]@Q$T M.F=O+9KE7M&_..S@7N#;ZEY4>S,]Q0'^9 MO#L/@W&3$6;3N4FE@!*;.W)YLG@"UZ]%G/L6[P>AEPBYYT"A271'Q@@L&!K

MY\B@G2HJNM9MS[H;S8%)LH_>+,\Y!<<0K0)BLI%:B3 S7--UX2X>_GL= .,W2]*ZR%F^ M VZ3Z;57F"Z290DR1P.*C 21\0B&1E%S^)C2K8]*VB#?

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|%X;1:3D=]3_V M!U?GI7598E%IE-&!9JJ6Q64-7J8 -AD7:=C>YK@"O0L__&#<^#;F:YC1NA#0 M3+JK0%KLLJ_&[#X<\$8W?G%M9K/",OA695+*@,*!UI^2^2@T<7(1?G"JW^_MREOSV A=XC#OD,\UC-:8QV=D>O9LD-^-^L-1Q3=?!%0V5EGNP++@@+ZJUR86 MA!2TLDI:E\LJ7O&RS]_=6MK,\,/&5FOL_59,? :#AY!L%AZ0%4FN&BTPI#?KY4N1D?E=:,M6+23TAHA5J5('0I%F!BFL=L_ M"V869M2\"]_JKL("%V,>]8GX6G:A,95E$6Y%?A;]7[F[M:"#2II+&%TZFV]CUQ%H07.7XZN+?WN<MBVPJY,!X;2C]!#C/"[2-2^^H8;VBF&F*8[DMRDOK*&1Z;+GD, ^P')LJ]4-!UXEG*B=49RW[O>V$,B!B69[8S?LYW MEB \ MPX^#ZX>-LWFS!"DC%QZTRX&@&1*G]1&$,_]XF+F,]VSJ/_"8 V&YM4$[;%ZP M:"E]TP^Q?]Z??+N#O4?K)"277U(H(*8!'0YBB FDLTC6<$PV[_^Y'L(#47'-L$[!UFX!CW?6CJ[MN5JY[K+L^UET_*@*/==?'NNM% MU!WKKI\R><>ZZV/==:=UU]L?G1_KKH]UU\>ZZV/=]:'N>M]%F\>ZZV/=]:'N M^DES?*R[/M9=KUYWO56-S+'N^EAW?:R[:FFT8]WU(REO.]9=/RV^CG77CYZB M8]WUHZ?H6'?]Z"DZUET?ZZZ/==?'NNL%>_3'NNMCW?6QIO8=_T457>LN5[6 M73\Z41[KKAOK[%AW?:R[:NNCW77Q[KK8]WU\[Z6'?]9$7TU.NNYU/H ML_$8)^P^+X S^?1/HZWOZ=]G:>&B[*L_6L;#HR:4123I0)F2(5M*$ M8U703B0*LUOOY>ZU/)M",Z,,>6\^!U//:AAX9!'H56."%2$*:QTE/8GR['5T ML%9Y]CH&WW=Y]DI9]V@-MQ[)4#7RLX)&1M\![6/6.8L2%&OM7S^QNJ:U*%^G MKFD-T^^\7&45<,>ZIK5I7*^N:0,.=BX4$VWUZPMXKP,H).?/:Z&AT"R;%3+A M^(XFD,=:U]29/M8Q_8[KFI0J3JJ0P I;0&D9P$4C(*LD-;/*NR ?<'2?8%W3M6H2L4=>TCC5W5]?D%;?&99*SD80*D8$+KD T299BN-1QE43/IU/7M"F[C6S8 M^!5^?CG(YYA?_>.R_[E">C:-YA87Y\R-,8A_-ZUGCV"7'RIO[VO$2A6)ZX<@EHRIH>=1,N M7_,),P5?@19#X5KW2EBK&Y> "BB9&WY$89]_&*L@Z"B66H]!/-&&O14DL87IM.X@@[D&8I"HJ,@W"AEP3A>L"R!EP89.52BI;^!,7Q0.QPZXUL8[%.]#"NQ%^ M#0U<\U(&8QS3>GC45W^IAO+!UK@0O.A2@4PL)J-[@.MKJC!B*0SMNB1#\Q20U='MW@%IQ>EP)X1TD,XIQ?5V.$@+H"F1)1/D0S-$>F.\4>"PUH0P M$3*3%#_YUFEI\ Y&'&T.GGK8K.41I>X3+/7#J-F4$LJ0CO,X+2KI9$N0V32 M0F[L /O278N_A$P9*=Y,"U1E I'"*^M0+& M"+0R4@K3.A_D(4Q/7B>=&+^#).A%R4W3*:WF0 :G,R_10PZ1(GAO!4UG,H+BM)3,>DC&WV_1TDFDVQ_(LSNV.51M9OH._(I[<]YZ&C.!|"43?9J3+0QXM!)8\ M&$^.1.DDV2F[WF8*X$PAC,^,WCFU%FHWQ-YEB$\?WP_/SU]RIRI@0$MY32-V@9P3!)*GEV(1B6ORPKNQ>1//! -=&CF'=5R_5"J\-(Y*Q+8H"R-/],< M5A(#:1E7HJ3$96N_8HUI8CWIW_O!+[$@+>]Y1EQ/A*(Y+QK0"0D*60+/78#H MM9.Z9*OY*F7PZSQSMW7R72ETN .#-^Y0<2_.#\-).+^;(NZ5D\5.NS58"A-C MS0FU6D)T65HNY7UH:)X__.#MY^^KL[/3=AY/?3_[/LP\GIV]?_.W9 M^]_NOP)K@^3Q39^T=0)YDR$V2B)_C^/)Z'*6;3--TQK0VCK&T9=K[BQ%HIS9MR("KNM4=E(10#]@9)A>X3_6_C46W"JZMZV#2)\R7YU@=^&M/FSZ)YH*:VC"> MC*^.J45Q*B>D]4+7BO6@L;;FMN!++";[&K&W?N_6@+>K5//E:K53]|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s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{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

*LP&E$+FC,T?D(8FQ2/VR-"%5C7;+EEEMW%=$]&V,ELAO/+$GT=,&?. V3Q'"*F5M;(P&V!)}RR<*
*MD2ZVCJ5NCVYX&Z653B>#**2#N7*2TB)AX,_PH]ZCA)3^R?0"|\^^C$$?GBY%7 ME]T=R#[SEG:,\=KIY0N6 MG[DB-*
0F!G+^4ZD1%9\!+17:^QE#A$\;6@=EMQC;*^+,T_2Q\8PY1)[A*A'N M$Z:)4_&;^NK!MW&F7XQFYR/M@W7/-3E2&/*5L%'-5Z4!0)#3'*
MHH!B18A6N9!#ZX#EYZ=N OI!LQ.W$73QY*=^.MH3"L?A?/K=XB%W^]L8MQ: M]G 4I[27Y$E+O\;:"P#K[-YVD8SPI.J^M^*
MBM._1XD6_K&L03NKLIFM_Z.5.[C-6CH%:UNNXS#AW28$F1R9=H^=L38I[JPJ M4%*F&TEB A<3 D>7R*V02FGQZICZ2,SYZ(FZBU([$/3WR?
C+9YQ^-2P7CY5.M MC\]DD@+DXA,HBQR'@%2#+HHKI@MK9]$[Z,8WJT_G%8G3572(4ZT< 2O0IT_*
M;CN(9T6A++E(R"P$4,*1H9RD!1E5MME[9+Q'(OA&0,<6$=K'D6@G^:;%I\7;9 M6F+92>)6_Z SY1CSM$' 2%9 &3]IW^<_/[7NS_>G9S^]>G=
*(@1V>O'M6YC^F*P]D_^@=5Q,,8?YU:(GXT^8 M+J93.N+?A-EHCVAB5SA[QPN'$U:CB.!UR?3B.9;NXELO;$ML'Z\!U1XTD_'T*
*M%K[K_<(B3\7+")S1_>FDA!533WC4GE#=[$WW6;@M5A LXCC'F"6T00L4@D> M7)UBQ$#5:7?!IDQ'@65H402+W0*_^X(?*
IYX..YNC#\,JO>C"3=>KO[-C]5: MEQVO\++\N<)Q^+/P_C=((;B/=:KIVXN3D_PD7 :W(KA0TK'F;U2U@'3P,.2Q? M-K&VD=YZ9)=?
0EP'<.7!;0.Q4V!Q"W'BA>V5NTFZC36RX&H)#'I';6&R'V= M'H@(#I.BK:0ES9R)>R5OG6QR..H\%(Z .;NH8R#&S[.X6R 0FN"9?4)N:*
M;F^8@&B9@524#B)B6NAI.]V)E;05(S>;:<6'5WI5E<69 M0BQUCI873?LFD\=?0#..R/(4[30P3)>.@]7 \9S6KTFZ1Q$F>+Q,TS;E,JG@"6(.FV*
*M376\>TH!4&1=,1;I6G134 2MAKK<2DMFVLL2U73CUMC.1;@3ZZ? M:\^2%H%9)B&5FGPDL@)7T *:Q%6*'IUMG9"S"[[AB=98O>L;G[3738>[Z^3O*
M,#JO 0H"76?$G];-M-AO-=OL^G=GC(R%NJL6U/('Z#3T_LB0=I(YEG!P'WS M$VI+;"^-/UUTTN%:>_=?%Z/YCVL\Q_[]8706.%>&.0,A](I)UM8-
*@&+%C%% MX41N?=:LP_'2.+&WK#LTOMFXXC/#"@\UQNV3"J!**37LZ:%DM(R78$ML[19M M!//2F-!&ZAV&B=ZPU1Y:NT,AM=,:,$.LDE$1^6G1&*
H^BV'XRZ%UC==VR%ZS MQ=M!=_U:^;TUK*[R6&\:5PH1+>B45&.0:Z'<,8E%UPKGBB=,:,2O.V%KMB')YU M/72]@P6\MZ)Z=.FZF-*
$VFLW>3K[%T;)FLM94TA[#\;S6QX_H.V&9:WO9O=75P59^6"IG3+ 8%$G# MZ%S;2Y$Y'YWC8+/6F&0TKGE^S\.(7B1O&BIAHSG=N[#A).?
%CZTY^F4R_;9L M:-6V6N'!;_0I0=A^67O6%=0QI&N4?\..LH%9GLB.5HN3 I.H64%T%V6.R+(H MQ>E'I/KH1_;99;ON!R]S3"+C0B!Q-
*P5)MR@SJ@X2X(#)R22P//>$KXZU(@DXQ+@RH[#6$^G@J9=:M]ID9@U'K5VT-%!>Q67*1XD:31W4;'7!FDY+;D"R#@(JC.0:*
MB&!;MSYYQHDW.RERA\2;7;0PY!'"5')T/D6@RJS61U5;;R$S43HOH]!#F6(0[!,)TFTNX06GF@P_,VR%[[_(6=M+=]K_VGB'[8^0L8M0V1)1!"9E#
M2PC!U98\(C&6K"_IM@0N+YOZWNOK(F)RP+H/GBP=T05>B8@] MU48C,RB;#P6[!^*H6N+OI*%)2_'VR)';T.J-L:R4]72-YE"';AH$IXL YK01*
*M,OI"4FAM.QY'E]&.@9 &LNZ0HM*TA]LV:_G9('23PI*"(#W[+CY%N\?>(#0: M9X32=)S;6CE3)PN[0MM:2Y;0"]0N^%?:'U"A]ELV9RC(/.,,V#6NUJR)<*
;OACN)D6R2<;'MM- [28YKTAH7>8Q_C2=Q1ANJ"F(1:;R32FC?G(]6[>ZO5W79OF>+=?5^IV]\ MIH, ;>U#G8=;SAU6(SU?)UJOCUDMZ#^!O.;@ZL
H#4ZX.C\JFAB_AGM.=!Y%W5W&0^XQG;@7EN!JKX2U4RXFF;CF/> 9$IX7^BON77]QG&8 M=\>AY7M3X/9440?
*SKJ9TDPSE<_U9+D_XP*Y3LVI/YVS"=_B Q+=.ZA78N)%>'_MT9E:SRW)9D1 5DYU9I1&&3K5!

M_B8.N]DM YBUY9UTJ:T?;;N)N)T6,S/I%<&VT\Z#Y1:W51/[42TMWZ#/N_[X

MW64==+R[;#\R":C.>I&XY6[FQB230'O8I60:,G8:6S"^N%XN6__4=5GJ4);'

MWN6=@8%Y;HR);4M%&G1>R3YQ,]UX%H!A)>=2=CMM=4ILAV="4^$&7+5JB%9A M,+

[5$V<'GF7!EXK7K5SCYR]H4*%,L1M2EB^*0/W[FY!JWASX.=)RU'[UY MV4N[Z=B[M.>#[4R]HC]+W#.V(3AL30GQQ$P[M^V =U,U']_70%NJJ

MAQJAY=!U;XZ1N)BT[; =>OZ.'B.%/]KL8^Q8XP[4'XK\X5Z4CSK;M;\E.EC MI+YGW[:S4[N!X$00(M4L20Q1R'U(PTA"AGW?9[$71,QH-[C.[^UTQ]=XC*

MX#J]6:\>6:<>=>$LO>Z.5^]CJMKTEWMJ[&>]4[{AUF:'7_<(VFGK&CS-`C;-M@5<3[S7,=' S&6MB!:%94,?HMM-%RPO0S(#GZH^]FNCF)T(CA,Z?

#%V#8^_/ M,L(%_.8T%=E6\E''1R,"LQTC;<3M'R>MWKNTU.+&=KF3VP^QJTJL%BBB8>I' M"!)?"G6,#"E,?

*4R@3$1")1(\BJ+%LRAI85]S\319FZ]^G[CQ"MC2 T03O)R M8X:/+;HX@*(,$D8])B&7^L;6UW4K*690^CKD2OT_MPL6=HWA"-U;5UP'I*V! MH?*

*M_/.2Z(*C.^]6-Q]BF$@;K5\+8.1Z$ MTT4R#=X=VY8EUW"=!!],V3;O[],X->_*.6[8NFG[> MS%3>]S4;EE<:6]Y!RSQHN0]CJ9G>-[.1[--P$$?*

MI/DHVQ_TU; ?16%YE;OSTL2J5]&"']_=6=S5[HIT_@@^6AH[U=4)XOCV]2CW MH\[+NR/-=C ^D#_!'S\@4L+)[XCI6Y@H&MWU&TNWJ

*J8SKO/ENNU4K=JW>'MPBCTPE1 YNDJB)1R2-)00A1@'$7*WUR]P=]@DD>YMGW1KB M:*

[%4Z(\M5F@W"6;FS0S0VBW\/JH=2[HD$JB9N@(U6TVECH:QF;K_C8+'>14_ M.RY>J1K?**A.5]4;-YSEYOZ-?5W\U\?__K*(*:*Q%R00<4_]X],4II0%,$D3

M&26))UAB=.6W&?'J'5_\#OY:]_6K%;9 M]_=9WNSW!W^P-VD_JS7F>S3RK\ORFA=/:D6]7Y('4^/VQ.L3?^DU5:#)0K_O

MZ0,M!^;6[RGIS]O!#@2W6R!G9 ;_:?.S.0SPHTRF$^-.9OI?$:HOA%][M'+ M@TZZ"E*8A&J/D3"($(.(R102Q"24R,/<]_V <*M2X8PY=T6L"A0*

*U7>5./15Y;1F\SW34[YQLS\JU@2_4? MO@AC$:>8<\A$0)39)V-(D]2'$692!CY+6$)\LJ]T:DC.'116=X15TNSH0J> MU#F*U>R!JNY6^4.6*

UXLU5^K^H_UI_994.=!-EO8KJ&S6^H-]<;00@(;'J[Z MQ\^."Z>91\8RNTLG.DJR[APA8Q",/Z8OSLBF^=W4O+]9EE4XK{X)7_*WF85

*MJP^=QKD\)T>86 TTA$%-60<8W&>/M2_JEX^?;H%F0OUA79KFBY\!X{S)[8' MRRLP0PA:+Y*K))^SDHY+\3D]['P)/F=%VTGO.?^T?7+/;:ZF3(?*

*#?!9.9,]Z MM/=%^=_D;?ZL#D9%^5(W5?@F>!U(4"U0C)*0^0G$4>)!%$8<4MT+ M,U9[/E*&>,C2P#2W9R0/$R_X#5EZ$P&LE6JSH7P#&3JC!UY*

*MMD2="T7OY^E<.M3(6%NU6Q3Y*LO7@M^]\TG]_6ONV?0MVWLE[=%'>AO[IBTG ME7X]QB# B$*=80IEPD2(4BXA:'?,<\C;YKM"K<_'T5T2=#;>*

<@:)C MK3HX(%I&FC]<+K,#XRM-@MUFT^<.;%BXVKLPKN?E^*.[A]K#?]X3PN@JX-4A M9_/&Q;]'"]\=@(2(Z-LE\OB=[T]J#WA;;&F[E>7C-6![EO-*

XR;)HMP0:(D M]I(0I2]$PZ*20A)ZA&(@B0(4BXC&5]U6K&B/O61N^,%2&7HD):+GCE^U253 M6L;#6B%LICPGP\WRB-Z:]+D'TBZ.-*

*Z7@V0KH;_45N#F#GWVTZ1@<7 6.6M&> M-P9T#"P'X9RC!AEYO];VD5+Z;R%Y*F08A5 2BB'B.(TYA1ZE(LP"5,9ZF*/ MYA7.>F-;:1#*

[ZF3W^I5+&@OT83"\3QLGG.5%6BW1F<11^]NS0]9=79OU1[[W MONQ0I(.+LB./C#YA/1456=8%%JI-4/51NZ'Z2:[%V^*19/E"X(AAB4,8,H1T

MZR,,"?'5D8HS3$@D8VE6)^=''/B;>S3NNFDHM0-,%OS64+8NBC\?9^!@T-7K6 M1QY[X,8<6RX1V]T19107_5+V&R=M#S ?#DE&&

MHTRW!1Q\%SMM#@:?TG?<3\!2V%'742;CSW8O92%L_X+!*YC7[FZHWZYPO!=?- M3^O>A+KZB%H0ZT=M!.X5#;[1^4KJ*.*

*ZEXN"08DJ2!*8LBG1_'@\2'DM(Q*$ M+'*0B26/3VZH+^)AXAVTYJQM=-TTWZVI>&^; 8UO"^JDK8>S1.6 ,K#]WF%A:?I?#86?YF0DZSNH[,_9*

M%I^9D#O6GN$KXWPI;8?&ST(?=71F^M:LW-;9>_?M23"=MI8]JD?NY!?U:265 MYLAT#",I5V_)2EQ_RZH%XH2G41) +]'7)#,88I\78\X\9&0**

*<>B^>]M?GB3 MM0@]&27]X XCFGH0(5T-2G()HUB($+, (BX7N7C0!4[,]+8)6:-UGC;KO$_<_M_I*V?Y,=#U13&X^@F9YTALK(^-&&*OBAH_^CCBX_A?*

IUI;Y$F2+31$>^^]:Z MS7\N"OY[MESNE?"0/HL9%Q'D1+L /11"2@2#,4%A1'&$B6<4#,)=Q,;@'>K MK^ILM.6IC0FN&T>9.Z;7Q-*

HNQVRS^D5V.&UOJGL[^\60R,J/JG%Y8%^KT"],K15TXU%EY] $8,>(' MA*4\A9$,/8@"9?BHG^_/4HDE22QRU_]#E,,22KK]$MCQH[L5YX':]?W?M;J

*MENEMSFKUW;5XGQ9H=Q[W*9BQ,%CXFCVU M"1U8".GA((8^$FKC]8B$)*(>% &.@EBF-*96B3,G*4VLB5NZH$_83NN>QLA, M<3J1W$[W'1-*

Z@KR6LY(Y4C:GZJ4M@UY#MYX88]LCN)DS,]WSBC,Q\H;O)-PZ;F'# M[:X+LV/XJC=Q,[5;< JK\S8,;KA[I?8,3J$]W;;!+9EQ"GTS8*_DR7:I^[&' M$QE',.&

*<0(1"!BGF$@:"8DQB(3FU4L^#U"96MN^O;S^#OUQ_^/4=^.7=]9=? M/[_[Y=W'^R]VNG08+C/-Z P$.SW74U"[53VG4%-&,CI2.L.T9E4A1F+O*P2S*

MER9IQ?PA(S1;9JN7)K7B8[%J.L!>/RA3L5K=Z+K7;JF1Y<(3,0VY.H_%C/D0 MA1Z'E/H"4I_X'B.841'9!6VZ8FWRP,Y^0V)0;?OI%C4_VCAX;#KKYFUG7;]*

*M4JA_7]QZ3YHV.';:OJ&\ELT4V*PS=VD?Y TWXWHA:W-OR_%LG9&M,9RG>[(Y M6]!3AV5K,"VL_-N//S9[2EN);+4NU?7V.N?UZ5[P:Z:84-9AK52DB-*

*-4>C&& M 9(Q1#3T(1$L@EC(_*E)IS*A=HE1AI0GMN%V^*C/RRTG8,N*2?G'"^$U4Y.3 M@&:G!UWA-2*IR%)V9_E"IG1G3@6RA.,PR\=V@)%M',X?*

*ZQ(U'RP]QAQ],[KO M=$VN2Y3;.9E"R\?T)#D:)V7PS^R3-(XQ[M4[^C#;X]XI9IM0-(13RA@4]2G>.LD/)##V((13#VF*_V>4%D;-4.50U.H[HR*

MKL"6,FA).\/);(MV([V=_CHN^ 1MT\X+YVC3'2 TZRY[7N#];=7@C4O]+C^K

*M,X"^>K_+MY\IL@M.I9<0&L"84*D6LBA%CW1:G0++U1S@0?:RCX0IHXEW0CZY(W_O34$;>!:Z#, ^(Z]PFK]+X)H:]2B#-&15R?*

>>IO$T7XMBI;TE77%H6-RGS\Q M7"BRW1(=+ZW566% IE$GA6/CS79.&!"F?TH8>FS;-OD7Y/CJ2$H9OOB1:+:+3([;VW MO).2.-KB#L>?=4L[*=*

[^%G;ZP8N[_]:EOJJ[]:I:D5R'@BZ8'^$(<08C*A*(M8L&4<8I"R#WI,U]ZL4C]Q9/:0 M>UY Q6W]#)&V^G_N$C;^]:YI[-GW/H\S] MO"VWU

Q7=_NMVSI5XUO\'B+I4P^E.;0IR&%"#$$L?H1>B*D/.8^]U/6(ODN M-[P^=8MC1]8>19'SR?$S4W>N$+'3?+LMD1O"5Z!'>I(^R"<%=-__^)#4;_4]*

*M/BGT0+_CT^^,#(#5@]Y6U5KPM[4S_E.CAVHRJ;JO2"6XXN!)Y%4=U_F^**7(M5H(O/&7,Q)$?0*4Y XB((! S&D-.O#3!.5/_85T0Q;U%T.L%/(V(GKBW-*

*X)J M#D%6LPC6N:[1#ZEL6+$$H-YT)F*_"DWJCJ.Z]BMMXJ'Y*+ILA,U4R.^'+A(MUIH\:/C:ZJ-]PB+TVF:S_@8<..PS!5!P"YBDF]A)5Y U*

=@'80;>JB MS'&]\E-9,"%XG73TA2QU<95?B+[!7+W&X9 E_. VFMVD:#X4B?V=.?58F- MAF=?Q!Q+ /L2 ^#%@2

MRX!2$?/4JIC2.8I3^X$[^FTOO67+@:7>.0^=F9YQ"HBEEWB#14W!JA\WNJ7O ML!Z1J:BN"@R=I3=OQ2!3\0I !E_.(C1JJOIY?%[IO1!#'R?(:5)1+&]3),*

MO"'$Q(O4\N<1E2CP4II;K?RC5"9>[9HFT$3'Q5HJ]JLT/<,V'<1&U"5W M,@]FVF)N=.V4RV[?SG[9ECZ'VRHO5V [%9\V4[%A=)6GQ?"-D7?S[$LO5X3*

*MT M!'.P(>NG8%_7?Z8LU===H'V,*Q8F^,,:OVRF4NBE$^;+X] MWK]["[[<7]^_.UV^P'CI';(\$*_6/MPLJO:7[7KJ#37+4CEDO5L%1_XR;L?*

M]\@>ONI,JV>U-3^(CVM]IGF;+=?JLX.[Y6O^MW432[Z(O6!!MR4I.BP-429 M.GS$$8PE4O_GATD2>C8[Z$@^)EY

*[Z34"=6%!%RSHO.MMW<7XV]PQX)NMKG. M *7=@NX8 BU'H&&I[@+77.GV&+H"+;M78,N;NPWX0G <;26WHK&K*@I5M[(*Y .!\7-$!0C*

M\E(,1'26DS)$:.^9\% .O#W-13%Z:W&6[/:.Z9[?ZCW8Q/).EKEFS$%'@)2A M8.J%(41!*B!&<0+CA*8RY A%-)G(7W] M#N?4WM$-]O4/[PRPG](S.HS7_&*

J1$_Q\KS[18?@N<(B>&=B^%>6FD$\]J:EF^ M,KU[V]>VM#V+[H.5\V:^E-=T7.A#FTB1,*#,B';U:$KZG 10QD%E$4RD:$T M:C PEH&)U6"O0N!UO2*

*;KMJ/WKR EC%0!/ZP;YX#43A5^ MWVB:-W^<&M5Q_1VG0M>JI>,ET QT;1PU[&R-&2\1NM|[\:)Q1H;XZ<2"IH[C M+S:-^QA[,B"0<$R5M8M\2.**

(P51@/_0(I3X/K.+ZCE&9.I2O3IG[QRV] "I M&;",XSN^CYE1>K'4=MJU$7C3\7B"+TA@5Q%Y1VE.6\DWI"8!]%W@P_;+4HN*

MLL4[9>>M7N!)MUNN!MI4PF]\7XO8)U'$$@^F/% +D\8QI!Y5_S N$T_0! NC MJ+NSE;VDM>T=9 TO5*7/-6FV_[J$Q_*@*

*MTXA^HI_Z%;C).RPM;RBH]^KRY\C-6V#>4/B#&O.F[XU3!O=E70#FI9=R?FI>ZA8^C0NEQF2Y?6@;@3Y*V=DE=?),3TN MZLG,TA./CZP7),JFN3^+7#*

*< N<[Y-7]4MK@.OM;ADN^^Z;(;HOMF*GLXD(*G MRD+6KFB&$,216L:^$*$(@L@C@=69V8KZU/%7/_\+>7SZUVO+8CY6^)FM[,E0 ML5OO+1OJ[@-*

PP4D=![+(",.EXFT 2C4'!5D]>]KQ%>,, NTF)2!'FA,8CF ?'Z4+@I7BJU\3 M=7M:5CP*73&]2R?+\K6BM G/JA1/=U)?-'117)-^4Q_A>K4J.[JN*_7<%_K.*

*M4.>B%;5VO,V5%2&JU2(-?8])Y$&?<@;1+I2.):CR!L63(BX5N0AN:J*69^9Y: MI_4E 4M]^U#K-K81PUK-S3VQPSKR.YXN.P6[.U.-%%TCB/:==*

FT[95M9=%,(M<">;6]%-F&PK$.A+!.X+L"L3Z(3Z/N?=/+CL.YW_<3%IW^/WP"J>[15F8R , M;DYN9HN>>P6(^T%WKT%^ZF/-

IK:"EWH8!6D,8YKX$)&4Z]YH$@8IQ1&G.$&1 M5W3C7SHA0%F4:1.-;Y5R;&3E*96.4U[@R;(03>P M;_FX(,AA!R)$>COUL1_@T +AW@]

[5K8IHAMVZ+Q>;,,Q<0%-F_$&\)ZPN'MJU5@UC0C#S84APJLR'D$#L"PEY&(N8^$RBR&C)GB(P\4IM M2(*.IOG)\"@8YX_NEXIHMQSWI#N_#LW$-

*#^J7BKNN",EZ:1.'?.&1!DXCQU] M;;:#TQ#3_1/X',CIW#95\'72W$GKYE:Q'7=>KU.A3AQG*ISE>[%M]4;Q?W? M%*

I$444@0A5'($$2,Q1#S5!D$(4J5OB$HI%8]FR_D9^I[WO7C(RGK2OPW7W63 MD4K;#==W-[=[+A%ECFM^BWPH;6>2"3&\)IX/9LN+XY8Q#7&/-=#D1

UYH9KL M1Z!Y!#63+N^3W<#EZH;Y0F[FO7-V]W!+;2C82 G' NC%4<1#EL8TY;'T--D)E9E_A_#_QD-S^RND%AW,'U-!INSK#G91LXR0Z\ M/-MY]KP*

*_5.MP=-C^YDJHU!/[[NZ]=SF0%;5:2R,1A'C?@1)K(ZO""N5A$-=_M]8C%F ?88P%5B?7(6H3*Z6&Y/;(;6E8#0-E>*)T);Z=9CJ0W'G.CY%@5OIY*

*M#M&:N6&G@=B"3E-7K(W*N[[6;U_+;.5.O?)!18LPDFHSD^1)R$B40 IE1'T M&$-A(&DH4Z-.#B'>YH.;FPL4"C[,4K 6WLA,&A1HP$8Z_-YMU,,AVWS 8?*

M!.BPC&%]>_DY+? M/S[\(E92"[YUF1JHB(''?U82-55PGSWJ8WY#VFS9#$D\K"$<"6NG(X(C?IY5 MZLPU$&=@HYZN]W!&=]NW$-CSK@*#*

*(3]EI3)HZX*K7\4JZ89=\;:3^MZXL1+ M&.*AA(1""*$ H@EHS"6OA\G?I@0SFR2=$P)6ZU1^W!V'8[UU%(%.OU)1[?J M6NRZ=*

*(9V0%O6S3#&T]"A.0%*EH[+HZ7;-6P=&YL_W=2PW92"9ZO3L#DHX#Z, MP62UW$^0?>6RIL-@G*_P?N0]^[WZOB1U+XBR?/-RF_,FL*OA1GWLW;E-*

*^88D M4#3UM7"=8WVE;X$5_>PYXVNR--^UC\I^?LN^5&Q+F_Z\Q.X*TIX3;]2^?73 MV3;M(7'Z._;@<^.VZ^MGDBWU,.^+4G>?W[:9?ROH:OO;*

*(I8A9B+ T$,I@BCU M?9B&?@"E%%X248$"N];0IH2G-]D[-J L2E@I1@\7]'OMG>RV:V,\S;;K*5"R MW:X5&EM*5V 7, MZ:]SKCX3Y7-*

3(DK9\I0'D82<2PE1$OL0,ZGO_"@.!?,Q3ZTBQ,.0FUA?]P? 2 M54=K&"TSM> 0 SMM<"C^!'6UC&1S5F!KF-K,E:,,1#\LN67VVMC<#\+%1_*X

*M*3Z#@C#E50[?@>1.HEB.-4P,A#O@QH$/)(VJ5\[!*8P3P7(-?T;),[]H P-M6ZN7B&=OA@M0DYHD?^.X',[2-*

O:&GSE:X[APATD:)YX;65RZZPWQYN67.ONC M/CN]+\4_UB)G\+_6.H#9/Z]=Q!"/!,$0>]2$A,H")3X3 + ZH-(J4L: Y\0KI-MD04;NI;%I V

,UN>CN&P6[%'D7"^HUJ(Z]8M_%>>M)FT-P4%+:XM6QG2&: M=*]>3=M>"]2%%_HBXH1!$8<)1%$:0:Q4 @RC""N[.DD3;M1XW(S?N8N$B:B'K22,*

MWAJWY1]+W+[-GY4)OY.X?30^MUKX.$^DQA&5"D$%/(8L0X9&(4"C5'!RJ M<.9%W$R+O:K0&0=7X!L*QE P/OA[F.K15PV*V:6QFQ8Y^^F?*

*@=H1&^YZM2.N M3N07.*REYP0H1Y;,9;S,:N,X@6W?^G$SJ/V=WVU>*9)E>^/QJ5AF3)%1G+ / M62YN5^+QW+(S'&6ZA=42![WM6$>^KG^K>1!\K3?*

YWS0OH&;&T?68A=BC;LM, MQI_M\LQ"V/Y=FLUK%Q[N>|>&OV:KK[_F!=7..>V:O\V?E&7Q66@YLV56+YO/ MVC.O77EO2)55=L$##$B2"''11-[\F5%

MRI6E/\ 1FS8+:,I]9X[55MT5]KGN@DA6@XB'+\[J2I&R#;T:Z$YQ-E0A\'"(* M:>C[$%'101H3!!/,$G3F/HY5^5]R"/KN@X1?L,GP%-BR#FN>K-*

DRY'G("5Y1C0%W[K5RQ]SI. M+L?@GO2(N:8S;1^M32G!Z^*.;[/.-%TIKN[DFW6EMG)%IEHD4@I$@AAZ" N(MXDCI8\(B2*,TE(''!0N,TD,L:$Y\.NXX:,

[&?,N#5K%TPX6=FC6!TDOS.@;(M3AGN8O-V%YLWY[&Q5FLY6TCK25"849U4^%A#LZO.;5)>IB/,58'V:)(8(B_631X1@[F@7L!TS31FY(%WP

[$BJ6KI+.L*^F<+L6N M[3CUEZ9LHG:2VJF:"Z?$3 O-![2M:Z!?K4B>K)G=Q,47==']J]T:V:L"--Q. M4LS5#7".=-V%S,RJ!MT

*MZ\A'8TZ(DV._^V^T*F[UX\KX]RXWCL3ZRI%:EVM MZH..6@^:ILBK]D!S_5BL30NN'8AZWK4X5DH[17%;P'/RV:7'''1%F7/Y;?Z#Y*

MDMZ.L+ ^3Z7;L[R/CY3G/-/QD^8ED_#:_(4_9BBQ[%X8++XR3((DD%!X/=#$) M"5.,)&01IB$1/D^053VO\R0G7V4=

*[4E4.L9P0%K^+",CS^/G]G6[A85VU6Y M 403UW4?6_)7._?X#@/CC:5U%1)_GN"\P?#& !R$P9N_:;_]N("M*_C690O*

*MEKOEZ1&FOEZWV$QLY#Z_=:H1V6[)FB"CNAT^^EY"4?MK@/#SK;7GA>MO_,: M/.V@ZN;-DE15)C-6SV0=_*DV7,))E, 0Z<[0L;XK2X, 1K['(D2*

(/:MCNQG MZ$V\5G>+/8)=^N?B14?A9{8).T3%;CE?!,AE=2U/BSE%V+ M3@Z\-N)$^O"PNOF:/WS]_PO9'F;ZSK M6VT'GMK]?G@HQ0-*

*9B;:\N+8R/ZGG]5FPOC;9+XO=54V010FNE\HT;8M/Z)O\ M?=_W5)2K.K +=*7+=_; .IO8XKAL/0\&9^HI[\#2Q'\-]!UF[5P$Y[BCOS6U M^?*

P#8X'8<2,'F1L5L"71[)<=G<@"\2Q%X8LA3B($40HC& :\10B'B 6,67O MA)9I #OC3ZS-VBCWFN3F"LXVRG\7D&%]XD!,.XUA)^&*

(J/VC%.0S$/_Z8O=$P4WP12\&4!FYC%BQ.Z,?>G>%L3G+U96H)=R$!UN?THW?*

*MWX@O%=ENY8R5UFHS'!)IU'YW=,#9MK0AF=C]=MVL0V//0<9+BD$,<>1PBX0E(O#2"B 2<^5XL@E!LUOZNPCI-)26@;K28C53VRPK$)RWR3*C*

M_DIML:R@.=T&RVZ8$049"5TO2?DAJU9[']>=,JS>&F!BA='2!9KPE:W'Z[34 MYPUJ)P+;+?:^K).L;"-YQE5C/#GJ?"49SPFV4Y?Q[,,79I UT?0?Q+-8AET5*

MIA#Y=:5D[&0:FU O@+K?J9* MUF2J_%#S D++PLE#X)GMVXX@L5NV_42>ANX5: &8H*B3@8BN4VN.4'J=+)G3 M(I],>!EX9=P*UZ.VMV++9?*

*$[40*\%5*4I>#WY%N=(=-4*=,SHF/$FB:]N#MG^L-;T?STX]D 66M=,A871PK& MFORL6FG^TQ*WB2=* M\+=;P?O)<>ZTPCD)':W^DV1F7>7GA-U?*

S6>?=U"2N:L$RUBY)LMM0H&_0 GV ML$@)\}'G$U!IF,4P%#F$2IXDOX@<"+@"SR.@["WX\[T'R2NM$W/&V^X0<\V'B\ M-'E -H0M/8&4)]M=H?*

*(./#_M0Q<@98%L.5AHFK.9T6>HJCS:;*O5]QV+!'"# M)9[/OSTRMZ49\'U1OLN?L!+(ZR9W2ZV@FI2S!Y'K(CD+&@;4PY) &0L.$?<$ MI)&O+(*

T%2%B)$SL\F%-"4\>H](C#LH&9=O^#Z88FFF,*9"QTQF=-;##FQ M7MC&@OY<:B?E6_WCUD^G[>;V]7#3N+ Y>;D/N;4!^?R5Q$3X6FJ72:%U'$\[M

K%1UQ\V=&:[$!DA?/^*9,SKHZV8^COR63"1U1<)&U>)HM0T$]2J;^\.CX:A MEW D(1>Q@(C@1-DT4AV&>.K3,&4RP-32IAG!QM2:K&.AWL[?

%FNZDNLEZ'BU M-G7& &UL^$P,G[49U&F>CJ$KL MGPU1C%DT927$9 -.XLI3%,S&TW70#4$2OJ MDM$N.)Q_B$C-

*%O6E79OUJ6N[;$(<$Q}IOOQ,19!Y&,?B(# .$?,*2D'-D M?08[1FEJE=30!>*;WKS;ZKC%ZJLN+M0P)9;GD8/ MYA5HJ3H^7@T)YO(\=93._*

>H(7&/GI@&7QBYG-5IBV?+]2I[[K7C>_>-+==<-M:VS^/3>E7;L'?R'2EU5=OJDRCK-@3M-25A81A$@D,>Z>*RL395./:@AT1(*

M?!X2GE@UX'+"U=1J0O$(,R9[W3F5WFC8["J5;1BMSPZ?ONBVVTU]LLHR@,3- M9!EJFKFGP%(K]=CK-0,%[W; O]D#OV52]_5N&[JXOW-

VBILKI>>$IWD5I$L8 M#Y2IT\"=X/BN9#6X2V=NLNN)1!HONG!#'Q(/*8!PF6/N0T3GS/#R,_L+K M/] PL4+Z_#TGK#=GGRZ89RU$CDIDB.%*

*M<#C^K{O|'C|"_7T@R.KKCX^D:S4SN8[^.:('SXH!<#K&)7JOG@CFM #P>_D M@M)0"!{XRH3Q.*P+-.5.4>C!- XZ0!'$D JL"JZ;4)UZD=_4$9JDX@$O-*

*B!U M4?5LPY[E@<8<4;/%/ E.=HM\RX*V&303L.:B"5VK=-E#*D#'B7K&89%36^E= MU3,UICMOZ5),. ZJE%H/X**:_'60Q^%8D*'Q.W41?VHD- 5#*

(NE&O[A-E=+ M6E2K11@DF%+.8<03!%$0I:""DD!"6=+MA)O MBT>2Y0L:L$!(%,'4HT0=\V("4Y$$$'NIAT+U4QA8W5F=)SEKQ&"/ Z!9L%O(

M!OB9+6FWJ%BZ; 8! ,\U!\U>AIL+ZVC-&Q"<=?6; ["O!R5>'-GJNKX3?T]8 M[;JKO\-A1+(%Q3R)-"%ZQ()B8@QI$AMX-Q'2"16<3;'B$R\ZMM CX[F^6^U*

*M.3IF*_Q2F>W6M+6X]@V?!^1QUE_T'MR@1G%B1]0F)+ ARC%'-(P3]#G!SP(A4_CV,I! M>Q$W4R]O1>T*,-T676R)UG$IY8:E^N_V/>;'SP!-_$C-_8*!K[N**

*<*P..KY(MH1|(XWCB 0ZQ.:|%?@RO%GG73GQ.G6V=GGQGKOZ>HVKU9E7>;MD?P M1=GAA-_E?R%EIL]$G\E*^ L=MQYA#T$IA&X X>GRS&D "1)1(%*

.:lL2S\^&; M$9YX*6H:^@!=Y[.!6>@"""4U=,':QHY^V]CQ,5L*=8BVK1QF#+"IG]\|;+;> M?KH"6Q:NFNXJH.%"]UWI^ ":;$9<7 ':2.[L&,"0[\V6

*'1B'5P*6[X^LO*3# M!^[5NW5%+YN2[?T7)U8!-2V@B5D6[MD1SFSYCL;+,HUN17)6H&Q0 E<%=7;&*

*MGK=NSC&Q#LKC''WHLL"T]T4ILH>\J>3.7NY+=41NNOW\K QG[;Y0*26+5XO(R= MJ3?]QZ9.7;EA4O#F$OKZ[N;63@E=B+N98IH/33ME==*

*:NUC75VL]UHZVVFXO MY-P[Z-T Y4BK7SWHL($P5Z@0J5EE99]]L M+BRO=&DO_8),TWTL)K~/J?/TK-SM .@FIV?C^ON'1HH?ZT*N5Z"5!+2BU+>O*

M5X!H:<#!%K&5YT]'8'QW4VW>;>/[F_)Q'3N^NZFW:@4R[RP,M!.9B9'96I+, M''VR_KGE@TSFRK'\B+TUA=.(SP1(&@Y0PB/P(0W7(BJ%'0YV>Z/D*

ML(HY&L_*U >MKB+X4T-NNBZ]>P@;WJ?,@IOU/FS;H[<#^=,9D"?MT'LTYSTQXH25C8NR)MR+H;TO='}@'0-2+-7H#[>Y4ANB6BUX

*MZ(64$0PE$@(B'""H]\CI-K]^X/O8]XA5VH=C_B96A!]$5?T)'*M\K..V#*V M\QT>0=8R:1G-Z7H*S93]*TZ,G:;UJH5\!5]>#R+&=]D&'=\S5TRV!W3.\LD6*

*MW'U_M93MH1U56'D$F9$A\6T>SGUQS?ZQSDI1L]<6RE&|-<7R%ZD?,BDI@XSC M *+0C[5O*X54>)2&B+(P%HMC.B\P;56P%Q M$%IO]*

*[:]'_u:@A>5?DL;&)<1QI'M_(@$)"@ED!{DDH+$7>(.6QKUQ)[:\ M-"%'S'V-?WO,^WY%2V*W/.OI0Q]P7Q)SE^0%B<;Y0>GQLH'>(3M 4==_^G9*

MO&E'6.R[O([]>70^OCH1KEZT$VQUG?-W2C$\ZAU-6OPM'# MJ. Q)!$3+$:,PP$J'';;'G>%FGSX|*VZ&)I C-"P-GPT0GS9 O-L"X;2*

*MB8F$[LH*G"8U=PV!LT(?*1AP_IVQ$5)/K;FD"Z#0U2*44>J3U(-*ZX40R81" MC B!,?%EY"/!/(2[$\Z]3>C3+IT1!YK[$;D,&ZK;8\$57=LXICUTO%0B%'.J*

M=%RHT/$0AT3C%$510@(DXH RNXBP$;!%G#G4Z+MQA\-)Y\;IGP9H=FR*=3C)2RA<1##E*44HH0J_T*6&[IV;V]/@AF"VJD.'9KZ8./-.+Z CG MCM9/?*

^19E\X1D?97S;%'QBV87[\T F/F_N'V/Y#<+B@/XN&%!K="..!Y!MF#!E[M1\U?&ETX4+<+TU7R/I'RKORRTLJC+I;Z291UXXB%YXDT$!Q!*I$/$0X1)+@N*

*M)R0$"P.I2PA.51(Z3W-B@Z3AH.LD^43,2L9U1SZSNMFE25KJA7I)/S[*1GPFB M9I.+8YSL=& +4=O:3]%77RO0<-!6.5<\-*W^G-8,-)787>W*

*LQ3GKB%H"L&1 M6H+&KU[<$?#=-^U$;YM]*76D*QJEK#D!O=R+;ZLW2J]_CVP);#;XQ$IBOXG= M%>BQI3U/^XR-*

;@)HB.6PUI@%1CL=8HT@^$US!6]V'.1&7@R)BRZ AA1?]PV@_M'2 #?0 M!QI[DU$)]=+7ZYR_%<-]B6=0W).]T/%,E%E(DA$0LA(*3$+$3R - M$@DE]4/?*

QR04+)SW]0F]R+W]"N+ ^?XEGH3O%79NA^'@3/U\#N"P],=WT.B M1QBTE%TZ_PT$='83,$1KYFL! [$/[PA,7A]fRI^+Y7.6/]R4@F>K]X352]0K MV,*

)9:%0:SO$>I4G'!)"8YBJ!4\CM!V(?KV^0E^V/$?D3K#K-0,%IA);6>%##8HTR MLH\..)L-/21.WT0>?&[MK@N,&<.0Q6D,$8ZP,HMY

/TH0)Z/TD!2]Z1,>Q;F=N M$R*[#74$RF.[[+3865YSB!6HH>NX ?0%_ 94@C^''#8\]3H03=+.<#PFCO.]*

M$0S,NH&/!VA_5[]@I'F+L]W7R>R!KO1(HQ!&/A&ZRI!N7DPYC'$8)7%"61)9 MW3QJW[<#TRN7;[N>O.^ $ M-E?%VW8'O:Q [G6N]/)?6,S-*

6:3S;9M8KLQ.GP9B,BC$8PB$>OBE0E,(\EA M&(1)0!/>$B,J9%K1'UBA;CI@*[!?EMNVHS,7I/ET:VFI_V4W>3(6BGWIR" M-*

*[J*5O+MXT15G49]NR50N:$.EA M[D,J?*6=8A9#G"8)]*@0:8(CCKS0)MC[,G:LU-6(Y11[A]!M#4CP+_\'![[_ MKX!MN.K]U@?4*;%GL5?*

B;_/[B=6T!UE39KZ' M0ZTE<(8'7-M11_BUM<;H8VR:,K.?5_ GUX!K8LF]V[8D-K";CI4<5?!;K=9F# MIDJXA;_[N.P&W4+Q;,T=X^4V.

*{7/2C4.&_W\2'G\W)$V MKL 5Q: .L3!;BA=):+<(^|)-$'9Q4A*7A?AVQI^_E-XQ\8X6PSOZH'V*VF?Q M+/)U''7SYD/>[SWX295;P11"&'HHY@:G0&:,Q(I*

D:0I9%%./)XG.4S,M676& MUO0A4IJZ;EG3DJ_/T74#Y>: ?-4K'.H#:],QUC8WE\NJ: M_^U];ITX$#.2> M((7CC)BC3M2GQISM2'U&J/Z9^MRC8ZNRY.).*

*[D5WDF_9X_KQ35&6=3_H&_*D M_K)Z6; @EHCA$*8XU4WR/ %QB'S(8F7$*UO"CT*KD[8-\8G?LF9%7_RS)OQ8 MMMQ<@<>&'T [A@!K.;*M_&(!M-*

G98"KX[+1!A]Q>X/85:%D!&U[S3GD1M28 ML8? 61$:"](S5ZFQ!^6PC,V(,<:IH&TM\$U_!YNJ_+' 44IP"@/&U!DGI!+2 M("60>X)SF1

*:R]1&*5WLS1[JJO/OVS]U.ABU*8=XQS!+F9>IH/2#N%M=?C M8-M@QK+#P09^)ZV\W*+F2,==R.RL6L\-(S*Q%OOSNBPS1I3=\&>Q M%.H_K+"N*

W84&T.[Z4)+>TCW>"FC@7ITW-H @U(X\K4.49B7I-F0.@#TV7H MV7$+L7'7WDF+;E2+@&$_P@&" <$,(JRCUB7AD.$X]#CG8<"03=C3"!XFCG5J*

MKPIT>=GC;6_M5O08D,T6_,30V>F#$0WN'#SZIL+(-I71Y<, M9>](O1^B\R]4L.+:G%RM/^FSR/_7G)SL)+'BIY:6BJN9,#1? MYD1WE%+JP]IG4?

*=';YFL]5.?S2NPUX#D:K<#B4-[QS%^KHP@5VS-.QDY!O/ M7'(JON,N4L![JZJ%%O1G 101E))+T I@GV(^1Q^,@P2&Q*J8P3&YB4^M,*

*M1R2RJOTSCKHB-?B9*3YWJ-BILS.=D6KJ,_1&VI%RZNY(#;'OHS_2CN#&'9)V MWQIM8]4]Q#\+)K)G[=K57;S2)(AQE$A(<<"4P20C2"A-*

8.2G2$8QYU)8]>X^ M2F7B1;ZSIE,JS" ;:GK:*6O+7YZ+I?% MI'T]48$LRN!V^H/3E3THK#LKX@B-N4V"TV(>V=\"AZW:G5W(G7Z6I5UZ."'

*M+!>W*_%8+6@<>GY ,0S]$*EURSU(@_#6))(!@)3+_)MUNT).A.O7$T5;,F" MWS1A4%.VS'0_A9/9TG4@O:6G=(S@UHOTC%B.ENDI*K,NU#.B[B_5R<_*

*MDD?!WWT3;*V[,]])F3&U'D8$?)X=:.K=5-,'&P9 Q\&8R,_SH)QW2#K%PVZ5 MGH=B@F!08WE'>2+/<SZ;))8T+XGTORE">IOM^E-*

*#*68I0F'$<(<(H_Z$ >1 M@#&+L4B]B(=![P*P*]SQ5>O^%/#[]ZUN'%;>O6U*'5:R,*/<4(;W@Q2BGWH>3C" MB:"ASZT.S .T)E[TNVG99$/686IV#S (#3L-*

<"Q%&VP)3YBE?2C=5)G: M/4JOFZU]/+9C.TCKXQ;UW\5V#7SZ(D# ^+C6NL*';ZP7*M/&V)WZU6U M4EM!EC^HMX"686*UU2_I3'[X;LN.7NS6<*

*M8>+%B 8P\6,$9D_I@E#, IC0F*1,AG-F\S4\J'S(V.YQF&G5"D.RT,;<(M:#D!#2LZQfY5N3TVKD#+H#OE.Q((1PK9EOJI.2GHD-/N*>^PP|L4!_EL9@'?R*

MKLP>LJ8AT]OBD63Y@C.NC3,),?,I1+Y ,/527^EO05$4AR1,C(L"G QL5)N MJ((>6?!';0]C0(3H$S[#&<"2TG5:85%[S-\'2@%7Y-N8O!9C.(V]*

*M1LY!LG8=;3FH_4\27;O MVULKIZ]HZQOY8T4Z/XK5G,Q7+U+!1!3[$62<)! %#$-*B80>A2A8\6$;X", K1&F2=#:<#NH#4WU^: >)P]-RG45H,?*

I1@-6(:CAY[- M=+Q4^+YM>?%8%Y28_%CD15?9N:&Z>[_FTUB&H<#0YU)")"(?TH!&T&-A%%] M(Y[.!>N:$)W8Z&Q6T ^-^O^QZP9<;_D1=2G/

6AF;KJ&98SZ#/;Y4]MAD1@'TEY<.(SN#[((TX8%]+ M?LE1\F;P<'W9@7%'D"F.A@V!USL$[@@X>-S;?=+ ^8/>AR!_N1?FHHPG5T?%]

MENN@ZP^"5..+K.'UAY0.JS+4B?%Z6:DW \BZ(N\1.G MVWX_NYJ#)K-'\:!LR<8V4LRL+4*SAR 95J(.T;#3ES9 ."T.82#MJ&#LH7%G M"\,V$*X?*

*@&WRN+TE=;163#*7D>3G^QM:?&+,D#G "0^EA73HS@1BG"42"*Q6; MQFF;&+O.73/W/;G4+RIO-H8E[S[Y65L M)K[F9(TS(U]!T]R,S:E0'3!&G9.MU]-*

OG7-MNK"';>WZ(T"9.0CM:?A;>&ZJ_S0WB \B9R_7W[)J00,9(^P3R$-/+5.U M,"%52Q?R&(D@%G[B)58Y!X9TIXXDZW,!>FR 'A]V*]<44+/E/*

*%,EFO5&O%>V13D*1/5=<[O!?N: M%\O0?W:WFB'1<7E$GH!Y&$"(<"IGX0}(-P1!,B!%)VG>D=@QG)B75'QP38 MQV+;FUQ^ ERK6C42B0$IS5]SVV%*

*(1F?FAD,Q,Y*4*[7;YL/>$+*$$<=D+] M0P/3%Q:H#"<%N,)CI_[YA\G-J;OD2P3RS& "]_A;E@M-YD7!!.OZ1L G71LE MJ?E2BG=RJ?^R,1W4NKT4;]7?*

Z7Q9&K]+EK.4I9CE,D8X8Q'"!5:HB E#&,L0 M%T5!N1"P+K$ ZE;?]8L:P78HF[Q8DQZ[]$A77_GOZ_E^T]R_6/.G<930)"V M,[Y\H^?*

*8DJEB(FBXJ/HC7@6'8!I6FFB/SSY-8/F]]6ZRISQQ/RUK*RN-018AE%":(IFF&,*,8$1$)Q# G*BPBP:G5+,'3*

*MRX^=Q[$E&!B*0QZ'#1[]2N!R*6'G'"B@]6'NEZ/OO.HG.V=5_VMW3L\L.LE1 M[!>H/6T#GW)\F=L/E&@&]\YHB..,$H((-9G0(J6H("I#,9,LBZ.HRB6L(2*8*

MA9$/KE*T/Q LQ!=H+1\;8*$/B>#3AXIF)XSO<&0Y?KW(X ,^T9T!.GJQ MNZ_DIH[^(<6CH2#+ ^>-->@7D8B9AG.4=,%85V)B$EJ,P%(B04W/Q.

*<%"P]ARA MD55+0S;HT(4IF;, V:D2'V+#%,8)B3W6W=O*Y>GDGR4SZ?D>$O;P%]^WNVL MOJ,+DT9X_TW*S6>S0WKAR@HMPB)AH?;R51CE"!,B$*

TSBK(B)UPE21$S##FK MYPB-?%8;LD%%-V@)PX[K68SLCJL/R6"]7Y#-[)JRJA=\#I1=[?]G>KLFI+ ML(7A*FCA\7U1,B2SIZ-*

*\ELRD1WE{V,.C//AYU^G9]:C9IF*J6THUBZG,0ZX] M:TYDB'"4QD@;_TJ_?B5GF(5OB1"VJ8SY5.T_+;Q\7J+V,'*

*M2!.+,S_*OF"EN5G<(IA0Q)G]\9(M.AZ4/HN^_3 V?6FX5T!/ M%I#[I>"83R%OU]]5*_#5?+'8#'**010R+I(Y^8--\@N$P0T6D%!>A M*@@%-[*Q4W*>)*

9Z5 W1ZDZS(1O\^5!EEGH=:0&0TE>2 M:0^E;--AT4^2CNU>,0E%'"'E V4_0=_%(# M#MAK80)'?,,D6OJV.58 5/(`'+W9I#9K#-A AE K/W\,"M

*MK*Z[5;E9R\U\744=FQ22QC^>A5P2F:@0);GB'!*>FQ8XLM-V3IQ1CR7.:@+]] M FB/K#(;3]H\L;] \/L>,]HSJ9.CS#1=X$4T!&$[PVDDW&";M*

M9[0KN\]'F MDY554Y_@%W,CN397U=KP.C_QF$;F@(>OT;L RM/.X85#DUUW1AIH&+[_ERKNE1,^RL/1RLP-1T_4-ID4GM=B7,9+HH)*)$)$2$#"'NK

M)O]I-AWRD\W75 .4W24V3%.D3%SH>6T:GC7E M&Y078202BB(1QB9FPQ"C68I2G*1Y1K(H5Z!<.1NB(^L/PT+=^>4JZ')1A5=K*

M/F\]PPI(.Z7A&QZ8RN@BLR4ZOK]0B)2>=(05R4DU[:2$0_T >M9-.YR<4/Z^ M:?T6JTC.(Y,X;#6?EJC.)0%)&@B=,A5%B%?^Q(3;R-*

FA)F[NOAO:V33Q=M+%9_F72%TOSKO{(TF"\#\]6]WJ7_E<7-GQH.8ONB%UDY/^ (.IA^V6'WM8$65 M:;)PW4)5-

*]E:2S$W*4>EUJKO!SH1@M6'C?">U$8OJ4G5A8W0AVK"ZAG7N:?E MYE;=FR3SY@5'&!$RQA))QDTW ED@[7XD*!%A(;*(FS]@TTX/*(RL"-[?_OT>*

M.L/T$(.3[33CU;38)"EY(]#B;VH_6= M0P"!,2!VVNPB(6$JK)6N(C:"-?-6%&_36@_7GWA&ZQGQCB>SGOL@_$[JWL3! MS+O%-

*$A84[XQK4";X5UMK.7FZ?MB]2)E9R;/5C'%-"2*)]HZR7%3[B/C&.6Y MBN-,Q5Q(87M9=1DKHP=&&N;JP2&&O:##WU5PO0T\MCSN3;$"]$:X<$N&+ [VF M QH:5;D08X=."Q>";7^+-AWH;M=KXWW!09=N?F#]JN8V]D,!DUW1^@.C>WWE: M<:(4U#IIZC"5]FIZF;<%5]K\2Q*E#<$B*K2#' N4$%:$BI(P*:S>.?Y9&_D=`M=`$*:I/0>)R).GX*ZOGMM#-C7V>38.^OBU-0F_TYSD1]W13402A?*P7U/&-O M.P5U$-"+4U"'*:5I'2QB["%$=$ M9 +1.& <(JUPB0F2&2))D'&=9S+%571"0]L@*N.8D,*P$.UZ"EIE@RXV]_0D! M===BR'PDJF!JT1LG!7(? 96^;CP2;ER%^^9<,9' [R-YC74-6F\R4=A"Q:S>[M/ Z? C7*W+)?7XI_EW7I]_X._+]MOL>5;?#(@5'?JR=!'8<=.R/GL0Z.C M/\Y+3A=W4N^@^*A_5LX$3W!.\ARQPJ27AG&"BBR)48JUD\GS+)?**KVTE\K(MY[.E&]2$@YIR4)&V.Y7]&/6?2V^2PTZFD]#6QI!*]PJ@^2^R^X@\]ZMR5&T$JP]C'82^AA_'FY_\F]Y+V?2M26(6,A8JE(FH0%@? 2%3$.$(Q3XN"*5E$ MF55CG^.E1SYX+;'A;C9#$ P?,7?!8.?*7B;083K-OM,).EAJLF-S6H3N63GS M";B9>+U8W/R4_- FD*KZG&_FX6N_Z05O;BGUKC)T1M%@$6]K!CKB]B=@+P+"=_MZ$MVV-$Y}[9G\]!&."<:L72AR0Q%&_&ZU]+5Y]VN,S[/*9LOM"LHRUL%:(37 M9J(Q)F(2<8ZDRC*$I:2(YH6YR(@X+>)<)8E5;UI/_(R=_E-3"18[+DV>R$5# M[WSM1*YPS 7&2.+,)!/1%!$68Z2R/%6"%+&B$C*/:LL[87<1-"&^ M0+ <#W/RT(\H(F9R>@/)TMW,I-Y->Z'B"[O 6Q]>R_CHR-CX&85F2I)R@/,XX MPCAEB!211!G+:9Q+DD4%*.7\/*F17S1C=64$M5'U(SU,^3AT9O3>9G58[A&[M,[Y.&]5A@6TZ-'IIM[IK6/)5EIOU,]\!FVH5_0^Y_B'?O3SH96^5B4COVN*D M:<3"L$@13N,$81Y21!0C*"9)'$6,,1F!;% `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

*HC GMR-7UC\=J*H,IS+M^V@"",B>?GR F4P7L]'_7/S0\ MC]JNJX9*&/H:MZ9B]*

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|>, *[TQW*)F;1 F8%BNM2>$^UZ,@+1LE1O/C :BPW\>%*9T@T7WKD M+)UI5<.0N$>G?? !MP/\WYK5+;:))BGN8HS[A$ MF/$(T5BD* I5'BD9$56(=BR!W3GN)VCU1=X?/0 [SI5;)5K*P6IIPC*:>E ; M\K#C/("=W9GV@(?;W+V&KBGDOFV&8@1;%JZ"FHG@OA<6\#&WDl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

*(%BQ%/$_U834C#DC*&!*)R#*6ZI\RJUNF(4)C)|]TFK=<_M!?\5_2T,_WZADP^'81]V&OP!0#L])Z47;:%_#*LEX0[*U[7V"XV>^]H/@Q MS6T$[#&^>Q^?S+RV$:)K0%M]WBWV:UI\W:JOT@Q=X*8>21OF=;.XG.9$%"1`M48A-119/4)%QC&+,>5*03-$(%-\]2VED+56UDENI8(\R+%!['B2[8*P7T6'Z MZ:34(W34&Q3-4\CT/)U)PZ*#XAZ&/HH--(>C,4X M!>^<@?0"?%S"I^YHA,!L=55LMHTRK;:4=_;DQ9@%'(WU8+O6O MFQ]_NZ>P()B@GB1"+U[+-1;6F8(9WDB>)J*.,$0+?TZNP?7ZQ__V#V[U\>K M[GL=:,W5J#>CM,AV_*J&B:@WTR:V:O@^F!OI[@?1WGKSSN< MAZ]+_P0N[.M?U:WNS17XM*Q^-I,RBT+&&4IRHV^QHH@6E*,B4JF0N9 R!J6* M#I,<^U9PUX]_4??C7]8GM3,=:+ZL?^:8G?\\FG::T"]&,!77Z:K? C"LXF{JB ML6E^T[*I(FNI0AO O/=`]&+_B @OCODGR?X.MWO!P$XV|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`=0"" (VAWZD7"",B5.$,&[VL,%]=7E M'D!)YV]W<$>X4>2BZO^TXV5WFU?3Y_"8 MK36Y'K\O5\S$;,Q]^J?E]^=-N3^+8C_1IC)[VKNPVF RPT/:J;+1C!5YP:(L M11CA F&L_3T29@6B6(192,*0QP)X33X)XZ-?L'|ZTN;CNHT6:T9_R/6FFJTC M)-MT6E\ ;]NGV=8XE7K[E$0D)A1APA@J*,D0RSDE"=.J/06-W7Y#FWI!!+3. ME)@O V6R(JMNI,%:|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ae="R%,QX"OXT7)G6[H8M8(,.,!V"G-4.&"*M+01D5]$^O+7]%YA\"5LTX5G1KHCX2HP8&TY\V-JH5G]/T:.>%+N@M]&VUT$^4 M-__S; (KSEF+7%J7I4E/N6G7E.(H24A#$*"T0+I(,D2B.$N:/CL= 0A/WT/) =P3G9'^D"IITB&ADBF"YJIX:IO_0X(N0,1;"T8X M!Q-W8'2&Z+@!H_M2EXZN;D&//EI8P75US;,:N M-3.;_;TW+2#K9N(SR9+8E"\@F6%3_)$(Q(3$*$Z+(F."A+*@L/*&09I6Q_B2 M0H>*;CU=IS2*5>CWY&+U71L[&\F_+5>+U6/MINT:8$);J0SB;J9TMX ,H;R[N1+(7M3ZFV]'JEZS;$\DZ)EYNN0.7G-I@;:?M/$+G61!;T0U^:3GX MM6K=7$.TX^(^/@'^O+):XTJ0'|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{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§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|[GRSD H6WCG8 TA-W18.# MJ3#750!$9)U3K%AG&"<)Y3% 1Y2&B MQ'3IP#&G808)89TC-+(MT2$;5'0#0WAH$@(,*CO%X0, F))PDQVL!H8$\W3D MSY*9]'@/"7MXE <_[W9L#V(Z]8 QDW,T2VB:1.9RBV2,F39H(2(R0"A-\BCD M6,6,@P8^G*4T\L&]/0@6K^4/N7P&)O"_+TO]-I^KN11-XEA(TD)1 M2A%/A#ZT& M4L+1 &0T+*0BA(2]L#FTOE9$/;%W.$L, $S_,?4F+NR(YDMJ_M?2RM).D[DG]!SG'4,2m*ZRU)SF&5N*U1]#NP_# (V*>EF/^8BV=:SZZVC(3M M/S7R&=H1^]_VT:T#N8:C6>XBP<{)CHXWF_,\^T[AJ(.E)@L_G1:A&VXZ\PF' MIF? S\ONJI(N_KU?/W[0=7B^6,QSS%2DI$E,Q-.GF.6"HSQ%DB MXY!&4D16PR.\%Q^M M\7"3\JEP%)]NPXAQQLWLV@B1(@T1+\)"E@'IU%0=6K?5-7[MC@6<7=AI%#!@+^?KV_>?COK-W-&U53+V&)V63^4L3]%B>W?U,'_2'[E5]_JGI:IGF^L'YBL1S1A) MPZ3(!2*X;K^7"'<1"[6 4F%)1A"2DL"I57XR-K,.W_ 7?=PQV:\#,SS4?T%D< MGG;%3EN]!M8P9=9P>!7L\.XPN5=&MKU"KQDU-7M=5JM,F[X-<9C X1<];^,W M/+$U\>P-OV >#] [PO/X%XJSFAL9[6GZ;$2Z36)CB61P1;8V1$!4135!!TD2& M$6=AGH(N6V7'UT%ML0"KJD%\|JG]&L:-K-VN5HBWE33NB0!':!EJ1<,8"J MI]WXAI#G\65' O@<7+9:?/J194>"G1Q6=ORIBYW-=KKC%[DQ"W]MXDQ M!ONEOG$#>]>=V$=GZ&_5/_6J4J2!X:CN=G@UB=|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|>[=V1-EP%AJW@1_FWH.(LZ+#63'VU-MOSL&8CA\HSP>? #!UX8C<"/?/;H@XW4H#24UV5^T&0?<&VW$%-YOC84V7I=*G M56NLNJZM:N+[<;ZD2SZGBTYRB\GM*T__JLD9I04)M4N#4<13@C C.2)93)%2*

M81&SD-"$)Q#KQ"=S(VNO+>%N@AC,=/&Z%79&SFL!#--O)[$=(=]W##0\F4E> M69O4H!H#U$/3;QO0:\-ES7YY-3\Y;913X0B^U*6^Q'/?C#:
M96*Z33@#B0L:4'9>FIY)8R<>FFQDV'F&N[,_>CX%UPV[:)'I:*0UT)W>JG8/M/\@-G2_*73!3&TN*L)P@F=$"X3R.$4F40*&,:8)S%6%J5<$
ICQVD'@7ZJR8M"6Y5T&4G:/AQB!;#01{61J-!![[1>CNH@:8_CH.>\X1'CRA")SC"D>B?T@A8M;\D)C'
Q#Z8M.BS@YOA^I//U'W3Q+#LE;A]WWS[?;EBL:8A38RU*FDK]S-1 MS#^?UVMM8%8\MBU*7ZJU9F&8QA'-8U2D7"&<1#DJ1$103M.8I!'-> 3*^QB%
MR[%=8K@ V,:!O.*QE70+6C^2[,< M='FN2YP/&[?IMMFM__5(OZR\L,BJRGN(CX_X::!D5)@//(R;C$G-L MF*_2?&\D+?]B)PT%^WO5^6FK.X[=Q9)%&&
<)'G",.\185*,T3"+(ID M*J,L@?52L:,[=K!%;IIABW.^S0\Q:.B3OJ@SJ.U(6C/35-N]YD:X&G4:W.F/-M2.V@KEX]_7%3_57*O1038"#:=B/L%/
(\,)4;:L9E+O@EJ/>I@-%]]4 MQI+JM%UA8% D9+1R(75(2@D4J>^1M9HQT7@^R,GJ[-4P:,;]KN_+V4P?W\<3E7 M[]^.;9$+Y>BLK(DL*\4SXMJ_&
[U=]G6E/31,4$ MY06.C;')4:%M3!1*G,8\)'',(O"PX6&ZH^=:E775W5R;B[7CR9[+^5*69;#Z MOID_S?]='^GOZ]7CFCZYC"'V)!P^=N"W^7+^]/S4C.D-
(\JT^2Q15,0) MP@HGJ$B5U.J"YUBQ5*34>M[WLHCJ]>&EOUP@7VQ^X_S1<+ #FQ#QN,DX;!, M7S]8'^]R<8&G!2C.R_@] ?@N=_FU#6-4C]
(_6U\FB_K"S']0]M,[[XU1G<# MMZ2#/=J!(6Z?OMT+0_^1\8D _)7G(#PHZ=I&,J<4Z]Z%)TNHMA&OFSYM]7EX M H]I.%#/V'F42_[2)@=+]IG^5S_-
-.8M%5AFSB#(N$>9ABEC,B,@P"T\I<'@@6F M^%HNSD?H/3H EXCNR3,'D9]4/76=&WUS,[I/Q0@'A)G M2D4-261R%BMERUK%&7N-U'(LJ!
(&ZD=F>I/>R=?5TX.S?;%3F[\K3L[ ]\WW M^MI^I>ON*YUOOM(9R-M6@RW#[<6+%;=3=(,_'3OG;>%/8.F=^L.?#N+Q1O$.
MUIZ\C9TJ*NH:F*ZJNPI6WQ.*8B])&21IX$,4QPG.0I0(74VIL ;#G,E.RL.T MM#O"TM0ILJZCLCA+7ZIVKH/8P5S=&V1@P60[MC)?% \V?94=?!!-
S3HKS(9Z MU;A16UOQUF-N@I,+[A";OW_;,89^U4YN(P">T--M;&7S^-^'HKQ]Q-43_EXN
M7M26[UP]1E@8*GV8)8$P8+,89AAQ2(5!RY"'&$LBW<#?,2(3Z[HU6;"FJQ_I M.@K,>*S/A;AF.N> I./.K;[(^E$]%Z+;A?-,/K91]&Y,I(&PW=%79XO7C3'?
M#]2-/FN>X[NKJ' =SJDLOC'+[.V_,;&R6)$R3-\=D' \;7>:<&;JX;['=,>% M WJR&F7KCHMDE:,[L-QLE;GCHO3S<0-
/F>^3V]=G562JNSM6ST^\)V[Q&WBM MY?T-X?$_*0]A$VO3WR-KZ<9WAHU@9OMA4*:NUM=1V[!=8:QVPGJ1V7[_=]GN M_];O_9V=YWZU%+^-
K&Z^B6TC]0!0>IZR&_'-MMA:=2XPV+CE#LQWINQ=>2LL7*3V L"F(<0(X#L8'[-(2Y
MGV*8TC2/J$=3SO3;0AVF,761"/O1F^VBZ!KT3CH"R[C'Z$!8LRUZ0$X+A_'H M[X%^QZC3!;=L&V7PH[.ET)G/;*ZP-VOE!^AQ*<>AWF2R@XD
8:8)R%D#(4T]Q,OU!M^/4Y]$M^ ^(RCH*R%W:-CI(HM?"2.5!??@&8: M66 V!.4G2%]/;;YQ:F>'XTW2E=^;A&'"DRR N8>$793)\0:$()C'09#Z* F#
M4.O"ARGAJ<,#&OW\#8>B:$.JY_U, 91AN.$DC$YHS: GL//>#"-DWZDY@QX8 MQ[LS:+YO;O7\C8XO\7/^/E^4LM7+5%@04Q86O]-Y,%3W15
MQNJ'Q$\IAY$P>^3],0JS)(HAPU[HHS"/LT2K:,&6@8G5BKSI((L22I350K-3 MES64XZ;2U "9J9..&]"RD;Z.!U?%N:5%9[Z1M?4N-J9
M8K;XNC'43L%DP'RS6G8VH^X4H?NFWDGKF&ON]7';=>>>\;"U",!@X2$PMK# M1-A]+,(PS7"011[UXT2KM\(@E8EU<*]@OD?
9S*8;1FE<\SJ1W4R]3B^VOH)T M(KZ=%NQUSJ0]&)02]6M[6W]VE(6(1R+O0.8L+]1 G,TI3#/ PBFB81B[S,Q.D'>19B&&JCB2ZR'F5]8I74T07LI[2Q
MN]J)4MVE)-TMU\6&!\ENLA[_)IKVS,Q(&UH[QK=95Y_EE[G/.IKV$,_@<=:C/T MJ]YI'07QA%NMXVO;*=;;JGPMY%R13V7UL7S)&_ZR$+1D3X+ZGOK"?
TM)"G,O MSR&*,OIY".88<^G$>(XCI0*"G6(3:P(+QYQ]2!V7%.VW9B5(EQI13.]-PB9
MGCYS!829GEI1D%$65J@VZT+K5(P6#5"=WBY;/,!OW]BK@!@O_N1.&>F(I$C) M#)*:57GH"+VK%+3>L2S&6W7'_-!U?/_.'I1G=_ZSJ.\SG/K$CR,8LBB
*"$9 MS,4NAR1EF2]L)!I3;%2!-T1M:E>L(V5863>(C]6=B:UH7?640%_2#HNJ^5T MY'%5(C=(:]ZZ.!VQ]XKAM%XRSVYR:%]Y615F!OS-
R+-2YD$%S\43ZDGU:QAGX\]3('ZF9* M9#K '5YL= &=5=+'FNALB:%38>DGCTY>R\Y$^8I_RL[Y7]CRH7F\X7?%$_L+ MH\)R%U1P_?AI4?Y0_^W?
^ZF79L)!@1GA!*(LIC:/$RK^Q' >1[[*L%8*V)CR MQ%]OXP,L%"-RK56'%? H:,E MN0 M&TH/2< D)^W/W)E&QL(,I/TZ6C,'6H) M4&R[0>S.^\;-
&OJ[:=SO@:-ZNWNX@W&OV[7!I=[5 MWXKZGRI8@KP\\%F>0"_V0XA\BF&:(@9CPL(\XFE$D%'H>(C8>]3]G%[!<\OJ1<]\N?%1%>/=&N MF[U^;^)-
>/E3'&[%S8 BIA^_V1%M/"IC+Y5A,D;2 9IB&05'#DM@%?+866]V M0.9A$?KAB2-/3%Y=\IDMY8$J&R70IV)9R'MS#%&7AHV5
)5KS%B&6^U>'7T3QJWP5S MPX/9N.;D<^^[;#.[RON^2^6))H+SUY^,,?:K5]%H GI"+8HN!3ME?$YI(:G@ MQ2NQ\'?>V'FAW$:0RH'!J,.I!!G+(=Q%B>
(^5&< M9$:Q&&..IE:MO]_>?KG\>GE]=_X%?+JZ/K^^N!)_NKK^=//MZ_G=ULE_(
M.GB,JZ50C/4MJ[X_XOXFP;&7<$P#F(8)@8A&*4PY]2#S(D;2.*&8YT8AX6.4 MIG:USK]=7UU_@YN+[^:[W\Y_W9I&-\]BI!FU-;%W(;QV(ZD#*("170BK3
] MFZM(Z5$Z\\8_Q\3=BVJ.OF [8.'C2VN\F U76+TU\9;K#QY8D32=K[6<#S& M82^;V;8Z-%=A5#R+D0J[DIPP3F&]U,RC%'9%V!^CL/>$W?
FUG2&XX>L;^;=5 MR8M&U@%_$ORM*M?NRHO>4,GV5KD7)-G#/(1)Y,L8!\E@2L0_F!^'"BS:M?NT<$'TSMWY_T,9IID MKB]@?*"[\W1R>^ H5E-!'<
[MH2#E>V++=O5SX80UE=?TV(%T>>1_%73)WBYPQ;I?MH!B1E/9:R0.9/DX\F#J MIQ[T_,CS(A83GVNWBMY=?.*]UY(#DIY^&XX]
(9WVZFRGD06'4;V1-/O M+G**B':=170^GE%3D6,B##04V7MEMF8BQYCM-QC^HS=&?RY+.F/8B$3EU?B
M8RT?"F'C]\Z#]:&D%T=RP'V(8(*C'"*649BE(8,\3#,4A5$:9D93]LS(3ZPY M/M_MUU$L'S9NQRVK/N"Z("H/7&8WZ6'8O*IZ=R"6K)T!G()7/@MV():+E8
MX*I]1OWE\;853KZ%GM::$&$SM=6!VX^/;KCI1274%1*@.&ISH"Z'D%IAX6PR
MJ1GUF<>56D&S/\/4;AF+,=R,56V16%V_B*W^;;DYSW5'"\+I;^SA9;'V>U>,6=^CB"1XF&0*>,RVN08RJVIO M@_ZTVA#IAUNF@,HN#.,$,J,XC:GL_$;
[:5FB^N8"M>/]QB_;ZXV5YW4-BWP MSA>+\@<6 &B/Y)X6A%VQ)*>?>;-"^5+"82OX#J&G\4T@#SG$),4@11&(4P]?U< MG]>E$8X)G&F-
=)PD,K$AQ46336->>RNOP% >F&SD\4V4I;F$EN4" Y(Y*SJ MIQ"-F0OY!L3OBTR\B&<_#*:.(S2A#"98G7D!SK9X&XZ0FWE?>G]'_ "UYH.@#P0 0'
#)@H&l/8R7ANOB# 6S?3@, M@$7!S0@2!IZ%,T3L/(?_9E4)GLMBV0 NGI&Y1-E-#3\P4+=X+15>M,.K^5&" MYK%\J64M0/-
#//JF7G0T'T@/CB'78'B!^4Q_+4&V3'N]-\P35U^;:G"JJ?Z MAKP-)ZV:#NV6%PM:?%:T!>\6-WJT&T^=N#=B3>A(EZ M- UZD!V2?CV..)4?WK;)Q/K
>^L+INN[!+VT_]@6T8E8<3[5_[*BVOP,WWH?5" M!;_DYS/3<9*IL[8??(^W,[!A&[2/R_^[\\/M-TS;KSG(*+S;=W 43)F/[UD# M-;-_CMT@T/P,V-0,EF;FW?
J%B77Y[>6-2=E?J6V\60E@ILT$[XZMM#VF+6OT MRKGML3W&M^OO=O_RE)+],_QS]#TDC;*4@(!'.H!?*2CN/<(AI0F : M(N0C/XIS8E&>?Y#6Q#NB-
U>@?Z%E1=TPSBF9[9X0@\LZUE#8)?2R@>$ZK MX]3>*]T&I#U>W#[]BD?;PPT.1QJO3\IY;/1K@%'),4B@V,88XR1)(4C_W M0QY[*-;*
((Z3FGA+^W\.CT?],X-@_S!>&FD/9RB8;>=A &S2'L-(&*0]G"%B ME_:X6;(NZ]$(-<.LTA[+8LEPPO,%_:0TN0K;2'WANV[0^OEO0: M/VG/=MAZ:6+U)$F8-
CM()K$?O!>$;I[_'(0D)#Z1=R\R@F074LQAEG@4^G&>^1QY(4?) M_2NK\G+^S=LG^\L!I^=WNP/#["!M4>@37HTZ_*VC??QVO['WK2>D(P=\A-BL
M/KB>X+MNN.9;)YS4MZ7PZEE35,J"^L"6C!>-K_^N/XH_+1GM?M0Y6JF7^2G) M*609DEWSQ"$DUO9ADH:1SSC/B,7Q;<;#U&?
Z[>4'B[\OB*.\2I@.'1L]L2>>&?V]*\L_'MKF7"K'E;\ZZCB >4DA2&.,Z$\<9SF%,L;!"*Y-W0 78J/^Y%M6)]KF@Q;->6]$F,"P=U//"Z&7;
M_.!VT!;KUES^[#+JJ]YB]PPQ[+'(A\+!(Q#%H0=3C!'DR,\#C&+,0R/=H4-T MEK!#L>F'AQ4G%HZ+%H(>IS1,PT1X>VDLK^_+[4L0@R'B?AID@3#
[XOM&WV=V MCJ"MRSP;@GJZUC4N9JIVK[WB&1 ,2!]P56BUXL&A.V@BLK.LK ;)F=.S^B#L MYVD-WCW!3;PHGYXK]BB\3C4*>]7Z3)"
[6KZR]I;W7QA]8)IQL91_\X'QLF+? M&%F(K57P@J@TV?F2WN&?]UG"\G#+)2IF-UXF."@Y;SD&/]3/0,0\4]V#%OM L;]WG MPH(&6PFX4VX5?
6.QU^C6]G=DK,^MF,#X7I$75T.$S(Z*R'Q/2 [QX6,U"T M.S1N9;O!JGF3X>1&'$,R'/2LPLQODJSJ6D00(2S/,\AS'D!$A8> ,68P]G&6 MD83&-#0:+]]\[,3,:
CT+E]I\TDHIS?0-=4.JOJ]7,5.-%A_%\D+,7!@YO5LS.=/O<$UGK@]Q^,;/ M;-3M#HCS5UPLI!WZJ:R-XP7[R/+F.R,OE6".U>>$O#S)SM6,"H;J^O=EQ?"B
M^+?X3UPLVUB(C$M2$F1)0BD,TU18F(1F$,>>!V,44!;Q&,>,F^A_)UQ-K-Y[M7(#GBL$&_P00:TZ L/R7===[7<68Q?
_,;RZNS'2_F\^CI]IG!]U0,437@2(Y2D0?"#5?CC 1%L8Y0^.*H$)Z;.'"4CS_@FE$9I6;+6BD353>V M/A=4)_P$R;LI9%S MI%8M_TP#
,2Q##"Q((/#U*8^\R#&&8DCZ]_!!G7\]67OT&R8&9*0M\Z'EQ*DN (M.](NXW(-]B!EV?3, ^_"])6-QM. .I+Y2[%D5V+U^IX%,<^%)H,8(1^B/)"M-9H
M!PS^D)(!)=HOE]'>_,+*FEMJU\#LT/CU_P-^_73YWO?XO^8'/J&_^P1/K> M)YD_F[[/@MUQJ.X+T"\%SHM%T;RM2T?5SR_;+%-
/VT!&#=A'UO[GGO"N4?4 MAU&&$42QK9$Y= MRY(Z\ZG""0 R4S'ZV'0W<8#SF6<&WHM-;M)8?I\3OK" M;LUU.GC-LK1PL5!W+%>3XK9! M0?
>JU8:?GJ*3\+J151Y',4D2>9$C2B#":08Q3B,8YQXF*,190(TF@>B1G6/' M=JT%G#P!YAX0F[TI\V*!TDC9@9G+/TK/T?1]!F0%ALU/442NPMOO-VBTX
M,/P&8\;#)/8@23)9?D1"F/JQ.-2#/ IC'W%"G;Z5CE*$&#B@4':PKHZ_4?IS6L(Z(_9Q-HOVA>.? 5+U^X6.*EOI MUCB^/#\OWLX?
*J;"K;>L*DIZGX8(H3FD5^K!6B MU*8X\9;?XD'E1VK%!< K-L[D/!G!B'[*?0_)8;4P"3YF:F$;&D$?M R\PTT MMY- HU^8X!PBNQH%!U
9U2T8B3U0PJ"WSFS5#$9B]0L;S%[\56LL^I5_JY>+9]? MFOH;DV@5BT*=%]]D]P'YZ_H!UT6]+L6XDYU#N%"5UZRYIRA%H;#Z(6(1@RAG MD? '*
(8DR,,L#$(O](W\@0EYG?@D6),"Y8NJ^?K"7L7',+S>.>6WTK/J?Y$Q M8*;+-\K]#/3X!C\$XZ#/.6A9!]N\GX$U]T"O?]8O/UN+H'I]3]"7=3JD73=F
MG8#3]^G,.AWD1UNS3DC2HMCMX:&YK%1_\?.G1KNN;>NMJ?-=#P^5NJL/!,ER-MRVO=1\)64'1=BJ M'CO\A)W]]$V8\=5+%[^]*&OICHN?
B;W+OJSO\61^1D,6"\LG6S4WRF/JP9CD M$4]\($XCH^9&.D0GWH!;+ #)@TI!=5R<<+]*'U]:\4U3&8;UP5"QF:#BY"8@I){1N_:J8RML-
QP5$ZU<[NM2EXT4!QFF8FP]?L63%2+^8CV=K^AT^X>BB69OKC!'3UM,H\F)V2 MK!C/59QU#29;WKI11.ZTT.D0.=)-)S R]\8Z';!=/>9@1?-"G
\OM=''1=2U[MAST5_U;K7SR*3@E'-(PRC#WM6AQ=HA,; M1-]?GH2Z>I/!G15'H,\2;'DR:/RAC>:PWIH*(S,--82)R5T:>Y3T2W.F0,NN
M.F>-6ME'C2A>'#42,15VH"9'>ZG9RG),A>M7YAB_:]$GK2JL#6_-6[=S/" M[5Y Z[-$F'@XBB.(?)S -$D)#/,PSAD)4\JT9IX-$9D\:-G(PJJEJZXVF_1, M.P;-
N+)S(:!ME!1!!W)[2&0#F0VZ*#F0';+)FI6&)AU5!L1;JBIVK%7Y^NK M-L+\5FNUL6>M'<]]ZV^SNNP?>_"1:],<\#O\\Y95'XO%BV!)=9&]STGD<1H@
M8<7)R8R<)1"G>0A3[]4>]X,PBHSZ&3GF;V(%U_V"]QI=M.JEE9N*L.=VK]IJ M#RM9.A-/*@:!:\42T"OP%7[E/IK35TQU?24\G_?ZRL9.\4'7=\MS=1^OV./
MRO&]PJ 77*1J:_QWO;X=NHO3P&I.R?:*7=S>]930'O W9Z$C)FBIZRXE\,< M%[>/Y9)=O[1M=[GG$8Y'F',D?&V.&,SRC,(H3GS/R](P\;3FFQU:?&(5J\@!
M10^T!/44Y$$ZDA5=KA@"VN%,J"..>I>$>'+-=NJ$/5A=-6ZA^ M6S,!5EPXC)Z;B>VL:%^-+Z,PU]R9 {)?,&[UM.Q2)/>."=M?7Z_,E51?<+UZJ
M2GC0+>&N*-H3!VZ ,P+C/,DA\CP*4Q9AF(=^G,G$710:>4OZI">/]"A& .LX M46GN5IN0EADK56(
K9XZF08PTTA1B]5E'ZNVI47'1Z=J)NA68RZ_LP$_VH1G MGM9C"LC^Z!WC%4XJQ[LNF[^SYB,3N_2I6#)JWGQ.8ZWW+MT3C '!&=BP9E7&
M=QRK874Q!4QF2L("(?"'^T9T!AB<6B%XG,![U V.BGNDFG#\/?,4T;>B_J?4 M*[\+ :H&"_.\8/5MN2C(6_O/S:]U1CWBY3Z!*/Y
MKYLTTB<[=9VA9$2=DENLZ"=5# <3RU- XN9=CB""&@9 '[T_[9*IAN I9^3
MF@8TNRS5,'ANTE3F\@XDK@P6FRV592Y@/EE\,9U2(>)7X6FI\XZ7R&A/DE9 MZL& Y+*$D@X,>BP8MU M[SE?;%(.I_ M)X:
'&A>8KJ^>93DEI5W,O5A>&MQY[6I0Z67-T"1. ^VRXJZLXP&-$\0T#'!: M26@4F#@BBU4,8G>MV<(-1X3H1Q:./7)BHX?5;6%A=7>WCNG-
SH7BO>O'V[>/ M+_ ""J!$;Y?);N5A*BO9">4^8'D:^#R"&,J3 89R8B7L\"/C%IO M3\[QU >]JO9XD#'I9_S63L%<5<.V)<#D7R]%W;9^L>P#,=FGU+,5?
JD/9*;F M^CTA>MRO^D-0('367MN'_5X1>ZTB>G* /Z0DH!/%H84R&^RN&T1,QN_[M(F8 M&OZCS2(F)VQ97LRJXE4-
7EIS>L,W/UQWJ;CW0A(S/Q*N7>ASB(B/8"[."(B\ MR \13M(\P49UPYJ$)];W&XI@L6D0LQD/9UC? '9J@V[WA$Y!91F)UWOM[+7MNC[2_X/1AK5F
[7C9RHP1KE6_KTA?_C/Z AQ$D<0\1P)/$D3#Y@BCO DIBS'1K&X9)3;P06N)@3U1U(M\D9+UZT
M2GC0+>&N*-H3!VZ ,P+C/,DA\CP*4Q9AF(=^G,G$710:>4OZI">/]"A& .LX M46GN5IN0EADK56(
K9XZF08PTTA1B]5E'ZNVI47'1Z=J)NA68RZ_LP$_VH1G MGM9C"LC^Z!WC%4XJQ[LNF[^SYB,3N_2I6#)JWGQ.8ZWW+MT3C '!&=BP9E7&
M=QRK874Q!4QF2L("(?"'^T9T!AB<6B%XG,![U V.BGNDFG#\/?,4T;>B_J?4 M*[\+ :H&"_.\8/5MN2C(6_O/S:]U1CWBY3Z!*/Y
MKYLTTB<[=9VA9$2=DENLZ"=5# <3RU- XN9=CB""&@9 '[T_[9*IAN I9^3
MF@8TNRS5,'ANTE3F\@XDK@P6FRV592Y@/EE\,9U2(>)7X6FI\XZ7R&A/DE9 MZL& Y+*$D@X,>BP8MU M[SE?;%(.I_ M)X:
'&A>8KJ^>93DEI5W,O5A>&MQY[6I0Z67-T"1. ^VRXJZLXP&-$\0T#'!: M26@4F#@BBU4,8G>MV<(-1X3H1Q:./7)BHX?5;6%A=7>WCNG-
SH7BO>O'V[>/ M+_ ""J!$;Y?);N5A*BO9">4^8'D:^#R"&,J3 89R8B7L\"/C%IO M3\[QU >]JO9XD#'I9_S63L%<5<.V)<#D7R]%W;9^L>P#,=FGU+,5?
JD/9*;F M^CTA>MRO^D-0('367MN'_5X1>ZTB>G* /Z0DH!/%H84R&^RN&T1,QN_[M(F8 M&OZCS2(F)VQ97LRJXE4-
7EIS>L,W/UQWJ;CW0A(S/Q*N7>ASB(B/8"[."(B\ MR \13M(\P49UPYJ$)];W&XI@L6D0LQD/9UC? '9J@V[WA$Y!91F)UWOM[+7MNC[2_X/1AK5F
[7C9RHP1KE6_KTA?_C/Z AQ$D<0\1P)/$D3#Y@BCO DIBS'1K&X9)3;P06N)@3U1U(M\D9+UZT
UO.W=0F"VVP>D'_*F<*@7V'@#Z[J@*;7PJCD@(] 0?*"$86 MF*UT0$^0?KF YAM.)F/(.R7RPY__+.K["%/D$Q[",/03B$*UZ3!BO9) R:VP-).+KJ
P%!GK<4N^>KNYXKR&>@Z MZ8,_)!/3C6XX).HTXQ:V*+WGB(1#(H^,_3CXBMW.OBB?GHI&!=V%K;,.Q9," MU9L9"9MJMASC" 4TAWZ&?8BR.
("8!CX,DY1X?NCG.-*JG;0C/W4BXN;KUZN[MKY?7=]_!^?5'<'%S?7=U_?GR^N+]\KN9#C"$54\M3
>6F;#\;$Y\S;PS&)ACI!E9/E=PTC&HLM$58=$@F9T'0@T1F M#GD.';H?X!Q\VCQ6\)>&%\TCP17[_E;+HCNA#^X8>5R6B_)!)=64_YECSOS(M#R).
(4HIHF\ZTTACK@P%[CJQ*4;L] C.?'&W3 !.B[4,=?G0]]YUP1Q/);A M'AJSG:V!BD5L0Q,>_.1B'>YCL8AVG_!(9Q3S,!!Z(?6@N-%L,Q$RP?BS$\$U[
MSZE9&F21W[DY7YBU+Y^C\+DA5AM M!RY)T-S=V<9"WZ.QEM#<:1""*5H3W(PX*HE#OV-[_=E=BX/B'?(>#C]H7JK<
M%>VHP)EFF7+OE8DW2T=)\QI"KCC#V^,$2;H=\#EINS5?&N^BE4;(#;MLIZNX0)EECU<+$JL_WPIEZ_6."Z_M]DIZHBB(O=##,,^B!"
(_$LK.3V*8YH1E81I3GMK-Q'3,Z,0JL2T14O0L[SZX M_C\Z"O%7@-M,;?:0G] D:VH\7%}!<,WF^]P\F CLHQ<.I)G'KJ]7+X6 A<9
MM5I<+!A>_OZ\;J^7$2\B*88D9T*Q"CT+OOXPN[*KB'& M#;J<]E)4DG1X,:YP9(3]YN.$[!B!= 7)E^$K/JLE!ST^#DSOJ9N MYXX&@8 MW,Q4EF/(C
)0%@!8!:A,Z,P6P+(0OA_@LGG=SG-L&X *3[1BCV+YXI5MQ@!< ML^9J^?#/&(,$H^G* D)1KY1=,PQ?Q.K*#F
HUBS!!XE3X8>H^L/HN1DNN9N5M]R(FAW M7"$4(IY!%D6,XC2*(018Y[0N8"68(Q3K6F MI1PG,;'&_% 5 CGP"1-UZQ-(!L -!RT+9JKS #YZVN\TJ,"[F[?
@2?-8SF'!FS>5N5#A9J6Y5&1ES*/!0SZ,+FI=^:!$;@K%DZ;>+N#VWBXQRT;9CMV& B+) & M(J=_[5'YL2YOV;_*B@:#ZI\W+9" ?M\HE5#W(@657^

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|*6N"I*%09C M6>0'4<)@Z(+MM MJ(../%C1US]>Q^ :MSX<@F"V'0?DMRCX'P-"W]IP"(B=3=$#YJD#YGD7&$?- M(#1E'3?QE:8S6C0%*5O*NB^8AF2)(^,OBS8#9?5I4OQ$=XN7JI*)C15$>EZ M)$;H1X2$S(-)FB00I<*"P#{)Q'^RF 4LRKW,+$2I27ARYZLE;IR T 9.,V(Y M1RFAD?+03MNJ,/A#'1<@#\4'V"2"2*FPKL*<^]2G3?L:0C&7AC4]'US\^=< M0!EV1U:,O,0G22140LXARED&<412&(68X2R-PB#4CLCTUIUXVTM"^L=V7]YQ M6\52"K/=*FE8&"!}2?2-#4N){ R+P4]C9#<<8'O 1N@_/9L]<(#%_ME_Z*\M M!_L4]7-9X\7GJGQY7E\;D9E--5#HA=&;9U:I+W51UDU]PV4HHOY>+NA]DN1) MZ/$,!C"$(5^#C%B"HX8V'D]"D8N9I7= (G\PXU.AVR MO

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}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

*[*5O0K<;V3?-PHGK4/B=1@>V&3QO\4FTF6F@L-5,);^A+&T[[*2+2(9+I4B*?-24K]/>?M=%U[/+-D/ M(`HE|MG"'*F_=[,O[T>2/OZ3X.?*

WFAN/%VXN5AADOB(L3MR12]X$$&4!(KL!8 M1B$(I.BO5=RJL*=. MBTR, :LM*PP?!#S1!#,\$S/QG&1'UPK5>Q.Y7]\;;7L-VF[!H|EG<"\PB7!'A*

M94BH$;<@4J;@H\L0-$FL]'YV,72ZJUF!^*6SQ^4]X;MS1VX-TF|HZB<5,HV5 MNJQC[:WFKW4N95>:(F553$-EF;J%Y%AS);7DCHA>Z70[C'P-XN--J< M-;-

*N2GB7N44;E/=?Y50Z!@'.4 6*BF!\PDK>KY/2[U'D?DF26YLQ#7ZAC*L2$[J;F;%[IM09-\#K@G\] M!_=<'*_69#NUM%P=<"D-I;"NB$"9%IDS>&M?*

*=0;H[4N?F,-V] M7QNH7E.ZB879-%9IILMWY/88^ M?=\ ]#>G_*2*V,$!;T] R&]!(LK%.C,@XY1>//P;*E1WK5]]/7N'+[=^N^U MW"3;8'XJ%M$ N!;99*

RJ'PU6WRF -E%)(:6AH9.&/54;*;1>!MWS#KR?0/0 M?V9&@BEB"9" XDAE_N@!KPUMMQ^T)E*+IRJ_4[V&7'ZW3)O)%W8R"?5EOY6*

M7E4LF:. ^I/DPN-%^GUC<'[K?]Q;/F&GQQ=62T%E:6$6?6&X4!2\BP7RS,E M<_:Q=J38T^.+2K@4HX6AQFNMZ3+$)_BK?*

K]W5LS_Y9=IB#N]YXVH+A$[QC+P%A3EC#KB4K;^=C!=?-M M1'U=3ROVA/K.??[S7!4MM529@=6"OR2BD0L82R(=W**

[6D=.WQGA>![C>\FK+L0TNR-R;Z\-R][]#Y%\$(HT,XQE[.6-K,U M4-^5?*]K"V];K#?AW1817O3P%\-L)&GH43ZZ3T M^Y'V=>WQ545_OYY_K6P77]SX>;*

*M0<[+IOI 4FH-21)XH6@7TDFPA?:-D90E+C9*DMKM.N]+T,RV1R4L/-Q:WL'> M#1Q6WB_MB)WY-QF;'WX>S*

;%,$QLTU05B$(]9,+P&1@1%)/;:I];/RL M0(U@:0M//P6:G (8>Z/!N_ MX43+41LS=\?OF#M|=G0_[_VYKVP9P@7:XF(P7* ;:5 MH0ZZD2D!,A2R8E&W") M-*

D)0+J1((=8F+GPD1+\(V=Z?CP_#=S!N ^@X+U=G+Z<_%BHLM;E21!&EI)<) M9&M%4%8,"DQ\%0$%K15H3IEW9/"]'OR40TM=8S= &H.(I:*

<:'TW.G'#>#1^ MZ[X.YVYTI8S4/!#C-03N"RFVP6 T0042X.0DC$BU:Z3GA6HWT.#:NBI9_0&*

*M$'2:Y]JL8UT3JU]I03RJ8#%MP_48YX$R&>=!QE2.*TNLB2G:VKV25DO2[^9] M-\+G MY.FYQ4;U JN:[1O T,O$?XV]E 416#,PFB+?/-LPCE6 B(TF6&:*-S*

M;2;7QU(TC1_OJ)_B7'@_F?[AIC% E+%98!#EW&)R M9[T"IR0#ZW(.P63#=0=-TS<1L9&MP2T1\9@"IC/W-("^.YL6CQLC",YTRL0!

MB1+M%C$_Q$01(Z[5CBFB+65*KA'U=/*O&N63<32=-M5UH('!]][_>D4J -O>$'(`()I9&8*EPK,*C.C*N@D?0JU;\(ZC+^`QOV.W!

MT\V@?,6FWG+^#C!=#4HD#8FYB!;E :R@$LJ=(,$3ICLT5@;ND\+TNP>V3RS6 M\4?40>*8UXC$+%HEY';W?#;%] M

*FA+B_=*5+;)>^$!$5ZPPJ8O62%=L\F"40)+=]ZBJ8G3(&OO9:PC5[_[8_M$ M6'4O-8&]A;V.9K/+%_]=3LO2OPR%B^![W6\W+;[1HM(+QZ(Q8U*

*M)KC:2%=(0Q*X$"3P3 V37B6M:Y<=N\C;[W/OO:=V^_!J_\1U+ZC\5S>Z3*LU M'G@OG>0A ?%1@) Z@*<:M=7,2V:M-*3V!LWF4O;+;MH :&MYL($]G'?*

*#:\.8 MQG%V9]M@X)D*T48TF8V%)Y)'-!DW$%.F02@JF*^.PES R],L)ND^<[>R%7A^7 M7FOQ<3B>3!#W6CZ4QR- MU'%*

*(573M^6'N%3M%Q^WG'X^RE\>X+RA7_QGNS8BW9'[:$]H)A4AI6+X]-XP: MT'"&A*NTY;E#>K-'\E3@XRV?>3*=E-H]OOGQ.]K_:'SU.G[\^2#,L>]:#].M*

M!:SUF(ID"I)8B147_F(#YKOE:#SAEP$+^-J7\S:6LI$;,KLB: 7]:I?N:J\ MN7,>%"4C@F:/A97)('0D8+)F("4U,0BMX^VBU<\)7&< ZMK/3Q_";6+T!N"R

*M4?\P3Q)UF6F(*B74S1#PU P%# U'Z MEA]I=CXY3:A1&([2O5X"YY--W2*]4<$E#DP+##H)Z"BZR#,EE00A%&_C:Z4$7*

M>O1{U6?/TZ%W(#0P&=XE'#D,%R[&WX_2PM?C>'!1 L#_6QZ04F6S\5J#-+T MXR4)? X4J/*+]US:V-*

JO>M>1]^LN'_T/#R1K.W)N"Y'"9I4\R^T%;CB/]I MB]\#Y#';\CE!(M[" \ HK!,8C&*V("ZHX%@"K[V2:DTH9(@' DX!\82FCM M(_]UA>OWEGMS0.*

[&J0V@=3$OKV;:TKA7LV^OO60JV0R!486K3@I@RO,2RS)3 M^$=:5D\2GA2FWWOLS:&QCM.:N-3Y^(J#C=&NB-N+$9LS)CV.""YD)=KAVEW*

*MT@*BRL209*EZV/VC W;!IZ3K]]>Z48U\7<,OL=R,PCEX;4291!H&K@3'}@B L^,Z^\)D=2L$$9)91I1PM.%9ZYQ&E5#1*!NKLKB*

*MU1HYP9[7WVUB(M^WS-/PR='XX6>?3 ,2]9818X4;@" M6&O Y)A136D"L5H)%5ZX3[RC"*U1%53%VS[=T\ZC[X4V*Z]VZ]NR-Q=H!])I*

*M;V*Y;1"Y19OZ"#Y+"51KSF)T0J1.]F_6$:XU7H). F$WKFJ@!%[_ZLNJ:UL# MK0+EF3'@BJ"V3@2P/A2F(V,=9RZ%ZFVX=I,X-*

4"3M"Z1Z=N#^$):EOG+>]Z MJ]Z^7Z3OOQ#%5)IC4)<.@6I[K8]RV6:9+36A> ! M+BQN-4Z$GD/K1LY](P^H5G9!YL]*

M<;J@0Q))Z 3,!YQHRDHL_M":S&?OB/36Q]KD+YM+V0@'^9X>P=5R5P-Q\<3] MN#H%.PC_=3FO0/!HP")

*MP'FJ;8A!D^I'V2*U>0CNKU!;R<7M8&ZZ22D%!?/I<[=_.-36XEBA>>X=H8R&;?//6 M&2H[=6%#R_/[R?2NKHNXO*H \U2HHQE$-Z60]2$BE*KP!*

($E@G1!%J[&_6& M(C;Y'"*WKJ-F%^YJ(H>O;<^4F& W9Z1A0R\)JMWA!#$+1I=,"U%]P*&5/UKIKK2]?O*

*M(5*SH78CIS405I_0[/UP[,;AB7O4UF<;G"GM.&RY[F(P =(*RC.16/8O:*K-_M/[*YE/W66?O>\;SEK@;BXVGZ>I65'^=WR<\'6 CR7"Z>9HDV$]1$\,DIX(1$*

*MIB4+OGK;E(,P%T6WY6$+Y_M1^BDCYA>?)D=3S^D&>85,>;4I0"'\1NG^1%@9;+@)59_GGIB2>W6+O*W.26 M9USR/190WW*H-*

8ZK:1Y.1NX.I]G"_M#L=?ER6;XSEFFQ-P7JY4";S;'+<./'&.BU)//Z133E>-Q4;;\6_H_?'.CM'C8C'8VZJX[8#-?I-(#K;K>K;X0V$X Y, ML"3G<:/?

*II/+KS=9U!.G(R$:QS(F4$02S*TUS]#$@-S+N=#+.ZO]^-A>ZZ8.F60<@\)RT]1!U*JR(=P9:F1<81PQ0+ MI/ZCA/UJV&*UMFL:A@F#21L.UGG;D"Y#3/X-*

YX(,-E;\M):0XZ@3!)@K>1 M0_36&4U2B*GVW;A]ZM?O>7F;$ZA+B.S8N@T--JW3!62O%D(S)$9"H8#*K+R\ MIF"30 O%R!*GTAE9^S52?/\.UET*

#D0VECF30)I27CE]H, MZNZX4:=P9&O?\NI^'"ZV[#N%MPGLC+U:#;-^-;D\6'ON2YL/@1O>UZZKK[?TA M^VF!^XS:^-^B'RYQEPID?H"WN

*O22,&0\(YX&CE@-%E/]RKJ?5@0AW, MW[KI] >N$7[UH\LTB$13&W*AV6!8T),H(&M&<%6(B?,N\H47!6NXZ^TF M.%D5#.LZI8%U^G[T'D3JO,3U*

*J6WI-@GE>N6# C--$H2&5;!U>^[WI6@8;*(M7;"S@YD; ,EN:8!1AG/%$Z2H,RK+T6Y:4LP*K-0A!Q:K4Y1UG\SU';XZ?S@_.CXTQ;IV:I/J9!QO2A/K9 MC:];*

MXF=\NN0B=W9# .,5U<^W.@V[!N!H4@ ;#)45AJO.$.^"24$,] MQ.A6^[IO%

*<%WY@O=18A2UX\FL\MI.D=GOAF5J[DDYNR3+&USRX7&T=^DWV]H_G1\2D?6*BS:KYW='9V^-/YT>??C]\=WQR>+H(M9V=;!-*

LG/JA"O%U'Q%HA=_5^WG+_';[IQ:,.#DL&+R88"4#P84!Z2O!JJ22 MVFU+,QN*N'-OUWN?^L+&YZHI$]3BG+L(-)=DQ#L+CN)DL9%K(CQS]>GH*

M=Y6YW$#9)08?M7W=IW?;#(!GOY^GMT\.'HT_OCTX_; MYITO?F2%H+B9V$UEI('H((7 ,EK2TEZK_"Z%A'62U$+H(%2NO1761$9Z$..P M#.)&-

*X,K$8>M7L8D0;9K4%ZC2F%UDYL()P(-IQ&FCV+M>^Z;*QD#]# M3KD)(A^&T&Z]VF;_ ,WX^-W2CCY\./CT[OC\+X>G1QB%/OUV],;#X<'9V>'Y MV:?*

#\RW"YCJ?6B%R;BQ\I>#YVV02_QB.1HC,AYR+MRBY@217-!-N-'!,' C& ML8;R!AQ3"C+.35UZ M,@93^R'H9A+V&P;[P];#<->AW]J,=5?)U:??

*#DY/,4XL4]YMZN/5GU,AGJTA M8*WJ,/GY"C@1(U,.3@,)F8(@3B"<& .CI&,BA)!U;?*_U9+L7.O>^]1;$!MB M?>+4 Z<,YXOA @PC&51(E'G)2?*

*#52]C\5HO1[N_T<%: 63MQDWWAY__'AT MOIB,F&DL-[!^,\2)>KA-]'CNTV\<(EE7V$J11%!>#)=MF\LI_6*OX7/"Y#FM M6]!T=D&Q2(%Y%S]UP&L1C*

*0&7!5B4*R6/U0PV[FABO0C$V0!. MND+0S3,XS@0H@^NILIP+4?L@8C,)^XU2W6'KT2EM=WYK,Z:=G1^__?>_ '']X M=WAZ=OB_?S\Z_\]M=L<>?TB-_;*

*71*MX0+#TZW&^2U1RFD;EWMW;R6P^6U"9 M^$)EKGI1G S21)3%I,'C\5(^879!"9$!3$'232N_)G7YCW95,,^ MCP?VA,"\!Y39[89\0[>OOW]X^\?*

*#LX/EYM%F"B=G![^Y?#3V=%?#X\^X9>' M'X[/MLGHUOWD"K%Q*R4]! ^N =!*(2B(P8= *_U,&S'#3^4YU> M^[X$%7(U=,,7G'7#;^4%[^0B?9K,*

*[ZSR5DFA(H] M6 @(G7@LTB@?&*IM-3C MH78U_)),_0:L'1"P(N&J9_PV \[IX5\//_V^58UX\U=?WE|.YNC1Z>T^99+,%V*W&#DK%&^X?*

*$1B05*2H_9!&E\[M%UA3M-UOGP1O ,OM1EVWOQ^=O3I\.SL^.3\Z,/1_UE<{7C[EX/3W];*1,]6HT+N.L* M6RU>*

*(9@NPY(@>"'S>I%JKZ:SXX[A/\$!C^6M@$2T.4]PK5/$8&H='4^UGS:M M+5R5UR?/#;1]SR-1*S5E F*2% U26).=-Y!\YM0Y*]VIO5>UC9Q]Q[(N\+7R*

M64N7_FLSLIV4,N?XT_5I_\GQV?GIX?G1Z><[,WA!\/W1^_G1Y\W";4 M;?3Q%6+?]NK4V!]_V7-8H&@^G"ZNTZS87 TZ$F.T+$NN!.%" &\T+I.(6>&P*

*M#+"T^J/']<7;F=*WU"&+49;M6R?XL3?#O4GCE(>K#\6-2M*RY$$&4QK,, G. M1HWI@A26J9!*

(J6M=V\K:^U9^)UA[Q.Z[#T^V&1Z7VS_G!_^Q5:)W!V]7"&Y/ M"E,I=BVW#,[=]Q7XH<&DS+F']$PI%'@ JZ(§7 %#TC1S)FKSPSXCSJZQ:<5' MWZ)62&-

*<+I605T55&L'3:(K*7+D-N14^TG8<_+T&V-J8>)A3*GF@3;CQN'! MZ:>C3[^=G1R>GF'I=;A%\'CT$14BR/-BU=K3=M,QYM"%UG%Q^G&#E^BHC=PS*

M2+DT0,K"@%OZEC,=.<5DN?9NS5.R[$Q'_.!S;['K;9:1) /1^E@HRSD8G3)" MV1.;#-&4UM[@?E*8GG>V:^#@$7UO%<.W&33>'9X>_??@?"'JA'7+[]

<7COYR M^.ZW.RFQ49K6W?)Z39]>XMNJS;V&=?11,&PZ6(2U(1),D!:H-CX1 M[:UTM;?=GA6HW\A4#1WT(_I,9MSQ=$]T5CF#Z7 M]>0T?*

9U,%]V[KV&3A'(IL0PBE">$]6G6]H/OC< ME;-\"2[*D]) ^LCP3,UJ#SUB(>&%2$M(I)6K?VEI#K)ZI"VM@X]$-R\K.:#.P MK"#0.IF,AN7>_#:7#9[YM&

[8OE8+VQ3'0C). ^.G'[?OSVN'F3D]T[/IIJ M47WVXSKC=%LE;D_.;C8:03/OP"A%T'%"P"((@$BJDX"$U)]PV#/S&YGX4N MEZ-4.M%OP *V!-*

*>\F:9OW*CT]3{[DM(<1;UEPUE9%'LOC58J@XN<@,A4@$E8 M(YO(B/>"1.=KOW_K0O M7XO9[K"BB>R,D@RP@ U8THZ,URE*ADZO]*N9EJ?*

*IMI=$_'BO[K0$D M'HWQL])LODRWEXQ]BV\ Y=O58O%$X]-D/%F6D^//2]6O['VH)6-!%*L&*

M&Q@(%7'N1H6KB/3.2"P71:P=;;>3="T.W7/\^(]YIXDS=!S=/Q;3>/]'S6>:L& M+@3# ^3+AB"DOOO@P_)8>V?'P^]56\(W>]R.X%=9X@9FTMZ75/&<6O-

,, /A M69974@\WXE8>B587K-_RO'M@]N_--M?C-?),0I()#4"LP\AO!3B9F1**2%J=)69'D9MBD-L$/T\OP]V[KH&J^32% MD9O-*

*AGD8EO7;Y7PMS1]H+;5F%\4'G1*N+S8S\.5Y(Z6$E,2)B=6O.]>1O-|% MO")N>W!DF\OS-3'AUNOO@P^HR)78X0JZ+MN=3]3QTH6!.Z%!...K \AA!,DX%*

MY5GS4+M3Q9X8$U=^=DE),6?], '1^.,*I]@##MCHK@O@1,9DE)=C"GT#<(H MYZ,76=>^:;2%F'USC]5'UHJ+OIWZKH&%]LSAU#_''U[RG]TA8?*

*MD=;$2A4L=T!SCB "L> 2#T"P<(JJL*U5;]9=1)^%]I] M@+@'#S> ZP]I-IM,CZ^WXA!XCOYM,X-\ACUVZZ3RY<_LEO:VT]1S77)2]5W6*

*M@A*P%..;T+10T[@$A)<.-X$()6NG6YV3WY9=TC>7L^$89\WQU_GPXOJ0](N; M?GY8704:8KD#@K'=!Q!8T.'<,!+K+$4)3S+*^AWSE**

*[>RUQVO[\2Q"USU]/V'#1P^4.!V _ W&AP+I8V,65 T^]^]3R(1HJJM?5=Y0Q+ZS MORZ1N^OM0M*_")-OZ4W/TKF6QH.S>YR3[OIUAG](U)?*

0RXC_(1;20.NE"/DT\SJJ. M];UD'B)EBO&@K>7=Q<1G17L]5-Z;(.GI2%C/3VU&OX=4MUM'N"<^J ,VWB[O

M&#S%Q9JEBE9K7%%E1D=3Q3CPR^9H4%IU6N7I5VQ(#UF$E@-&-!I#/'7W!F&6LU1)6T9"0Q16L366XI:J-\OIM@Z.F U)W3 MFJH?

*_I;&G[^4%/=;FKK/Z=/EA4_3X[Q0^6$45II1DY4 SLIU,>(C.)XT$+0Q M(5EQUV%INX&@/=\CZ!;773FLS65S;>KF],E3-AQAGWS473*LI,*

+$+4BD6:GOL&:L$N(W-QR7]V='XYLW-G?>W6 0 MR)/I17G0?>>T/#OB"T52B!P7"UM8X5GP6-H'ZKF+BG?)]U)'B=?+7[T)>I]A M4.D!"TTE#BL-|

*(3BD]F"(N:&@OOP@8.SEA,GKQPX++(($$IO3OP-XK**02;#0Z$3K%03,/:FY5O]9L=O7\,L7C<=G1P)KA*B>[GY@Y0Z5VBD#* MCF&YH K=-'5@.:/ZJ*

*^/F8:/@%Y[1;"U*O_OM^X9O'_YK*FK?3+TK"]\Q^^T3 MX=5K%KKET4S^,%E>:<YX;8H:RC16PS1@M2&4YF@>9T%::E30R099FXYOSRKV*

*M2V302]1O#T=MU]\K&VIL7:L^]VE==?_HL_9]MM>#BB(Z(@6H;!.&V!3 *9; M"%Z. A3CLC:'69<]0%9,G>4;S3NWJG'"?DRN#(O+SVD*E]-*

*R+'QG&;I]V"2T M"*5G;:X\H;0L<^"ML:!Q"MN@B)"L-N5+504:[C&R">]6B([]79D=N^SRBKT6QIVAO(^'=T2SM_\N$N%NZ#21=WOL-UHKYF/"IB.6-*

,2+L&Y M((9FUE(7 16>YMO7=GZK?JZ1V9-U[296#[NJ;0]#_%3'15)ZZ<.\\DGF_Q0 MJ9PA.4){J5S64QQ<) Z_S-J:$+/UU=.EKAI

W;08#T%&H[41MM%+4)AI[."[MS6@,KXYT M484M%@.FN(s9 XI2 LC6"3H2) M]9+[2'VL7>[M(&Z_F5TG&-V7\YK Z=U$]#C?/\[F4]RDG"*

*]F.'*S+/SR2W) M8HIWZ!E(#BHY"S$;AK-3*;"1,@C$"T8#X]34?BY91_)^L[^.T+MWE[:9%ZYH M@/[HUZY;+$B#(REGMNH02NB000EP!!+L:[*,D>CL(;*

MYTWEV@/^#/TC-D'4W7/,;KS2P/)\KSG1VWM$2@??A[.!B9IRSC40S3$K=E" MU\)#LE(3K45DU>^(OR!2/S#L$ 23[CS2-L#>32[<<#Q07$0B/:K!G*

21& 4T M'Z8BWJ$RU'DE.N@G[QO0O?!]>&UA3_: -B/F1+-?$[&4M]-TH?4[FZ M/0C6*,=Q8F:F\C7+.RV@<9CX'7CIV8Q^)U;V"N*5K/-RM[0-YNWFD*

M=%NTBGSS8Z-FE(O%1H>D:7EH&I4M%.O,@&-!@_?&)^XY]4?(.Q'LWX@O[]$ MLD%\-#!K-E+PD[M(5P$H6B--*

*YA&LB!Z$C18<+9>F50PI$$Y,]6.M+47M-XEH M$77/I< =0:#G>_/_/HSC],-M>NOJ;3-)RL1P;5.2EDO45H&Q&%*XT)QG*J2/ M#\@75FX6/?*

SEK:2"\K.Q61"8SCI"29 M2X,HD\$E22"6FQM&9_RCZN?5JT7IY[1D?VMR#0^T":2KJ:6MT=)*!22H4%JF MEU-*

*T6\YX/+7*9F9D;9KM)X7I^7)##5>_#)\M[-X>@*[*>7>DX2+.B6E41WC M";P/":CD.F4I<'I5?Z"X2I#F@+.-DY^'SA86[Q$VL^E\<)-2GH4T=M/A9#&;*

*MG/7662%)UD44!I7+P?MXE=;]8U;%V MWW"YDOOW\>QK"L,\3/%]%B5#L_8^ T_9+NEC;(H4'$DN"9J-LVM=)7D),D\) MT$]TJ>3426T+-P*3]Y-*

I"FYV'1>)BL+%(,$[+!.$$ &%]QX8+QSU43!]U^*J M6Q.C]T?O$2\U?+H")#O8MX%TY:85!ZKQULU1C^GDZY?T=N2&%[,W/VZ_-0R+

MU74QKUC$^B]I#R0IK#)#\,6N 4%%F8O^>T'66YHVR&:VD;.?]LK[[DZ]UT# M^'RDQ-6LE4Z&& T#'6S&6H-*

D\#0&")$E)D56PM0N[)\0I=^4NGL,/:SK4\$A M#>#J+^6)67#CZ_TNJE,5C$@=-'&O-2NQ%C *D+*P$J3\=K'YP[$Z)FJM89;*

*M)_5LW'/R=.K&GY>;&DIIKTTRP(,7()QFN+*K!,1YSH*53*FU[O"D"_=#+(@6 M#-3K6[2VMVH+4+A",*

*)8&6TTALN2*Y8C=%,2QH0Q,Q!+F$DU"JP[0_:7,6_1 MK(?NWL)R/3O\XW \O+B\N!:<&9^$RJ"X3B H51BT"F$_+IC*)!+H>@02+[C\ MWJ*

],WT;ETUJV%]OQ[OO=P0G.DF"]Q)(@4N6<"F!C&!45IEXY5QZ[4Q>\GQ M=P?MY^)&-<=O;;^>SY376?D^#,?I\)XN.|SBZD:)#) (3VB>Y %#H@.B@T#+

M)"7\@I)CZ]<)-X.N!0S]^K";JW?0)QU[R#_ ^7/\\O9C&*^^&"3*"<\A@J4: M%UV>(AB)>E))5#34!>4[N%"YE:QMOUO8$CK/W:SIRH\-*

X/5D.@DIQ<4SQW?# M;VDV'\[1O,?YNC%;F@VBE8GK$""+Q6&=+,KQ"$KDS S%X%Z]X?0:8K5]Z;$._M"FM[I^=U=PUU/]7Y<3[']GPV29N\,

*24]77;*LH1C9L*9IE%E1?-+[U W'++M M&SN[:I+ZS<0Q:X?;M_9$9T-1&!666L@J( );<(DQ:?2.$%R0EA,6>OJ?8E7 MR-*

MLFS6\DHXGS6OO;1C&_IZK][<'1EKDFO=**6)>WTY_'4AK]M#.YV_V3OC72!2 M :,2+;M1Z!(G5CP5)!"RJTQ8]?G:+Q'4+Z2ZP\&3N[B64Al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|C&OOU5_<6WNI4 M=0W80F2A;//R6RH+7\6E0??QE>HP.GBE)^CT<>8]F|WB0/K7;!96U!*.CQ[MY0'/ZP!9Q,QEPM-7O>]P2Q+?1-YU1[R,#Z>\|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{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|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|A=8"^ ,6PBF.8Q>:U8P;\\P&XT0FE9PBO/M:[.PK[`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|QGQBPJBH:@-;:1\QRJYQ T1T)=4.KQ5+5.ZOM6]#3Y0K>CYC>HYMM)#8U"ZK8R<2!31%N> M(ZI>4@RAO09'@@5E\>"AY?7+']8K8GRN[M.!]?77T<3_YVDSBP5GA*!,GC$0Y0>&<.2+1N/0\ 0/%+#=&LP#:"8WRBFAMWU)A`:CP['Y94+44[8"Y+2K.$9!@'D4A9L60<>"L-ESE]23>9 M<+/--_N;3]8QGCH5?O]#:I_GZW(\4M11_<)A4*.WRZOQEI?4.L@BJV1YI=(&U4?(4+[L'W")A%WY>3MQH>K6R.7'^RV)#^"!E$:F@R A592I 5&"9-,"1!^5M4E'7/CC/$M-O_O,0 M8*JCAP8]2\W&98'K/LL6#P/UKL$T7H\$TP(,%EX,$XS:WRPBM=^HEE#1K\I MT$. .:%_9-P"?^Z2[9$5R0H$D% -21018&0P$ER(/CG'K:EN@;>'26='\(>"RM]ZQWATE)/'3E+;_{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|O>5]RE()..C->@@11]HDR M8+1@0,N,=I])PET')=6OD=6OL]X=W&IKI V0O?Y^FH)BS&8.*12?5#D,2T39M\D09\8HE(7VG36)OOCVQHY3W;AIJ#G7+2J`@/#.6E'H,B^8YZ@4`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|/PZ[BVS%-+ MNLQYYF!M)![_9VVH[6;6H;Q?%[0*PAX;SAY4VL#%OBG74B!A\!:P;O4,)!TT%#T+QH&IGXK8DL=]PJE7D5E)IM>3YOGGB\@+U$;6_ M+B^`_\;536'M2WFX*CF0V63H;V:E.N]R?(JA21D7-IX/_U\[^@^,E)F7TRI- MR>%5K8\"PLJY"A\T"Z(VE7>W7#2K^7NQ"5N0.4-F.K7I? 2U\?XK\]^#G0(MW 84/I[X ((ANU9%!]KHB/]WPO-N%FOM1W>_1KTG4%=6YYN \ !OGB299F (M]R H#?AW3H*RRF;-E5>TF^5<+U'5;_U'3_#;2A7-@:MX5@NF4KSCZ33-SO*E M^V?@K+#.S1LW4@:!/PV<5!&B(R)%$SQSM2.Q;>CKM\CC("KJ)XW\KV-7).L MLX_6&9"Z'#UD%QS3"FS.PG%O](FUZX[]\#O*);>(5Q=S6\;YN?I>W':_'T6 M9QOC+Z&%#]*HP[E$+PN%O79:$EDO'U&[TKT;\1L#6OPFP]U%L XA&INYX'WBM M^0LJ $# 1L@R;PI9NPOX;;SQ\4X+#_179V, M\GARO5@66.TY_\4?W\'+_>;L=/U(WU4A"H%7ML$0C@&UFD"(0FFB& A1O]& M'NF/T#3&DGT=_D@7*=Q,YLN!CO\I*:L4%^'7]?>;V;+"_@D9R_H8/(*)&P;2M90%"F@B62@I<)]>4RS%7GTI;A?!&G^BWP==CHW9XA;9I##\G'_X_O '6I6C]_A')Y5K62=[U8PGQT(H))=_9 F MPQ]N41Q;!D?.9RT?C>*?*7XM#Y;W.\K6E/T%8ZDO8\I8+]"4@NP-D4(D7-+ M@B"&UC:]>Y"[?T 0U]]>#GI(01E!T2^R5,OBZT]P1A$P60C%G$PAUYX9N#.Q M?7>0'P;-3QN(#]';!N*8=8R>#Z?_,Y_R%;R3V9>IUGBSE$DU>-4%QT'&[/": MX<&PVE/07]+GS4%Q%TAL ,2=]-,4UF[7;MU-84HY*TZ\@6@MGM9D:"D99^!) M3%P:GSRIG=AYB9[VL+:;UI^%TYXJ: !.JV3HJLNJ<+,I.'7$89A\|:21\SP MTLBB$@>;,[RP((C(XGB10QJR3)BDI:I>XOTA0WZ-6.H)3/26T@"@WG)0^IK1T M#E9<6*YM"@92#N@(9*?)H<.JDGM_.V^KXPJ)Y)R4EZV2ZT[<02L5AZ8E$YR'8VNOJ!S/25]SS0YP'VVH]@;,_^' MY&=W/N/<7Z3&6#20NI!<7M:$!\]CP-^Z@#\@HL1]%T8JI:*56^NPL=M>WF.@. M3:?N>G708@I)>.(5^7>8H%N7*)IDH W+HJ*H_"6P]+7V[U_OI^$7(("CPMGA>>'Z&YO$BCX7AR.I[AD;I)G]U/5*=?X//M 2+7?4X[D:H?>.#B'6LXL4M.&'$*111 7 MLDMH!S,+H# (l,%4 L^B@!RU#$ISX:N/<]F-TK[!U\HC1V6=-H#<-6RL-E!0 M28DD#*@7N924.#!EK:SWGGN-%I77Q3S+#%]^TW=(V'K:3R%K">D75Y64/*XM\09@\TS2 ME"7B25D^:"3'(V6% YOQM\00(82,,K':(^;WR%5WYJIW YP*,F\ .?,2[1]L M,;_B(2"\L&6N+OH%%I0)&6CK2F#\+LHB%]+3;\N53<(JB3])H;B

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
M>450)$Q32QG\R4_=-6$GD'MU3=A%XPW09D,%OPX>CDFPD$RNZ^:&"F0P5TAH M$S'5,5)?NLKF=75-.(0X!73>`'.V5.XSZF+ ."$X8N?:H0@&F69/-Z4@HC,F MR-([VNOKFG (@PKIO@$6;? W]XJW<:(1MG29NR$9BAR<8.!XK&0@G!B;2M|(M;)E.@T4#[?GRI>!LEYFKU6N%D\8K@Y3*E3HI=^A6<*(/DDCX->$82S>CQ-TA MN@Y6,=C[T6D/#)H@U#(0^/;O;W$RBRM|+12L,I,;F"K+%8(4L\9C$9[HM]2_UFUF!M9GM._0 @-T#=Q7+,SU1/-MXU=8@OILFJS4&O3;Y>U4_<)N$O%YUHJ:K"@&GO$C()%Z[F&Y1O N;"6L!BB MD++T^Z+E9M]PR']//;JVSN\<'NG(-RC:I'Q?9O"RV2#$$FV-3A@O$M>8(-D*_M'"$39;O5KL]K!06GU/#%ZF&DK0E=XT;Y6=#S!2%/)B%K(/E$A<& LXM($%L MI"4UB#!/"<$R2%XZBEA>BH:#C\,:Z2, W[*Q?K1%/5[^(.BNNLF*\1*3Q+Q" M4B^>T=$ D9-@$S@F@1)*90@'FO/BDV[841_6X->%?_]UT?M*:1JZ2T?5IPMO-IH:9\#;;=.<[!MXM60JN(9).OPK9U.1I/+#9&WS;;'NH1A+A81DK/2G2/(1@>8)>TDMEAZX7NL MFST_WV"CGW*T/@8D#3A ;[7XL9MO?1/B3LVYFZ_,/?[R?07-U:||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
M$F1YLL@[*Q(G'*M4.I[R?!9U65:/$5U1>!H@V/;D.6&,I YV% EN$!R2\SN+ MU.=W%AG6@C*IBF_?AR=>O\;B\D,V\7(0-L#'Q>'WKI[AYO&A^"+QR%)(#5L M+>)4@S">*<0<#RH8S9HGG/Q@FU<_ M3C[_O:WMR?GOW]^NP@XGE]?7=GI3;?6F_D-)+^&N=OYG9JZR>?HKZ=3V' .M3,H>=#H%XK/'4U>A". S=1 ^]C4O?7(F_G>O M%E$/$9FD1#G8AT1^8(TPV/NT0U'1H%.*$A=_2;_'M!IAXG$)LXFVA=!KB9#KM!%K.FCT0C@AD",FOV\?(]+1<|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{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|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`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|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}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`'V:@',+K0BD3M& MD'(D-_Y3S64J1!/A*MB9[UN:?K^[U>]-_ _T&0ZD!,WFKME,[M["XNF]? M%S)0&A.L&B$]+<&7"FN.0>UI-/I3LEK9M'+P::GX&!Q="J?<^\S*M8 MV>T'_CJ3T8-S$9#C%BRVD@1.A<*"-%S;)((CJE=?W0WC]PMXY^:2L5@:,,!X MK8O=$^89248A'2A,W)IL?W/$E23+G%,>?(!6JEE^^HN67R7BAM3'88E<=!CQ_ "N=5(@*2@! M.RJ9]*6;H6R?43]V_E27.4A;(>7]|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|=HLSHJ@_5X9=_\JN_Y@DJG7R>7G_QA9N^%H>MD
MVNT$73_EU'^W:'TFR]OIXKY@H!2_&^UP<.6+*K46_**N^#S<+%N4TME(YOK15<-@_,><'"0?MUX MU?#;JO>NEQ)^ZNN30;R3OJ#\?7'R|\7)3MA\["8?8U<"E,JWD>UKL0WFV<#5C_]^GD$?-=4V>9>7\Y50!T>;'@6;P^5%0%T7[36 MJZ(R/K<3FMCO6PT*Y/;M'"0:LF@!_K>&]53&;WS^:_3?W9],ML^G8V'UW9 MY=52N2SY7A^HEBFZ+ZJ[]*TRPF?7<[#QD\7ST^5,Z>91]Z6.[HOEBPIJ9P/\MV,W_&>]VZE@JC;O/!ZIEDA;8+%]46V6$W\&@W23>2EKB0G3#D-4R2O=%<;MJ MV1+ME^OXI5L5?X.?+!_#H']UH_5NS@OR8_^^FR0!B#Q?Z[M>)1&?C7[+_:O-W$2TVA^ M<+++$7A^L=U5?D@Y]]=H6)<",C>WDML?[U;=L;NKJK1N-1_.,,K[;?E^LEQM0 MB!2[,,,=$UA)%V_+L/42" H8?/]

X]=#?[CIL-0OHT_>A,H >CUPD^V?+9 MD_GRR M-W_,/L4IG+:N[,3'THD_?<8_8%V#<@[/];D:I-]%ZPXH/%R13Z6O?2'T5_37 M\|'W>IFXK;WAR<.K)^Q'HP/=5WUU/XVH'D\|?CI].X??3XH@+QMX'K95UNA MZ';32V7H/L6N $[WH]3,*7E9U]T6P>LG^<"4/A:!X^E8|6]A=P1E@Q+^SE4|MYD[S=W|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|K>:VZM+NHC=.+GUW8\OOED1Z$04.N&K-8/97^\MFBF=DY5OG*'&2Y. MC85,XZ8Q][4YV1.X%W13V^V\3>@_^7Y9S#9N'+1>AY)}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|)CCNGW> ^E*73^_-'HO9%N*A?166.UM;3*;O)FD>2XA*I9_O&',7C4!+45% M7E!.]0R"^^JOGIQ.<]YT?E7A M203@P*<(MGRFR+L$?<4H\$C!LT\]H\6>S7XW#GM(!/INN#?Y)9O#GR=8.V#% M3K@O8?$HYKO%&;5O"NZF=G MZ9.AJF&S5=MK46FHNO1D/%YC2\]TR]T\< -8 M;>F<^Z)"_NZ\7FL-_=V%_>\N[+M%M.,3\93+:'ZP>_UH]&]%\'N"\]D@!E5'Y M?#V.!#M:LE<3NF_S&-Z-[>5!\&P:LUJ1^VXXO;"2^N'\(3#;,FHQJO;=8'M9 M,4T8P,6|(AHSAE^G59%[6%CX8LEHM^_ZF\+E"MVK*$A0#;/&JU,O:#[&!SL-T>&*97H^6C\(4LX=,1ZU6N[V,--^BC":S>_O5M M-"T)U9,!Z]6E[X/4>FTT=0OU\N)%8#H;JAZ5>;[@/-4 TW 7ER7<[&A]!S_ZS #7P9O% M*'X=_/!3SSA2X%YX_?@'79JLA@\/ARYU|GYY]$:NCK?B]OBFI:>^]E^&K9OGMQVZ^FFJ9>'__KS02_C\0YRWZ&]ZBK_XB_\?96?S?_^/_ U!+ P04 " #$ MA&Q9,GIU2#8$ "U$ %0 &)A>"TR,#(T,#DS,&5X,S(Q+FAT;>58;6_; M-A#^ OE|!V5B:);L-[)3H#4R[#TP]HN&|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

+\4F*#0A8IWP:YXO1I8%*'5IP(!YPEPCH2DE M!0D;1A5^;';V[LG0W=GLML-2FIP#14ROT)20RI|G,\+=ZU3N'A=KC+%Z.954 M4/]3"/V]#%>;!
.PZE#4&10[E2MH&CZ28,J',DT M90[%)H.KO 1\+L*H,Z5HT'Q,BLHX*0N#0Z9P98DIEN>E''7IO,^]AN2+RE*H\ M(HH-)<@.2B*P6D(TSSB!D!<4I1F
7<51/5J%KK%*1P6,HXB;ZS3)L I-VYE@ MUK5FO$,1=9-(3Q4AU0RHSEG!)OE B+PX?P[7FY&H2&T(>R=T*WN*Z>R6IG 7
M\F^VK'VY;$W3.%H#DO8[G5-8YQL59>YM"I.,:+]ZWSI5A(OF.-A?>ZNV_8<3 MXD3$;WX.00VN$\D@Z0HFLCD/S-,>22KF9@IY+6E;RZGG?:,GE M-
POUPTZHML*/LH2;JP/**.OP/!0/XQ(55\L$DZZU,T6:0$VN.EV:,|: M@M$]G1,%/:FH3B(I*!=1>%Q5VVIEBNM:CF5ND*>4QGY;ISUU0H9*,-W-.05 M;9B%
(D/&\T&I;2A'+I5J9G+F:X.0$U"3ZQ@:%7@3E>8S[XZ$ZO,,AF<,D\B<\M/ZCM\\ MWT|[X>)0&E^38#5<^VIDR0H?
L M8,&20!9\/7%I\^.)D.LV(D&!9K41@U6W9 M(1*2U=4!0F?L2U1MN@2T/-IZK4H*-H410+?@E[6IF(^]'8_Z@Z>Q'1^I:,_] MMN,?<&ZCHPU^V?C&&
[IQH+;83T,HR3GZ\1LG_#-5 0;>>N*-0$6#W1&WMMO: MET#U'>#V'"*MQBSI%6GJ !A+LX]_TNP^C:7]2&5?[[>T+T#-*!8,34'&<[3G
M<1HY]_!"6:F[^95//BD=!Z6:]42!N7(G5&0^HB=[)M.I2H:2W7THO43;=+3M M%N*MK6(F U&V]J4(W%>^=LMIO5-F$044L8M
=8'FAT)6!77NC9GW>Q$W6DX MG8912#>Z[LC6.LCH7DY#3A#$W(C89Y>-=H0[EX]+,(FHEN;4C(!AVSF92C*=,2 MF3[4'(=\RL5'Y9&U DP8Q"
^)#R':9?;)KM@N[,OR)V ;,I3BE M7*$VC/ ""KEU1BP4>FAD$%O7C'RJY*Z3KW4),P-6H5?J?F42']#>@! +EF!_ M'-1CX^[2EVEFUU'IF^S+_%U!,+B8)V
M2!GCIB06%TDGBCT6H\LSZ_+$0TQ7U(0QC M0-1EWM6ZE_B$2C&^ZP?U)J4?:Y\A--ADT@4=Y4N4X,LJ4:I+$C MK=?,5KB_QG(/BVNW?]B(O^X8 -O
RG]?MUM'!>Q!^;)++W7K[_NS\|/+J@K#E M/6_X?G3^EK#EP_.WWM7H GZFGUA X1?K(LW[>X|?>WRC)OA!Q]#E/!K# *18
M"#I*59)UHA(X]Y8DS8WI\Z7%]ERRE=M;U45)_2%-G8|7Q!M\5BG'5^D8O@6- MD(-W7!75LGPR%L6!%/?L+?H.TM<)T+)(55XY?
(PUX4*N+8RB)M\SBI0;V6[< M:-5.\5!0K\B#7(#20' #*OLD6C=!/6]]JV#OT54=T^$PQP">Q2FO*.5EA%O MJJ^"W'M:>
[M+0#V]MS&.,X1ID[4AZM%GQ(6H39?^: +ISN4)2 MZ-$7@>720@3>(,0(46\(X-'/Z=!P$S0+4 2BW0QTEP)U.$36R(I MW?,P$SX'Z%.8%
[DAXU37L/A+=:1Y2+0-5Z%7I"M*7;EWH%Q^\F]TP&G./^%= MM[% 9MQ&IR1\P3[QH(]8TKN8Y'VS<T.@6WI7]&[NOE$38DJ_!<*&MB4=*'
MDWVO72C"&IFI'$2L!O+\5037K\2+28+O[4Q%9*]PIDRN5 R&SY"G,G,Q'<8D M"6G>8HFYL5_ FT1^B"%RV"HY8U%]QZK"S(H"8X:4LF':1-9P,H5-
4@*\&6<1 MXE=M!(5PFSK;Q=BY/6>3Z-W#@Z61+61UTHNA WA\:"[1.E4G;!,Y0)Q#;>@N M>^@3W.8.1\UM!+^8TN0T)R75H_?BW#;.[:-GZ-SN;N:
(Z\LFET4#1F'=1EO;NS*&&+ MDW_MD8VG&?H%P3"RZJO<5,KE6F$663O-&$BFZK5;\#I/']"W*L'4VT80N_+G/FP2V-
BP=W.!^LO>Y/X>GFQ@"ZS'9[CQ+?!8I3C6VP*[_<-7 M[+1+%DCIHN) L-9V/@VF6Z^4%-&Y& QS)#NL/T3LII]M89R*>@,[Q$+989=(_M^#.T55
K("X,'(F===&V1YZMR\5NQB0:7?UV$7'8U-S:'"8,]]DH]ZC4E9W^Q[N4DX-NU#RR:<1]GCP((UQ'5MI.8\0_06)7HT(Y$M \?=:O_J1?8@_M#?_D"8
2#SJ%MX7ER]#$MS+_=6_CQO7Z]J;5E'R=E'6=)*BVH-!F][1X*;J M!0*![CP!5YO0AM0,-8LUG&)>BMSLGRNTY951'\]RM$3CQ+^DVEQ#Y\9\]*J
M!6+J*1OI1JU-(2"+N9X'\A6V5'?V3Y=_O6;_D)P>:K6$)M@!2VQ\#YF(HBC, MOA!?)*D+Y!-H&.6F:D@4,].WPW/WE]Z/W^XN)LL[X&"I$O>3JKG15*;-
*8+I[*968,%RY3KVGRWQ$ M&8MUSKN1N=+H1VO 6,(T\X+,O"%SPA#V"-VJG*';E&AF7LP X3@4F&&=T ,; MG2O,+,]#6^4,;Z%T%O$+GY2ON&2.PQ!7"
<$\<&"Z8YWGH2X+[PM0IH5;HY#>* M"65: J&8"C,;(<(!T>FXTOJ2>Z(*7SH'\!\[T 7 M-)>T^KR(M*\@P#[2QC%2'';<5Y@2HH^VFRYZK)*M#_H'^LY-
*!BT2!T ML)5G=;?_[9L+@+YZA@'0EVWT1;<1Z2&,=YX4&GM6D*B$$Y%(*U?OKI<)^E(3 M-!3TY$);1H3*,FRFZ'>]W'E&I<[A7,]*D%'75[84<
8L\Z*A1MF601BJ.7Q M[I/7C<&_+(,ON QRIBU2?L38IZ!{U=H(TY>9^#LS0<:36XK:<%1PM(?R?=B\ M&UV<70[9EU=2."W!F<[^0)G+=+?W:7\<)UQ'U?
%@-1F2]R2 VIB.:SB[#&V9(M&5HHSKN\":%U;N7T%@^O&)!9^!GMQR.Q'SE&1LF"FA_-S<:B-#&.HF &U@)# M+%M3Y/Z"]<'HQFV2W @,T3' 'O$!
(7,MWL7Q9%? @BJ;GQK4M, .#EKQ#HG M_@)M=8)XEV??YS5N"$;;PYR9SYWE55H?SRI6I#Z6Q"?'+.6RRDT=$WS]_L;AD=>MULPQ6WFYO*C6CS,9
MSD1,5:I(U(@81$0//$:732C%!SG=MVP:R3Y_,8X>=P9]1Q=+09*FG';![O:Y M.*3E?'8.9R0NK9[/1<.9L_[7/HU?9OI19QHCYBHU3O"*]BTQ1%?
_UKBHP[T] MHE%)2"FZ48XRB12QDN)/S_ORI%==TK#/$QVP*B$G:[I78S9@;0XYPI]4GK MU!2&$J,&_M9/H&C2WFNAB4]U1I?,#<&?
A4^A0;.7FT,&5DR2 @-!)E""! !. M"*;4;B(X^#SS"R:"($)CFDTG!=6)NV5*N$!TLF8^\TDGU>11OE6#;4\DK(67]= M/C?,Z2?6(@AP;?# SM?M2,(S[MYG
;N27-7-XAWP(+3,$-HKQ'>D=]B#8=W!)84^<^R@2A5*HP=K &!H,V$<@_MD;]FR8\H@N;R) Y1X HV^DWHB@2=2QFZSV[LPRT MTT'7C4,O*
<?01_0B=-&\11ZME\U^U-]KVVVL'7'&D(%P$=]OSO@MO6Z%+SQ/-M%] +Y)HI6[XUV1*W*IHBW$6S,BPDZ0.O=7"12*WM^$ _"KM0>9BRAG<6(UT0
MZFV<13OD+3,X>770(WBPX,NVI G4$5VL@Y;6WHEWVO^Y?]'WL*NO7GM[AWN[M_<'NP<[>P5=?%.L A3>\)O;;UL2F2[^PG(#)QL78
;FO169E6V0%"E@5](J# M@&51DG+$3#MF]>YE]&I<\>7B*Y;0VLV0"H(4S5>G1F!3!9H7G((&.1P_0YQ# M5R,UMNX1%Q%MX7+367/-
FP.C%D4L&:GD@6M@\6E*@-4$V *]9X('FZ-7W4F: MPH-;8;=D6FV!+1H%!EM"X])<(UZ($E'A _28^FH(8I%S8 MUF'*15ZKZFZM'&5#AA%7-&JK@^
RK]^: R$7'=.3A ET JJ.9N!TJ3/)#U6J M6VE6#ZW6%: A$B\$!,"QT99(D!1C]MHK3(VE8%JO_HZC%8L)AZY:VPC54"F M&?21G"2,;Y)
(8H.U)ZS(,/DB*M8:GM1-*U@''56P+L,BY77R4?2(C2M90Y? MLZV47D]7E$8779F6LTQ?K46?UK&4Y2"U9HE7K@ON,/R4R490?F%],%,I3-
1\HGD'M(\@3_8+FDRI!]?5/L"=CGAQT5%>>)]QI.TVO#X^-8Z'2N M?]"Z.9N7'TW'M6@K+1IIR4GG$L;/N<.JPACAEBDT$FJ:I&6W&M9_58HR1(2O
MNE29WI$RL7&,M; '*8>XXI7*5/(<+R5>8LM4>LI/8RE,R[J HSHUR @IN60I MH!T?)3[=
[96BNHI42=.L"EL0M<[4Q(IIY0D<8#')*0^O(%4:WWN@Z.XG'IZ? M[#GJK.S!C)R-BQ:M8$L=Q4H914X;RBJL,!5KTB%;+*?@Z>]MC,"6OP@*,%.P
M"AG"3/"SBD*V$R@)C:I-(FDDZN5TWF*4 .0M^5M,?"'7.=&D@S*AB7WQ/L0# MYD4:FZ"FX/I0#T'^?/\;/5H*]V]/^YYLX3=-%X%__R*;T"D3._:_YGW,QG
MZ/O190_1D]OO>1]BI7_^Z*>?;GW0E=XJE8)A%%[SB(8_@2&]6AW=W#8TY4Q M&\]TP0WZEW6($23##4F?
#TZ2$3*$;%2JNS&8%B|**TUYTP:J$)7B0Q M+ #RJLA$O355(,*C7+3#EE/+M?Y)V!_\PU1G@PW'8""_8D9OO6^+EID"50V(]UYE=QFG M28BN(1)@"<H
MY=);JDK6W$=;MTLC<<393 *7B@AP9S4&I^;=K?>Y&:;36O.ZG+FT%L@Z8WG)YAIE"9CA#5X=1%G[7:GC19E\48!B_T4UQO;Q5KKS0*
MQE&FZQ_]\F9R2N%9[.BB[:N4#S]]MN%9SU-G3S **2PY8]_]_5LO-A0Q3GC# M.OZ"PC"]9.'G'0(L;Y884TPO6CI!V8=ZUG0Y") T?F B(PD//"L?XR(+2==''
MJ]]*3T^'/!U8]=Q6\|(*D76\@^&!\M$.AW6I_!1,KW1;)QBZV\Q&'8CK&6 M!V;RZ'[ZP8TVW[6_P)U M_$L*0=YU!.V!>*&?))7G(NBWB,]0IWDA=!)NK5
M71>(6_[VUMYV>>>-?+-,!:;'TV%D7S;O(R]YTL)".K;L!55E^!=J.5=52ZV M2X<7%7KM82V0B9A418]XF0H^F: M-'!M@6B[&J3N93>L MO1L&'=T-
OX+FB*4=.K$;9M(8,G^=-'!939C)5%N[=)1%KT1C7BV^0;T1@=B9I MW(GF57:)Y!['Z2,I>R4U_F5QK[^X6]-8-HVH(TYF]6[*6,"" MGD;A1+AE:
[4G$**,__VB&8[=XDW5T>,71SE,7/\?9KV1@NQIH/&&9O4TXHC,D@S8S.(X>K2Z3E]"BA 05[+BR*O7:7*2O MD7Y.'2R6+QQ4U\[A>M378Y1O69^;W
MX.3%,LAW+73:*\4X0_!;:,/RG%R,SFF3@$"Y^'7-Z&LRPVRZ%VU+34A*\GIOI;=W.%"FN ?S& M== P!13_[F&'%D4ZF1$%Y5REUYA9@SIS
LJYR;,P<4#BJB)5F"!QG,@74XB^ M9!W!!-\08,_I0A7XD?J,]9\RR7S$X54&8KMO2A*R?E2"E@N4,PY@'(E/NUZF1>W
M\N>H",2QU(/5*;GXM9N,Y#;#!+/=F)A^+Q@W(;76DJR6X21[PT<4P2?,HH]\ M#&;C1M=1K9XW UE]@Z,H*%N)W]HUD)V,5)2E'/[FTEQN;]U2[-#WS/$-
Z3#7 M*I:X)(3GP(TQ=J=C!63*E%Y6CEGKAPWZQX;IQ2XAK*,*#3,3ZV G9()=_ZDS MH7?.))9JI>IBE5E%+/E"V4K"<,RMF5'Q)03IP0.*;EC"2S M8\))HB
X(U1HG4;D""A$Q8LJC2!@=W48\@-]8A'++H#C:@0',CE0OC4?OHR)Z MVZ9L3I61*4FQ_3C\7ZF9PQL1MZX*,G:,/%1.8UB$CP[8C@B_H0L:3XD>YW.R
MC;29!E8=$EF>3#[US'M3IS4UQB8G3\T0$?2;F0@HG=2DBS6D_4N.6%6XU">^ M;9(%[%9Q\C5/?7UZDY82B!CX59.B3U+4^6TA=?IL!#*\36NAA\7-
\S0<@QV* M]P;]!D9'5@OS]&%5Q;-F^).VVX-0X7*)6&'0ECW]!()-)QTS0LB<0\9M5G\L M'HR:38&.4DP1ZEG]"P/,%4^S8Q>C=;'@Y\C[|
['$APDUP46RP>D+&1(,,+=,2U>$P M%=67 #$U9V2O[50E) L+3:4]],DMQW&(K,WFKC$^%[%O-\DGKL40*;!X*J=3
M!@=)Y*=6P)#&"DW>M/VY6"@8O<_>V2.UI+WVN&-H;-SU3E.XX0$Q%'\<>F.O M'BY)TBR08H= L;CX2]20&GC\$*BI7LV12W,18H;HUKXN-
;$E1ZQOZ# T$M>1 M'SFN.A*W';ALK67_S,R>S3GD)C4EJ"N.XCGS9&YD(V8M.Y%?&V9>YQ95A;.S M&VN,1[LA6J-IK!CJV\JG##K6?)'7 -C-75Y#Y=
(<5]6<#A& M*J 5RAM@HB;]|FR!Q@6%K9C2+(F5-_$C^ 0">;G\U%@_8W4=OPX?I^U/Z083
M/E\Q:%K!W#+L%WH8V90PNV/;N)D4GF25IFVUC"WO4&EFRT##F__3CPM,>AD8 MVZCA)=M23R 2$^E6=Z[MN<3OU:Z ?
GOAL,%S#8<|$358Z_=G__6LM/OAV_=G MVV>75Q?#J[,/YYTP^)K) MP51*0\-*SMYD$^2V-'P"-%\:>QX(J:!19*Z10PUNR[>HX)U<3NE\?U;,;ON
MSE17ORGD!?#%TO6@?\RG9E9=Q45L';,P7ULCO&\2T!%ZU:(=/:UFUP=F31?5' MHS'&6#6F7);XZAS8$=O(-
ZYJOA[Z_!M>C%TE<*7%>+5<./F5;DO&_N33=9K M8;HCC9K2?Z\?<5!=X?MHM20VO#?)B?/P4A9=G4I38F/##6P/<6/ICZZ.WAJ 7^&4C
M,KP+P[T&/]BS7XNK$?2IH$|(! 42Q1@C:GN9%"E[BUWRP9>A7.VZ.7H-"K2/ M?(#>EE,O+KU6VYK3LG[6&PF;3*>AT,/ Q5+>R9!:1HE4B)!R]Y*WY-
TFZ25->/,!TPB*/?^I=]4"R1ORP]CY"[J<9:,+J4IQ3Q* M%(^EM8EI) LI1%M?5U+H3^.I2DD;^GE.3@A[X),L)Z1BO,;"]\RS4'W$T(F MN']S8CY'7Q,W2V63-
*0D/EU^W>D)+?ZY+_AB(?!4LCMUB0 B#L?^=FU%/;TG M?7L MKWG"F#KGK1K46@8G!5@Y1Z20S]02A1>]%,;40]1:I.6E-:GUO]6:7\V
MY>YQ;1.4:KX)B2(1$O+1$0T6;)>$2K)@6:)9PLQ984SD63U\1@,IS*[)99%>:%&:'*FI$MW[18*.*H6E([D84*CQR)WDY4 M2F\CI'(VF:F@B+HGIS<02/Z-
TO[(%.M)4ARQD.=]D=%$3C # 0\^&&-)B^1% MPN8;[P0N78:DW8CVN(<[^SD/K=:=>%<9;0G3I1:4$U51AZ3.4*-:;?B23$F M()%<"
[;!X+>Y7NS[NY0GPAL1%1?4P$;''8D V"]S A.EE"[=3$01,=5]0%([MO%?33C1K>)3]S_F=K)\A*!XV'\,Q%W _MJ%8X'7 -ACLPDN0M)V+$/"HF/;: MF\44<
7@I"4S MHNH)(?5X$!]*1 A6 MCF1"%8"OT?:Q?DWI!5%2/WCXL?CKBB>(V,_5J3[[\T6D*"D-1F,;8E* H\XB MZ#\-;V""BF](\7N
K3.T&Y8<=32&I+N@_[#C_;UKN_#Y!D;"Z9"XK.VNP'K+EP-O.7=L8(MF.7:QWM?CV=OA<"_ ML*87L7!0HW(5[<4,$S291"O)^5#]{T-+
<_RE9K,L.IPY#G+!7?E68SZ8HC$ M)5^D?7N[N]XITOR&.2=>#V^P+(AWWO^CW_/^\#,L,9;C,]IV3_MP^=Z@LP'$ M1USN?\HA2I
!;6]+$;P@/[KO+E1W0>(LPFK#-)0]QLW30^LY=+$%Z-M$\V M?=# VZ^:)K63G6)N6L[NW?7MNV?UGY):M3%[M2NWCX\?1^=NS__+N M3PG[9'AO?
_YP\1X)@S1WT+T(9._1Y;F?7L/JD?TWZ$AN-6TL.-*G# 4"%>+2 M5I(<(]?DO H9U30(H!:,_VA9C\MTY0PB0H^_MP;!BW8'O[L18U78IC=7@D:KO-
;W]=4G#WGN%@O,\<:"#Q(1"!5?M-G(9?=88 MZ-(K]IN'OE0L8V=PO FMGB;#WU0IQ-IDG/2/CG6R@Z%NT"R/MIHPHWQ +EGA
MEHAP.O]P=?;SV2FQ:GAOAU<5 56;YX=(G"/N3"YA,VN4EY:BK%,FIR+ M1.TDLWLY^CB\:)O;RFY]]C,!Z<[,RK:E.?K ?.4#GIS?3%?PRO3TW/U,%%I, M
6[Z.HPJ:N"M/88A" M*>IM283'1D@B3*YHA MDMTQ0YCCK,C#VT;N-:#!V?]"/%K:HE[H;PZ[, M%*/+7.+;3%&L!';+6(%V<">;6NZ4[<-(/$;OH)@[<%
MRKPI%?V05S-S?,.!:5-G1MZI0,Z$B#M8XGMK_VA;U_EVZY O,*X-33R\ MOCQ4Q_W]@\9Y1^4#-28&="T=6$T1.QJUP=APJH19!@Q[T554,$Z#K,)WJ>:4
M=VY4$X.Y,&Z.]FHVB!Z[%II^O&P6CK%5[C%,C^,GX+5NZ@^\UX+9=(4>ZD$X M=30JN,PE*79+G*TYCZ>P(,=IV#9_@[66S\88? ;,%5BMT$]54!
<+K#P[=?0@ M6!(9DPD@2,\L%4U9FPO9- X*7!6'_K.U!#IF(P^9L))+PYI$JVH!)UVJ%JMG MKB9>+OL,RSS,0S:|K"/2,2ZJ;PR9&3Q!AG
N^X%/UNW(BO%?9%)PJ:^74)\) M]1T\HU#?PW;ZAO8U(@'Q_$P/9Y-4O?I8%$ES5K/%8(-['M=N<9P<+)E M8!%L.VX*F!0-
6\F+E+CF2UYG\2T$R@^P_72:UM0H?(J?(SK%SQOY3]X;SC(Q M?A)2E\SK@T1EI0HDDXE;,"!*ER^R37'8!+E, G5-ZC=P#N)8OY4KJ&V%;E_1 MIT);A3N*
(MSQP,-SL](<20D!>6A["/QX[!*]QWA*X3BU)TX)?0 M/;+<+G4\"-CL2MGOF"OEH^2\N*+_0*?G2:T8Z ;HWA%BG?D9UPYW:DK>ADYM
M!LP,$9+L=WB])-W,-FNTQ/CMW1/2!@G<"2RUY+;"(<.%A[$QW014R% M/:F[Y!%-IE,K!BJE7V53OE9KS];>I4XP#^ZR%%G0Q^K3%N_'
M'1/@M=E\@",\>_+[:_B3NZY-=_#;Z9#*MNQ++[UN80L>@88&X8ES-7,CZ:N M>*%K:ZM3"HUB%!5.@!7U2;6@I9)-
^!J48"C$\7]Q_<'<@%XI&KE8V1V'G+C*JZ_7K-]< M$+?2>B)[')4T0F']07#@-/JH,/3:1BAM9K)X:2'5]H7TKT".0M374B.BL,R MWIP+OW+.!=X&NP>.-
DSCU33E^.TUOQL?9-C+7=;R3&K=TNI(Q2AB$*%P]V2D ME8119)3)N[2IG1<&?6) +*WB#AC$M(C>W=S'4<#S:DSC MBMJ9CR6W,O6YAP5:
BXO'&%R1THV(3[']1#F2%+Z)Z?*"/W(97;R(IQ8*N9R] M!\N!Q.6I:D0[@1N48%L'?
YIB\@(H=.DD+KJLKQ:DI%00[2,YASR:@(H]2A.I6YNHL=:"!=??;HO8*U!\B^B{[@G@_EUO)AB3F M1>"<+9(HG' "T(RH]A2Q"?G"-'@DF\Y7B^OLE6E,?
D3O\:D%*)%D4 ^D6)I$AR>(T)[-) M,QT0OI+AT% 1FE$(!RG\"ON71&\8W_B9WOSF%8LTO/'Q*51!0V2OL ^%B=0TC MA2(JC*?P/ENZ-
)&+]6@YB&*6%KHD>AC_5:3+]JO)BE[9EHZ9M-)HHR-^YZR/;C/"V_&V]"LCB9F\&)2^*X_C6-D%T MF6#=P[<>:T?Y7SY(2R?
BV%2F%@W!X4*'3S<4P^ZACSV$GF_1 M^4IEUC)J92 \G@GX0+XFXH%2BN M07!)9QB;>:AX*K
Q!1:2,26/;25AVI"5'1BR,YWU%VLAX$N@#5N3[;K98%BB MB,Y \X^@O@6:%%I(;..Q#=]3J[G5N6)C7JQ-7)K3\Z D&X%5\S0^_@=T9D))8 M>_YCJG+/-
E[5L3A^/5C%$1Q:+42+8GU[YEQ#RT5A)6,*Z!?L B5>%&*(G*M@ MV1QF@F.<[1HVK@@Q@$,_LM/R8I(/Y?","%L0 7YC%5U/\L1T:,RD6W3
M@D)8LK9[fJ'2.B=9G%F<$2=#$[2G9.S1K+5#G!QL>TZ2+SK4HG+E1T;+]E-+_"*T?_@ MB#M;\\," >9HB2RYR"(9D#8];O3AU*3&B=3(X.V1GU8-P=

{8R 9HYD&%5E) MRR7>RR9TQ6K>[K'T8J,;)B3+=4:;]NB6W-((UH+N:F>0/2(S;C9BAG -DQW<
MM(PGV((ELY4U3R$V3F>>415@Y\,)'B))/NU\6M@^"QAM[7KH(<$/9I_[Z3C4 M- MFFIV:,PR&; _+*;6E7R'2%5VX;%S(S)XA7IW?'%A8_E'8Z]1KV<:\N'1?L
M-;?KG7:,+'(<*ZKK)\.$I2D)3Y@L<*W982-K/\O8/:&U?)2\.#ISKB95%AQ^_MS"Q3K!]DF5SXYWU2R :3!GB%'Y#V M@@95D9-#F_QZ:$U-
%,+@D5@(/Z2PXG)!FP$-|SR%>RU-XG_"TY10,E&@*%,(MWQ]24)YI77QN_0)YZ&0?0$M6@;R^/8?>T3?OT.N,#%+=D4&-:HB;UNF/D25P
M3(JLEXQA/(4J]@3-HZ-2^_[Q6"M!W,KYP>27(+ZE$+$Z69Z&?*2B\AG]ANZ9 MG3<3AR(#-/0>B)QXAYPTN:1XXA=XQDZ,
(L&>PES185VPTL/R+KD%,9G-PH7%MC- 1V-QVQ$ZG%"I+T@+R7MF<[RD-M"@=C6L!0L7>"(G/D
M='BV!^]T,XMY,.CO#II6,Q>34/6U*"LWB9F3%MG-KF4-D2)(_G',"];?4N+% M>)' .A5SED_-&D&YR9!!T[/LB4-
?)@6P#9S*"WBOW2?/7D=VL8>Z#LO(QH!) MOS3E\C,E+L/J\/"WR&2[T):LGX,DQ@H]P M1!V:MQO%:C=]NU:YS,2'$2A]CF85.&V-4("J;3BU-
F!3@>PA3ZL&^3DF+O15 MOX;;CH$0@OZ5"5MX<&@]$MFI+HMSKXS@)[5;KSNS6^OJ;T\#(7%JESMTH[=U M<+SM@:F89DSK/5'APC%?
9"]6C%P!0]+&X;^9C ?F8I[$%-M(P MFC259B()E;'K.3G=EC1!S)PT*8S"*QG*YAU]GLQ\=-I;'U[/.]= $BXD=:$B MT5[>)&!NX&/7=0=BK
*#E2%H'H';*VJ/64 P'&R!14LK;7TE5N M)\$$Y!(9&$;F, SWT\Z?"\'7VF]>L-6=TH8]F> MZU+J8&I_W7M+6 M%8@R=-
(C<(,@%:8X,NFA:6[)TJH[69RL6_GH*/;>,,SY\/.WA$BR6(IHSY]I1 MPF]2Y!QE+R6K.&]VT#X@BB8A%\L#::G2<@3KV:[13YU9HR>:J]*<'&E-IL0Y
MU6K*F%X03*2EM$5G\FGK44M2]<"V\C^3JHK^C[DAMX39L6JUDV_4D":-DSB/ MJPJ?9MJL8;WQ!\RUPE_GB"6>4SX+*5ALK>
<*_47H2/[,8>0%Z(P1WXRNW\RI M2T(/D6!V8V"V"%6OV=[H5G(3FOB5<4.2:N,\;&Q(^6S&27SQ21N?]*MOWB>] M(=EVYUXD?TN''4LX&P8,$$1+UT34
ML\:3V*%+\KEN M%K ^T&_!:JEBY\VZS<:VW*\-?V=0'5AJV9'L>.64GM^2,]YP1)9;?6>#R9%S MHYO%&*AJ*D4M;NQJ-Z4:KANC!E-J.QOIN>;DY6
M'^0ERBVXDK'N4PJ;ZE'2,-=GZUGJ6,I#24:0T(:EW,."HWZ,"HL]V_& SCB;WP'E]BK(.M!]H)CA,AG:#@=]<5!$Z!#IF>]N1&2
!X(OZ:.2+)*B>G>*C"BXS:ZT= 1 M4%9'QGX69F6J](>.->72W3V25D-#,N5!+(%-??\P$NE.= M,Q>T8-@9? ."%[Q[?1A?
(G&GWC\XD=4<;+%%;>1N+\O9YKKRZD 1'%l,G-); D$+&I#(LGNH#7?&&FK12568T(^_N$"*1D*.PL3*-#\T.===PE/=?U060MVLV$?!$&
MQG+/)98?)*PPR>%.=IK#YJ#]G6?NF_3RL?4')8(W0,4J MK:F6#DKX)5RZG=S:S9+ MQ...2<3WL!]4%/FQ GW?N*S[KD:J-UCO:M$?
M"@0!)UN&)V'M>?;+^>BM]^9/;_3^X[L/?YX&WF_G5V?O MO*M?X,.?KT87'1^#EHRMRAC\=MDV_/SMJ[% MZ.JW"_SAZL,C561OGKE_?'\R>/WKA7?
ZX?QJ>'H%'_=?;TXD?O<3#M3&QX,G MA];DY@<$%@@LH]'YSQ\N3D?#-^]&?>_L9JI>%Z/3T=GOO+AH]6&#>W:=_7'V
M[AW>^Q:7)*VT7X>_C^"V_QR=7N$7I17;\4W7/%W#T]/11^P+[BG]"O7SS9_-M;]2??
N2"2\9$1!+8'>0Z]A>9^D'_\1KQ^9&__"&,Z95TT^OR,!Q"^Z@J}YS, M,A0T*ORSV$LGA_V]_6,TF7*PD_) OUBLJ3Y94__*@_IO!\?]D]WVGW?[@],:?
MOM!C_T5-YF;#P&0+/_Z/[_:_LU8D*2_[("T^>X/RDD![IC8VR:)L8);=H?U7-MKQS5D?(G])>M:ZW9&'XZSW]LK\)_K_'?,^]N5JA>5LC+"EF]0BS=N,%
$=MX MQ>$E O-%%CZ#]? &5OJP +,SA1L" SNY*#'@OBR=E27J3W%TGN:U%3C:(2=(= M_T5]\SKVQ,]5LLX]^N8B1'N[5SI"]/C#W&Q>&O;1EA%]
[&G_Q_>#H]W7]7_O MN1@>UP@>G.SV#W=1E[=8P?1;HT&ZO]_?.VS_>>6]JW\\O,>3Q12N2)L!W_Y% M5$(>L,<7)K1;KY*RM^2+*;H;]97$ CAW4I-
3G<4VGOMWIW;7&Y36SQ,?KV$N M8%-.E=.Q%6(?3ZF.WLO_0YUQL[H MV",39?1-PD<@^1[SI9.:-591<@NCI^EGF#[=Z>0TIWO/K?2G*=^G7]LXI- K
M\AQ+173,%#'$SI@S4:H8;NIC;R@F N/%:SQ0$PG]_D!P-;Q*"_W-M0U5-)W; M&W.*EIF.]4ZXG6.H7#F3(MDM8Z[4,#53B=7?]'?0,-#*4X+-90M%' P3?9Q
M1,.43/M>G2;CH1OEY;>'_/:XVO?Q /38W8>$F/9?]0\/#KEXBD+U:?/G(M%;7VZ#Z1[Z]\XC[TTCOB:K)@\F3Q]SD44E5#\76ZZ=TU%O_8_7SXOAP__S*C
M^CQ&].0Y:]=^UM%C[N=/^W9]9H,O[S/[US@)EO!_LWP>_?3_ 5!+ P04 M" #$A&Q94/7W+;(' 2)@ %@ &)A>"TR,#(T,#DS,'AE>#,Q,2YH=&WM
M6MMRX[@1?<]7(';%ZZFB9%$7RY8]KO+,>"O.0[*[V:K-6PHBFQ;*),$%0,G* MU^/2-RZT0?G- ">3UR17YQ/2*87?SC_8ZLE/NFD+]AT
M(C$D':6BM]]\$;^E9&]%J]74^]BKN5WR>ZG6Y?_*;-K9K*4.Z4R^EBT<_Y M47@^/_*#G(]U.K\X3]54]/3]GNK)TWAPTAMFP]-
A/T[&DHAZPU[<38ZS3B?+ M_AGOH2FJAS;6S7-ZOU>HLC4A'G_4[[:'@\J=S53]}J.XT_G3G]JZ<9[ITF$\ M@_;A9^AFHS-
'=ZXEZ'IHCC1N3:C_8[_=\8EK4P6*I^/?K@T2N8_ M1%:6MF7]I"P46_4O@B4PRC_.@]%#M,Y520O#XRZ;>O6//U]_N/Y5J.)V?-_.
M=7>EN8"3E>C8_2Z9G""&2;SK!9_).-4IA+IE"Z%SL3'B:),7-U14CLU)?&W M#*5D'O7F9W2436=Z0N$P<%\>GO7XDI!670'I*Z8X!_
_YV]_J[W4D_]+MP7ZWUSL3 M5VUQF1>D4AF)Q,=Q#A^E.]@?G)SM"K]*IBDHH953ADGN+@"I, .E&[5ZS^UA MW%Y8_EQCWI^"[K!]/&2?K\5$
O^&IHIF8$XW45;\7$L#C.=S\0M5V@ WI?A1 MFT+$G=;/#*(/\@[EXII70ND7EWI9[E ME-Y0%&)C0D12C;5=:D@>AI"J!
_,15TZ4Q,,APAZ/42HI"CPQ(:*3#(%&*$+ MY:G$U]NH4%)"UDHSYRJ%O"7/*,L^+=ZE, 9#YEY,&\I)E(%XHEJ)YK D!3YF M$Y5,A*W¥SZK]C PUG; #A;
(Y5)8%>Z;Y108Q[0SSTM7K265 T.:2VIXJ?P[(+6Y8O^!1/2&D@#:-B6G0?* M[@V482#V\R%T48,E^NO3G;AS\N)X1&
[ZPH#LM82>:LLZZM>@]:+KF4],@D'. M;QLB42$%5$F=2R9LN.6-6.DQ6@1U7T]*\&M,7!&F MH@WL[DYB.T,8L)^JE)$I+;8!S-;2 M691Y "VWZ]O2D"
=XU#56TJ -CZG"))M$F] 3ZCO$2J4(.'*.$*EX@7 79 MFK]SRV>("W MBZ_TI?&U9,,0NDT(\!ZX2;9\R5;P3Q!\[7V2/[M+%\LA6K$/D^$Z)%=$
MQ*#Z@@1B(^]SIM[%*S_0MT613*.;(G]'ZLD15P>:I@G^_D$, %LUIF M;OS/&?!BM='OM8+Y?F759>*W_._^OQWZ/EQZF2.G0H[G;T=@"6]<$T7 0:.W
MRVW)C.0M"VC(L;R$^NS0GR@NSF*^"%W-#B)L]K<0EDS1T-*2KQY%8I-3H@G@ MA-0O"BIN(>&V+@ &S))WIM&)K:=6_P4*_6KV*Y<0XLR
$"'+$F#R' 27^M+>! M4Q1T3)53G4^)Q:R4-]VAM6EHCXH]UW-"Z6RB]?)>V %N+Z+TK>_DWS%)\N(M;[G$_=9NG=]<-3V, 7,R+
<0VEY6ET>+'&=2@RN5\I$H?*]_HK!EOK)W3Q8BO MGJ7TP[..+2Q<#-G77;WUD?N72SK_]K=X][MCQ9WVG&C94]U.^BW!
[WA3MT>>9.#V9@86\GR_5YO;I&@F>Y1M[H3\?VI:8[MP]D)T_)<*!E_#'"PWP>_=^M-Z%+8#4S\823'79OQXEI0.6P1"/ASY/$PL?7 M/VO/.%.O?
S(^3]0RD?@)&UG%-')/V?[W)N/ISSV^9CZ,/+4^3>YQ]R&[#T[: M@X?\WN=7SYHI?((*^PQ;_!6:6(S)'.S'QYVSN!OYCZ,>%:X"S!5VOJ+N5$X MIY[2QB=-
*¥KQTM-9%C\$OM-IM\YBNHYZ_X)NO(?POV:U!+ P04 " #$ MA&Q9<+_E2Z\' #$) %@ &)A>"TR,#(T,#DS,'AE>#,Q.BYH=&WM6MMR MVS@2?
=^OP-JU&;=*DD5='5EQE7.9&>_.#?%,S^[8%$4T)99#@ *!DS==O=X.Z MV)83)9.UY:U-5611N'6C#\[I)CF>A=QNM+9=.3V=!=-
J=GOC=NFL]E[$]Z&#@8C7/^#1>CT]Y MD?'$]N7%6.FYT.KUD1ZQV>L_2U!H_AR$0T=XFBC"U@9GG3(U/?_^O[JS=4'T4U:G=MV;KLKW10]
M#K8<#7#6+8-3W&%PCVKQ6W!!9S]50=M"V$R\G6G(Q+>ZD$6*LXL?,VP%]Z W M3VO^3Y7SE<35@A6_5 :\2+]RF?1.Y$LA"R62OJOT+4P
_$KI)7306//]S?I M3!93$)=IH.;D5;??$-*+2T2Z K5G /]+_O9V^GO5$/^T8,2'EOC.204-D7(ME^B<#"^.^V?G^^*NE$HA%S0-9+B[G142-
;I>A%&S^]BN):V5Y8^UYNTMZ Q: M@R'Y?5F<@["P5S# BDSS+07/U?2(;C-4OP"I74(F$)\:UTNDG;S9T+/&WF# M]>**CD#!IPD/SU61MC
HKYYM4#J'$I0WTF,H<-/SI;@NI,* FB+Z.38N1D19 M/-2%1;W#):0ND "6HBJ"JP -1_5C(<1029'C%1DJ,DEGWPF;:^80[G>O0P$I
M>"_=DKKD\AJ82M9S>OR-CB(N:5A%;ZY)M4/5Q&X%#D=+%,)C,=/I3/B*/C;C M%^"@GH0$DVS"MV/-Q M9&MIW 2PP6)CL=EMM>LB0X:
(RJJ+U%0H*@22K6@U$&":6*7$&!,\";;&;/!7 MA]I?61HAKC1-W* >E<$."#]+R.#E/-N32C\3F;$+OT*D@ZGVP9%@2OHQVHU6 M-K: Y5?
&W+/V66.K=RC8^G K$"^.SSK)\-S7Z*GEG(Z^C9D7A^A*2 <,!@RN MGAB@H E !$Z,]C/J3MURI#VB/KI6VJ?&^@K'2Z:R(J2F=34/BS%R<(-@6(
M]ACI6PG15C;5/X&M;(JNX]6.6F=6\PLBI"V01M"0+7LOE-U:*,.%R, ^[T,4> M)-%?GNXDJ,,GQR,FI4\,RG¥K>$9.OP,/Z3N&AF7!T[AID&*FLO+[#R'IF@!B
MH%XIBJ&M'$Z K#/7GKD,>T'!\U ZNV'!;29U8"2#JE;##3 :-NKB==*2Z?) 1TUF[F]H)DJ3SK*9]"SZ#+S60]H4.!ZH2%*3 %U6AE)
MA(UNL1$;/<814=VWDQ+\-@'JB)R*XT%].8<>!&@GAPG:O:GH'G;W}[&](8RP MGVM%R)0>RP!B:^D1U90'$ERE4ROH()BUG&BCPY(T>M>R=)
890R@=9V^*PV) MHG!3.U16KD0 >\XITM0ZQ09P1CF% E,%@SC&%BCI@% 7S)8C5O$@Z1)Y^9FC M-7UJM/9:W1XY_7XN3<4\1*&$+,.
<3L\Q"'Y';K9,"?;@U7BY.UUC<.) Y$0? MD\)K<+#%NS#_'+=&RCCS3Y=D(C)*I?F\P9Q)] >QA8M\'SQI9X:7VLVC*&[
M#P&J@>MDBUMVXNPS.):)DV:9IY2C06QJX8];<^H"_TUU!G,NG.-$?\2Z*.'E@ M2(:(17:ZTJLV',L9X/*=*ONB6MOU,EHUDWZ=,!"O,<)!,>'S?
M1DO,0B_1I, M7F)N_$L9\.JTP1^5 M1O/Y9%5%RB7_R_^70U^'2R\-YE28X_%C$;2$"M=4 -^*@UMMU6;(>4T"&G,L
MEE#.#OF.XNI>S&>AJZX@8K&_@["DPH$>UGSU(!+KG!*()PP]6M$%?VLX-:*.Z6)NS1Q(MS HYK6]:NYKV("^-70*V+F8VKS>Q(=A\1
^'Y\3]F"#4CQUYO=A MOFKUNQUZ=!P<_E>KA>NGRBU^JGP:U/VV0:^5](MV]
MICUEDZ/9N#&^E,7KH^[1:D"]W:-.>2,2VT^/*0)W]R9NRV,=.7Y<_^*XATCC MS]O/*M>(]K?@(]ZUR;<]=Z1&$^$1!PF^XR-
6SAW^=CW&%AW^+KR_@;2B>E3] MAKF<^_EK34T$TCGH?828[1&;Z;SN<[FY@7'WI84OVN2FMYR=*HWB#=0[W7L+9 MG#BFXO9FB)S@L:O"_2&?
>&^G_HQQ$9WRVTO_5!+ P04 " #$A&Q9:'L. M5C<$ #[#P %@ &)A>"TR,#(T,#DS,'AE>#,R,BYH=&W55U%OVS80?M^O
MX!PL30!+EF@[MF4G0.JF6 .;PMDNW[FV@12HF2I$]227V?OV.I.38R=(&*^IE M?C L'^]X]WT?CZ?9TI;B;+9DA)Y]-_L^BM
KE=E/_(;$NR66\'.VCBS7GB>]?PFLX6BZ[,9Y3>(MT],.3]F8CO XGQ V&4QH?W*","G79*+],E M<_MG QR/AI6=WG)]EUF:)#]T_-*S6:&DA?TT^(>?(
LN69MXBEVJ%W_\=/GR\CWJXQCOYKE=+M'74+%550B]E7$.$#.]UY3G3%M> M\)Q8KB12!9HO.2O0:RZ)S"$Z>E.
E6GTMM:F)I"652@=H]_BJW@>HRN6.\?# M@_0DF:;]8=)]M.[_MDYBT#E5E3L#VY7LY#])3AP"=LG0%=$+(IF)WJP$6Z/S MW#H+3I(G_J-
JAO\8W4_*R;0^QC]] EE703%7JQ87EM^P]#O0!]Z]YGA%&#O M/DHPD11=.EYXV;PYSW-52^LZ1KL(0'A)5K H+)5>-A#D4N8Q.G+('1Z,,4ZF
M*"57!VE(J[Z*M"[8B3T\&(ZG3^'O!$"O"*50 M>218 9K"[4'ET]&81?V3/5-\E!ZWJ>]KTUT,<#|>C5W1#NHM>M/1U*!W-=&@-M!
[%&O[)*:0!>HM=*ERA-HG>H4-H3]&FSJH)\%$4,T*3)U!<+I@.C/:!>7\1-M ?T%%[#@EMME8!A$K;D%%7FY7JSR)9'7/IV2&^-;F/0K*5QW:,DT P5LZS*D
MU\H2%;6 ;'*H1KB@FXTT^U1SS=R=9YR(]HGSB]PC]"D='M'CC?KNN\ M.1'-Y>OW"^9FSAI/XCX>N5'+PGOE:;MQ,X7%?@KK6?K0-L3Q<(P?
-2=Q^]CM M%[?F40]H C $R3CO]3NO0P)WA:H72W6'+,7 ?FP#+OHZ5'V\/ M#P;00/TWVKG&-X]](/A,=8FK[8F(-
&KR8TH%-2K!*6J+>_YP[0.BYX_"MYGN MO@K.GF_7YB+\?T.Z/K=3@<U.ME/$W1;:9 M((Z1!^^N=P?/=^3DSH4LX/35]]'+%UYWF^_P\MWS+_U_U!+
0(4 Q0 (M ,2$;%D^RQ^CT>X! .9%(0 " 0 !B87@M,C R-# Y M,S N:'1M4$L! A0#% @ Q(1L68]?]!+V%P AA0! ! M (!_ ^X! &)A>"TR,#(T,#DS, 'YXHP M
#^_P$ % @ $C!D(8F%X+3(P,C0P.3,P7V-A;"YX;6Q0 M2P$"% ,4 " #$A&Q9C?W\XO"" 9$@8 % @ $_ . (M8F%X+3(P,C0P.3,P7V1E9BYX;6Q02P$"% ,4 "
#$A&Q9W9E9P:=7 0#N M6PT % @ %ANP(8F%X+3(P,C0P.3,P7VQA8BYX;6Q02P$" M% ,4 " #$A&Q94\ZS91G0 ""TR M,#
(T,#DS,'AE>#$P,BYH=&U02P$"% ,4 " #$A&Q9BPVB*J=2 !Q-0(M%@ @ &D\P0 8F%X+3(P,C0P.3,P>&5X,3 S+FAT;5!+ 0(4 M Q0 (,2$;%E0]?"TR,#
(T,#DS,'AE>#,Q,BYH=&U02P$" M% ,4 " #$A&Q9:'L.5C<$ #[#P %@ @ %(5@4 8F%X I+3(P,C0P.3,P>&5X,S(R+FAT;5!+!08 # , !L# "S6@4 ! end XML
104 bax-20240930_htm.xml IDEA: XBRL DOCUMENT 0000010456 2024-01-012024-09-30 0000010456
bax:CommonStock100PerValueMemberexch:XCHI 2024-01-012024-09-30 0000010456 bax:CommonStock100PerValueMemberexch:XNYS 2024-01-
012024-09-30 0000010456 bax:GlobalNotes13Due2025Memberexch:XNYS 2024-01-012024-09-30 0000010456
bax:GlobalNotes13Due2029Memberexch:XNYS 2024-01-012024-09-30 0000010456 2024-10-31 0000010456 2024-09-30 0000010456 2023-12-31
0000010456 2024-07-012024-09-30 0000010456 2023-07-012023-09-30 0000010456 2023-01-012023-09-30 0000010456 us-*

gaap:CommonStockMember 2024-06-30 0000010456 us-gaap:TreasuryStockCommonMember 2024-06-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000010456 us-gaap:RetainedEarningsMember 2024-06-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000010456 us-gaap:ParentMember 2024-06-30 0000010456 us-gaap:NoncontrollingInterestMember 2024-06-30 0000010456 2024-06-30 0000010456 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000010456 us-gaap:ParentMember 2024-07-012024-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000010456 us-gaap:CommonStockMember 2024-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2024-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000010456 us-gaap:RetainedEarningsMember 2024-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000010456 us-gaap:ParentMember 2024-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2024-09-30 0000010456 us-gaap:CommonStockMember 2023-12-31 0000010456 us-gaap:TreasuryStockCommonMember 2023-12-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000010456 us-gaap:RetainedEarningsMember 2023-12-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000010456 us-gaap:ParentMember 2023-12-31 0000010456 us-gaap:NoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000010456 us-gaap:ParentMember 2024-01-012024-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2024-01-012024-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2024-01-012024-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000010456 us-gaap:CommonStockMember 2023-06-30 0000010456 us-gaap:TreasuryStockCommonMember 2023-06-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000010456 us-gaap:RetainedEarningsMember 2023-06-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000010456 us-gaap:ParentMember 2023-06-30 0000010456 us-gaap:NoncontrollingInterestMember 2023-06-30 0000010456 2023-06-30 0000010456 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000010456 us-gaap:ParentMember 2023-07-012023-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000010456 us-gaap:CommonStockMember 2023-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2023-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000010456 us-gaap:RetainedEarningsMember 2023-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000010456 us-gaap:ParentMember 2023-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2023-09-30 0000010456 2023-09-30 0000010456 us-gaap:CommonStockMember 2022-12-31 0000010456 us-gaap:TreasuryStockCommonMember 2022-12-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000010456 us-gaap:RetainedEarningsMember 2022-12-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000010456 us-gaap:ParentMember 2022-12-31 0000010456 us-gaap:NoncontrollingInterestMember 2022-12-31 0000010456 2022-12-31 0000010456 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0000010456 us-gaap:ParentMember 2023-01-012023-09-30 0000010456 us-gaap:NoncontrollingInterestMember 2023-01-012023-09-30 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000010456 us-gaap:TreasuryStockCommonMember 2023-01-012023-09-30 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000010456 srt:ScenarioForecastMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember 2024-12-31 0000010456 srt:ScenarioForecastMemberus-gaap:DiscontinuedOperationsHeldforsaleMemberbax:KidneyCareMember 2024-10-012025-03-31 0000010456 srt:MinimumMembersrt:ScenarioForecastMemberus-gaap:DiscontinuedOperationsHeldforsaleMemberbax:KidneyCareMember 2024-10-012025-03-31 0000010456 srt:MaximumMembersrt:ScenarioForecastMemberus-gaap:DiscontinuedOperationsHeldforsaleMemberbax:KidneyCareMember 2024-10-012025-03-31 0000010456 us-gaap:HurricaneMember 2024-07-012024-09-30 0000010456 us-gaap:HurricaneMember 2024-09-30 0000010456 us-gaap:HurricaneMemberus-gaap:SubsequentEventMember 2024-11-012024-11-01 0000010456 bax:KidneyCareManufacturingAndSupplyAgreementMembersrt:ScenarioForecastMember 2024-12-312024-12-31 0000010456 bax:KidneyCareTransitionServicesAgreementMembersrt:ScenarioForecastMember 2024-12-312024-12-31 0000010456 2023-09-292023-09-29 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember 2024-07-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember 2023-07-012023-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:BioPharmaSolutionsMember 2024-07-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:BioPharmaSolutionsMember 2023-07-012023-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-07-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-07-012023-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember 2024-01-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember 2023-01-012023-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:BioPharmaSolutionsMember 2024-01-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:BioPharmaSolutionsMember 2023-01-012023-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-012024-09-30 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-012023-09-30 0000010456 us-gaap:SegmentDiscontinuedOperationsMember 2024-09-30 0000010456 us-gaap:SegmentDiscontinuedOperationsMember 2023-12-31 0000010456 us-gaap:PropertyPlantAndEquipmentMember 2024-01-012024-09-30 0000010456 us-gaap:PropertyPlantAndEquipmentMember 2023-01-012023-09-30 0000010456 bax:MedicalProductsAndTherapiesMember 2023-12-31 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2023-12-31 0000010456 bax:PharmaceuticalsMember 2023-12-31 0000010456 bax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 bax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 bax:MedicalProductsAndTherapiesMember 2024-09-30 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2024-09-30 0000010456 bax:PharmaceuticalsMember 2024-09-30 0000010456 us-gaap:CustomerRelationshipsMember 2024-09-30 0000010456 bax:DevelopedTechnologyIncludingPatentsMember 2024-09-30 0000010456 us-gaap:TradeNamesMember 2024-09-30 0000010456 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0000010456 us-gaap:TradeNamesMember 2024-09-30 0000010456 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000010456 us-gaap:CustomerRelationshipsMember 2023-12-31 0000010456 bax:DevelopedTechnologyIncludingPatentsMember 2023-12-31 0000010456 us-gaap:TradeNamesMember 2023-12-31 0000010456 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000010456 us-gaap:TradeNamesMember 2023-12-31 0000010456 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000010456 bax:BridgeFacilityMemberbax:SeniorUnsecuredTermLoansMember 2024-07-17 0000010456 us-gaap:SeniorNotesMember 2024-07-17 0000010456 srt:ScenarioForecastMemberus-gaap:SeniorNotesMember 2025-01-012025-12-31 0000010456 us-gaap:LineOfCreditMemberbax:SeniorUnsecuredTermLoansMember 2024-09-30 0000010456 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0000010456 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0000010456 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000010456 us-gaap:SeniorNotesMember 2024-01-012024-09-30 0000010456 bax:EnvironmentalCleanUpMemberbax:SuperfundSitesMember 2024-09-30 0000010456 bax:EnvironmentalCleanUpMemberbax:SuperfundSitesMember 2023-12-31 0000010456 bax:ExposureToEthyleneOxideMember 2020-03-012020-03-31 0000010456 bax:ExposureToEthyleneOxideMember 2023-12-312024-09-30 0000010456 bax:ExposureToEthyleneOxideMember 2024-07-162024-07-16 0000010456 2024-09-11 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-012024-09-30 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-012024-09-30 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-012024-09-30 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-012023-09-30 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-012023-09-30 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-012023-09-30 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000010456 us-

gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-07-012024-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000010456 us-gaap:FairValueHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000010456 us-gaap:FairValueHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000010456 srt:MinimumMember 2024-01-012024-09-30 0000010456 srt:MaximumMember 2024-01-012024-09-30 0000010456 2024-10-01 2024-09-30 0000010456 2025-01-01 2024-09-30 0000010456 2026-01-01 2024-09-30 0000010456 2027-01-01 2024-09-30 0000010456 2028-01-01 2024-09-30 0000010456 srt:MaximumMemberbax:ManufacturingArrangementsMember 2024-01-012024-09-30 0000010456 srt:MinimumMemberbax:SoftwareArrangementsMember 2024-01-012024-09-30 0000010456 srt:MaximumMemberbax:SoftwareArrangementsMember 2024-01-012024-09-30 0000010456 srt:MinimumMemberbax:ConsumableMedicalProductsMember 2024-01-012024-09-30 0000010456 srt:MaximumMemberbax:ConsumableMedicalProductsMember 2024-01-012024-09-30 0000010456 bax:ManufacturingArrangementsMember 2024-09-30 0000010456 bax:ManufacturingArrangementsMember 2023-12-31 0000010456 bax:SoftwareArrangementsMember 2024-09-30 0000010456 bax:SoftwareArrangementsMember 2023-12-31 0000010456 bax:BundledEquipmentAndConsumableMedicalProductsContractsMember 2024-09-30 0000010456 bax:BundledEquipmentAndConsumableMedicalProductsContractsMember 2023-12-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-09-30 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0000010456 us-gaap:OtherNoncurrentAssetsMember 2024-09-30 0000010456 us-gaap:OtherNoncurrentAssetsMember 2023-12-31 0000010456 bax:AccruedExpensesAndOtherCurrentLiabilitiesMember 2024-09-30 0000010456 bax:AccruedExpensesAndOtherCurrentLiabilitiesMember 2023-12-31 0000010456 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0000010456 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0000010456 bax:A2020AndPriorYearsMember 2024-09-30 0000010456 bax:A2021Member 2024-09-30 0000010456 bax:A2022Member 2024-09-30 0000010456 bax:A2023Member 2024-09-30 0000010456 bax:A2024Member 2024-09-30 0000010456 bax:BusinessOptimizationProgramsMember 2024-07-012024-09-30 0000010456 bax:BusinessOptimizationProgramsMember 2023-07-012023-09-30 0000010456 bax:BusinessOptimizationProgramsMember 2024-01-012024-09-30 0000010456 bax:BusinessOptimizationProgramsMember 2023-01-012023-09-30 0000010456 us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember 2024-07-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember 2024-07-012024-09-30 0000010456 us-gaap:EmployeeSeveranceMember 2024-07-012024-09-30 0000010456 us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember 2024-07-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember 2024-07-012024-09-30 0000010456 bax:ContractTerminationAndOtherCostsMember 2024-07-012024-09-30 0000010456 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0000010456 us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember 2023-07-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember 2023-07-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember 2023-07-012023-09-30 0000010456 us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember 2023-07-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember 2023-07-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMemberbax:ContractTerminationAndOtherCostsMember 2023-07-012023-09-30 0000010456 bax:ContractTerminationAndOtherCostsMember 2023-07-012023-09-30 0000010456 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0000010456 us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0000010456 us-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0000010456 us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember 2024-01-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember 2024-01-012024-09-30 0000010456 bax:ContractTerminationAndOtherCostsMember 2024-01-012024-09-30 0000010456 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0000010456 us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember 2023-01-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember 2023-01-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember 2023-01-012023-09-30 0000010456 us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember 2023-01-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember 2023-01-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMemberbax:ContractTerminationAndOtherCostsMember 2023-01-012023-09-30 0000010456 bax:ContractTerminationAndOtherCostsMember 2023-01-012023-09-30 0000010456 us-gaap:CostOfSalesMemberbax:AssetImpairmentMember 2023-01-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:AssetImpairmentMember 2023-01-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMemberbax:AssetImpairmentMember 2023-01-012023-09-30 0000010456 bax:AssetImpairmentMember 2023-01-012023-09-30 0000010456 us-gaap:CostOfSalesMember 2023-01-012023-09-30 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0000010456 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0000010456 us-gaap:EmployeeSeveranceMemberbax:RestructuringWithinHSTSegmentMember 2024-07-012024-09-30 0000010456 us-gaap:EmployeeSeveranceMemberbax:RestructuringWithinHSTSegmentMember 2024-01-012024-09-30 0000010456 us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember 2024-01-012024-09-30 0000010456 us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember 2023-07-012023-09-30 0000010456 us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember 2023-01-012023-09-30 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2023-12-31 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2024-01-012024-09-30 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2024-09-30 0000010456 us-gaap:PensionPlansDefinedBenefitMember 2024-07-012024-09-30 0000010456 us-gaap:PensionPlansDefinedBenefitMember 2023-07-012023-09-30 0000010456 us-

gaap:PensionPlansDefinedBenefitMember 2024-01-012024-09-30 0000010456 us-gaap:PensionPlansDefinedBenefitMember 2023-01-012023-09-30 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-07-012024-09-30 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-012023-09-30 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-012024-09-30 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMember 2024-09-30 0000010456 us-gaap:ForeignExchangeContractMember 2023-12-31 0000010456 us-gaap:ForeignExchangeContractMember 2024-01-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2023-12-31 0000010456 us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember 2024-09-30 0000010456 us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember 2023-12-31 0000010456 us-gaap:FairValueHedgingMember 2023-10-31 0000010456 bax:A04SeniorNotesDueMay2024Member 2023-10-31 0000010456 bax:A130SeniorNotesDueMay2025Member 2017-05-31 0000010456 bax:A13SeniorNotesDueMay2029Member 2019-05-31 0000010456 bax:A13SeniorNotesDueMay2029Member 2017-05-31 0000010456 bax:A04SeniorNotesDueMay2024Member 2019-05-31 0000010456 us-gaap:NetInvestmentHedgingMember 2024-09-30 0000010456 us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000010456 us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000010456 us-gaap:NondesignatedMember 2024-09-30 0000010456 us-gaap:NondesignatedMember 2023-12-31 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2024-07-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2023-07-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2024-07-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2023-07-012023-09-30 0000010456 us-gaap:NetInvestmentHedgingMember 2024-07-012024-09-30 0000010456 us-gaap:NetInvestmentHedgingMember 2023-07-012023-09-30 0000010456 us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2024-07-012024-09-30 0000010456 us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2024-07-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-012023-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2024-01-012024-09-30 0000010456 us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2023-01-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2024-01-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2023-01-012023-09-30 0000010456 us-gaap:FairValueHedgingMember 2024-01-012024-09-30 0000010456 us-gaap:FairValueHedgingMember 2023-01-012023-09-30 0000010456 us-gaap:FairValueHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-012024-09-30 0000010456 us-gaap:FairValueHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-012023-09-30 0000010456 us-gaap:NetInvestmentHedgingMember 2024-01-012024-09-30 0000010456 us-gaap:NetInvestmentHedgingMember 2023-01-012023-09-30 0000010456 us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-012024-09-30 0000010456 us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-012023-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-012024-09-30 0000010456 us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-012023-09-30 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2024-09-30 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2024-09-30 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2023-12-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2023-12-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000010456 us-gaap:LongTermDebtMember 2024-09-30 0000010456 us-gaap:LongTermDebtMember 2023-12-31 0000010456 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000010456 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000010456 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000010456 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000010456 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000010456 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000010456 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000010456 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000010456 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000010456 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-06-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-06-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-06-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-06-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-07-012024-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-07-012024-09-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-07-012023-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-07-012023-09-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-09-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-09-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-12-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-12-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2022-12-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2022-12-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-01-012024-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-01-012024-09-30 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-01-012023-09-30 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-01-012023-09-30 0000010456 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000010456 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000010456 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000010456 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000010456 us-gaap:OtherAssetsMember 2024-09-30 0000010456 us-gaap:DebtSecuritiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberus-

gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMembercountry:USbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMembercountry:USbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMembercountry:USbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMembercountry:USbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember 2023-07-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMembercountry:US 2024-07-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMembercountry:US 2023-07-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0000010456 country:US 2024-07-012024-09-30 0000010456 us-gaap:NonUsMember 2024-07-012024-09-30 0000010456 country:US 2023-07-012023-09-30 0000010456 us-gaap:NonUsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMembercountry:USbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMembercountry:USbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-

gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMembercountry:USbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMembercountry:USbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMembercountry:USbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember 2023-01-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMembercountry:US 2024-01-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMember 2024-01-012024-09-30 0000010456 us-gaap:CorporateNonSegmentMembercountry:US 2023-01-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000010456 us-gaap:CorporateNonSegmentMember 2023-01-012023-09-30 0000010456 country:US 2024-01-012024-09-30 0000010456 us-gaap:NonUsMember 2024-01-012024-09-30 0000010456 country:US 2023-01-012023-09-30 0000010456 us-gaap:NonUsMember 2023-01-012023-09-30 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2024-07-012024-09-30 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2023-07-012023-09-30 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2024-01-012024-09-30 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2023-01-012023-09-30 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2024-07-012024-09-30 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2023-07-012023-09-30 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2024-01-012024-09-30 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2023-01-012023-09-30 0000010456 us-gaap:OperatingSegmentsMember 2024-07-012024-09-30 0000010456 us-gaap:OperatingSegmentsMember 2023-07-012023-09-30 0000010456 us-gaap:OperatingSegmentsMember 2024-01-012024-09-30 0000010456 us-gaap:OperatingSegmentsMember 2023-01-012023-09-30 0000010456 us-gaap:MaterialReconcilingItemsMember 2024-07-012024-09-30 0000010456 us-gaap:MaterialReconcilingItemsMember 2023-07-012023-09-30 0000010456 us-gaap:MaterialReconcilingItemsMember 2024-01-012024-09-30 0000010456 us-gaap:MaterialReconcilingItemsMember 2023-01-012023-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:EUR bax:site bax:lawsuit bax:complaint bax:de-designation bax:terminate bax:segmentfalse2024Q30000010456--12-31CHXP1YP1YP3MP1YP1YP1YP1Y10-Qtrue2024-09-30false1-4448BAXTER INTERNATIONAL INC.DE36-0781620One Baxter Parkway,Deerfield,IL60015224.948.2000Common Stock, $1.00 par valueCommon Stock, $1.00 par valueBAX (NYSE)BAX (NYSE)NYSE1.3% Global Notes due 2025BAX 25NYSE1.3% Global Notes due 2029BAX 29NYSEYesYesLarge Accelerated Filerfalsefalsefalse5105875811420000000307800000065000000620000001729000000171900000021030000001918000000720000000706000000281120000000020000000006834949446834949446830000006830000001730328221758618931108400000011230000000639100000006389000000153647000000-355400000078720000008402000000700000006600000079420000000846800000026676000000282760000002699000000259900000007883000000768700000-127000000-251000000-367000000100000012000000340000000-150000006900000064000000232000000210000008000000270000007000000059000000610000003700000001620000000-380000008300000024740000002900000002455000000144000000251100000-128000000241700000000040000003000000090000006000000400000030000009000000600000001400000002508000000-137000000241100000000.120.070.32-0.080.120.070.32-0.080.154.88-0.594.840.154.86-0.594.840.274.95-0.274.760.274.93-0.274.765100000000507000000509000000506000000512000000509000000511000000506000000610000003700000001620000000-380000001900000012000000-300000020000001060000000-360000000-610000000-390000002000000003000000600000010000002000000110000003000000200000030000000-900000050000002000000100000009100000000-320000000-610000000-400000001520000000500000001010000007800000083000000247400000000-290000000245500000000-110000000-1000000-150000000-100000090000000134000000-350000001620000000000040000001000000500000009000000013000000000-360000001570000001730000002604000000-326000000261200000032500000026090000000-225000000253400000040000003000000990000006000000000-400000003210000002606000000-230000000252800000068300000068300000017300000-111040000006353000000155390000000-382800000076430000006500000077080000001400000001400000001400000018100000018100000018100000020000000380000005800001108400000006391000000155290000000-364700000078720000007000000079420000006830000006830000001760000000-112300000006389000000161140000000-355400000084020000006600000084680000000-137000000-137000000090000000-128000000-93000000-93000000-4000000-970000003000000146000000200000014800000014800000044800000044800000044800000000-1000000-100000068300000068300000017300000-110840000006391000000155290000000-364700000078720000007000000079420000006830000006830000001770000000-112960000006341000000136550000000-381400000055690000006200000056310000002508000000250800000030000002511000000980000009800000098000000100000004700000027000011249000000063680000001601500000-371600000008101000000650000008166000000683000000683000000179000000-113890000006322000000140500000000-383300000058330000006200000058950000002411000000241100000060000000241700000011700000011700000011700000030000001400000004630000000-300000068300000068300000017600000-112490000006368000000160150000000-371600000008101000000650000008166000000-128000000241700000000-290000000245500000001620000000-380000007520000007200000000-136000000-239000000750000000900000000-210000000-190000004200000030000000-20000000-250000001700000000-520000001800000001200000006100000041000000030000001610000001920000000-261000000-71000000-630000003760000007920000001550000004030000005310000001195000000314000000340000000900000004000000034000000-8000000-19000000-281000000-325000000-1400000003768000000-421000000344300000082700000035300000002140000004430000004390000000630000008600000000-15000000-62000000-1222000000-554000000-45000000-370000003900000023000000-111800000040700000031980000001722000000208000000057920000006580000007200000001422000000057200000000142000000030780000000571OF PRESENTATION The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report). In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business, which will be known as Vantive, for an aggregate purchase price of $3.80 billion. After giving effect to certain closing adjustments, we currently expect to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the range of $3.15 billion to $3.25 billion. The transaction is currently expected to close in late 2024 or early 2025, subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions. We determined that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations presentation. See Note 2 for additional information. Hurricane Helene In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations at that facility. We are actively working with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we work to fully restore our North Cove manufacturing operations. Our insurance policies generally cover the repair or replacement of our

assets that suffer loss or damage, less applicable deductibles and subject to any coverage limits and exclusions, and we are working closely with our insurance carriers and claims adjusters to ascertain the full amount of insurance proceeds due to us as a result of the damages and the loss we suffered as a result of Hurricane Helene (which proceeds are likely to be less than the applicable losses). Our insurance policies also provide coverage for interruption to our business, including lost profits, and reimbursement for other expenses and costs that have been incurred relating to the damages and losses suffered. In the third quarter of 2024, we recorded $25 million of pre-tax net charges related to damages caused by Hurricane Helene. This consisted of $44 million related to the write-off of damaged inventory and fixed assets offset by a receivable of $19 million, which is the amount of the loss, net of our insurance deductible, related to insurance recoveries expected as a result of those asset write-offs. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three and nine month periods ended September 30, 2024. At this time, the full amount of combined property damage and business interruption costs cannot be estimated and any additional insurance recoveries are not realizable, and accordingly, no additional amounts have been recorded as of September 30, 2024. On November 1, 2024, we received $101 million of cash related to insurance proceeds which included recoveries for expenses incurred after the balance sheet date. We expect to receive additional related insurance proceeds in the future. Risks and Uncertainties Supply Constraints and Global Economic Conditions In recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing of raw materials and on transportation costs, some of these challenges (such as additional transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future. The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report). In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.38000000003500000000315000000032500000002500000044000000190000001010000000 Risks and Uncertainties Supply Constraints and Global Economic Conditions In recent years, we have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle East, tensions amongst China, Taiwan, and the U.S., and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing of raw materials and on transportation costs, some of these challenges (such as additional transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest of increasing the availability of intravenous and peritoneal dialysis solutions for our customers while we work to fully remediate our North Cove facility) are expected to have a negative impact on our results of operations in the future. DISCONTINUED OPERATIONS A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation for two strategic actions, as described below. Discontinued Operations - Kidney Care On August 12, 2024, we entered into an EPA to sell our Kidney Care business, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. That business, which is comprised of our Kidney Care segment, provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. Pursuant to the EPA, we expect to sell the Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion. After giving effect to certain adjustments, we currently expect to receive approximately $3.50 billion of net pre-tax cash proceeds (approximately $3.15 billion to $3.25 billion after tax). The transaction is currently expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. We intend to use the net after-tax proceeds from this transaction to repay certain of our debt obligations, consistent with our stated capital allocation priorities. We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the pending sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation. Upon closing of the pending sale of the Kidney Care business, Baxter and Vantive will enter into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a long-term Master Services Agreement, a Distribution Agreement, a Transition Services Agreement (Kidney Care TSA), and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities will provide each other with certain dialysis-related products, other products, product components and fulfillment services for a period up to 10 years post-closing (with certain extension rights as provided therein). Pursuant to the Kidney Care TSA, Baxter and the entities that will be divested in connection with the pending Kidney Care sale (the Kidney Care divested entities) will provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights as provided therein) to help ensure business continuity and help minimize disruptions to the entities' operations post-closing. Services to be provided under the TSA include IT, supply chain and certain other corporate and administrative services. Pursuant to the EPA, Baxter will retain (i) the manufacture and sale of saline solutions and (ii) the plastics operations of Baxter and its subsidiaries at its Mountain Home, Arkansas facility, which is not part of the Kidney Care segment. Discontinued Operations - BioPharma Solutions On September 29, 2023, we sold our BioPharma Solutions (BPS) business to Advent International and Warburg Pincus (collectively, the BPS buyers). The BPS business, which was historically reported within our former Americas segment, provided contract manufacturing and development services, which include sterile fill-finish manufacturing and support services across clinical and commercial applications, primarily serving customers in the pharmaceutical industry. BPS was historically operated through our former, wholly-owned subsidiaries Baxter Pharmaceutical Solutions LLC, a Delaware limited liability company, and Baxter Oncology GmbH, a German limited liability company (collectively, the BPS divested entities). We concluded that our BPS business met the criteria to be classified as held-for-sale in May 2023. We analyzed the quantitative and qualitative factors relevant to the divestiture of our BPS business, including its significance to our overall net income and earnings per share, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation. At closing of the transaction, Baxter entered into a Transition Services Agreement (BPS TSA) and a Master Commercial Manufacturing and Supply Agreement (BPS MSA) with the divested entities. Pursuant to the BPS TSA, Baxter and the BPS

divested entities provide to each other, on an interim basis, specific transition services for up to 24 months post-closing to help ensure business continuity and minimize disruptions. Services provided under the BPS TSA include finance, information technology, human resources, integrated supply chain, and certain other administrative services. Pursuant to the BPS MSA, the BPS divested entities provide development, manufacturing, regulatory, and other related services for certain Baxter pharmaceutical products for up to 5 years post-closing (with certain extension rights as provided therein). Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td colspan="3" style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td colspan="3" style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td colspan="3" style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Kidney Care</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">BioPharma Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,109 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">191 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,300 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,048 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gross margin</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt

solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">171 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">258 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">273 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other operating income, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Operating income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(230)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(136)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations before gain on disposition and income taxes</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(236)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(144)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gain on disposition</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax expense (benefit)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(250)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">522 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income from discontinued operations, net of tax</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,460 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,474 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Less: Net income

attributable to noncontrolling interest included in discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Net income attributable to Baxter stockholders included in discontinued operations</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,460 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,471 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Kidney Care</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">BioPharma Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,375 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-

align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">469 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,375 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,763 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,125 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,125 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gross margin</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">453 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">253 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">706 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">691 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">735 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill impairment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2"

style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other operating income, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Operating income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(193)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(342)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(193)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(135)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations before income taxes</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(362)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

(157)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gain on disposition</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax expense (benefit)</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(258)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">536 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations, net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(104)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,559 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Less: Net income attributable to noncontrolling interests included in discontinued operations</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Net income (loss) attributable to Baxter stockholders included in discontinued operations</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(110)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-

align:right;vertical-align:bottom">2,559 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,449 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the three and nine months ended September 30, 2024, selling, general and administrative expenses (SG&A) includes $69 million and $236 million, respectively, of separation-related costs incurred in connection with the pending sale of our Kidney Care business. For the three months ended September 30, 2023, SG&A includes separation-related costs of $67 million and $8 million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively. For the nine months ended September 30, 2023, SG&A includes separation-related costs of $108 million and $15 million, incurred in connection with the pending sale of our Kidney Care business and the sale of BPS, respectively.</div><div style="margin-top:10pt">The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">658 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable, net of allowances</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">971 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">906 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">186 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current assets of discontinued operations</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,892 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,179 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,542 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">276 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other intangible assets, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">209 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">188 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">317 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Non-current assets of discontinued operations</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,534 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,949 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Assets of discontinued operations</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,426 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,128 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Current maturities of finance lease obligations</td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ccceff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Accounts payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">679 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Current liabilities of discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,089 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,040 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term finance lease obligations, less current portion</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">186 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">173 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">349 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Non-current liabilities of discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">575 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">551 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Liabilities of discontinued operations</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,664 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,591 </td><td style="background-color:#cceeff;border-bottom:3pt double

#000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
3800000000350000000031500000003250000000P10YP30MP24MP5Y The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Kidney Care</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">BioPharma Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,109 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">191 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,300 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,048 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gross margin</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0

2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">171 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">258 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">273 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other operating income, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Operating income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(230)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(136)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations before gain on disposition and income taxes</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(236)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(144)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gain on disposition</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax expense (benefit)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(250)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">522 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income from discontinued operations, net of tax</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,460 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,474 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Less: Net income attributable to noncontrolling interest included in discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Net income attributable to Baxter stockholders included in discontinued operations</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,460 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,471 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Kidney Care</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">BioPharma Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,375 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">469 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,375 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,763 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,125 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,125 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Gross margin</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">453 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">253 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">706 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">691 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">735 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development expenses</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill impairment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other operating income, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Operating income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(193)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(342)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(193)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(135)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations before income taxes</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(362)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(157)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gain on disposition</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax expense (benefit)</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(258)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">536 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Income (loss) from discontinued operations, net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(104)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,559 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Less: Net income attributable to noncontrolling interests included in discontinued operations</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Net income (loss) attributable to Baxter stockholders included in discontinued operations</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(110)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,559 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,449 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt">The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">658 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable, net of allowances</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">971 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">906 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">186 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current assets of discontinued operations</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,892 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,179 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,542 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">276 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other intangible assets, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">209 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">188 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">317 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Non-current assets of discontinued operations</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,534 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,949 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Assets of discontinued operations</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,426 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,128 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Current maturities of finance lease obligations</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Accounts payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">679 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Current liabilities of discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,089 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,040 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term finance lease obligations, less current portion</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">186 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">173 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">349 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Non-current liabilities of discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">575 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">551 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Liabilities of discontinued operations</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,664 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,591 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
1155000000110900000001910000001155000000130000000073100000010480000000810000007310000001129000000424000000610000006230000000940000001060000000-136000000-1000000-100000000-1000000-10000008000000-50000000-20000008000000-7000000113000000-23600000009200000011300000-144000000000289000000002890000000300000002500000000522000000300000002720000008300000014000000024600000008300000024740000004000000300000000400000030000007900000011930000003420000000207000000-193000000-1350000000-2000000000-20000002000000-180000000-20000002000000-20000000-191000000-362000000020500000-191000000-157000000000289000000002890000000099000000-258000000053600000009900000027800000-290000000-104000000025590000-290000000245500000090000006000000009000000600000-299000000-110000000025590000-29900000024490000006900000023600000067000000800000010800000015000000658000000116000000104500000097100000096000000090600000FINANCIAL INFORMATION Allowance for Doubtful Accounts <span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle">Three Months Ended September 30,</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">67 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Charged to costs and expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Write-offs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Inventories <table

*style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">532 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">530 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in process</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">256 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,315 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,154 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,103 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Property, Plant and Equipment, Net <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, at cost</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7,605 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7,650 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4,772)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4,779)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,833 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,871 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> Interest Expense, Net <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-*

height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net of capitalized interest</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">101 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">308 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">394 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(57)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(27)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">87 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">127 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">251 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">367 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> Other (Income) Expense, Net<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange losses, net</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">49 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Pension and other postretirement benefit plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Change in fair value of marketable equity securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Non-marketable investment impairments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">(1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(12)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> Non-Cash Operating and Investing Activities Right-of-use operating lease assets obtained in exchange for lease obligations for the nine months ended September 30, 2024 and 2023 were $54 million and $55 million, respectively. Purchases of property, plant and equipment included in accounts payable as of September 30, 2024 and 2023 were $34 million and $30 million, respectively. Allowance for Doubtful Accounts The following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle">Three Months Ended September 30,</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:

height:100%">2023</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">67 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Charged to costs and expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Write-offs</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
67000000610000006200000050000000400000020000004000000170000003000000-1000000600000020000003000000-2000000-5000000-1000000650000006600000065000000660000000 Inventories <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">532 </td><td

*style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">530 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in process</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">256 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,315 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,154 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,103 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>532000000530000000256000000234000000131500000011540000002103000000191800000 0<div style="margin-top:13pt">Property, Plant and Equipment, Net <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, at cost</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7,605 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7,650 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4,772)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4,779)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,833 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,871 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div>760500000076500000004772000000477900000028330000002871000000<div style="margin-top:10pt">Interest Expense, Net</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net of capitalized interest</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">101 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid*

#000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">308 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">394 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(57)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(27)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">87 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">127 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">251 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">367 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div>-101000000-136000000-308000000-394000000-14000000-9000000-57000000-27000000-87000000-127000000-251000000-367000000<div style="margin-top:13pt">Other (Income) Expense, Net<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange losses, net</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">49 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Pension and other postretirement benefit plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">(37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Change in fair value of marketable equity securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Non-marketable investment impairments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">(1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(12)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> -7000000-10000000-21000000-49000000-9000000-15000000-34000000-37000000030000003000000-30000000000-13000000-10000004000000180000001300000010000001200000034000000-150000005400000055000000340000003000000GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The following is a reconciliation of goodwill by segment.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical Products and Therapies</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Healthcare Systems and Technologies</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Pharmaceuticals</td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1,241 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3,989 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">563 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none">

</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5,793 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2024</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,234 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,989 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">560 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">5,783 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:10pt">Other intangible assets, net</div><div style="margin-top:10pt">The following is a summary of our other intangible assets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite-lived intangible assets</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Customer relationships</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Developed technology, including patents</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Trade names</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other amortized intangible assets</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Trade names</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">In process Research and Development</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">
Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross other intangible assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">963 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">87 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">8,459 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(824)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,027)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(92)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(67)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3,010)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Other intangible assets, net</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,566 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1,155 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">871 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5,449 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross other intangible assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,181 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">86 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">8,458 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">

</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(654)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,782)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(38)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(66)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,540)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Other intangible assets, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,736 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,399 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">926 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">20 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> Intangible asset amortization expense was $159 million and $147 million for the three months ended September 30, 2024 and 2023, respectively, and $471 million and $434 million for the nine months ended September 30, 2024 and 2023, respectively.<div style="margin-bottom:6pt;margin-top:9pt">The following is a reconciliation of goodwill by segment.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical Products and Therapies</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Healthcare Systems and Technologies</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Pharmaceuticals</td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1,241 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3,989 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">563 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5,793 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,234 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,989 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">560 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">5,783 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 124100000039890000005630000005793000000-70000000-3000000-10000000123400000039890000000560000000057830000000 The following is a summary of our other intangible assets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite-lived intangible assets</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Customer relationships</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Developed technology, including patents</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Trade names</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other amortized intangible assets</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Trade names</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">In process Research and Development</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">
Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross other intangible assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">963 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">87 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">8,459 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(824)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,027)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(92)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(67)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3,010)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Other intangible assets, net</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,566 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1,155 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">871 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5,449 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross other intangible assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">3,181 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">86 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">8,458 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(654)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,782)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(38)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(66)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,540)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-

align:left;vertical-align:top">Other intangible assets, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2,736 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,399 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">926 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">20 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">680 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">157 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
339000000031820000009630000008700000068000000015700000084590000008240000002027000000920000006700000030100000002566600000ARRANGEMENTS Credit Facilities On July 17, 2024, we entered into a credit agreement in which a group of banks have committed to provide us senior unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under the bridge facility will be available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the pending sale of our Kidney Care business. Borrowings under the bridge facility will bear interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We will also incur a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banks' funding commitments under the bridge facility will terminate upon the earliest to occur of: (i) our consummation of the debt repayments and tax payments described above without us having borrowed under the bridge facility, (ii) our election to terminate the commitments under the bridge facility, (iii) our receipt of net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business), (iv) the occurrence of three drawings under the bridge facility, and (v) December 31, 2024. Outstanding borrowings under the bridge facility will mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we are required to use the net cash proceeds from certain transactions (including from the pending sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contains financial and other covenants, including a net leverage covenant, and provides for customary events of default. There were no borrowings outstanding under this bridge facility as of September 30, 2024. In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. The amendment further provided for the reduction of the capacity under our U.S dollar-denominated revolving credit facility from $2.50 billion to $2.00 billion on the earlier of September 30, 2024 or the date of the sale of our Kidney Care business. Costs incurred in connection with the amendment were not material. In addition to our U.S. dollar-denominated revolving credit facility with a current capacity of $2.00 billion, our Euro-denominated revolving credit facility has a capacity of €200 million. Each of the facilities matures in 2026. There were no borrowings outstanding under these credit facilities as of September 30, 2024 or December 31, 2023. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of September 30, 2024 we have capacity to draw on the full amounts under our credit facilities. In the first nine months of 2024, we repaid $822 million of senior notes at maturity.
20500000000.000.013220.00250250000000002000000000020000000000200000000000822000000COMMITMENTS AND CONTINGENCIES We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of September 30, 2024 and December 31, 2023, our total recorded reserves with respect to legal and environmental matters were $41 million and $25 million, respectively. We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims. In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others' rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. Environmental We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup

if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of September 30, 2024 and December 31, 2023, our environmental reserves, which are measured on an undiscounted basis, were $30 million and $15 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations. General Litigation In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 25 lawsuits (after giving effect to the amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. We acquired Hill-Rom Holdings, Inc. (Hillrom) on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws. On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery. On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020" and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint.

* 4100000025000000630000000150000000225401STOCKHOLDERS' EQUITY Cash Dividends Cash dividends declared per share for the three months ended September 30, 2024 and 2023 were $0.29 and for the nine months ended September 30, 2024 and 2023 were $0.87. Stock Repurchase Programs In July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first nine months of 2024 and 2023 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of September 30, 2024.0.290.290.870.87001300000000ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-top:10pt">Comprehensive income includes all changes in stockholders' equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.</div><div style="margin-bottom:6pt;margin-top:10pt">The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (losses)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">CTA</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Pension and OPEB plans</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Hedging activities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div>Balance as of December 31, 2023</div></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(2,985)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(452)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-*

align:right;vertical-align:top">(120)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,554)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(90)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Amounts reclassified from AOCI (a)</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Net other comprehensive income (loss) </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(92)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(93)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2024</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,077)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(455)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(118)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,647)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (losses)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">CTA</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Pension and OPEB plans</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Hedging activities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of December 31, 2022</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,386)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(331)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(119)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,833)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(62)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Amounts reclassified from AOCI (a)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Net other comprehensive income (loss) </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2023</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,263)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(347)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(109)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-bottom:3pt double

#000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,716)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt">(a) See table below for details about these reclassifications.</div><div style="margin-top:10pt">The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three and nine months ended September 30, 2024 and 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amounts reclassified from AOCI (a)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of impact in income statement</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension and OPEB items</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs or credits</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on hedging activities</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total net of tax</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amounts reclassified from AOCI (a)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of impact in income statement</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">CTA</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Reclassification of cumulative translation loss to earnings from BPS divestiture</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension and OPEB items</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid

#000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs or credits</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Pension settlement from BPS divestiture</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on hedging activities</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(174)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(164)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total net of tax</td></tr></table> (a) Amounts in parentheses indicate reductions to net income Refer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the nine months ended September 30, 2024 and 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (losses)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">CTA</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Pension and OPEB plans</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Hedging activities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of December 31, 2023 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(2,985)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(452)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(120)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,554)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(90)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Amounts reclassified from AOCI (a)</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Net other

comprehensive income (loss) </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(92)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(93)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,077)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(455)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(118)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">(3,647)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (losses)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">CTA</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Pension and OPEB plans</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Hedging activities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of December 31, 2022</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,386)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(331)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(119)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,833)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(62)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Amounts reclassified from AOCI (a) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Net other comprehensive income (loss) </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of September 30, 2023</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,263)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(347)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(109)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,716)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt">(a) See table below for details about these reclassifications.</div>-2985000000-452000000-12000000003000000-3554000000-92000000020000000-900000000300000000300000-92000000-3000000020000000-93000000-3077000000-455000000-11800000003000000-3647000000-3386000000-331000000-11900000003000000-3833000000-62000000015000000-47000000-185000000160000005000000-164000000123000000-160000001000000001170000000-3263000000-347000000-10900000003000000-3716000000<div style="margin-top:10pt">The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three and nine months ended September 30, 2024 and 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amounts reclassified from AOCI (a)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of impact in income statement</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension and OPEB items</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs or credits</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-

align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on hedging activities</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt

solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total net of tax</td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amounts reclassified from AOCI (a)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of impact in income statement</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">CTA</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Reclassification of cumulative translation loss to earnings from BPS divestiture</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(185)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension and OPEB items</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs or credits</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Pension settlement from BPS divestiture</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income from discontinued operations, net of tax</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on hedging activities</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total before tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Less: Tax effect</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Income tax expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Net of tax</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(174)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(164)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Total net of tax</td></tr></table> (a) Amounts in parentheses indicate reductions to net income 1000000400000001000000100000030000004000000-9000000-1000000-40000000-5000000300000001000000020000000300000030000001850000001850000000-185000000-18500000005000000150000004000000400000009000000190000000300000090000001600000030000001000000010000000200000050000001740000001640000000REVENUES Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract's transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days. Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the

surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed. As of September 30, 2024, we had $2.75 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products and Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue over the remainder of 2024, 25% in 2025, 20% in each of 2026 and 2027 and 10% thereafter. Significant Judgments Revenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three and nine months ended September 30, 2024 and 2023 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement. Contract Balances The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.54 billion as of September 30, 2024 and December 31, 2023.</div><div style="margin-top:10pt">For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled </div><div style="margin-top:10pt">contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years. </div><div style="margin-top:10pt">The following table summarizes our contract assets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract manufacturing services</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Software sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bundled equipment and consumable medical products contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract assets</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months. The following table summarizes contract liability activity for the nine months ended September 30, 2024 and 2023. The contract

liability balance represents the transaction price allocated to the remaining performance obligations. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">173 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">New revenue deferrals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">383 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">401 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue recognized upon satisfaction of performance obligations</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(389)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(407)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the nine months ended September 30, 2024 and 2023, $94 million and $111 million of revenue was recognized that was included in contract liabilities as of December 31, 2023 and 2022, respectively.</div><div style="margin-top:10pt">The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">54 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract assets</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-

top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">124 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">128 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract liabilities</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Disaggregation of Net Sales Refer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location. Lease Revenue We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the three and nine months ended September 30, 2024 and 2023 were:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales-type lease revenue</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease revenue</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Our net investment in sales-type leases was $36 million as of September 30, 2024, of which $5 million originated in 2020 and prior, $10 million in 2021, $5 million in 2022, $7 million in 2023, and $9 million in 2024.</div>P30DP90D27500000000.250.250.200.200.1000001540000000154000000P90DP5YP7Y<div style="margin-top:10pt">The following table summarizes our contract assets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract manufacturing services</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Software sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bundled equipment and consumable medical products contracts</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract assets</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt">The following table summarizes contract liability activity for the nine months ended September 30, 2024 and 2023. The contract liability balance represents the transaction price allocated to the remaining performance obligations.</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2024</div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">169 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">173 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">New revenue deferrals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">383 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">401 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue recognized upon satisfaction of performance obligations</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(389)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(407)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the nine months ended September 30, 2024 and 2023, $94 million and $111 million of revenue was recognized that was included in contract liabilities as of December 31, 2023 and 2022, respectively.</div><div style="margin-top:10pt">The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">54 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract assets</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">124 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">128 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-

color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
4000000400000046000000450000009500000011600000014500000016500000016900000017300000038300000040100000038900000040700000200000016000000016900000094000000111000000540000005300000091000000112000000145000000165000000124000000128000000360000004style="margin-top:10pt">The components of lease revenue for the three and nine months ended September 30, 2024 and 2023 were:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales-type lease revenue</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>

<td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt">The components of lease revenue for the three and nine months ended September 30, 2024 and 2023 were:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales-type lease revenue</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
3000000220000008000000600000010200000098000002880000003020000001000000030000002200000001500000011500000010300000031600000

OPTIMIZATION CHARGES In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network,

*employing disciplined cost management, and centralizing and streamlining certain support functions. The related costs of those actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $5 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those related to our newly implemented operating model, intended to simplify and streamline our operations, and to the extent further cost savings opportunities are identified (including after completion of the pending Kidney Care sale), we would incur additional restructuring charges and costs to implement business optimization programs in future periods.</div><div>
</div><div>During the three and nine months ended September 30, 2024 and 2023, we recorded the following charges related to business optimization programs.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Restructuring charges</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">36 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">140 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Costs to implement business optimization programs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total business optimization charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">18 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">48 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">49 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">167 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> For segment reporting purposes, business optimization charges are unallocated expenses. Costs to implement business optimization programs for the three and nine months ended September 30, 2024 and 2023, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense. During the three and nine months ended September 30, 2024 and 2023, we recorded the following restructuring charges.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in*

millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">SG&A</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">R&D</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">29 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">39 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td

colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">31 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">25 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">29 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">31 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">36 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">R&D</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-

color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">25 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">89 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">124 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Asset impairments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">28 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">102 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">140 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> For the three and nine months ended September 30, 2024, $7 million and $14 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to business optimization initiatives within our Healthcare Systems and Technologies segment. Additionally, for the nine months ended September 30, 2024, $7 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to our recent implementation of a new operating model intended to simplify and streamline our operations. For the three and nine months ended September 30, 2023, $11 million and $79 million, respectively, of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our previously announced new operating model intended to simplify and streamline our operations. </div><div style="margin-top:10pt">The following table summarizes activity in the liability related to our restructuring initiatives. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liability balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">95 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">42 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(59)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Reserve adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liability balance as of September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">74 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt">Substantially all of our restructuring liabilities as of September 30, 2024 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025.</div>5000000<div>During the three and nine months ended September 30, 2024 and 2023, we recorded the following charges related to business optimization programs.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Restructuring charges</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">36 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">140 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Costs to implement business optimization programs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total business optimization charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">18 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">48 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">49 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">167 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
150000041000000360000001400000003000007000000130000027000000180000004800000049000000167000000 During the three and nine months ended September 30, 2024 and 2023, we recorded the following restructuring charges.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,

2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">SG&A</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">R&D</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">29 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">39 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">31 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">25 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">29 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">31 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">36 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">COGS</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">SG&A</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">R&D</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Employee termination costs</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">25 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">89 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">124 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contract termination and other costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Asset impairments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Total restructuring charges</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">28 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">102 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">10 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">140 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
2000000100000001200000003000000300000020000001300000015000000600000002900000040000003900000002000000020000000600000037
style="margin-top:10pt">The following table summarizes activity in the liability related to our restructuring initiatives.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liability balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">95 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">42 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(59) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Reserve adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liability balance as of September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
950000004200000059000000080000004000000740000000PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension benefits</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Service cost</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected return on plan assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(160)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net periodic pension cost</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">

</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">OPEB</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest cost</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of net loss and prior service credit</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net periodic OPEB cost (income)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt">The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pension benefits</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Service cost</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-

align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected return on plan assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(160)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of net losses and prior service costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net periodic pension cost</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">OPEB</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest cost</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of net loss and prior service credit</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0

1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net periodic OPEB cost (income)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
4000000600000013000000180000003300000045000000123000000137000000430000005700000016000000001660000004000000-1000000-11000000-4000000-2000000-5000000-13000000-70000002000000200000060000006000000500000060000001400000018000000-3000000-4000000-8000000-12000000INCOME TAXES Our effective income tax rate was 11.6% and 42.2% for the three months ended September 30, 2024 and 2023, respectively, and 30.2% and 281.0% for the nine months ended September 30, 2024 and 2023, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards. For the three months ended September 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix, the tax impacts of the write-off of damaged inventory and fixed assets at our North Cove facility caused by Hurricane Helene, and a change in our assertion on the reinvested foreign earnings related to the pending sale of our Kidney Care segment allocated to continuing operations, partially offset by a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment. For the nine months ended September 30, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $26 million valuation allowance recorded to reduce the carrying amount of a tax attribute carryforward in the U.S. related to the pending sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, an increase in income tax expense resulting from internal reorganization transactions related to the pending sale of our Kidney Care segment, and an increase in our liabilities for various uncertain tax positions, partially offset by a favorable geographic earnings mix. For the three months ended September 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, partially offset by a favorable geographic earnings mix. For the nine months ended September 30, 2023, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a $30 million increase in the valuation allowance related to a deferred tax asset from a tax basis step-up that arose from previously enacted Swiss tax reform legislation, an increase in the valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and excess tax shortfalls on stock compensation awards.0.1160.4220.3022.8100.21260000000260000000300000000EARNINGS PER SHARE<div style="margin-top:10pt">The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.</div><div style="margin-top:10pt">The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income (loss) from continuing operations</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(38)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Net income attributable to noncontrolling interests included in continuing operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income (loss) from continuing operations attributable to Baxter stockholders</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income (loss) from discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,474 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Net income attributable to noncontrolling interests included in discontinued operations</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income (loss) from discontinued operations attributable to Baxter stockholders</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,471 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,449 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net income (loss) attributable to Baxter stockholders</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,508 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(137)</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,411 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table is a reconciliation of basic shares and diluted shares. <table style="border-collapse:collapse;display:inline-table;margin-

bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic shares</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">510 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">507 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">509 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Diluted shares</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">512 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">509 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">511 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Basic and diluted shares are the same for nine months ended September 30, 2023 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 18 million and 19 million shares issuable under equity awards for the three and nine months ended September 30, 2024, and 18 million and 25 million shares issuable under equity awards for the three and nine months ended September 30, 2023, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income (loss) from continuing operations</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td

style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(38) </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Net income attributable to noncontrolling interests included in continuing operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income (loss) from continuing operations attributable to Baxter stockholders</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income (loss) from discontinued operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,474 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(290)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Net income attributable to noncontrolling interests included in discontinued operations</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income (loss) from discontinued operations attributable to Baxter stockholders</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,471 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(299)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,449 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net income (loss) attributable to Baxter stockholders</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,508 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(137)</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">2,411 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
610000003700000016200000-380000000000061000000370000001620000000-380000008300000024740000000-290000000245500000040000003000000900000060000007900000002471000000-299000000244900000014000000025080000000-137000000241100000 The following table is a reconciliation of basic shares and diluted shares. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic shares</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">510 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">507 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">509 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Diluted shares</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">512 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">509 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">511 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
5100000005070000005090000005060000002000000200000005120000005090000005110000005060000001800000019000000180000
INSTRUMENTS AND HEDGING ACTIVITIES We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.
 We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Renminbi, Japanese Yen, Swedish Krona, Mexican Peso, Australian Dollar, Canadian Dollar, Turkish Lira, and Indian Rupee. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures. We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features. Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges. Cash Flow Hedges We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item.

*Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively. The notional amounts of foreign exchange contracts designated as cash flow hedges were $225 million and $340 million as of September 30, 2024 and December 31, 2023, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at September 30, 2024 is 12 months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of September 30, 2024 and December 31, 2023. Fair Value Hedges We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt. There were no outstanding interest rate contracts designated as fair value hedges as of September 30, 2024 and December 31, 2023. In October 2023, we entered into a foreign currency forward contract with a notional amount of $798 million and designated that derivative as a fair value hedge of our €750 million of 0.40% senior notes due May 2024. This forward contract matured in May 2024. Net Investment Hedges In May 2017, we issued €600 million of 1.3% senior notes due May 2025. In May 2019, we issued €750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. In May 2019, we issued €750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above. As of September 30, 2024, we had an accumulated pre-tax unrealized translation gain in AOCI of $18 million related to the Euro-denominated senior notes. Dedesignations If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. There were no cash flow hedge dedesignations in the first nine months of 2024 or 2023 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first nine months of 2024 or 2023. If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. There were no net investment hedges terminated during the first nine months of 2024 or 2023. Undesignated Derivative Instruments We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month. The total notional amount of undesignated derivative instruments was $527 million as of September 30, 2024 and $305 million as of December 31, 2023.</div><div style="margin-top:10pt">Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments</div><div style="margin-top:10pt">The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended September 30, 2024 and 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in OCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss)
in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) reclassified from AOCI into income</td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td*

<table><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Interest expense, net</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net investment hedges</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(68)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">57 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss) in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in income</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#ccceff;border-top:1pt

*solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in OCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss)
in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) reclassified from AOCI into income</td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-*

color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net investment hedges</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss) in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in income</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024, $8 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. </div><div style="margin-top:10pt">Derivative Assets and Liabilities</div><div style="margin-top:10pt">The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of September 30, 2024.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:41.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in asset positions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in liability positions</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative instruments designated as hedges</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">7</td></tr>

</table> The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in asset positions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in liability positions</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td></tr><tr><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Prepaid expenses and other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative instruments designated as hedges</td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives. The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Asset</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Liability</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Asset</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Gross amounts recognized in the condensed consolidated balance sheets</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying amount of hedged item</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cumulative amount of fair value hedging adjustment included
 in the carrying amount of the hedged item (a)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-bottom:3pt

double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt">(a) These fair value hedges were terminated in 2018 and earlier periods.</div>225000000340000000P12M0000798000000750000000O.00406000000000.0137500000000.0137500000000.00401800000000000000527000000 style="margin-top:10pt">The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended September 30, 2024 and 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in OCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss)
in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) reclassified from AOCI into income</td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Interest expense, net</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net investment hedges</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(68)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">57 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss) in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in income</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in OCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss)
in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) reclassified from AOCI into income</td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td

colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Interest expense, net</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net investment hedges</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid

#000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of gain (loss) in income statement</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain (loss) recognized in income</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value hedges</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in asset positions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in liability positions</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative instruments designated as hedges</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total derivative instruments</td><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td colspan="2" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">7</td></tr></table> The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in asset positions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives in liability positions</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance sheet location</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative instruments</td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Prepaid expenses and other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Accrued expenses and other current liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative instruments designated as hedges</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign exchange contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-

align:bottom">Prepaid expenses and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Accrued expenses and other current liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total derivative instruments</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2000000200000000500000020000007000000410000000400000005000000450000005000000 The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Asset</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Liability</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Asset</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Liability</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Gross amounts recognized in the condensed consolidated balance sheets</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">41 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td

style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
2000000700000045000000500000010000001000000400000040000001000000600000041000000100000 The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying amount of hedged item</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cumulative amount of fair value hedging adjustment included
 in the carrying amount of the hedged item (a)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a) These fair value hedges were terminated in 2018 and earlier periods. 1000000001000000003000000030000000FAIR VALUE MEASUREMENTS The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of fair value measurement</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices in active markets for identical assets
(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant other
observable inputs
(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable inputs
(Level 3)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Available-for-sale debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px

1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Marketable equity securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">16 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">13 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contingent payments related to acquisitions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">19 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">12 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td

style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of fair value measurement</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices in active markets for identical assets
(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant other
observable inputs
(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable inputs
(Level 3)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Available-for-sale debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Marketable equity securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">90 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">44 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-

align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contingent payments related to acquisitions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">19 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">14 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> As of September 30, 2024 and December 31, 2023, cash and cash equivalents of $1.42 billion and $3.08 billion, respectively, included money market funds of approximately $427 million and $1.63 billion, respectively, which are considered Level 2 in the fair value hierarchy.</div><div style="margin-top:10pt">For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.</div><div style="margin-top:10pt">Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.</div><div style="margin-top:10pt">Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue </div><div style="margin-top:10pt">estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. </div><div style="margin-top:10pt">The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at beginning of period</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-

align:right;vertical-align:bottom">21 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at end of period</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td></tr><tr><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at beginning of period</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">84 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Change in fair value recognized in earnings</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Transfers out of Level 3</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at end of period</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> During the nine months ended September 30, 2023, available-for-sale debt securities were reclassified from Level 3, upon conversion to marketable equity securities, which are classified as Level 1 in the fair value hierarchy, upon initial public offerings of the investees. Financial Instruments Not Measured at Fair Value In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of September 30, 2024 and December 31, 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Book values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values(a)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Current maturities of long-term debt and finance lease obligations</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">2,498 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">2,667 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">2,493 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">2,621 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Long-term debt and finance lease obligations</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10,437 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">11,089 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">9,612 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10,026 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities. Investments Without Readily Determinable Fair Values The carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $33 million as of September 30, 2024 and December 31, 2023. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. Those investments are included in Other non-current assets on our condensed consolidated balance sheets. During the first nine months of 2023, several of our investees either completed or were in the process of undertaking new financing rounds at lower enterprise valuations as compared to their valuations at the time of our investments. As a result, we recognized $8 million of impairments of equity investments without readily determinable fair values in the prior year period. In addition, we recognized a $5 million impairment of a convertible debt investment, which is accounted for as an available-for-sale security, during the first nine months of 2023. The fair value measurements of investments in non-marketable equity and convertible debt securities are classified as Level 3 in the fair value hierarchy because they involve significant unobservable inputs.</div><div style="margin-top:10pt">The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of fair value measurement</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices in active markets for identical assets
(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant other
observable inputs
(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable inputs
(Level 3)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Available-for-sale debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td

style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Marketable equity securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">16 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">13 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">2 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Contingent payments related to acquisitions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">19 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">7 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">12 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of fair value measurement</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in

millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices in active markets for identical assets
(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant other
observable inputs
(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable inputs
(Level 3)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Available-for-sale debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Marketable equity securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">44 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">90 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">44 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">45 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">19 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">14 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 2000000020000000100000000100000013000000130000000160000001300000020000001000000070000000700000001200000000120000000
style="margin-top:10pt">The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at beginning of period</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at end of period</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Contingent payments related to acquisitions</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Available-for-sale debt securities</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at beginning of period</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">84 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Change in fair value recognized in earnings</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Transfers out of Level 3</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Fair value at end of period</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ccceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
1400000010000002100000017000000200000002000000012000000100000019000000170000001400000010000008400000027000000001400000-5000000000-5000000200000005100000001200000010000001900000017000000For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of September 30, 2024 and December 31, 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Book values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values(a)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Current maturities of long-term debt and finance lease obligations</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">2,498 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">2,667 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">2,493 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:top">2,621 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Long-term debt and finance lease obligations</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10,437 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">11,089 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">9,612 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10,026 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.
249800000026670000002493000000262100000010437000000110890000009612000000100260000003300000080000000-5000000SEGMENT

INFORMATION In the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this new operating model, our business is currently comprised of four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care (which we are planning to divest through the pending sale and accordingly, the results are reported in discontinued operations as discussed in Note 1). The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities and royalty income under a business development arrangement that ended in early 2023 when we acquired the related product rights. Disaggregation of Net Sales The following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Infusion Therapies and Technologies </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">613 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">457 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,070 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">570 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">433 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,003 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Advanced Surgery </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">149 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">123 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">139 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">116 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Medical Products and Therapies</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">762 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3"

style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">709 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">549 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,258 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Care and Connectivity Solutions </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">335 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">121 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">456 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">317 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">126 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">443 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top"> Front Line Care </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">222 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">74 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">296 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">234 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">67 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">301 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Healthcare Systems and Technologies </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">557 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">752 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">551 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">193 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">744 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Injectables and Anesthesia </td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">178 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">143 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">321 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">156 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">351 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Drug Compounding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">

229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Pharmaceuticals</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">178 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">410 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">588 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">385 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,500 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,199 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,699 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,467 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,132 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,599 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-

height:100%">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Infusion Therapies and Technologies </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,718 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,363 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,081 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,654 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,264 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,918 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Advanced Surgery </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">366 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">812 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">433 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">340 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">773 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Medical Products and Therapies</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,164 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,729 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,893 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,087 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,604 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,691 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Care and Connectivity Solutions </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">945 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">365 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,310 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">926 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">381 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,307 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Front Line Care </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">635 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">222 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td

colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">857 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">681 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">230 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">911 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Healthcare Systems and Technologies </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,580 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">587 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,167 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,607 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">611 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,218 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Injectables and Anesthesia </td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">566 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">424 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">990 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">550 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">437 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">987 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Drug Compounding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">665 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">665 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Pharmaceuticals</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">566 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,202 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,768 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">550 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,102 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,652 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">30 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">55 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">56 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">73 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4,340 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,543 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">7,883 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4,300 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,334 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">7,634 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
 Geographic Sales Information Our net sales are attributed to the following geographic regions based on the location of the customer. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,467 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,340 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,300 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Emerging markets1 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">347 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">353 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">985 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Rest of world2 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">852 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,542 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,349 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,699 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,599 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,883 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,634 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan). 2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand. Segment Operating Income We use segment operating income to evaluate the performance of our segments and to make resource allocation decisions. Segment operating income represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of segment operating income to income from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the Kidney Care segment in the pending sale, are now presented as unallocated corporate costs. The following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Medical Products and Therapies</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">268 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">245 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">706 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Healthcare Systems and Technologies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Pharmaceuticals</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">464 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">474 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,282 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,336 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Unallocated corporate costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(73)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(73)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(227)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(285)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Intangible asset amortization expense</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(159)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(147)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(471)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(434)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Legal matters</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Business optimization items</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(18)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:top">(48)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(49)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(167)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Acquisition and integration items</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">European Medical Devices Regulation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(32)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Hurricane Helene costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Product-related items</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total operating income </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">155 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">179 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">449 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">403 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">127 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">251 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">367 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Income from continuing operations before income taxes</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">69 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Our chief operating decision maker does not receive any asset information by reportable segment and, accordingly, we do not report asset information by reportable segment. 4 The following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Infusion Therapies and Technologies </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">613 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">457 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,070 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">570 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">433 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,003 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Advanced Surgery </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">149 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">123 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">139 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">116 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Medical Products and Therapies</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid

#000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">762 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">709 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">549 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,258 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Care and Connectivity Solutions </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">335 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">121 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">456 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">317 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">126 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">443 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Front Line Care </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">222 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">74 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">296 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">234 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">67 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">301 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Healthcare Systems and Technologies </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">557 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">752 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">551 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">193 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">744 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Injectables and Anesthesia </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">178 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">143 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">321 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">156 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">351 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Drug Compounding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Pharmaceuticals</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">178 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">410 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">588 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">385 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,500 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,199 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,699 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,467 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,132 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,599 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-

align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Infusion Therapies and Technologies </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,718 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,363 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,081 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,654 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,264 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">2,918 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Advanced Surgery </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">366 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">812 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">433 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">340 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">773 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Medical Products and Therapies</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,164 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,729 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,893 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,087 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,604 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,691 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Care and Connectivity Solutions </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">945 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">365 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,310 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">926 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">381 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">1,307 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Front Line Care </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">635 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">222 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">857 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">230 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">911 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Healthcare Systems and Technologies </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,580 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">587 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,167 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,607 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">611 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,218 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"> Injectables and Anesthesia </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">566 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">424 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">990 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">550 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">437 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">987 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Drug Compounding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">665 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">665 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Pharmaceuticals</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">566 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,202 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,768 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">550 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,102 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,652 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">30 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">55 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">56 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">73 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4,340 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,543 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">7,883 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">4,300 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">3,334 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">7,634 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
6130000004570000001070000000570000000433000000100300000014900000012300000027200000013900000011600000025500000076200
style="margin-top:10pt">Our net sales are attributed to the following geographic regions based on the location of the customer. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,467 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,340 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,300 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Emerging markets1 </td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">347 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">353 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">985 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Rest of world2 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">852 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,542 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,349 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total Baxter</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,699 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,599 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,883 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,634 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan). 2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
150000000014670000004340000000430000000034700000035300000010010000009850000008520000007790000000254200000023490000006
following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Medical Products and Therapies</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">268 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">245 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">706 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Healthcare Systems and Technologies</td><td colspan="2"

style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom">Pharmaceuticals</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">464 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">474 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,282 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,336 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Unallocated corporate costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(73)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(73)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(227)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(285)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Intangible asset amortization expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(159)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(147)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(471)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(434)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Legal matters</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Business optimization items</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(48)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(49)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(167)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Acquisition and integration items</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">European Medical Devices Regulation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(32)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Hurricane Helene costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Product-related items</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Total operating income </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">155 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">179 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">449 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">403 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Interest expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">127 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">251 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">367 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other (income) expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Income from continuing operations before income taxes</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">69 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
</table>
2680000002450000007330000007060000001360000001150000003230000003270000005800000010800000021100000028400000020000006
73000000-73000000-227000000-285000000-159000000-147000000-471000000-434000000-17000000-13000000-17000000-13000000-18000000-
48000000-49000000-167000000-5000000-2000000-16000000-2000000-9000000-12000000-25000000-32000000-250000000-250000000-30000000-
300000001550000001790000004490000004030000000-87000000-127000000-251000000-367000000100000012000000340000000-
150000006900000064000000232000000210000000falsefalsefalsefalse The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of September 30, 2024, December 31, 2023, and September 30, 2023 (in millions):

September 30, 2024	December 31, 2023	September 30, 2023
Cash and cash equivalents	$1,420	$3,078	$5,716
Restricted cash included in other non-current assets	2	4	4
Cash, cash equivalents and restricted cash	$1,422	$3,082	$5,720

&PO=V]R:W-H965T

ZFQ=H18*[YVH=8NH+U18^WHL);QZD!"!V&OUL$.PEY-5LW! <''XF:_^03> M!O\=F2_]8$]W\RDP;\C_C20W[3D+$?9_AX\%>YH2]]FT^